
@article{717,
  title = {Short-{{Course Versus Standard Chemoradiation}} in {{T3 Rectal Cancer}}},
  year = {2011},
  month = may,
  journal = {The Oncologist},
  volume = {16},
  number = {5},
  pages = {717--721},
  issn = {1083-7159},
  doi = {10.1634/theoncologist.2011-0052},
  abstract = {The pros and cons of short-course radiation therapy and standard chemoradiation in T3 rectal cancer are presented.},
  pmcid = {PMC3228203},
  pmid = {21586661},
  keywords = {Rectal;RT},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K6MLX5U7\\2011 - Short-Course Versus Standard Chemoradiation in T3 .pdf}
}

@article{aaronson365,
  type = {Journal {{Article}}},
  title = {The {{European Organization}} for {{Research}} and {{Treatment}} of {{Cancer QLQ-C30}}: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology},
  author = {Aaronson, N. K. and Ahmedzai, S. and Bergman, B. and Bullinger, M. and Cull, A. and Duez, N. J. and Filiberti, A. and Flechtner, H. and Fleishman, S. B. and {de Haes}, J. C. and {al}, et},
  year = {1993},
  journal = {J Natl Cancer Inst},
  volume = {85},
  number = {5},
  pages = {365--76},
  issn = {0027-8874 (Print) 0027-8874 (Linking)}
}

@article{abel515,
  title = {Frailty and the Management of Hematologic Malignancies},
  author = {Abel, Gregory A. and Klepin, Heidi D.},
  year = {2018},
  month = feb,
  journal = {Blood},
  volume = {131},
  number = {5},
  pages = {515--524},
  issn = {1528-0020},
  doi = {10.1182/blood-2017-09-746420},
  abstract = {The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematologist, we propose elements of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frailty screening, development of disease-specific measures, and inclusion of functional and patient-reported outcomes alongside survival.},
  langid = {english},
  pmid = {29141942},
  keywords = {Aged,Aged; 80 and over,Frail Elderly,Frailty,Hematologic Neoplasms,Humans,Late Onset Disorders},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NRBWC449\\Abel_Klepin_2018_Frailty and the management of hematologic malignancies.pdf}
}

@article{ahmadi1443,
  title = {Accurate Detection of Metabolically Active "Brown" and "White" Adipose Tissues with Computed Tomography},
  author = {Ahmadi, Naser and Hajsadeghi, Fereshteh and Conneely, Mark and Mingos, Mark and Arora, Rohit and Budoff, Matthew and Ebrahimi, Ramin},
  year = {2013},
  month = nov,
  journal = {Academic Radiology},
  volume = {20},
  number = {11},
  pages = {1443--1447},
  issn = {1878-4046},
  doi = {10.1016/j.acra.2013.08.012},
  abstract = {BACKGROUND: Adipose tissues (AT) are highly metabolically active complex endocrine organs and are classified into white (WAT) and brown AT (BAT) with proinflammatory and anti-inflammatory characteristics. The current study investigated the accuracy of computed tomography (CT) to quantitatively detect BAT and WAT based on Hounsfield unit (HU) threshold compared to standardized uptake values (SUVs) of corresponding AT with the use of positron emission tomography (PET). METHODS: One hundred twenty-four patients who underwent whole-body (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT were studied. The SUVs and HUs of regions of BAT and WAT were measured and compared in these scans. The receiver operator characteristic (ROC) analysis was used to detect the HU threshold values for the detection of BAT and WAT. RESULTS: The CT HU of BAT, with high (18)F-FDG uptake, was significantly higher compared to WAT (-67.1~{$\pm~$}8.2 [-10 to -87] versus -93.5~{$\pm~$}10.1 [-88 to -190], P~=~.0006). Generalized linear-regression models revealed that mean CT HU of BAT was 26.4 HU higher than that of WAT (P~=~.001). A strong agreement between CT HU and PET SUV in measuring metabolically active AT (r(2)~=~0.81, P~=~.0001) was observed. The ROC curve showed that the optimal cutoff value of CT HU to detect BAT was HU~{$\geq$}-87 with sensitivity of 83.3\% and specificity of 100\%, and the negative CT HU below -87 is highly specific for WAT. CONCLUSION: In our study, CT can accurately and quantitatively detect BAT and WAT based on CT HU threshold, which is -10 to -87 for~BAT and -88 to -190 for WAT.},
  langid = {english},
  pmid = {24119358},
  keywords = {Adipose Tissue; Brown,Adipose Tissue; White,Adult,Brown adipose tissue,Brown Adipose Tissue,computed tomography,Female,Fluorodeoxyglucose F18,Hounsfield units,Humans,Male,Multimodal Imaging,positron emission tomography,Positron-Emission Tomography,Radiopharmaceuticals,Sensitivity and Specificity,standard uptake value,Tomography; X-Ray Computed,white adipose tissue}
}

@article{aikou114,
  title = {Antrum Preserving Double Tract Method for Reconstruction Following Proximal Gastrectomy},
  author = {Aikou, T. and Natsugoe, S. and Shimazu, H. and Nishi, M.},
  year = {1988},
  month = jan,
  journal = {The Japanese Journal of Surgery},
  volume = {18},
  number = {1},
  pages = {114--115},
  issn = {0047-1909},
  doi = {10.1007/BF02470857},
  abstract = {The antrum preserving double tract method was originally designed in order to gain the smooth transfer of larger foods through the duodenal route. Surgical improvement was then made at a few points when carrying out the anastomosis between the residual stomach and the jejunum. In the clinical field, this method is characterized by a better transfer of large foods into the duodenum than the conventional double tract method. The clinical investigation revealed that gastrin release remained after the operation due to both the good passage and the presence of food in the residual stomach. The antrum preserving double tract method is a reasonable and simple method which can maintain physiological pancreaticocibal synchronism.},
  langid = {english},
  pmid = {3386066},
  keywords = {Anastomosis; Surgical,Gastrectomy,Gastric Emptying,Humans,Jejunostomy,Postgastrectomy Syndromes,Proximal Gastrectomy,Pyloric Antrum}
}

@article{ajani3953,
  title = {Phase {{II}} Trial of Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma ({{RTOG}} 9904): Quality of Combined Modality Therapy and Pathologic Response},
  shorttitle = {Phase {{II}} Trial of Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma ({{RTOG}} 9904)},
  author = {Ajani, Jaffer A. and Winter, Kathryn and Okawara, Gordon S. and Donohue, John H. and Pisters, Peter W. T. and Crane, Christopher H. and Greskovich, John F. and Anne, P. Rani and Bradley, Jeffrey D. and Willett, Christopher and Rich, Tyvin A.},
  year = {2006},
  month = aug,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {24},
  number = {24},
  pages = {3953--3958},
  issn = {1527-7755},
  doi = {10.1200/JCO.2006.06.4840},
  abstract = {PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal. We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20\% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points. PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible. A negative laparoscopic evaluation was required. Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after chemoradiotherapy was completed. Quality of therapy was assessed with other end points. RESULTS: Twenty institutions participated. Forty-nine patients were entered and 43 were assessable (12\% stage IB; 37\% stage II; and 52\% stage III). The pathCR and R0 resection rates were 26\% and 77\%, respectively. At 1 year, more patients with pathCR (82\%) are living than those with less than pathCR (69\%). Grade 4 toxicity occurred in 21\% of patients. Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98\%, 44\%, and 63\% of patients, respectively. A D2 dissection was performed in 50\% of patients. Of 18 major radiotherapy variations, 17 were due to the lack of inclusion of the L3-4 vertebral interphase as prespecified. CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20\% in a cooperative group setting. The quality of surgery improved (50\% with D2 dissection) possibly because surgery was part of this trial. With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.},
  langid = {english},
  pmid = {16921048},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Disease-Free Survival,Female,Gastrectomy,Humans,Male,Middle Aged,Neoadjuvant Therapy,Radiotherapy; Adjuvant,Stomach Neoplasms,Survival Analysis,Treatment Outcome}
}

@article{ajani855,
  type = {Journal {{Article}}},
  title = {Esophageal and {{Esophagogastric Junction Cancers}}, {{Version}} 2.2019, {{NCCN Clinical Practice Guidelines}} in {{Oncology}}},
  author = {Ajani, J. A. and D'Amico, T. A. and Bentrem, D. J. and Chao, J. and Corvera, C. and Das, P. and Denlinger, C. S. and Enzinger, P. C. and Fanta, P. and Farjah, F. and Gerdes, H. and Gibson, M. and Glasgow, R. E. and Hayman, J. A. and Hochwald, S. and Hofstetter, W. L. and Ilson, D. H. and Jaroszewski, D. and Johung, K. L. and Keswani, R. N. and Kleinberg, L. R. and Leong, S. and Ly, Q. P. and Matkowskyj, K. A. and McNamara, M. and Mulcahy, M. F. and Paluri, R. K. and Park, H. and Perry, K. A. and Pimiento, J. and Poultsides, G. A. and Roses, R. and Strong, V. E. and Wiesner, G. and Willett, C. G. and Wright, C. D. and McMillian, N. R. and Pluchino, L. A.},
  year = {2019},
  journal = {J Natl Compr Canc Netw},
  volume = {17},
  number = {7},
  pages = {855--883},
  issn = {1540-1413 (Electronic) 1540-1405 (Linking)},
  doi = {10.6004/jnccn.2019.0033}
}

@article{akinyemiju715,
  title = {Race/Ethnicity and Socio-Economic Differences in Colorectal Cancer Surgery Outcomes: Analysis of the Nationwide Inpatient Sample},
  shorttitle = {Race/Ethnicity and Socio-Economic Differences in Colorectal Cancer Surgery Outcomes},
  author = {Akinyemiju, Tomi and Meng, Qingrui and {Vin-Raviv}, Neomi},
  year = {2016},
  month = sep,
  journal = {BMC cancer},
  volume = {16},
  number = {1},
  pages = {715},
  issn = {1471-2407},
  doi = {10.1186/s12885-016-2738-7},
  abstract = {BACKGROUND: The purpose of this study was to examine racial and socio-economic differences in the receipt of laparoscopic or open surgery among patients with colorectal cancer, and to determine if racial and socio-economic differences exist in post-surgical complications, in-hospital mortality and hospital length of stay among patients who received surgery. METHODS: We conducted a cross-sectional analysis of hospitalized patients with a primary diagnosis of colorectal cancer between 2007 and 2011 using data from Nationwide Inpatient Sample. ICD-9 codes were used to capture primary diagnosis, surgical procedures, and health outcomes during hospitalization. We used logistic regression analysis to determine racial and socio-economic predictors of surgery type, post-surgical complications and mortality, and linear regression analysis to assess hospital length of stay. RESULTS: A total of 122,631 patients were admitted with a primary diagnosis of malignant colorectal cancer between 2007 and 2011. Of these, 17,327 (14.13~\%) had laparoscopic surgery, 70,328 (57.35~\%) received open surgery, while 34976 (28.52~\%) did not receive any surgery. Black (36~\%) and Hispanic (34~\%) patients were more likely to receive no surgery compared with Whites (27~\%) patients. However, among patients that received any surgery, there were no racial differences in which surgery was received (laparoscopic versus open, p\,=\,0.2122), although socio-economic differences remained, with patients from lower residential income areas significantly less likely to receive laparoscopic surgery compared with patients from higher residential income areas (OR: 0.74, 95~\% CI: 0.70-0.78). Among patients who received any surgery, Black patients (OR\,=\,1.07, 95~\% CI: 1.01-1.13), and patients with Medicare (OR\,=\,1.16, 95 \% CI: 1.11-1.22) and Medicaid (OR\,=\,1.15, 95~\% CI: 1.07-1.25) insurance experienced significantly higher post-surgical complications, in-hospital mortality (Black OR\,=\,1.18, 95~\% CI: 1.00-1.39), and longer hospital stay (Black {$\beta$}\,=\,1.33, 95~\% CI: 1.16-1.50) compared with White patients or patients with private insurance. CONCLUSION: Racial and socio-economic differences were observed in the receipt of surgery and surgical outcomes among hospitalized patients with malignant colorectal cancer in the US.},
  langid = {english},
  pmcid = {PMC5011892},
  pmid = {27595733},
  keywords = {Adult,Aged,Colorectal Neoplasms,CRC,Cross-Sectional Studies,Digestive System Surgical Procedures,Ethnicity,Female,Healthcare Disparities,Hospital Mortality,Humans,Inpatients,Laparoscopy,Length of Stay,Male,Middle Aged,Postoperative Complications,Racial Groups,Socioeconomic Factors,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\732GSSW3\\Akinyemiju et al_2016_Race-ethnicity and socio-economic differences in colorectal cancer surgery.pdf}
}

@article{akkerman1512,
  title = {Surgical Techniques to Prevent Delayed Gastric Emptying after Esophagectomy with Gastric Interposition: A Systematic Review},
  shorttitle = {Surgical Techniques to Prevent Delayed Gastric Emptying after Esophagectomy with Gastric Interposition},
  author = {Akkerman, Ronald D. L. and Haverkamp, Leonie and {van Hillegersberg}, Richard and Ruurda, Jelle P.},
  year = {2014},
  month = oct,
  journal = {The Annals of Thoracic Surgery},
  volume = {98},
  number = {4},
  pages = {1512--1519},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2014.06.057},
  abstract = {Delayed gastric emptying is observed in 10\% to 50\% of patients after esophagectomy with gastric interposition. The effects of gastric interposition diameter, pyloric drainage, reconstructive route, and anastomotic site on postoperative gastric emptying were systematically reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Most studies showed superior passage of the gastric tube compared with the whole stomach. Pyloric drainage is not significantly associated with the risk of developing delayed gastric emptying after esophagectomy. For reconstructive route and anastomotic site, available evidence on delayed gastric emptying is limited. Prospectively randomized studies with standardized outcome measurements are recommended.},
  langid = {english},
  pmid = {25152385},
  keywords = {Esophagectomy,Gastric Emptying,Humans,Postoperative Complications,Stomach}
}

@article{al-batran1948,
  title = {Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma ({{FLOT4}}): A Randomised, Phase 2/3 Trial},
  shorttitle = {Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma ({{FLOT4}})},
  author = {{Al-Batran}, Salah-Eddin and Homann, Nils and Pauligk, Claudia and Goetze, Thorsten O. and Meiler, Johannes and Kasper, Stefan and Kopp, Hans-Georg and Mayer, Frank and Haag, Georg Martin and Luley, Kim and Lindig, Udo and Schmiegel, Wolff and Pohl, Michael and Stoehlmacher, Jan and Folprecht, Gunnar and Probst, Stephan and Prasnikar, Nicole and Fischbach, Wolfgang and Mahlberg, Rolf and Trojan, J{\"o}rg and Koenigsmann, Michael and Martens, Uwe M. and {Thuss-Patience}, Peter and Egger, Matthias and Block, Andreas and Heinemann, Volker and Illerhaus, Gerald and Moehler, Markus and Schenk, Michael and Kullmann, Frank and Behringer, Dirk M. and Heike, Michael and Pink, Daniel and Teschendorf, Christian and L{\"o}hr, Carmen and Bernhard, Helga and Schuch, Gunter and Rethwisch, Volker and {von Weikersthal}, Ludwig Fischer and Hartmann, J{\"o}rg T. and Kneba, Michael and Daum, Severin and Schulmann, Karsten and Weniger, J{\"o}rg and Belle, Sebastian and Gaiser, Timo and Oduncu, Fuat S. and G{\"u}ntner, Martina and Hozaeel, Wael and Reichart, Alexander and J{\"a}ger, Elke and Kraus, Thomas and M{\"o}nig, Stefan and Bechstein, Wolf O. and Schuler, Martin and Schmalenberg, Harald and Hofheinz, Ralf D. and {FLOT4-AIO Investigators}},
  year = {2019},
  month = may,
  journal = {Lancet (London, England)},
  volume = {393},
  number = {10184},
  pages = {1948--1957},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(18)32557-1},
  abstract = {BACKGROUND: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours. METHODS: In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 plus either 200 mg/m2 fluorouracil as continuous intravenous infusion or 1250 mg/m2 capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin and 2600 mg/m2 fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01216644. FINDINGS: Between Aug 8, 2010, and Feb 10, 2015, 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists. 360 patients were assigned to ECF/ECX and 356 patients to FLOT. Overall survival was increased in the FLOT group compared with the ECF/ECX group (hazard ratio [HR] 0{$\cdot$}77; 95\% confidence interval [CI; 0.63 to 0{$\cdot$}94]; median overall survival, 50 months [38{$\cdot$}33 to not reached] vs 35 months [27{$\cdot$}35 to 46{$\cdot$}26]). The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was similar in the two groups (96 [27\%] in the ECF/ECX group vs 97 [27\%] in the FLOT group), as was the number of toxic deaths (two [{$<$}1\%] in both groups). Hospitalisation for toxicity occurred in 94 patients (26\%) in the ECF/ECX group and 89 patients (25\%) in the FLOT group. INTERPRETATION: In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX. FUNDING: The German Cancer Aid (Deutsche Krebshilfe), Sanofi-Aventis, Chugai, and Stiftung Leben mit Krebs Foundation.},
  langid = {english},
  pmid = {30982686},
  keywords = {Adenocarcinoma,Administration; Oral,Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Cisplatin,Digestive System Surgical Procedures,Disease-Free Survival,Docetaxel,Esophagogastric Junction,Female,Fluorouracil,Humans,Leucovorin,Male,Middle Aged,Neoplasm Staging,Oxaliplatin,Stomach Neoplasms,Treatment Outcome}
}

@article{aleixo102839,
  title = {Myosteatosis and Prognosis in Cancer: {{Systematic}} Review and Meta-Analysis},
  shorttitle = {Myosteatosis and Prognosis in Cancer},
  author = {Aleixo, G. F. P. and Shachar, S. S. and Nyrop, K. A. and Muss, H. B. and Malpica, Luis and Williams, G. R.},
  year = {2020},
  month = jan,
  journal = {Critical Reviews in Oncology/Hematology},
  volume = {145},
  pages = {102839},
  issn = {1879-0461},
  doi = {10.1016/j.critrevonc.2019.102839},
  abstract = {BACKGROUND: The evidence that body composition parameters influence multiple cancer outcomes is rapidly expanding. Excess adiposity deposits in muscle tissue, termed myosteatosis, can be detected in CT scans through variations in the density of muscle tissues (Hounsfield Units). Patients with similar muscle mass but different amounts of intramuscular adipose infiltration have increased chemotherapy toxicity, time to tumor progression and other adverse outcomes among different cancer types. Our review examines the impact of myosteatosis on overall survival (OS) in patients with cancer. METHODS: A systematic search of the literature was conducted on PubMed/ MEDLINE, Cochrane CENTRAL, and EMBASE. Meta-analysis was conducted using a random-effects model. Risk of bias was evaluated using the Newcastle-Ottawa Quality assessment for cohort studies, funnel plot (publication bias), and GRADE summary of findings tool from Cochrane. RESULTS: A total of 4880 articles were screened from which 40 articles selected, including 21,222 patients. The overall mean proportion of patients with myosteatosis was 48 \% (range 11-85 \%). Using skeletal muscle density (SMD), patients classified as having myosteatosis had 75 \% greater mortality risk compared to non-myosteatosis patients (HR 1.75 95 \% CI 1.60-1.92, 40 studies) (p {$<$} .00001) (i2 = 62 \%). Specifically, myosteatosis was prognostic for worse OS in patients with gynecological, renal, periampullary/pancreatic, hepatocellular, gastroesophageal, and colorectal carcinoma, and lymphomas. CONCLUSION: Our analysis of the literature shows that cancer patients with myosteatosis have shorter survival. Our findings suggest that in oncological practice, muscle density assessment is valuable as a prognostic parameter.},
  langid = {english},
  pmid = {31877534},
  keywords = {Adipose tissue infiltration,Body composition,Body Composition,Cancer,Cohort Studies,Humans,Muscle mass,Muscle; Skeletal,Muscular Diseases,Myosteatosis,Neoplasms,Obesity,Prognosis,Tomography; X-Ray Computed}
}

@article{ali607,
  title = {Lean Body Mass as an Independent Determinant of Dose-Limiting Toxicity and Neuropathy in Patients with Colon Cancer Treated with {{FOLFOX}} Regimens},
  author = {Ali, Raafi and Baracos, Vickie E. and Sawyer, Michael B. and Bianchi, Laurent and Roberts, Sarah and Assenat, Eric and Mollevi, Caroline and Senesse, Pierre},
  year = {2016},
  month = apr,
  journal = {Cancer Medicine},
  volume = {5},
  number = {4},
  pages = {607--616},
  issn = {2045-7634},
  doi = {10.1002/cam4.621},
  abstract = {Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose-limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue was measured by computerized tomography (CT) and used to evaluate the LBM compartment of the whole body. In prospective randomized clinical trials conducted in France (n = 58), for patients given FOLFOX-based regimens according to body surface area, values of oxaliplatin/kg LBM were highly variable, ranging from 2.55 to 6.6 mg/kg LBM. A cut point of 3.09 mg oxaliplatin/kg LBM for developing toxicity was determined by Receiver Operating Characteristic (ROC) analysis, below this value 0/17 (0.0\%) of patients experienced DLT; in contrast above this value 18/41 (44.0\%) of patients were dose reduced or had treatment terminated owing to toxicity ({$\geq$}Grade 3 or neuropathy {$\geq$}Grade 2); for 9/41 the DLT was sensory neuropathy. These findings were validated in an independent cohort of colon cancer patients (n = 80) receiving FOLFOX regimens as part of standard care, in Canada. Low LBM is a significant predictor of toxicity and neuropathy in patients administered FOLFOX-based regimens using conventional body surface area (BSA) dosing.},
  langid = {english},
  pmcid = {PMC4831278},
  pmid = {26814378},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Body composition,Body Composition,Body Mass Index,Body Surface Area,Canada,chemo,chemotherapy toxicity,Cohort Studies,colon cancer,Colonic Neoplasms,crc,Drug-Related Side Effects and Adverse Reactions,Female,Fluorouracil,France,Humans,irinotecan,lean body mass,Leucovorin,Male,Middle Aged,Nervous System Diseases,neuropathy,Organoplatinum Compounds,oxaliplatin,Population Surveillance},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UD5W9E2R\\Ali et al_2016_Lean body mass as an independent determinant of dose-limiting toxicity and.pdf}
}

@article{amarasinghe580806,
  title = {A {{Deep Learning Model}} to {{Automate Skeletal Muscle Area Measurement}} on {{Computed Tomography Images}}},
  author = {Amarasinghe, Kaushalya C. and Lopes, Jamie and Beraldo, Julian and Kiss, Nicole and Bucknell, Nicholas and Everitt, Sarah and Jackson, Price and Litchfield, Cassandra and Denehy, Linda and Blyth, Benjamin J. and Siva, Shankar and MacManus, Michael and Ball, David and Li, Jason and Hardcastle, Nicholas},
  year = {2021},
  journal = {Frontiers in Oncology},
  volume = {11},
  pages = {580806},
  issn = {2234-943X},
  doi = {10.3389/fonc.2021.580806},
  abstract = {BACKGROUND: Muscle wasting (Sarcopenia) is associated with poor outcomes in cancer patients. Early identification of sarcopenia can facilitate nutritional and exercise intervention. Cross-sectional skeletal muscle (SM) area at the third lumbar vertebra (L3) slice of a computed tomography (CT) image is increasingly used to assess body composition and calculate SM index (SMI), a validated surrogate marker for sarcopenia in cancer. Manual segmentation of SM requires multiple steps, which limits use in routine clinical practice. This project aims to develop an automatic method to segment L3 muscle in CT scans. METHODS: Attenuation correction CTs from full body PET-CT scans from patients enrolled in two prospective trials were used. The training set consisted of 66 non-small cell lung cancer (NSCLC) patients who underwent curative intent radiotherapy. An additional 42 NSCLC patients prescribed curative intent chemo-radiotherapy from a second trial were used for testing. Each patient had multiple CT scans taken at different time points prior to and post- treatment (147 CTs in the training and validation set and 116 CTs in the independent testing set). Skeletal muscle at L3 vertebra was manually segmented by two observers, according to the Alberta protocol to serve as ground truth labels. This included 40 images segmented by both observers to measure inter-observer variation. An ensemble of 2.5D fully convolutional neural networks (U-Nets) was used to perform the segmentation. The final layer of U-Net produced the binary classification of the pixels into muscle and non-muscle area. The model performance was calculated using Dice score and absolute percentage error (APE) in skeletal muscle area between manual and automated contours. RESULTS: We trained five 2.5D U-Nets using 5-fold cross validation and used them to predict the contours in the testing set. The model achieved a mean Dice score of 0.92 and an APE of 3.1\% on the independent testing set. This was similar to inter-observer variation of 0.96 and 2.9\% for mean Dice and APE respectively. We further quantified the performance of sarcopenia classification using computer generated skeletal muscle area. To meet a clinical diagnosis of sarcopenia based on Alberta protocol the model achieved a sensitivity of 84\% and a specificity of 95\%. CONCLUSIONS: This work demonstrates an automated method for accurate and reproducible segmentation of skeletal muscle area at L3. This is an efficient tool for large scale or routine computation of skeletal muscle area in cancer patients which may have applications on low quality CTs acquired as part of PET/CT studies for staging and surveillance of patients with cancer.},
  langid = {english},
  pmcid = {PMC8138051},
  pmid = {34026597},
  keywords = {convolutional neural networks,deep learning,image segmentation,lung cancer,ML,sarcopenia,skeletal muscle},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2M6ERGTI\\Amarasinghe et al_2021_A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed.pdf}
}

@article{amini1671,
  title = {Approaches to {{Assessment}} of {{Muscle Mass}} and {{Myosteatosis}} on {{Computed Tomography}}: {{A Systematic Review}}},
  shorttitle = {Approaches to {{Assessment}} of {{Muscle Mass}} and {{Myosteatosis}} on {{Computed Tomography}}},
  author = {Amini, Behrang and Boyle, Sean P. and Boutin, Robert D. and Lenchik, Leon},
  year = {2019},
  month = sep,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {74},
  number = {10},
  pages = {1671--1678},
  issn = {1758-535X},
  doi = {10.1093/gerona/glz034},
  abstract = {BACKGROUND/OBJECTIVE: There is increasing use of computed tomography (CT) in sarcopenia research using a wide variety of techniques. We performed a systematic review of the CT literature to identify the differences between approaches used. METHODS: A comprehensive search of PubMed from 1983 to 2017 was performed to identify studies that used CT muscle measurements to assess muscle mass and myosteatosis. The CT protocols were evaluated based on anatomic landmark(s), thresholding, muscle(s) segmented, key measurement (ie, muscle attenuation, cross-sectional area, volume), derived variables, and analysis software. From the described search, 657 articles were identified and 388 studies met inclusion criteria for this systematic review. RESULTS: Muscle mass was more commonly assessed than myosteatosis (330 vs. 125). The most commonly assessed muscle or muscle groups were total abdominal wall musculature (142/330 and 49/125 for muscle mass and myosteatosis, respectively) and total thigh musculature (90/330 and 48/125). The most commonly used landmark in the abdomen was the L3 vertebra (123/142 and 45/49 for muscle mass and myosteatosis, respectively). Skeletal muscle index and intermuscular adipose tissue were the most commonly used measures of abdominal wall muscle mass (114/142) and myosteatosis (27/49), respectively. Cut points varied across studies. A significant majority of studies failed to report important CT technical parameters, such as use of intravenous contrast and slice thickness (94\% and 63\%, respectively). CONCLUSIONS: There is considerable variation in the CT approaches used for the assessment of muscle mass and myosteatosis. There is a need to develop consensus for CT-based evaluation of sarcopenia and myosteatosis.},
  langid = {english},
  pmcid = {PMC7357454},
  pmid = {30726878},
  keywords = {Adipose Tissue,Body composition,Body Composition,Humans,Imaging,Muscle,Muscle; Skeletal,Review,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\33P3IH5S\\Amini et al_2019_Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography.pdf}
}

@article{anandavadivelan185,
  title = {Cachexia in Patients with Oesophageal Cancer},
  author = {Anandavadivelan, Poorna and Lagergren, Pernilla},
  year = {2016},
  month = mar,
  journal = {Nature Reviews. Clinical Oncology},
  volume = {13},
  number = {3},
  pages = {185--198},
  issn = {1759-4782},
  doi = {10.1038/nrclinonc.2015.200},
  abstract = {Oesophageal cancer is a debilitating disease with a poor prognosis, and weight loss owing to malnutrition prevails in the majority of patients. Cachexia, a multifactorial syndrome characterized by the loss of fat and skeletal muscle mass and systemic inflammation arising from complex host-tumour interactions is a major contributor to malnutrition, which is a determinant of tolerance to treatment and survival. In patients with oesophageal cancer, cachexia is further compounded by eating difficulties owing to the stage and location of the tumour, and the effects of neoadjuvant therapy. Treatment with curative intent involves exceptionally extensive and invasive surgery, and the subsequent anatomical changes often lead to eating difficulties and severe postoperative malnutrition. Thus, screening for cachexia by means of percentage weight loss and BMI during the cancer trajectory and survivorship periods is imperative. Additionally, markers of inflammation (such as C-reactive protein), dysphagia and appetite loss should be assessed at diagnosis. Routine assessments of body composition are also necessary in patients with oesophageal cancer to enable assessment of skeletal muscle loss, which might be masked by sarcopenic obesity in these patients. A need exists for clinical trials examining the effectiveness of therapeutic and physical-activity-based interventions in mitigating muscle loss and counteracting cachexia in these patients.},
  langid = {english},
  pmid = {26573424},
  keywords = {Body Composition,Cachexia,Chachexia,Esophageal Neoplasms,GE,Humans,Nutrition Assessment,Nutritional Status,Predictive Value of Tests,Quality of Life,Risk Assessment,Risk Factors,Treatment Outcome,Weight Loss}
}

@article{anandavadivelan410,
  title = {Impact of Weight Loss and Eating Difficulties on Health-Related Quality of Life up to 10\,Years after Oesophagectomy for Cancer},
  author = {Anandavadivelan, P. and Wikman, A. and Johar, A. and Lagergren, P.},
  year = {2018},
  month = mar,
  journal = {The British Journal of Surgery},
  volume = {105},
  number = {4},
  pages = {410--418},
  issn = {1365-2168},
  doi = {10.1002/bjs.10686},
  abstract = {BACKGROUND: Severe weight loss is experienced by patients with eating difficulties after surgery for oesophageal cancer. The aim of this prospective cohort study was to asssess the influence of eating difficulties and severe weight loss on health-related quality of life (HRQoL) up to 10\,years after oesophagectomy. METHODS: Data on bodyweight and HRQoL were collected at 6\,months, 3, 5 and 10\,years in patients who underwent surgery for oesophageal cancer in Sweden between 2001 and 2005. Exposures were percentage weight loss, and eating difficulties defined by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-OES18 questionnaire. Outcomes were HRQoL scores from the EORTC QLQ-C30 questionnaire. Repeated-measures ANOVA, adjusting for potential confounders, was used to assess the association between eating difficulties and weight loss (4 exposure groups) and HRQoL scores at each time point. Mean score differences (MDs) between time points or exposure groups were defined as clinically relevant in accordance with evidence-based interpretation guidelines. RESULTS: In total, 92 of 104 10-year survivors (88{$\cdot$}5 per cent) responded to the questionnaires. Weight loss was greatest within 6\,months of surgery. Patients with eating difficulties with or without weight loss reported clinically and statistically significantly worsened HRQoL in almost all aspects. The largest MD was seen between 5 and 10\,years after surgery for global quality of life, physical, role and social function (MD -22 to -30), as well for fatigue, nausea, dyspnoea, insomnia, appetite loss and diarrhoea (MD 24-36). CONCLUSION: Eating difficulties are associated with deterioration in several aspects of HRQoL up to 10\,years after surgery for oesophageal cancer.},
  langid = {english},
  pmid = {29160918},
  keywords = {Adult,Aged,Aged; 80 and over,Esophagectomy,Feeding and Eating Disorders,Female,Follow-Up Studies,GE,Health Status Indicators,Humans,Male,Middle Aged,Postoperative Complications,Prospective Studies,Quality of Life,Weight Loss}
}

@article{andre2207,
  title = {Pembrolizumab in {{Microsatellite-Instability-High Advanced Colorectal Cancer}}},
  author = {Andr{\'e}, Thierry and Shiu, Kai-Keen and Kim, Tae Won and Jensen, Benny Vittrup and Jensen, Lars Henrik and Punt, Cornelis and Smith, Denis and {Garcia-Carbonero}, Rocio and Benavides, Manuel and Gibbs, Peter and {de la Fouchardiere}, Christelle and Rivera, Fernando and Elez, Elena and Bendell, Johanna and Le, Dung T. and Yoshino, Takayuki and Van Cutsem, Eric and Yang, Ping and Farooqui, Mohammed Z. H. and Marinello, Patricia and Diaz, Luis A. and {KEYNOTE-177 Investigators}},
  year = {2020},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {383},
  number = {23},
  pages = {2207--2218},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa2017699},
  abstract = {BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown. METHODS: In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks. Patients receiving chemotherapy could cross over to pembrolizumab therapy after disease progression. The two primary end points were progression-free survival and overall survival. RESULTS: At the second interim analysis, after a median follow-up (from randomization to data cutoff) of 32.4 months (range, 24.0 to 48.3), pembrolizumab was superior to chemotherapy with respect to progression-free survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95\% confidence interval [CI], 0.45 to 0.80; P\,=\,0.0002). The estimated restricted mean survival after 24 months of follow-up was 13.7 months (range, 12.0 to 15.4) as compared with 10.8 months (range, 9.4 to 12.2). As of the data cutoff date, 56 patients in the pembrolizumab group and 69 in the chemotherapy group had died. Data on overall survival were still evolving (66\% of required events had occurred) and remain blinded until the final analysis. An overall response (complete or partial response), as evaluated with Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was observed in 43.8\% of the patients in the pembrolizumab group and 33.1\% in the chemotherapy group. Among patients with an overall response, 83\% in the pembrolizumab group, as compared with 35\% of patients in the chemotherapy group, had ongoing responses at 24 months. Treatment-related adverse events of grade 3 or higher occurred in 22\% of the patients in the pembrolizumab group, as compared with 66\% (including one patient who died) in the chemotherapy group. CONCLUSIONS: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).},
  langid = {english},
  pmid = {33264544},
  keywords = {Adult,Aged,Aged; 80 and over,Antibodies; Monoclonal; Humanized,Antineoplastic Agents; Immunological,Antineoplastic Combined Chemotherapy Protocols,Biomarkers; Tumor,Brain Neoplasms,Colorectal Neoplasms,Female,Fluorouracil,Humans,Immune Checkpoint Inhibitors,Immunotherapy,Kaplan-Meier Estimate,Male,Microsatellite Instability,Middle Aged,Mutation,Neoplastic Syndromes; Hereditary,Progression-Free Survival,StageIV},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4WDJWKEP\\AndrÃ© et al. - 2020 - Pembrolizumab in Microsatellite-Instability-High A.pdf}
}

@article{antoun847,
  title = {No Evidence for Changes in Skeletal Muscle Mass or Weight during First-Line Chemotherapy for Metastatic Colorectal Cancer},
  author = {Antoun, Sami and Bayar, Mohamed Amine and Dyevre, Val{\'e}rie and Lanoy, Emilie and Smolenschi, Cristina and Ducreux, Michel},
  year = {2019},
  month = aug,
  journal = {BMC cancer},
  volume = {19},
  number = {1},
  pages = {847},
  issn = {1471-2407},
  doi = {10.1186/s12885-019-6086-2},
  abstract = {BACKGROUND: Studies over the past 10\,years strongly support an association between skeletal muscle mass (SMM) depletion and outcome in metastatic colorectal cancer (mCRC). Factors influencing SMM changes over time are, however, poorly studied. We analyzed the impact of SMM on overall survival and chemotherapy toxicities in mCRC patients treated with first-line chemotherapy. Changes in weight and body composition were evaluated during follow-up. METHODS: Patients enrolled in the randomized phase II ACCORD trial comparing two chemotherapy regimens were screened. Body composition parameters (SMM, adipose tissue) were assessed prospectively with computed tomography (CT) imaging, and toxicities were recorded. Mixed models were used to assess weight and BC changes during 4\,months of treatment follow-up. RESULTS: Among 145 patients included in ACCORD, 76 had available baseline CT scans and were included in the current study. Mean age was 60.6\,{$\pm$}\,10.0\,years, 50\% were women, 82\% had colon cancer, and 62\% had two or more metastatic sites. At baseline, 49\% had lost at least 5\% of their initial weight, including 26\% who had lost more than 10\%; 53\% had SMM depletion. In this homogenous cohort, there were no statistically significant associations between SMM depletion and overall survival, progression-free survival or chemotherapy toxicity. There were no decreases in weight or SMM during follow-up. Weight and SMM changes were not influenced by diarrhea either grade 3-4 or any grade (reported in 74\% of patients). For patients with weight loss {$\geq$}10\% at baseline, SMM increased significantly after 4\,months of follow-up and after disease stabilization following chemotherapy (P\,=\,0.008). CONCLUSIONS: In a homogenous mCRC cohort, SMM depletion was not associated with survival or chemotherapy toxicity. Despite most patient experiencing diarrhea, no changes in weight or SMM were found during 4\,months of follow-up. However, hypotheses deriving from our exploratory study have to be tested in further larger sample size studies. TRIAL REGISTRATION: Clinicaltrials.gov NCT00423696 (2011).},
  langid = {english},
  pmcid = {PMC6714393},
  pmid = {31462288},
  keywords = {Body Composition,Body Weight,Chemotherapy toxicity,Colorectal Neoplasms,Tomography; X-Ray Computed,Weight loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\YF6SSVDZ\\Antoun et al. - 2019 - No evidence for changes in skeletal muscle mass or.pdf}
}

@article{aparicio249,
  title = {Half of Elderly Patients Routinely Treated for Colorectal Cancer Receive a Sub-Standard Treatment},
  author = {Aparicio, Thomas and Navazesh, Atika and Boutron, Isabelle and Bouarioua, Nadia and Chosidow, Denis and Mion, Mathieu and Choudat, Laurence and Sobhani, Iradj and Mentr{\'e}, France and Soul{\'e}, Jean Claude},
  year = {2009},
  month = sep,
  journal = {Critical Reviews in Oncology/Hematology},
  volume = {71},
  number = {3},
  pages = {249--257},
  issn = {1879-0461},
  doi = {10.1016/j.critrevonc.2008.11.006},
  abstract = {BACKGROUND: Several database studies report a lack of care in elderly patients with colorectal cancer. PURPOSE: To describe the management of elderly patients admitted for colorectal cancer; to identify factors associated with standard management according to recommendations and to study factors influencing the survival. PATIENTS AND METHODS: All consecutive patients over 75 years managed for a colorectal adenocarcinoma in our hospital from 1995 to 2000 and followed until 2006 were retrospectively included. The appropriateness of the management of their disease according to the recommendations available at that time was assessed. Several risk factors in receiving the standard cancer treatment were tested using univariate and then multivariate logistic regression. Risk factors of survival were studied using univariate and then multivariate survival analysis. RESULTS: One hundred and ten patients were included. Median age was 82 years (range: 75-96). A surgical treatment was performed in 96 patients. The median overall survival was 32 (1-108) months. A standard cancer treatment according to recommendations was performed in 53 (48\%) patients: adjuvant chemotherapy in 6/23 patients with stage III tumour, palliative chemotherapy in 3/18 patients with stage IV tumour and adjuvant radiotherapy in 4/14 patients who had a rectal tumour resection. Multivariate analysis retains tumour stage I or II (OR=7.6, 95\% C.I.=[2.9-19.9], p{$<$}0.0001) as the only factor associated with standard treatment and presence of metastasis (HR=3.9, 95\% C.I. [1.4-10.8], p=0.005), and Charlson's score {$>$}3 (HR=28.9, 95\% C.I. [2.5-335.6], p=0.001) as independent risk factors of poor survival. CONCLUSIONS: Fifty two percent of elderly patients have had a sub-standard cancer treatment. The majority had a surgical treatment, but only a few received chemotherapy or radiotherapy. Metastasis, older age and Charlson's comorbidity score are the main prognosis factors of poor survival.},
  langid = {english},
  pmid = {19131256},
  keywords = {Aged,Aged; 80 and over,Antineoplastic Protocols,Carcinoma,Cohort Studies,Colorectal Neoplasms,Comorbidity,Elderly,Female,Follow-Up Studies,Humans,Male,Retrospective Studies,Risk Factors,Survival Analysis}
}

@article{arends11,
  title = {{{ESPEN}} Guidelines on Nutrition in Cancer Patients},
  author = {Arends, Jann and Bachmann, Patrick and Baracos, Vickie and Barthelemy, Nicole and Bertz, Hartmut and Bozzetti, Federico and Fearon, Ken and H{\"u}tterer, Elisabeth and Isenring, Elizabeth and Kaasa, Stein and Krznaric, Zeljko and Laird, Barry and Larsson, Maria and Laviano, Alessandro and M{\"u}hlebach, Stefan and Muscaritoli, Maurizio and Oldervoll, Line and Ravasco, Paula and Solheim, Tora and Strasser, Florian and {de van der Schueren}, Marian and Preiser, Jean-Charles},
  year = {2017},
  month = feb,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {36},
  number = {1},
  pages = {11--48},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2016.07.015},
  abstract = {Cancers are among the leading causes of morbidity and mortality worldwide, and the number of new cases is expected to rise significantly over the next decades. At the same time, all types of cancer treatment, such as surgery, radiation therapy, and pharmacological therapies are improving in sophistication, precision and in the power to target specific characteristics of individual cancers. Thus, while many cancers may still not be cured they may be converted to chronic diseases. All of these treatments, however, are impeded or precluded by the frequent development of malnutrition and metabolic derangements in cancer patients, induced by the tumor or by its treatment. These evidence-based guidelines were developed to translate current best evidence and expert opinion into recommendations for multi-disciplinary teams responsible for identification, prevention, and treatment of reversible elements of malnutrition in adult cancer patients. The guidelines were commissioned and financially supported by ESPEN and by the European Partnership for Action Against Cancer (EPAAC), an EU level initiative. Members of the guideline group were selected by ESPEN to include a range of professions and fields of expertise. We searched for meta-analyses, systematic reviews and comparative studies based on clinical questions according to the PICO format. The evidence was evaluated and merged to develop clinical recommendations using the GRADE method. Due to the deficits in the available evidence, relevant still open questions were listed and should be addressed by future studies. Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. They may be driven by inadequate food intake, decreased physical activity and catabolic metabolic derangements. To screen for, prevent, assess in detail, monitor and treat malnutrition standard operating procedures, responsibilities and a quality control process should be established at each institution involved in treating cancer patients. All cancer patients should be screened regularly for the risk or the presence of malnutrition. In all patients - with the exception of end of life care - energy and substrate requirements should be met by offering in a step-wise manner nutritional interventions from counseling to parenteral nutrition. However, benefits and risks of nutritional interventions have to be balanced with special consideration in patients with advanced disease. Nutritional care should always be accompanied by exercise training. To counter malnutrition in patients with advanced cancer there are few pharmacological agents and pharmaconutrients with only limited effects. Cancer survivors should engage in regular physical activity and adopt a prudent diet.},
  langid = {english},
  pmid = {27637832},
  keywords = {Anorexia,Cachexia,Cancer,Chemotherapy,Diet,Evidence-Based Medicine,Exercise,Exercise training,Guideline,Hematopoietic stem cell transplantation,Humans,Malnutrition,Meta-Analysis as Topic,Neoplasms,Nutrition assessment,Nutrition Assessment,Nutrition Policy,Nutrition therapy,Nutritional Requirements,Nutritional Status,Observational Studies as Topic,Palliative care,Radiotherapy,Randomized Controlled Trials as Topic,Sarcopenia,Societies; Scientific,Surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9MEZCJSV\\Arends et al_2017_ESPEN guidelines on nutrition in cancer patients.pdf}
}

@article{argiles477,
  title = {The Metabolic Basis of Cancer Cachexia},
  author = {Argil{\'e}s, J. M. and Alvarez, B. and {L{\'o}pez-Soriano}, F. J.},
  year = {1997},
  month = sep,
  journal = {Medicinal Research Reviews},
  volume = {17},
  number = {5},
  pages = {477--498},
  issn = {0198-6325},
  doi = {10.1002/(sici)1098-1128(199709)17:5<477::aid-med3>3.0.co;2-r},
  langid = {english},
  pmid = {9276862},
  keywords = {Adipose Tissue,Cachexia,Carbohydrate Metabolism,Energy Metabolism,Humans,Insulin Resistance,Muscle; Skeletal,Neoplasms}
}

@article{asgestandardsofpracticecommittee1,
  title = {The Role of Endoscopy in the Management of Premalignant and Malignant Conditions of the Stomach},
  author = {{ASGE Standards of Practice Committee} and Evans, John A. and Chandrasekhara, Vinay and Chathadi, Krishnavel V. and Decker, G. Anton and Early, Dayna S. and Fisher, Deborah A. and Foley, Kimberly and Hwang, Joo Ha and Jue, Terry L. and Lightdale, Jenifer R. and Pasha, Shabana F. and Sharaf, Ravi and Shergill, Amandeep K. and Cash, Brooks D. and DeWitt, John M.},
  year = {2015},
  month = jul,
  journal = {Gastrointestinal Endoscopy},
  volume = {82},
  number = {1},
  pages = {1--8},
  issn = {1097-6779},
  doi = {10.1016/j.gie.2015.03.1967},
  langid = {english},
  pmid = {25935705},
  keywords = {Adenocarcinoma,Gastrointestinal Stromal Tumors,Gastroscopy,GIST,Humans,Lymphoma; B-Cell; Marginal Zone,Metaplasia,Polyps,Precancerous Conditions,Stomach,Stomach Neoplasms}
}

@article{auerbach1301,
  title = {Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients with Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial},
  shorttitle = {Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients with Chemotherapy-Related Anemia},
  author = {Auerbach, Michael and Ballard, Harold and Trout, J. Richard and McIlwain, Marilyn and Ackerman, Alan and Bahrain, Huzefa and Balan, Stefan and Barker, Lance and Rana, Jeevindra},
  year = {2004},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {22},
  number = {7},
  pages = {1301--1307},
  issn = {0732-183X},
  doi = {10.1200/JCO.2004.08.119},
  abstract = {PURPOSE: Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients. METHODS: This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb},
  langid = {english},
  pmid = {15051778},
  keywords = {Abnormalities; Drug-Induced,Administration; Oral,Aged,Anemia,Antineoplastic Agents,Cancer,Erythropoietin,Female,Humans,Infusions; Intravenous,Iron,Iron-Dextran Complex,Male,Middle Aged,Neoplasms,Prospective Studies,Quality of Life,Recombinant Proteins}
}

@article{awad74,
  title = {Marked Changes in Body Composition Following Neoadjuvant Chemotherapy for Oesophagogastric Cancer},
  author = {Awad, Sherif and Tan, Benjamin H. and Cui, Helen and Bhalla, Ashish and Fearon, Kenneth C. H. and Parsons, Simon L. and Catton, James A. and Lobo, Dileep N.},
  year = {2012},
  month = feb,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {31},
  number = {1},
  pages = {74--77},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2011.08.008},
  abstract = {BACKGROUND \& AIMS: Patients with sarcopenia [reduced fat free mass (FFM)] have a higher incidence of chemotherapy-related toxicity and decreased survival. As there are no such data in patients with oesophagogastric cancer (OGC), this study investigated changes in body composition in OGC patients receiving neoadjuvant chemotherapy (NAC). METHODS: OGC patients who had CT scans before and after NAC were studied. CT images at the L3 vertebral level were analysed using SliceOmatic(\textregistered ) software to derive estimates of FFM and fat mass (FM). Comparisons were made between pre- and post-NAC CT images. Data are reported as mean~{$\pm~$}SD. RESULTS: Forty-seven patients (34 male) aged 63~{$\pm~$}12 years were studied and 79\% completed their course of NAC. The interval between CT scans was 107~{$\pm~$}27 days. The proportion of patients with sarcopenia increased from 57\% pre-NAC to 79\% post-NAC (p~=~0.046). During NAC there were significant reductions in estimated FFM and FM (2.9~{$\pm~$}4.7~kg, p~{$<~$}0.0001 and 1.3~{$\pm~$}3.2~kg, p~=~0.007, respectively). No association was demonstrated between loss of FFM and non-completion of NAC, increased hospital stay or mortality. CONCLUSIONS: In patients with OGC commencing NAC, sarcopenia was present in 57\%. NAC was associated with further reductions in FFM and an increase in the proportion of patients becoming sarcopenic.},
  langid = {english},
  pmid = {21875767},
  keywords = {Aged,Body Composition,Female,Gastrointestinal Neoplasms,Hospitalization,Humans,Length of Stay,Male,Middle Aged,Neoadjuvant Therapy,Obesity,Pilot Projects,Postoperative Care,Prevalence,Sarcopenia,Treatment Outcome}
}

@article{azab,
  type = {Journal {{Article}}},
  title = {Impact of {{Chemoradiation-to-Surgery Interval}} on {{Pathological Complete Response}} and {{Short-}} and {{Long-Term Overall Survival}} in {{Esophageal Cancer Patients}}},
  author = {Azab, B. and Amundson, J. R. and Picado, O. and Ripat, C. and Macedo, F. I. and Franceschi, D. and Livingstone, A. S. and Yakoub, D.},
  year = {2018},
  journal = {Ann Surg Oncol},
  issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
  doi = {10.1245/s10434-018-6897-4}
}

@article{bae32,
  title = {Intravenous Contrast Medium Administration and Scan Timing at {{CT}}: Considerations and Approaches},
  shorttitle = {Intravenous Contrast Medium Administration and Scan Timing at {{CT}}},
  author = {Bae, Kyongtae T.},
  year = {2010},
  month = jul,
  journal = {Radiology},
  volume = {256},
  number = {1},
  pages = {32--61},
  issn = {1527-1315},
  doi = {10.1148/radiol.10090908},
  abstract = {The continuing advances in computed tomographic (CT) technology in the past decades have provided ongoing opportunities to improve CT image quality and clinical practice and discover new clinical CT imaging applications. New CT technology, however, has introduced new challenges in clinical radiology practice. One of the challenges is with intravenous contrast medium administration and scan timing. In this article, contrast medium pharmacokinetics and patient, contrast medium, and CT scanning factors associated with contrast enhancement and scan timing are presented and discussed. Published data from clinical studies of contrast medium and physiology are reviewed and interpreted. Computer simulation data are analyzed to provide an in-depth analysis of various factors associated with contrast enhancement and scan timing. On the basis of basic principles and analysis of the factors, clinical considerations and modifications to protocol design that are necessary to optimize contrast enhancement for common clinical CT applications are proposed.},
  langid = {english},
  pmid = {20574084},
  keywords = {Anthropometry,Clinical Protocols,Computer Simulation,Contrast,Contrast Media,Humans,Infusions; Intravenous,Injections; Intravenous,Radiation Dosage,Radiographic Image Enhancement,Radiographic Image Interpretation; Computer-Assisted,Time Factors,Tomography; X-Ray Computed}
}

@article{bahadoer29,
  title = {Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision ({{TME}}) versus Preoperative Chemoradiotherapy, {{TME}}, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer ({{RAPIDO}}): A Randomised, Open-Label, Phase 3 Trial},
  shorttitle = {Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision ({{TME}}) versus Preoperative Chemoradiotherapy, {{TME}}, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer ({{RAPIDO}})},
  author = {Bahadoer, Renu R. and Dijkstra, Esm{\'e}e A. and {van Etten}, Boudewijn and Marijnen, Corrie A. M. and Putter, Hein and Kranenbarg, Elma Meershoek-Klein and Roodvoets, Annet G. H. and Nagtegaal, Iris D. and {Beets-Tan}, Regina G. H. and Blomqvist, Lennart K. and Fokstuen, Tone and Ten Tije, Albert J. and Capdevila, Jaume and Hendriks, Mathijs P. and Edhemovic, Ibrahim and Cervantes, Andr{\'e}s and Nilsson, Per J. and Glimelius, Bengt and {van de Velde}, Cornelis J. H. and Hospers, Geke A. P. and {RAPIDO collaborative investigators}},
  year = {2021},
  month = jan,
  journal = {The Lancet. Oncology},
  volume = {22},
  number = {1},
  pages = {29--42},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(20)30555-6},
  abstract = {BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control. METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Patients were eligible if they were aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, had a biopsy-proven, newly diagnosed, primary, locally advanced rectal adenocarcinoma, which was classified as high risk on pelvic MRI (with at least one of the following criteria: clinical tumour [cT] stage cT4a or cT4b, extramural vascular invasion, clinical nodal [cN] stage cN2, involved mesorectal fascia, or enlarged lateral lymph nodes), were mentally and physically fit for chemotherapy, and could be assessed for staging within 5 weeks before randomisation. Eligible participants were randomly assigned (1:1), using a management system with a randomly varying block design (each block size randomly chosen to contain two to four allocations), stratified by centre, ECOG performance status, cT stage, and cN stage, to either the experimental or standard of care group. All investigators remained masked for the primary endpoint until a prespecified number of events was reached. Patients allocated to the experimental treatment group received short-course radiotherapy (5\hphantom{,}\texttimes\hphantom{,}5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, and a chemotherapy-free interval between days 15-21) or nine cycles of FOLFOX4 (oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin [folinic acid] 200 mg/m2 intravenously on days 1 and 2, followed by bolus fluorouracil 400 mg/m2 intravenously and fluorouracil 600 mg/m2 intravenously for 22 h on days 1 and 2, and a chemotherapy-free interval between days 3-14) followed by total mesorectal excision. Choice of CAPOX or FOLFOX4 was per physician discretion or hospital policy. Patients allocated to the standard of care group received 28 daily fractions of 1{$\cdot$}8 Gy up to 50{$\cdot$}4 Gy or 25 fractions of 2{$\cdot$}0 Gy up to 50{$\cdot$}0 Gy (per physician discretion or hospital policy), with concomitant twice-daily oral capecitabine 825 mg/m2 followed by total mesorectal excision and, if stipulated by hospital policy, adjuvant chemotherapy with eight cycles of CAPOX or 12 cycles of FOLFOX4. The primary endpoint was 3-year disease-related treatment failure, defined as the first occurrence of locoregional failure, distant metastasis, new primary colorectal tumour, or treatment-related death, assessed in the intention-to-treat population. Safety was assessed by intention to treat. This study is registered with the EudraCT, 2010-023957-12, and ClinicalTrials.gov, NCT01558921, and is now complete. FINDINGS: Between June 21, 2011, and June 2, 2016, 920 patients were enrolled and randomly assigned to a treatment, of whom 912 were eligible (462 in the experimental group; 450 in the standard of care group). Median follow-up was 4{$\cdot$}6 years (IQR 3{$\cdot$}5-5{$\cdot$}5). At 3 years after randomisation, the cumulative probability of disease-related treatment failure was 23{$\cdot$}7\% (95\% CI 19{$\cdot$}8-27{$\cdot$}6) in the experimental group versus 30{$\cdot$}4\% (26{$\cdot$}1-34{$\cdot$}6) in the standard of care group (hazard ratio 0{$\cdot$}75, 95\% CI 0{$\cdot$}60-0{$\cdot$}95; p=0{$\cdot$}019). The most common grade 3 or higher adverse event during preoperative therapy in both groups was diarrhoea (81 [18\%] of 460 patients in the experimental group and 41 [9\%] of 441 in the standard of care group) and neurological toxicity during adjuvant chemotherapy in the standard of care group (16 [9\%] of 187 patients). Serious adverse events occurred in 177 (38\%) of 460 participants in the experimental group and, in the standard of care group, in 87 (34\%) of 254 patients without adjuvant chemotherapy and in 64 (34\%) of 187 with adjuvant chemotherapy. Treatment-related deaths occurred in four participants in the experimental group (one cardiac arrest, one pulmonary embolism, two infectious complications) and in four participants in the standard of care group (one pulmonary embolism, one neutropenic sepsis, one aspiration, one suicide due to severe depression). INTERPRETATION: The observed decreased probability of disease-related treatment failure in the experimental group is probably indicative of the increased efficacy of preoperative chemotherapy as opposed to adjuvant chemotherapy in this setting. Therefore, the experimental treatment can be considered as a new standard of care in high-risk locally advanced rectal cancer. FUNDING: Dutch Cancer Foundation, Swedish Cancer Society, Spanish Ministry of Economy and Competitiveness, and Spanish Clinical Research Network.},
  langid = {english},
  pmid = {33301740},
  keywords = {Adenocarcinoma,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy; Adjuvant,Digestive System Surgical Procedures,Disease Progression,Dose Fractionation; Radiation,Europe,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Neoplasm Staging,Rectal Neoplasms,Rectal;TNT,Time Factors,Treatment Failure,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\X9YP39PC\\Bahadoer et al. - 2021 - Short-course radiotherapy followed by chemotherapy.pdf}
}

@article{baidya626,
  title = {Analgesic Efficacy and Safety of Thoracic Paravertebral and Epidural Analgesia for Thoracic Surgery: A Systematic Review and Meta-Analysis},
  shorttitle = {Analgesic Efficacy and Safety of Thoracic Paravertebral and Epidural Analgesia for Thoracic Surgery},
  author = {Baidya, Dalim Kumar and Khanna, Puneet and Maitra, Souvik},
  year = {2014},
  month = may,
  journal = {Interactive Cardiovascular and Thoracic Surgery},
  volume = {18},
  number = {5},
  pages = {626--635},
  issn = {1569-9285},
  doi = {10.1093/icvts/ivt551},
  abstract = {Though once considered the gold standard, epidural anaesthesia has complications that may be significant and include hypotension, urinary retention, partial or patchy block and, in rare cases, devastating neurological injuries also. Paravertebral block (PVB) is an alternative technique for unilateral surgical procedures like thoracotomy, which may offer similar analgesic effectiveness and a more favourable side-effect profile than epidural analgesia. This systematic review and meta-analysis of published randomized clinical trials aims to compare thoracic paravertebral with thoracic epidural analgesia (TEA) in thoracotomy for lung surgery. Five hundred and forty-one patients from 12 clinical trials have been included in this systematic review and meta-analysis. We found that visual analogue scale (VAS) scores at rest and during activity/coughing at 4-8, 24 and 48 h postoperatively were similar in both the PVB and TEA groups. Considering studies not included in the previous meta-analysis, a VAS score on activity at 48 h is significantly better in the PVB group (mean difference 0.40 cm; 95\% confidence interval [95\% CI] 0.77, 0.02; Mantel-Haenszel (M-H) fixed). Hypotension (odds ratio 0.13; 95\% CI 0.06, 0.31; M-H fixed) and urinary retention are more common in the epidural analgesia group. So, we conclude that thoracic PVB may be as effective as thoracic epidural analgesia for post-thoracotomy pain relief and is also associated with fewer complications.},
  langid = {english},
  pmid = {24488821},
  keywords = {Analgesia; Epidural,Anesthetics; Local,Chi-Square Distribution,Humans,Nerve Block,Odds Ratio,Pain Measurement,Pain; Postoperative,Post-thoracotomy pain,Risk Factors,Thoracic epidural,Thoracic paravertebral,Thoracotomy,Time Factors,Treatment Outcome}
}

@article{baijal358,
  title = {Understanding Frailty in Cancer Patients},
  author = {Baijal, Pooja and Periyakoil, Vyjeyanthi},
  year = {2014 Sep-Oct},
  journal = {Cancer Journal (Sudbury, Mass.)},
  volume = {20},
  number = {5},
  pages = {358--366},
  issn = {1540-336X},
  doi = {10.1097/PPO.0000000000000068},
  abstract = {As population ages, the number of older adults with cancer is increasing rapidly. Chronological age per se is a poor guide for an oncologist to determine tolerance to cancer treatment. Older adults have been underrepresented in cancer clinical trials, leading to paucity of guidelines to meet the treatment challenges in this population. To evaluate an older adult with cancer, oncologists must understand age-related changes and identify the subset of population who is vulnerable and at risk of cancer treatment toxicity. Comprehensive geriatric assessments focusing on functional status, multimorbidity, nutritional status, cognitive impairment, and psychosocial support help recognize heterogeneity among older adults, leading to individualized approaches toward cancer treatment. The treatment decisions need to be made in collaboration with the patient's values and preferences.},
  langid = {english},
  pmid = {25299146},
  keywords = {Aged,Aged; 80 and over,Disease Management,Frail Elderly,Frailty,Geriatric Assessment,Humans,Neoplasms,Syndrome}
}

@article{baker181,
  type = {Journal {{Article}}},
  title = {Drain Amylase Aids Detection of Anastomotic Leak after Esophagectomy},
  author = {Baker, E. H. and Hill, J. S. and Reames, M. K. and Symanowski, J. and Hurley, S. C. and Salo, J. C.},
  year = {2016},
  journal = {J Gastrointest Oncol},
  volume = {7},
  number = {2},
  pages = {181--8},
  issn = {2078-6891 (Print) 2078-6891 (Linking)},
  doi = {10.3978/j.issn.2078-6891.2015.074}
}

@article{balducci1695,
  title = {New {{Advances}} in {{Supportive Care}}: {{Chemoprotective Agents}} as {{Novel Opportunities}} in {{Geriatric Oncology}}},
  shorttitle = {New {{Advances}} in {{Supportive Care}}},
  author = {Balducci, Lodovico and Falandry, Claire and List, Alan},
  year = {2022},
  month = dec,
  journal = {Current Oncology Reports},
  volume = {24},
  number = {12},
  pages = {1695--1703},
  issn = {1534-6269},
  doi = {10.1007/s11912-022-01324-x},
  abstract = {PURPOSE OF REVIEW: To explore the effectiveness of trilaciclib and ALRN-6924 in the prevention of cancer chemotherapy-induced toxicity in older patients. New chemoprotective agents are necessary because age is the main risk factor for chemotherapy complications that account largely for the poorer outcome of cancer in the elderly. Trilaciclib and ALRN-6924 cause a reversible block of the proliferation of normal cells through cell cycle arrest (CCA). With this mechanism, they may prevent the toxicity of cycle-active cancer treatment including neutropenia, anemia, thrombocytopenia, lymphopenia, mucositis, and alopecia. RECENT FINDINGS: Myelopoietic growth factors may prevent neutropenia in the aged, but they may cause severe bone pain, may aggravate thrombocytopenia and anemia, and may cause myelodysplasia and acute leukemia as a late complication. The prevention of thrombocytopenia, anemia, mucositis, and alopecia is unsatisfactory at present. These complications may jeopardize the treatment outcome as they require a reduction of treatment dose/intensity and because many patients find the resulting symptoms intolerable. In three studies of patients with extensive disease small cell lung cancer (ES-SCLC), trilaciclib reduced the severity and duration of neutropenia and thrombocytopenia as well as the need for blood transfusions. In addition, it produced a significant expansion of T-cell clones. Trilaciclib received FDA approval for the prevention of chemotherapy-induced myelosuppression in patients with ES-SCLC. ALRN-6924 is currently studied in phase II study of ES-SCLC. In a phase IB of 38 patients, ALRN-6924 prevented myelosuppression to an extent comparable with trilaciclib. Both drugs proved as effective in patients 65 and older as they were in the younger ones. In an "ex vivo" study, ALRN-6924 protected the epithelial stem cells of hair follicles from taxanes and promised to prevent alopecia. The possibility that CCA of tumor cells may reduce the effectiveness of cycle-active chemotherapy is a major concern. For this reason, the use of trilaciclib, an inhibitor of CDK 4/6, should be limited to tumors with inactivated RB1, and the use of ALRN-6924, an inhibitor of P53, should be limited to tumors with inactivated P53. Chemotherapy-related toxicities limit dose intensity and contribute to significant morbidity and mortality in elderly cancer patients. Trilaciclib and ALRN-6924 are of particular interest to geriatric oncologists because of their novel mechanism of action. Ameliorating chemotherapy-induced toxicities holds the promise of transforming the practice of geriatric oncology by enabling chemotherapeutic regimens that are currently not feasible for this patient population. Specifically, these agents may prevent chemotherapy-induced neutropenia and thrombocytopenia, perhaps the most life-threatening complications of cytotoxic chemotherapy, thereby obviating the need for the use of rescue strategies such as hematopoietic growth factors. In addition, these agents offer the potential for broad tissue protection from other chemotherapy-related toxicities, including mucositis, diarrhea, and alopecia, which historically have been poorly managed. Importantly, by preventing a spectrum of chemotherapy-related toxicities, these agents may permit the administration of chemotherapy at full-dose intensity, prevent functional decline, and grant maintenance of resilience to older cancer patients. As a result, the successful prevention of chemotherapy-induced side effects may not only mitigate the costs of care but also improve patient outcomes and quality of life. Finally, chemoprotective strategies offer the opportunity to apply geriatric principles to clinical trials of cancer treatment. In particular, they may allow the testing of prolongation of "active life expectancy" as a major goal of clinical trials in elderly patients. They may also enable novel and more practical forms of clinical trials. By assessing the risk of chemotherapy-related toxicity with the Chemotherapy Risk Assessment Scale for High Age Patients (CRASH) or the Cancer and Aging Research Group (CARG) instruments, these agents may permit researchers to utilize patients as their own controls and endorse the approval of supportive care drugs based upon the risk profile of individual patients.},
  langid = {english},
  pmid = {35986858},
  keywords = {Aged,Alopecia,Anemia,Antineoplastic Agents,Cancer chemotherapy,CDK 4/6,Cell cycle arrest,Chemoprotection,ChemoProtective,Clinical Trials; Phase II as Topic,Elderly,Humans,Lung Neoplasms,Mucositis,Neutropenia,Novel chemoprotective agents,P53,Quality of Life,Small Cell Lung Carcinoma,Thrombocytopenia,Trilaciclib; ALRN-6924,Tumor Suppressor Protein p53}
}

@article{bang315,
  title = {Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after {{D2}} Gastrectomy ({{CLASSIC}}): A Phase 3 Open-Label, Randomised Controlled Trial},
  shorttitle = {Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after {{D2}} Gastrectomy ({{CLASSIC}})},
  author = {Bang, Yung-Jue and Kim, Young-Woo and Yang, Han-Kwang and Chung, Hyun Cheol and Park, Young-Kyu and Lee, Kyung Hee and Lee, Keun-Wook and Kim, Yong Ho and Noh, Sang-Ik and Cho, Jae Yong and Mok, Young Jae and Kim, Yeul Hong and Ji, Jiafu and Yeh, Ta-Sen and Button, Peter and Sirz{\'e}n, Florin and Noh, Sung Hoon and {CLASSIC trial investigators}},
  year = {2012},
  month = jan,
  journal = {Lancet (London, England)},
  volume = {379},
  number = {9813},
  pages = {315--321},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(11)61873-4},
  abstract = {BACKGROUND: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with stage II-IIIB gastric cancer. METHODS: The capecitabine and oxaliplatin adjuvant study in stomach cancer (CLASSIC) study was an open-label, parallel-group, phase 3, randomised controlled trial undertaken in 37 centres in South Korea, China, and Taiwan. Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only. Block randomisation was done by a central interactive computerised system, stratified by country and disease stage. Patients, and investigators giving interventions, assessing outcomes, and analysing data were not masked. The primary endpoint was 3 year disease-free survival, analysed by intention to treat. This study reports a prespecified interim efficacy analysis, after which the trial was stopped after a recommendation by the data monitoring committee. The trial is registered at ClinicalTrials.gov (NCT00411229). FINDINGS: 1035 patients were randomised (520 to receive chemotherapy and surgery, 515 surgery only). Median follow-up was 34{$\cdot$}2 months (25{$\cdot$}4-41{$\cdot$}7) in the chemotherapy and surgery group and 34{$\cdot$}3 months (25{$\cdot$}6-41{$\cdot$}9) in the surgery only group. 3 year disease-free survival was 74\% (95\% CI 69-79) in the chemotherapy and surgery group and 59\% (53-64) in the surgery only group (hazard ratio 0{$\cdot$}56, 95\% CI 0{$\cdot$}44-0{$\cdot$}72; p{$<$}0{$\cdot$}0001). Grade 3 or 4 adverse events were reported in 279 of 496 patients (56\%) in the chemotherapy and surgery group and in 30 of 478 patients (6\%) in the surgery only group. The most common adverse events in the intervention group were nausea (n=326), neutropenia (n=300), and decreased appetite (n=294). INTERPRETATION: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer. FUNDING: F Hoffmann-La Roche and Sanofi-Aventis.},
  langid = {english},
  pmid = {22226517},
  keywords = {Adenocarcinoma,Aged,Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Chemotherapy; Adjuvant,Deoxycytidine,Disease-Free Survival,Female,Fluorouracil,Gastrectomy,Humans,Male,Middle Aged,Organoplatinum Compounds,Oxaliplatin,Stomach Neoplasms,Survival Rate}
}

@article{baracos1133S,
  title = {Body Composition in Patients with Non-Small Cell Lung Cancer: A Contemporary View of Cancer Cachexia with the Use of Computed Tomography Image Analysis},
  shorttitle = {Body Composition in Patients with Non-Small Cell Lung Cancer},
  author = {Baracos, Vickie E. and Reiman, Tony and Mourtzakis, Marina and Gioulbasanis, Ioannis and Antoun, Sami},
  year = {2010},
  month = apr,
  journal = {The American Journal of Clinical Nutrition},
  volume = {91},
  number = {4},
  pages = {1133S-1137S},
  issn = {1938-3207},
  doi = {10.3945/ajcn.2010.28608C},
  abstract = {BACKGROUND: The prominent clinical feature of cachexia has traditionally been understood to be weight loss; however, in recognition of the potential for divergent behavior of muscle and adipose tissue, cachexia was recently defined as loss of muscle with or without loss of fat mass. Detailed assessments are required to verify body composition in patients with cancer cachexia. DESIGN: We adopted a population-based approach to study body composition in patients with cancer, with the use of diagnostic computed tomography images acquired for cancer diagnosis and follow-up. A prospective cohort of 441 patients with non-small cell lung cancer, who were referred consecutively to a regional medical oncology service in Alberta, Canada, was evaluated. RESULTS: At referral (median time to death: 265 d), mean body mass index (BMI; in kg/m(2)) was 24.9, with 47.4\% of patients being overweight or obese. Only 7.5\% overall were underweight as conventionally understood (BMI {$<$} 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8\% and was present in patients in all BMI categories. A much higher proportion of men (61\%) than women (31\%) met the criteria for sarcopenia. CONCLUSIONS: Wasting of skeletal muscle is a prominent feature of patients with lung cancer, despite normal or heavy body weights. The significance of muscle wasting in normal-weight, overweight, and obese patients as a nutritional risk factor, as a prognostic factor, and as a predictor of cancer treatment toxicity is discussed in this article.},
  langid = {english},
  pmid = {20164322},
  keywords = {Aged,Antineoplastic Agents,Body Composition,Body Mass Index,Body Weight,Cachexia,Carcinoma; Non-Small-Cell Lung,Female,Humans,Lung Neoplasms,Male,Middle Aged,Muscle; Skeletal,Muscular Atrophy,Prognosis,Prospective Studies,Risk Factors,Sex Factors,Tomography; X-Ray Computed}
}

@article{baracos527,
  type = {Journal {{Article}}},
  title = {Psoas as a Sentinel Muscle for Sarcopenia: A Flawed Premise},
  author = {Baracos, V. E.},
  year = {2017},
  journal = {J Cachexia Sarcopenia Muscle},
  volume = {8},
  number = {4},
  pages = {527--528},
  issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
  doi = {10.1002/jcsm.12221},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ISMMY3L7\\Baracos_2017_Psoas as a sentinel muscle for sarcopenia.pdf}
}

@article{baranov131,
  title = {Outcomes of Curative Esophageal Cancer Surgery in Elderly: {{A}} Meta-Analysis},
  shorttitle = {Outcomes of Curative Esophageal Cancer Surgery in Elderly},
  author = {Baranov, Nikolaj S. and Slootmans, Cettela and {van Workum}, Frans and Klarenbeek, Bastiaan R. and Schoon, Yvonne and Rosman, Camiel},
  year = {2021},
  month = feb,
  journal = {World Journal of Gastrointestinal Oncology},
  volume = {13},
  number = {2},
  pages = {131--146},
  issn = {1948-5204},
  doi = {10.4251/wjgo.v13.i2.131},
  abstract = {BACKGROUND: An increasing number of older patients is undergoing curative, surgical treatment of esophageal cancer. Previous meta-analyses have shown that older patients suffered from more postoperative morbidity and mortality compared to younger patients, which may lead to patient selection based on age. However, only studies including patients that underwent open esophagectomy were included. Therefore, it remains unknown whether there is an association between age and outcome in patients undergoing minimally invasive esophagectomy. AIM: To perform a systematic review on age and postoperative outcome in esophageal cancer patients undergoing esophagectomy. METHODS: Studies comparing older with younger patients with primary esophageal cancer undergoing curative esophagectomy were included. Meta-analysis of studies using a 75-year age threshold are presented in the manuscript, studies using other age thresholds in the Supplementary material. MEDLINE, Embase and the Cochrane Library were searched for articles published between 1995 and 2020. Risk of bias was assessed with the Newcastle-Ottawa Scale. Primary outcomes were anastomotic leak, pulmonary and cardiac complications, delirium, 30- and 90-d, and in-hospital mortality. Secondary outcomes included pneumonia and 5-year overall survival. RESULTS: Seven studies (4847 patients) using an age threshold of 75 years were included for meta-analysis with 755 older and 4092 younger patients. Older patients (9.05\%) had higher rates of 90-d mortality compared with younger patients (3.92\%), (confidence interval = 1.10-5.56). In addition, older patients (9.45\%) had higher rates of in-hospital mortality compared with younger patients (3.68\%), (confidence interval = 1.01-5.91). In the subgroup of 2 studies with minimally invasive esophagectomy, older and younger patients had comparable 30-d, 90-d and in-hospital mortality rates. CONCLUSION: Older patients undergoing curative esophagectomy for esophageal cancer have a higher postoperative mortality risk. Minimally invasive esophagectomy may be important for minimizing mortality in older patients.},
  langid = {english},
  pmcid = {PMC7896422},
  pmid = {33643529},
  keywords = {Age,Clinical outcome,Elderly,Esophageal cancer,Minimally invasive esophagectomy,Open esophagectomy,Perioperative mortality},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\72I2KLDH\\Baranov et al_2021_Outcomes of curative esophageal cancer surgery in elderly.pdf}
}

@article{barnard1686,
  title = {Machine {{Learning}} for {{Automatic Paraspinous Muscle Area}} and {{Attenuation Measures}} on {{Low-Dose Chest CT Scans}}},
  author = {Barnard, Ryan and Tan, Josh and Roller, Brandon and Chiles, Caroline and Weaver, Ashley A. and Boutin, Robert D. and Kritchevsky, Stephen B. and Lenchik, Leon},
  year = {2019},
  month = dec,
  journal = {Academic Radiology},
  volume = {26},
  number = {12},
  pages = {1686--1694},
  issn = {1878-4046},
  doi = {10.1016/j.acra.2019.06.017},
  abstract = {RATIONALE AND OBJECTIVES: To develop and evaluate an automated machine learning (ML) algorithm for segmenting the paraspinous muscles on chest computed tomography (CT) scans to evaluate for presence of sarcopenia. MATERIALS AND METHODS: A convolutional neural network based on the U-Net architecture was trained to perform muscle segmentation on a dataset of 1875 single slice CT images and was tested on 209 CT images of participants in the National Lung Screening Trial. Low-dose, noncontrast CT examinations were obtained at 33 clinical sites, using scanners from four manufacturers. The study participants had a mean age of 71.6 years (range, 70-74 years). Ground truth was obtained by manually segmenting the left paraspinous muscle at the level of the T12 vertebra. Muscle cross-sectional area (CSA) and muscle attenuation (MA) were recorded. Comparison between the ML algorithm and ground truth measures of muscle CSA and MA were obtained using Dice similarity coefficients and Pearson correlations. RESULTS: Compared to ground truth segmentation, the ML algorithm achieved median (standard deviation) Dice scores of 0.94 (0.04) in the test set. Mean (SD) muscle CSA was 14.3 (3.6) cm2 for ground truth and 13.7 (3.5) cm2 for ML segmentation. Mean (SD) MA was 41.6 (7.6) Hounsfield units (HU) for ground truth and 43.5 (7.9) HU for ML segmentation. There was high correlation between ML algorithm and ground truth for muscle CSA (r2\,=\,0.86; p {$<$} 0.0001) and MA (r2\,=\,0.95; p {$<$} 0.0001). CONCLUSION: The ML algorithm for measurement of paraspinous muscles compared favorably to manual ground truth measurements in the NLST. The algorithm generalized well to a heterogeneous set of low-dose CT images and may be capable of automated quantification of muscle metrics to screen for sarcopenia on routine chest CT examinations.},
  langid = {english},
  pmcid = {PMC6878160},
  pmid = {31326311},
  keywords = {Aged,Algorithms,chest,Chest CT,Female,Humans,Machine learning,Machine Learning,Male,Middle Aged,ML,Muscle,Myosteatosis,Paraspinal Muscles,Radiation Dosage,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BI4NH6UT\\Barnard et al_2019_Machine Learning for Automatic Paraspinous Muscle Area and Attenuation Measures.pdf}
}

@article{barret583,
  title = {Sarcopenia Is Linked to Treatment Toxicity in Patients with Metastatic Colorectal Cancer},
  author = {Barret, Maximilien and Antoun, Sami and Dalban, C{\'e}cile and Malka, David and Mansourbakht, Touraj and Zaanan, Aziz and Latko, Ewa and Taieb, Julien},
  year = {2014},
  journal = {Nutrition and Cancer},
  volume = {66},
  number = {4},
  pages = {583--589},
  issn = {1532-7914},
  doi = {10.1080/01635581.2014.894103},
  abstract = {Chemotherapy toxicity could be linked to decreased skeletal muscle (sarcopenia). We evaluated the effect of sarcopenia on chemotherapy toxicity among metastatic colorectal cancer (mCRC) patients. All consecutive mCRC patients in 3 hospitals were enrolled in this prospective, cross-sectional, multicenter study. Several nutritional indexes and scores were generated. Computed tomography (CT) images were analyzed to evaluate cross-sectional areas of muscle tissue (MT), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT). Toxicities were evaluated in the 2 mo following clinical evaluation. Fifty-one mCRC patients were included in the study. Sarcopenia was observed in 71\% of patients (39\% of women and 82\% of men) whereas only 4\% and 18\% were considered as underweight using body mass index (BMI) or severely malnourished using the Nutritional Risk Index (NRI), respectively. Grade 3-4 toxicities were observed in 28\% of patients. In multivariate analysis including age, sex, BMI, sarcopenia, SAT, and VAT, the only factor associated with Grade 3-4 toxicities was sarcopenia (odds ratio = 13.55; 95\% confidence interval [1.08; 169.31], P = 0.043). In mCRC patients undergoing chemotherapy, sarcopenia was much more frequently observed than visible malnutrition. Despite the small number of patients included in our study, we found sarcopenia to be significantly associated with severe chemotherapy toxicity.},
  langid = {english},
  pmid = {24707897},
  keywords = {Body Composition,Colorectal Neoplasms,crc,Sarcopenia}
}

@article{basch557,
  type = {Journal {{Article}}},
  title = {Symptom {{Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment}}: {{A Randomized Controlled Trial}}},
  author = {Basch, E. and Deal, A. M. and Kris, M. G. and Scher, H. I. and Hudis, C. A. and Sabbatini, P. and Rogak, L. and Bennett, A. V. and Dueck, A. C. and Atkinson, T. M. and Chou, J. F. and Dulko, D. and Sit, L. and Barz, A. and Novotny, P. and Fruscione, M. and Sloan, J. A. and Schrag, D.},
  year = {2016},
  journal = {J Clin Oncol},
  volume = {34},
  number = {6},
  pages = {557--65},
  issn = {1527-7755 (Electronic) 0732-183X (Linking)},
  doi = {10.1200/JCO.2015.63.0830}
}

@article{bastit1611,
  title = {Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alpha Administered Every 3 Weeks with or without Intravenous Iron in Patients with Chemotherapy-Induced Anemia},
  author = {Bastit, Laurent and Vandebroek, An and Altintas, Sevilay and Gaede, Bernd and Pint{\'e}r, Tam{\'a}s and Suto, Tamas S. and Mossman, Tony W. and Smith, Kay E. and Vansteenkiste, Johan F.},
  year = {2008},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {26},
  number = {10},
  pages = {1611--1618},
  issn = {1527-7755},
  doi = {10.1200/JCO.2006.10.4620},
  abstract = {PURPOSE: The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard practice (oral iron or no iron). PATIENTS AND METHODS: In this multicenter, randomized, open-label, phase III study, 396 patients with nonmyeloid malignancies and hemoglobin (Hb) less than 11 g/dL received darbepoetin alpha 500 microg with (n = 200) or without (n = 196) IV iron once every 3 weeks (Q3W) for 16 weeks. RESULTS: The hematopoietic response rate (proportion of patients achieving Hb {$>$}or= 12 g/dL or Hb increase of {$>$}or= 2 g/dL from baseline) was significantly higher in the IV iron group: 86\% versus 73\% in the standard practice group (difference of 13\% [95\% CI, 3\% to 23\%]; P = .011). Fewer RBC transfusions (week 5 to the end of the treatment period) occurred in the IV iron group: 9\% versus 20\% in the standard practice group (difference of -11\% [95\% CI, -18\% to -3\%]; P = .005). Both treatments were well tolerated with no notable differences in adverse events. Serious adverse events related to iron occurred in 3\% of patients in the IV iron group and were mostly gastrointestinal in nature. CONCLUSION: Addition of IV iron to darbepoetin alpha Q3W in patients with chemotherapy-induced anemia was well tolerated, resulting in an improved hematopoietic response rate and lower incidence of transfusions compared with darbepoetin alpha alone.},
  langid = {english},
  pmid = {18375890},
  keywords = {Anemia,Antineoplastic Agents,Cancer,Darbepoetin alfa,Drug Therapy; Combination,Erythropoietin,Female,Hematinics,Humans,Infusions; Intravenous,Iron,Male,Middle Aged,Neoplasms,Treatment Outcome}
}

@article{bausys2096,
  title = {The {{Role}} of {{Prehabilitation}} in {{Modern Esophagogastric Cancer Surgery}}: {{A Comprehensive Review}}},
  shorttitle = {The {{Role}} of {{Prehabilitation}} in {{Modern Esophagogastric Cancer Surgery}}},
  author = {Bausys, Augustinas and Mazeikaite, Morta and Bickaite, Klaudija and Bausys, Bernardas and Bausys, Rimantas and Strupas, Kestutis},
  year = {2022},
  month = apr,
  journal = {Cancers},
  volume = {14},
  number = {9},
  pages = {2096},
  issn = {2072-6694},
  doi = {10.3390/cancers14092096},
  abstract = {Esophagogastric cancer is among the most common malignancies worldwide. Surgery with or without neoadjuvant therapy is the only potentially curative treatment option. Although esophagogastric resections remain associated with major surgical trauma and significant postoperative morbidity. Prehabilitation has emerged as a novel strategy to improve clinical outcomes by optimizing physical and psychological status before major surgery through exercise and nutritional and psychological interventions. Current prehabilitation programs may be unimodal, including only one intervention, or multimodal, combining the benefits of different types of interventions. However, it still is an investigational treatment option mostly limited to clinical trials. In this comprehensive review, we summarize the current evidence for the role of prehabilitation in modern esophagogastric cancer surgery. The available studies are very heterogeneous in design, type of interventions, and measured outcomes. Yet, all of them confirm at least some positive effects of prehabilitation in terms of improved physical performance, nutritional status, quality of life, or even reduced postoperative morbidity. However, the optimal interventions for prehabilitation remain unclear; thus, they cannot be standardized and widely adopted. Future studies on multimodal prehabilitation are necessary to develop optimal programs for patients with esophagogastric cancer.},
  langid = {english},
  pmcid = {PMC9102916},
  pmid = {35565226},
  keywords = {esophageal cancer,esophagectomy,exercise,gastrectomy,gastric cancer,prehabilitation},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2G6QAEGI\\Bausys et al_2022_The Role of Prehabilitation in Modern Esophagogastric Cancer Surgery.pdf}
}

@article{becher,
  title = {The {{Incidence}} and {{Cumulative Risk}} of {{Major Surgery}} in {{Older Persons}} in the {{United States}}},
  author = {Becher, Robert D. and Wyk, Brent Vander and {Leo-Summers}, Linda and Desai, Mayur M. and Gill, Thomas M.},
  year = {2021},
  month = jul,
  journal = {Annals of Surgery},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000005077},
  abstract = {OBJECTIVE: The objective of this study was to estimate the incidence and cumulative risk of major surgery in older persons over a 5-year period and evaluate how these estimates differ according to key demographic and geriatric characteristics. BACKGROUND: As the population of the United States ages, there is considerable interest in ensuring safe, high-quality surgical care for older persons. Yet, valid, generalizable data on the occurrence of major surgery in the geriatric population are sparse. METHODS: We evaluated data from a prospective longitudinal study of 5,571 community-living fee-for-service Medicare beneficiaries, aged 65 or older, from the National Health and Aging Trends Study (NHATS) from 2011 to 2016. Major surgeries were identified through linkages with Centers for Medicare \& Medicaid Services data. Population-based incidence and cumulative risk estimates incorporated NHATS analytic sampling weights and cluster and strata variables. RESULTS: The nationally-representative incidence of major surgery per 100 person-years was 8.8, with estimates of 5.2 and 3.7 for elective and non-elective surgeries. The adjusted incidence of major surgery peaked at 10.8 in persons 75-79{$\mkern1mu$}years, increased from 6.6 in the non-frail group to 10.3 in the frail group, and was similar by sex and dementia. The 5-year cumulative risk of major surgery was 13.8\%, representing nearly 5 million unique older persons, including 12.1\% in persons 85-89{$\mkern1mu$}years, 9.1\% in those {$\geq$}90{$\mkern1mu$}years, 12.1\% in those with frailty, and 12.4\% in those with probable dementia. CONCLUSIONS: Major surgery is a common event in the lives of community-living older persons, including high-risk vulnerable subgroups.},
  langid = {english},
  pmcid = {PMC8758792},
  pmid = {34261884},
  keywords = {Geriatric},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AQ93UPIG\\Becher et al_2021_The Incidence and Cumulative Risk of Major Surgery in Older Persons in the.pdf}
}

@article{bedenne1160,
  title = {Chemoradiation Followed by Surgery Compared with Chemoradiation Alone in Squamous Cancer of the Esophagus: {{FFCD}} 9102},
  shorttitle = {Chemoradiation Followed by Surgery Compared with Chemoradiation Alone in Squamous Cancer of the Esophagus},
  author = {Bedenne, Laurent and Michel, Pierre and Bouch{\'e}, Olivier and Milan, Chantal and Mariette, Christophe and Conroy, Thierry and Pezet, Denis and Roullet, Bernard and Seitz, Jean-Fran{\c c}ois and Herr, Jean-Philippe and Paillot, Bernard and Arveux, Patrick and Bonnetain, Franck and Binquet, Christine},
  year = {2007},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {25},
  number = {10},
  pages = {1160--1168},
  issn = {1527-7755},
  doi = {10.1200/JCO.2005.04.7118},
  abstract = {PURPOSE: Uncontrolled studies suggest that chemoradiation has similar efficacy as surgery for esophageal cancer. Therefore, a randomized trial was carried out to compare, in responders only, chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors. PATIENTS AND METHODS: Eligible patients had operable T3N0-1M0 thoracic esophageal cancer. Patients received two cycles of fluorouracil (FU) and cisplatin (days 1 to 5 and 22 to 26) and either conventional (46 Gy in 4.5 weeks) or split-course (15 Gy, days 1 to 5 and 22 to 26) concomitant radiotherapy. Patients with response and no contraindication to either treatment were randomly assigned to surgery (arm A) or continuation of chemoradiation (arm B; three cycles of FU/cisplatin and either conventional [20 Gy] or split-course [15 Gy] radiotherapy). Chemoradiation was considered equivalent to surgery if the difference in 2-year survival rate was less than 10\%. RESULTS: Of 444 eligible patients, 259 were randomly assigned; 230 patients (88.8\%) had epidermoid cancer, and 29 (11.2\%) had glandular carcinoma. Two-year survival rate was 34\% in arm A versus 40\% in arm B (hazard ratio for arm B v arm A = 0.90; adjusted P = .44). Median survival time was 17.7 months in arm A compared with 19.3 months in arm B. Two-year local control rate was 66.4\% in arm A compared with 57.0\% in arm B, and stents were less required in the surgery arm (5\% in arm A v 32\% in arm B; P {$<$} .001). The 3-month mortality rate was 9.3\% in arm A compared with 0.8\% in arm B (P = .002). Cumulative hospital stay was 68 days in arm A compared with 52 days in arm B (P = .02). CONCLUSION: Our data suggest that, in patients with locally advanced thoracic esophageal cancers, especially epidermoid, who respond to chemoradiation, there is no benefit for the addition of surgery after chemoradiation compared with the continuation of additional chemoradiation.},
  langid = {english},
  pmid = {17401004},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Combined Modality Therapy,Esophageal Neoplasms,Female,Humans,Length of Stay,Male,Middle Aged,Positron-Emission Tomography,Quality of Life,Radiotherapy,Radiotherapy Dosage},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4U2Z558T\\Bedenne et al. - 2007 - Chemoradiation followed by surgery compared with c.pdf}
}

@article{belharbi95,
  title = {Spotting {{L3}} Slice in {{CT}} Scans Using Deep Convolutional Network and Transfer Learning},
  author = {Belharbi, Soufiane and Chatelain, Cl{\'e}ment and H{\'e}rault, Romain and Adam, S{\'e}bastien and Thureau, S{\'e}bastien and Chastan, Mathieu and Modzelewski, Romain},
  year = {2017},
  month = aug,
  journal = {Computers in Biology and Medicine},
  volume = {87},
  pages = {95--103},
  issn = {1879-0534},
  doi = {10.1016/j.compbiomed.2017.05.018},
  abstract = {In this article, we present a complete automated system for spotting a particular slice in a complete 3D Computed Tomography exam (CT scan). Our approach does not require any assumptions on which part of the patient's body is covered by the scan. It relies on an original machine learning regression approach. Our models are learned using the transfer learning trick by exploiting deep architectures that have been pre-trained on imageNet database, and therefore it requires very little annotation for its training. The whole pipeline consists of three steps: i) conversion of the CT scans into Maximum Intensity Projection (MIP) images, ii) prediction from a Convolutional Neural Network (CNN) applied in a sliding window fashion over the MIP image, and iii) robust analysis of the prediction sequence to predict the height of the desired slice within the whole CT scan. Our approach is applied to the detection of the third lumbar vertebra (L3) slice that has been found to be representative to the whole body composition. Our system is evaluated on a database collected in our clinical center, containing 642 CT scans from different patients. We obtained an average localization error of 1.91{$\pm$}2.69 slices (less than 5~mm) in an average time of less than 2.5~s/CT scan, allowing integration of the proposed system into daily clinical routines.},
  langid = {english},
  pmid = {28558319},
  keywords = {Convolutional neural networks,Deep learning,Humans,Lumbar Vertebrae,Machine Learning,Maximum intensity projection,ML,Neural Networks; Computer,Radiology Information Systems,Sarcopenia,Slice detection,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KQYPEFNC\\Belharbi et al. - 2017 - Spotting L3 slice in CT scans using deep convoluti.pdf}
}

@article{bellieni243,
  title = {Different {{Impact}} of {{Definitions}} of {{Sarcopenia}} in {{Defining Frailty Status}} in a {{Population}} of {{Older Women}} with {{Early Breast Cancer}}},
  author = {Bellieni, Andrea and Fusco, Domenico and Sanchez, Alejandro Martin and Franceschini, Gianluca and Di Capua, Beatrice and Allocca, Elena and Di Stasio, Enrico and Marazzi, Fabio and Tagliaferri, Luca and Masetti, Riccardo and Bernabei, Roberto and Colloca, Giuseppe Ferdinando},
  year = {2021},
  month = mar,
  journal = {Journal of Personalized Medicine},
  volume = {11},
  number = {4},
  pages = {243},
  issn = {2075-4426},
  doi = {10.3390/jpm11040243},
  abstract = {Sarcopenia is a geriatric syndrome characterized by losses of quantity and quality of skeletal muscle, which is associated with negative outcomes in older adults and in cancer patients. Different definitions of sarcopenia have been used, with quantitative data more frequently used in oncology, while functional measures have been advocated in the geriatric literature. Little is known about the correlation between frailty status as assessed by comprehensive geriatric assessment (CGA) and sarcopenia in cancer patients. We retrospectively analyzed data from 96 older women with early breast cancer who underwent CGAs and Dual X-ray Absorptiometry (DXA) scans for muscle mass assessment before cancer treatment at a single cancer center from 2016 to 2019 to explore the correlation between frailty status as assessed by CGA and sarcopenia using different definitions. Based on the results of the CGA, 35 patients (36.5\%) were defined as frail. Using DXA Appendicular Skeletal Mass (ASM) or the Skeletal Muscle Index (SMI=ASM/height\^2), 41 patients were found to be sarcopenic (42.7\%), with no significant difference in prevalence between frail and nonfrail subjects. Using the European Working Group on Sarcopenia in Older People (EWGSOP2) definition of sarcopenia (where both muscle function and mass are required), 58 patients were classified as "probably" sarcopenic; among these, 25 were sarcopenic and 17 "severely" sarcopenic. Only 13 patients satisfied both the requirements for being defined as sarcopenic and frail. Grade 3-4 treatment-related toxicities (according to Common Terminology Criteria for Adverse Events) were more common in sarcopenic and frail sarcopenic patients. Our data support the use of a definition of sarcopenia that includes both quantitative and functional data in order to identify frail patients who need tailored treatment.},
  langid = {english},
  pmcid = {PMC8066315},
  pmid = {33810556},
  keywords = {Cancer; CGA,frailty,older cancer patients,physical performance,sarcopenia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WIFIRXIP\\Bellieni et al_2021_Different Impact of Definitions of Sarcopenia in Defining Frailty Status in a.pdf}
}

@article{ben-david1748,
  type = {Journal {{Article}}},
  title = {Prospective {{Comprehensive Swallowing Evaluation}} of {{Minimally Invasive Esophagectomies}} with {{Cervical Anastomosis}}: {{Silent Versus Vocal Aspiration}}},
  author = {{Ben-David}, K. and Fullerton, A. and Rossidis, G. and Michel, M. and Thomas, R. and Sarosi, G. and White, J. and Giordano, C. and Hochwald, S.},
  year = {2015},
  journal = {J Gastrointest Surg},
  volume = {19},
  number = {10},
  pages = {1748--52},
  issn = {1873-4626 (Electronic) 1091-255X (Linking)},
  doi = {10.1007/s11605-015-2889-x}
}

@article{bennettCD007334,
  title = {Surgery versus Radical Endotherapies for Early Cancer and High-Grade Dysplasia in {{Barrett}}'s Oesophagus},
  author = {Bennett, Cathy and Green, Susi and DeCaestecker, John and Almond, Max and Barr, Hugh and Bhandari, Pradeep and Ragunath, Krish and Singh, Rajvinder and Jankowski, Janusz},
  year = {2020},
  month = may,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {5},
  pages = {CD007334},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD007334.pub5},
  abstract = {BACKGROUND: Barrett's oesophagus is one of the most common pre-malignant lesions in the world. Currently the mainstay of therapy is surgical management of advanced cancer but this has improved the five-year survival very little since the 1980s. As a consequence, improved survival relies on early detection through endoscopic surveillance programmes. Success of this strategy relies on the fact that late-stage pre-malignant lesions or very early cancers can be cured by intervention. Currently there is considerable controversy over which method is best: that is conventional open surgery or endotherapy (techniques involving endoscopy). OBJECTIVES: We used data from randomised controlled trials (RCTs) to examine the effectiveness of endotherapies compared with surgery in people with Barrett's oesophagus, those with early neoplasias (defined as high-grade dysplasia (HGD) and those with early cancer (defined as carcinoma in-situ, superficially invasive, early cancer or superficial cancer T-1m (T1-a) and T-1sm (T1-b)). SEARCH METHODS: We used the Cochrane highly sensitive search strategy to identify RCTs in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, EBMR, Controlled Trials mRCT and ISRCTN, and LILACS, in July and August 2008. The searches were updated in 2009 and again in April 2012. SELECTION CRITERIA: Types of studies: RCTs comparing endotherapies with surgery in the treatment of high-grade dysplasia or early cancer. All cellular types of cancer were included (i.e. adenocarcinomas, squamous cell carcinomas and more unusual types) but will be discussed separately. TYPES OF PARTICIPANTS: patients of any age and either gender with a histologically confirmed diagnosis of early neoplasia (HGD and early cancer) in Barrett's or squamous lined oesophagus. Types of interventions; endotherapies (the intervention) compared with surgery (the control), all with curative intent. DATA COLLECTION AND ANALYSIS: Reports of studies that meet the inclusion criteria for this review would have been analysed using the methods detailed in Appendix 9. MAIN RESULTS: We did not identify any studies that met the inclusion criteria. In total we excluded 13 studies that were not RCTs but that compared surgery and endotherapies. AUTHORS' CONCLUSIONS: This Cochrane review has indicated that there are no RCTs to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. The problems with such randomised methods are standardising surgery and endotherapies in all sites, standardising histopathology in all centres, assessing which patients are fit or unfit for surgery and making sure there are relevant outcomes for the study (i.e. long-term survival (over five or more years)) and no progression of HGD.},
  langid = {english},
  pmcid = {PMC7390331},
  pmid = {32442322},
  keywords = {Barrett Esophagus,Esophageal Neoplasms,Esophagoscopy,Humans,Precancerous Conditions}
}

@article{bergamin766,
  title = {Liberal {{Versus Restrictive Transfusion Strategy}} in {{Critically Ill Oncologic Patients}}: {{The Transfusion Requirements}} in {{Critically Ill Oncologic Patients Randomized Controlled Trial}}},
  shorttitle = {Liberal {{Versus Restrictive Transfusion Strategy}} in {{Critically Ill Oncologic Patients}}},
  author = {Bergamin, Fabricio S. and Almeida, Juliano P. and Landoni, Giovanni and Galas, Filomena R. B. G. and Fukushima, Julia T. and Fominskiy, Evgeny and Park, Clarice H. L. and Osawa, Eduardo A. and Diz, Maria P. E. and Oliveira, Gisele Q. and Franco, Rafael A. and Nakamura, Rosana E. and Almeida, Elisangela M. and Abdala, Edson and Freire, Maristela P. and Filho, Roberto K. and Auler, Jose Otavio C. and Hajjar, Ludhmila A.},
  year = {2017},
  month = may,
  journal = {Critical Care Medicine},
  volume = {45},
  number = {5},
  pages = {766--773},
  issn = {1530-0293},
  doi = {10.1097/CCM.0000000000002283},
  abstract = {OBJECTIVE: To assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when compared with a liberal strategy in cancer patients with septic shock. DESIGN: Single center, randomized, double-blind controlled trial. SETTING: Teaching hospital. PATIENTS: Adult cancer patients with septic shock in the first 6 hours of ICU admission. INTERVENTIONS: Patients were randomized to the liberal (hemoglobin threshold, {$<$} 9\,g/dL) or to the restrictive strategy (hemoglobin threshold, {$<$} 7\,g/dL) of RBC transfusion during ICU stay. MEASUREMENTS AND MAIN RESULTS: Patients were randomized to the liberal (n = 149) or to the restrictive transfusion strategy (n = 151) group. Patients in the liberal group received more RBC units than patients in the restrictive group (1 [0-3] vs 0 [0-2] unit; p {$<$} 0.001). At 28 days after randomization, mortality rate in the liberal group (primary endpoint of the study) was 45\% (67 patients) versus 56\% (84 patients) in the restrictive group (hazard ratio, 0.74; 95\% CI, 0.53-1.04; p = 0.08) with no differences in ICU and hospital length of stay. At 90 days after randomization, mortality rate in the liberal group was lower (59\% vs 70\%) than in the restrictive group (hazard ratio, 0.72; 95\% CI, 0.53-0.97; p = 0.03). CONCLUSIONS: We observed a survival trend favoring a liberal transfusion strategy in patients with septic shock when compared with the restrictive strategy. These results went in the opposite direction of the a priori hypothesis and of other trials in the field and need to be confirmed.},
  langid = {english},
  pmid = {28240687},
  keywords = {Aged,Blood,Critical Care,Critical Illness,Double-Blind Method,Erythrocyte Transfusion,Female,Hospitals; University,Humans,Intensive Care Units,Length of Stay,Middle Aged,Neoplasms,Proportional Hazards Models,Severity of Illness Index,Shock; Septic,Time Factors}
}

@article{bergeron765,
  title = {Endoscopic Ultrasound Is Inadequate to Determine Which {{T1}}/{{T2}} Esophageal Tumors Are Candidates for Endoluminal Therapies},
  author = {Bergeron, Edward J. and Lin, Jules and Chang, Andrew C. and Orringer, Mark B. and Reddy, Rishindra M.},
  year = {2014},
  month = feb,
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  volume = {147},
  number = {2},
  pages = {765-771: Discussion 771-773},
  issn = {1097-685X},
  doi = {10.1016/j.jtcvs.2013.10.003},
  abstract = {OBJECTIVES: Esophageal endoscopic ultrasound is now regarded as essential in the staging of esophageal carcinoma. There is an increasing trend toward endoluminal therapies (ie, endoscopic mucosal resection and radiofrequency ablation) for pre-cancer or early-stage cancers because of concerns of high morbidity associated with esophagectomy. This study reviews our institutional experience with preoperative endoscopic ultrasound staging of early esophageal cancers in patients who underwent an esophagectomy to evaluate the accuracy of staging by endoscopic ultrasound and how this affects treatment recommendations. METHODS: A prospective esophagectomy database of all patients undergoing an esophagectomy for esophageal cancer at a single high-volume institution was retrospectively reviewed for patients with early-stage esophageal cancer. This study analyzed patients with clinical Tis to T1 disease, as predicted by preoperative endoscopic ultrasound, and correlated this with the pathologic stages after esophagectomy. The surgical outcomes were evaluated to assess the safety of esophagectomy as a treatment modality. RESULTS: From 2005 to 2011, 107 patients (93 male, 14 female) with a mean age of 66 years (range, 39-91 years) were staged by preoperative endoscopic ultrasound to have esophageal high-grade dysplasia, carcinoma in situ, or T1 cancer and underwent an esophagectomy. Tumor depth was correctly staged by endoscopic ultrasound in only 39\% (23/59) of pT1a tumors (invading into the lamina propria or muscularis mucosa) and 51\% (18/35) of pT1b tumors (submucosal). Of the endoscopic ultrasound-staged cT1a-lpN0 lesions, there were positive lymph nodes in 15\% of pathologic specimens (2/13). Patients with pT1a-mm lesions had a 9\% rate of pathologic lymph node involvement (1/11), and those with pT1b tumors had a 17\% rate of lymph node spread (6/35). Esophagectomy was performed in all 107 patients with a 30-day mortality rate of less than 1\% (1/107). CONCLUSIONS: The sensitivity and specificity of endoscopic ultrasound for determining true pathologic staging are poor for early-stage esophageal cancers. Lesions thought to be cT1a-lpN0 by endoscopic ultrasound have at least pN1 disease in 15\% of cases. Endoluminal therapy of these lesions based on endoscopic ultrasound undertreats a significant number of patients. Esophagectomy is still the standard therapy for early-stage esophageal cancers in the majority of patients.},
  langid = {english},
  pmid = {24314788},
  keywords = {7,8.1,8.4,8.7,Adult,Aged,Aged; 80 and over,Barrettâs esophagus,BE,Carcinoma,Catheter Ablation,Decision Support Techniques,EAC,EMR,endomucosal resection,endoscopic ultrasound,Endosonography,esophageal adenocarcinoma,Esophageal Neoplasms,Esophagectomy,EUS,Female,Hospital Mortality,Hospitals; High-Volume,Humans,Lymphatic Metastasis,Male,Michigan,Middle Aged,negative predictive value,Neoplasm Invasiveness,Neoplasm Staging,NPV,Patient Selection,PDT,PET,photodynamic therapy,positive predictive value,positron emission tomography,Postoperative Complications,PPV,Predictive Value of Tests,radiofrequency ablation,Retrospective Studies,RFA,Risk Factors,THE,Time Factors,transhiatal esophagectomy,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZK6NMRZU\\Bergeron et al. - 2014 - Endoscopic ultrasound is inadequate to determine w.pdf}
}

@article{bergese107,
  type = {Journal {{Article}}},
  title = {Efficacy Profile of Liposome Bupivacaine, a Novel Formulation of Bupivacaine for Postsurgical Analgesia},
  author = {Bergese, S. D. and Ramamoorthy, S. and Patou, G. and Bramlett, K. and Gorfine, S. R. and Candiotti, K. A.},
  year = {2012},
  journal = {J Pain Res},
  volume = {5},
  pages = {107--16},
  issn = {1178-7090 (Electronic) 1178-7090 (Linking)},
  doi = {10.2147/JPR.S30861}
}

@article{bergman635,
  type = {Journal {{Article}}},
  title = {The {{EORTC QLQ-LC13}}: A Modular Supplement to the {{EORTC Core Quality}} of {{Life Questionnaire}} ({{QLQ-C30}}) for Use in Lung Cancer Clinical Trials. {{EORTC Study Group}} on {{Quality}} of {{Life}}},
  author = {Bergman, B. and Aaronson, N. K. and Ahmedzai, S. and Kaasa, S. and Sullivan, M.},
  year = {1994},
  journal = {Eur J Cancer},
  volume = {30A},
  number = {5},
  pages = {635--42},
  issn = {0959-8049 (Print) 0959-8049 (Linking)}
}

@article{berkelmans41,
  title = {Direct {{Oral Feeding Following Minimally Invasive Esophagectomy}} ({{NUTRIENT II}} Trial): {{An International}}, {{Multicenter}}, {{Open-label Randomized Controlled Trial}}},
  shorttitle = {Direct {{Oral Feeding Following Minimally Invasive Esophagectomy}} ({{NUTRIENT II}} Trial)},
  author = {Berkelmans, Gijs H. K. and Fransen, Laura F. C. and {Dolmans-Zwartjes}, Annemarie C. P. and Kouwenhoven, Ewout A. and {van Det}, Marc J. and Nilsson, Magnus and Nieuwenhuijzen, Grard A. P. and Luyer, Misha D. P.},
  year = {2020},
  month = jan,
  journal = {Annals of Surgery},
  volume = {271},
  number = {1},
  pages = {41--47},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000003278},
  abstract = {OBJECTIVE: Patients undergoing an esophagectomy are often kept nil-by-mouth postoperatively out of fear for increasing anastomotic leakage and pulmonary complications. This study investigates the effect of direct start of oral feeding following minimally invasive esophagectomy (MIE) compared with standard of care. BACKGROUND: Elements of enhanced recovery after surgery (ERAS) protocols have been successfully introduced in patients undergoing an esophagectomy. However, start of oral intake, which is an essential part of the ERAS protocols, remains a matter of debate. METHODS: Patients in this multicenter, international randomized controlled trial were randomized to directly start oral feeding (intervention) after a MIE with intrathoracic anastomosis or to receive nil-by-mouth and tube feeding for 5 days postoperative (control group). Primary outcome was time to functional recovery. Secondary outcome parameters included anastomotic leakage, pneumonia rate, and other surgical complications scored by predefined definitions. RESULTS: Baseline characteristics were similar in the intervention (n = 65) and control (n = 67) group. Functional recovery was 7 days for patients receiving direct oral feeding compared with 8 days in the control group (P = 0.436). Anastomotic leakage rate did not differ in the intervention (18.5\%) and control group (16.4\%, P = 0.757). Pneumonia rates were comparable between the intervention (24.6\%) and control group (34.3\%, P = 0.221). Other morbidity rates were similar, except for chyle leakage, which was more prevalent in the standard of care group (P = 0.032). CONCLUSION: Direct oral feeding after an esophagectomy does not affect functional recovery and did not increase incidence or severity of postoperative complications.},
  langid = {english},
  pmid = {31090563},
  keywords = {Aged,Anastomotic Leak,Enteral Nutrition,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Minimally Invasive Surgical Procedures,Postoperative Care,Prospective Studies,Quality of Life,Recovery of Function,Treatment Outcome}
}

@article{bernard1535,
  title = {Inclusion {{Across}} the {{Lifespan}}: {{NIH Policy}} for {{Clinical Research}}},
  shorttitle = {Inclusion {{Across}} the {{Lifespan}}},
  author = {Bernard, Marie A. and Clayton, Janine A. and Lauer, Michael S.},
  year = {2018},
  month = oct,
  journal = {JAMA},
  volume = {320},
  number = {15},
  pages = {1535--1536},
  issn = {1538-3598},
  doi = {10.1001/jama.2018.12368},
  langid = {english},
  pmid = {30326521},
  keywords = {Adolescent,Age Distribution,Aged,Cancer;Elderly,Child,Clinical Trials as Topic,Data Interpretation; Statistical,Female,Guidelines as Topic,Humans,Infant,Male,National Institutes of Health (U.S.),Organizational Policy,Research Support as Topic,United States}
}

@article{berry1266,
  type = {Journal {{Article}}},
  title = {A Comprehensive Evaluation for Aspiration after Esophagectomy Reduces the Incidence of Postoperative Pneumonia},
  author = {Berry, M. F. and Atkins, B. Z. and Tong, B. C. and Harpole, D. H. and D'Amico, T. A. and Onaitis, M. W.},
  year = {2010},
  journal = {J Thorac Cardiovasc Surg},
  volume = {140},
  number = {6},
  pages = {1266--71},
  issn = {1097-685X (Electronic) 0022-5223 (Linking)},
  doi = {10.1016/j.jtcvs.2010.08.038}
}

@article{beukema85,
  title = {Is Cardiac Toxicity a Relevant Issue in the Radiation Treatment of Esophageal Cancer?},
  author = {Beukema, Jannet C. and {van Luijk}, Peter and Widder, Joachim and Langendijk, Johannes A. and Muijs, Christina T.},
  year = {2015},
  month = jan,
  journal = {Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology},
  volume = {114},
  number = {1},
  pages = {85--90},
  issn = {1879-0887},
  doi = {10.1016/j.radonc.2014.11.037},
  abstract = {PURPOSE: In recent years several papers have been published on radiation-induced cardiac toxicity, especially in breast cancer patients. However, in esophageal cancer patients the radiation dose to the heart is usually markedly higher. To determine whether radiation-induced cardiac toxicity is also a relevant issue for this group, we conducted a review of the current literature. METHODS: A literature search was performed in Medline for papers concerning cardiac toxicity in esophageal cancer patients treated with radiotherapy with or without chemotherapy. RESULTS: The overall crude incidence of symptomatic cardiac toxicity was as high as 10.8\%. Toxicities corresponded with several dose-volume parameters of the heart. The most frequently reported complications were pericardial effusion, ischemic heart disease and heart failure. CONCLUSION: Cardiac toxicity is a relevant issue in the treatment of esophageal cancer. However, valid Normal Tissue Complication Probability models for esophageal cancer are not available at present.},
  langid = {english},
  pmid = {25554226},
  keywords = {Cardiac toxicity,Cardiotoxicity,Esophageal cancer,Esophageal Neoplasms,Female,Heart,Heart Diseases,Humans,Incidence,Male,Radiation Dosage,Radiation Injuries,Radiotherapy,Radiotherapy Dosage}
}

@article{beukinga8,
  title = {Predicting {{Response}} to {{Neoadjuvant Chemoradiotherapy}} in {{Esophageal Cancer}} with {{Textural Features Derived}} from {{Pretreatment 18F-FDG PET}}/{{CT Imaging}}},
  author = {Beukinga, Roelof J and Hulshoff, Jan B and {van Dijk}, Lisanne V and Muijs, Christina T and Burgerhof, Johannes G M and {Kats-Ugurlu}, Gursah},
  pages = {8},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\J2Q4U2X2\\Beukinga et al. - Predicting Response to Neoadjuvant Chemoradiothera.pdf}
}

@article{biere1887,
  type = {Journal {{Article}}},
  title = {Minimally Invasive versus Open Oesophagectomy for Patients with Oesophageal Cancer: A Multicentre, Open-Label, Randomised Controlled Trial},
  author = {Biere, S. S. and {van Berge Henegouwen}, M. I. and Maas, K. W. and Bonavina, L. and Rosman, C. and Garcia, J. R. and Gisbertz, S. S. and Klinkenbijl, J. H. and Hollmann, M. W. and {de Lange}, E. S. and Bonjer, H. J. and {van der Peet}, D. L. and Cuesta, M. A.},
  year = {2012},
  journal = {Lancet},
  volume = {379},
  number = {9829},
  pages = {1887--92},
  issn = {1474-547X (Electronic) 0140-6736 (Linking)},
  doi = {10.1016/S0140-6736(12)60516-9}
}

@article{bilku15a,
  title = {Role of Preoperative Carbohydrate Loading: A Systematic Review},
  shorttitle = {Role of Preoperative Carbohydrate Loading},
  author = {Bilku, D. K. and Dennison, A. R. and Hall, T. C. and Metcalfe, M. S. and Garcea, G.},
  year = {2014},
  month = jan,
  journal = {Annals of the Royal College of Surgeons of England},
  volume = {96},
  number = {1},
  pages = {15--22},
  issn = {1478-7083},
  doi = {10.1308/003588414X13824511650614},
  abstract = {INTRODUCTION: Surgical stress in the presence of fasting worsens the catabolic state, causes insulin resistance and may delay recovery. Carbohydrate rich drinks given preoperatively may ameliorate these deleterious effects. A systematic review was undertaken to analyse the effect of preoperative carbohydrate loading on insulin resistance, gastric emptying, gastric acidity, patient wellbeing, immunity and nutrition following surgery. METHODS: All studies identified through PubMed until September 2011 were included. References were cross-checked to ensure capture of cited pertinent articles. RESULTS: Overall, 17 randomised controlled trials with a total of 1,445 patients who met the inclusion criteria were identified. Preoperative carbohydrate drinks significantly improved insulin resistance and indices of patient comfort following surgery, especially hunger, thirst, malaise, anxiety and nausea. No definite conclusions could be made regarding preservation of muscle mass. Following ingestion of carbohydrate drinks, no adverse events such as apparent or proven aspiration during or after surgery were reported. CONCLUSIONS: Administration of oral carbohydrate drinks before surgery is probably safe and may have a positive influence on a wide range of perioperative markers of clinical outcome. Further studies are required to determine its cost effectiveness.},
  langid = {english},
  pmcid = {PMC5137663},
  pmid = {24417824},
  keywords = {Administration; Oral,Beverages,Diabetes Mellitus; Type 2,Dietary Carbohydrates,ERAS,Gastric Acid,Gastric Emptying,Health Status,Humans,Immunity,Insulin Resistance,Nutritional Status,Patient Safety,Postoperative Complications,Preoperative Care,Randomized Controlled Trials as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MUIN35L3\\Bilku et al_2014_Role of preoperative carbohydrate loading.pdf}
}

@article{birkmeyer1128,
  type = {Journal {{Article}}},
  title = {Hospital Volume and Surgical Mortality in the {{United States}}},
  author = {Birkmeyer, J. D. and Siewers, A. E. and Finlayson, E. V. and Stukel, T. A. and Lucas, F. L. and Batista, I. and Welch, H. G. and Wennberg, D. E.},
  year = {2002},
  journal = {N Engl J Med},
  volume = {346},
  number = {15},
  pages = {1128--37},
  issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
  doi = {10.1056/NEJMsa012337}
}

@article{birkmeyer2117,
  title = {Surgeon Volume and Operative Mortality in the {{United States}}},
  author = {Birkmeyer, John D. and Stukel, Therese A. and Siewers, Andrea E. and Goodney, Philip P. and Wennberg, David E. and Lucas, F. Lee},
  year = {2003},
  month = nov,
  journal = {The New England Journal of Medicine},
  volume = {349},
  number = {22},
  pages = {2117--2127},
  issn = {1533-4406},
  doi = {10.1056/NEJMsa035205},
  abstract = {BACKGROUND: Although the relation between hospital volume and surgical mortality is well established, for most procedures, the relative importance of the experience of the operating surgeon is uncertain. METHODS: Using information from the national Medicare claims data base for 1998 through 1999, we examined mortality among all 474,108 patients who underwent one of eight cardiovascular procedures or cancer resections. Using nested regression models, we examined the relations between operative mortality and surgeon volume and hospital volume (each in terms of total procedures performed per year), with adjustment for characteristics of the patients and other characteristics of the providers. RESULTS: Surgeon volume was inversely related to operative mortality for all eight procedures (P=0.003 for lung resection, P{$<$}0.001 for all other procedures). The adjusted odds ratio for operative death (for patients with a low-volume surgeon vs. those with a high-volume surgeon) varied widely according to the procedure--from 1.24 for lung resection to 3.61 for pancreatic resection. Surgeon volume accounted for a large proportion of the apparent effect of the hospital volume, to an extent that varied according to the procedure: it accounted for 100 percent of the effect for aortic-valve replacement, 57 percent for elective repair of an abdominal aortic aneurysm, 55 percent for pancreatic resection, 49 percent for coronary-artery bypass grafting, 46 percent for esophagectomy, 39 percent for cystectomy, and 24 percent for lung resection. For most procedures, the mortality rate was higher among patients of low-volume surgeons than among those of high-volume surgeons, regardless of the surgical volume of the hospital in which they practiced. CONCLUSIONS: For many procedures, the observed associations between hospital volume and operative mortality are largely mediated by surgeon volume. Patients can often improve their chances of survival substantially, even at high-volume hospitals, by selecting surgeons who perform the operations frequently.},
  langid = {english},
  pmid = {14645640},
  keywords = {Aged,Cardiovascular Surgical Procedures,Databases; Factual,Female,General Surgery,Hospitals,Humans,Logistic Models,Male,Medicare,Neoplasms,Outcome Assessment; Health Care,Surgical Procedures; Operative,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6CFPE35V\\Birkmeyer et al. - 2003 - Surgeon volume and operative mortality in the Unit.pdf}
}

@article{bizekis402,
  type = {Journal {{Article}}},
  title = {Initial Experience with Minimally Invasive {{Ivor Lewis}} Esophagectomy},
  author = {Bizekis, C. and Kent, M. S. and Luketich, J. D. and Buenaventura, P. O. and Landreneau, R. J. and Schuchert, M. J. and {Alvelo-Rivera}, M.},
  year = {2006},
  journal = {Ann Thorac Surg},
  volume = {82},
  number = {2},
  pages = {402-6; discussion 406-7},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2006.02.052}
}

@article{blauwhoff-buskermolen1339,
  title = {Loss of {{Muscle Mass During Chemotherapy Is Predictive}} for {{Poor Survival}} of {{Patients With Metastatic Colorectal Cancer}}},
  author = {{Blauwhoff-Buskermolen}, Susanne and Versteeg, Kathelijn S. and {de van der Schueren}, Marian A. E. and {den Braver}, Nicole R. and Berkhof, Johannes and Langius, Jacqueline A. E. and Verheul, Henk M. W.},
  year = {2016},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {34},
  number = {12},
  pages = {1339--1344},
  issn = {1527-7755},
  doi = {10.1200/JCO.2015.63.6043},
  abstract = {PURPOSE: Low muscle mass is present in approximately 40\% of patients with metastatic colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in skeletal muscle during palliative chemotherapy in patients with mCRC and its association with treatment modifications and overall survival. PATIENTS AND METHODS: In 67 patients with mCRC (mean age {$\pm$} standard deviation, 66.4 {$\pm$} 10.6 years; 63\% male), muscle area (square centimeters) was assessed using computed tomography scans of the third lumbar vertebra before and during palliative chemotherapy. Treatment modifications resulting from toxicity were evaluated, including delay, dose reduction, or termination of chemotherapy. Multiple regression analyses were performed for the association between change in muscle area and treatment modification and secondly overall survival. RESULTS: Muscle area of patients with mCRC decreased significantly during 3 months of chemotherapy by 6.1\% (95\% CI, -8.4 to -3.8; P {$<$} .001). Change in muscle area was not associated with treatment modifications. However, patients with muscle loss during treatment of 9\% or more (lowest tertile) had significantly lower survival rates than patients with muscle loss of less than 9\% (at 6 months, 33\% v 69\% of patients alive; at 1 year, 17\% v 49\% of patients alive; log-rank P = .001). Muscle loss of 9\% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95\% CI, 2.21 to 9.05; P {$<$} .001). CONCLUSION: Muscle area decreased significantly during chemotherapy and was independently associated with survival in patients with mCRC. Further clinical evaluation is required to determine whether nutritional interventions and exercise training may preserve muscle area and thereby improve outcome.},
  langid = {english},
  pmid = {26903572},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Body Weight,Cachexia,Colorectal Neoplasms,Disease Progression,Female,Health Status,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Muscle; Skeletal,Muscular Atrophy,Neoplasm Metastasis,Palliative Care,Proportional Hazards Models,Prospective Studies,Radiography,Risk Assessment,Risk Factors,Time Factors,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VDU3ZQQI\\Blauwhoff-Buskermolen and Versteeg - Loss of Muscle Mass During Chemotherapy Is Predict.pdf}
}

@article{blazeby1384,
  type = {Journal {{Article}}},
  title = {Clinical and Psychometric Validation of an {{EORTC}} Questionnaire Module, the {{EORTC QLQ-OES18}}, to Assess Quality of Life in Patients with Oesophageal Cancer},
  author = {Blazeby, J. M. and Conroy, T. and Hammerlid, E. and Fayers, P. and Sezer, O. and Koller, M. and Arraras, J. and Bottomley, A. and Vickery, C. W. and Etienne, P. L. and Alderson, D. and {European Organisation for}, Research and {Treatement of Cancer}, Gastrointestinal and {Quality of Life}, Groups},
  year = {2003},
  journal = {Eur J Cancer},
  volume = {39},
  number = {10},
  pages = {1384--94},
  issn = {0959-8049 (Print) 0959-8049 (Linking)}
}

@article{blazeby1912,
  type = {Journal {{Article}}},
  title = {Development of an {{EORTC}} Questionnaire Module to Be Used in Quality of Life Assessment for Patients with Oesophageal Cancer. {{The EORTC Quality}} of {{Life Study Group}}},
  author = {Blazeby, J. M. and Alderson, D. and Winstone, K. and Steyn, R. and Hammerlid, E. and Arraras, J. and Farndon, J. R.},
  year = {1996},
  journal = {Eur J Cancer},
  volume = {32A},
  number = {11},
  pages = {1912--7},
  issn = {0959-8049 (Print) 0959-8049 (Linking)}
}

@article{blencowe658,
  type = {Journal {{Article}}},
  title = {Reporting of Short-Term Clinical Outcomes after Esophagectomy: A Systematic Review},
  author = {Blencowe, N. S. and Strong, S. and McNair, A. G. and Brookes, S. T. and Crosby, T. and Griffin, S. M. and Blazeby, J. M.},
  year = {2012},
  journal = {Ann Surg},
  volume = {255},
  number = {4},
  pages = {658--66},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0b013e3182480a6a}
}

@article{blum1635,
  title = {Validation of the {{Consensus-Definition}} for {{Cancer Cachexia}} and Evaluation of a Classification Model--a Study Based on Data from an International Multicentre Project ({{EPCRC-CSA}})},
  author = {Blum, D. and Stene, G. B. and Solheim, T. S. and Fayers, P. and Hjermstad, M. J. and Baracos, V. E. and Fearon, K. and Strasser, F. and Kaasa, S. and {Euro-Impact}},
  year = {2014},
  month = aug,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {25},
  number = {8},
  pages = {1635--1642},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdu086},
  abstract = {BACKGROUND: Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival. PATIENTS AND METHODS: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models. RESULTS: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated. CONCLUSION: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.},
  langid = {english},
  pmid = {24562443},
  keywords = {Aged,Algorithms,cachexia,Cachexia,cancer,classification,Consensus,Decision Support Techniques,Female,Humans,International Cooperation,Male,Middle Aged,Neoplasms,Prognosis,Survival Analysis,validation,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PZPRLN2E\\Blum et al_2014_Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a.pdf}
}

@article{blum293,
  title = {The Impact of Intravenous Iron Supplementation in Elderly Patients Undergoing Major Surgery},
  author = {Blum, Lea Valeska and Zierentz, Philipp and Hof, Lotta and Kloka, Jan Andreas and Messroghli, Leila and Zacharowski, Kai and Meybohm, Patrick and Choorapoikayil, Suma},
  year = {2022},
  month = apr,
  journal = {BMC geriatrics},
  volume = {22},
  number = {1},
  pages = {293},
  issn = {1471-2318},
  doi = {10.1186/s12877-022-02983-y},
  abstract = {BACKGROUND: Age and preoperative anaemia are risk factors for poor surgical outcome and blood transfusion. The aim of this study was to examine the effect of iron supplementation in iron-deficient (ID) elderly patients undergoing major surgery. METHOD: In this single-centre observational study, patients\,{$\geq$}\,65 years undergoing major surgery were screened for anaemia and ID. Patients were assigned to the following groups: A- (no anaemia); A-,ID+,T+ (no anaemia, iron-deficient, intravenous iron supplementation); A+ (anaemia); and A+,ID+,T+ (anaemia, iron-deficient, intravenous iron supplementation). RESULTS: Of 4,381 patients screened at the anaemia walk-in clinic, 2,381 (54\%) patients were {$\geq$}\,65 years old and 2,191 cases were included in analysis. The ID prevalence was 63\% in patients with haemoglobin (Hb)\,{$<$}\,8~g/dl, 47.2\%~in patients with Hb from 8.0 to 8.9~g/dl, and 44.3\% in patients with Hb from 9 to 9.9~g/dl. In severely anaemic patients, an Hb increase of 0.6 (0.4; 1.2) and 1.2 (0.7; 1.6) g/dl was detected with iron supplementation 6-10 and {$>$}\,10 days before surgery, respectively. Hb increased by 0 (-0.1; 0) g/dl with iron supplementation 1-5 days before surgery, 0.2 (-0.1; 0.5) g/dl with iron supplementation 6-10 days before surgery, and 0.2 (-0.2; 1.1) g/dl with supplementation\,{$>$}\,10 days before surgery (p\,{$<$}\,0.001 for 1-5 vs. 6-10 days). Overall, 58\% of A+,ID+,T+ patients showed an Hb increase of {$>$}\,0.5~g/dl. The number of transfused red blood cell units was significantly lower in patients supplemented with iron (0 (0; 3)) compared to non-treated anaemic patients (1 (0; 4)) (p\,=\,0.03). Patients with iron supplementation\,{$>$}\,6 days before surgery achieved mobility 2 days earlier than patients with iron supplementation\,{$<$}\,6 days. CONCLUSIONS: Intravenous iron supplementation increases Hb level and thereby reduces blood transfusion rate in elderly surgical patients with ID anaemia.},
  langid = {english},
  pmcid = {PMC8988356},
  pmid = {35392839},
  keywords = {Aged,Anemia,Dietary Supplements,Elderly,Erythrocyte Transfusion,Geriatric patients,Hemoglobins,Humans,Intravenous iron,Iron,Iron deficiency,Patient care,Surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4XYN927K\\Blum et al_2022_The impact of intravenous iron supplementation in elderly patients undergoing.pdf}
}

@article{blumenthal2451,
  type = {Journal {{Article}}},
  title = {The {{Affordable Care Act}} at 5 {{Years}}},
  author = {Blumenthal, D. and Abrams, M. and Nuzum, R.},
  year = {2015},
  journal = {N Engl J Med},
  volume = {372},
  number = {25},
  pages = {2451--8},
  issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
  doi = {10.1056/NEJMhpr1503614}
}

@article{bonadonna901,
  title = {Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer: The Results of 20 Years of Follow-Up},
  shorttitle = {Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer},
  author = {Bonadonna, G. and Valagussa, P. and Moliterni, A. and Zambetti, M. and Brambilla, C.},
  year = {1995},
  month = apr,
  journal = {The New England Journal of Medicine},
  volume = {332},
  number = {14},
  pages = {901--906},
  issn = {0028-4793},
  doi = {10.1056/NEJM199504063321401},
  abstract = {BACKGROUND: Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone. Here we report a 20-year follow-up of this investigation. METHODS: In 1973 we began a trial involving 386 women who were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant combination chemotherapy (207 women). All patients were admitted to the Istituto Nazionale Tumori in Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology. RESULTS: After a median follow-up of 19.4 years, the patients given adjuvant combination chemotherapy had significantly better rates of relapse-free survival (unadjusted relative risk of relapse, 0.71; 95 percent confidence interval, 0.56 to 0.90; P = 0.004; adjusted relative risk, 0.65, 95 percent confidence interval, 0.51 to 0.83; P {$<$} 0.001) and total survival (unadjusted relative risk of death, 0.78; 95 percent confidence interval, 0.62 to 0.99; P = 0.04; adjusted relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P = 0.03). With the exception of postmenopausal women, a benefit from adjuvant chemotherapy was evident in all subgroups of patients. CONCLUSIONS: The long-term results of this trial of adjuvant combination chemotherapy confirm our preliminary observations of the effectiveness of the treatment in women with node-positive breast cancer.},
  langid = {english},
  pmid = {7877646},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Breast Neoplasms,Chemotherapy; Adjuvant,Cyclophosphamide,Disease-Free Survival,Dose Intensity,Female,Fluorouracil,Follow-Up Studies,Humans,Lymph Nodes,Lymphatic Metastasis,Mastectomy; Radical,Methotrexate,Middle Aged,Regression Analysis,Treatment Outcome}
}

@article{bonilha77,
  type = {Journal {{Article}}},
  title = {Radiation Exposure Time during {{MBSS}}: Influence of Swallowing Impairment Severity, Medical Diagnosis, Clinician Experience, and Standardized Protocol Use},
  author = {Bonilha, H. S. and Humphries, K. and Blair, J. and Hill, E. G. and McGrattan, K. and Carnes, B. and Huda, W. and {Martin-Harris}, B.},
  year = {2013},
  journal = {Dysphagia},
  volume = {28},
  number = {1},
  pages = {77--85},
  issn = {1432-0460 (Electronic) 0179-051X (Linking)},
  doi = {10.1007/s00455-012-9415-z}
}

@article{bonilha922,
  type = {Journal {{Article}}},
  title = {Radiation {{Risks}} to {{Adult Patients Undergoing Modified Barium Swallow Studies}}},
  author = {Bonilha, H. S. and Huda, W. and Wilmskoetter, J. and {Martin-Harris}, B. and Tipnis, S. V.},
  year = {2019},
  journal = {Dysphagia},
  volume = {34},
  number = {6},
  pages = {922--929},
  issn = {1432-0460 (Electronic) 0179-051X (Linking)},
  doi = {10.1007/s00455-019-09993-w}
}

@article{bonvalot1366,
  title = {Preoperative Radiotherapy plus Surgery versus Surgery Alone for Patients with Primary Retroperitoneal Sarcoma ({{EORTC-62092}}: {{STRASS}}): A Multicentre, Open-Label, Randomised, Phase 3 Trial},
  shorttitle = {Preoperative Radiotherapy plus Surgery versus Surgery Alone for Patients with Primary Retroperitoneal Sarcoma ({{EORTC-62092}}},
  author = {Bonvalot, Sylvie and Gronchi, Alessandro and Le P{\'e}choux, C{\'e}cile and Swallow, Carol J. and Strauss, Dirk and Meeus, Pierre and {van Coevorden}, Frits and Stoldt, Stephan and Stoeckle, Eberhard and Rutkowski, Piotr and Rastrelli, Marco and Raut, Chandrajit P. and Hompes, Daphne and De Paoli, Antonino and Sangalli, Claudia and Honor{\'e}, Charles and Chung, Peter and Miah, Aisha and Blay, Jean Yves and Fiore, Marco and Stelmes, Jean-Jacques and Dei Tos, Angelo P. and Baldini, Elizabeth H. and Liti{\`e}re, Saskia and Marreaud, Sandrine and Gelderblom, Hans and Haas, Rick L.},
  year = {2020},
  month = oct,
  journal = {The Lancet. Oncology},
  volume = {21},
  number = {10},
  pages = {1366--1377},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(20)30446-0},
  abstract = {BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival. METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged {$\geq$}18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50{$\cdot$}4 Gy (in 28 daily fractions of 1{$\cdot$}8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018. FINDINGS: Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43{$\cdot$}1 months (IQR 28{$\cdot$}8-59{$\cdot$}2). 128 (96\%) patients from the surgery alone group had surgery, and 119 (89\%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4{$\cdot$}5 years (95\% CI 3{$\cdot$}9 to not estimable) in the radiotherapy plus surgery group and 5{$\cdot$}0 years (3{$\cdot$}4 to not estimable) in the surgery only group (hazard ratio 1{$\cdot$}01, 95\% CI 0{$\cdot$}71-1{$\cdot$}44; log rank p=0{$\cdot$}95). The most common grade 3-4 adverse events were lymphopenia (98 [77\%] of 127 patients in the radiotherapy plus surgery group vs one [1\%] of 128 patients in the surgery alone group), anaemia (15 [12\%] vs ten [8\%]), and hypoalbuminaemia (15 [12\%] vs five [4\%]). Serious adverse events were reported in 30 (24\%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10\%) of 128 patients in the surgery alone group. One (1\%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events. INTERPRETATION: Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma. FUNDING: European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.},
  langid = {english},
  pmid = {32941794},
  keywords = {Aged,Disease-Free Survival,Europe,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,North America,PreopRT,Radiotherapy; Adjuvant,Radiotherapy; Conformal,Retroperitoneal Neoplasms,Sarcoma,Treatment Outcome}
}

@article{borch64,
  title = {Gastric {{Carcinoids}}},
  author = {Borch, Kurt and Ahr{\'e}n, Bo and Ahlman, H{\aa}kan and Falkmer, Sture and Gran{\'e}rus, G{\"o}ran and Grimelius, Lars},
  year = {2005},
  month = jul,
  journal = {Annals of Surgery},
  volume = {242},
  number = {1},
  pages = {64--73},
  issn = {0003-4932},
  doi = {10.1097/01.sla.0000167862.52309.7d},
  abstract = {Gastric carcinoids can be divided into different subtypes. Sixty-five prospectively followed cases were studied regarding biologic behavior, treatment, and prognosis. Tumor aggressiveness varied significantly in relation to type. Differentiated management strategy is recommended as used in the present study.},
  pmcid = {PMC1357706},
  pmid = {15973103},
  keywords = {carcinoid},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4YDAPAV6\\Borch et al. - 2005 - Gastric Carcinoids.pdf}
}

@article{bosch,
  title = {Time Intervals in the Care Pathway to Cancer Diagnosis during the {{COVID-19}} Pandemic: {{A}} Large Retrospective Study from a High-Volume Center},
  shorttitle = {Time Intervals in the Care Pathway to Cancer Diagnosis during the {{COVID-19}} Pandemic},
  author = {Bosch, Xavier and {Montori-Palacin}, Elisabet and {Mart{\'i}nez-Ferrer}, Rosa and Aldea, Anna and Moreno, Pedro and {L{\'o}pez-Soto}, Alfonso},
  year = {2022},
  month = aug,
  journal = {International Journal of Cancer},
  issn = {1097-0215},
  doi = {10.1002/ijc.34260},
  abstract = {Despite extensive research on cancer care during the COVID-19 pandemic, evidence on the impact on prediagnostic time intervals is lacking. To better understand how COVID-19 changed the pathway to diagnosis of cancer, we examined the length of intervals from symptom onset to diagnosis for 13 common cancer types with known clinical stage over 1-year nonpandemic period (March 2019 to March 2020; N~=~844) and three biannual COVID periods (March 2020 to September 2021; N~=~1172). We analyzed the patient interval (from first symptoms to presentation to a physician), the primary care/emergency department interval (from presentation with relevant symptoms to a primary care or emergency department physician to referral to a hospital-based diagnosis center) and the hospital interval (from referral to diagnosis). Compared to nonpandemic data, there were significant changes across COVID periods. The pandemic mostly impacted patient intervals for cancers diagnosed over the first 6 months after onset in March 2020. Overall median patient intervals were longest in the early COVID period (39 [IQR 22-64] days) and shortest in the nonpandemic period (20 [IQR 13-30] days; Kruskal-Wallis test [{$\chi$}2 ], P\,{$<$}\,.0001). Differences in clinical stage between periods were relevant, with cancers from the mid-period (September 2020 to March 2021) showing the most advanced stage. A shift to later stage was plausibly a result of delayed intervals in the early COVID period. Since intervals are eventually relevant to prognosis, our results provide a baseline against which the impact of improvement strategies to minimize the negative outcomes of COVID-19-associated cancer delays can be assessed and implemented.},
  langid = {english},
  pmcid = {PMC9539134},
  pmid = {36053784},
  keywords = {Covid,COVID-19,diagnostic interval,patient interval,primary care interval,stage},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QZ5Y9T58\\Bosch et al_2022_Time intervals in the care pathway to cancer diagnosis during the COVID-19.pdf}
}

@article{boshier,
  title = {Assessment of Body Composition and Sarcopenia in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis},
  shorttitle = {Assessment of Body Composition and Sarcopenia in Patients with Esophageal Cancer},
  author = {Boshier, P. R. and Heneghan, R. and Markar, S. R. and Baracos, V. E. and Low, D. E.},
  year = {2018},
  month = aug,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {31},
  number = {8},
  issn = {1442-2050},
  doi = {10.1093/dote/doy047},
  abstract = {There has recently been increased interest in the assessment of body composition in patients with esophageal cancer for the purpose of nutritional evaluation and prognostication. This systematic review and meta-analysis intends to summarize and critically evaluate the current literature concerning the assessment of body composition in patients with esophageal cancer and to assess its potential implication upon early and late outcomes. A systematic literature search (up to August, 2017) was conducted for studies describing the assessment of body composition in patients with esophageal and gastroesophageal junctional cancer. Meta-analysis of postoperative outcomes including long-term survival was performed using random effects models. Twenty-nine studies reported the assessment of body composition in 3193 patients. Methods used to assess body composition in patients with esophageal cancer included computerized tomography (n~=~18 studies), bioelectrical impedance analysis (n~=~10), and dual-energy X-ray absorptiometry (n~=~1). Significant variability was observed in regard to study design and the criteria used to define individual parameters of body composition. Sarcopenic patients had a higher incidence of postoperative pulmonary complications (7 studies, OR 2.03, 95\% CI 1.32-3.11, P~=~0.001) after esophagectomy. Meta-analysis of six studies presenting long-term outcomes after esophagectomy identified significantly worse survival in patients who were sarcopenic (HR 1.70, 95\% CI 1.33- 2.17, P~{$<~$}0.0001). The assessment of body composition has the potential to become a clinically useful tool that could support decision-making in patients with esophageal cancer. Current evidence is however weakened by inconsistencies in methods of assessing and reporting body composition in this patient group.},
  langid = {english},
  pmid = {29846548},
  keywords = {Body Composition,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Nutrition Assessment,Postoperative Complications,Sarcopenia,Survival Rate,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\3SV8VBHV\\Boshier et al_2018_Assessment of body composition and sarcopenia in patients with esophageal cancer.pdf}
}

@article{botsen955,
  type = {Journal {{Article}}},
  title = {Dynapenia Could Predict Chemotherapy-Induced Dose-Limiting Neurotoxicity in Digestive Cancer Patients},
  author = {Botsen, D. and Ordan, M. A. and Barbe, C. and Mazza, C. and Perrier, M. and Moreau, J. and Brasseur, M. and Renard, Y. and Tailliere, B. and Slimano, F. and Bertin, E. and Bouche, O.},
  year = {2018},
  journal = {BMC Cancer},
  volume = {18},
  number = {1},
  pages = {955},
  issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
  doi = {10.1186/s12885-018-4860-1},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KQB55RJE\\Botsen et al_2018_Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in.pdf}
}

@article{boutin1046,
  title = {Influence of {{IV Contrast Administration}} on {{CT Measures}} of {{Muscle}} and {{Bone Attenuation}}: {{Implications}} for {{Sarcopenia}} and {{Osteoporosis Evaluation}}},
  shorttitle = {Influence of {{IV Contrast Administration}} on {{CT Measures}} of {{Muscle}} and {{Bone Attenuation}}},
  author = {Boutin, Robert D. and Kaptuch, Justin M. and Bateni, Cyrus P. and Chalfant, James S. and Yao, Lawrence},
  year = {2016},
  month = nov,
  journal = {AJR. American journal of roentgenology},
  volume = {207},
  number = {5},
  pages = {1046--1054},
  issn = {1546-3141},
  doi = {10.2214/AJR.16.16387},
  abstract = {OBJECTIVE: The objective of our study was to characterize enhancement of muscle and bone that occurs on standardized four-phase contrast-enhanced CT. MATERIALS AND METHODS: Two musculoskeletal radiologists reviewed standardized four-phase abdominal CT scans obtained with IV contrast material. The psoas area was measured, and the mean attenuation (in Hounsfield units) was recorded for the aorta, psoas muscles, posterior paraspinal muscles, and L4 vertebral body. CT attenuation measures were compared between anatomic regions and imaging phases with the paired t test; associations between measures were examined with the Pearson correlation coefficient (R). RESULTS: The study included 201 patients (97 men, 104 women; mean age, 57.7 {$\pm$} 12.5 [SD] years). Subject age was inversely correlated with unenhanced attenuation in the psoas muscles, posterior paraspinal muscles, and L4 (p {$<$} 0.001). The psoas muscles, posterior paraspinal muscles, and L4 enhanced significantly (p {$<$} 0.001) at all three contrast-enhanced phases. The greatest muscle enhancement was observed on delayed phase scans, whereas the greatest enhancement in L4 was seen on portal phase imaging. The unenhanced attenuation of the psoas muscles was significantly and negatively correlated with enhancement of the psoas muscles at the portal and delayed phases (p {$<$} 0.05 and p {$<$} 0.01, respectively), but these correlations were not seen for the posterior paraspinal muscles. Age was positively correlated with posterior paraspinal muscle enhancement at the portal and delayed phases in men (p {$<$} 0.05 and p {$<$} 0.01, respectively) but not in women. CONCLUSION: Contrast enhancement of commonly measured muscle and bone regions is routinely observed and should be considered when using CT attenuation values as biomarkers of sarcopenia and osteoporosis. Furthermore, CT enhancement may be significantly influenced by age, sex, and unenhanced tissue attenuation.},
  langid = {english},
  pmid = {27556335},
  keywords = {Adult,Aged,Aged; 80 and over,Aorta; Abdominal,contrast media,Contrast Media,CT,Female,Humans,Lumbar Vertebrae,Male,Methods,Middle Aged,osteoporosis,Osteoporosis,Paraspinal Muscles,Psoas Muscles,Retrospective Studies,sarcopenia,Sarcopenia,skeletal muscle,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TVCT8ZE9\\Boutin et al_2016_Influence of IV Contrast Administration on CT Measures of Muscle and Bone.pdf}
}

@article{boutin575,
  title = {Imaging of {{Sarcopenia}}},
  author = {Boutin, Robert D. and Houston, Denise K. and Chaudhari, Akshay S. and Willis, Marc H. and Fausett, Cameron L. and Lenchik, Leon},
  year = {2022},
  month = jul,
  journal = {Radiologic Clinics of North America},
  volume = {60},
  number = {4},
  pages = {575--582},
  issn = {1557-8275},
  doi = {10.1016/j.rcl.2022.03.001},
  abstract = {Sarcopenia is currently underdiagnosed and undertreated, but this is expected to change because sarcopenia is now recognized with a specific diagnosis code that can be used for billing in some countries, as well as an expanding body of research on prevention, diagnosis, and management. This article focuses on practical issues of increasing interest by highlighting 3 hot topics fundamental to understanding sarcopenia in older adults: definitions and terminology, current diagnostic imaging techniques, and the emerging role of opportunistic computed tomography.},
  langid = {english},
  pmid = {35672090},
  keywords = {Aged,Computed tomography (CT),Elderly,Frailty,Humans,Opportunistic imaging,Population health,Review,Sarcopenia,Tomography; X-Ray Computed}
}

@article{boutinW208,
  title = {{{CT}} of {{Patients With Hip Fracture}}: {{Muscle Size}} and {{Attenuation Help Predict Mortality}}},
  shorttitle = {{{CT}} of {{Patients With Hip Fracture}}},
  author = {Boutin, Robert D. and Bamrungchart, Sara and Bateni, Cyrus P. and Beavers, Daniel P. and Beavers, Kristen M. and Meehan, John P. and Lenchik, Leon},
  year = {2017},
  month = jun,
  journal = {AJR. American journal of roentgenology},
  volume = {208},
  number = {6},
  pages = {W208-W215},
  issn = {1546-3141},
  doi = {10.2214/AJR.16.17226},
  abstract = {OBJECTIVE: Our objective was to determine the association between muscle cross-sectional area and attenuation, as measured on routine CT scans, and mortality in older patients with hip fracture. MATERIALS AND METHODS: A retrospective 10-year study of patients with hip fracture was conducted with the following inclusion criteria: age 65 years or older, first-time hip fracture treated with surgery, and CT of the chest, abdomen, or pelvis. This yielded 274 patients (70.4\% women; mean [{$\pm$} SD] age, 81.3 {$\pm$} 8.3 years). On each CT scan, two readers independently measured the size (cross-sectional area, indexed for patient height) and attenuation of the paravertebral muscle at T12 and the psoas muscle at L4. We then determined the association between overall mortality and the muscle size and muscle attenuation, while adjusting for demographic variables (age, sex, ethnicity, and body mass index), American Society of Anesthesiologists (ASA) classification, and Charlson comorbidity index (CCI). RESULTS: The overall mortality rate increased from 28.3\% at 1 year to 79.5\% at 5 years. Mortality was associated with decreased thoracic muscle size (odds ratio [OR], 0.66; 95\% CI, 0.49-0.87). This association persisted after adjusting for demographic variables (OR, 0.69; 95\% CI, 0.50-0.95), the ASA classification (OR, 0.70; CI, 0.51-0.97), and the CCI (OR, 0.72; 95\% CI, 0.52-1.00). Similarly, decreased survival was associated with decreased thoracic muscle attenuation after adjusting for all of these combinations of covariates (OR, 0.67-0.72; 95\% CI, 0.49-0.99). Decreased lumbar muscle size and attenuation trended with decreased survival but did not reach statistical significance. CONCLUSION: In older adults with hip fractures, CT findings of decreased thoracic paravertebral muscle size and attenuation are associated with decreased overall survival.},
  langid = {english},
  pmcid = {PMC5898447},
  pmid = {28267356},
  keywords = {Aged; 80 and over,California,Causality,Comorbidity,CT,Female,hip fracture,Hip Fractures,Humans,ICC,Male,mortality,muscle,Organ Size,Prevalence,Proportional Hazards Models,Reproducibility of Results,Retrospective Studies,Risk Assessment,sarcopenia,Sarcopenia,Sensitivity and Specificity,Survival Analysis,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jcsal\\Documents\\Work\\boutinW208 - Annotations (832022, 90347 PM).md;C\:\\Users\\jsalo01\\Zotero\\storage\\SEUXZRN6\\Boutin et al_2017_CT of Patients With Hip Fracture.pdf}
}

@article{bower82,
  title = {Nutritional Management during Neoadjuvant Therapy for Esophageal Cancer},
  author = {Bower, Matthew R. and Martin II, Robert C.G.},
  year = {2009},
  journal = {Journal of Surgical Oncology},
  volume = {100},
  number = {1},
  pages = {82--87},
  issn = {1096-9098},
  doi = {10.1002/jso.21289},
  abstract = {Patients undergoing neoadjuvant therapy for esophageal cancer are at a high risk for malnutrition due to the effects of chemoradiation, dysphagia, and malignancy induced cachexia. Preparation for esophagectomy requires careful assessment of nutritional risk and adequate supplementation as indicated. Supplementation via the enteral route is preferred to the parenteral route but requires feeding tube placement. Endoscopically placed silicone stents have also shown promise as a means to alleviate malnutrition and avoid invasive feeding tubes. J. Surg. Oncol. 2009;100:82\textendash 87. \textcopyright{} 2009 Wiley-Liss, Inc.},
  langid = {english},
  keywords = {enteral nutrition,esophageal stenting,parenteral nutrition},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.21289}
}

@article{bozzetti2107,
  title = {Forcing the Vicious Circle: Sarcopenia Increases Toxicity, Decreases Response to Chemotherapy and Worsens with Chemotherapy},
  shorttitle = {Forcing the Vicious Circle},
  author = {Bozzetti, F.},
  year = {2017},
  month = sep,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {28},
  number = {9},
  pages = {2107--2118},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdx271},
  abstract = {Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials. The examination of the computed tomography scan at the level of the third lumbar vertebra-a common procedure for staging many tumours-has allowed the oncologist to evaluate the muscle mass and to collect many retrospective data on the prevalence of sarcopenia and its clinical consequences. Sarcopenia is a condition affecting a high percentage of patients with a range depending on type of primary tumour and stage of disease. It is noteworthy that patients may be sarcopenic even if their nutritional status is apparently maintained or they are obese. Sarcopenic patients exhibited higher chemotherapy toxicity and poorer compliance with oncological treatments. Furthermore, several antineoplastic drugs appeared to worsen the sarcopenic status. Therapeutic approaches are several and this review will focus on those validated by randomized controlled trials. They include the use of {$\omega$}-3-enriched oral nutritional supplements and orexigenic agents, the administration of adequate high-protein regimens delivered enterally or parenterally, and programmes of physical exercise. Better results are expected combining different procedures in a multimodal approach. In conclusion, there are several premises to prevent/treat sarcopenia. The oncologist should coordinate this multimodal approach by selecting priorities and sequences of treatments and then involving a nutrition health care professional or a physical therapist depending on the condition of the single patient.},
  langid = {english},
  pmid = {28911059},
  keywords = {Antineoplastic Agents,cancer and sarcopenia,chemo,Humans,Neoplasms,Prevalence,Prognosis,Randomized Controlled Trials as Topic,sarcopenia,Sarcopenia,sarcopenia and chemotherapy,sarcopenia and prognosis,sarcopenia and toxicity,sarcopenia therapy,Tomography; X-Ray Computed}
}

@article{bozzetti698,
  title = {Postoperative Complications in Gastrointestinal Cancer Patients: The Joint Role of the Nutritional Status and the Nutritional Support},
  shorttitle = {Postoperative Complications in Gastrointestinal Cancer Patients},
  author = {Bozzetti, Federico and Gianotti, Luca and Braga, Mario and Di Carlo, Valerio and Mariani, Luigi},
  year = {2007},
  month = dec,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {26},
  number = {6},
  pages = {698--709},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2007.06.009},
  abstract = {BACKGROUND \& AIMS: This study investigated the effects of nutritional support on postoperative complications, in relation with demographic and nutritional factors, intraoperative factors, type and routes of nutritional regimens. METHODS: A series of 1410 subjects underwent major abdominal surgery for gastrointestinal cancer and received various types of nutritional support: standard intravenous fluids (SIF; n=149), total parenteral nutrition (TPN; n=368), enteral nutrition (EN; n=393), and immune-enhancing enteral nutrition (IEEN; n=500). Postoperative complications, considered as major (if lethal or requiring re-operation, or transfer to intensive care unit), or otherwise minor, were recorded. RESULTS: Major and minor complications occurred in 101 (7.2\%) and 446 (31.6\%) patients, respectively. Factors correlated with postoperative complications at multivariate analysis were pancreatic surgery, (p{$<$}0.001), advanced age (p=0.002), weight loss (p=0.019), low serum albumin (p=0.019) and nutritional support (p=0.001). Nutritional support reduced morbidity versus SIF with an increasing protective effect of TPN, EN, and IEEN. This effect remained valid regardless the severity of risk factors identified at the multivariate analysis and it was more evident by considering infectious complications only. CONCLUSIONS: Pancreatic surgery, advanced age, weight loss and low serum albumin are independent risk factors for the onset of postoperative complications. Nutritional support, particularly IEEN, significantly reduced postoperative morbidity.},
  langid = {english},
  pmid = {17683831},
  keywords = {Age Factors,Aged,Colorectal Neoplasms,Enteral Nutrition,Female,Fluid Therapy,Gastrointestinal Neoplasms,Humans,Immune System,Male,Middle Aged,Morbidity,Multivariate Analysis,Nutrition,Nutritional Status,Nutritional Support,Pancreatic Neoplasms,Parenteral Nutrition; Total,Perioperative Care,Postoperative Care,Postoperative Complications,Risk Factors,Serum Albumin,Stomach Neoplasms,Survival Analysis,Time Factors,Treatment Outcome,Weight Loss}
}

@article{bray394,
  type = {Journal {{Article}}},
  title = {Global Cancer Statistics 2018: {{GLOBOCAN}} Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries},
  author = {Bray, F. and Ferlay, J. and Soerjomataram, I. and Siegel, R. L. and Torre, L. A. and Jemal, A.},
  year = {2018},
  journal = {CA Cancer J Clin},
  volume = {68},
  number = {6},
  pages = {394--424},
  issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
  doi = {10.3322/caac.21492}
}

@article{bridda32,
  title = {Peritoneal {{Mesothelioma}}: {{A Review}}},
  shorttitle = {Peritoneal {{Mesothelioma}}},
  author = {Bridda, Alessio and Padoan, Ilaria and Mencarelli, Roberto and Frego, Mauro},
  year = {2007},
  month = may,
  journal = {Medscape General Medicine},
  volume = {9},
  number = {2},
  pages = {32},
  issn = {1531-0132},
  abstract = {Background Malignant peritoneal mesothelioma (MPM) is a rare aggressive tumor of the peritoneum, regarded as a universally fatal disease. It is poorly described and the knowledge of its natural history is very limited. Occupational and environmental asbestos exposure still remains a public health problem around the world. The incidence has increased in the past 2 decades. Only 20\% to 33\% of all mesotheliomas arise from the peritoneum itself; the pleura is the most common site of origin.},
  pmcid = {PMC1994863},
  pmid = {17955087},
  keywords = {Mesothelioma}
}

@article{briez310,
  title = {Open versus Laparoscopically-Assisted Oesophagectomy for Cancer: A Multicentre Randomised Controlled Phase {{III}} Trial - the {{MIRO}} Trial},
  shorttitle = {Open versus Laparoscopically-Assisted Oesophagectomy for Cancer},
  author = {Briez, Nicolas and Piessen, Guillaume and Bonnetain, Franck and Brigand, C{\'e}cile and Carrere, Nicolas and Collet, Denis and Doddoli, Christophe and Flamein, Renaud and Mabrut, Jean-Yves and Meunier, Bernard and Msika, Simon and Perniceni, Thierry and Peschaud, Fr{\'e}d{\'e}rique and Prudhomme, Michel and Triboulet, Jean-Pierre and Mariette, Christophe},
  year = {2011},
  month = jul,
  journal = {BMC cancer},
  volume = {11},
  pages = {310},
  issn = {1471-2407},
  doi = {10.1186/1471-2407-11-310},
  abstract = {BACKGROUND: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10\% and 30 to 50\%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma. METHODS/DESIGN: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A. DISCUSSION: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50\% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery. TRIAL REGISTRATION: NCT00937456 (ClinicalTrials.gov).},
  langid = {english},
  pmcid = {PMC3156811},
  pmid = {21781337},
  keywords = {Adenocarcinoma,Adult,Aged,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Esophagus,Follow-Up Studies,Humans,Kaplan-Meier Estimate,Laparoscopy,Lymph Node Excision,Middle Aged,Postoperative Care,Preoperative Care,Prospective Studies,RCT,Stomach,Thoracotomy,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7VMHRS64\\Briez et al_2011_Open versus laparoscopically-assisted oesophagectomy for cancer.pdf}
}

@article{bril8,
  title = {Interobserver Agreement of Skeletal Muscle Mass Measurement on Head and Neck {{CT}} Imaging at the Level of the Third Cervical Vertebra},
  author = {Bril, S I},
  year = {2019},
  pages = {8},
  abstract = {Objectives\hspace{0.6em} Skeletal muscle mass (SMM) is most often assessed in cancer patients on abdominal computed tomography (CT) imaging at the level of the third lumbar vertebra (L3). Abdominal CT imaging is not routinely performed in head and neck cancer (HNC) patients. Recently, a novel method to assess SMM on a single transversal CT slice at the level of the third cervical vertebra (C3) was published. The objective of this study was to assess the robustness of this novel C3 measurement method in terms of interobserver agreement. Patients and methods\hspace{0.6em} Patients diagnosed with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at our center between 2007 and 2011 were evaluated. Fifty-four patients with were randomly selected for analysis. Six observers independently measured the cross-sectional muscle area (CSMA) at the level of C3 using a predefined, written protocol as instruction. Interobserver agreement was assessed using intraclass correlation coefficients (ICCs), a Bland\textendash Altman plot and Fleiss' kappa ({$\kappa$}). Results\hspace{0.6em} The agreement in vertebra selection between all observers was excellent (Fleiss' {$\kappa$}: 0.96). There was a substantial agreement between all observers in single slice selection (Fleiss' {$\kappa$}: 0.61). For all CSMA measurements, ICCs were excellent (0.763\textendash 0.969; all p\,{$<$}\,0.001). The Bland\textendash Altman plot showed good agreement between measurements, with narrow limits of agreement. Conclusion\hspace{0.6em} Interobserver agreement for SMM measurement at the level of C3 was excellent. Assessment of SMM at the level of C3 is easy and robust and can performed on routinely available imaging in HNC patients.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VPYBEXJB\\Bril - 2019 - Interobserver agreement of skeletal muscle mass me.pdf}
}

@article{brown203,
  title = {Scaling of Computed Tomography Body Composition to Height: Relevance of Height-Normalized Indices in Patients with Colorectal Cancer},
  shorttitle = {Scaling of Computed Tomography Body Composition to Height},
  author = {Brown, Justin C. and Heymsfield, Steven B. and Caan, Bette J.},
  year = {2022},
  month = feb,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {13},
  number = {1},
  pages = {203--209},
  issn = {2190-6009},
  doi = {10.1002/jcsm.12847},
  abstract = {BACKGROUND: Body weight scales to height with a power of {$\approx$}2 (weight/height2 ), forming the basis of body mass index (BMI). The corresponding scaling of body composition measured by abdominal computed tomography (CT) to height has not been established. The objective of this analysis was to quantify the scaling of body composition measured by a single-slice axial abdominal CT image (skeletal muscle, and visceral, subcutaneous, and total adipose tissue) to height in patients with colorectal cancer (CRC). METHODS: This cross-sectional study included non-Hispanic white males and females, aged 18-80~years, who were diagnosed with stage I-III CRC at an integrated health care system in North America between January 2006 and December 2011. Body composition was measured by a single-slice axial CT image of the third lumbar vertebra and analysed with a semi-automated threshold segmentation procedure. Allometric regression models were used to quantify height scaling powers ({$\beta~\pm~$}standard error) for each body composition measure, adjusted for age, for males and females. An interaction test was used to determine if height scaling powers were statistically significantly different between males and females. RESULTS: Among 2036 subjects, the mean (standard deviation) age was 64~{$\pm~$}11~years, 1008 (49.5\%) were female, and the mean (standard deviation) BMI was 27.9~{$\pm~$}5.4~kg/m2 . Powers for skeletal muscle area were 1.06~{$\pm~$}0.12 for males and 0.80~{$\pm~$}0.12 for females (P~=~0.049). Powers for visceral adipose tissue area were 1.81~{$\pm~$}0.64 for males and 0.57~{$\pm~$}0.79 for females (P~=~0.16). Powers for subcutaneous adipose tissue area were 2.04~{$\pm~$}0.42 for males and 0.81~{$\pm~$}0.45 for females (P~=~0.056). Powers for total abdominal adipose tissue area were 1.80~{$\pm~$}0.46 for males and 0.76~{$\pm~$}0.50 for females (P~=~0.20). CONCLUSIONS: Body composition measured by single-slice axial abdominal CT, particularly muscle area, scales to height with age-adjusted powers that are different than 2 and are distinct between males and females. These observations may have implications for the development of height-adjusted body composition indices in patients with cancer.},
  langid = {english},
  pmcid = {PMC8818649},
  pmid = {34741439},
  keywords = {Adiposity,Adolescent,Adult,Aged,Aged; 80 and over,Allometric analysis,Body Composition,Body Height,Colorectal Neoplasms,Cross-Sectional Studies,Female,Height,Humans,Male,Methods,Middle Aged,Nutritional assessment,Obesity,Scaling powers,Skeletal muscle,Tomography; X-Ray Computed,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PSS995DR\\Brown et al_2022_Scaling of computed tomography body composition to height.pdf}
}

@article{buentzel4603,
  title = {Sarcopenia as {{Prognostic Factor}} in {{Lung Cancer Patients}}: {{A Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Sarcopenia as {{Prognostic Factor}} in {{Lung Cancer Patients}}},
  author = {Buentzel, Judith and Heinz, Judith and Bleckmann, Annalen and Bauer, Christoph and R{\"o}ver, Christian and Bohnenberger, Hanibal and Saha, Shekhar and Hinterthaner, Marc and Baraki, Hassina and Kutschka, Ingo and Emmert, Alexander},
  year = {2019},
  month = sep,
  journal = {Anticancer Research},
  volume = {39},
  number = {9},
  pages = {4603--4612},
  issn = {1791-7530},
  doi = {10.21873/anticanres.13640},
  abstract = {BACKGROUND/AIM: Sarcopenia describes the loss of skeletal muscle mass. While this condition is associated with a high mortality in cancer patients, its influence on survival is still underestimated. PATIENTS AND METHODS: A systematic review for articles was performed using the PubMed database, Cochrane Library, Biomed Central, Science Direct and by manual search. We used data of overall survival in sarcopenic patients for assessing the death risk. We extracted hazard ratio estimates from univariate and multivariate Cox proportional hazards models for meta-analysis. RESULTS: A total of 15 studies were eligible for meta-analysis including a total of 2,521 lung cancer patients. Univariate meta-analysis revealed a two-fold increased death risk in sarcopenic patients; multivariate meta-analysis yielded a significant, three-fold elevated risk of death. This higher mortality is independent of tumour stage. CONCLUSION: Muscle loss is an independent risk factor for increased death risk in lung cancer patients independent of cancer stage. This argues for implementing screening for sarcopenia into cancer care.},
  langid = {english},
  pmid = {31519557},
  keywords = {Humans,Lung,lung cancer,Lung Neoplasms,meta-analysis,Muscle; Skeletal,Neoplasm Staging,Organ Size,prognosis,Prognosis,Proportional Hazards Models,review,Sarcopenia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\36PYZKKE\\Buentzel et al_2019_Sarcopenia as Prognostic Factor in Lung Cancer Patients.pdf}
}

@article{bundred1603,
  title = {Body Composition Assessment and Sarcopenia in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis},
  shorttitle = {Body Composition Assessment and Sarcopenia in Patients with Pancreatic Cancer},
  author = {Bundred, James and Kamarajah, Sivesh K. and Roberts, Keith J.},
  year = {2019},
  month = dec,
  journal = {HPB},
  volume = {21},
  number = {12},
  pages = {1603--1612},
  issn = {1365-182X},
  doi = {10.1016/j.hpb.2019.05.018},
  abstract = {Background Numerous studies have suggested an association between sarcopenia in pancreatic cancer and adverse outcomes. This systematic review examines the evidence for the impact of sarcopenia on post-operative complications and survival Methods A systematic literature search was conducted to identify randomised and non-randomised studies of sarcopenia in pancreatic cancer. Meta-analyses of intra- and post-operative outcomes were performed (operating time, all complications, major complications, pancreatic fistulae, peri-operative mortality, overall survival). Results Forty-two studies reported the assessment of body composition in 7619 patients. Methods used to assess body composition in patients with pancreatic cancers were computerized tomography (n~=~34), bioelectrical impedance analysis (n~=~7), and dual-energy-X-ray-absorptiometry (n~=~1). Only 10 studies reported the impact of pre-operative sarcopenia upon post-operative outcomes. Sarcopenia was associated with increased peri-operative mortality (OR: 2.40, CI95\%:1.19\textendash 4.85, p~{$<~$}0.01) and decreased overall survival by univariable (HR: 1.95, CI95\%:1.35\textendash 2.81, p~{$<~$}0.001) and multivariable analysis (HR: 1.78, CI95\%:1.54\textendash 2.05). Sarcopenia was not significantly associated with all complications (OR: 0.96, CI95\%:0.78\textendash 1.19) or pancreatic fistula (OR: 0.95, CI95\%: 0.59\textendash 1.54). Conclusions Assessment of sarcopenia in pancreatic cancer provides prognostic value but, more importantly, may provide a basis for therapeutic intervention. However, variation in the methods of assessing and reporting sarcopenia in this patient group limits the assessment of post-operative outcomes currently.},
  langid = {english},
  keywords = {Pancreas},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K53G8HMW\\Bundred et al_2019_Body composition assessment and sarcopenia in patients with pancreatic cancer.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\FALFAH88\\S1365182X19305684.html}
}

@article{burns311,
  title = {A {{Machine Learning Algorithm}} to {{Estimate Sarcopenia}} on {{Abdominal CT}}},
  author = {Burns, Joseph E. and Yao, Jianhua and Chalhoub, Didier and Chen, Joseph J. and Summers, Ronald M.},
  year = {2020},
  month = mar,
  journal = {Academic Radiology},
  volume = {27},
  number = {3},
  pages = {311--320},
  issn = {1878-4046},
  doi = {10.1016/j.acra.2019.03.011},
  abstract = {RATIONALE AND OBJECTIVES: To assess whether a fully-automated deep learning system can accurately detect and analyze truncal musculature at multiple lumbar vertebral levels and muscle groupings on abdominal CT for potential use in the detection of central sarcopenia. MATERIALS AND METHODS: A computer system for automated segmentation of truncal musculature groups was designed and created. Abdominal CT scans of 102 sequential patients (mean age 68 years, range 59-81 years; 53 women, 49 men) conducted between January 2015 and February 2015 were assembled as a data set. Truncal musculature was manually segmented on axial CT images at multiple lumbar vertebral levels as reference standard data, divided into training and testing subsets, and analyzed by the system. Dice similarity coefficients were calculated to evaluate system performance. IRB approval was obtained, with waiver of informed consent in this retrospective study. RESULTS: System performance as gauged by the Dice coefficients, for detecting the total abdominal muscle cross-section at the level of the third and fourth lumbar vertebrae, were, respectively, 0.953 {$\pm$} 0.015 and 0.953 {$\pm$} 0.011 for the training set, and 0.938 {$\pm$} 0.028 and 0.940 {$\pm$} 0.026 for the testing set. Dice coefficients for detecting total psoas muscle cross-section at the level of the third and fourth lumbar vertebrae, were, respectively, 0.942 {$\pm$} 0.040 and 0.951 {$\pm$} 0.037 for the training set, and 0.939 {$\pm$} 0.028 and 0.946 {$\pm$} 0.032 for the testing set. CONCLUSION: This system fully-automatically and accurately segments multiple muscle groups at all lumbar spine levels on abdominal CT for detection of sarcopenia.},
  langid = {english},
  pmid = {31126808},
  keywords = {Adults,Aged,Aged; 80 and over,Algorithms,Computer applications-detection/diagnosis,CT,Female,Humans,Machine Learning,Male,Middle Aged,ML,Musculoskeletal,Oncology,Radiographic Image Interpretation; Computer-Assisted,Retrospective Studies,Sarcopenia,Tomography; X-Ray Computed}
}

@article{bustiE94,
  title = {Anemia and {{Iron Deficiency}} in {{Cancer Patients}}: {{Role}} of {{Iron Replacement Therapy}}},
  shorttitle = {Anemia and {{Iron Deficiency}} in {{Cancer Patients}}},
  author = {Busti, Fabiana and Marchi, Giacomo and Ugolini, Sara and Castagna, Annalisa and Girelli, Domenico},
  year = {2018},
  month = sep,
  journal = {Pharmaceuticals (Basel, Switzerland)},
  volume = {11},
  number = {4},
  pages = {E94},
  issn = {1424-8247},
  doi = {10.3390/ph11040094},
  abstract = {Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and overall prognosis. The pathogenesis is complex and typically multifactorial, with iron deficiency (ID) often being a major and potentially treatable contributor. In turn, ID in cancer patients can be due to multiple concurring mechanisms, including bleeding (e.g., in gastrointestinal cancers or after surgery), malnutrition, medications, and hepcidin-driven iron sequestration into macrophages with subsequent iron-restricted erythropoiesis. Indeed, either absolute or functional iron deficiency (AID or FID) can occur. While for absolute ID there is a general consensus regarding the laboratory definition (that is ferritin levels {$<$}100 ng/mL {$\pm$} transferrin saturation (TSAT) {$<$}20\%), a shared definition of functional ID is still lacking. Current therapeutic options in cancer anemia include iron replacement, erythropoietic stimulating agents (ESAs), and blood transfusions. The latter should be kept to a minimum, because of concerns regarding risks, costs, and limited resources. Iron therapy has proved to be a valid approach to enhance efficacy of ESAs and to reduce transfusion need. Available guidelines focus mainly on patients with chemotherapy-associated anemia, and generally suggest intravenous (IV) iron when AID or FID is present. However, in the case of FID, the upper limit of ferritin in association with TSAT {$<$}20\% at which iron should be prescribed is a matter of controversy, ranging up to 800 ng/mL. An increasingly recognized indication to IV iron in cancer patients is represented by preoperative anemia in elective oncologic surgery. In this setting, the primary goal of treatment is to decrease the need of blood transfusions in the perioperative period, rather than improving anemia-related symptoms as in chemotherapy-associated anemia. Protocols are mainly based on experiences of Patient Blood Management (PBM) in non-oncologic surgery, but no specific guidelines are available for oncologic surgery. Here we discuss some possible approaches to the management of ID in cancer patients in different clinical settings, based on current guidelines and recommendations, emphasizing the need for further research in the field.},
  langid = {english},
  pmcid = {PMC6315653},
  pmid = {30274354},
  keywords = {anemia,cancer,hepcidin,iron deficiency,patient blood management},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WR9I6TIN\\Busti et al_2018_Anemia and Iron Deficiency in Cancer Patients.pdf}
}

@article{caan1008,
  title = {Explaining the {{Obesity Paradox}}: {{The Association}} between {{Body Composition}} and {{Colorectal Cancer Survival}} ({{C-SCANS Study}})},
  shorttitle = {Explaining the {{Obesity Paradox}}},
  author = {Caan, Bette J. and Meyerhardt, Jeffrey A. and Kroenke, Candyce H. and Alexeeff, Stacey and Xiao, Jingjie and Weltzien, Erin and Feliciano, Elizabeth Cespedes and Castillo, Adrienne L. and Quesenberry, Charles P. and Kwan, Marilyn L. and Prado, Carla M.},
  year = {2017},
  month = jul,
  journal = {Cancer Epidemiology, Biomarkers \& Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology},
  volume = {26},
  number = {7},
  pages = {1008--1015},
  issn = {1538-7755},
  doi = {10.1158/1055-9965.EPI-17-0200},
  abstract = {Background: Body composition may partially explain the U-shaped association between body mass index (BMI) and colorectal cancer survival.Methods: Muscle and adiposity at colorectal cancer diagnosis and survival were examined in a retrospective cohort using Kaplan-Meier curves, multivariable Cox regression, and restricted cubic splines in 3,262 early-stage (I-III) male (50\%) and female (50\%) patients. Sarcopenia was defined using optimal stratification and sex- and BMI-specific cut points. High adiposity was defined as the highest tertile of sex-specific total adipose tissue (TAT). Primary outcomes were overall mortality and colorectal cancer-specific mortality (CRCsM).Results: Slightly over 42\% patients were sarcopenic. During 5.8 years of follow-up, 788 deaths occurred, including 433 from colorectal cancer. Sarcopenic patients had a 27\% [HR, 1.27; 95\% confidence interval (CI), 1.09-1.48] higher risk of overall mortality than those who were not sarcopenic. Females with both low muscle and high adiposity had a 64\% higher risk of overall mortality (HR, 1.64; 95\% CI, 1.05-2.57) than females with adequate muscle and lower adiposity. The lowest risk of overall mortality was seen in patients with a BMI between 25 and {$<$}30 kg/m2, a range associated with the greatest number of patients (58.6\%) who were not at increased risk of overall mortality due to either low muscle or high adiposity.Conclusions: Sarcopenia is prevalent among patients with non-metastatic colorectal cancer, and should, along with adiposity be a standard oncological marker.Impact: Our findings suggest a biologic explanation for the obesity paradox in colorectal cancer and refute the notion that the association between overweight and lower mortality is due solely to methodologic biases. Cancer Epidemiol Biomarkers Prev; 26(7); 1008-15. \textcopyright 2017 AACR.},
  langid = {english},
  pmcid = {PMC5647152},
  pmid = {28506965},
  keywords = {Adiposity,Aged,Body Mass Index,Cause of Death,Colorectal Neoplasms,Female,Follow-Up Studies,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Neoplasm Staging,Obesity,Prevalence,Retrospective Studies,Risk Factors,Sarcopenia,Sex Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\REEYF855\\Caan et al. - Explaining the Obesity Paradox The Association be.pdf}
}

@article{callahan1357,
  title = {Automated {{Frailty Screening At-Scale}} for {{Pre-Operative Risk Stratification Using}} the {{Electronic Frailty Index}}},
  author = {Callahan, Kathryn E. and Clark, Clancy J. and Edwards, Angela F. and Harwood, Timothy N. and Williamson, Jeff D. and Moses, Adam W. and Willard, James J. and Cristiano, Joseph A. and Meadows, Kellice and Hurie, Justin and High, Kevin P. and Meredith, J. Wayne and Pajewski, Nicholas M.},
  year = {2021},
  month = may,
  journal = {Journal of the American Geriatrics Society},
  volume = {69},
  number = {5},
  pages = {1357--1362},
  issn = {0002-8614},
  doi = {10.1111/jgs.17027},
  abstract = {BACKGROUND: Frailty is associated with numerous post-operative adverse outcomes in older adults. Current pre-operative frailty screening tools require additional data collection or objective assessments, adding expense and limiting large-scale implementation. OBJECTIVE: To evaluate the association of an automated measure of frailty integrated within the Electronic Health Record (EHR) with post-operative outcomes for nonemergency surgeries. DESIGN: Retrospective cohort study. SETTING: Academic Medical Center. PARTICIPANTS: Patients 65 years or older that underwent nonemergency surgery with an inpatient stay 24 hours or more between October 8th, 2017 and June 1st, 2019. EXPOSURES: Frailty as measured by a 54-item electronic frailty index (eFI). OUTCOMES AND MEASUREMENTS: Inpatient length of stay, requirements for post-acute care, 30-day readmission, and 6-month all-cause mortality. RESULTS: Of 4,831 unique patients (2,281 females (47.3\%); mean (SD) age, 73.2 (5.9) years), 4,143 (85.7\%) had sufficient EHR data to calculate the eFI, with 15.1\% categorized as frail (eFI {$>$} 0.21) and 50.9\% pre-frail (0.10 {$<$} eFI {$\leq$} 0.21). For all outcomes, there was a generally a gradation of risk with higher eFI scores. For example, adjusting for age, sex, race/ethnicity, and American Society of Anesthesiologists class, and accounting for variability by service line, patients identified as frail based on the eFI, compared to fit patients, had greater needs for post-acute care (odds ratio (OR) = 1.68; 95\% confidence interval (CI) = 1.36\textendash 2.08), higher rates of 30-day readmission (hazard ratio (HR) = 2.46; 95\%CI = 1.72\textendash 3.52) and higher all-cause mortality (HR = 2.86; 95\%CI = 1.84\textendash 4.44) over 6 months' follow-up. CONCLUSIONS: The eFI, an automated digital marker for frailty integrated within the EHR, can facilitate pre-operative frailty screening at scale.},
  pmcid = {PMC8127394},
  pmid = {33469933},
  keywords = {eFI},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GB5F8Q7E\\Callahan et al_2021_Automated Frailty Screening At-Scale for Pre-Operative Risk Stratification.pdf}
}

@article{campbell806,
  type = {Journal {{Article}}},
  title = {Conduit {{Vascular Evaluation}} Is {{Associated}} with {{Reduction}} in {{Anastomotic Leak After Esophagectomy}}},
  author = {Campbell, C. and Reames, M. K. and Robinson, M. and Symanowski, J. and Salo, J. C.},
  year = {2015},
  journal = {J Gastrointest Surg},
  volume = {19},
  number = {5},
  pages = {806--12},
  issn = {1873-4626 (Electronic) 1091-255X (Linking)},
  doi = {10.1007/s11605-015-2794-3}
}

@article{canoui-poitrine2236,
  title = {The {{Prognostic Value}} of {{Eight Comorbidity Indices}} in {{Older Patients}} with {{Cancer}}: {{The ELCAPA Cohort Study}}},
  shorttitle = {The {{Prognostic Value}} of {{Eight Comorbidity Indices}} in {{Older Patients}} with {{Cancer}}},
  author = {{Canoui-Poitrine}, Florence and Segaux, Lauriane and Benderra, Marc-Antoine and About, Fr{\'e}d{\'e}gonde and Tournigand, Christophe and Laurent, Marie and Caillet, Philippe and Audureau, Etienne and Ferrat, Emilie and Lagrange, Jean-Leon and Paillaud, Elena and {Bastuji-Garin}, Sylvie and On Behalf Of The Elcapa Study Group, null},
  year = {2022},
  month = apr,
  journal = {Cancers},
  volume = {14},
  number = {9},
  pages = {2236},
  issn = {2072-6694},
  doi = {10.3390/cancers14092236},
  abstract = {BACKGROUND: A prognostic assessment is crucial for making cancer treatment decisions in older patients. We assessed the prognostic performance (relative to one-year mortality) of eight comorbidity indices in a cohort of older patients with cancer. METHODS: We studied patients with cancer aged {$\geq$}70 included in the Elderly Cancer Patient (ELCAPA) cohort between 2007 and 2010. We assessed seven nonspecific indices (Charlson Comorbidity Index (CCI), three modified versions of the CCI, the Elixhauser Comorbidity Index, the Gagne index, and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)) and the National Cancer Institute Comorbidity Index. RESULTS: Overall, 510 patients were included. Among patients with nonmetastatic cancer, all the comorbidity indices were independently associated with 1-year mortality (adjusted hazard ratios (aHRs) of 1.44 to 2.51 for one standard deviation increment; p \&lt; 0.05 for all) and had very good discriminant ability (Harrell's C \&gt; 0.8 for the eight indices), but were poorly calibrated. Among patients with metastatic cancer, only the CIRS-G was independently associated with 1-year mortality (aHR (95\% confidence interval): 1.26 [1.06-1.50]). Discriminant ability was moderate (0.61 to 0.70) for the subsets of patients with metastatic cancer and colorectal cancer. CONCLUSION: Comorbidity indices had strong prognostic value and discriminative ability for one-year mortality in older patients with nonmetastatic cancer, although calibration was poor. In older patients with metastatic cancer, only the CIRS-G was predictive of one-year mortality.},
  langid = {english},
  pmcid = {PMC9105640},
  pmid = {35565364},
  keywords = {cancer,comorbidities,indices,mortality,older patients,Prognostic Scales},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CYHSP938\\Canoui-Poitrine et al_2022_The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer.pdf}
}

@article{cao751,
  title = {Meta-Analysis of Endoscopic Submucosal Dissection versus Endoscopic Mucosal Resection for Tumors of the Gastrointestinal Tract},
  author = {Cao, Y. and Liao, C. and Tan, A. and Gao, Y. and Mo, Z. and Gao, F.},
  year = {2009},
  month = sep,
  journal = {Endoscopy},
  volume = {41},
  number = {9},
  pages = {751--757},
  issn = {1438-8812},
  doi = {10.1055/s-0029-1215053},
  abstract = {BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) has been developed to overcome the limitations of endoscopic mucosal resection (EMR). We aimed to compare the outcomes of these two methods. METHODS: Databases, including Pubmed, EMBASE, and The Cochrane Library, were searched to identify studies comparing ESD with EMR for premalignant and malignant lesions of the gastrointestinal tract. In a meta-analysis, primary end points were the en bloc resection rate and the curative resection rate; secondary end points were operation time, and rates of bleeding, perforation, and local recurrence. RESULTS: 15 nonrandomized studies (seven full-text and eight abstracts) were identified. Meta-analysis showed higher en bloc and curative resection rates (odds ratio [OR] 13.87, 95 \%CI 10.12 - 18.99; OR 3.53, 95 \%CI 2.57 - 4.84) irrespective of lesion size. Subgroup analysis showed higher en bloc and curative resection rates with ESD for esophageal, gastric, and colorectal neoplasms, and for lesions of size {$<$} 10 mm, 10 mm {$<$} 20 mm, and {$>$} 20 mm. Local recurrence was lower with ESD (OR 0.09, 95 \%CI 0.04 - 0.18). But ESD was more time-consuming than EMR (weighted mean difference [WMD] 1.76; 95 \%CI 0.60 - 2.92), and showed high procedure-related bleeding and perforation rates (OR 2.20, 95 \%CI 1.58 - 3.07; OR 4.09, 95 \%CI 2.47 - 6.80). CONCLUSIONS: ESD showed better en bloc and curative resection rates and local recurrence compared with EMR, but was more time-consuming and had higher rates of bleeding and perforation complications. These results need to be confirmed by high quality trials and further studies in the west.},
  langid = {english},
  pmid = {19693750},
  keywords = {Adenocarcinoma,Dissection,Electrocoagulation,Endoscopy; Gastrointestinal,Gastric Mucosa,Gastrointestinal Neoplasms,Humans,Neoplasm Recurrence; Local,Treatment Outcome}
}

@article{cardona1257,
  title = {The {{STRASS}} Trial: An Important Step in the Right Direction},
  shorttitle = {The {{STRASS}} Trial},
  author = {Cardona, Kenneth},
  year = {2020},
  month = oct,
  journal = {The Lancet. Oncology},
  volume = {21},
  number = {10},
  pages = {1257--1258},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(20)30429-0},
  langid = {english},
  pmid = {32941793},
  keywords = {Connective Tissue Diseases,Humans,PreopRT,Retroperitoneal Neoplasms,Sarcoma,Soft Tissue Neoplasms}
}

@article{carli49,
  title = {Surgical {{Prehabilitation}} in {{Patients}} with {{Cancer}}: {{State-of-the-Science}} and {{Recommendations}} for {{Future Research}} from a {{Panel}} of {{Subject Matter Experts}}},
  shorttitle = {Surgical {{Prehabilitation}} in {{Patients}} with {{Cancer}}},
  author = {Carli, Francesco and Silver, Julie K. and Feldman, Liane S. and McKee, Andrea and Gilman, Sean and Gillis, Chelsia and {Scheede-Bergdahl}, Celena and Gamsa, Ann and Stout, Nicole and Hirsch, Bradford},
  year = {2017},
  month = feb,
  journal = {Physical Medicine and Rehabilitation Clinics of North America},
  volume = {28},
  number = {1},
  pages = {49--64},
  issn = {1558-1381},
  doi = {10.1016/j.pmr.2016.09.002},
  abstract = {This review by a 10-member panel of experts in surgical prehabilitation addresses processes that may improve oncologic care. Surgical prehabilitation is the process on the continuum of care that occurs between the time of cancer diagnosis and the beginning of surgical treatment. The panel focused on the current state-of-the-science and recommended future research that would help to identify the elements that enhance preoperative physical, nutritional, and psychological health in anticipation of surgery, mitigate the burden of disease, facilitate the return of patient health status to baseline values, decrease postoperative morbidity, and reduce health care costs.},
  langid = {english},
  pmid = {27913000},
  keywords = {Anxiety,Cancer,Exercise,Humans,Neoplasms,Nutrition,Outcome,Prehab,Prehabilitation,Preoperative Care,Surgery}
}

@article{carroll1706,
  title = {Elimination of {{Routine Feeding Jejunostomy After Esophagectomy}}},
  author = {Carroll, Paul A. and Yeung, Jonathan C. and Darling, Gail E.},
  year = {2020},
  month = nov,
  journal = {The Annals of Thoracic Surgery},
  volume = {110},
  number = {5},
  pages = {1706--1713},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2020.04.072},
  abstract = {BACKGROUND: Feeding jejunostomy is frequently used to ensure nutritional intake after esophagectomy. Early return to diet is demonstrated to enhance recovery in major abdominal surgery. Early oral feeding is safe and effective in recent randomized controlled trials in esophagectomy. This study assesses the implications of eliminating the insertion of jejunostomy after esophagectomy. METHODS: A retrospective study was undertaken between 2014 and 2017 with follow-up over the first year. Fifty patients did not have a jejunostomy, compared with 46 patients who had conventional treatment. Outcomes measured included change in relative weight and body mass over 1 year, complications, and nutritional reinterventions. RESULTS: Median weight loss at 1 year was 10.7 kg (range, -8 to 55.6) whereas median percent weight loss was 12\% (range, -10.1\% to 39.2\%). Patients without jejunostomy lost more weight during the first month (P~= .002). Thereafter, at 6 of 12 months, there were no differences in actual or relative weight loss. Obese patients lost more weight in the group without jejunostomy compared with those who had it (9.9 versus 5 kg; P~= .004). This effect was not seen in normal or overweight patients. Complications were similar, whereas leaks were more common in the jejunostomy group (15.2\% versus 2\%; P~= .019). Nutritional reinterventions were similar during index admission and subsequent readmissions (7 versus 5 patients; P~= .640). CONCLUSIONS: Routine jejunostomy use delays rather than prevents weight loss after esophagectomy. Oral route nutrition allows patients to maintain sufficient nutrition and does not increase complications or requirement for nutritional interventions after surgery. Routine use of jejunostomy may not be required in modern practice.},
  langid = {english},
  pmid = {32504612},
  keywords = {Adult,Aged,Aged; 80 and over,Enteral Nutrition,Esophagectomy,Female,Humans,Jejunostomy,Male,Middle Aged,Outcome Assessment; Health Care,Postoperative Care,Retrospective Studies,Weight Loss}
}

@article{carson2453,
  title = {Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery},
  author = {Carson, Jeffrey L. and Terrin, Michael L. and Noveck, Helaine and Sanders, David W. and Chaitman, Bernard R. and Rhoads, George G. and Nemo, George and Dragert, Karen and Beaupre, Lauren and Hildebrand, Kevin and Macaulay, William and Lewis, Courtland and Cook, Donald Richard and Dobbin, Gwendolyn and Zakriya, Khwaja J. and Apple, Fred S. and Horney, Rebecca A. and Magaziner, Jay and {FOCUS Investigators}},
  year = {2011},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {365},
  number = {26},
  pages = {2453--2462},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1012452},
  abstract = {BACKGROUND: The hemoglobin threshold at which postoperative red-cell transfusion is warranted is controversial. We conducted a randomized trial to determine whether a higher threshold for blood transfusion would improve recovery in patients who had undergone surgery for hip fracture. METHODS: We enrolled 2016 patients who were 50 years of age or older, who had either a history of or risk factors for cardiovascular disease, and whose hemoglobin level was below 10 g per deciliter after hip-fracture surgery. We randomly assigned patients to a liberal transfusion strategy (a hemoglobin threshold of 10 g per deciliter) or a restrictive transfusion strategy (symptoms of anemia or at physician discretion for a hemoglobin level of {$<$}8 g per deciliter). The primary outcome was death or an inability to walk across a room without human assistance on 60-day follow-up. RESULTS: A median of 2 units of red cells were transfused in the liberal-strategy group and none in the restrictive-strategy group. The rates of the primary outcome were 35.2\% in the liberal-strategy group and 34.7\% in the restrictive-strategy group (odds ratio in the liberal-strategy group, 1.01; 95\% confidence interval [CI], 0.84 to 1.22), for an absolute risk difference of 0.5 percentage points (95\% CI, -3.7 to 4.7). The rates of in-hospital acute coronary syndrome or death were 4.3\% and 5.2\%, respectively (absolute risk difference, -0.9\%; 99\% CI, -3.3 to 1.6), and rates of death on 60-day follow-up were 7.6\% and 6.6\%, respectively (absolute risk difference, 1.0\%; 99\% CI, -1.9 to 4.0). The rates of other complications were similar in the two groups. CONCLUSIONS: A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk. (Funded by the National Heart, Lung, and Blood Institute; FOCUS ClinicalTrials.gov number, NCT00071032.).},
  langid = {english},
  pmcid = {PMC3268062},
  pmid = {22168590},
  keywords = {Aged,Aged; 80 and over,Anemia,Blood Transfusion,Erythrocyte Transfusion,Female,Follow-Up Studies,Hemoglobins,Hip Fractures,Humans,Male,Middle Aged,Mortality,Postoperative Complications,Risk Factors,Surgery,Treatment Outcome,Wound Infection},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\C7E6V85R\\Carson et al_2011_Liberal or restrictive transfusion in high-risk patients after hip surgery.pdf}
}

@article{carsonCD002042,
  title = {Transfusion Thresholds for Guiding Red Blood Cell Transfusion},
  author = {Carson, Jeffrey L. and Stanworth, Simon J. and Dennis, Jane A. and Trivella, Marialena and Roubinian, Nareg and Fergusson, Dean A. and Triulzi, Darrell and Dor{\'e}e, Carolyn and H{\'e}bert, Paul C.},
  year = {2021},
  month = dec,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {12},
  pages = {CD002042},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD002042.pub5},
  abstract = {BACKGROUND: The optimal haemoglobin threshold for use of red blood cell (RBC) transfusions in anaemic patients remains~an active field of research.~Blood is a scarce resource, and in some countries, transfusions are less safe than in others because of inadequate testing for viral pathogens. If a liberal transfusion policy does not improve clinical outcomes, or if it is equivalent, then adopting a more restrictive approach could be recognised as the standard of care.~ OBJECTIVES: The aim of this review update was to compare 30-day mortality and other clinical outcomes for participants randomised to restrictive versus liberal red blood cell (RBC) transfusion thresholds (triggers) for all clinical conditions. The restrictive transfusion threshold uses a lower haemoglobin concentration~as a threshold for~transfusion (most commonly, 7.0 g/dL to 8.0 g/dL), and the liberal transfusion threshold uses a higher haemoglobin concentration as a threshold for transfusion (most commonly, 9.0 g/dL to 10.0 g/dL). SEARCH METHODS: We identified trials~through updated searches: CENTRAL (2020, Issue 11), MEDLINE (1946 to November 2020), Embase (1974 to November 2020), Transfusion Evidence Library (1950 to November 2020), Web of Science Conference Proceedings Citation Index (1990 to~November 2020), and trial registries (November~2020). We~ checked the reference lists of other published reviews and relevant papers to identify additional trials. We were aware of one trial identified in earlier searching that was in the process of being published (in February 2021), and we were able to include it before this review was finalised. SELECTION CRITERIA: We included randomised trials of surgical or medical participants that recruited adults or children, or both. We excluded studies that focused on neonates. Eligible trials assigned intervention groups on the basis of different transfusion schedules or thresholds or 'triggers'. These thresholds would be defined by a haemoglobin (Hb) or haematocrit (Hct) concentration~below which an~RBC~transfusion would be administered; the~haemoglobin concentration remains the most commonly applied marker~of the need for RBC transfusion in clinical practice.~We included trials in which investigators had allocated participants to higher thresholds or more liberal transfusion strategies compared to more restrictive ones, which might include no transfusion. As in previous versions of this review, we did not exclude unregistered trials published after 2010 (as per the policy of the Cochrane Injuries Group, 2015), however, we did conduct analyses to consider the differential impact of results of trials for which prospective registration could not be confirmed. ~ DATA COLLECTION AND ANALYSIS: We identified trials for inclusion and extracted data using Cochrane methods. We pooled risk ratios of clinical outcomes across trials using a random-effects model. Two review authors~independently extracted data and assessed risk of bias. We conducted predefined analyses by clinical subgroups. We defined participants randomly allocated to the lower transfusion threshold as being in the 'restrictive transfusion' group and those randomly allocated to the higher transfusion threshold as being in the 'liberal transfusion' group. MAIN RESULTS: A total of~48~trials, involving data from 21,433 participants (at baseline), across a range of clinical contexts (e.g. orthopaedic, cardiac, or vascular surgery; critical care; acute blood loss (including gastrointestinal bleeding); acute coronary syndrome; cancer; leukaemia; haematological malignancies), met the eligibility criteria. The haemoglobin concentration used to define the restrictive transfusion group in most trials (36) was between 7.0 g/dL and 8.0 g/dL. ~Most trials included only adults; three trials focused on children. The included studies were generally at low risk of bias for key domains including allocation concealment and incomplete outcome data. Restrictive transfusion strategies reduced the risk of receiving at least one RBC transfusion by 41\% across a broad range of clinical contexts (risk ratio (RR) 0.59, 95\% confidence interval (CI) 0.53 to 0.66; 42 studies, 20,057~participants; high-quality evidence), with a large amount of heterogeneity between trials (I{$^2$} = 96\%). Overall, restrictive transfusion strategies did not increase or decrease the risk of 30-day mortality compared with liberal transfusion strategies (RR 0.99, 95\% CI 0.86 to 1.15; 31 studies, 16,729 participants; I{$^2$} = 30\%; moderate-quality evidence) or any of the other outcomes assessed (i.e. cardiac events (low-quality evidence), myocardial infarction, stroke, thromboembolism (all high-quality evidence)). High-quality evidence shows that the liberal transfusion threshold did not affect the risk of infection (pneumonia, wound infection, or bacteraemia). Transfusion-specific reactions are uncommon and were inconsistently reported within trials. We noted less certainty in the strength of evidence to support the safety of restrictive transfusion thresholds for the following predefined clinical subgroups: myocardial infarction, vascular surgery, haematological malignancies, and chronic bone-marrow disorders. AUTHORS' CONCLUSIONS: Transfusion~at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41\% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted~30-day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and selected clinical contexts, such as myocardial infarction, chronic cardiovascular disease, neurological injury or traumatic brain injury, stroke, thrombocytopenia, and cancer or haematological malignancies, including chronic~bone marrow failure.~ Further work is needed to improve our understanding of outcomes other than mortality.~Most trials compared only two~separate thresholds for haemoglobin concentration, which may not identify the~actual optimal threshold for transfusion in a particular patient. Haemoglobin concentration may not be the most informative marker of the need for transfusion in individual patients with different degrees of physiological adaptation to anaemia. Notwithstanding these issues, overall findings provide good evidence that transfusions with allogeneic RBCs can be avoided in most patients with haemoglobin thresholds between the range of 7.0 g/dL and 8.0 g/dL.~Some patient subgroups~might benefit from RBCs~to maintain higher haemoglobin concentrations; research efforts should focus on these clinical contexts.},
  langid = {english},
  pmcid = {PMC8691808},
  pmid = {34932836},
  keywords = {Anemia,Erythrocyte Transfusion,Hematocrit,Hemoglobins,Humans,Prospective Studies,Randomized Controlled Trials as Topic}
}

@article{cassidy740,
  title = {I {{COUGH}}: Reducing Postoperative Pulmonary Complications with a Multidisciplinary Patient Care Program},
  shorttitle = {I {{COUGH}}},
  author = {Cassidy, Michael R. and Rosenkranz, Pamela and McCabe, Karen and Rosen, Jennifer E. and McAneny, David},
  year = {2013},
  month = aug,
  journal = {JAMA surgery},
  volume = {148},
  number = {8},
  pages = {740--745},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2013.358},
  abstract = {IMPORTANCE: Postoperative pulmonary complications can be a devastating consequence of surgery. Validated strategies to reduce these adverse outcomes are needed. OBJECTIVES: To design, implement, and determine the efficacy of a suite of interventions for reducing postoperative pulmonary complications. DESIGN: A before-after trial comparing our National Surgical Quality Improvement Program (NSQIP) pulmonary outcomes before and after implementing I COUGH, a multidisciplinary pulmonary care program. SETTING: An urban, academic, safety-net hospital. PARTICIPANTS: All patients who underwent general or vascular surgery at our institution during a 1-year period before and after implementation of I COUGH. INTERVENTIONS: A multidisciplinary team developed a strategy to reduce pulmonary complications based on comprehensive patient and family education and a set of standardized electronic physician orders to specify early postoperative mobilization and pulmonary care. Designated by the acronym I COUGH, the program emphasizes incentive spirometry, coughing and deep breathing, oral care (brushing teeth and using mouthwash twice daily), understanding (patient and family education), getting out of bed at least 3 times daily, and head-of-bed elevation. Nursing and physician education promoted a culture of mobilization and I COUGH interventions. I COUGH was implemented for all general surgery and vascular surgery patients at our institution in August 2010. MAIN OUTCOMES AND MEASURES: The NSQIP-reported incidence and risk-adjusted ratios of postoperative pneumonia and unplanned intubation, which NSQIP reports as observed-expected (OE) ratios for the 1-year period before implementing I COUGH and as odds ratios (ORs, statistically comparable to OE ratios) for the period after its implementation. RESULTS: Before implementation of I COUGH, our incidence of postoperative pneumonia was 2.6\%, falling to 1.6\% after its implementation, and risk-adjusted outcomes fell from an OE ratio of 2.13 to an OR of 1.58. The incidence of unplanned intubations was 2.0\% before I COUGH and 1.2\% after I COUGH, with risk-adjusted outcomes decreasing from an OE ratio of 2.10 to an OR of 1.31. CONCLUSIONS AND RELEVANCE: I COUGH, a standardized postoperative care program emphasizing patient education, early mobilization, and pulmonary interventions, reduced the incidence of postoperative pneumonia and unplanned intubation among our patients.},
  langid = {english},
  pmid = {23740240},
  keywords = {Cohort Studies,Comprehensive Health Care,Cough,Female,Hospitalization,Humans,Intubation; Intratracheal,Lung Diseases,Male,Patient Care Team,Postoperative Care,Postoperative Complications,Program Evaluation,Respiration; Artificial,Respiratory},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DD67P3XR\\Cassidy et al_2013_I COUGH.pdf}
}

@article{casson205,
  type = {Journal {{Article}}},
  title = {What Is the Optimal Distal Resection Margin for Esophageal Carcinoma?},
  author = {Casson, A. G. and Darnton, S. J. and Subramanian, S. and Hiller, L.},
  year = {2000},
  journal = {Ann Thorac Surg},
  volume = {69},
  number = {1},
  pages = {205--9},
  issn = {0003-4975 (Print) 0003-4975 (Linking)}
}

@article{castoro1375,
  title = {Complete Clinical Response after Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?},
  shorttitle = {Complete Clinical Response after Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus},
  author = {Castoro, Carlo and Scarpa, Marco and Cagol, Matteo and Alfieri, Rita and Ruol, Alberto and Cavallin, Francesco and Michieletto, Silvia and Zanchettin, Giampietro and {Chiarion-Sileni}, Vanna and Corti, Luigi and Ancona, Ermanno},
  year = {2013},
  month = aug,
  journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
  volume = {17},
  number = {8},
  pages = {1375--1381},
  issn = {1873-4626},
  doi = {10.1007/s11605-013-2269-3},
  abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (CT-RT) before oesophagectomy is standard management for squamous cell carcinoma(SCC) of the thoracic oesophagus. The aim of this study was to compare the outcome of patients who had clinical complete response(CR) with neoadjuvant CT-RT + oesophagectomy with the survival of patients who had clinical CR and were not operated on. PATIENTS AND METHODS: Seventy-seven consecutive patients with SCC of the thoracic oesophagus with CR with neoadjuvant CT-RT presenting at the Regional Center of Esophageal Diseases from 1992 to 2008 were included in this retrospective study on a prospectively collected database. Thirty-nine patients underwent oesophagectomy (CT-RT + oesophagectomy), while 38(CT-RT) were not operated on because they were considered unfit for surgery or refused the operation. Patients' outcome and survival were compared. RESULTS: In the CT-RT + oesophagectomy group, clinical CR was confirmed after histological examination of the surgical specimen in 27/39 (69.2 \%) patients. Five-year overall survival rates were 50.0 \% in the CT-RT + oesophagectomy group and 57.0 \% in the CT-RT group (p=0.99); 5-year disease-free survival rates were 55.5\%in the CT-RT + oesophagectomy group and 34.6\%in the CTRT group (p=0.15). Even after adjusting for propensity score, age, ASA and clinical stage, the treatment regimen did not show a statistically significant effect on overall survival (adjusted p=0.65) nor on disease-free survival (adjusted p=0.15). CONCLUSION: In our group of patients with clinical CR after neoadjuvant CT-RT for SCC of the thoracic oesophagus, waiting for recurrence and then using salvage surgery did not negatively impact their survival compared to patients treated with surgery. More accurate restaging protocols are warranted to improve decision making after CR with neoadjuvant CT-RT.},
  langid = {english},
  pmid = {23797888},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Chemoradiotherapy; Adjuvant,Cisplatin,Disease-Free Survival,Dose Fractionation; Radiation,Esophageal Neoplasms,Esophagectomy,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Retrospective Studies,Survival Rate}
}

@article{catae043453,
  title = {International Multicentre Observational Study to Evaluate the Association between Perioperative Red Blood Cell Transfusions and 1-Year Mortality after Major Cancer Surgery ({{ARCA-1}}): Study Design, Statistical Analysis Plan and Study Protocol},
  shorttitle = {International Multicentre Observational Study to Evaluate the Association between Perioperative Red Blood Cell Transfusions and 1-Year Mortality after Major Cancer Surgery ({{ARCA-1}})},
  author = {Cata, Juan and Ramirez, Maria and Forget, Patrice and Chen, Lee-Lynn and {Diaz-Cambronero}, Oscar and Chen, Wankun and Warner, Matthew A. and Knopfelmacher Couchonal, Adriana and Pelosi, Paolo and Cuellar, Luis and Corrales, German and Romero, Carlos and Lobo, Francisco and Saager, Leif and Castro Tapia, Jorge and Kiberenge, Roy and Feng, Lei and Serpa Neto, Ary},
  year = {2021},
  month = mar,
  journal = {BMJ open},
  volume = {11},
  number = {3},
  pages = {e043453},
  issn = {2044-6055},
  doi = {10.1136/bmjopen-2020-043453},
  abstract = {INTRODUCTION: Blood transfusion is still common in patients undergoing major cancer surgery. Blood transfusion can be associated with poor prognosis in patients with cancer. Perioperative Care in the Cancer Patient -1 (ARCA-1) aims to assess in a large cohort of patients the current incidence, pattern of practice and associations between perioperative blood transfusions and 1-year survival in patients undergoing major cancer surgery. METHODS AND ANALYSIS: ARCA-1 is a prospective international multicentre observational study that will include adult patients scheduled to have major cancer surgical procedures with the intention to cure, and an overnight planned hospital admission. The study will be opened for 1\,year for enrolment (7 January 2020-7 February 2021). Each centre will enrol patients for 30 days. The primary endpoint of this study is all-cause mortality 1\,year after major cancer surgery. Secondary endpoints are rate of perioperative blood product use, cancer-specific mortality at 1 year and PFSs and 30-day morbidity and mortality. ETHICS AND DISSEMINATION: This study was approved by the Institutional Review Board at The University of Texas-MD Anderson Cancer Center. The study results will be published in peer-reviewed journals and disseminated at international conferences. TRIAL REGISTRATION NUMBER: NCT04491409.},
  langid = {english},
  pmcid = {PMC7978332},
  pmid = {33737431},
  keywords = {Adult,adult oncology,blood bank \& transfusion medicine,Blood Transfusion,Erythrocyte Transfusion,Humans,Morbidity,Multicenter Studies as Topic,Neoplasms,Observational Studies as Topic,Perioperative Care,Prospective Studies,surgery,SurgOnc},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LAKJWD6U\\Cata et al_2021_International multicentre observational study to evaluate the association.pdf}
}

@article{cederholm1,
  title = {{{GLIM}} Criteria for the Diagnosis of Malnutrition - {{A}} Consensus Report from the Global Clinical Nutrition Community},
  author = {Cederholm, T. and Jensen, G. L. and Correia, M. I. T. D. and Gonzalez, M. C. and Fukushima, R. and Higashiguchi, T. and Baptista, G. and Barazzoni, R. and Blaauw, R. and Coats, A. and Crivelli, A. and Evans, D. C. and Gramlich, L. and {Fuchs-Tarlovsky}, V. and Keller, H. and Llido, L. and Malone, A. and Mogensen, K. M. and Morley, J. E. and Muscaritoli, M. and Nyulasi, I. and Pirlich, M. and Pisprasert, V. and {de van der Schueren}, M. a. E. and Siltharm, S. and Singer, P. and Tappenden, K. and Velasco, N. and Waitzberg, D. and Yamwong, P. and Yu, J. and Van Gossum, A. and Compher, C. and {GLIM Core Leadership Committee} and {GLIM Working Group}},
  year = {2019},
  month = feb,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {38},
  number = {1},
  pages = {1--9},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2018.08.002},
  abstract = {RATIONALE: This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS: In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS: A two-step approach for the malnutrition diagnosis was selected, i.e., first screening to identify "at risk" status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSION: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re-considered every 3-5 years.},
  langid = {english},
  pmid = {30181091},
  keywords = {Adult,Assessment,Consensus,Diagnosis,Humans,Internationality,Leadership,Malnutrition,Nutrition Assessment,Nutritional Status,Screening,Societies; Scientific},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FLBP7M29\\Cederholm et al_2019_GLIM criteria for the diagnosis of malnutrition - A consensus report from the.pdf}
}

@article{cella1179,
  type = {Journal {{Article}}},
  title = {The {{Patient-Reported Outcomes Measurement Information System}} ({{PROMIS}}) Developed and Tested Its First Wave of Adult Self-Reported Health Outcome Item Banks: 2005-2008},
  author = {Cella, D. and Riley, W. and Stone, A. and Rothrock, N. and Reeve, B. and Yount, S. and Amtmann, D. and Bode, R. and Buysse, D. and Choi, S. and Cook, K. and Devellis, R. and DeWalt, D. and Fries, J. F. and Gershon, R. and Hahn, E. A. and Lai, J. S. and Pilkonis, P. and Revicki, D. and Rose, M. and Weinfurt, K. and Hays, R. and Group, Promis Cooperative},
  year = {2010},
  journal = {J Clin Epidemiol},
  volume = {63},
  number = {11},
  pages = {1179--94},
  issn = {1878-5921 (Electronic) 0895-4356 (Linking)},
  doi = {10.1016/j.jclinepi.2010.04.011}
}

@article{cella570,
  type = {Journal {{Article}}},
  title = {The {{Functional Assessment}} of {{Cancer Therapy}} Scale: Development and Validation of the General Measure},
  author = {Cella, D. F. and Tulsky, D. S. and Gray, G. and Sarafian, B. and Linn, E. and Bonomi, A. and Silberman, M. and Yellen, S. B. and Winicour, P. and Brannon, J. and {al}, et},
  year = {1993},
  journal = {J Clin Oncol},
  volume = {11},
  number = {3},
  pages = {570--9},
  issn = {0732-183X (Print) 0732-183X (Linking)},
  doi = {10.1200/JCO.1993.11.3.570}
}

@article{cercek2363,
  title = {{{PD-1 Blockade}} in {{Mismatch Repair-Deficient}}, {{Locally Advanced Rectal Cancer}}},
  author = {Cercek, Andrea and Lumish, Melissa and Sinopoli, Jenna and Weiss, Jill and Shia, Jinru and {Lamendola-Essel}, Michelle and El Dika, Imane H. and Segal, Neil and Shcherba, Marina and Sugarman, Ryan and Stadler, Zsofia and Yaeger, Rona and Smith, J. Joshua and Rousseau, Benoit and Argiles, Guillem and Patel, Miteshkumar and Desai, Avni and Saltz, Leonard B. and Widmar, Maria and Iyer, Krishna and Zhang, Janie and Gianino, Nicole and Crane, Christopher and Romesser, Paul B. and Pappou, Emmanouil P. and Paty, Philip and {Garcia-Aguilar}, Julio and Gonen, Mithat and Gollub, Marc and Weiser, Martin R. and Schalper, Kurt A. and Diaz, Luis A.},
  year = {2022},
  month = jun,
  journal = {The New England Journal of Medicine},
  volume = {386},
  number = {25},
  pages = {2363--2376},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa2201445},
  abstract = {BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer. METHODS: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy. RESULTS: A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100\%; 95\% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).},
  langid = {english},
  pmid = {35660797},
  keywords = {Antibodies; Monoclonal; Humanized,Antineoplastic Agents,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy,DNA Mismatch Repair,Humans,Immunotherapy,Neoadjuvant Therapy,Neoplasm Staging,Neoplasms; Second Primary,Programmed Cell Death 1 Receptor,Prospective Studies,Rectal Neoplasms,Rectum,Treatment Outcome}
}

@article{cerfolio1187,
  type = {Journal {{Article}}},
  title = {Fast Tracking after {{Ivor Lewis}} Esophagogastrectomy},
  author = {Cerfolio, R. J. and Bryant, A. S. and Bass, C. S. and Alexander, J. R. and Bartolucci, A. A.},
  year = {2004},
  journal = {Chest},
  volume = {126},
  number = {4},
  pages = {1187--94},
  issn = {0012-3692 (Print) 0012-3692 (Linking)},
  doi = {10.1378/chest.126.4.1187}
}

@article{cespedesfeliciano4868,
  title = {Muscle Mass at the Time of Diagnosis of Nonmetastatic Colon Cancer and Early Discontinuation of Chemotherapy, Delays, and Dose Reductions on Adjuvant {{FOLFOX}}: {{The C-SCANS}} Study},
  shorttitle = {Muscle Mass at the Time of Diagnosis of Nonmetastatic Colon Cancer and Early Discontinuation of Chemotherapy, Delays, and Dose Reductions on Adjuvant {{FOLFOX}}},
  author = {Cespedes Feliciano, Elizabeth M. and Lee, Valerie S. and Prado, Carla M. and Meyerhardt, Jeffrey A. and Alexeeff, Stacey and Kroenke, Candyce H. and Xiao, Jingjie and Castillo, Adrienne L. and Caan, Bette J.},
  year = {2017},
  month = dec,
  journal = {Cancer},
  volume = {123},
  number = {24},
  pages = {4868--4877},
  issn = {1097-0142},
  doi = {10.1002/cncr.30950},
  abstract = {BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer. METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients). Patients' muscle mass was quantified using clinically acquired computed tomography scans. The authors quantified chemotherapy doses, treatment dates, and related toxicities using the electronic medical record. In logistic regression models adjusting for age, sex, and American Joint Committee on Cancer stage of disease, the authors examined associations of muscle tertiles with early treatment discontinuation ({$<$}6 cycles), treatment delay ({$>$}3 days off schedule for {$\geq$}3 times), and/or dose reduction (relative dose intensity\,{$\leq$}\,0.70, based on planned treatment). RESULTS: The average age of the patients at the time of diagnosis was 58.7 years; BSA was 1.9\,m2 and body mass index was 28.7\,kg/m2 . Compared with the highest sex-specific tertile of muscle mass, patients in the lowest tertile were more likely to experience toxicities and had twice the risk of adverse outcomes while receiving FOLFOX; for early discontinuation, the odds ratio (OR) was 2.34 (95\% confidence interval [95\% CI], 1.04-5.24; P for trend\,=\,.03), whereas the ORs were 2.24 (95\% CI, 1.37-3.66; P for trend\,=\,.002) for treatment delay and 2.28 (95\% CI, 1.19-4.36; P for trend\,=\,.01) for dose reduction. CONCLUSIONS: Lower muscle mass is associated with greater toxicity and poor chemotherapy adherence among patients receiving FOLFOX. Many chemotherapy drugs are dosed based on BSA, but treatment may be better individualized if muscle mass is considered. Cancer 2017;123:4868-77. \textcopyright{} 2017 American Cancer Society.},
  langid = {english},
  pmcid = {PMC5716836},
  pmid = {28881381},
  keywords = {Adult,Aged,Analysis of Variance,Antineoplastic Combined Chemotherapy Protocols,body composition,Body Composition,Body Mass Index,body surface area,chemotherapy,Chemotherapy; Adjuvant,Chi-Square Distribution,Colectomy,colon cancer,Colonic Neoplasms,Databases; Factual,dose-limiting toxicity,Dose-Response Relationship; Drug,Drug Administration Schedule,Female,Fluorouracil,Humans,Kaplan-Meier Estimate,Leucovorin,Male,Middle Aged,Muscle; Skeletal,Neoplasm Invasiveness,Neoplasm Staging,Organ Size,Organoplatinum Compounds,Prognosis,relative dose intensity,Retrospective Studies,Risk Assessment,skeletal muscle mass,Statistics; Nonparametric,Survival Analysis,Tomography; X-Ray Computed,Treatment Outcome,United States,Withholding Treatment}
}

@article{chan147,
  title = {Population-{{Based Patterns}} and {{Factors Associated With Underuse}} of {{Palliative Systemic Therapy}} in {{Elderly Patients With Metastatic Colon Cancer}}},
  author = {Chan, Matthew and {Hugh-Yeun}, Kiara and Gresham, Gillian and Speers, Caroline H. and Kennecke, Hagen F. and Cheung, Winson Y.},
  year = {2017},
  month = jun,
  journal = {Clinical Colorectal Cancer},
  volume = {16},
  number = {2},
  pages = {147--153},
  issn = {1938-0674},
  doi = {10.1016/j.clcc.2016.08.004},
  abstract = {BACKGROUND: We compared the patterns and factors associated with chemotherapy and bevacizumab use in elderly versus young patients with metastatic colon cancer (mCC) and determined the effect of systemic therapy on overall survival (OS) according to age. MATERIALS AND METHODS: Patients diagnosed with mCC from 2009 to 2010 in British Columbia, Canada were reviewed and categorized as elderly patients (age~{$\geq$} 70 years) and young patients (age~{$<$} 70 years). Cox regression models adjusted for age and confounders were used to determine the effect of systemic therapy on OS. RESULTS: We identified 1013 patients with a median age of 67 years. Of the 1013 patients, 42\% were elderly and 58\% were young; 57\% were men; and 66\% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Fewer elderly patients were offered systemic therapy compared with young patients (48\% vs. 77\%; P~{$<$} .001). Among those treated, elderly patients were less likely than young patients to receive combination chemotherapy (47\% vs. 81\%; P~{$<$} .0001) and bevacizumab (19\% vs. 47\%; P~{$<$} .0001). The most common reasons for no treatment were similar for the elderly and young patients: patient choice, poor ECOG PS, and significant comorbidities. Advanced age alone was also cited as a reason for elderly but not for young patients (7\% vs. 0\%). When treated, the risk of adverse events and treatment interruptions was comparable between age groups. The receipt of systemic therapy was associated with improved OS in both elderly (hazard ratio [HR], 0.45; 95\% confidence interval [CI], 0.37-0.56; P~{$<$} .0001) and young (HR, 0.43; 95\% CI, 0.35-0.53; P~{$<$} .0001) patients, regardless of age (interaction P {$>$} .05). CONCLUSION: In carefully selected elderly patients, the outcomes from systemic therapy were comparable to those for young patients. Thus, age alone should not be a barrier to treatment of mCC.},
  langid = {english},
  pmid = {27670894},
  keywords = {Adult,Age Factors,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Bevacizumab,British Columbia,Capecitabine,Colonic Neoplasms,Elderly,Female,FOLFIRI,FOLFOX,Humans,Male,mCC,Middle Aged,Neoplasm Metastasis,Outcomes,Palliative Care,Patient Selection,Proportional Hazards Models,Survival Rate,Young Adult}
}

@article{charette134,
  title = {Prognostic Value of Adipose Tissue and Muscle Mass in Advanced Colorectal Cancer: A Post Hoc Analysis of Two Non-Randomized Phase {{II}} Trials},
  shorttitle = {Prognostic Value of Adipose Tissue and Muscle Mass in Advanced Colorectal Cancer},
  author = {Charette, Nicolas and Vandeputte, Caroline and Ameye, Lieveke and Bogaert, Camille Van and Krygier, Jonathan and Guiot, Thomas and Deleporte, Am{\'e}lie and Delaunoit, Thierry and Geboes, Karen and Van Laethem, Jean-Luc and Peeters, Marc and Demolin, Gauthier and Holbrechts, St{\'e}phane and Flamen, Patrick and Paesmans, Marianne and Hendlisz, Alain},
  year = {2019},
  month = feb,
  journal = {BMC cancer},
  volume = {19},
  number = {1},
  pages = {134},
  issn = {1471-2407},
  doi = {10.1186/s12885-019-5319-8},
  abstract = {BACKGROUND: The prognostic value of body composition in cancer patients has been widely studied during the last decade. The main finding of these studies is that sarcopenia, or skeletal muscle depletion, assessed by CT imaging correlates with a reduced overall survival (OS). By contrast, the prognostic value of fat mass remains ill-defined. This study aims to analyze the influence of body composition including both muscle mass and adipose tissue on OS in a homogeneous population of advanced colorectal cancer (CRC) patients. METHODS: Among 235 patients with chemorefractory advanced CRC included in the SoMore and RegARd-C trials, body composition was assessed in 217 patients on baseline CT images. The relationship between body composition (sarcopenia, muscle density, subcutaneous and visceral fat index and density), body mass index (BMI) and OS were evaluated. RESULTS: Patients with a higher BMI had a better OS ({$\geq$}30 versus {$<$}\,30, HR: 0.50; 0.33-0.76). Those with low muscle index and muscle density had an increased mortality (HR: 2.06; 1.45-2.93 and HR: 1.54; 1.09-2.18, respectively). Likewise, low subcutaneous and visceral fat index were associated with an increased risk of dying (HR: 1.63; 1.23-2.17 and 1.48; 1.09-2.02 respectively), as were a high subcutaneous and visceral adipose tissue density (HR: 1.93; 1.44-2.57 and 2.40; 1.79-3.20 respectively). In multivariate analysis, a high visceral fat density was the main predictor of poor survival. CONCLUSIONS: Our results confirm the protective role of obesity in CRC patients at an advanced stage, as well as the negative prognostic impact of muscle depletion on survival. More importantly, our data show for the first time that visceral adipose tissue density is an important prognostic factor in metastatic CRC. TRIAL REGISTRATION: NCT01290926 , 07/02/2011 and NCT01929616 , 28/08/2013.},
  langid = {english},
  pmcid = {PMC6371452},
  pmid = {30744591},
  keywords = {Adipose tissue,Adipose Tissue,Adult,Aged,Aged; 80 and over,Biomarkers,Body Composition,Body Mass Index,Brown Adipose Tissue,Chemotherapy,Clinical Trials; Phase II as Topic,Colorectal cancer,Colorectal Neoplasms,Female,Humans,Image Processing; Computer-Assisted,Male,Middle Aged,Muscle; Skeletal,Myosteatosis,Obesity,Organ Size,Positron Emission Tomography Computed Tomography,Prognosis,Proportional Hazards Models,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\E4NWUS9D\\Charette et al. - 2019 - Prognostic value of adipose tissue and muscle mass.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\LD5A4K3W\\Charette et al. - 2019 - Prognostic value of adipose tissue and muscle mass.pdf}
}

@article{charlote128,
  type = {Journal {{Article}}},
  title = {Patient {{Activation Mediates Health Literacy Associated}} with {{Hospital Utilization}} among {{Whites}}},
  author = {Charlot, M. and Winter, M. R. and Cabral, H. and Wolf, M. S. and Curtis, L. M. and Hanchate, A. and {Paasche-Orlow}, M.},
  year = {2017},
  journal = {Health Lit Res Pract},
  volume = {1},
  number = {3},
  pages = {e128-e135},
  issn = {2474-8307 (Print)},
  doi = {10.3928/24748307-20170621-01}
}

@article{chatterton354,
  title = {Positron Emission Tomography Changes Management and Prognostic Stratification in Patients with Oesophageal Cancer: Results of a Multicentre Prospective Study},
  shorttitle = {Positron Emission Tomography Changes Management and Prognostic Stratification in Patients with Oesophageal Cancer},
  author = {Chatterton, B. E. and Ho Shon, I. and Baldey, A. and Lenzo, N. and Patrikeos, A. and Kelley, B. and Wong, D. and Ramshaw, J. E. and Scott, A. M.},
  year = {2009},
  month = mar,
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  volume = {36},
  number = {3},
  pages = {354--361},
  issn = {1619-7089},
  doi = {10.1007/s00259-008-0959-y},
  abstract = {OBJECTIVES: The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis. METHODS: In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis. RESULTS: A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41\%). Significant changes in management (high or medium impact) were observed in 38\% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p {$<$} 0.05), but was not related to SUV(max). CONCLUSION: These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.},
  langid = {english},
  pmid = {18931839},
  keywords = {Aged,Disease-Free Survival,Esophageal Neoplasms,Female,Fluorine Radioisotopes,Fluorodeoxyglucose F18,Humans,Male,Neoplasm Staging,Positron-Emission Tomography,Prognosis,Prospective Studies,Radiopharmaceuticals,Tomography; X-Ray Computed}
}

@article{chen106,
  type = {Journal {{Article}}},
  title = {The Effect of Ultrasound-Guided Intercostal Nerve Block, Single-Injection Erector Spinae Plane Block and Multiple-Injection Paravertebral Block on Postoperative Analgesia in Thoracoscopic Surgery: {{A}} Randomized, Double-Blinded, Clinical Trial},
  author = {Chen, N. and Qiao, Q. and Chen, R. and Xu, Q. and Zhang, Y. and Tian, Y.},
  year = {2020},
  journal = {J Clin Anesth},
  volume = {59},
  pages = {106--111},
  issn = {1873-4529 (Electronic) 0952-8180 (Linking)},
  doi = {10.1016/j.jclinane.2019.07.002}
}

@article{chen3395,
  title = {Evaluation of Determinants for Age Disparities in the Survival Improvement of Colon Cancer: Results from a Cohort of More than 486,000 Patients in the {{United States}}},
  shorttitle = {Evaluation of Determinants for Age Disparities in the Survival Improvement of Colon Cancer},
  author = {Chen, Fa and Wang, Fei and Bailey, Christina E. and Murff, Harvey J. and Berlin, Jordan D. and Shu, Xiao-Ou and Zheng, Wei},
  year = {2020},
  journal = {American Journal of Cancer Research},
  volume = {10},
  number = {10},
  pages = {3395--3405},
  issn = {2156-6976},
  abstract = {Over the past two decades, elderly colon cancer patients experienced less improvement in survival than their younger counterparts, yet the contributing factors remain unknown. We aimed to evaluate factors that may contribute to the age disparity of survival improvement among patients with colon cancer. Using data from the National Cancer Database, we identified patients diagnosed with colon cancer between 2004 and 2012 with follow-up data up to 2017. The hazard ratios (HR) and 95\% confidence intervals (CI) for 5-year OS associated with study variables were estimated using multivariable Cox regression. Among 486,284 patients included in this study, elderly patients (aged {$\geq$}75) had a lower adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines (\% of non-adherence: 45.3\%) than younger patients (aged {$<$}50, 19.3\%; P{$<$}0.001). After adjusting for demographics, access to care and clinical characteristics, compared with patients diagnosed between 2004 and 2006, younger and older patients diagnosed between 2010 and 2012 experienced 16\% (HR: 0.84, 95\% CI: 0.81-0.88) and 6\% (HR: 0.94, 95\% CI: 0.93-0.95) reductions in mortality (P for interaction=1.42\texttimes 10-5), respectively. After an additional adjustment for guideline adherence status, no significant difference in the improvement of survival was noted (P for interaction=0.17). The association patterns were similar regardless of tumor stage, race, and high comorbidity scores (all P for interaction{$>$}0.05). Several patient-related factors were identified in association with noncompliance to NCCN guidelines, including comorbidity status. However, over 60\% of noncompliance elderly patients had a Charlson comorbidity score of 0. The observed age disparity in survival improvement among colon cancer patients was primarily explained by a slower improvement in adherence to NCCN treatment guidelines in elderly than younger patients. Many older adults were not receiving recommended therapies despite minimal comorbidities. Our findings call for measures to increase adherence to treatment guidelines among elderly patients to improve survival.},
  langid = {english},
  pmcid = {PMC7642646},
  pmid = {33163278},
  keywords = {Colon cancer,CRC,elderly populations,guideline adherence,survival improvement}
}

@article{chen5246,
  type = {Journal {{Article}}},
  title = {Post-Discharge Complications after Esophagectomy Account for High Readmission Rates},
  author = {Chen, S. Y. and Molena, D. and Stem, M. and Mungo, B. and Lidor, A. O.},
  year = {2016},
  journal = {World J Gastroenterol},
  volume = {22},
  number = {22},
  pages = {5246--53},
  issn = {2219-2840 (Electronic) 1007-9327 (Linking)},
  doi = {10.3748/wjg.v22.i22.5246}
}

@article{chen98,
  type = {Journal {{Article}}},
  title = {Hand-Grip Strength Is a Simple and Effective Outcome Predictor in Esophageal Cancer Following Esophagectomy with Reconstruction: A Prospective Study},
  author = {Chen, C. H. and Ho, Chang and Huang, Y. Z. and Hung, T. T.},
  year = {2011},
  journal = {J Cardiothorac Surg},
  volume = {6},
  pages = {98},
  issn = {1749-8090 (Electronic) 1749-8090 (Linking)},
  doi = {10.1186/1749-8090-6-98},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TTQXQ9W9\\Chen et al. - 2011 - Hand-grip strength is a simple and effective outco.pdf}
}

@article{chibaudel1228,
  title = {Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A {{GERCOR}} Study},
  shorttitle = {Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer},
  author = {Chibaudel, Benoist and Bonnetain, Franck and Tournigand, Christophe and {Bengrine-Lefevre}, Leila and Teixeira, Luis and Artru, Pascal and Desram{\'e}, J{\'e}r{\^o}me and Larsen, Annette K. and Andr{\'e}, Thierry and Louvet, Christophe and {de Gramont}, Aimery},
  year = {2011},
  journal = {The Oncologist},
  volume = {16},
  number = {9},
  pages = {1228--1238},
  issn = {1549-490X},
  doi = {10.1634/theoncologist.2011-0039},
  abstract = {BACKGROUND: The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer. PATIENTS AND METHODS: Eight hundred three patients treated with FOLFOX or FOLFIRI in three prospective trials were randomly separated into learning (n = 535) and validation (n = 268) samples. Eleven baseline variables were evaluated in univariate and multivariate analysis as prognostic factors for overall survival, and a prognostic score was developed. RESULTS: Independent prognostic factors identified in multivariate analysis for overall survival were performance status (PS) (p {$<$} .001), serum lactate dehydrogenase (LDH) (p {$<$} .001), and number of metastatic sites (p = .005). A prognostic score based on these three variables was found efficient (Harrell's C index 0.61). This new model was improved by selecting only PS and LDH (Harrell's C index 0.64). Three risk groups for death could be identified: a low-risk group (n = 184; median overall survival [OS] 29.8 months), an intermediate-risk group (n = 223; median OS 19.5 months), and a high-risk group (n = 128; median OS 13.9 months). Median survival for the low-, intermediate-, and high-risk groups were 26.8, 21.1, and 16.5 months, respectively, in the validation sample (Harrell's C index 0.63). CONCLUSIONS: Serum LDH level was the main prognostic factor in predicting survival, followed by WHO PS. We identified three risk groups for death depending on these two baseline parameters. This simple prognostic model can be useful for clinician's use and patient stratification in future clinical trials.},
  langid = {english},
  pmcid = {PMC3228179},
  pmid = {21859820},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Camptothecin,Colorectal Neoplasms,CRC,Disease-Free Survival,Female,Fluorouracil,Humans,Irinotecan,L-Lactate Dehydrogenase,Leucovorin,Male,Middle Aged,Models; Statistical,Neoplasm Metastasis,Organoplatinum Compounds,Oxaliplatin,Prognosis,Survival Analysis,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XNZWXSA8\\Chibaudel et al_2011_Simplified prognostic model in patients with oxaliplatin-based or.pdf}
}

@article{chirieac1347,
  title = {Posttherapy Pathologic Stage Predicts Survival in Patients with Esophageal Carcinoma Receiving Preoperative Chemoradiation},
  author = {Chirieac, Lucian R. and Swisher, Stephen G. and Ajani, Jaffer A. and Komaki, Ritsuko R. and Correa, Arlene M. and Morris, Jeffrey S. and Roth, Jack A. and Rashid, Asif and Hamilton, Stanley R. and Wu, Tsung-Teh},
  year = {2005},
  month = apr,
  journal = {Cancer},
  volume = {103},
  number = {7},
  pages = {1347--1355},
  issn = {0008-543X},
  doi = {10.1002/cncr.20916},
  abstract = {BACKGROUND: In patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether survival was better predicted by pretherapy clinical stage or by posttherapy pathologic stage. METHODS: The authors studied 235 consecutive patients with pretherapy clinical Stage II, III, or IVA (according to American Joint Committee on Cancer criteria) carcinoma of the esophagus or esophagogastric junction who were treated with chemoradiation followed by esophagectomy. Posttherapy cancer status was classified using pathologic stage and semiquantitative assessment of residual carcinoma. Clinicopathologic features, residual carcinoma status, and pretherapy and posttherapy stage were compared with disease-free and overall survival. RESULTS: Posttherapy pathologic stage was Stage 0 in 29\% of patients, Stage I in 11\% of patients, Stage II in 34\% of patients, Stage III in 20\% of patients, and Stage IV in 6\% of patients. Cancer downstaging occurred in 56\% of patients. In univariate analysis, disease-free and overall survival were predicted by posttherapy pathologic stage (both with P {$<$} 0.001), margin status (P = 0.002 and P = 0.01, respectively), extent of residual carcinoma (both with P {$<$} 0.001), and downstaging (both with P = 0.001), but not by age, gender, type of cancer, pretherapy clinical stage, or preoperative regimen. However, in multivariate analysis, disease-free and overall survival were independently predicted by posttherapy pathologic stage (both with P = 0.02). Extent of residual carcinoma was a marginally significant predictor of overall survival (P = 0.04). CONCLUSIONS: Posttherapy pathologic stage was the best available predictor of outcome for patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent chemoradiation therapy followed by esophagectomy. The findings in the current study supported the concept of downstaging by preoperative therapy.},
  langid = {english},
  pmid = {15719440},
  keywords = {Carcinoma,Chemotherapy; Adjuvant,Combined Modality Therapy,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Humans,Lymphatic Metastasis,Male,Middle Aged,naCRT,Neoadjuvant Therapy,Prognosis,Radiotherapy; Adjuvant,Survival Rate}
}

@article{chiu794,
  title = {Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy with Chemoradiotherapy for Treatment of Squamous Esophageal Cancer: {{Early}} Results from the {{Chinese University Research Group}} for {{Esophageal Cancer}} ({{CURE}})},
  shorttitle = {Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy with Chemoradiotherapy for Treatment of Squamous Esophageal Cancer},
  author = {Chiu, Philip W. Y. and Chan, Angus C. W. and Leung, S. F. and Leong, H. T. and Kwong, K. H. and Li, Micheal K. W. and {Au-Yeung}, Alex C. M. and Chung, Sydney C. S. and Ng, Enders K. W.},
  year = {2005},
  month = aug,
  journal = {Journal of Gastrointestinal Surgery},
  volume = {9},
  number = {6},
  pages = {794--802},
  issn = {1873-4626},
  doi = {10.1016/j.gassur.2005.05.005},
  abstract = {We conducted a prospective randomized trial to compare the efficacy and survival outcome by chemoradiation with that by esophagectomy as a curative treatment. From July 2000 to December 2004, 80 patients with potentially resectable squamous cell carcinoma of the mid or lower thoracic esophagus were randomized to esophagectomy or chemoradiotherapy. A two-or three-stage esophagectomy with two-field dissection was performed. Patients treated with chemoradiotherapy received continuous 5-.uorouracil infusion (200 mg/m2/day) from day 1 to 42 and cisplatin (60 mg/m2) on days 1 and 22. The tumor and regional lymphatics were concomitantly irradiated to a total of 50\textendash 60 Gy.Tumor response was assessed by endoscopy, endoscopic ultrasonography, and computed tomography scan. Salvage esophagectomy was performed for incomplete response or recurrence. Forty-four patients received standard esophagectomy, whereas 36 were treated with chemoradiotherapy. Median follow-up was 16.9 months. The operative mortality was 6.8\%. The incidence of postoperative complications was 38.6\%. No difference in the early cumulative survival was found between the two groups (RR = 0.89; 95\% confidence interval, 0.37-2.17; log-rank test P =0.45). There was no difference in the disease-free survival. Patients treated with surgery had a slightly higher proportion of recurrence in the mediastinum, whereas those treated with chemoradiation sustained a higher proportion of recurrence in the cervical or abdominal regions. Standard esophagectomy or chemoradiotherapy offered similar early clinical outcome and survival for patients with squamous cell carcinoma of the esophagus. The challenge lies in the detection of residue disease after chemoradiotherapy.},
  langid = {english},
  keywords = {Carcinoma of esophagus,chemoradiation,chemoradiotherapy,esophagectomy,squamous cell carcinoma}
}

@article{chmelo173,
  title = {A Feasibility Trial of Prehabilitation before Oesophagogastric Cancer Surgery Using a Multi-Component Home-Based Exercise Programme: The {{ChemoFit}} Study},
  shorttitle = {A Feasibility Trial of Prehabilitation before Oesophagogastric Cancer Surgery Using a Multi-Component Home-Based Exercise Programme},
  author = {Chmelo, Jakub and Phillips, Alexander W. and Greystoke, Alastair and Charman, Sarah J. and Avery, Leah and Hallsworth, Kate and Welford, Jenny and Cooper, Matthew and Sinclair, Rhona C. F.},
  year = {2022},
  month = aug,
  journal = {Pilot and Feasibility Studies},
  volume = {8},
  number = {1},
  pages = {173},
  issn = {2055-5784},
  doi = {10.1186/s40814-022-01137-6},
  abstract = {BACKGROUND: Treatment for locally advanced oesophagogastric adenocarcinoma involves neoadjuvant chemotherapy which has a negative impact on patient fitness. Using 'prehabilitation' to increase activity levels and fitness may affect physiology, postoperative outcomes and improve patient wellbeing and quality of life. The aims of the trial were to address the feasibility and acceptability of recruiting participants to a home-based prehabilitation programme and provide data to allow design of future studies. METHODS: We recruited patients to a single-arm feasibility trial of home-based exercise prehabilitation. Eligible patients were aged {$\geq$}18years, had operable oesophageal or gastric adenocarcinoma and were receiving neoadjuvant chemotherapy at our tertiary referral hospital. All participants commenced a home-based exercise programme utilising pedometers and step counting to target daily aerobic exercise sessions alongside daily strengthening exercises. A weekly telephone consultation directed the exercise programme and facilitated weekly data collection. The primary (feasibility) outcomes for the trial were (a) recruitment rate, (b) completion rate, (c) engagement with the programme (use of pedometers, recording step counts, telephone consultations) and (d) compliance with exercise sessions, exercise intensity and strengthening exercises. RESULTS: There were 42 patients recruited, and the recruitment rate was 72.4\% (42/58). 92.3\% (36/39) of patients completed the exercise programme. There was 98.7\% (IQR 93.2-100.0\%) compliance with wearing a pedometer and recording data, and 100.0\% (IQR 93.1-100.0\%) compliance with a weekly telephone consultation. Exercise sessions and strengthening exercises were completed 70.2\% (IQR 53.1-88.9\%) and 69.4\% (IQR 52.1-84.3\%) of the time, respectively. Appropriate exercise intensity was recorded 96\% (IQR 85.4-99.4\%) of the time. There were no adverse events. Participants were enrolled in the exercise programme for a median of 91 days (IQR 84 to 105 days). CONCLUSIONS: The results of this trial support the feasibility and acceptability of recruiting participants to an appropriately powered randomised controlled trial of prehabilitation. TRIAL REGISTRATION: Clinicaltrials.gov NCT04194463 . Registered on 11th December 2019-retrospectively registered.},
  langid = {english},
  pmcid = {PMC9360697},
  pmid = {35945625},
  keywords = {Exercise,Feasibility,Home-based training,Oesophagogastric cancer,Prehabilitation,Surgical oncology},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\R9DEQAJI\\Chmelo et al_2022_A feasibility trial of prehabilitation before oesophagogastric cancer surgery.pdf}
}

@article{choie0139749,
  title = {Skeletal {{Muscle Depletion Predicts}} the {{Prognosis}} of {{Patients}} with {{Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy}}, {{Independent}} of {{Body Mass Index}}},
  author = {Choi, Younak and Oh, Do-Youn and Kim, Tae-Yong and Lee, Kyung-Hun and Han, Sae-Won and Im, Seock-Ah and Kim, Tae-You and Bang, Yung-Jue},
  year = {2015},
  journal = {PloS One},
  volume = {10},
  number = {10},
  pages = {e0139749},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0139749},
  abstract = {INTRODUCTION: Body composition has emerged as a prognostic factor in cancer patients. We investigated whether sarcopenia at diagnosis and loss of skeletal muscle during palliative chemotherapy were associated with survival in patients with pancreatic cancer. METHODS: We retrospectively reviewed the clinical outcomes of pancreatic cancer patients receiving palliative chemotherapy between 2003 and 2010. The cross-sectional area of skeletal muscle at L3 by computed tomography was analyzed with Rapidia 3D software. We defined sarcopenia as a skeletal muscle index (SMI){$<$} 42.2 cm2/m2 (male) and {$<$} 33.9 cm2/m2 (female) using ROC curve. RESULTS: Among 484 patients, 103 (21.3\%) patients were sarcopenic at diagnosis. Decrease in SMI during chemotherapy was observed in 156 (60.9\%) male and 65 (40.6\%) female patients. Decrease in body mass index (BMI) was observed in 149 patients (37.3\%), with no gender difference. By multivariate analysis, sarcopenia (P{$<$} 0.001), decreasedBMI and SMI during chemotherapy (P = 0.002, P = 0.004, respectively) were poor prognostic factors for overall survival (OS). While the OS of male patients was affected with sarcopenia (P{$<$} 0.001) and decreased SMI (P = 0.001), the OS of female patients was influenced with overweight at diagnosis (P = 0.006), decreased BMI (P = 0.032) and decreased SMI (P = 0.014). Particularly, while the change of BMI during chemotherapy did not have impact on OS within the patients with maintained SMI (P = 0.750), decrease in SMI was associated with poor OS within the patients with maintained BMI (HR 1.502; P = 0.002). CONCLUSIONS: Sarcopenia at diagnosis and depletion of skeletal muscle, independent of BMI change, during chemotherapy were poor prognostic factors in advanced pancreatic cancer.},
  langid = {english},
  pmcid = {PMC4593598},
  pmid = {26437072},
  keywords = {Adult,Aged,Aged; 80 and over,Body Composition,Body Mass Index,Female,Humans,Male,Middle Aged,Muscle; Skeletal,Muscular Atrophy,Palliative Care,Pancreatic Neoplasms,Prognosis,Radiography,Retrospective Studies,Sarcopenia,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CPVGMWC9\\Choi et al_2015_Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced.pdf}
}

@article{chong252,
  title = {Should {{Transfusion Trigger Thresholds Differ}} for {{Critical Care Versus Perioperative Patients}}? {{A Meta-Analysis}} of {{Randomized Trials}}},
  shorttitle = {Should {{Transfusion Trigger Thresholds Differ}} for {{Critical Care Versus Perioperative Patients}}?},
  author = {Chong, Matthew A. and Krishnan, Rohin and Cheng, Davy and Martin, Janet},
  year = {2018},
  month = feb,
  journal = {Critical Care Medicine},
  volume = {46},
  number = {2},
  pages = {252--263},
  issn = {1530-0293},
  doi = {10.1097/CCM.0000000000002873},
  abstract = {OBJECTIVE: To address the significant uncertainty as to whether transfusion thresholds for critical care versus surgical patients should differ. DESIGN: Meta-analysis of randomized controlled trials. SETTING: Medline, EMBASE, and Cochrane Library searches were performed up to 15 June 2016. PATIENTS: Trials had to enroll adult surgical or critically ill patients for inclusion. INTERVENTIONS: Studies had to compare a liberal versus restrictive threshold for the transfusion of allogeneic packed RBCs. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 30-day all-cause mortality, sub-grouped by surgical and critical care patients. Secondary outcomes included myocardial infarction, stroke, renal failure, allogeneic blood exposure, and length of stay. Odds ratios and weighted mean differences were calculated using random effects meta-analysis. To assess whether subgroups were significantly different, tests for subgroup interaction were used. Subgroup analysis by trials enrolling critically ill versus surgical patients was performed. Twenty-seven randomized controlled trials (10,797 patients) were included. In critical care patients, restrictive transfusion resulted in significantly reduced 30-day mortality compared with liberal transfusion (odds ratio, 0.82; 95\% CI, 0.70-0.97). In surgical patients, a restrictive transfusion strategy led to the opposite direction of effect for mortality (odds ratio, 1.31; 95\% CI, 0.94-1.82). The subgroup interaction test was significant (p = 0.04), suggesting that the effect of restrictive transfusion on mortality is statistically different for critical care (decreased risk) versus surgical patients (potentially increased risk or no difference). Regarding secondary outcomes, for critically ill patients, a restrictive strategy resulted in reduced risk of stroke/transient ischemic attack, packed RBC exposure, transfusion reactions, and hospital length of stay. In surgical patients, restrictive transfusion resulted in reduced packed RBC exposure. CONCLUSIONS: The safety of restrictive transfusion strategies likely differs for critically ill patients versus perioperative patients. Further trials investigating transfusion strategies in the perioperative setting are necessary.},
  langid = {english},
  pmcid = {PMC5770109},
  pmid = {29189348},
  keywords = {Blood Transfusion,Critical Care,Humans,Perioperative Care,Randomized Controlled Trials as Topic,Surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H8JX3SH5\\Chong et al_2018_Should Transfusion Trigger Thresholds Differ for Critical Care Versus.pdf}
}

@article{christensen947,
  title = {Muscle Dysfunction in Cancer Patients},
  author = {Christensen, J. F. and Jones, L. W. and Andersen, J. L. and Daugaard, G. and Rorth, M. and Hojman, P.},
  year = {2014},
  month = may,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {25},
  number = {5},
  pages = {947--958},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdt551},
  abstract = {BACKGROUND: Muscle dysfunction is a prevalent phenomenon in the oncology setting where patients across a wide range of diagnoses are subject to impaired muscle function regardless of tumor stage and nutritional state. Here, we review the current evidence describing the degree, causes and clinical implications of muscle dysfunction in cancer patients. The efficacy of exercise training to prevent and/or mitigate cancer-related muscle dysfunction is also discussed. DESIGN: We identified 194 studies examining muscular outcomes in cancer patients by searching PubMed and EMBASE databases. RESULTS: Muscle dysfunction is evident across all stages of the cancer trajectory. The causes of cancer-related muscle dysfunction are complex, but may involve a wide range of tumor-, therapy- and/or lifestyle-related factors, depending on the clinical setting of the individual patient. The main importance of muscle dysfunction in cancer patients lies in the correlation to vital clinical end points such as cancer-specific and all-cause mortality, therapy complications and quality of life (QoL). Such associations strongly emphasize the need for effective therapeutic countermeasures to be developed and implemented in oncology practice. Significant progress has been made over the last decade in the field of exercise oncology, indicating that exercise training constitutes a potent modulator of skeletal muscle function in patients with cancer. CONCLUSION: There are clear associations between muscle dysfunction and critical clinical end points. Yet there is a discrepancy between timing of exercise intervention trials, which can improve muscle function, and study populations in whom muscle function are proven prognostic important for clinical end points. Thus, future exercise trials should in early-stage patients, be powered to evaluate clinical outcomes associated with improvements in muscle function, or be promoted in advanced stage settings, aiming to reverse cancer-related muscle dysfunction, and thus potentially improve time-to-progression, treatment toxicity and survival.},
  langid = {english},
  pmid = {24401927},
  keywords = {Animals,cancer,exercise,Exercise Therapy,Humans,muscle mass,muscle strength,Muscle Strength,Muscle; Skeletal,Neoplasms,Quality of Life,skeletal muscle,Treatment Outcome}
}

@article{clancy574,
  title = {Prospective Evaluation of Social Risks, Physical Function, and Cognitive Function in Prediction of Non-Elective Rehospitalization and Post-Discharge Mortality},
  author = {Clancy, Heather A. and Zhu, Zheng and Gordon, Nancy P. and Kipnis, Patricia and Liu, Vincent X. and Escobar, Gabriel J.},
  year = {2022},
  month = apr,
  journal = {BMC health services research},
  volume = {22},
  number = {1},
  pages = {574},
  issn = {1472-6963},
  doi = {10.1186/s12913-022-07910-w},
  abstract = {BACKGROUND: Increasing evidence suggests that social factors and problems with physical and cognitive function may contribute to patients' rehospitalization risk. Understanding a patient's readmission risk may help healthcare providers develop tailored treatment and post-discharge care plans to reduce readmission and mortality. This study aimed to evaluate whether including patient-reported data on social factors; cognitive status; and physical function improves on a predictive model based on electronic health record (EHR) data alone. METHODS: We conducted a prospective study of 1,547 hospitalized adult patients in 3 Kaiser Permanente Northern California hospitals. The main outcomes were non-elective rehospitalization or death within 30~days post-discharge. Exposures included patient-reported social factors and cognitive and physical function (obtained in a pre-discharge interview) and EHR-derived data for comorbidity burden, acute physiology, care directives, prior utilization, and hospital length of stay. We performed bivariate comparisons using Chi-square, t-tests, and Wilcoxon rank-sum tests and assessed correlations between continuous variables using Spearman's rho statistic. For all models, the results reported were obtained after fivefold cross validation. RESULTS: The 1,547 adult patients interviewed were younger (age, p\,=\,0.03) and sicker (COPS2, p\,{$<$}\,0.0001) than the rest of the hospitalized population. Of the 6 patient-reported social factors measured, 3 (not living with a spouse/partner, transportation difficulties, health or disability-related limitations in daily activities) were significantly associated (p\,{$<$}\,0.05) with the main outcomes, while 3 (living situation concerns, problems with food availability, financial problems) were not. Patient-reported cognitive (p\,=\,0.027) and physical function (p\,=\,0.01) were significantly lower in patients with the main outcomes. None of the patient-reported variables, singly or in combination, improved predictive performance of a model that included acute physiology and longitudinal comorbidity burden (area under the receiver operator characteristic curve was 0.716 for both the EHR model and maximal performance of a random forest model including all predictors). CONCLUSIONS: In this insured population, incorporating patient-reported social factors and measures of cognitive and physical function did not improve performance of an EHR-based model predicting 30-day non-elective rehospitalization or mortality. While incorporating patient-reported social and functional status data did not improve ability to predict these outcomes, such data may still be important for improving patient outcomes.},
  langid = {english},
  pmcid = {PMC9052530},
  pmid = {35484624},
  keywords = {Adult,Aftercare,Cognition,Cognitive function,Humans,Patient Discharge,Patient Readmission,Physical function,Post-discharge outcomes,Predictive modeling,Prospective Studies,Readmission,Readmission risk,Social determinants of health,Social factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\W2IMSTSD\\Clancy et al_2022_Prospective evaluation of social risks, physical function, and cognitive.pdf}
}

@article{clegg353,
  title = {Development and Validation of an Electronic Frailty Index Using Routine Primary Care Electronic Health Record Data},
  author = {Clegg, Andrew and Bates, Chris and Young, John and Ryan, Ronan and Nichols, Linda and Ann Teale, Elizabeth and Mohammed, Mohammed A. and Parry, John and Marshall, Tom},
  year = {2016},
  month = may,
  journal = {Age and Ageing},
  volume = {45},
  number = {3},
  pages = {353--360},
  issn = {1468-2834},
  doi = {10.1093/ageing/afw039},
  abstract = {BACKGROUND: frailty is an especially problematic expression of population ageing. International guidelines recommend routine identification of frailty to provide evidence-based treatment, but currently available tools require additional resource. OBJECTIVES: to develop and validate an electronic frailty index (eFI) using routinely available primary care electronic health record data. STUDY DESIGN AND SETTING: retrospective cohort study. Development and internal validation cohorts were established using a randomly split sample of the ResearchOne primary care database. External validation cohort established using THIN database. PARTICIPANTS: patients aged 65-95, registered with a ResearchOne or THIN practice on 14 October 2008. PREDICTORS: we constructed the eFI using the cumulative deficit frailty model as our theoretical framework. The eFI score is calculated by the presence or absence of individual deficits as a proportion of the total possible. Categories of fit, mild, moderate and severe frailty were defined using population quartiles. OUTCOMES: outcomes were 1-, 3- and 5-year mortality, hospitalisation and nursing home admission. STATISTICAL ANALYSIS: hazard ratios (HRs) were estimated using bivariate and multivariate Cox regression analyses. Discrimination was assessed using receiver operating characteristic (ROC) curves. Calibration was assessed using pseudo-R(2) estimates. RESULTS: we include data from a total of 931,541 patients. The eFI incorporates 36 deficits constructed using 2,171 CTV3 codes. One-year adjusted HR for mortality was 1.92 (95\% CI 1.81-2.04) for mild frailty, 3.10 (95\% CI 2.91-3.31) for moderate frailty and 4.52 (95\% CI 4.16-4.91) for severe frailty. Corresponding estimates for hospitalisation were 1.93 (95\% CI 1.86-2.01), 3.04 (95\% CI 2.90-3.19) and 4.73 (95\% CI 4.43-5.06) and for nursing home admission were 1.89 (95\% CI 1.63-2.15), 3.19 (95\% CI 2.73-3.73) and 4.76 (95\% CI 3.92-5.77), with good to moderate discrimination but low calibration estimates. CONCLUSIONS: the eFI uses routine data to identify older people with mild, moderate and severe frailty, with robust predictive validity for outcomes of mortality, hospitalisation and nursing home admission. Routine implementation of the eFI could enable delivery of evidence-based interventions to improve outcomes for this vulnerable group.},
  langid = {english},
  pmcid = {PMC4846793},
  pmid = {26944937},
  keywords = {Aged,Aged; 80 and over,Cohort Studies,cumulative deficit,Databases; Factual,eFI,electronic frailty index,electronic health record,Electronic Health Records,Female,Frail Elderly,frailty,Geriatric Assessment,Homes for the Aged,Hospitalization,Humans,Male,Nursing Homes,older people,Outcome Assessment; Health Care,Predictive Value of Tests,primary care,Primary Health Care,Proportional Hazards Models,Retrospective Studies,Survival Analysis,United Kingdom},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8FCHYIUN\\Clegg et al_2016_Development and validation of an electronic frailty index using routine primary.pdf}
}

@article{cohen3865,
  title = {Frailty as Determined by a Comprehensive Geriatric Assessment-Derived Deficit-Accumulation Index in Older Patients with Cancer Who Receive Chemotherapy},
  author = {Cohen, Hj and Smith, D and Sun, Cl and Tew, W and Mohile, Sg and Owusu, C and Klepin, Hd and Gross, Cp and Lichtman, Sm and Gajra, A and Filo, J and Katheria, V and Hurria, A},
  year = {2016},
  month = dec,
  journal = {Cancer},
  volume = {122},
  number = {24},
  pages = {3865},
  publisher = {{Cancer}},
  issn = {1097-0142},
  doi = {10.1002/cncr.30269},
  abstract = {A deficit-accumulation frailty index can be constructed from a CGA in older patients with cancer and can indicate the frailty status of the population. The frailty status so determined is associated both with outcomes likely because of chemotherapy toxicity and with those likely because of age-relat \ldots},
  langid = {english},
  pmid = {27529755},
  keywords = {CGA},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ISBK5YCX\\Hj et al_2016_Frailty as determined by a comprehensive geriatric assessment-derived.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\AZJFCSI6\\27529755.html}
}

@article{colcord3040,
  title = {Preoperative {{Muscle Strength Is}} a {{Predictor}} of {{Outcomes After Esophagectomy}}},
  author = {Colcord, Madison E. and Benbow, Jennifer H. and Trufan, Sally and Gower, Nicole L. and Byrne, Meredith E. and Shea, Reilly E. and Watson, Michael D. and Hill, Joshua S. and Squires, M. Hart and Salo, Jonathan C.},
  year = {2021},
  month = dec,
  journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
  volume = {25},
  number = {12},
  pages = {3040--3048},
  issn = {1873-4626},
  doi = {10.1007/s11605-021-05183-y},
  abstract = {BACKGROUND: Sarcopenia, loss of muscle mass and strength, has been associated with more frequent complications after esophagectomy. This study compared hand-grip strength, muscle mass, and intramuscular adipose tissue as predictors of postoperative outcomes and mortality after esophagectomy. METHODS: Minimally invasive esophagectomy was performed on 175 patients with esophageal cancer. Skeletal muscle index and skeletal muscle density were derived from preoperative CTs. Hand-grip strength was measured using dynamometer. Univariate and multivariable analyses were performed. RESULTS: Preoperative hand-grip strength was normal in 91 (52\%), intermediate in 43 (25\%), and weak in 41 (23\%) patients. Hand-grip strength was significantly correlated with both skeletal muscle index and skeletal muscle density. Postoperative pneumonia occurred in 8/41 (20\%) patients with weak strength compared to 4/91 (4\%) with normal strength (p\,=\,0.006; Cochran-Armitage Test). Prolonged postoperative ventilation occurred in 11/41 (27\%) patients with weak strength compared to 11/91 (12\%) with normal strength (p\,=\,0.036). Median length of stay was 9~days in patients with weak strength compared to 7~days for those with normal strength (p\,=\,0.005; Kruskal-Wallis Test). Discharge to non-home location occurred in 15/41 (37\%) with weak strength compared to 8/91 (9\%) with normal strength (p\,{$<$}\,0.001). Postoperative mortality at 90~days was 4/41 (10\%) with weak strength compared with no mortalities (0/91) in the normal strength group (p\,=\,0.004). Mortality at 1~year was 18/39 (46\%) in patients with weak strength compared to 6/81 (7\%) with normal strength, among 158 patients with 1-year follow-up (p\,{$<$}\,0.001). CONCLUSIONS: Preoperative hand-grip strength was found to be a powerful predictor of postoperative pneumonia, length of stay, discharge to non-home location, and mortality after esophagectomy.},
  langid = {english},
  pmid = {34729696},
  keywords = {Esophageal Neoplasms,Esophagectomy,Hand Strength,Hand-grip strength,Humans,Muscle; Skeletal,Postoperative Complications,Sarcopenia}
}

@article{collins200,
  title = {Physical Performance and Muscle Mass in the Assessment of Sarcopenia and Its Association with Receipt and Completion of Planned Treatment in Non-Small Cell Lung Cancer},
  author = {Collins, Jemima Tunung Tagal},
  pages = {200},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\P7DAWKE5\\Collins - Physical performance and muscle mass in the assess.pdf}
}

@article{conroy702,
  title = {Neoadjuvant Chemotherapy with {{FOLFIRINOX}} and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer ({{UNICANCER-PRODIGE}} 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial},
  shorttitle = {Neoadjuvant Chemotherapy with {{FOLFIRINOX}} and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer ({{UNICANCER-PRODIGE}} 23)},
  author = {Conroy, Thierry and Bosset, Jean-Fran{\c c}ois and Etienne, Pierre-Luc and Rio, Emmanuel and Fran{\c c}ois, {\'E}ric and {Mesgouez-Nebout}, Nathalie and Vendrely, V{\'e}ronique and Artignan, Xavier and Bouch{\'e}, Olivier and Gargot, Dany and Boige, Val{\'e}rie and {Bonichon-Lamichhane}, Nathalie and Louvet, Christophe and Morand, Clotilde and {de la Fouchardi{\`e}re}, Christelle and Lamfichekh, Najib and Juzyna, B{\'e}ata and {Jouffroy-Zeller}, Claire and Rullier, Eric and Marchal, Fr{\'e}d{\'e}ric and Gourgou, Sophie and Castan, Florence and Borg, Christophe and {Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group}},
  year = {2021},
  month = may,
  journal = {The Lancet. Oncology},
  volume = {22},
  number = {5},
  pages = {702--715},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(21)00079-6},
  abstract = {BACKGROUND: Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant chemotherapy before preoperative chemoradiotherapy could reduce the risk of distant recurrences. METHODS: We did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France. Eligible patients were adults aged 18-75 years and had newly diagnosed, biopsy-proven, rectal adenocarcinoma staged cT3 or cT4 M0, with a WHO performance status of 0-1. Patients were randomly assigned (1:1) to either the neoadjuvant chemotherapy group or standard-of-care group, using an independent web-based system by minimisation method stratified by centre, extramural extension of the tumour into perirectal fat according to MRI, tumour location, and stage. Investigators and participants were not masked to treatment allocation. The neoadjuvant chemotherapy group received neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 [intravenous oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2, followed by intravenous 400 mg/m2 fluorouracil bolus and then continuous infusion at a dose of 2400 mg/m2 over 46 h every 14 days for six cycles] or capecitabine [1250 mg/m2 orally twice daily on days 1-14 every 21 days]). The standard-of-care group received chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy (for 6 months). The primary endpoint was disease-free survival assessed in the intention-to-treat population at 3 years. Safety analyses were done on treated patients. This trial was registered with EudraCT (2011-004406-25) and ClinicalTrials.gov (NCT01804790) and is now complete. FINDINGS: Between June 5, 2012, and June 26, 2017, 461 patients were randomly assigned to either the neoadjuvant chemotherapy group (n=231) or the standard-of-care group (n=230). At a median follow-up of 46{$\cdot$}5 months (IQR 35{$\cdot$}4-61{$\cdot$}6), 3-year disease-free survival rates were 76\% (95\% CI 69-81) in the neoadjuvant chemotherapy group and 69\% (62-74) in the standard-of-care group (stratified hazard ratio 0{$\cdot$}69, 95\% CI 0{$\cdot$}49-0{$\cdot$}97; p=0{$\cdot$}034). During neoadjuvant chemotherapy, the most common grade 3-4 adverse events were neutropenia (38 [17\%] of 225 patients) and diarrhoea (25 [11\%] of 226). During chemoradiotherapy, the most common grade 3-4 adverse event was lymphopenia (59 [28\%] of 212 in the neoadjuvant chemotherapy group vs 67 [30\%] of 226 patients in the standard-of-care group). During adjuvant chemotherapy, the most common grade 3-4 adverse events were lymphopenia (18 [11\%] of 161 in the neoadjuvant chemotherapy group vs 42 [27\%] of 155 in the standard-of-care group), neutropenia (nine [6\%] of 161 vs 28 [18\%] of 155), and peripheral sensory neuropathy (19 [12\%] of 162 vs 32 [21\%] of 155). Serious adverse events occurred in 63 (27\%) of 231 participants in the neoadjuvant chemotherapy group and 50 (22\%) of 230 patients in the standard-of-care group (p=0{$\cdot$}167), during the whole treatment period. During adjuvant therapy, serious adverse events occurred in 18 (11\%) of 163 participants in the neoadjuvant chemotherapy group and 36 (23\%) of 158 patients in the standard-of-care group (p=0{$\cdot$}0049). Treatment-related deaths occurred in one ({$<$}1\%) of 226 patients in the neoadjuvant chemotherapy group (sudden death) and two (1\%) of 227 patients in the standard-of-care group (one sudden death and one myocardial infarction). INTERPRETATION: Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy. Therefore, the PRODIGE 23 results might change clinical practice. FUNDING: Institut National du Cancer, Ligue Nationale Contre le Cancer, and R\&D Unicancer.},
  langid = {english},
  pmid = {33862000},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy,Female,Fluorouracil,Humans,Irinotecan,Leucovorin,Male,Middle Aged,Neoadjuvant Therapy,Oxaliplatin,Quality of Life,Rectal Neoplasms,Rectal;TNT}
}

@article{cooper8,
  title = {Characterization of {{Anthropometric Changes}} That {{Occur During Neoadjuvant Therapy}} for {{Potentially Resectable Pancreatic Cancer}}},
  author = {Cooper, Amanda B and Slack, Rebecca and Fogelman, David and Holmes, Holly M and Petzel, Maria and Parker, Nathan and Balachandran, Aparna and Garg, Naveen and {Ngo-Huang}, An and Varadhachary, Gauri and Evans, Douglas B and Lee, Jeffrey E and Aloia, Thomas and Conrad, Claudius and Vauthey, Jean-Nicolas and Fleming, Jason B and Katz, Matthew H G},
  pages = {8},
  abstract = {Background. Little is known about changes in body composition that may occur during neoadjuvant therapy for pancreatic cancer. This study was designed to characterize these changes and their potential relationships with therapeutic outcomes.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7WWM6EAL\\Cooper et al. - Characterization of Anthropometric Changes that Oc.pdf}
}

@article{corona883,
  title = {Trends in {{Esophageal Cancer Mortality}} and {{Stage}} at {{Diagnosis}} by {{Race}} and {{Ethnicity}} in the {{United States}}},
  author = {Corona, Edgar and Yang, Liu and Esrailian, Eric and Ghassemi, Kevin A. and Conklin, Jeffrey L. and May, Folasade P.},
  year = {2021},
  month = aug,
  journal = {Cancer causes \& control: CCC},
  volume = {32},
  number = {8},
  pages = {883--894},
  issn = {1573-7225},
  doi = {10.1007/s10552-021-01443-z},
  abstract = {INTRODUCTION: Esophageal cancer (EC) is an aggressive malignancy with poor prognosis. Mortality and disease stage at diagnosis are important indicators of improvements in cancer prevention and control. We examined United States trends in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) mortality and stage at diagnosis by race and ethnicity. METHODS: We used Surveillance, Epidemiology, and End Results (SEER) data to identify individuals with histologically confirmed EAC and ESCC between 1 January 1992 and 31 December 2016. For both EAC and ESCC, we calculated age-adjusted mortality and the proportion presenting at each stage by race/ethnicity, sex, and year. We then calculated the annual percent change (APC) in each indicator by race/ethnicity and examined changes over time. RESULTS: The study included 19,257 EAC cases and 15,162 ESCC cases. EAC mortality increased significantly overall and in non-Hispanic Whites from 1993 to 2012 and from 1993 to 2010, respectively. EAC mortality continued to rise among non-Hispanic Blacks (NHB) (APC\,=\,1.60, p\,=\,0.01). NHB experienced the fastest decline in ESCC mortality (APC\,=\,- 4.53, p\,{$<$}\,0.001) yet maintained the highest mortality at the end of the study period. Proportions of late stage disease increased overall by 18.5 and 24.5 percentage points for EAC and ESCC respectively; trends varied by race/ethnicity. CONCLUSION: We found notable differences in trends in EAC and ESCC mortality and stage at diagnosis by race/ethnicity. Stage migration resulting from improvements in diagnosis and treatment may partially explain recent trends in disease stage at diagnosis. Future efforts should identify factors driving current esophageal cancer disparities.},
  langid = {english},
  pmcid = {PMC8236464},
  pmid = {34003396},
  keywords = {Adenocarcinoma,Adult,Esophageal cancer,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Ethnicity,Female,Head and Neck Neoplasms,Health disparities,Humans,Incidence,Male,Mortality,Race,Stage at diagnosis,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UGGJ54G9\\Corona et al. - 2021 - Trends in Esophageal Cancer Mortality and Stage at.pdf}
}

@article{correa-de-araujo591,
  type = {Journal {{Article}}},
  title = {Skeletal Muscle Function Deficit: A New Terminology to Embrace the Evolving Concepts of Sarcopenia and Age-Related Muscle Dysfunction},
  author = {{Correa-de-Araujo}, R. and Hadley, E.},
  year = {2014},
  journal = {J Gerontol A Biol Sci Med Sci},
  volume = {69},
  number = {5},
  pages = {591--4},
  issn = {1758-535X (Electronic) 1079-5006 (Linking)},
  doi = {10.1093/gerona/glt208}
}

@article{cotton681,
  title = {Late {{Recurrence}} of {{Barrett}}'s {{Esophagus After Complete Eradication}} of {{Intestinal Metaplasia}} Is {{Rare}}: {{Final Report From Ablation}} in {{Intestinal Metaplasia Containing Dysplasia Trial}}},
  shorttitle = {Late {{Recurrence}} of {{Barrett}}'s {{Esophagus After Complete Eradication}} of {{Intestinal Metaplasia}} Is {{Rare}}},
  author = {Cotton, Cary C. and Wolf, W. Asher and Overholt, Bergein F. and Li, Nan and Lightdale, Charles J. and Wolfsen, Herbert C. and Pasricha, Sarina and Wang, Kenneth K. and Shaheen, Nicholas J. and {AIM Dysplasia Trial Group}},
  year = {2017},
  month = sep,
  journal = {Gastroenterology},
  volume = {153},
  number = {3},
  pages = {681-688.e2},
  issn = {1528-0012},
  doi = {10.1053/j.gastro.2017.05.044},
  abstract = {BACKGROUND \& AIMS: The goal of treatment for Barrett's esophagus (BE) with dysplasia is complete eradication of intestinal metaplasia (CEIM). The long-term durability of CEIM has not been well characterized, so the frequency and duration of surveillance are unclear. We report results from a 5-year follow-up analysis of patients with BE and dysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal Metaplasia Containing Dysplasia (AIM) trial. METHODS: Participants for the AIM Dysplasia trial (18-80 years old) were recruited from 19 sites in the United States and had endoscopic evidence of non-nodular dysplastic BE {$\leq$}8~cm in length. Subjects (n~= 127) were randomly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a sham endoscopic procedure; patients in the sham group were offered RFA treatment 1 year later, and all patients were followed for 5 years. We collected data on BE recurrence (defined as intestinal metaplasia in the tubular esophagus) and dysplastic BE recurrence among patients who achieved CEIM. We constructed Kaplan-Meier estimates and applied parametric survival analysis to examine proportions of patients without any recurrence and without dysplastic recurrence. RESULTS: Of 127 patients in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria. Of those 119, 110 (92\%) achieved CEIM. Over 401 person-years of follow-up (mean, 3.6 years per patient; range, 0.2-5.8 years), 35 of 110 (32\%) patients had recurrence of BE or dysplasia, and 19 (17\%) had dysplasia recurrence. The incidence rate of BE recurrence was 10.8 per 100 person-years overall (95\% CI, 7.8-15.0); 8.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI, 4.9-14.0), and 13.5 per 100 person-years among patients with baseline high-grade dysplasia (95\% CI 8.8-20.7). The incidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95\% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-grade dysplasia (95\%~CI 4.2-12.5). Neither BE nor dysplasia recurred at a constant rate. There was a greater probability of recurrence in the first year following CEIM than in the following 4 years combined. CONCLUSIONS: In this analysis of prospective cohort data from the AIM Dysplasia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dysplastic disease; most recurrences occurred during the first year after CEIM. However, patients who achieved CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence. Studies are needed to determine when surveillance can be decreased or discontinued; our study did not identify any BE or dysplasia recurrence after 4 years of surveillance.},
  langid = {english},
  pmcid = {PMC5581683},
  pmid = {28579538},
  keywords = {Aged,Barrett Esophagus,Catheter Ablation,Disease Progression,Esophagus,Female,Follow-Up Studies,HGD,High Grade Dysplasia,Humans,Incidence,Kaplan-Meier Estimate,LGD,Long-term Outcome,Low Grade Dysplasia,Male,Metaplasia,Middle Aged,Mucous Membrane,Population Surveillance,Prognostic Factor,Prospective Studies,Recurrence,Time Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AXWXYKRT\\Cotton et al. - 2017 - Late Recurrence of Barrett's Esophagus After Compl.pdf}
}

@article{coughlin,
  type = {Journal {{Article}}},
  title = {Use of Consumer Wearable Devices to Promote Physical Activity among Breast, Prostate, and Colorectal Cancer Survivors: A Review of Health Intervention Studies},
  author = {Coughlin, S. S. and Caplan, L. S. and Stone, R.},
  year = {2020},
  journal = {J Cancer Surviv},
  issn = {1932-2267 (Electronic) 1932-2259 (Linking)},
  doi = {10.1007/s11764-020-00855-1}
}

@article{cox187,
  title = {Regression {{Models}} and {{Life}}-{{Tables}}},
  author = {Cox, DR},
  year = {1972},
  journal = {Journal of the Royal Statistical Society  Series B  Methodological},
  pages = {187--202},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\D4VMRDYK\\Journal of the Royal Statistical Society  Series B  Methodological - January 1972 - Cox - Regression Models and LifeâTables.pdf}
}

@article{crabtree1509,
  title = {Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival},
  shorttitle = {Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma},
  author = {Crabtree, Traves D. and Yacoub, Wael N. and Puri, Varun and Azar, Riad and Zoole, Jennifer Bell and Patterson, G. Alexander and Krupnick, A. Sasha and Kreisel, Daniel and Meyers, Bryan F.},
  year = {2011},
  month = may,
  journal = {The Annals of Thoracic Surgery},
  volume = {91},
  number = {5},
  pages = {1509-1515; discussion 1515-1516},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2011.01.063},
  abstract = {BACKGROUND: Patients often receive induction therapy based on endoscopic ultrasound (EUS)-identified nodal spread (N1) or deep tumor invasion (T3), although controversy exists regarding the role of induction therapy for early stage disease. We aim to evaluate the reliability of EUS in identifying early stage disease and the subsequent impact on treatment and outcomes. METHODS: We retrospectively studied 149 patients who underwent EUS and esophagectomy for adenocarcinoma between January 2000 and December 2008. Computed tomography (CT) was performed in all patients, whereas positron emission tomography (PET) was performed in 91\%. Clinical stage (c), pathologic stage (p), operative mortality, and survival were recorded. RESULTS: Unanticipated pathologic nodal disease was similar in patients with cT1N0 and cT2N0 tumors (6/25 [24\%] versus 7/18 [38.8\%]; p=0.6). Among the 18 cases of cT2N0 disease, 9 (50\%) were pathologically staged as T1N0, 8 (44\%) were upstaged to pT3N0-1, and 1 (6\%) was pT2N0. One case of cT1N0 tumor (4\%) was upstaged to pT3N0. Among patients with cT1-2N0 tumors, 5-year disease-free survival for the group that was appropriately staged was 89.8\% versus 39.9\% for the group that had a higher pathologic stage than their clinical stage (ie, {$>$}T2N0) (p{$<$}0.001). Operative mortality for patients with cT1-2N0 tumors was 0/43 (0\%), which was no different from that in the higher clinical stage groups with (1/37, 2.7\%) or without (2/68, 2.9\%) induction therapy (p=0.5). Multivariate analysis identified marked/intense uptake on staging PET (odds ratio, 5.76, 95\%; confidence interval, 1.25 to 26.52; p=0.021) to be a factor predictive of upstaging of cT1-2N0 tumors. CONCLUSIONS: Current staging techniques are inadequate for predicting T1-2N0 disease in esophageal adenocarcinoma. Survival is excellent with operation alone in patients with tumors appropriately staged as T1-2N0, although patients with tumors upstaged to greater than T2N0 have significantly worse survival. Other preoperative factors such as PET uptake may help select patients with cT1-2N0 tumors that will be upstaged at resection.},
  langid = {english},
  pmid = {21435632},
  keywords = {Adenocarcinoma,Aged,Biopsy; Needle,Cohort Studies,Confidence Intervals,Diagnostic Imaging,Disease-Free Survival,Endosonography,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Hospital Mortality,Humans,Immunohistochemistry,Male,Middle Aged,Multivariate Analysis,Neoplasm Invasiveness,Neoplasm Staging,Odds Ratio,Positron-Emission Tomography,Postoperative Complications,Retrospective Studies,Risk Assessment,Survival Analysis,Tomography; X-Ray Computed,Treatment Outcome}
}

@article{crabtree382,
  title = {Evaluation of the Reliability of Clinical Staging of {{T2 N0}} Esophageal Cancer: A Review of the {{Society}} of {{Thoracic Surgeons}} Database},
  shorttitle = {Evaluation of the Reliability of Clinical Staging of {{T2 N0}} Esophageal Cancer},
  author = {Crabtree, Traves D. and Kosinski, Andrzej S. and Puri, Varun and Burfeind, William and Bharat, Ankit and Patterson, G. Alexander and Hofstetter, Wayne and Meyers, Bryan F.},
  year = {2013},
  month = aug,
  journal = {The Annals of Thoracic Surgery},
  volume = {96},
  number = {2},
  pages = {382--390},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2013.03.093},
  abstract = {BACKGROUND: Clinical staging of esophageal cancer has improved with positron-emission tomography/computed tomography and endoscopic ultrasound imaging. Despite such progress, small single-center studies have questioned the reliability of clinical staging of T2 N0 esophageal cancer. This study broadly examines the adequacy of clinical staging of T2 N0 disease using The Society of Thoracic Surgeons database. METHODS: We retrospectively studied 810 clinical stage T2 N0 patients from 2002 to 2011, with 58 excluded because of incomplete pathologic staging data. Clinical stage, pathologic stage, and preoperative characteristics were recorded. Logistic regression analysis was used to identify factors associated with upstaging at the time of surgical intervention. RESULTS: Among 752 clinical stage T2 N0 patients, 270 (35.9\%) received induction therapy before the operation. Of 482 patients who went directly to surgical intervention, 132 (27.4\%) were confirmed as pathologic T2 N0, 125 (25.9\%) were downstaged (ie, T0-1 N0), and 225 (46.7\%) were upstaged at the operation (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pathologic T3-4 N0) accounted for 41 patients (18.2\%), whereas exclusive nodal upstaging (ie, pathological T1-2 N1-3) accounted for 100 (44.5\%). Combined tumor and nodal upstaging (ie, pathological T3-4 N1-3) accounted for 84 patients (37.3\%). Among patients who received induction therapy, 103 (38.1\%) were upstaged vs 225 (46.7\%) without induction therapy (p = 0.026). Comparing the induction therapy group and the primary surgical group, postoperative 30-day mortality (3.7\% vs 3.7\%, p {$>$} 0.99) and morbidity (46.3\% vs 45\%, p = 0.76) were similar. CONCLUSIONS: Despite advances in staging techniques, clinical staging of T2 N0 esophageal cancer remains unreliable. Recognizing T2 N0 as a threshold for induction therapy in esophageal cancer, many surgeons have opted to treat T2 N0 disease with induction therapy, even though one-quarter of these patients will be pathologic T1 N0. Although this study demonstrated similar perioperative morbidity and mortality with and without induction therapy, further study is needed to examine the effect of upstaging on long-term survival.},
  langid = {english},
  pmcid = {PMC4017898},
  pmid = {23731608},
  keywords = {7,Adenocarcinoma,American Society of Anesthesiologists,ASA,c,Carcinoma; Squamous Cell,Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study,CI,clinical staging,computed tomography,confidence interval,CROSS,CT,Databases; Factual,EMR,esophageal mucosal resection,Esophageal Neoplasms,esophageal ultrasound,EUS,false negative,false positive,Female,fine needle aspiration,FN,FNA,FP,G1,G2,G3,G4,General Thoracic Surgery Database,grade moderately differentiated,grade poorly differentiated,grade undetermined,grade undifferentiated,grade well differentiated,GTSDB,Gx,Humans,Male,Middle Aged,Negative predictive value,Neoplasm Staging,NPV,odds ratio,OR,p,Pathologic staging,PET,positive predictive value,Positron emission tomography,PPV,Reproducibility of Results,Retrospective Studies,SD,Society of Thoracic Surgeons,standard deviation,STS,TN,TP,true negative,True positive},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QMVXN4W3\\Crabtree et al_2013_Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer.pdf}
}

@article{craig1381,
  type = {Journal {{Article}}},
  title = {International Physical Activity Questionnaire: 12-Country Reliability and Validity},
  author = {Craig, C. L. and Marshall, A. L. and Sjostrom, M. and Bauman, A. E. and Booth, M. L. and Ainsworth, B. E. and Pratt, M. and Ekelund, U. and Yngve, A. and Sallis, J. F. and Oja, P.},
  year = {2003},
  journal = {Med Sci Sports Exerc},
  volume = {35},
  number = {8},
  pages = {1381--95},
  issn = {0195-9131 (Print) 0195-9131 (Linking)},
  doi = {10.1249/01.MSS.0000078924.61453.FB}
}

@article{crawford925,
  title = {Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer},
  author = {Crawford, Jeffrey and Denduluri, Neelima and Patt, Debra and Jiao, Xiaolong and Morrow, Phuong Khanh and Garcia, Jacob and Barron, Richard and Lyman, Gary H.},
  year = {2020},
  month = feb,
  journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
  volume = {28},
  number = {2},
  pages = {925--932},
  issn = {1433-7339},
  doi = {10.1007/s00520-019-04875-1},
  abstract = {PURPOSE: The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association between chemotherapy intensity and survival in advanced NSCLC. METHODS: This retrospective cohort study included adults with advanced lung cancer who received first-line myelosuppressive platinum-based chemotherapy (January 2007-December 2010) in \textasciitilde\,230 US Oncology Network community practices. Dose delays {$\geq$}\,7~days, dose reductions {$\geq$}\,15\%, and RDI relative to standard regimens were described. Overall survival (OS) was measured using Kaplan-Meier and Cox proportional hazard (PH) models. RESULTS: Among 3866 patients with advanced NSCLC, 32.4\% experienced dose delays {$\geq$}\,7~days, 50.1\% experienced dose reductions {$\geq$}\,15\%, and 40.4\% had RDI {$<$}\,85\%. Reduced RDI was also common regardless of baseline ECOG PS (ECOG PS {$\geq$}\,2, 56.2\%; ECOG PS 0, 33.6\%) and tumor subgroup (squamous cell carcinoma, 52.2\%; adenocarcinoma, 36.0\%). When stratified by chemotherapy intensity measures, significant OS differences were observed only for dose delays. Median (95\% CI) OS was 1.02~years (0.96-1.12) for dose delays {$\geq$}\,7~days and 0.71~years (0.66-0.77) for dose delays {$<$}\,7~days. In multivariable Cox PH analysis, dose delays {$\geq$}\,7~days (HR\,=\,0.71; 95\% CI\,=\,0.63-0.80) and RDI {$\geq$}\,85\% (HR\,=\,1.18; 95\% CI\,=\,1.05-1.32) were significantly associated with decreased mortality. CONCLUSIONS: Dose delays, dose reductions, and reduced RDI were common, and dose delays {$\geq$}\,7~days and high RDI were significantly associated with decreased mortality. These results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.},
  langid = {english},
  pmcid = {PMC6954126},
  pmid = {31172284},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Non-Small-Cell Lung,Chemotherapy,Community health services,DoseIntensity,Female,Humans,Lung cancer,Lung Neoplasms,Male,Retrospective studies,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8LIJPGT8\\Crawford et al_2020_Relative dose intensity of first-line chemotherapy and overall survival in.pdf}
}

@article{crenshaw823,
  type = {Journal {{Article}}},
  title = {Extracorporeal Gastric Stapling Reduces the Incidence of Gastric Conduit Failure after Minimally Invasive Esophagectomy},
  author = {Crenshaw, G. D. and Shankar, S. S. and Brown, R. E. and Abbas, A. E. and Bolton, J. S.},
  year = {2010},
  journal = {Am Surg},
  volume = {76},
  number = {8},
  pages = {823--8},
  issn = {0003-1348 (Print) 0003-1348 (Linking)}
}

@article{crestcollaborativegroup1073,
  title = {Colorectal {{Endoscopic Stenting Trial}} ({{CReST}}) for Obstructing Left-Sided Colorectal Cancer: Randomized Clinical Trial},
  shorttitle = {Colorectal {{Endoscopic Stenting Trial}} ({{CReST}}) for Obstructing Left-Sided Colorectal Cancer},
  author = {{CReST Collaborative Group}},
  year = {2022},
  month = nov,
  journal = {British Journal of Surgery},
  volume = {109},
  number = {11},
  pages = {1073--1080},
  issn = {0007-1323},
  doi = {10.1093/bjs/znac141},
  abstract = {Colorectal cancer often presents with obstruction needing urgent, potentially life-saving decompression. The comparative efficacy and safety of endoluminal stenting versus emergency surgery as initial treatment for such patients is uncertain.Patients with left-sided colonic obstruction and radiological features of carcinoma were randomized to endoluminal stenting using a combined endoscopic/fluoroscopic technique followed by elective surgery 1\textendash 4 weeks later, or surgical decompression with or without tumour resection. Treatment allocation was via a central randomization service using a minimization procedure stratified by curative intent, primary tumour site, and severity score (Acute Physiology And Chronic Health Evaluation). Co-primary outcome measures were duration of hospital stay and 30-day mortality. Secondary outcomes were stoma formation, stenting completion and complication rates, perioperative morbidity, 6-month survival, 3-year recurrence, resource use, adherence to chemotherapy, and quality of life. Analyses were undertaken by intention to treat.Between 23 April 2009 and 22 December 2014, 245 patients from 39 hospitals were randomized. Stenting was attempted in 119 of 123 allocated patients (96.7 per cent), achieving relief of obstruction in 98 of 119 (82.4 per cent). For the 89 per cent treated with curative intent, there were no significant differences in 30-day postoperative mortality (3.6 per cent (4 of 110) versus 5.6 per cent (6 of 107); P = 0.48), or duration of hospital stay (median 19 (i.q.r. 11\textendash 34) versus 18 (10\textendash 28) days; P = 0.94) between stenting followed by delayed elective surgery and emergency surgery. Among patients undergoing potentially curative treatment, stoma formation occurred less frequently in those allocated to stenting than those allocated to immediate surgery (47 of 99 (47.5 per cent) versus 72 of 106 (67.9 per cent); P = 0.003). There were no significant differences in perioperative morbidity, critical care use, quality of life, 3-year recurrence or mortality between treatment groups.Stenting as a bridge to surgery reduces stoma formation without detrimental effects. Registration number: ISRCTN13846816 (http://www.controlled-trials.com).},
  keywords = {Stage IV},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JRYKA4JJ\\6672717.html}
}

@article{crosarateixeira52,
  title = {The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients with an {{ECOG}} Performance Status of 3 and 4},
  author = {Crosara Teixeira, Marcela and Marques, Daniel Fernandes and Ferrari, Anezka Celis and Alves, Michel Fabiano Silva and Alex, Alexandra Khichfy and Sabbaga, Jorge and Hoff, Paulo M. and Riechelmann, Rachel P.},
  year = {2015},
  month = mar,
  journal = {Clinical Colorectal Cancer},
  volume = {14},
  number = {1},
  pages = {52--57},
  issn = {1938-0674},
  doi = {10.1016/j.clcc.2014.09.010},
  abstract = {BACKGROUND: Although chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS {$>$} 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only. PATIENTS AND METHODS: We retrospectively analyzed all consecutive mCRC patients who started first-line chemotherapy at our institution in a 4-year period. A multivariable Cox regression model was used to adjust for prognostic factors and logistic regression, to identify predictive factors of Grade 3/4 toxicity. RESULTS: From June 2008 to June 2012, 240 consecutive patients were included: 100 (41.7\%) had an ECOG PS of 0/1, 75 (31.3\%) ECOG PS of 2, and 65 (27\%) ECOG PS of 3/4. Median survival for patients treated with chemotherapy was 18.4 months for patients with ECOG PS of 0/1, 10.8 months for those with ECOG PS of 2, and 6.8 months for patients with ECOG PS of 3/4. Among those with ECOG PS of 3/4, chemotherapy use led to a nonsignificant survival gain (median, 6.8 vs. 2.3 months for BSC; P = .13). Factors significantly associated with worse survival in an adjusted analysis were right-sided tumors (hazard ratio [HR], 2.97; P = .005) and ECOG PS status (ECOG PS 2 vs. 0/1; HR, 1.67; P = .025, and ECOG PS 3/4 vs. 0/1; HR, 2.67; P {$<$} .0001). The rate of Grade {$\geq$} 3 toxicities during the first cycle did not differ significantly across ECOG groups; likely because 40\% of ECOG PS 3/4 patients received upfront dose-reduced therapy. The rates of treatment-related hospitalization were similar across all ECOG groups. All deaths were disease-associated. CONCLUSION: Our retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.},
  langid = {english},
  pmid = {25442812},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Agents,Best supportive care,Chemotherapy,Colorectal cancer,Colorectal Neoplasms,Dose-Response Relationship; Drug,Drug Monitoring,Female,Hospitalization,Humans,Logistic Models,Male,Middle Aged,Neoplasm Metastasis,Palliative Care,Poor performance status,Prognosis,Retrospective Studies,Survival Rate,Treatment Outcome}
}

@article{cunningham11,
  title = {Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer},
  author = {Cunningham, David and Allum, William H. and Stenning, Sally P. and Thompson, Jeremy N. and {Van de Velde}, Cornelis J. H. and Nicolson, Marianne and Scarffe, J. Howard and Lofts, Fiona J. and Falk, Stephen J. and Iveson, Timothy J. and Smith, David B. and Langley, Ruth E. and Verma, Monica and Weeden, Simon and Chua, Yu Jo and MAGIC Trial Participants, null},
  year = {2006},
  month = jul,
  journal = {The New England Journal of Medicine},
  volume = {355},
  number = {1},
  pages = {11--20},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa055531},
  abstract = {BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer. METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival. RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P{$<$}0.001). CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).},
  langid = {english},
  pmid = {16822992},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Cisplatin,Disease-Free Survival,Epirubicin,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Fluorouracil,Gastrectomy,Humans,Male,Middle Aged,Perioperative Care,Stomach Neoplasms,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QRE45YL7\\Cunningham et al. - 2006 - Perioperative chemotherapy versus surgery alone fo.pdf}
}

@article{cuschieri7,
  type = {Journal {{Article}}},
  title = {Endoscopic Oesophagectomy through a Right Thoracoscopic Approach},
  author = {Cuschieri, A. and Shimi, S. and Banting, S.},
  year = {1992},
  journal = {J R Coll Surg Edinb},
  volume = {37},
  number = {1},
  pages = {7--11},
  issn = {0035-8835 (Print) 0035-8835 (Linking)}
}

@article{custodio1526,
  title = {Nomogram-Based Prediction of Survival in Patients with Advanced Oesophagogastric Adenocarcinoma Receiving First-Line Chemotherapy: A Multicenter Prospective Study in the Era of Trastuzumab},
  shorttitle = {Nomogram-Based Prediction of Survival in Patients with Advanced Oesophagogastric Adenocarcinoma Receiving First-Line Chemotherapy},
  author = {Custodio, A. and {Carmona-Bayonas}, A. and {Jim{\'e}nez-Fonseca}, P. and S{\'a}nchez, M. L. and Viudez, A. and Hern{\'a}ndez, R. and Cano, J. M. and Echavarria, I. and Pericay, C. and Mangas, M. and Visa, L. and Buxo, E. and Garc{\'i}a, T. and Rodr{\'i}guez Palomo, A. and {\'A}lvarez Mance{\~n}ido, F. and Lacalle, A. and Macias, I. and Azkarate, A. and Ramchandani, A. and Fern{\'a}ndez Montes, A. and L{\'o}pez, C. and Longo, F. and S{\'a}nchez Bayona, R. and Lim{\'o}n, M. L. and {D{\'i}az-Serrano}, A. and Hurtado, A. and Madero, R. and G{\'o}mez, C. and Gallego, J.},
  year = {2017},
  month = jun,
  journal = {British Journal of Cancer},
  volume = {116},
  number = {12},
  pages = {1526--1535},
  publisher = {{Nature Publishing Group}},
  issn = {1532-1827},
  doi = {10.1038/bjc.2017.122},
  abstract = {To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy.},
  copyright = {2017 The Author(s)},
  langid = {english},
  keywords = {Stage4},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KZAXNPF9\\Custodio et al. - 2017 - Nomogram-based prediction of survival in patients .pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\I9RXBV8K\\bjc2017122.html}
}

@article{daddimanie30951,
  title = {A {{Prospective Study Correlating Preoperative Modified Frailty Index With One-Year Mortality}} in the {{Elderly With Hip Fractures}}},
  author = {Daddimani, Ravi M. and Madhava Murthy, Srinath K. and Sharan, Prateek M. and Patil, Arvind D.},
  year = {2022},
  month = oct,
  journal = {Cureus},
  volume = {14},
  number = {10},
  pages = {e30951},
  issn = {2168-8184},
  doi = {10.7759/cureus.30951},
  abstract = {Background Hip fractures occur frequently in the elderly population over the age of 60 years following low-energy domestic falls. The postoperative mortality after hip fracture surgery depends on numerous factors like comorbidities, pre-fall ambulatory status, nutritional status, cognition, and overall physical health. In this context, the physiological age and reserve play~a vital role in mortality after hip fracture surgeries. This physiological reserve is measured in terms of "frailty."~There are many frailty indices that assess the physiological reserves of an elderly patient. The modified frailty index (MFI) is one of the validated indexes predicting postoperative complications and mortality. So we concluded there is a need to assess the patients with MFI preoperatively, based on which mortality and postoperative complications could be predicted in our patients. Materials and methods We included 100 patients aged more than 60 years with intertrochanteric and neck of the femur fractures, who were managed surgically. We followed the patients for one year and observed the immediate and late complications and mortality at the end of one year. To reduce bias, patients with pathological fractures, revision surgeries, contralateral fractures, high-energy trauma, younger than 60 years of age, and previous proximal femur fracture surgery on the side of injury were excluded from the study. Results The primary objective was to study the correlation between the MFI with one-year mortality. We observe that the MFI score had a significant effect on mortality at one year (p-value = 0.0316). With a unit increase in the MFI score, the odds of death increase by a factor of 1.52. Conclusion There is a strong correlation between MFI with one-year mortality and postoperative complications after hip fracture surgeries in the elderly. This MFI can be used as a preoperative predictive model to predict the mortality and postoperative complications after hip fractures in the elderly. It will also help patients and their caretakers in decision-making and elucidating surgery choices.},
  langid = {english},
  pmcid = {PMC9711920},
  pmid = {36465740},
  keywords = {elderly,elderly hip fractures,modified frailty index,mortality,odds ratio,postoperative complications},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PYUYMFXD\\Daddimani et al_2022_A Prospective Study Correlating Preoperative Modified Frailty Index With.pdf}
}

@article{dahya7,
  title = {Computed Tomography\textendash Derived Skeletal Muscle Index: {{A}} Novel Predictor of Frailty and Hospital Length of Stay after Transcatheter Aortic Valve Replacement},
  author = {Dahya, Vishal and Xiao, Jingjie and Prado, Carla M and Burroughs, Penny and McGee, Dan and Silva, Aline C and Hurt, Julian E and Mohamed, Shafi G and Noel, Thomas and Batchelor, Wayne},
  year = {2016},
  journal = {American Heart Journal},
  volume = {182},
  pages = {7},
  abstract = {Objectives To determine the prevalence of low skeletal muscle mass in patients undergoing transcatheter aortic valve replacement (TAVR) and whether skeletal muscle mass measured from preoperative computed tomography (CT) images provides value in predicting postoperative length of stay (LOS). Background There are limited data on the use of body composition as a frailty measure in TAVR patients and no studies have determined if this measure predicts LOS. Methods We studied 104 consecutive patients who underwent TAVR at Tallahassee Memorial Hospital from 2012 to 2016. Patient demographics, standard frailty measures (hand grip, albumin, and 5-m walk test), clinical comorbidities, echocardiographic data, and Valve Academic Research Consortium II major complications were recorded prospectively. Skeletal muscle index (SMI) [skeletal muscle mass cross-sectional area at L3/height2] was measured from CT images using Slice-O-Matic software (Tomovision, Montreal, Quebec, Canada). Clinical outcomes were assessed and multivariate methods used to determine predictors of LOS. Results Sarcopenia was prevalent in men (83\%) and women (56\%). Patients who suffered from a major complication had significantly longer length of stay (13 vs 4.6 days, P b .0001). Skeletal muscle index correlated with age, sex, body mass index, handgrip strength, and previous coronary artery bypass graft surgery, but not major complications. A multivariate model including all univariate predictors of LOS showed SMI, major complications, transapical access, atrial fibrillation, and chronic obstructive pulmonary syndrome as independent predictors of LOS. For every 14-cm2/m2 increase in SMI, there was a 1-day reduction in LOS. None of the standard measures of frailty predicted LOS. Conclusions Skeletal muscle index, a measure of sarcopenia readily determined from pre-TAVR CT scans, independently predicts TAVR LOS better than standard frailty testing. Further evaluation of SMI as a frailty measure after TAVR and other cardiovascular procedures is warranted. (Am Heart J 2016;182:21-7.)},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TXQKBX4M\\Dahya et al. - 2016 - Computed tomographyâderived skeletal muscle index.pdf}
}

@article{dale336,
  title = {How {{Is Geriatric Assessment Used}} in {{Clinical Practice}} for {{Older Adults With Cancer}}? {{A Survey}} of {{Cancer Providers}} by the {{American Society}} of {{Clinical Oncology}}},
  shorttitle = {How {{Is Geriatric Assessment Used}} in {{Clinical Practice}} for {{Older Adults With Cancer}}?},
  author = {Dale, William and Williams, Grant R. and R MacKenzie, Amy and {Soto-Perez-de-Celis}, Enrique and Maggiore, Ronald J. and Merrill, Janette K. and Katta, Sweatha and Smith, Kimberly T. and Klepin, Heidi D.},
  year = {2021},
  month = jun,
  journal = {JCO oncology practice},
  volume = {17},
  number = {6},
  pages = {336--344},
  issn = {2688-1535},
  doi = {10.1200/OP.20.00442},
  abstract = {PURPOSE: For patients with cancer who are older than 65 years, the 2018 ASCO Guideline recommends geriatric assessment (GA) be performed. However, there are limited data on providers' practices using GA. Therefore, ASCO's Geriatric Oncology Task Force conducted a survey of providers to assess practice patterns and barriers to GA. METHODS: Cancer providers treating adult patients including those {$\geq$} 65 years completed an online survey. Questions included those asking about awareness of ASCO's Geriatric Oncology Guideline (2018), use of validated GA tools, and perceived barriers to using GA. Descriptive statistics and statistical comparisons between those aware of the Guideline and those who were not were conducted. Statistical significance was set at P {$<$} .05. RESULTS: Participants (N = 1,277) responded between April 5 and June 5, 2019. Approximately half (53\%) reported awareness of the Guideline. The most frequently used GA tools, among those aware of the Guideline and those who were not, assessed functional status (69\% v 50\%; P {$<$} .001) and falls (62\% v 45\%; P {$<$} .001). Remaining tools were used {$<$} 50\% of the time, including tools assessing weight loss, comorbidities, cognition, life expectancy, chemotherapy toxicity, mood, and noncancer mortality risk. GA use was two to four times higher among those who are aware of the Guideline. The most frequent barriers for those who reported being Guideline aware were lack of resources, specifically time (81.7\%) and staff (77.0\%). In comparison, those who were unaware of the Guideline most often reported the following barriers: lack of knowledge or training (78.4\%), lack of awareness about tools (75.2\%), and uncertainty about use of tools (75.0\%). CONCLUSION: Among providers caring for older adults, 52\% were aware of the ASCO Guideline. Some domains were assessed frequently (eg, function, falls), whereas other domains were assessed rarely (eg, mood, cognition). Guideline awareness was associated with two to four times increased use of GA and differing perceived barriers. Interventions facilitating Guideline-consistent implementation will require various strategies to change behavior.},
  langid = {english},
  pmcid = {PMC8462667},
  pmid = {33064058},
  keywords = {Accidental Falls,Aged,CGA,Geriatric Assessment,Humans,Medical Oncology,Neoplasms,Surveys and Questionnaires,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VBCDQWX2\\Dale et al_2021_How Is Geriatric Assessment Used in Clinical Practice for Older Adults With.pdf}
}

@article{dale3420,
  title = {"{{Staging}} the Aging" When Considering Androgen Deprivation Therapy for Older Men with Prostate Cancer},
  author = {Dale, William},
  year = {2009},
  month = jul,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {27},
  number = {21},
  pages = {3420--3422},
  issn = {1527-7755},
  doi = {10.1200/JCO.2009.22.9104},
  langid = {english},
  pmid = {19506150},
  keywords = {Aging,Androgen Antagonists,Fatigue,Health Services for the Aged,Hot Flashes,Humans,Male,Prostatic Neoplasms,Testosterone}
}

@article{daly135,
  title = {A Window beneath the Skin: How Computed Tomography Assessment of Body Composition Can Assist in the Identification of Hidden Wasting Conditions in Oncology That Profoundly Impact Outcomes},
  shorttitle = {A Window beneath the Skin},
  author = {Daly, L. E. and Prado, C. M. and Ryan, A. M.},
  year = {2018},
  month = may,
  journal = {The Proceedings of the Nutrition Society},
  volume = {77},
  number = {2},
  pages = {135--151},
  issn = {1475-2719},
  doi = {10.1017/S0029665118000046},
  abstract = {Advancements in image-based technologies and body composition research over the past decade has led to increased understanding of the importance of muscle abnormalities, such as low muscle mass (sarcopenia), and more recently low muscle attenuation (MA), as important prognostic indicators of unfavourable outcomes in patients with cancer. Muscle abnormalities can be highly prevalent in patients with cancer (ranging between 10 and 90 \%), depending on the cohort under investigation and diagnostic criteria used. Importantly, both low muscle mass and low MA have been associated with poorer tolerance to chemotherapy, increased risk of post-operative infectious and non-infectious complications, increased length of hospital stay and poorer survival in patients with cancer. Studies have shown that systemic antineoplastic treatment can exacerbate losses in muscle mass and MA, with reported loss of skeletal muscle between 3 and 5 \% per 100 d, which are increased exponentially with progressive disease and proximity to death. At present, no effective medical intervention to improve muscle mass and MA exists. Most research to date has focused on treating muscle depletion as part of the cachexia syndrome using nutritional, exercise and pharmacological interventions; however, these single-agent therapies have not provided promising results. Rehabilitation care to modify body composition, either increasing muscle mass and/or MA should be conducted, and its respective impact on oncology outcomes explored. Although the optimal timing and treatment strategy for preventing or delaying the development of muscle abnormalities are yet to be determined, multimodal interventions initiated early in the disease trajectory appear to hold the most promise.},
  langid = {english},
  pmid = {29745361},
  keywords = {Body composition,Body Composition,Cachexia,Cancer,CT computed tomography,DLT dose-limiting toxicity,GI gastrointestinal,HR hazard ratio,HU Hounsfield unit,Humans,MA muscle attenuation,Muscle attenuation,Muscle; Skeletal,Muscular Atrophy,Myosteatosis,Neoplasms,Sarcopenia,SMA skeletal muscle area,SMI skeletal muscle index,Survival,Tomography; X-Ray Computed,Wasting Syndrome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7BZ4HD4N\\Daly et al_2018_A window beneath the skin.pdf}
}

@article{daly315,
  type = {Journal {{Article}}},
  title = {Loss of Skeletal Muscle during Systemic Chemotherapy Is Prognostic of Poor Survival in Patients with Foregut Cancer},
  author = {Daly, L. E. and Ni Bhuachalla, E. B. and Power, D. G. and Cushen, S. J. and James, K. and Ryan, A. M.},
  year = {2018},
  journal = {J Cachexia Sarcopenia Muscle},
  volume = {9},
  number = {2},
  pages = {315--325},
  issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
  doi = {10.1002/jcsm.12267},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JR3VTVDM\\Daly et al. - Loss of skeletal muscle during systemic chemothera.pdf}
}

@article{davis391,
  type = {Journal {{Article}}},
  title = {Rapid Estimate of Adult Literacy in Medicine: A Shortened Screening Instrument},
  author = {Davis, T. C. and Long, S. W. and Jackson, R. H. and Mayeaux, E. J. and George, R. B. and Murphy, P. W. and Crouch, M. A.},
  year = {1993},
  journal = {Fam Med},
  volume = {25},
  number = {6},
  pages = {391--5},
  issn = {0742-3225 (Print) 0742-3225 (Linking)}
}

@article{day1023,
  type = {Journal {{Article}}},
  title = {Patient-{{Reported Outcomes Accurately Measure}} the {{Value}} of an {{Enhanced Recovery Program}} in {{Liver Surgery}}},
  author = {Day, R. W. and Cleeland, C. S. and Wang, X. S. and Fielder, S. and Calhoun, J. and Conrad, C. and Vauthey, J. N. and Gottumukkala, V. and Aloia, T. A.},
  year = {2015},
  journal = {J Am Coll Surg},
  volume = {221},
  number = {6},
  pages = {1023-30 e1-2},
  issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
  doi = {10.1016/j.jamcollsurg.2015.09.011}
}

@article{dealmeida29,
  title = {Transfusion Requirements in Surgical Oncology Patients: A Prospective, Randomized Controlled Trial},
  shorttitle = {Transfusion Requirements in Surgical Oncology Patients},
  author = {{de Almeida}, Juliano Pinheiro and Vincent, Jean-Louis and Galas, Filomena Regina Barbosa Gomes and {de Almeida}, Elisangela Pinto Marinho and Fukushima, Julia T. and Osawa, Eduardo A. and Bergamin, Fabricio and Park, Clarice Lee and Nakamura, Rosana Ely and Fonseca, Silvia M. R. and Cutait, Guilherme and Alves, Joseane Inacio and Bazan, Mellik and Vieira, Silvia and Sandrini, Ana C. Vieira and Palomba, Henrique and Ribeiro, Ulysses and Crippa, Alexandre and Dalloglio, Marcos and Diz, Maria del Pilar Estevez and Kalil Filho, Roberto and Auler, Jose Otavio Costa and Rhodes, Andrew and Hajjar, Ludhmila Abrahao},
  year = {2015},
  month = jan,
  journal = {Anesthesiology},
  volume = {122},
  number = {1},
  pages = {29--38},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000511},
  abstract = {BACKGROUND: Several studies have indicated that a restrictive erythrocyte transfusion strategy is as safe as a liberal one in critically ill patients, but there is no clear evidence to support the superiority of any perioperative transfusion strategy in patients with cancer. METHODS: In a randomized, controlled, parallel-group, double-blind (patients and outcome assessors) superiority trial in the intensive care unit of a tertiary oncology hospital, the authors evaluated whether a restrictive strategy of erythrocyte transfusion (transfusion when hemoglobin concentration {$<$}7 g/dl) was superior to a liberal one (transfusion when hemoglobin concentration {$<$}9 g/dl) for reducing mortality and severe clinical complications among patients having major cancer surgery. All adult patients with cancer having major abdominal surgery who required postoperative intensive care were included and randomly allocated to treatment with the liberal or the restrictive erythrocyte transfusion strategy. The primary outcome was a composite endpoint of mortality and morbidity. RESULTS: A total of 198 patients were included as follows: 101 in the restrictive group and 97 in the liberal group. The primary composite endpoint occurred in 19.6\% (95\% CI, 12.9 to 28.6\%) of patients in the liberal-strategy group and in 35.6\% (27.0 to 45.4\%) of patients in the restrictive-strategy group (P = 0.012). Compared with the restrictive strategy, the liberal transfusion strategy was associated with an absolute risk reduction for the composite outcome of 16\% (3.8 to 28.2\%) and a number needed to treat of 6.2 (3.5 to 26.5). CONCLUSION: A liberal erythrocyte transfusion strategy with a hemoglobin trigger of 9 g/dl was associated with fewer major postoperative complications in patients having major cancer surgery compared with a restrictive strategy.},
  langid = {english},
  pmid = {25401417},
  keywords = {Abdominal Neoplasms,Brazil,Double-Blind Method,Erythrocyte Transfusion,Female,Follow-Up Studies,Hemoglobins,Humans,Intensive Care Units,Male,Middle Aged,Outcome Assessment; Health Care,Postoperative Complications,Prospective Studies,Risk,SurgOnc}
}

@article{decoster288,
  title = {Screening Tools for Multidimensional Health Problems Warranting a Geriatric Assessment in Older Cancer Patients: An Update on {{SIOG}} Recommendations\textdagger},
  shorttitle = {Screening Tools for Multidimensional Health Problems Warranting a Geriatric Assessment in Older Cancer Patients},
  author = {Decoster, L. and Van Puyvelde, K. and Mohile, S. and Wedding, U. and Basso, U. and Colloca, G. and Rostoft, S. and Overcash, J. and Wildiers, H. and Steer, C. and Kimmick, G. and Kanesvaran, R. and Luciani, A. and Terret, C. and Hurria, A. and Kenis, C. and Audisio, R. and Extermann, M.},
  year = {2015},
  month = feb,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {26},
  number = {2},
  pages = {288--300},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdu210},
  abstract = {BACKGROUND: Screening tools are proposed to identify those older cancer patients in need of geriatric assessment (GA) and multidisciplinary approach. We aimed to update the International Society of Geriatric Oncology (SIOG) 2005 recommendations on the use of screening tools. MATERIALS AND METHODS: SIOG composed a task group to review, interpret and discuss evidence on the use of screening tools in older cancer patients. A systematic review was carried out and discussed by an expert panel, leading to a consensus statement on their use. RESULTS: Forty-four studies reporting on the use of 17 different screening tools in older cancer patients were identified. The tools most studied in older cancer patients are G8, Flemish version of the Triage Risk Screening Tool (fTRST) and Vulnerable Elders Survey-13 (VES-13). Across all studies, the highest sensitivity was observed for: G8, fTRST, Oncogeriatric screen, Study of Osteoporotic Fractures, Eastern Cooperative Oncology Group-Performance Status, Senior Adult Oncology Program (SAOP) 2 screening and Gerhematolim. In 11 direct comparisons for detecting problems on a full GA, the G8 was more or equally sensitive than other instruments in all six comparisons, whereas results were mixed for the VES-13 in seven comparisons. In addition, different tools have demonstrated associations with outcome measures, including G8 and VES-13. CONCLUSIONS: Screening tools do not replace GA but are recommended in a busy practice in order to identify those patients in need of full GA. If abnormal, screening should be followed by GA and guided multidisciplinary interventions. Several tools are available with different performance for various parameters (including sensitivity for addressing the need for further GA). Further research should focus on the ability of screening tools to build clinical pathways and to predict different outcome parameters.},
  langid = {english},
  pmid = {24936581},
  keywords = {Aged,Aged; 80 and over,Female,geriatric assessment,Geriatric Assessment,Geriatrics,Humans,Male,Mass Screening,Medical Oncology,Neoplasms,older cancer patients,Screening,screening tools},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CCTMH6WF\\Decoster et al_2015_Screening tools for multidimensional health problems warranting a geriatric.pdf}
}

@article{deftereose035824,
  type = {Journal {{Article}}},
  title = {Nutritional {{Outcomes}} of Patients {{Undergoing Resection}} for Upper {{gastroIntestinal}} Cancer in {{AuStralian Hospitals}} ({{NOURISH}}): Protocol for a Multicentre Point Prevalence Study},
  author = {Deftereos, I. and Yeung, J. M. C. and Carter, V. M. and Isenring, E. and Kiss, N. K. and Group, Nourish Point Prevalence Study},
  year = {2020},
  journal = {BMJ Open},
  volume = {10},
  number = {5},
  pages = {e035824},
  issn = {2044-6055 (Electronic) 2044-6055 (Linking)},
  doi = {10.1136/bmjopen-2019-035824}
}

@article{degraaf988,
  title = {The Role of Staging Laparoscopy in Oesophagogastric Cancers},
  author = {{de Graaf}, G. W. and Ayantunde, A. A. and Parsons, S. L. and Duffy, J. P. and Welch, N. T.},
  year = {2007},
  month = oct,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {33},
  number = {8},
  pages = {988--992},
  issn = {0748-7983},
  doi = {10.1016/j.ejso.2007.01.007},
  abstract = {AIMS: Selection of patients for treatment of oesophagogastric cancers rests on accurate staging. Laparoscopy has become a safe and effective staging tool in upper gastrointestinal cancers because of its ability to detect small peritoneal and liver metastases missed by imaging techniques. The aim of this study was to evaluate the role of staging laparoscopy (SL) in determining resectability of oesophagogastric cancers. METHODS: A review of 511 patients with oesophagogastric cancers referred to our centre during a 7-year period was performed. Four hundred and sixteen of them assessed to have resectable tumours after preoperative staging with CT and/or ultrasound underwent SL. The main outcome measure was the number of patients in whom laparoscopy changed treatment decision. RESULTS: Staging laparoscopy changed treatment decision in 84 cases (20.2\%): locally advanced disease in 17, extensive lymph node disease in four and distant metastases (liver and peritoneum) in 63 cases. The sensitivity of laparoscopy for resectability was 88\%. Eighty-one percent of patients who had combined CT scan and EUS were resectable at surgery compared with 65\% of those who had CT scan alone (statistically significant with P-value{$<$}0.05). Of those patients deemed resectable by SL 8.1\% were found to be unresectable at laparotomy, 16 with locally advanced disease and 11 with metastases. CONCLUSION: Staging laparoscopy avoided unnecessary laparotomy in 20.2\% of our patients and was most useful in adenocarcinoma, distal oesophageal, GOJ and gastric cancers and probably not necessary in lesions of the upper two-third of the oesophagus.},
  langid = {english},
  pmid = {17344017},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Esophageal Neoplasms,Evaluation Studies as Topic,Female,Humans,Laparoscopy,Male,Middle Aged,Neoplasm Staging,Predictive Value of Tests,Retrospective Studies,Sensitivity and Specificity,Stomach Neoplasms,Tomography; X-Ray Computed,Ultrasonography}
}

@incollection{dejaeger,
  type = {Book {{Section}}},
  title = {Presbyphagia},
  booktitle = {Seminars in {{Dysphagia}}},
  author = {Dejaeger, Marian and Liesenborghs, Claudia and Dejaeger, Eddy},
  editor = {Speyer, Renee and Bogaardt, Hans},
  year = {2015},
  publisher = {{IntechOpen}},
  doi = {10.5772/60780}
}

@article{dejager276,
  title = {Disparities in {{Surgical Access}}: {{A Systematic Literature Review}}, {{Conceptual Model}}, and {{Evidence Map}}},
  shorttitle = {Disparities in {{Surgical Access}}},
  author = {{de Jager}, Elzerie and Levine, Adele A. and Udyavar, N. Rhea and Burstin, Helen R. and Bhulani, Nizar and Hoyt, David B. and Ko, Clifford Y. and Weissman, Joel S. and Britt, L. D. and Haider, Adil H. and {Maggard-Gibbons}, Melinda A.},
  year = {2019},
  month = mar,
  journal = {Journal of the American College of Surgeons},
  volume = {228},
  number = {3},
  pages = {276--298},
  issn = {1879-1190},
  doi = {10.1016/j.jamcollsurg.2018.12.028},
  langid = {english},
  pmcid = {PMC6391739},
  pmid = {30803548},
  keywords = {Health Services Accessibility,Healthcare Disparities,Humans,Race,Surgical Procedures; Operative,United States}
}

@article{delaney819,
  title = {Clinical Outcomes and Resource Utilization Associated with Laparoscopic and Open Colectomy Using a Large National Database},
  author = {Delaney, Conor P. and Chang, Eunice and Senagore, Anthony J. and Broder, Michael},
  year = {2008},
  month = may,
  journal = {Annals of Surgery},
  volume = {247},
  number = {5},
  pages = {819--824},
  issn = {1528-1140},
  doi = {10.1097/SLA.0b013e31816d950e},
  abstract = {OBJECTIVES: To clarify national clinical and economic laparoscopic colectomy outcomes, we conducted a study of patients who underwent colectomy by laparoscopic or open approaches. BACKGROUND: Laparoscopy is becoming the preferred approach for colectomy in benign and malignant diseases. Although it is associated with significant clinical benefits, economic outcomes have varied. METHODS: We analyzed cohorts of patient-level data from Premier Inc.'s Perspective Rx Comparative Database, which collects data from more than 500 hospitals throughout the United States. By reviewing hospital charge data, patients who underwent elective colectomies from July 1, 2004, through June 30, 2006, were identified using International Classification of Diseases, 9th Revision, Clinical Modification procedure codes. The colectomy had to be listed as the primary or secondary procedure of the hospitalization. Primary outcomes included transfusion rates, in-hospital complications, readmissions within 30 days, reoperations, length of stay, total hospitalization costs, and discharge dispositions and services. RESULTS: We identified 32,733 patients who had elective colectomies throughout 402 hospitals; 11,044 (33.7\%) were laparoscopic and 21,689 (66.3\%) were open colectomies. The mean age was 64.2 +/- 13.9 years and 53.8\% were women. Laparoscopic colectomy patients had a longer mean operative time (195 +/- 76 vs. 178 +/- 80 minutes; P {$<$} 0.0001) and higher total hospital costs (\$8076 vs. \$7678; P = 0.0002). Laparoscopic patients had shorter mean length of stay (7.0 vs. 8.1; P {$<$} 0.0001) and fewer mean intensive care unit days (0.7 +/- 3.8 vs. 1.3 +/- 5.2 days; P {$<$} 0.0001). The laparoscopic cohort also had lower rates of transfusions (odds ratio [OR] = 0.68; P {$<$} 0.0001), in-hospital complications (OR = 0.89; P {$<$} 0.0001), and readmissions within 30 days (OR = 0.89; P = 0.0051), although reoperation rates were slightly, but significantly increased (OR = 1.78; P = 0.002). Laparoscopic colectomy patients were more likely to be discharged home without nursing care (OR = 0.70; P {$<$} 0.0001). CONCLUSION: Evaluation of a national administrative data set showed that patients who underwent laparoscopic colectomy had shorter intensive care unit and total hospital stays, fewer complications, lower mortality, fewer readmissions, and less use of skilled nursing facilities after discharge. There was a small but significant increase in reoperation rates and in-hospital costs with laparoscopic colectomy. Improved application of enhanced recovery programs and operative efficiencies may further improve resource utilization associated with laparoscopic colectomy.},
  langid = {english},
  pmid = {18438119},
  keywords = {Aged,Cohort Studies,Colectomy,Colonic Diseases,CRC,Databases; Factual,Female,Health Care Costs,Health Resources,Humans,Laparoscopy,Length of Stay,Male,Middle Aged,Retrospective Studies,Treatment Outcome,United States}
}

@article{delmonico769,
  type = {Journal {{Article}}},
  title = {Alternative Definitions of Sarcopenia, Lower Extremity Performance, and Functional Impairment with Aging in Older Men and Women},
  author = {Delmonico, M. J. and Harris, T. B. and Lee, J. S. and Visser, M. and Nevitt, M. and Kritchevsky, S. B. and Tylavsky, F. A. and Newman, A. B. and Health, Aging and Body Composition, Study},
  year = {2007},
  journal = {J Am Geriatr Soc},
  volume = {55},
  number = {5},
  pages = {769--74},
  issn = {0002-8614 (Print) 0002-8614 (Linking)},
  doi = {10.1111/j.1532-5415.2007.01140.x}
}

@article{dengdoy115,
  title = {Preoperative Sarcopenia Is a Predictor of Poor Prognosis of Esophageal Cancer after Esophagectomy: A Comprehensive Systematic Review and Meta-Analysis},
  shorttitle = {Preoperative Sarcopenia Is a Predictor of Poor Prognosis of Esophageal Cancer after Esophagectomy},
  author = {Deng, Han-Yu and Zha, Panpan and Peng, Lei and Hou, Liang and Huang, Kai-Li and Li, Xiao-Yun},
  year = {2019},
  month = mar,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {32},
  number = {3},
  pages = {doy115},
  issn = {1442-2050},
  doi = {10.1093/dote/doy115},
  abstract = {The impact of preoperative sarcopenia on long-term survival of esophageal cancer patients after esophagectomy remains unclear. We conducted an updated meta-analysis focusing on current topic comprehensively. We systematically searched relevant studies investigating the impact of preoperative sarcopenia on survival of patients with surgically treated esophageal cancer in PubMed, Embase, and Web of Science up to July 20, 2018. Data of 3-year and 5-year overall survival (OS) rates as well as hazard ratio (HR) of OS and disease-free survival (DFS) were collected for analysis by using the STATA 12.0 package. Finally, a total of 11 cohort studies consisting of 1520 patients (795 sarcopenic patients and 725 nonsarcopenic patients) were included for analysis. Our meta-analysis showed that patients with sarcopenia had a significantly lower 3-year (51.6\% vs. 65.4\%, P~{$<~$}0.001) and 5-year OS rate (41.2\% vs. 52.2\%, P~=~0.018) than those without sarcopenia. Sarcopenia was found to be an independent predictor of poor OS (HR~=~1.58; 95\% confidence interval (CI)~=~[1.35, 1.85]; P~{$<~$}0.001) and DFS (HR~=~1.46; 95\% CI~=~[1.12, 1.90]; P~=~0.005) in esophageal cancer patients after esophagectomy. No obvious heterogeneities or publication bias were observed during analysis. Therefore, patients with sarcopenia had a significantly worse prognosis than those without after surgical resection of esophageal cancer. Preoperative sarcopenia is an independent unfavorable prognostic factor for esophageal cancer patients after esophagectomy. However, high-quality studies with appropriate adjustments for confounding factors are needed to confirm our conclusions.},
  langid = {english},
  pmid = {30496385},
  keywords = {Adult,Aged,Aged; 80 and over,Disease-Free Survival,esophageal cancer; esophagectomy,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,meta-analysis,Middle Aged,Postoperative Complications,Preoperative Period,prognosis,Prognosis,Proportional Hazards Models,Risk Factors,sarcopenia,Sarcopenia,Survival Rate}
}

@article{dengdoz100,
  title = {It Is Time to Consider Incorporating Sarcopenia Assessment in the Management of Esophageal Cancer},
  author = {Deng, Han-Yu and Jiang, Rui},
  year = {2019},
  month = dec,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {32},
  number = {12},
  pages = {doz100},
  issn = {1442-2050},
  doi = {10.1093/dote/doz100},
  langid = {english},
  pmid = {31907511},
  keywords = {esophageal cancer,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Humans,Prognosis,sarcopenia,Sarcopenia}
}

@article{derstine279,
  title = {Optimal Body Size Adjustment of {{L3 CT}} Skeletal Muscle Area for Sarcopenia Assessment},
  author = {Derstine, Brian A. and Holcombe, Sven A. and Ross, Brian E. and Wang, Nicholas C. and Su, Grace L. and Wang, Stewart C.},
  year = {2021},
  month = jan,
  journal = {Scientific Reports},
  volume = {11},
  number = {1},
  pages = {279},
  issn = {2045-2322},
  doi = {10.1038/s41598-020-79471-z},
  abstract = {Measurements of skeletal muscle cross-sectional area (SMA) at the level of the third lumbar (L3) vertebra derived from clinical computed tomography (CT) scans are commonly used in assessments of sarcopenia, the loss of skeletal muscle mass and function associated with aging. As SMA is correlated with height and Body Mass Index (BMI), body size adjustment is necessary to fairly assess sarcopenic low muscle mass in individuals of different height and BMI. The skeletal muscle index, a widely used measure, adjusts for height as [Formula: see text] but uses no BMI adjustment. There is no agreed upon standard for body size adjustment. We extracted L3 SMA using non-contrast-enhanced CT scans from healthy adults, split into 'Under-40' and 'Over-40' cohorts. Sex-specific allometric analysis showed that height to the power of one was the optimal integer coefficient for height adjusted SMA in both males and females. We computed two height-adjusted measures [Formula: see text] and [Formula: see text], comparing their Pearson correlations versus age, height, weight, and BMI separately by sex and cohort. Finally, in the 'Under-40' cohort, we used linear regression to convert each height-adjusted measure into a z-score ([Formula: see text], [Formula: see text]) adjusted for BMI. [Formula: see text] was less correlated with height in both males and females ([Formula: see text], [Formula: see text] and [Formula: see text], [Formula: see text]) than [Formula: see text] ([Formula: see text] and [Formula: see text], [Formula: see text]). [Formula: see text] was uncorrelated with BMI and weight, and minimally correlated with height in males and females ([Formula: see text], [Formula: see text] and [Formula: see text], [Formula: see text]). The final [Formula: see text] equation was: [Formula: see text], where [Formula: see text], [Formula: see text], [Formula: see text], and sex = 1 if male, 0 if female. We propose [Formula: see text] for optimal height adjustment and the [Formula: see text] score for optimal height and BMI adjustment. By minimizing correlations with height and BMI, the [Formula: see text] score produces unbiased assessments of relative L3 skeletal muscle area across the full range of body sizes.},
  langid = {english},
  pmcid = {PMC7801425},
  pmid = {33431971},
  keywords = {Adult,Body Mass Index,Body Size,Female,Humans,Male,Methods,Middle Aged,Muscle; Skeletal,Reference Standards,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UBN6IHVC\\Derstine et al_2021_Optimal body size adjustment of L3 CT skeletal muscle area for sarcopenia.pdf}
}

@article{devasconcellos8,
  title = {Inpatient Palliative Chemotherapy Is Associated with High Mortality and Aggressive End-of-Life Care in Patients with Advanced Solid Tumors and Poor Performance Status},
  author = {{de Vasconcellos}, Vitor Fiorin and Bonadio, Renata RCC and Avan{\c c}o, Guilherme and Negr{\~a}o, Marcelo Vailati and Riechelmann, Rachel Pimenta},
  year = {2019},
  pages = {8},
  abstract = {Background: The benefit of palliative chemotherapy (PC) in patients with advanced solid tumors and poor performance status (ECOG-PS) has not been prospectively validated, which makes treatment decision challenging. We aimed to evaluate the overall survival, factors associated with early mortality, and adoption of additional procedures in hospitalized patients with advanced cancer and poor ECOG-PS treated with PC. Methods: We analyzed a retrospective cohort of patients with advanced cancer treated with PC during hospitalization at an academic cancer center in Brazil from 2014 to 2016. Eligibility criteria included: ECOG-PS 3\textendash 4 and start of first-line PC; or ECOG-PS {$\geq$} 2 and start of second or subsequent lines. Primary endpoint was 30-day survival from start of PC. Kaplan-Meier method was used for survival estimates and Cox regression for factors associated with 30-day mortality. Results: Two hundred twenty-eight patients were eligible. 21.9, 66.7 and 11.4\% of patients had ECOG-PS 2, 3 and 4, respectively. 49.6\% had gastrointestinal tumors. Median follow-up was 49 days (range 1\textendash 507). 98.2\% of patients had died, 32\% during the index hospitalization. The 30-day and 60-day survival rates were 55.7 and 38.5\%, respectively. 30\% of patients were admitted to the intensive care unit. In a multivariable analysis, ECOG-PS 3/4 (HR 2.01; P = 0.016), hypercalcemia (HR 2.19; P = 0.005), and elevated bilirubin (HR 3.17; P {$<$} 0.001) were significantly associated with 30-day mortality. Conclusions: Patients with advanced cancer and poor ECOG-PS had short survival after treatment with inpatient PC. Inpatient PC was associated with aggressive end-of-life care. Prognostic markers such as ECOG-PS, hypercalcemia and elevated bilirubin can contribute to the decision-making process for these patients.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ITQJIV9B\\de Vasconcellos et al. - 2019 - Inpatient palliative chemotherapy is associated wi.pdf}
}

@article{deyo613,
  title = {Adapting a Clinical Comorbidity Index for Use with {{ICD-9-CM}} Administrative Databases},
  author = {Deyo, R. A. and Cherkin, D. C. and Ciol, M. A.},
  year = {1992},
  month = jun,
  journal = {Journal of Clinical Epidemiology},
  volume = {45},
  number = {6},
  pages = {613--619},
  issn = {0895-4356},
  doi = {10.1016/0895-4356(92)90133-8},
  abstract = {Administrative databases are increasingly used for studying outcomes of medical care. Valid inferences from such data require the ability to account for disease severity and comorbid conditions. We adapted a clinical comorbidity index, designed for use with medical records, for research relying on International Classification of Diseases (ICD-9-CM) diagnosis and procedure codes. The association of this adapted index with health outcomes and resource use was then examined with a sample of Medicare beneficiaries who underwent lumbar spine surgery in 1985 (n = 27,111). The index was associated in the expected direction with postoperative complications, mortality, blood transfusion, discharge to nursing home, length of hospital stay, and hospital charges. These associations were observed whether the index incorporated data from multiple hospitalizations over a year's time, or just from the index surgical admission. They also persisted after controlling for patient age. We conclude that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.},
  langid = {english},
  pmid = {1607900},
  keywords = {Aged,Comorbidity,Cormorbidity,Databases; Factual,Female,Humans,Lumbar Vertebrae,Male,Medical Records,Medicare,Spinal Diseases,Treatment Outcome,United States}
}

@article{dieterich365,
  type = {Journal {{Article}}},
  title = {Postoperative {{Complications Predict}} 30-{{Day Readmission}} in {{Geriatric General Surgery Patients}}},
  author = {Dieterich, J. D. and Divino, C. M.},
  year = {2017},
  journal = {Am Surg},
  volume = {83},
  number = {4},
  pages = {365--370},
  issn = {1555-9823 (Electronic) 0003-1348 (Linking)}
}

@article{dijk10,
  title = {Low Skeletal Muscle Radiation Attenuation and Visceral Adiposity Are Associated with Overall Survival and Surgical Site Infections in Patients with Pancreatic Cancer},
  author = {Dijk, David P J},
  pages = {10},
  abstract = {Background Cancer cachexia and skeletal muscle wasting are related to poor survival. In this study, quantitative body composition measurements using computed tomography (CT) were investigated in relation to survival, post-operative complications, and surgical site infections in surgical patients with cancer of the head of the pancreas. Methods A prospective cohort of 199 patients with cancer of the head of the pancreas was analysed by CT imaging at the L3 level to determine (i) muscle radiation attenuation (average Hounsfield units of total L3 skeletal muscle); (ii) visceral adipose tissue area; (iii) subcutaneous adipose tissue area; (iv) intermuscular adipose tissue area; and (v) skeletal muscle area. Sexspecific cut-offs were determined at the lower tertile for muscle radiation attenuation and skeletal muscle area and the higher tertile for adipose tissues. These variables of body composition were related to overall survival, severe post-operative complications (Dindo\textendash Clavien {$\geq$} 3), and surgical site infections (wounds inspected daily by an independent trial nurse) using Coxregression analysis and multivariable logistic regression analysis, respectively. Results Low muscle radiation attenuation was associated with shorter survival in comparison with moderate and high muscle radiation attenuation [median survival 10.8 (95\% CI: 8.8\textendash 12.8) vs. 17.4 (95\% CI: 14.7\textendash 20.1), and 18.5 (95\% CI: 9.2\textendash 27.8) months, respectively; P {$<$} 0.008]. Patient subgroups with high muscle radiation attenuation combined with either low visceral adipose tissue or age {$<$}70 years had longer survival than other subgroups (P = 0.011 and P = 0.001, respectively). Muscle radiation attenuation was inversely correlated with intermuscular adipose tissue (rp = \`A0.697, P {$<$} 0.001). High visceral adipose tissue was associated with an increased surgical site infection rate, OR: 2.4 (95\% CI: 1.1\textendash 5.3; P = 0.027). Conclusions Low muscle radiation attenuation was associated with reduced survival, and high visceral adiposity was associated with an increase in surgical site infections. The strong correlation between muscle radiation attenuation and intermuscular adipose tissue suggests the presence of ectopic fat in muscle, warranting further investigation. CT image analysis could be implemented in pre-operative risk assessment to assist in treatment decision-making.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\T3X28F6Q\\Dijk - Low skeletal muscle radiation attenuation and visc.pdf}
}

@article{dijksterhuis199,
  title = {Association between Body Composition, Survival, and Toxicity in Advanced Esophagogastric Cancer Patients Receiving Palliative Chemotherapy},
  author = {Dijksterhuis, Willemieke P.M. and Pruijt, Maarten J. and {van der Woude}, Stephanie O. and Klaassen, Remy and Kurk, Sophie A. and {van Oijen}, Martijn G.H. and {van Laarhoven}, Hanneke W.M.},
  year = {2019},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {10},
  number = {1},
  pages = {199--206},
  issn = {2190-6009},
  doi = {10.1002/jcsm.12371},
  abstract = {Background Palliative systemic treatment in patients with advanced or metastatic esophagogastric cancer may result in improved overall survival and quality of life but can also lead to considerable toxicity. In various cancer types, severe muscle mass depletion (sarcopenia) and poor muscle strength are associated with decreased survival and increased chemotherapy-related toxicity. The aim of this study is to determine the impact of body composition on survival and chemotherapy toxicity in esophagogastric cancer patients treated with first-line palliative chemotherapy. Methods A total of 88 patients with advanced esophagogastric cancer treated with standard first-line palliative systemic therapy consisting of capecitabine and oxaliplatin (CapOx) between January 2010 and February 2017 were included. Skeletal muscle index (SMI), reflecting muscle mass, and skeletal muscle density (SMD), associated with muscle strength, were measured using pre-treatment of all patients and evaluation computed tomography scans after three treatment cycles of 65 patients and were used to determine sarcopenia and sarcopenic obesity (i.e. sarcopenia and body mass index {$>$}25 kg/m2). The associations between body composition (SMI, SMD, sarcopenia, and sarcopenic obesity) and survival and toxicity were assessed using univariable and multivariable Cox and logistic regression analyses, respectively. Results Of 88 patients, 75\% was male, and median age was 63 (interquartile range 56\textendash 69) years. The majority of patients had an adenocarcinoma (83\%). Before start of treatment, 49\% of the patients were sarcopenic, and 20\% had sarcopenic obesity. Low SMD was observed in 50\% of patients. During three cycles CapOx, SMI significantly decreased, with a median decrease of 4\% (interquartile range -8.6\textendash -0.4). Median progression-free and overall survival were 6.9 and 10.1 months. SMI, SMD, sarcopenia, and sarcopenic obesity (both pre-treatment and after three cycles) were neither associated with progression-free nor overall survival. Pre-treatment SMD was independently associated with grade 3\textendash 4 toxicity (odds ratio 0.94; 95\% confidence interval 0.89\textendash 1.00) and sarcopenic obesity with grade 2\textendash 4 neuropathy (odds ratio 3.82; 95\% confidence interval 1.20\textendash 12.18). Conclusions Sarcopenia was not associated with survival or treatment-related toxicity in advanced esophagogastric cancer patients treated with CapOx. Pre-treatment sarcopenic obesity was independently associated with the occurrence of grade 2\textendash 4 neurotoxicity and skeletal muscle density with grade 3\textendash 4 toxicity.},
  langid = {english},
  keywords = {Body composition,Esophageal cancer,Gastric cancer,Palliative treatment,Sarcopenia,Skeletal muscle mass},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcsm.12371},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H4RJEKLA\\Dijksterhuis et al. - 2019 - Association between body composition, survival, an.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\PKFAI9K6\\Dijksterhuis et al. - Association between body composition, survival, an.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\ZZJU985R\\jcsm.html}
}

@incollection{dimitriosschizas,
  type = {Book {{Section}}},
  title = {Esophageal {{Abnormalities}}},
  booktitle = {Nutritional {{Management}} of {{Esophageal Cancer Patients}}},
  author = {Dimitrios Schizas, Irene Lidoriki, Demetrios Moris and Liakakos, Theodore},
  editor = {Chai, Jianyuan},
  year = {2017}
}

@article{dinge96233,
  title = {A Comparison of the Analgesia Efficacy and Side Effects of Paravertebral Compared with Epidural Blockade for Thoracotomy: An Updated Meta-Analysis},
  shorttitle = {A Comparison of the Analgesia Efficacy and Side Effects of Paravertebral Compared with Epidural Blockade for Thoracotomy},
  author = {Ding, Xibing and Jin, Shuqing and Niu, Xiaoyin and Ren, Hao and Fu, Shukun and Li, Quan},
  year = {2014},
  journal = {PloS One},
  volume = {9},
  number = {5},
  pages = {e96233},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0096233},
  abstract = {OBJECTIVE: The most recent systematic review and meta-analysis comparing the analgesic efficacy and side effects of paravertebral and epidural blockade for thoracotomy was published in 2006. Nine well-designed randomized trials with controversial results have been published since then. The present report constitutes an updated meta-analysis of this issue. SUMMARY OF BACKGROUND: Thoracotomy is a major surgical procedure and is associated with severe postoperative pain. Epidural analgesia is the gold standard for post-thoracotomy pain management, but has its limitations and contraindications, and paravertebral blockade is increasingly popular. However, it has not been decided whether the analgesic effect of the two methods is comparable, or whether paravertebral blockade leads to a lower incidence of adverse side effects after thoracotomy. METHODS: Two reviewers independently searched the databases PubMed, EMBASE, and the Cochrane Library (last performed on 1 February, 2013) for reports of studies comparing post-thoracotomy epidural analgesia and paravertebral blockade. The same individuals independently extracted data from the appropriate studies. RESULT: Eighteen trials involving 777 patients were included in the current analysis. There was no significant difference in pain scores between paravertebral blockade and epidural analgesia at 4-8, 24, 48 hours, and the rates of pulmonary complications and morphine usage during the first 24 hours were also similar. However, paravertebral blockade was better than epidural analgesia in reducing the incidence of urinary retention (p{$<$}0.0001), nausea and vomiting (p{$\mkern1mu$}={$\mkern1mu$}0.01), hypotension (p{$<$}0.00001), and rates of failed block were lower in the paravertebral blockade group (p{$\mkern1mu$}={$\mkern1mu$}0.01). CONCLUSIONS: This meta-analysis showed that PVB can provide comparable pain relief to traditional EPI, and may have a better side-effect profile for pain relief after thoracic surgery. Further high-powered randomized trials are to need to determine whether PVB truly offers any advantages over EPI.},
  langid = {english},
  pmcid = {PMC4010440},
  pmid = {24797238},
  keywords = {Analgesia; Epidural,Female,Humans,Male,Nausea,Pain Management,Pain Measurement,Pain; Postoperative,Randomized Controlled Trials as Topic,Thoracostomy,Urinary Retention,Vomiting},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SHSTBDHX\\Ding et al_2014_A comparison of the analgesia efficacy and side effects of paravertebral.pdf}
}

@article{djourno527,
  title = {Prognostic Impact of Weight Loss in 1-Year Survivors after Transthoracic Esophagectomy for Cancer},
  author = {D'Journo, X. B. and Ouattara, M. and Loundou, A. and Trousse, D. and Dahan, L. and Nathalie, T. and Doddoli, C. and Seitz, J. F. and Thomas, P.-A.},
  year = {2012},
  month = aug,
  journal = {Diseases of the Esophagus},
  volume = {25},
  number = {6},
  pages = {527--534},
  issn = {1120-8694},
  doi = {10.1111/j.1442-2050.2011.01282.x},
  abstract = {Malnutrition is common 1 year after esophageal cancer surgery. However, the prognostic impact of this malnutrition on long-term outcome has been poorly reported. This study aims at determining the potential effect on disease-free survival (DFS) of weight loss observed at 1 year in disease-free survivors after curative esophageal resection. From a prospective single-institution database, 304 patients having undergone a transthoracic esophagectomy with two-field lymphadenectomy and gastric reconstruction between 1996 to 2008 were identified. Patients who died during the postoperative course (n= 24), patients who died within the first postoperative year (n= 12), patients who presented with an early recurrence within the first postoperative year (n= 20), and those who were lost to follow-up (n= 22) were excluded from the study, as well as those for whom the follow-up was shorter than 1 year (n= 21). The remaining 205 patients constituted a homogeneous group of 1-year disease-free survivors after full postoperative work-up and formed the material of the present study. Body weight (BW) values were collected before any treatment at the onset of symptoms (initial BW) and 1 year after esophagectomy. A 1-year weight loss (1-YWL) exceeding 10\% of the initial BW defined an important malnutrition. Impact of the 1-YWL{$\geq$} or \&lt;10\% of the initial BW on DFS was investigated. Logistic regression was performed to identify factors affecting DFS. The mean initial BW was 69.1 {$\pm$} 12{$\quad$}kg, corresponding to a mean body mass index (BMI) of 23.8 {$\pm$} 3{$\quad$}kg/m2. Preoperatively, 32 (15\%) patients were in the underweight category (BMI \&lt; 20{$\quad$}kg/m2), 110 (54\%) were in normal (BMI = 20\textendash 24{$\quad$}kg/m2), and 63 (31\%) were in the overweight category (BMI {$\geq$} 25{$\quad$}kg/m2). Mean 1-year BW was 63.5 {$\pm$} 12{$\quad$}kg. 1-YWL was \&lt;10\% of the initial BW in 92 patients (45\%) and {$\geq$}10\% in 113 patients (55\%). Accordingly, 5-year DFS rates were 66\% (median: 80 months) and 48\% (median: 51 months), respectively (P= 0.005). On multivariate analysis, only three independent variables affected the DFS significantly: clinical N stage (cN) status (P= 0.007; odds ratio: 1.99, 1.2\textendash 3.3), incomplete resection (P= 0.008, OR: 3.6, 1.3\textendash 9.3), and 1-YWL {$\geq$} 10\% (P= 0.004, OR: 2.1: 1.2\textendash 3.4). 1-YWL of or exceeding 10\% of the initial BW in 1-year disease-free survivors has a negative prognostic impact on DFS after esophagectomy for cancer. This information offers another view on the objectives of the perioperative nutritional care of these patients. Special vigilance program on the nutritional status in post-esophagectomy patients should be the rule.},
  keywords = {Weight Loss; GE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Q8NTH4KZ\\DâJourno et al. - 2012 - Prognostic impact of weight loss in 1-year survivo.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\9Z3UK2KA\\2328558.html}
}

@article{dolan320,
  title = {Significant Understaging Is Seen in Clinically Staged {{T2N0}} Esophageal Cancer Patients Undergoing Esophagectomy},
  author = {Dolan, J. P. and Kaur, T. and Diggs, B. S. and Luna, R. A. and Sheppard, B. C. and Schipper, P. H. and Tieu, B. H. and Bakis, G. and Vaccaro, G. M. and Holland, J. M. and Gatter, K. M. and Conroy, M. A. and Thomas, C. A. and Hunter, J. G.},
  year = {2016},
  month = may,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {29},
  number = {4},
  pages = {320--325},
  issn = {1442-2050},
  doi = {10.1111/dote.12334},
  abstract = {This study aimed to determine the impact of preoperative staging on the treatment of clinical T2N0 (cT2N0) esophageal cancer patients undergoing esophagectomy. We reviewed a retrospective cohort of 27 patients treated at a single institution between 1999 and 2011. Clinical staging was performed with computed tomography, positron emission tomography, and endoscopic ultrasound. Patients were separated into two groups: neoadjuvant therapy followed by surgery (NEOSURG) and surgery alone (SURG). There were 11 patients (41\%) in the NEOSURG group and 16 patients (59\%) in the SURG group. In the NEOSURG group, three of 11 patients (27\%) had a pathological complete response and eight (73\%) were partial or nonresponders after neoadjuvant therapy. In the SURG group, nine of 16 patients (56\%) were understaged, 6 (38\%) were overstaged, and 1 (6\%) was correctly staged. In the entire cohort, despite being clinically node negative, 14 of 27 patients (52\%) had node-positive disease (5/11 [45\%] in the NEOSURG group, and 9/16 [56\%] in the SURG group). Overall survival rate was not statistically significant between the two groups (P = 0.96). Many cT2N0 patients are clinically understaged and show no preoperative evidence of node-positive disease. Consequently, neoadjuvant therapy may have a beneficial role in treatment.},
  langid = {english},
  pmid = {25707341},
  keywords = {Adenocarcinoma,Adult,Aged,Chemoradiotherapy; Adjuvant,chemotherapy,esophageal cancer,Esophageal Neoplasms,esophagectomy,Esophagectomy,Esophagoscopy,Female,Humans,Lymphatic Metastasis,Male,Middle Aged,neoadjuvant therapy,Neoplasm Staging,oesophageal cancer,Outcome and Process Assessment; Health Care,Positron-Emission Tomography,Preoperative Period,radiation therapy,Survival Rate,Tomography; X-Ray Computed,United States}
}

@article{dolly1413,
  title = {Cancer Cachexia and Skeletal Muscle Atrophy in Clinical Studies: What Do We Really Know?},
  shorttitle = {Cancer Cachexia and Skeletal Muscle Atrophy in Clinical Studies},
  author = {Dolly, Adeline and Dumas, Jean-Fran{\c c}ois and Servais, St{\'e}phane},
  year = {2020},
  month = dec,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {11},
  number = {6},
  pages = {1413--1428},
  issn = {2190-6009},
  doi = {10.1002/jcsm.12633},
  abstract = {Research investigators have shown a growing interest in investigating alterations underlying skeletal muscle wasting in patients with cancer. However, skeletal muscle dysfunctions associated with cancer cachexia have mainly been studied in preclinical models. In the present review, we summarize the results of clinical studies in which skeletal muscle biopsies were collected from cachectic vs. non-cachectic cancer patients. Most of these studies suggest the presence of significant physiological alterations in skeletal muscle from cachectic cancer patients. We suggest a hypothesis, which connects structural and metabolic parameters that may, at least in part, be responsible for the skeletal muscle atrophy characteristic of cancer cachexia. Finally, we discuss the importance of a better standardization of the diagnostic criteria for cancer cachexia, as well as the requirement for additional clinical studies to improve the robustness of these conclusions.},
  langid = {english},
  pmcid = {PMC7749617},
  pmid = {33053604},
  keywords = {Cachexia,Cancer cachexia,Clinical studies,Humans,Mitochondria,Muscle; Skeletal,Muscular Atrophy,Myosteatosis,Neoplasms,Skeletal muscle alterations},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2Z86E73W\\Dolly et al_2020_Cancer cachexia and skeletal muscle atrophy in clinical studies.pdf}
}

@article{domachevskye13412,
  title = {Baseline {{18F-FDG PET}}/{{CT}} as Predictor of the Pathological Response to Neoadjuvant Therapy in Esophageal Cancer: {{A}} Retrospective Study},
  shorttitle = {Baseline {{18F-FDG PET}}/{{CT}} as Predictor of the Pathological Response to Neoadjuvant Therapy in Esophageal Cancer},
  author = {Domachevsky, Liran and Kashtan, Hanoch and Brenner, Baruch and Nidam, Meital and Morgenstern, Sara and Kundel, Yulia and Groshar, David and Bernstine, Hanna},
  year = {2018},
  month = dec,
  journal = {Medicine},
  volume = {97},
  number = {49},
  pages = {e13412},
  issn = {1536-5964},
  doi = {10.1097/MD.0000000000013412},
  abstract = {The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42\%, 50\% and 60\% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p{$\mkern1mu$}={$\mkern1mu$}.02] and 0.664 (confidence interval 0.527-0.802, P{$\mkern1mu$}={$\mkern1mu$}.048), respectively in differentiating patients with a complete (n{$\mkern1mu$}={$\mkern1mu$}44) or incomplete (n{$\mkern1mu$}={$\mkern1mu$}17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.},
  langid = {english},
  pmcid = {PMC6310504},
  pmid = {30544419},
  keywords = {Aged,Chemoradiotherapy,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Male,Middle Aged,Neoadjuvant Therapy,Positron Emission Tomography Computed Tomography,Prognosis,Radiopharmaceuticals,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QFQQS3RT\\Domachevsky et al. - 2018 - Baseline 18F-FDG PETCT as predictor of the pathol.pdf}
}

@article{dorth2099,
  title = {Patterns of Recurrence after Trimodality Therapy for Esophageal Cancer},
  author = {Dorth, Jennifer A. and Pura, John A. and Palta, Manisha and Willett, Christopher G. and Uronis, Hope E. and D'Amico, Thomas A. and Czito, Brian G.},
  year = {2014},
  month = jul,
  journal = {Cancer},
  volume = {120},
  number = {14},
  pages = {2099--2105},
  issn = {1097-0142},
  doi = {10.1002/cncr.28703},
  abstract = {BACKGROUND: Patterns of failure after neoadjuvant chemoradiotherapy and surgery for esophageal cancer are poorly defined. METHODS: All patients in the current study were treated with trimodality therapy for nonmetastatic esophageal cancer from 1995 to 2009. Locoregional failure included lymph node failure (NF), anastomotic failure, or both. Abdominal paraaortic failure (PAF) was defined as disease recurrence at or below the superior mesenteric artery. RESULTS: Among 155 patients, the primary tumor location was the upper/middle esophagus in 18\%, the lower esophagus in 32\%, and the gastroesophageal junction in 50\% (adenocarcinoma in 79\% and squamous cell carcinoma in 21\%) of patients. Staging methods included endoscopic ultrasound (73\%), computed tomography (46\%), and positron emission tomography/computed tomography (54\%). Approximately 40\% of patients had American Joint Committee on Cancer stage II disease and 60\% had stage III disease. The median follow-up was 1.3 years. The 2-year locoregional control, event-free survival, and overall survival rates were 86\%, 36\%, and 48\%, respectively. The 2-year NF rate was 14\%, the isolated NF rate was 3\%, and the anastomotic failure rate was 6\%. The 2-year PAF rate was 9\% and the isolated PAF rate was 5\%. PAF was found to be increased among patients with gastroesophageal junction tumors (12\% vs 6\%), especially for the subset with {$\geq$} 2 clinically involved lymph nodes at the time of diagnosis (19\% vs 4\%). CONCLUSIONS: Few patients experience isolated NF or PAF as their first disease recurrence. Therefore, it is unlikely that targeting additional regional lymph node basins with radiotherapy would significantly improve clinical outcomes.},
  langid = {english},
  pmcid = {PMC4519032},
  pmid = {24711267},
  keywords = {Adenocarcinoma,Adult,Aged,Anastomotic Leak,Antineoplastic Agents,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Chemoradiotherapy; Adjuvant,Disease-Free Survival,esophageal cancer,Esophageal Neoplasms,esophagectomy,Esophagectomy,Female,Fluorouracil,Humans,Kaplan-Meier Estimate,lymphatic irradiation,lymphatic metastasis,Lymphatic Metastasis,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,Platinum Compounds,Positron-Emission Tomography,Radiotherapy Dosage,Taxoids,Treatment Failure,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\99SP9W84\\Dorth et al. - 2014 - Patterns of recurrence after trimodality therapy f.pdf}
}

@article{dronkers67,
  type = {Journal {{Article}}},
  title = {The Association of Pre-Operative Physical Fitness and Physical Activity with Outcome after Scheduled Major Abdominal Surgery},
  author = {Dronkers, J. J. and Chorus, A. M. and {van Meeteren}, N. L. and {Hopman-Rock}, M.},
  year = {2013},
  journal = {Anaesthesia},
  volume = {68},
  number = {1},
  pages = {67--73},
  issn = {1365-2044 (Electronic) 0003-2409 (Linking)},
  doi = {10.1111/anae.12066}
}

@article{drummond515,
  title = {Routine Pre- and Post-Neoadjuvant Chemotherapy Fitness Testing Is Not Indicated for Oesophagogastric Cancer Surgery},
  author = {Drummond, R. J. and Vass, D. and Wadhawan, H. and Craig, C. F. and MacKay, C. K. and Fullarton, G. M. and Forshaw, M. J.},
  year = {2018},
  month = sep,
  journal = {Annals of the Royal College of Surgeons of England},
  volume = {100},
  number = {7},
  pages = {515--519},
  issn = {1478-7083},
  doi = {10.1308/rcsann.2018.0067},
  abstract = {Introduction There is a known correlation between anaerobic threshold (AT) during cardiopulmonary exercise testing and development of cardiopulmonary complications in high-risk patients undergoing oesophagogastric cancer surgery. This study aimed to assess the value of routine retesting following neoadjuvant chemotherapy. Methods Patients undergoing neoadjuvant chemotherapy with subsequent oesophagogastric cancer surgery with pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise data were identified from a prospectively maintained database. Measured cardiopulmonary exercise variables included AT and maximum oxygen uptake at peak exercise (VO2 peak). Anaerobic threshold values within 1 ml/kg/minute were considered static. Patients were grouped into AT ranges of less than 9 ml/kg/minute, 9-11 ml/kg/minute and greater than 11 ml/kg/minute. Outcome measures were unplanned intensive care stay, postoperative cardiovascular morbidity and mortality. Results Between May 2008 and August 2017, 42 patients from 675 total resections were identified, with a mean age of 65 years (range 49-84 years). Mean pre-neoadjuvant chemotherapy AT was 11.07 ml/kg/minute (standard deviation, SD, 3.24 ml/kg/minute, range 4.6-19.3 ml/kg/minute) while post-neoadjuvant chemotherapy AT was 11.19 ml/kg/minute (SD 3.05 ml/kg/minute, range 5.2-18.1 ml/kg/minute). Mean pre-neoadjuvant chemotherapy VO2 peak was 17.13 ml/kg/minute, while post-chemotherapy this mean fell to 16.59 ml/kg/minute. Some 44.4\% of patients with a pre-chemotherapy AT less than 9 ml/kg/minute developed cardiorespiratory complications compared with 42.2\% of those whose AT was greater than 9 ml/kg/minute (P = 0.914); 63.6\% of patients in the post-neoadjuvant chemotherapy group with an AT less than 9 ml/kg/minute developed cardiorespiratory complications. There was no correlation between direction of change in AT and outcome. Conclusion In our patient population, neoadjuvant chemotherapy does not appear to result in a significant mean reduction in cardiorespiratory fitness. Routine pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise testing is currently not indicated; however, larger studies are required to demonstrate this conclusively.},
  langid = {english},
  pmcid = {PMC6214048},
  pmid = {29692190},
  keywords = {Aged,Aged; 80 and over,Anaerobic Threshold,Antineoplastic Agents,Cardiorespiratory Fitness,Chemotherapy,Critical Care,Esophageal Neoplasms,Exercise Test,Exercise testing,Female,Gastrectomy,Humans,Length of Stay,Male,Middle Aged,Neoadjuvant Therapy,Oesophagectomy,Postoperative Complications,Prospective Studies,Stomach Neoplasms,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PLSI4I6D\\Drummond et al_2018_Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated.pdf}
}

@article{dumontier3053,
  title = {Contemporary {{Analysis}} of {{Electronic Frailty Measurement}} in {{Older Adults}} with {{Multiple Myeloma Treated}} in the {{National US Veterans Affairs Healthcare System}}},
  author = {DuMontier, Clark and Fillmore, Nathanael R. and Yildirim, Cenk and Cheng, David and La, Jennifer and Orkaby, Ariela R. and Charest, Brian and Cirstea, Diana and Yellapragada, Sarvari and Gaziano, John Michael and Do, Nhan and Brophy, Mary T. and Kim, Dae H. and Munshi, Nikhil C. and Driver, Jane A.},
  year = {2021},
  month = jun,
  journal = {Cancers},
  volume = {13},
  number = {12},
  pages = {3053},
  issn = {2072-6694},
  doi = {10.3390/cancers13123053},
  abstract = {Electronic frailty indices based on data from administrative claims and electronic health records can be used to estimate frailty in large populations of older adults with cancer where direct frailty measures are lacking. The objective of this study was to use the electronic Veterans Affairs Frailty Index (VA-FI-10)-developed and validated to measure frailty in the national United States (US) VA Healthcare System-to estimate the prevalence and impact of frailty in older US veterans newly treated for multiple myeloma (MM) with contemporary therapies. We designed a retrospective cohort study of 4924 transplant-ineligible veterans aged {$\geq$} 65 years initiating MM therapy within VA from 2004 to 2017. Initial MM therapy was measured using inpatient and outpatient treatment codes from pharmacy data in the VA Corporate Data Warehouse. In total, 3477 veterans (70.6\%) were classified as frail (VA-FI-10 {$>$} 0.2), with 1510 (30.7\%) mildly frail (VA-FI-10 {$>$} 0.2-0.3), 1105 (22.4\%) moderately frail (VA-FI-10 {$>$} 0.3-0.4), and 862 (17.5\%) severely frail (VA-FI-10 {$>$} 0.4). Survival and time to hospitalization decreased with increasing VA-FI-10 severity (log-rank p-value {$<$} 0.001); the VA-FI-10 predicted mortality and hospitalizations independently of age, sociodemographic variables, and measures of disease risk. Varying data sources and assessment periods reclassified frailty severity for a substantial portion of veterans but did not substantially affect VA-FI-10's association with mortality. Our study supports use of the VA-FI-10 in future research involving older veterans with MM and provides insights into its potential use in identifying frailty in clinical practice.},
  langid = {english},
  pmcid = {PMC8233717},
  pmid = {34207459},
  keywords = {frailty,frailty index,geriatric assessment,multiple myeloma},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VHQZG5JF\\DuMontier et al_2021_Contemporary Analysis of Electronic Frailty Measurement in Older Adults with.pdf}
}

@article{dunbar850,
  title = {The Risk of Lymph-Node Metastases in Patients with High-Grade Dysplasia or Intramucosal Carcinoma in {{Barrett}}'s Esophagus: A Systematic Review},
  shorttitle = {The Risk of Lymph-Node Metastases in Patients with High-Grade Dysplasia or Intramucosal Carcinoma in {{Barrett}}'s Esophagus},
  author = {Dunbar, Kerry B. and Spechler, Stuart Jon},
  year = {2012},
  month = jun,
  journal = {The American Journal of Gastroenterology},
  volume = {107},
  number = {6},
  pages = {850-862; quiz 863},
  issn = {1572-0241},
  doi = {10.1038/ajg.2012.78},
  abstract = {OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus. METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens. RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39 \% , 95 \% CI 0.86 \textendash{} 1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93 \% , 95 \% CI 1.19 \textendash{} 2.66 \%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes. CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1 \textendash{} 2 \%. Esophagectomy has a mortality rate that often exceeds 2 \%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.},
  langid = {english},
  pmcid = {PMC3578695},
  pmid = {22488081},
  keywords = {Adenocarcinoma,Barrett Esophagus,Carcinoma,Esophageal Neoplasms,Esophagectomy,Esophagoscopy,Humans,Incidence,Lymph Nodes,Lymphatic Metastasis,Mucous Membrane,Neoplasm Grading,Risk Assessment,Risk Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LL3AHQRI\\Dunbar and Spechler - 2012 - The risk of lymph-node metastases in patients with.pdf}
}

@article{dutta164,
  type = {Journal {{Article}}},
  title = {Health Related Quality of Life Assessment after Radical Cystectomy: Comparison of Ileal Conduit with Continent Orthotopic Neobladder},
  author = {Dutta, S. C. and Chang, S. C. and Coffey, C. S. and Smith, J. A., Jr. and Jack, G. and Cookson, M. S.},
  year = {2002},
  journal = {J Urol},
  volume = {168},
  number = {1},
  pages = {164--7},
  issn = {0022-5347 (Print) 0022-5347 (Linking)}
}

@article{easterling989,
  type = {Journal {{Article}}},
  title = {Pharyngeal Dysphagia in Postesophagectomy Patients: Correlation with Deglutitive Biomechanics},
  author = {Easterling, C. S. and Bousamra, M., 2nd and Lang, I. M. and Kern, M. K. and Nitschke, T. and Bardan, E. and Shaker, R.},
  year = {2000},
  journal = {Ann Thorac Surg},
  volume = {69},
  number = {4},
  pages = {989--92},
  issn = {0003-4975 (Print) 0003-4975 (Linking)}
}

@article{edwards113170L,
  title = {Abdominal Muscle Segmentation from {{CT}} Using a Convolutional Neural Network},
  author = {Edwards, Ka'Toria and Chhabra, Avneesh and Dormer, James and Jones, Phillip and Boutin, Robert D. and Lenchik, Leon and Fei, Baowei},
  year = {2020},
  month = feb,
  journal = {Proceedings of SPIE--the International Society for Optical Engineering},
  volume = {11317},
  pages = {113170L},
  issn = {0277-786X},
  doi = {10.1117/12.2549406},
  abstract = {CT is widely used for diagnosis and treatment of a variety of diseases, including characterization of muscle loss. In many cases, changes in muscle mass, particularly abdominal muscle, indicate how well a patient is responding to treatment. Therefore, physicians use CT to monitor changes in muscle mass throughout the patient's course of treatment. In order to measure the muscle, radiologists must segment and review each CT slice manually, which is a time-consuming task. In this work, we present a fully convolutional neural network (CNN) for the segmentation of abdominal muscle on CT. We achieved a mean Dice similarity coefficient of 0.92, a mean precision of 0.93, and a mean recall of 0.91 in an independent test set. The CNN-based segmentation method can provide an automatic tool for the segmentation of abdominal muscle. As a result, the time required to obtain information about changes in abdominal muscle using the CNN takes a fraction of the time associated with manual segmentation methods and thus can provide a useful tool in the clinical application.},
  langid = {english},
  pmcid = {PMC7309562},
  pmid = {32577045},
  keywords = {Convolutional Neural Networks,CT,Deep Learning,Image segmentation,Muscle imaging,Muscle Segmentation},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JHC5EGNM\\Edwards et al_2020_Abdominal muscle segmentation from CT using a convolutional neural network.pdf}
}

@article{elhenawy29,
  title = {Role of Preoperative Intravenous Iron Therapy to Correct Anemia before Major Surgery: Study Protocol for Systematic Review and Meta-Analysis},
  shorttitle = {Role of Preoperative Intravenous Iron Therapy to Correct Anemia before Major Surgery},
  author = {Elhenawy, Abdelsalam M. and Meyer, Steven R. and Bagshaw, Sean M. and MacArthur, Roderick G. and Carroll, Linda J.},
  year = {2015},
  month = mar,
  journal = {Systematic Reviews},
  volume = {4},
  pages = {29},
  issn = {2046-4053},
  doi = {10.1186/s13643-015-0016-4},
  abstract = {BACKGROUND: Preoperative anemia is a common and potentially serious hematological problem in elective surgery and increases the risk for perioperative red blood cell (RBC) transfusion. Transfusion is associated with postoperative morbidity and mortality. Preoperative intravenous (IV) iron therapy has been proposed as an intervention to reduce perioperative transfusion; however, studies are generally small, limited, and inconclusive. METHODS/DESIGN: We propose performing a systematic review and meta-analysis. We will search MEDLINE, EMBASE, EBM Reviews, Cochrane-controlled trial registry, Scopus, registries of health technology assessment and clinical trials, Web of Science, ProQuest Dissertations and Theses, and conference proceedings in transfusion, hematology, and surgery. We will contact our study drug manufacturer for unpublished trials. Titles and abstracts will be identified and assessed by two reviewers for potential relevance. Eligible studies are: randomized or quasi-randomized clinical trials comparing preoperative administration of IV iron with placebo or standard of care to reduce perioperative blood transfusion in anemic patients undergoing major surgery. Screening, data extraction, and quality appraisal will be conducted independently by two authors. Data will be presented in evidence tables and in meta-analytic forest plots. Primary efficacy outcomes are change in hemoglobin concentration and proportion of patients requiring RBC transfusion. Secondary outcomes include number of units of blood or blood products transfused perioperatively, transfusion-related acute lung injury, neurologic complications, adverse events, postoperative infections, cardiopulmonary complications, intensive care unit (ICU) admission/readmission, length of hospital stay, acute kidney injury, and mortality. Dichotomous outcomes will be reported as pooled relative risks and 95\% confidence intervals. Continuous outcomes will be reported using calculated weighted mean differences. Meta-regression will be performed to evaluate the impact of potential confounding variables on study effect estimates. DISCUSSION: Reducing unnecessary RBC transfusions in perioperative medicine is a clinical priority. This involves the identification of patients at risk of receiving transfusions along with blood conservation strategies. Of potential pharmacological blood conservation strategies, IV iron is a compelling intervention to treat preoperative anemia; however, existing data are uncertain. We propose performing a systematic review and meta-analysis evaluating the efficacy and safety of IV iron administration to anemic patients undergoing major surgery to reduce transfusion and perioperative morbidity and mortality. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015016771.},
  langid = {english},
  pmcid = {PMC4369835},
  pmid = {25874460},
  keywords = {Administration; Intravenous,Anemia,Clinical Protocols,Erythrocyte Transfusion,Hemoglobins,Humans,Iron,Length of Stay,Postoperative Complications,Preoperative Care,Research Design,Surgery,Systematic Reviews as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DVXJUD7K\\Elhenawy et al_2015_Role of preoperative intravenous iron therapy to correct anemia before major.pdf}
}

@article{elia597,
  title = {Differences in Fat, Carbohydrate, and Protein Metabolism between Lean and Obese Subjects Undergoing Total Starvation},
  author = {Elia, M. and Stubbs, R. J. and Henry, C. J.},
  year = {1999},
  month = nov,
  journal = {Obesity Research},
  volume = {7},
  number = {6},
  pages = {597--604},
  issn = {1071-7323},
  doi = {10.1002/j.1550-8528.1999.tb00720.x},
  abstract = {Despite extensive experimental studies on total starvation, many of the findings relating to protein, fat (plus ketone body), and carbohydrate metabolism remain confusing, although they become more consistent when considered in relation to the degree of initial obesity. During prolonged starvation, protein loss and percent energy derived from protein oxidation are 2- to 3-fold less in the obese than in the lean; percent urine N excreted as urea is 2-fold less in the obese; and the contribution of protein to net glucose production is only about half in the obese compared to lean subjects. During short-term starvation (first few days) the following differences are reported: hyperketonaemia is typically 2-fold greater in lean subjects, but associated with a 2-fold lower uptake of ketone bodies by forearm muscle; glucose tolerance becomes impaired more in lean subjects; and both protein turnover and leucine oxidation increase in the lean, but may show no significant change in the obese. It is no longer acceptable to describe the metabolic response to starvation as a single typical response. The differences between lean and obese subjects have important physiological implications, some of which are of obvious relevance to survival.},
  langid = {english},
  pmid = {10574520},
  keywords = {Blood Glucose,Body Weight,Carbohydrate Metabolism,Humans,Ketone Bodies,Lipid Metabolism,Obesity,Proteins,Starvation,Thinness}
}

@article{elliott82,
  title = {Weight {{Loss}}, {{Satiety}}, and the {{Postprandial Gut Hormone Response After Esophagectomy}}: {{A Prospective Study}}},
  shorttitle = {Weight {{Loss}}, {{Satiety}}, and the {{Postprandial Gut Hormone Response After Esophagectomy}}},
  author = {Elliott, Jessie A. and Docherty, Neil G. and Eckhardt, Hans-Georg and Doyle, Suzanne L. and Guinan, Emer M. and Ravi, Narayanasamy and Reynolds, John V. and le Roux, Carel W.},
  year = {2017},
  month = jul,
  journal = {Annals of Surgery},
  volume = {266},
  number = {1},
  pages = {82--90},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000001918},
  abstract = {OBJECTIVE: To prospectively characterize changes in body weight, satiety, and postprandial gut hormone profiles following esophagectomy. BACKGROUND: With improved oncologic outcomes in esophageal cancer, there is an increasing focus on functional status and health-related quality of life in survivorship. Early satiety and weight loss are common after esophagectomy, but the pathophysiology of these phenomena remains poorly understood. METHODS: In this prospective study, consecutive patients undergoing esophagectomy with gastric conduit reconstruction were studied preoperatively and at 10 days, 6 weeks, and 3 months postoperatively. Glucagon-like peptide 1 (GLP-1) immunoreactivity of plasma collected immediately before and at 15, 30, 60, 90, 120, 150, and 180 minutes after a standardized 400-kcal mixed meal was determined. Gastrointestinal symptom scores were computed using European Organization for Research and Treatment of Cancer questionnaires. RESULTS: Body weight loss at 6 weeks and 3 months postoperatively among 13 patients undergoing esophagectomy was 11.1{$\mkern1mu\pm\mkern1mu$}2.3\% (P {$<$} 0.001) and 16.3{$\mkern1mu\pm\mkern1mu$}2.2\% (P {$<$} 0.0001), respectively. Early satiety (P = 0.043), gastrointestinal pain and discomfort (P = 0.01), altered taste (P= 0.006), and diarrhea (P= 0.038) scores increased at 3 months postoperatively. Area under the curve for the satiety gut hormone GLP-1 was significantly increased from 10 days postoperatively (2.4{$\mkern1mu\pm\mkern1mu$}0.2-fold increase, P {$<$} 0.01), and GLP-1 peak increased 3.8{$\mkern1mu\pm\mkern1mu$}0.6-, 4.7{$\mkern1mu\pm\mkern1mu$}0.8-, and 4.4{$\mkern1mu\pm\mkern1mu$}0.5-fold at 10 days, 6 weeks, and 3 months postoperatively (all P {$<$} 0.0001). Three months postoperatively, GLP-1 area under the curve was associated with early satiety (P = 0.0002, R = 0.74), eating symptoms (P = 0.007, R = 0.54), and trouble enjoying meals (P = 0.0004, R = 0.73). CONCLUSIONS: After esophagectomy, patients demonstrate an exaggerated postprandial satiety gut hormone response, which may mediate postoperative changes in satiety, body weight, and gastrointestinal quality of life.},
  langid = {english},
  pmid = {27455150},
  keywords = {Aged,Blood Glucose,Esophageal Neoplasms,Esophagectomy,Female,Gastrointestinal Diseases,Glucagon-Like Peptide 1,Humans,Insulin,Male,Middle Aged,Pain,Postoperative Complications,Postprandial Period,Prospective Studies,Quality of Life,Satiety Response,Taste Disorders,Treatment Outcome,Weight Loss}
}

@article{elliott822,
  title = {Sarcopenia: {{Prevalence}}, and {{Impact}} on {{Operative}} and {{Oncologic Outcomes}} in the {{Multimodal Management}} of {{Locally Advanced Esophageal Cancer}}},
  shorttitle = {Sarcopenia},
  author = {Elliott, Jessie A. and Doyle, Suzanne L. and Murphy, Conor F. and King, Sinead and Guinan, Emer M. and Beddy, Peter and Ravi, Narayanasamy and Reynolds, John V.},
  year = {2017},
  month = nov,
  journal = {Annals of Surgery},
  volume = {266},
  number = {5},
  pages = {822--830},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002398},
  abstract = {OBJECTIVE: The aim of this article was to study the prevalence and significance of sarcopenia in the multimodal management of locally advanced esophageal cancer (LAEC), and to assess its independent impact on operative and oncologic outcomes. SUMMARY OF BACKGROUND DATA: Sarcopenia in cancer may confer negative outcomes, but its prevalence and impact on modern multimodal regimens for LAEC have not been systematically studied. METHODS: Two hundred fifty-two consecutive patients were studied. Lean body mass (LBM), skeletal muscle index (SMI), and fat mass (FM) were determined pre-treatment, preoperatively, and 1 year postoperatively. Sarcopenia was defined by computed tomography (CT) at L3 as SMI {$<$} 52.4{$\mkern1mu$}cm/m for males and SMI {$<$} 38.5{$\mkern1mu$}cm/m for females. All complications were recorded prospectively, including comprehensive complications index (CCI), Clavien-Dindo complication (CDC), and pulmonary complications (PPCs). Multivariable linear, logistic, and Cox regression analysis was performed. RESULTS: In-hospital mortality was 1\%, and CCI was 21{$\mkern1mu\pm\mkern1mu$}19. Sarcopenia increased (P = 0.02) from 16\% at diagnosis to 31\% post-neoadjuvant therapy, with loss of LBM (-3.0{$\mkern1mu\pm\mkern1mu$}5.4{$\mkern1mu$}kg, P {$<$} 0.0001), but not FM (-0.3{$\mkern1mu\pm\mkern1mu$}2.7{$\mkern1mu$}kg, P= 0.31) during treatment. On multivariable analysis, preoperative sarcopenia was associated with CCI (P = 0.043), and CDC {$\geq$}IIIb (P = 0.003). PPCs occurred in 36\% nonsarcopenic versus 55\% sarcopenic patients (P = 0.01). Sarcopenia did not impact disease-specific (P = 0.14) or overall survival (P = 0.11) after resection. At 1 year, 35\% had sarcopenia, significantly associated with pre-treatment BMI (P = 0.013) but not complications (P = 0.20). CONCLUSIONS: Sarcopenia increases through multimodal therapy, is associated with an increased risk of major postoperative complications, and is prevalent in survivorship. These data highlight a potentially modifiable marker of risk that should be assessed and targeted in modern multimodal care pathways.},
  langid = {english},
  pmid = {28796017},
  keywords = {Adenocarcinoma,Adult,Aged,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Hospital Mortality,Humans,Incidence,Linear Models,Logistic Models,Male,Middle Aged,Multivariate Analysis,Neoadjuvant Therapy,Postoperative Complications,Prevalence,Proportional Hazards Models,Prospective Studies,Risk Factors,Sarcopenia,Survival Analysis,Tomography; X-Ray Computed,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\78FHYWWV\\Elliott et al_2017_Sarcopenia.pdf}
}

@article{ellis25,
  title = {Racial and {{Ethnic Disparities}} in {{Cancer Survival}}: {{The Contribution}} of {{Tumor}}, {{Sociodemographic}}, {{Institutional}}, and {{Neighborhood Characteristics}}},
  shorttitle = {Racial and {{Ethnic Disparities}} in {{Cancer Survival}}},
  author = {Ellis, Libby and Canchola, Alison J. and Spiegel, David and Ladabaum, Uri and Haile, Robert and Gomez, Scarlett Lin},
  year = {2018},
  month = jan,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {36},
  number = {1},
  pages = {25--33},
  issn = {1527-7755},
  doi = {10.1200/JCO.2017.74.2049},
  abstract = {Purpose Racial/ethnic disparities in cancer survival in the United States are well documented, but the underlying causes are not well understood. We quantified the contribution of tumor, treatment, hospital, sociodemographic, and neighborhood factors to racial/ethnic survival disparities in California. Materials and Methods California Cancer Registry data were used to estimate population-based cancer-specific survival for patients diagnosed with breast, prostate, colorectal, or lung cancer between 2000 and 2013 for each racial/ethnic group (non-Hispanic black, Hispanic, Asian American and Pacific Islander, and separately each for Chinese, Japanese, and Filipino) compared with non-Hispanic whites. The percentage contribution of factors to overall racial/ethnic survival disparities was estimated from a sequence of multivariable Cox proportional hazards models. Results In baseline models, black patients had the lowest survival for all cancer sites, and Asian American and Pacific Islander patients had the highest, compared with whites. Mediation analyses suggested that stage at diagnosis had the greatest influence on overall racial/ethnic survival disparities accounting for 24\% of disparities in breast cancer, 24\% in prostate cancer, and 16\% to 30\% in colorectal cancer. Neighborhood socioeconomic status was an important factor in all cancers, but only for black and Hispanic patients. The influence of marital status on racial/ethnic disparities was stronger in men than in women. Adjustment for all covariables explained approximately half of the overall survival disparities in breast, prostate, and colorectal cancer, but it explained only 15\% to 40\% of disparities in lung cancer. Conclusion Overall reductions in racial/ethnic survival disparities were driven largely by reductions for black compared with white patients. Stage at diagnosis had the largest effect on racial/ethnic survival disparities, but earlier detection would not entirely eliminate them. The influences of neighborhood socioeconomic status and marital status suggest that social determinants, support mechanisms, and access to health care are important contributing factors.},
  langid = {english},
  pmcid = {PMC5756323},
  pmid = {29035642},
  keywords = {African Americans,Aged,Asian Americans,Breast Neoplasms,California,Colorectal Neoplasms,Educational Status,Female,Health Status Disparities,Hispanic or Latino,Humans,Lung Neoplasms,Male,Middle Aged,Neoplasms,Prostatic Neoplasms,Registries,Residence Characteristics,Risk Factors,Social Class,Survival Analysis,United States,Whites},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LE64NVKW\\Ellis et al. - 2018 - Racial and Ethnic Disparities in Cancer Survival .pdf}
}

@article{ellrichmann526,
  title = {Prospective Evaluation of Malignant Cell Seeding after Percutaneous Endoscopic Gastrostomy in Patients with Oropharyngeal/Esophageal Cancers},
  author = {Ellrichmann, M. and Sergeev, P. and Bethge, J. and Arlt, A. and Topalidis, T. and Ambrosch, P. and Wiltfang, J. and {Fritscher-Ravens}, A.},
  year = {2013},
  month = jul,
  journal = {Endoscopy},
  volume = {45},
  number = {7},
  pages = {526--531},
  issn = {1438-8812},
  doi = {10.1055/s-0033-1344023},
  abstract = {BACKGROUND AND STUDY AIMS: Insertion of a percutaneous endoscopic gastrostomy (PEG) is standard care for many patients with oropharyngeal (ENT) and esophageal malignancies in order to ensure enteral feeding. The current pull-through insertion technique involves direct contact with the tumor and case reports have demonstrated the presence of metastases at insertion sites. The aim of the current study was to prospectively evaluate the risk of malignant cell seeding and the development of abdominal wall metastases after PEG placement. PATIENTS AND METHODS: A total of 50 consecutive patients with ENT/esophageal tumors were included. After PEG placement (40 pull-through technique, 10 direct insertion), brush cytology was taken from the PEG tubing and the transcutaneous incision site. A second cytological assessment was performed after a follow-up period of 3 - 6 months. RESULTS: In total, 26 patients with ENT cancer, 13 with esophageal cancer, and one with esophageal infiltration of lung cancer underwent pull-through PEG placement with no immediate complications. Cytology following brushing of tubing and incision sites demonstrated malignant cells in 9 /40 cases (22.5 \%). Correlation analyses revealed a higher rate of malignant seeding in older patients and in those with higher tumor stages. At follow-up, cytology was undertaken in 32 /40 patients who had undergone pull-through PEG placement. Malignant cells were present in three on cytology, resulting in a metastatic seeding rate of 9.4 \%. CONCLUSION: This study showed that malignant cells were present in 22.5 \% of patients immediately after pull-through PEG placement; local metastases were verified at follow-up in 9.4 \%, all of which were from esophageal squamous cell carcinoma. This risk is particularly high in the older age group and in patients with higher tumor stages. Therefore, pull-through PEG placement should be avoided in these patients and direct access PEG favored instead.},
  langid = {english},
  pmid = {23780843},
  keywords = {Abdominal Neoplasms,Abdominal Wall,Aged,Carcinoma; Squamous Cell,Cytodiagnosis,Endoscopy; Gastrointestinal,Esophageal Neoplasms,Female,Follow-Up Studies,Gastrostomy,Humans,Male,Middle Aged,Neoplasm Seeding,Oropharyngeal Neoplasms,PEG,Prospective Studies,Risk Factors,Survival Rate,Treatment Outcome}
}

@article{erhunmwunsee234,
  title = {Socioeconomic {{Status}}, {{Not Race}}, {{Is Associated With Reduced Survival}} in {{Esophagectomy Patients}}},
  author = {Erhunmwunsee, Loretta and Gulack, Brian C. and Rushing, Christel and Niedzwiecki, Donna and Berry, Mark F. and Hartwig, Matthew G.},
  year = {2017},
  month = jul,
  journal = {The Annals of Thoracic Surgery},
  volume = {104},
  number = {1},
  pages = {234--244},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2017.01.049},
  abstract = {BACKGROUND: Black patients with esophageal cancer have worse survival than white patients. This study examines this racial disparity in conjunction with socioeconomic status (SES) and explores whether race-based outcome differences exist using a national database. METHODS: The associations between race and SES with overall survival of patients treated with esophagectomy for stages I to III esophageal cancer between 2003 and 2011 in the National Cancer Data Base were investigated using the Kaplan-Meier method and proportional hazards analyses. Median income by zip code and proportion of the zip code residents without a high school diploma were grouped into income and education quartiles, respectively and used as surrogates for SES. The association between race and overall survival stratified by SES is explored. RESULTS: Of 11,599 esophagectomy patients who met study criteria, 3,503 (30.2\%) were in the highest income quartile, 2,847 (24.5\%) were in the highest education quartile, and 610 patients (5\%) were black. Before adjustment for SES, black patients had worse overall survival than white patients (median survival 23.0 versus 34.7 months, log rank p {$<$} 0.001), and overall, survival times improved with increasing income and education (p~{$<$} 0.001 for both). After adjustment for putative prognostic factors, SES was associated with overall survival, whereas race was not. CONCLUSIONS: Prior studies have suggested that survival of esophageal cancer patients after esophagectomy is associated with race. Our study suggests that race is not significantly related to overall survival when adjusted for other prognostic variables. Socioeconomic status, however, remains significantly related to overall survival in our model.},
  langid = {english},
  pmid = {28410639},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Prognosis,Race,Racial Groups,Retrospective Studies,Risk Factors,Social Class,Socioeconomic Factors,Survival Rate,United States,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XB638PX3\\Erhunmwunsee et al. - 2017 - Socioeconomic Status, Not Race, Is Associated With.pdf}
}

@article{esnaola549,
  title = {Underuse of Surgical Resection in Black Patients with Nonmetastatic Colorectal Cancer: Location, Location, Location},
  shorttitle = {Underuse of Surgical Resection in Black Patients with Nonmetastatic Colorectal Cancer},
  author = {Esnaola, Nestor F. and Gebregziabher, Mulugeta and Finney, Chris and Ford, Marvella E.},
  year = {2009},
  month = oct,
  journal = {Annals of Surgery},
  volume = {250},
  number = {4},
  pages = {549--557},
  issn = {1528-1140},
  doi = {10.1097/SLA.0b013e3181b732a5},
  abstract = {OBJECTIVES: Studies have reported potential underuse of surgical resection in black patients with nonmetastatic colorectal cancer. Our objective was to determine the independent, adverse effect of race on surgical resection, controlling for tumor location, comorbidity, and socioeconomic/insurance status. METHODS: All cases of nonmetastatic colon/rectal cancer reported to our state's Central Cancer Registry from 1996 to 2002 were identified and linked to Inpatient/Outpatient Surgery Files and the 2000 Census. Comorbidity (Deyo-Charlson Index) was calculated using ICD-9-CM codes and educational level/income were estimated at the zip code level. Characteristics between whites and blacks were compared using [chi]2 tests. Odds ratios (OR) of resection were calculated using logistic regression analysis. RESULTS: We identified 5590/1932 white and 1906/466 black patients with colon/rectal cancer. Blacks were more likely to be younger, not married, rural, less educated, live in poverty, and uninsured/covered by Medicaid compared with whites (all P {$<$} 0.001). Underuse of surgery was far greater among blacks with rectal cancer (82.0\% vs. 89.3\% in whites, P{$<$} 0.001) compared with blacks with colon cancer (92.9\% vs. 94.5\% in whites, P {$<$} 0.001). After controlling for comorbidity/socioeconomic/insurance status and tumor location, the adjusted OR (95\% CI) for resection for blacks with colon cancer and blacks with rectal cancer living in poverty were 0.67 (0.51\textendash 0.88) and 0.20 (0.07\textendash 0.57), respectively. CONCLUSIONS: Black race is a powerful, independent predictor of underuse of surgery in rectal cancer patients living in poverty. It is incumbent on the gastroenterology/surgical community to determine whether misperceptions about rectal surgery or barriers to successfully navigating multidisciplinary, rectal cancer care may account for these disparities.},
  langid = {english},
  pmid = {19730243},
  keywords = {African Americans,Aged,Chi-Square Distribution,Colorectal Neoplasms,Colorectal Surgery,Comorbidity,Educational Status,Female,Humans,Income,Logistic Models,Male,Medically Uninsured,Middle Aged,Poverty Areas,Race,Registries,Risk Factors,Socioeconomic Factors,South Carolina,United States,Whites}
}

@article{extermann1824,
  title = {Comprehensive Geriatric Assessment for Older Patients with Cancer},
  author = {Extermann, Martine and Hurria, Arti},
  year = {2007},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {25},
  number = {14},
  pages = {1824--1831},
  issn = {1527-7755},
  doi = {10.1200/JCO.2007.10.6559},
  abstract = {PURPOSE: During the last decade, oncologists and geriatricians have begun to work together to integrate the principles of geriatrics into oncology care. The increasing use of a comprehensive geriatric assessment (CGA) is one example of this effort. A CGA includes an evaluation of an older individual's functional status, comorbid medical conditions, cognition, nutritional status, psychological state, and social support; and a review of the patient's medications. This article discusses recent advances on the use of a CGA in older patients with cancer. METHODS: In this article, we provide an update on the studies that address the domains of a geriatric assessment applied to the oncology patient, review the results of the first studies evaluating the use of a CGA in developing interventions to improve the care of older adults with cancer, and discuss future research directions. RESULTS: The evidence from recent studies demonstrates that a CGA can predict morbidity and mortality in older patients with cancer. Accumulating data show the benefits of incorporating a CGA in the evaluation of older patients with cancer. Prospective trials evaluating the utility of a CGA to guide interventions to improve the quality of cancer care in older adults are justified. CONCLUSION: Growing evidence demonstrates that the variables examined in a CGA can predict morbidity and mortality in older patients with cancer, and uncover problems relevant to cancer care that would otherwise go unrecognized.},
  langid = {english},
  pmid = {17488980},
  keywords = {Aged,CGA,Chemo,Cognition,Comorbidity,Disease Management,Geriatric Assessment,Humans,Medical Oncology,Neoplasms,Nutritional Status,Polypharmacy,Social Support}
}

@article{extermann241,
  title = {Use of Comprehensive Geriatric Assessment in Older Cancer Patients: Recommendations from the Task Force on {{CGA}} of the {{International Society}} of {{Geriatric Oncology}} ({{SIOG}})},
  shorttitle = {Use of Comprehensive Geriatric Assessment in Older Cancer Patients},
  author = {Extermann, Martine and Aapro, Matti and Bernabei, Roberto and Cohen, Harvey Jay and Droz, Jean-Pierre and Lichtman, Stuart and Mor, Vincent and Monfardini, Silvio and Repetto, Lazzaro and S{\o}rbye, Liv and Topinkova, Eva and {Task Force on CGA of the International Society of Geriatric Oncology}},
  year = {2005},
  month = sep,
  journal = {Critical Reviews in Oncology/Hematology},
  volume = {55},
  number = {3},
  pages = {241--252},
  issn = {1040-8428},
  doi = {10.1016/j.critrevonc.2005.06.003},
  abstract = {BACKGROUND: As more and more cancers occur in elderly people, oncologists are increasingly confronted with the necessity of integrating geriatric parameters in the treatment of their patients. METHODS: The International Society of Geriatric Oncology (SIOG) created a task force to review the evidence on the use of a comprehensive geriatric assessment (CGA) in cancer patients. A systematic review of the evidence was conducted. RESULTS: Several biological and clinical correlates of aging have been identified. Their relative weight and clinical usefulness is still poorly defined. There is strong evidence that a CGA detects many problems missed by a regular assessment in general geriatric and in cancer patients. There is also strong evidence that a CGA improves function and reduces hospitalization in the elderly. There is heterogeneous evidence that it improves survival and that it is cost-effective. There is corroborative evidence from a few studies conducted in cancer patients. Screening tools exist and were successfully used in settings such as the emergency room, but globally were poorly tested. The article contains recommendations for the use of CGA in research and clinical care for older cancer patients. CONCLUSIONS: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival. The task force cannot recommend any specific tool or approach above others at this point and general geriatric experience should be used.},
  langid = {english},
  pmid = {16084735},
  keywords = {Advisory Committees,Aged,Female,Geriatric Assessment,Geriatrics,Health Planning Guidelines,Humans,Male,Medical Oncology,Societies; Medical}
}

@article{extermann3377,
  title = {Predicting the Risk of Chemotherapy Toxicity in Older Patients: The {{Chemotherapy Risk Assessment Scale}} for {{High-Age Patients}} ({{CRASH}}) Score},
  shorttitle = {Predicting the Risk of Chemotherapy Toxicity in Older Patients},
  author = {Extermann, Martine and Boler, Ivette and Reich, Richard R. and Lyman, Gary H. and Brown, Richard H. and DeFelice, Joseph and Levine, Richard M. and Lubiner, Eric T. and Reyes, Pablo and Schreiber, Frederic J. and Balducci, Lodovico},
  year = {2012},
  month = jul,
  journal = {Cancer},
  volume = {118},
  number = {13},
  pages = {3377--3386},
  issn = {1097-0142},
  doi = {10.1002/cncr.26646},
  abstract = {BACKGROUND: Tools are lacking to assess the individual risk of severe toxicity from chemotherapy. Such tools would be especially useful for older patients, who vary considerably in terms of health status and functional reserve. METHODS: The authors conducted a prospective, multicentric study of patients aged {$\geq$}70 years who were starting chemotherapy. Grade 4 hematologic (H) or grade 3/4 nonhematologic (NH) toxicity according to version 3.0 of the Common Terminology Criteria for Adverse Events was defined as severe. Twenty-four parameters were assessed. Toxicity of the regimen (Chemotox) was adjusted using an index to estimate the average per-patient risk of chemotherapy toxicity (the MAX2 index). In total, 562 patients were accrued, and 518 patients were evaluable and were split randomly (2:1 ratio) into a derivation cohort and a validation cohort. RESULTS: Severe toxicity was observed in 64\% of patients. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score was constructed along 2 subscores: H toxicity and NH toxicity. Predictors of H toxicity were lymphocytes, aspartate aminotransferase level, Instrumental Activities of Daily Living score, lactate dehydrogenase level, diastolic blood pressure, and Chemotox. The best model included the 4 latter predictors (risk categories: low, 7\%; medium-low, 23\%; medium-high, 54\%; and high, 100\%, respectively; P(trend) {$<$} .001). Predictors of NH toxicity were hemoglobin, creatinine clearance, albumin, self-rated health, Eastern Cooperative Oncology Group performance, Mini-Mental Status score, Mini-Nutritional Assessment score, and Chemotox. The 4 latter predictors provided the best model (risk categories: 33\%, 46\%, 67\%, and 93\%, respectively; P(trend) {$<$} .001). The combined risk categories were 50\%, 58\%, 77\%, and 79\%, respectively; P(trend) {$<$} .001). Bootstrap internal validation and independent sample validation demonstrated stable risk categorization and P(trend) {$<$} .001. CONCLUSIONS: The CRASH score distinguished several risk levels of severe toxicity. The split score discriminated better than the combined score. To the authors' knowledge, this is the first score systematically integrating both chemotherapy and patient risk for older patients and has a potential for future clinical application.},
  langid = {english},
  pmid = {22072065},
  keywords = {Aged,Aged; 80 and over,Antineoplastic Agents,Antineoplastic Combined Chemotherapy Protocols,CRASH,Female,Humans,Male,Prospective Studies,Risk Assessment}
}

@article{eyck12,
  title = {Accuracy of {{Detecting Residual Disease After Neoadjuvant Chemoradiotherapy}} for {{Esophageal Cancer}}},
  author = {Eyck, Ben M and Onstenk, Barbera D and Noordman, Bo J and Nieboer, Daan and Spaander, Manon C W and Wijnhoven, Bas P L},
  year = {2020},
  journal = {Annals of Surgery},
  volume = {271},
  number = {2},
  pages = {12},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MC6KFAVT\\Eyck et al. - 2020 - Accuracy of Detecting Residual Disease After Neoad.pdf}
}

@article{facchinetti155,
  title = {First-Line Pembrolizumab in Advanced Non-Small Cell Lung Cancer Patients with Poor Performance Status},
  author = {Facchinetti, Francesco and Mazzaschi, Giulia and Barbieri, Fausto and Passiglia, Francesco and Mazzoni, Francesca and Berardi, Rossana and Proto, Claudia and Cecere, Fabiana Letizia and Pilotto, Sara and Scotti, Vieri and Rossi, Sabrina and Del Conte, Alessandro and Vita, Emanuele and Bennati, Chiara and Ardizzoni, Andrea and Cerea, Giulio and Migliorino, Maria Rita and Sala, Elisa and Camerini, Andrea and Bearz, Alessandra and De Carlo, Elisa and Zanelli, Francesca and Guaitoli, Giorgia and Garassino, Marina Chiara and Ciccone, Lucia Pia and Sartori, Giulia and Toschi, Luca and Dall'Olio, Filippo Gustavo and Landi, Lorenza and Pizzutilo, Elio Gregory and Bartoli, Gabriele and Baldessari, Cinzia and Novello, Silvia and Bria, Emilio and Cortinovis, Diego Luigi and Rossi, Giulio and Rossi, Antonio and Banna, Giuseppe Luigi and Camisa, Roberta and Di Maio, Massimo and Tiseo, Marcello},
  year = {2020},
  month = may,
  journal = {European Journal of Cancer (Oxford, England: 1990)},
  volume = {130},
  pages = {155--167},
  issn = {1879-0852},
  doi = {10.1016/j.ejca.2020.02.023},
  abstract = {BACKGROUND: Pembrolizumab is the first-line standard of care for advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)~{$\geq~$}50\%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence. PATIENTS AND METHODS: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS {$\geq$}50\% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR). RESULTS: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95\% confidence interval, 95\% CI, 1.6-2.5) and 3.0 months (95\% CI 2.4-3.5), respectively. 6-months PFR was 27\% (95\% CI 21-35\%). Patients with a PS 2 determined by comorbidities (n~=~41) had significantly better outcomes compared with disease burden-induced PS 2 (n~=~112). Indeed, 6-months PFR was 49\% versus 19\%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged. CONCLUSIONS: Outcomes of PS 2 NSCLC patients with PD-L1 TPS {$\geq$}50\% receiving first-line pembrolizumab were globally dismal~but strongly dependent on the reason conditioning the poor PS itself.},
  langid = {english},
  pmid = {32220780},
  keywords = {Aged,Antibodies; Monoclonal; Humanized,Carcinoma; Non-Small-Cell Lung,ECOG PS 2,Female,Humans,ICI,Immune checkpoint inhibitors,Immunotherapy,Lung Neoplasms,Male,NSCLC,PD-1,Programmed Cell Death 1 Receptor,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PK72TPXM\\Facchinetti et al_2020_First-line pembrolizumab in advanced non-small cell lung cancer patients with.pdf}
}

@article{facs6,
  title = {Procedure-Based Postoperative Risk Prediction Using {{NSQIP}} Data},
  author = {Facs, David E Clark},
  journal = {j o u r n a l o f s u r g i c a l r e s e a r c h},
  pages = {6},
  abstract = {Background: The National Surgical Quality Improvement Program (NSQIP) has proposed using procedure-based hierarchical models to predict adverse outcomes, but it is not clear whether this approach was used to develop the NSQIP ``Surgical Risk Calculator''. We therefore wished to demonstrate how procedure-based hierarchical models can be constructed and to describe their results. Methods: NSQIP data from 2015 were used to construct statistical models predicting 30-day postoperative mortality and morbidity, using two-level logistic regression with preoperative patient-level variables as fixed effects and procedure-specific codes as a random intercept. Model performance was validated using NSQIP data from 2014. Results: NSQIP for 2015 contained records for 885,502 patients, of whom 8986 died (1.0\%) and 104,836 suffered a complication (11.8\%). Complete model specifications and results are presented, including odds ratios for patient-level variable effects and random procedure effects. Most comorbidities were associated with increased morbidity and mortality, but overweight and obesity were associated with lower risk. Odds ratios for individual procedures ranged from 0.117 to 10.85 for mortality and from 0.615 to 8.09 for morbidity. Validation C-statistics were 0.940 for the mortality model and 0.833 for the morbidity model; Brier Scores were 0.0086 and 0.085, respectively. Graphs for 20 quantiles showed good conformity of observed and predicted risk. Conclusions: Procedure-based hierarchical logistic regression models of NSQIP outcomes had satisfactory overall performance statistics. Model specifications and results are provided for criticism and improvement, and several possible refinements are suggested.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MJYQ4WVN\\Facs - Procedure-based postoperative risk prediction usin.pdf}
}

@article{fagundes613,
  type = {Journal {{Article}}},
  title = {Symptom Recovery after Thoracic Surgery: {{Measuring}} Patient-Reported Outcomes with the {{MD Anderson Symptom Inventory}}},
  author = {Fagundes, C. P. and Shi, Q. and Vaporciyan, A. A. and Rice, D. C. and Popat, K. U. and Cleeland, C. S. and Wang, X. S.},
  year = {2015},
  journal = {J Thorac Cardiovasc Surg},
  volume = {150},
  number = {3},
  pages = {613-9 e2},
  issn = {1097-685X (Electronic) 0022-5223 (Linking)},
  doi = {10.1016/j.jtcvs.2015.05.057}
}

@article{faiz585,
  title = {{{ASO Author Reflections}}: {{Implementation}} of {{Age}} and {{Co-morbidity}} in the {{Treatment Guideline}} of {{Patients}} with {{Esophageal Squamous Cell Carcinoma}}},
  shorttitle = {{{ASO Author Reflections}}},
  author = {Faiz, Z. and Plukker, J. T. M.},
  year = {2019},
  month = dec,
  journal = {Annals of Surgical Oncology},
  volume = {26},
  number = {Suppl 3},
  pages = {585--586},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07361-4},
  langid = {english},
  pmcid = {PMC6901411},
  pmid = {31011909},
  keywords = {Comorbidity,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Humans},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MZUA9YHG\\Faiz_Plukker_2019_ASO Author Reflections.pdf}
}

@article{faiz986,
  title = {Impact of {{Age}} and {{Comorbidity}} on {{Choice}} and {{Outcome}} of {{Two Different Treatment Options}} for {{Patients}} with {{Potentially Curable Esophageal Cancer}}},
  author = {Faiz, Z. and {van Putten}, M. and Verhoeven, R. H. A. and {van Sandick}, J. W. and Nieuwenhuijzen, G. a. P. and {van der Sangen}, M. J. C. and Lemmens, V. E. P. P. and Wijnhoven, B. P. L. and Plukker, J. T. M.},
  year = {2019},
  month = apr,
  journal = {Annals of Surgical Oncology},
  volume = {26},
  number = {4},
  pages = {986--995},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07181-6},
  abstract = {PURPOSE: This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery. METHODS: In this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan-Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS). RESULTS: A total of 702 patients was included. Age {$\geq$}\,75~years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95\% confidence interval [CI] 4.72-15.58; and OR 3.09; 95\% CI 1.93-4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95\% CI 1.97-7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95\% CI 1.57-6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with {$\geq$}\,2 comorbidities or age {$\geq$}\,75~years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95\% CI 0.78-2.97; and HR 0.73; 95\% CI 0.13-4.14). CONCLUSIONS: Histological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with {$\geq$}\,2 comorbidities or age {$\geq$}\,75~years, dCRT may be the preferred strategy.},
  langid = {english},
  pmcid = {PMC6399439},
  pmid = {30719634},
  keywords = {Adenocarcinoma,Age Factors,Aged,Carcinoma; Squamous Cell,Chemoradiotherapy,Combined Modality Therapy,Comorbidity,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Netherlands,Prognosis,Retrospective Studies,SCCA,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MPJFEZPR\\Faiz et al. - 2019 - Impact of Age and Comorbidity on Choice and Outcom.pdf}
}

@article{fang155a,
  title = {Percutaneous Endoscopic Gastrostomy Prior to Esophagectomy for Esophageal Cancer - a Systematic Review and Meta-Analysis},
  author = {Fang, Hua-Chen and Farah, Musa Hassan and Shiue, Sheng-Jie and Cheng, Sheng-Wei and Shiue, Han-Shiang and Cheng, Chao-Ling and Chan, Tze-Sian and Liao, Ai-Ho and Wu, Ming-Shun},
  year = {2022},
  month = feb,
  journal = {Expert Review of Gastroenterology \& Hepatology},
  volume = {16},
  number = {2},
  pages = {155--162},
  issn = {1747-4132},
  doi = {10.1080/17474124.2022.2027754},
  abstract = {BACKGROUND: For resectable esophageal cancer (EC), it remains controversial whether to place percutaneous endoscopic gastrostomy (PEG) before the curative surgery to provide nutritional support during the neoadjuvant therapy. OBJECTIVE: To compare surgical outcomes for patients who received preoperative PEG and those without PEG placement (No-PEG) insertion prior to surgery in a potentially operable EC. METHODS: A comprehensive literature search was conducted to identify randomized and non-randomized studies comparing PEG and No-PEG groups. RESULTS: Four retrospective studies with a total number of 1,027 patients were identified and included in this meta-analysis. The differences in anastomotic leakage, anastomotic stricture, morbidity, pulmonary complications, wound infection, and hospital stay were not statistically significant between the two groups. Operation time was significantly shorter in the PEG group. There was no PEG-related gastric conduit failure and no leak from the PEG site in the PEG group. CONCLUSION: We conclude preoperative PEG for resectable EC is a safe procedure with no adverse effect on the gastric tube construction and anastomosis, it can be selectively inserted for EC patients with marked weight loss and malnutrition or those at risk of developing malnutrition during neoadjuvant therapy.},
  langid = {english},
  pmid = {35048757},
  keywords = {Esophageal Neoplasms,Esophagectomy,esophagus cancer,Gastroscopy,Gastrostomy,Humans,neoadjuvant therapy,Nutritional Support,Operative Time,Percutaneous endoscopic gastrostomy,Postoperative Complications,systematic review and meta-analysis}
}

@article{farrow996,
  title = {Impact of {{Age}} on {{Surgical Outcomes}} for {{Locally Advanced Esophageal Cancer}}},
  author = {Farrow, Norma E. and Raman, Vignesh and Jawitz, Oliver K. and Voigt, Soraya L. and Tong, Betty C. and Harpole, David H. and D'Amico, Thomas A.},
  year = {2021},
  month = mar,
  journal = {The Annals of Thoracic Surgery},
  volume = {111},
  number = {3},
  pages = {996--1003},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2020.06.055},
  abstract = {BACKGROUND: Older patients are often considered high-risk surgical candidates for locally advanced esophageal cancer, and the benefit of surgery in this population is unclear. This national analysis examines the effect of age on esophagectomy outcomes and compares surgery versus chemoradiation in older patients. METHODS: The National Cancer Database was used to identify patients with clinical stage II to III esophageal adenocarcinoma undergoing surgery or definitive chemoradiation between 2004 and 2015. Restricted cubic splines were used to examine the relationship between age and survival after esophagectomy, and maximally selected rank statistics were used to identify an age at which survival worsened. We used Cox proportional hazard models including an interaction term between age and treatment to compare overall survival, as well as survival of patients receiving esophagectomy versus definitive chemoradiation. RESULTS: Of 17,495 patients, 11,680 underwent esophagectomy and 5815 received chemoradiation. Survival after esophagectomy worsened with increasing age and decreased considerably after age 73 (hazard ratio~= 1.05, 95\% confidence interval, 1.04-1.06, per increasing year after 73 versus hazard ratio~= 1.01, 95\% confidence interval, 1.00-1.01, per increasing year to 73; both P {$<$} .001). Chemoradiation was increasingly used over surgery as age increased. The interaction between age and treatment was significant, and a graph of this interaction demonstrated a survival benefit for surgery over chemoradiation at most ages, including octogenarians. CONCLUSIONS: Survival worsens with age after esophagectomy for locally advanced esophageal cancer. However, esophagectomy is associated with improved survival compared with definitive chemoradiation at most ages, including octogenarians. Esophagectomy may be considered over chemoradiation for patients who can tolerate surgery regardless of age.},
  langid = {english},
  pmcid = {PMC8023276},
  pmid = {32853569},
  keywords = {Adenocarcinoma,Age,Age Factors,Aged,California,dCRT,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Neoplasm Staging,Risk Factors,Survival Rate,Treatment Outcome,Tri},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\YTK92LS2\\Farrow et al_2021_Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer.pdf}
}

@article{fearon489,
  type = {Journal {{Article}}},
  title = {Definition and Classification of Cancer Cachexia: An International Consensus},
  author = {Fearon, K. and Strasser, F. and Anker, S. D. and Bosaeus, I. and Bruera, E. and Fainsinger, R. L. and Jatoi, A. and Loprinzi, C. and MacDonald, N. and Mantovani, G. and Davis, M. and Muscaritoli, M. and Ottery, F. and Radbruch, L. and Ravasco, P. and Walsh, D. and Wilcock, A. and Kaasa, S. and Baracos, V. E.},
  year = {2011},
  journal = {Lancet Oncol},
  volume = {12},
  number = {5},
  pages = {489--95},
  issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
  doi = {10.1016/S1470-2045(10)70218-7},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AFZX2TJN\\Fearon et al_2011_Definition and classification of cancer cachexia.pdf}
}

@article{feeney489,
  type = {Journal {{Article}}},
  title = {Preoperative Physical Activity Levels and Postoperative Pulmonary Complications Post-Esophagectomy},
  author = {Feeney, C. and Reynolds, J. V. and Hussey, J.},
  year = {2011},
  journal = {Dis Esophagus},
  volume = {24},
  number = {7},
  pages = {489--94},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1111/j.1442-2050.2010.01171.x}
}

@article{feeney529,
  type = {Journal {{Article}}},
  title = {Assessment of Physical Fitness for Esophageal Surgery, and Targeting Interventions to Optimize Outcomes},
  author = {Feeney, C. and Hussey, J. and Carey, M. and Reynolds, J. V.},
  year = {2010},
  journal = {Dis Esophagus},
  volume = {23},
  number = {7},
  pages = {529--39},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1111/j.1442-2050.2010.01058.x}
}

@article{feliciano10,
  title = {Muscle {{Mass}} at the {{Time}} of {{Diagnosis}} of {{Nonmetastatic Colon Cancer}} and {{Early Discontinuation}} of {{Chemotherapy}}, {{Delays}}, and {{Dose Reductions}} on {{Adjuvant FOLFOX}}: {{The C}}\&\#8208;{{SCANS Study}}},
  author = {Feliciano, Elizabeth M Cespedes and Lee, Valerie S and Prado, Carla M and Meyerhardt, Jeffrey A and Alexeeff, Stacey and Kroenke, Candyce H and Xiao, Jingjie and Castillo, Adrienne L and Caan, Bette J},
  year = {2017},
  pages = {10},
  abstract = {BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer. METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients). Patients' muscle mass was quantified using clinically acquired computed tomography scans. The authors quantified chemotherapy doses, treatment dates, and related toxicities using the electronic medical record. In logistic regression models adjusting for age, sex, and American Joint Committee on Cancer stage of disease, the authors examined associations of muscle tertiles with early treatment discontinuation ({$<$}6 cycles), treatment delay ({$>$}3 days off schedule for  3 times), and/or dose reduction (relative dose intensity   0.70, based on planned treatment). RESULTS: The average age of the patients at the time of diagnosis was 58.7 years; BSA was 1.9 m2 and body mass index was 28.7 kg/m2. Compared with the highest sex-specific tertile of muscle mass, patients in the lowest tertile were more likely to experience toxicities and had twice the risk of adverse outcomes while receiving FOLFOX; for early discontinuation, the odds ratio (OR) was 2.34 (95\% confidence interval [95\% CI], 1.04-5.24; P for trend 5 .03), whereas the ORs were 2.24 (95\% CI, 1.37-3.66; P for trend 5 .002) for treatment delay and 2.28 (95\% CI, 1.19-4.36; P for trend 5 .01) for dose reduction. CONCLUSIONS: Lower muscle mass is associated with greater toxicity and poor chemotherapy adherence among patients receiving FOLFOX. Many chemotherapy drugs are dosed based on BSA, but treatment may be better individualized if muscle mass is considered. Cancer 2017;123:4868-77. VC 2017 American Cancer Society.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8H9IYA7X\\Feliciano et al. - 2017 - Muscle Mass at the Time of Diagnosis of Nonmetasta.pdf}
}

@article{felicianoe172319,
  title = {Association of {{Systemic Inflammation}} and {{Sarcopenia With Survival}} in {{Nonmetastatic Colorectal Cancer}}: {{Results From}} the {{C SCANS Study}}},
  shorttitle = {Association of {{Systemic Inflammation}} and {{Sarcopenia With Survival}} in {{Nonmetastatic Colorectal Cancer}}},
  author = {Feliciano, Elizabeth M. Cespedes and Kroenke, Candyce H. and Meyerhardt, Jeffrey A. and Prado, Carla M. and Bradshaw, Patrick T. and Kwan, Marilyn L. and Xiao, Jingjie and Alexeeff, Stacey and Corley, Douglas and Weltzien, Erin and Castillo, Adrienne L. and Caan, Bette J.},
  year = {2017},
  month = dec,
  journal = {JAMA oncology},
  volume = {3},
  number = {12},
  pages = {e172319},
  issn = {2374-2445},
  doi = {10.1001/jamaoncol.2017.2319},
  abstract = {Importance: Systemic inflammation and sarcopenia are easily evaluated, predict mortality in many cancers, and are potentially modifiable. The combination of inflammation and sarcopenia may be able to identify patients with early-stage colorectal cancer (CRC) with poor prognosis. Objective: To examine associations of prediagnostic systemic inflammation with at-diagnosis sarcopenia, and determine whether these factors interact to predict CRC survival, adjusting for age, ethnicity, sex, body mass index, stage, and cancer site. Design, Setting, and Participants: A prospective cohort of 2470 Kaiser Permanente patients with stage I to III CRC diagnosed from 2006 through 2011. Exposures: Our primary measure of inflammation was the neutrophil to lymphocyte ratio (NLR). We averaged NLR in the 24 months before diagnosis (mean count\,=\,3 measures; mean time before diagnosis\,=\,7 mo). The reference group was NLR of less than 3, indicating low or no inflammation. Main Outcomes and Measures: Using computed tomography scans, we calculated skeletal muscle index (muscle area at the third lumbar vertebra divided by squared height). Sarcopenia was defined as less than 52 cm2/m2 and less than 38 cm2/m2 for normal or overweight men and women, respectively, and less than 54 cm2/m2 and less than 47 cm2/m2 for obese men and women, respectively. The main outcome was death (overall or CRC related). Results: Among 2470 patients, 1219 (49\%) were female; mean (SD) age was 63 (12) years. An NLR of 3 or greater and sarcopenia were common (1133 [46\%] and 1078 [44\%], respectively). Over a median of 6 years of follow-up, we observed 656 deaths, 357 from CRC. Increasing NLR was associated with sarcopenia in a dose-response manner (compared with NLR\,{$<$}\,3, odds ratio,\,1.35; 95\% CI, 1.10-1.67 for NLR 3 to {$<$}5; 1.47; 95\% CI, 1.16-1.85 for NLR\,{$\geq$}\,5; P for trend\,{$<$}\,.001). An NLR of 3 or greater and sarcopenia independently predicted overall (hazard ratio [HR], 1.64; 95\% CI, 1.40-1.91 and HR, 1.28; 95\% CI, 1.10-1.53, respectively) and CRC-related death (HR, 1.71; 95\% CI, 1.39-2.12 and HR, 1.42; 95\% CI, 1.13-1.78, respectively). Patients with both sarcopenia and NLR of 3 or greater (vs neither) had double the risk of death, overall (HR, 2.12; 95\% CI, 1.70-2.65) and CRC related (HR, 2.43; 95\% CI, 1.79-3.29). Conclusions and Relevance: Prediagnosis inflammation was associated with at-diagnosis sarcopenia. Sarcopenia combined with inflammation nearly doubled risk of death, suggesting that these commonly collected biomarkers could enhance prognostication. A better understanding of how the host inflammatory/immune response influences changes in skeletal muscle may open new therapeutic avenues to improve cancer outcomes.},
  langid = {english},
  pmcid = {PMC5824285},
  pmid = {28796857},
  keywords = {Cohort Studies,Colorectal Neoplasms,Female,Humans,Lymphocyte Count,Male,Middle Aged,Neoplasm Staging,Neutrophils,Prognosis,Proportional Hazards Models,Prospective Studies,Risk Factors,Sarcopenia,Sarcopenia;Inflammation,Survival Analysis,Tomography; X-Ray Computed}
}

@article{feray311,
  title = {{{PROSPECT}} Guidelines for Video-Assisted Thoracoscopic Surgery: A Systematic Review and Procedure-Specific Postoperative Pain Management Recommendations},
  shorttitle = {{{PROSPECT}} Guidelines for Video-Assisted Thoracoscopic Surgery},
  author = {Feray, S. and Lubach, J. and Joshi, G. P. and Bonnet, F. and {Van de Velde}, M. and {PROSPECT Working Group *of the European Society of Regional Anaesthesia and Pain Therapy}},
  year = {2022},
  month = mar,
  journal = {Anaesthesia},
  volume = {77},
  number = {3},
  pages = {311--325},
  issn = {1365-2044},
  doi = {10.1111/anae.15609},
  abstract = {Video-assisted thoracoscopic surgery has become increasingly popular due to faster recovery times and reduced postoperative pain compared with thoracotomy. However, analgesic regimens for video-assisted thoracoscopic surgery vary significantly. The goal of this systematic review was to evaluate the available literature and develop recommendations for optimal pain management after video-assisted thoracoscopic surgery. A systematic review was undertaken using procedure-specific postoperative pain management (PROSPECT) methodology. Randomised controlled trials published in the English language, between January 2010 and January 2021 assessing the effect of analgesic, anaesthetic or surgical interventions were identified. We retrieved 1070 studies of which 69 randomised controlled trials and two reviews met inclusion criteria. We recommend the administration of basic analgesia including paracetamol and non-steroidal anti-inflammatory drugs or cyclo-oxygenase-2-specific inhibitors pre-operatively or intra-operatively and continued postoperatively. Intra-operative intravenous dexmedetomidine infusion may be used, specifically when basic analgesia and regional analgesic techniques could not be given. In addition, a paravertebral block or erector spinae plane block is recommended as a first-choice option. A serratus anterior plane block could also be administered as a second-choice option. Opioids should be reserved as rescue analgesics in the postoperative period.},
  langid = {english},
  pmcid = {PMC9297998},
  pmid = {34739134},
  keywords = {analgesia,Analgesics,Analgesics; Opioid,Anti-Inflammatory Agents; Non-Steroidal,Drug Therapy; Combination,evidence-based medicine,Humans,Nerve Block,Pain Management,Pain; Postoperative,postoperative pain,Practice Guidelines as Topic,Randomized Controlled Trials as Topic,systematic review,Thoracic Surgery; Video-Assisted,video-assisted thoracoscopic surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\C9Q7A8CT\\Feray et al_2022_PROSPECT guidelines for video-assisted thoracoscopic surgery.pdf}
}

@article{ferguson661,
  type = {Journal {{Article}}},
  title = {Preoperative Prediction of the Risk of Pulmonary Complications after Esophagectomy for Cancer},
  author = {Ferguson, M. K. and Durkin, A. E.},
  year = {2002},
  journal = {J Thorac Cardiovasc Surg},
  volume = {123},
  number = {4},
  pages = {661--9},
  issn = {0022-5223 (Print) 0022-5223 (Linking)},
  doi = {10.1067/mtc.2002.120350}
}

@article{fernando1144,
  type = {Journal {{Article}}},
  title = {The {{Society}} of {{Thoracic Surgeons}} Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated with General Thoracic Surgery: Executive Summary},
  author = {Fernando, H. C. and Jaklitsch, M. T. and Walsh, G. L. and Tisdale, J. E. and Bridges, C. D. and Mitchell, J. D. and Shrager, J. B.},
  year = {2011},
  journal = {Ann Thorac Surg},
  volume = {92},
  number = {3},
  pages = {1144--52},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2011.06.104}
}

@article{findlay11,
  title = {Predicting {{Pathologic Response}} of {{Esophageal Cancer}} to {{Neoadjuvant Chemotherapy}}: {{The Implications}} of {{Metabolic Nodal Response}} for {{Personalized Therapy}}},
  author = {Findlay, John M and Bradley, Kevin M and Wang, Lai Mun and Franklin, James M and Teoh, Eugene J and Gleeson, Fergus V and Maynard, Nicholas D and Gillies, Richard S and Middleton, Mark R},
  number = {5},
  pages = {11},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\T7EVK7JR\\Findlay et al. - Predicting Pathologic Response of Esophageal Cance.pdf}
}

@article{findlay413,
  type = {Journal {{Article}}},
  ids = {findlay413a},
  title = {Enhanced Recovery for Esophagectomy: A Systematic Review and Evidence-Based Guidelines},
  author = {Findlay, J. M. and Gillies, R. S. and Millo, J. and Sgromo, B. and Marshall, R. E. and Maynard, N. D.},
  year = {2014},
  journal = {Ann Surg},
  volume = {259},
  number = {3},
  pages = {413--31},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0000000000000349},
  pmid = {24253135},
  keywords = {ERAS,Esophageal Diseases,Esophagectomy,Evidence-Based Medicine,Humans,Postoperative Care,Practice Guidelines as Topic,Recovery of Function}
}

@article{finlayson729,
  title = {Outcomes in Octogenarians Undergoing High-Risk Cancer Operation: A National Study},
  shorttitle = {Outcomes in Octogenarians Undergoing High-Risk Cancer Operation},
  author = {Finlayson, Emily and Fan, Zhaohui and Birkmeyer, John D.},
  year = {2007},
  month = dec,
  journal = {Journal of the American College of Surgeons},
  volume = {205},
  number = {6},
  pages = {729--734},
  issn = {1879-1190},
  doi = {10.1016/j.jamcollsurg.2007.06.307},
  abstract = {BACKGROUND: Current information about outcomes in octogenarians undergoing cancer operations is limited largely to case series from selected centers. Population-based data can provide more realistic estimates of the risks and benefits of operations in this group. STUDY DESIGN: We performed a retrospective cohort study of patients undergoing major resections for lung, esophageal, and pancreas cancer. Using the Nationwide Inpatient Sample (1994 to 2003), we examined operative mortality and discharge disposition in octogenarians (aged 80+ years), relative to younger patients (aged 65 to 69 years) (n = 272,662). We then used the Surveillance and End Results-Medicare-linked database (1992 to 2001) to measure late survival in the elderly (n = 14,088). RESULTS: Operative mortality among octogenarians was substantially higher than that of younger patients (aged 65 to 69 years) for all three cancers (esophagectomy, 19.9\% versus 8.8\%, p {$<$} 0.0001; pancreatectomy, 15.5\% versus 6.7\%, p {$<$} 0.0001; lung resection, 6.9\% versus 3.7\%, p {$<$} 0.0001). A large proportion of octogenarians were transferred to extended care facilities after operation, ranging from 24\% after lung resection to 44\% after esophagectomy. Five-year survival in octogenarians was low for all three cancers: 11\% after pancreatectomy, 18\% after esophagectomy and 31\% after lung cancer resection. Survival among octogenarians with two or more comorbidities was worse than those with fewer comorbid diagnoses--10\% versus 14\% for pancreatectomy, 15\% versus 23\% for esophagectomy, and 27\% versus 37\% for lung resection. CONCLUSIONS: Population-based outcomes after high-risk cancer operation in octogenarians are considerably worse than typically reported in case series and published survival statistics. Such information might better inform clinical decision making in this high-risk group.},
  langid = {english},
  pmid = {18035254},
  keywords = {Age Factors,Aged,Aged; 80 and over,Cohort Studies,Comorbidity,Esophageal Neoplasms,Esophagectomy,Female,Humans,Lung Neoplasms,Male,Pancreatectomy,Pancreatic Neoplasms,Pneumonectomy,Retrospective Studies,SEER Program,Treatment Outcome,United States}
}

@article{fiorelli,
  type = {Journal {{Article}}},
  title = {Ultrasound-{{Guided Erector Spinae Plane Block Versus Intercostal Nerve Block}} for {{Post-Minithoracotomy Acute Pain Management}}: {{A Randomized Controlled Trial}}},
  author = {Fiorelli, S. and Leopizzi, G. and Menna, C. and Teodonio, L. and Ibrahim, M. and Rendina, E. A. and Ricci, A. and De Blasi, R. A. and Rocco, M. and Massullo, D.},
  year = {2020},
  journal = {J Cardiothorac Vasc Anesth},
  issn = {1532-8422 (Electronic) 1053-0770 (Linking)},
  doi = {10.1053/j.jvca.2020.01.026}
}

@article{fish379,
  type = {Journal {{Article}}},
  title = {Readmission {{After Ileostomy Creation}}: {{Retrospective Review}} of a {{Common}} and {{Significant Event}}},
  author = {Fish, D. R. and Mancuso, C. A. and {Garcia-Aguilar}, J. E. and Lee, S. W. and Nash, G. M. and Sonoda, T. and Charlson, M. E. and Temple, L. K.},
  year = {2017},
  journal = {Ann Surg},
  volume = {265},
  number = {2},
  pages = {379--387},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0000000000001683}
}

@article{flamen3202,
  title = {Utility of Positron Emission Tomography for the Staging of Patients with Potentially Operable Esophageal Carcinoma},
  author = {Flamen, P. and Lerut, A. and Van Cutsem, E. and De Wever, W. and Peeters, M. and Stroobants, S. and Dupont, P. and Bormans, G. and Hiele, M. and De Leyn, P. and Van Raemdonck, D. and Coosemans, W. and Ectors, N. and Haustermans, K. and Mortelmans, L.},
  year = {2000},
  month = sep,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {18},
  number = {18},
  pages = {3202--3210},
  issn = {0732-183X},
  doi = {10.1200/JCO.2000.18.18.3202},
  abstract = {PURPOSE: A prospective study of preoperative tumor-node-metastasis staging of patients with esophageal cancer (EC) was designed to compare the accuracy of 18-F-fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) with conventional noninvasive modalities. PATIENTS AND METHODS: Seventy-four patients with carcinomas of the esophagus (n = 43) or gastroesophageal junction (n = 31) were studied. All patients underwent attenuation-corrected FDG-PET imaging, a spiral computed tomography (CT) scan, and an endoscopic ultrasound (EUS). RESULTS: FDG-PET demonstrated increased activity in the primary tumor in 70 of 74 patients (sensitivity: 95\%). False-negative PET images were found in four patients with T1 lesions. Thirty-four patients (46\%) had stage IV disease. FDG-PET had a higher accuracy for diagnosing stage IV disease compared with the combination of CT and EUS (82\% v 64\%, respectively; P: =.004). FDG-PET had additional diagnostic value in 16 (22\%) of 74 patients by upstaging 11 (15\%) and downstaging five (7\%) patients. Thirty-nine (53\%) of the 74 patients underwent a 2- or 3-field lymphadenectomy in conjunction with primary curative esophagectomy. In these patients, tumoral involvement was found in 21 local and 35 regional or distant lymph nodes (LN). For local LN, the sensitivity of FDG-PET was lower than EUS (33\% v 81\%, respectively; P: =.027), but the specificity may have been higher (89\% v 67\%, respectively; P: = not significant [NS]). For the assessment of regional and distant LN involvement, compared with the combined use of CT and EUS, FDG-PET had a higher specificity (90\% v 98\%, respectively; P: =. 025) and a similar sensitivity (46\% v 43\%, respectively; P: = NS). CONCLUSION: PET significantly improves the detection of stage IV disease in EC compared with the conventional staging modalities. PET improves diagnostic specificity for LN staging.},
  langid = {english},
  pmid = {10986052},
  keywords = {Adenocarcinoma,Carcinoma; Squamous Cell,Esophageal Neoplasms,Fluorodeoxyglucose F18,Humans,Lymphatic Metastasis,Neoplasm Metastasis,Neoplasm Staging,Prospective Studies,Radionuclide Imaging,Radiopharmaceuticals,Sensitivity and Specificity,Tomography; X-Ray Computed,Ultrasonography},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FTZBZCJA\\Flamen et al_2000_Utility of positron emission tomography for the staging of patients with.pdf}
}

@article{fogelman307,
  title = {Does {{IGFR1}} Inhibition Result in Increased Muscle Mass Loss in Patients Undergoing Treatment for Pancreatic Cancer?},
  author = {Fogelman, David R. and Holmes, Holly and Mohammed, Khalil and Katz, Matthew H. G. and Prado, Carla M. and Lieffers, Jessica and Garg, Naveen and Varadhachary, Gauri R. and Shroff, Rachna and Overman, Michael J. and Garrett, Christopher and Wolff, Robert A. and Javle, Milind},
  year = {2014},
  month = dec,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {5},
  number = {4},
  pages = {307--313},
  issn = {2190-5991},
  doi = {10.1007/s13539-014-0145-y},
  abstract = {BACKGROUND: IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown. METHODS: We evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK-0646 (M), a monoclonal antibody directed against the IGF-1 protein, in patients with metastatic pancreatic cancer (MPC). Two different doses of M were tested, 5 and 10~mg/kg. We used the Slice-o-matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm(2)) at baseline and after 2 and 4~months of treatment. Patients received either gemcitabine with erlotinib (G\,+\,E), G\,+\,E\,+\,M, or G\,+\,M. Differences between the groups were compared using t tests. RESULTS: Fifty-three patients had both baseline and 2-month imaging available for analysis. Of these, 42 received M with their chemo, and 11 had G\,+\,E only. After 2~months of treatment, both groups demonstrated decrease in muscle mass. G\,+\,E patients lost 5.6~\% of muscle mass; M patients lost 9.1 and 8.6~\% after treatment with 5 and 10~mg/kg, respectively (p\,=\,0.53). Patients demonstrating a response lost less muscle (median 4.6~\%) than those with stable disease (9.6~\%) and progressive disease (8.9~\%, p\,=\,0.14). Muscle retention from baseline to 2-month imaging, defined as loss of {$<$}6~cm(2) of muscle, correlated with better survival than those patients demonstrating a muscle loss (HR 0.51, p\,=\,0.03). CONCLUSIONS: MPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop-out and death. There was a non-significant trend toward greater muscle mass loss in patients on anti-IGF-1R therapy. However, it is unclear if this loss translates into functional differences between patients.},
  langid = {english},
  pmcid = {PMC4248412},
  pmid = {24740741},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\L4QKBY29\\Fogelman et al_2014_Does IGFR1 inhibition result in increased muscle mass loss in patients.pdf}
}

@article{fominskiy511,
  title = {Liberal Transfusion Strategy Improves Survival in Perioperative but Not in Critically Ill Patients. {{A}} Meta-Analysis of Randomised Trials},
  author = {Fominskiy, E. and Putzu, A. and Monaco, F. and Scandroglio, A. M. and Karaskov, A. and Galas, F. R. B. G. and Hajjar, L. A. and Zangrillo, A. and Landoni, G.},
  year = {2015},
  month = oct,
  journal = {British Journal of Anaesthesia},
  volume = {115},
  number = {4},
  pages = {511--519},
  issn = {1471-6771},
  doi = {10.1093/bja/aev317},
  abstract = {BACKGROUND: Guidelines support the use of a restrictive strategy in blood transfusion management in a variety of clinical settings. However, recent randomized controlled trials (RCTs) performed in the perioperative setting suggest a beneficial effect on survival of a liberal strategy. We aimed to assess the effect of liberal and restrictive blood transfusion strategies on mortality in perioperative and critically ill adult patients through a meta-analysis of RCTs. METHODS: We searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, Transfusion Evidence Library, and Google Scholar up to 27 March 2015, for RCTs performed in perioperative or critically ill adult patients, receiving a restrictive or liberal transfusion strategy, and reporting all-cause mortality. We used a fixed or random-effects model to calculate the odds ratio (OR) and 95\% confidence interval (CI) for pooled data. We assessed heterogeneity using Cochrane's Q and I(2) tests. The primary outcome was all-cause mortality within 90-day follow-up. RESULTS: Patients in the perioperative period receiving a liberal transfusion strategy had lower all-cause mortality when compared with patients allocated to receive a restrictive transfusion strategy (OR 0.81; 95\% CI 0.66-1.00; P=0.05; I(2)=25\%; Number needed to treat=97) with 7552 patients randomized in 17 trials. There was no difference in mortality among critically ill patients receiving a liberal transfusion strategy when compared with the restrictive transfusion strategy (OR 1.10; 95\% CI 0.99-1.23; P=0.07; I(2)=34\%) with 3469 patients randomized in 10 trials. CONCLUSION: According to randomized published evidence, perioperative adult patients have an improved survival when receiving a liberal blood transfusion strategy.},
  langid = {english},
  pmid = {26385661},
  keywords = {anesthesia,blood transfusion,Blood Transfusion,Critical Care,critical illness,Critical Illness,Humans,mortality,perioperative care,Perioperative Care,Randomized Controlled Trials as Topic,Surgery,Survival Analysis,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6RZAQ5TW\\Fominskiy et al_2015_Liberal transfusion strategy improves survival in perioperative but not in.pdf}
}

@article{forshaw294,
  type = {Journal {{Article}}},
  title = {Is Cardiopulmonary Exercise Testing a Useful Test before Esophagectomy?},
  author = {Forshaw, M. J. and Strauss, D. C. and Davies, A. R. and Wilson, D. and Lams, B. and Pearce, A. and Botha, A. J. and Mason, R. C.},
  year = {2008},
  journal = {Ann Thorac Surg},
  volume = {85},
  number = {1},
  pages = {294--9},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2007.05.062}
}

@article{foster584a,
  title = {How Does Older Age Influence Oncologists' Cancer Management?},
  author = {Foster, Jill A. and Salinas, Gregory D. and Mansell, Dorcas and Williamson, James C. and Casebeer, Linda L.},
  year = {2010},
  journal = {The Oncologist},
  volume = {15},
  number = {6},
  pages = {584--592},
  issn = {1549-490X},
  doi = {10.1634/theoncologist.2009-0198},
  abstract = {BACKGROUND: Over half of new cancer cases occur in patients aged {$>$} or = 65 years. Many older patients can benefit from intensive cancer therapies, yet evidence suggests that this population is undertreated. METHODS: To assess preferences and influential factors in geriatric cancer management, practicing U.S. medical oncologists completed a survey containing four detailed vignettes exploring colon, breast, lung, and prostate cancer treatment. Participants were randomly assigned one of two surveys with vignettes that were identical except for patient age ({$<$}65 years or {$>$}70 years). RESULTS: Physicians in each survey group (n = 200) were demographically similar. Intensive therapy was significantly less likely to be recommended for an older than for a younger, but otherwise identical, patient in two of the scenarios. For a woman with metastatic colon cancer (Eastern Cooperative Oncology Group [ECOG] score, 1) for whom chemotherapy was recommended, nearly all oncologists chose an intensive regimen if the patient's age was 63; but if her age was 85, one fourth of the oncologists chose a less intensive treatment. Likewise, for stage IIA breast cancer (ECOG score, 0), 93\% recommended intensive adjuvant treatment for a previously healthy patient aged 63; but only 66\% said they would do so if the patient's age was 75. Oncologists commonly identified patient age as an influence on treatment choice, but were even more likely to cite performance status as a determining factor. CONCLUSIONS: Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities. Education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.},
  langid = {english},
  pmcid = {PMC3227998},
  pmid = {20495217},
  keywords = {Age Factors,Aged,Chemotherapy; Adjuvant,Elderly,Female,Geriatric Assessment,Health Care Surveys,Humans,Male,Medical Oncology,Neoplasms,Practice Patterns; Physicians',Surveys and Questionnaires,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7UG547Z7\\Foster et al_2010_How does older age influence oncologists' cancer management.pdf}
}

@article{frandsen516,
  title = {Increased Risk of Death Due to Heart Disease after Radiotherapy for Esophageal Cancer},
  author = {Frandsen, Jonathan and Boothe, Dustin and Gaffney, David K. and Wilson, Brent D. and Lloyd, Shane},
  year = {2015},
  month = oct,
  journal = {Journal of Gastrointestinal Oncology},
  volume = {6},
  number = {5},
  pages = {516--523},
  issn = {2078-6891},
  doi = {10.3978/j.issn.2078-6891.2015.040},
  abstract = {OBJECTIVE: To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses. RESULTS: We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P{$<$}0.05), with an absolute risk of HDRD of 2.8\%, 5.3\% and 9.4\% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P{$<$}0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P{$<$}0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P{$<$}0.0001) and multivariate (HR 1.62, P{$<$}0.0001) analyses. CONCLUSIONS: The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.},
  langid = {english},
  pmcid = {PMC4570919},
  pmid = {26487946},
  keywords = {Esophageal cancer (EC),heart disease,radiation therapy (RT)}
}

@article{fransen919,
  title = {Direct {{Oral Feeding After}} a {{Minimally Invasive Esophagectomy}}: {{A Single-Center Prospective Cohort Study}}},
  shorttitle = {Direct {{Oral Feeding After}} a {{Minimally Invasive Esophagectomy}}},
  author = {Fransen, Laura F. C. and Janssen, Thijs H. J. B. and Aarnoudse, Martijn and Nieuwenhuijzen, Grard A. P. and Luyer, Misha D. P.},
  year = {2022},
  month = may,
  journal = {Annals of Surgery},
  volume = {275},
  number = {5},
  pages = {919--923},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000004036},
  abstract = {OBJECTIVE: The aim of this single-center cohort study was to compare direct oral feeding (DOF) to standard of care after a minimally invasive esophagectomy (MIE) performed in a center with a stable and acceptable postoperative complication rate. BACKGROUND: A recent multicenter, international randomized controlled trial showed that DOF following a MIE is comparable to standard of care (nil-by-mouth). However, the effect of DOF was potentially influenced by postoperative complications. METHODS: Patients in this single-center prospective cohort study received either DOF (intervention) or nil-by-mouth for 5{$\mkern1mu$}days postoperative and tube feeding (standard of care, control group) following a MIE with intrathoracic anastomosis. Primary outcome was time to functional recovery and length of hospital stay. Secondary outcomes included anastomotic leakage, pneumonia, and other surgical complications. RESULTS: Baseline characteristics were similar in the intervention (n = 85) and control (n = 111) group. Median time to functional recovery was 7 and 9{$\mkern1mu$}days in the intervention and control group (P {$<$} 0.001), respectively. Length of hospital stay was 8 versus 10{$\mkern1mu$}days (P {$<$} 0.001), respectively. Thirty-day postoperative complication rate was significantly reduced in the intervention group (57.6\% vs 73.0\%, P = 0.024). Chyle leakage only occurred in the control group (18.9\%, P {$<$} 0.001). Anastomotic leakage, pneumonia, and other postoperative complications did not differ between groups. CONCLUSION: Direct oral feeding following a MIE results in a faster time to functional recovery and lower 30-day postoperative complication rate compared to patients that were orally fasted.},
  langid = {english},
  pmid = {32541215},
  keywords = {Anastomotic Leak,Cohort Studies,Esophageal Neoplasms,Esophagectomy,Humans,Minimally Invasive Surgical Procedures,Pneumonia,Postoperative Complications,Prospective Studies,Retrospective Studies,Treatment Outcome}
}

@article{fried255,
  type = {Journal {{Article}}},
  ids = {fried255a},
  title = {Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care},
  author = {Fried, L. P. and Ferrucci, L. and Darer, J. and Williamson, J. D. and Anderson, G.},
  year = {2004},
  journal = {J Gerontol A Biol Sci Med Sci},
  volume = {59},
  number = {3},
  pages = {255--63},
  issn = {1079-5006 (Print) 1079-5006 (Linking)},
  pmid = {15031310},
  keywords = {Aged,Comorbidity,Disabled Persons,Frail Elderly,Frailty,Geriatrics,Health Status,Humans,Prognosis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VKEQG255\\Fried et al_2004_Untangling the concepts of disability, frailty, and comorbidity.pdf}
}

@article{friedM146,
  title = {Frailty in Older Adults: Evidence for a Phenotype},
  shorttitle = {Frailty in Older Adults},
  author = {Fried, L. P. and Tangen, C. M. and Walston, J. and Newman, A. B. and Hirsch, C. and Gottdiener, J. and Seeman, T. and Tracy, R. and Kop, W. J. and Burke, G. and McBurnie, M. A. and {Cardiovascular Health Study Collaborative Research Group}},
  year = {2001},
  month = mar,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {56},
  number = {3},
  pages = {M146-156},
  issn = {1079-5006},
  doi = {10.1093/gerona/56.3.m146},
  abstract = {BACKGROUND: Frailty is considered highly prevalent in old age and to confer high risk for falls, disability, hospitalization, and mortality. Frailty has been considered synonymous with disability, comorbidity, and other characteristics, but it is recognized that it may have a biologic basis and be a distinct clinical syndrome. A standardized definition has not yet been established. METHODS: To develop and operationalize a phenotype of frailty in older adults and assess concurrent and predictive validity, the study used data from the Cardiovascular Health Study. Participants were 5,317 men and women 65 years and older (4,735 from an original cohort recruited in 1989-90 and 582 from an African American cohort recruited in 1992-93). Both cohorts received almost identical baseline evaluations and 7 and 4 years of follow-up, respectively, with annual examinations and surveillance for outcomes including incident disease, hospitalization, falls, disability, and mortality. RESULTS: Frailty was defined as a clinical syndrome in which three or more of the following criteria were present: unintentional weight loss (10 lbs in past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity. The overall prevalence of frailty in this community-dwelling population was 6.9\%; it increased with age and was greater in women than men. Four-year incidence was 7.2\%. Frailty was associated with being African American, having lower education and income, poorer health, and having higher rates of comorbid chronic diseases and disability. There was overlap, but not concordance, in the cooccurrence of frailty, comorbidity, and disability. This frailty phenotype was independently predictive (over 3 years) of incident falls, worsening mobility or ADL disability, hospitalization, and death, with hazard ratios ranging from 1.82 to 4.46, unadjusted, and 1.29-2.24, adjusted for a number of health, disease, and social characteristics predictive of 5-year mortality. Intermediate frailty status, as indicated by the presence of one or two criteria, showed intermediate risk of these outcomes as well as increased risk of becoming frail over 3-4 years of follow-up (odds ratios for incident frailty = 4.51 unadjusted and 2.63 adjusted for covariates, compared to those with no frailty criteria at baseline). CONCLUSIONS: This study provides a potential standardized definition for frailty in community-dwelling older adults and offers concurrent and predictive validity for the definition. It also finds that there is an intermediate stage identifying those at high risk of frailty. Finally, it provides evidence that frailty is not synonymous with either comorbidity or disability, but comorbidity is an etiologic risk factor for, and disability is an outcome of, frailty. This provides a potential basis for clinical assessment for those who are frail or at risk, and for future research to develop interventions for frailty based on a standardized ascertainment of frailty.},
  langid = {english},
  pmid = {11253156},
  keywords = {Aged,Aged; 80 and over,Cohort Studies,Disabled Persons,Fatigue,Female,Frail Elderly,Grip,Humans,Incidence,Male,Muscle Weakness,Phenotype,Prevalence,Sarcopenia,Sex Distribution,United States,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GZXJR3JC\\Fried et al_2001_Frailty in older adults.pdf}
}

@article{fromer92,
  type = {Journal {{Article}}},
  title = {Integrated Medical Processes: Redesigning Transitions of Care},
  author = {Fromer, L. and Pollack, C.},
  year = {2014},
  journal = {Hosp Pract (1995)},
  volume = {42},
  number = {4},
  pages = {92--8},
  issn = {2154-8331 (Print) 2154-8331 (Linking)},
  doi = {10.3810/hp.2014.10.1146}
}

@article{frontera1038,
  title = {Strength Conditioning in Older Men: Skeletal Muscle Hypertrophy and Improved Function},
  shorttitle = {Strength Conditioning in Older Men},
  author = {Frontera, W. R. and Meredith, C. N. and O'Reilly, K. P. and Knuttgen, H. G. and Evans, W. J.},
  year = {1988},
  month = mar,
  journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
  volume = {64},
  number = {3},
  pages = {1038--1044},
  issn = {8750-7587},
  doi = {10.1152/jappl.1988.64.3.1038},
  abstract = {The effects of strength conditioning on skeletal muscle function and mass were determined in older men. Twelve healthy untrained volunteers (age range 60-72 yr) participated in a 12-wk strength training program (8 repetitions/set; 3 sets/day; 3 days/wk) at 80\% of the one repetition maximum (1 RM) for extensors and flexors of both knee joints. They were evaluated before the program and after 6 and 12 wk of training. Weekly measurements of 1 RM showed a progressive increase in strength in extensors and flexors. By 12 wk extensor and flexor strength had increased 107.4 (P less than 0.0001) and 226.7\% (P less than 0.0001), respectively. Isokinetic peak torque of extensors and flexors measured on a Cybex II dynamometer increased 10.0 and 18.5\% (P less than 0.05) at 60 degrees/s and 16.7 and 14.7\% (P less than 0.05) at 240 degrees/s. The torque-velocity relationship showed an upward displacement of the curve at the end of training, mainly in the slow-velocity high-torque region. Midthigh composition from computerized tomographic scans showed an increase (P less than 0.01) in total thigh area (4.8\%), total muscle area (11.4\%), and quadriceps area (9.3\%). Biopsies of the vastus lateralis muscle revealed similar increases (P less than 0.001) in type I fiber area (33.5\%) and type II fiber area (27.6\%). Daily excretion of urinary 3-methyl-L-histidine increased with training (P less than 0.05) by an average 40.8\%. Strength gains in older men were associated with significant muscle hypertrophy and an increase in myofibrillar protein turnover.},
  langid = {english},
  pmid = {3366726},
  keywords = {Aged,Body Weight,Creatinine,Exercise Therapy,Humans,Hypertrophy,Male,Methylhistidines,Middle Aged,Muscles,Organ Size,Tomography; X-Ray Computed}
}

@article{fuchs2455,
  title = {Quantifying the Effect of Slice Thickness, Intravenous Contrast and Tube Current on Muscle Segmentation: {{Implications}} for Body Composition Analysis},
  shorttitle = {Quantifying the Effect of Slice Thickness, Intravenous Contrast and Tube Current on Muscle Segmentation},
  author = {Fuchs, Georg and Chretien, Yves R. and Mario, Julia and Do, Synho and Eikermann, Matthias and Liu, Bob and Yang, Kai and Fintelmann, Florian J.},
  year = {2018},
  month = jun,
  journal = {European Radiology},
  volume = {28},
  number = {6},
  pages = {2455--2463},
  issn = {1432-1084},
  doi = {10.1007/s00330-017-5191-3},
  abstract = {OBJECTIVES: To quantify the effect of IV contrast, tube current and slice thickness on skeletal muscle cross-sectional area (CSA) and density (SMD) on routine CT. METHODS: CSA and SMD were computed on 216 axial CT images obtained at the L3 level in 72 patients with variations in IV contrast, slice thickness and tube current. Intra-patient mean difference (MD), 95 \% CI and limits of agreement were calculated using the Bland-Altman approach. Inter- and intra-analyst agreement was evaluated. RESULTS: IV contrast significantly increased CSA by 1.88 \% (MD 2.33 cm2; 95 \% CI 1.76-2.89) and SMD by 5.99 \% (p{$<$}0.0001). Five mm slice thickness significantly increased mean CSA by 1.11 \% compared to 2 mm images (1.32 cm2; 0.78-1.85) and significantly decreased SMD by 11.64 \% (p{$<$}0.0001). Low tube current significantly decreased mean CSA by 4.79 \% (6.44 cm2; 3.78-9.10) and significantly increased SMD by 46.46 \% (p{$<$}0.0001). Inter- and intra-analyst agreement was excellent. CONCLUSIONS: IV contrast, slice thickness and tube current significantly affect CSA and SMD. Investigators designing and analysing clinical trials using CT for body composition analysis should report CT acquisition parameters and consider the effect of slice thickness, IV contrast and tube current on myometric data. KEY POINTS: \textbullet{} Intravenous contrast, slice thickness and tube current significantly affect myometric data. \textbullet{} Image acquisition parameter variations may obscure intrapatient muscle differences on serial measurements. \textbullet{} Investigators using CT for body composition analysis should report CT acquisition parameters.},
  langid = {english},
  pmid = {29318425},
  keywords = {Abdomen,Adult,Aged,Aged; 80 and over,Anthropometry,Body composition,Body Composition,Contrast,Contrast Media,Female,Humans,Image Interpretation; Computer-Assisted,Infusions; Intravenous,Male,Middle Aged,Muscle; Skeletal,Muscles,Positron Emission Tomography Computed Tomography,Radiographic Image Interpretation; Computer-Assisted,Tomography; X-Ray Computed,Young Adult}
}

@article{fuscoe13347,
  title = {Comprehensive Geriatric Assessment in Older Adults with Cancer: {{Recommendations}} by the {{Italian Society}} of {{Geriatrics}} and {{Gerontology}} ({{SIGG}})},
  shorttitle = {Comprehensive Geriatric Assessment in Older Adults with Cancer},
  author = {Fusco, Domenico and Ferrini, Alessandro and Pasqualetti, Giuseppe and Giannotti, Chiara and Cesari, Matteo and Laudisio, Alice and Ballestrero, Alberto and Scabini, Stefano and Odetti, Patrizio R. and Colloca, Giuseppe F. and Monzani, Fabio and Nencioni, Alessio and Antonelli Incalzi, Raffaele and Monacelli, Fiammetta and {Oncogeriatrics Group of the Italian Society of Gerontology, Geriatrics}},
  year = {2021},
  month = jan,
  journal = {European Journal of Clinical Investigation},
  volume = {51},
  number = {1},
  pages = {e13347},
  issn = {1365-2362},
  doi = {10.1111/eci.13347},
  abstract = {INTRODUCTION: Optimizing the approach to older adults with cancer is now a priority given the increasing frequency of new cancer diagnoses that are made in the older population. The comprehensive geriatric assessment (CGA) represents the gold-standard for (1) defining prognosis and ability to withstand cancer treatments, (2) exploring the multiple aspects that define the complexity of frail older persons, and (3) designing person-tailored interventions. MATERIALS AND METHODS: In this document, based on a comprehensive revision of the literature, the Italian Society for Geriatrics and Gerontology proposes a CGA model (ONCOGER CGA) to be adopted by oncology centers for their routine approach to older patients with cancer. RESULTS AND DISCUSSION: A widespread use of this standardized CGA format will facilitate comparisons across institutions, promote studies based on a multidimensional patient assessment, and foster the inclusion of geriatric endpoints in oncological clinical trials. Furthermore, we predict that the use of a standardized CGA approach will increase the integration of geriatricians into oncology care teams with the final result of improving therapeutic choices and clinical outcomes.},
  langid = {english},
  pmid = {32648990},
  keywords = {Aged,Aged; 80 and over,CGA,Cognition,comphrehensive geriatric assessment,Delphi Technique,Depression,Functional Status,Geriatric Assessment,Geriatrics,Humans,Italy,Multimorbidity,Neoplasms,Nutritional Status,older adult with cancer,Physical Functional Performance,Polypharmacy,Quality of Life,reccomendations of the Italian Geriatric Society,Sarcopenia,Societies; Medical,Socioeconomic Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LUB4CF5L\\Fusco et al_2021_Comprehensive geriatric assessment in older adults with cancer.pdf}
}

@article{futier428,
  title = {A Trial of Intraoperative Low-Tidal-Volume Ventilation in Abdominal Surgery},
  author = {Futier, Emmanuel and Constantin, Jean-Michel and {Paugam-Burtz}, Catherine and Pascal, Julien and Eurin, Mathilde and Neuschwander, Arthur and Marret, Emmanuel and Beaussier, Marc and Gutton, Christophe and Lefrant, Jean-Yves and Allaouchiche, Bernard and Verzilli, Daniel and Leone, Marc and De Jong, Audrey and Bazin, Jean-Etienne and Pereira, Bruno and Jaber, Samir and {IMPROVE Study Group}},
  year = {2013},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {369},
  number = {5},
  pages = {428--437},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1301082},
  abstract = {BACKGROUND: Lung-protective ventilation with the use of low tidal volumes and positive end-expiratory pressure is considered best practice in the care of many critically ill patients. However, its role in anesthetized patients undergoing major surgery is not known. METHODS: In this multicenter, double-blind, parallel-group trial, we randomly assigned 400 adults at intermediate to high risk of pulmonary complications after major abdominal surgery to either nonprotective mechanical ventilation or a strategy of lung-protective ventilation. The primary outcome was a composite of major pulmonary and extrapulmonary complications occurring within the first 7 days after surgery. RESULTS: The two intervention groups had similar characteristics at baseline. In the intention-to-treat analysis, the primary outcome occurred in 21 of 200 patients (10.5\%) assigned to lung-protective ventilation, as compared with 55 of 200 (27.5\%) assigned to nonprotective ventilation (relative risk, 0.40; 95\% confidence interval [CI], 0.24 to 0.68; P=0.001). Over the 7-day postoperative period, 10 patients (5.0\%) assigned to lung-protective ventilation required noninvasive ventilation or intubation for acute respiratory failure, as compared with 34 (17.0\%) assigned to nonprotective ventilation (relative risk, 0.29; 95\% CI, 0.14 to 0.61; P=0.001). The length of the hospital stay was shorter among patients receiving lung-protective ventilation than among those receiving nonprotective ventilation (mean difference, -2.45 days; 95\% CI, -4.17 to -0.72; P=0.006). CONCLUSIONS: As compared with a practice of nonprotective mechanical ventilation, the use of a lung-protective ventilation strategy in intermediate-risk and high-risk patients undergoing major abdominal surgery was associated with improved clinical outcomes and reduced health care utilization. (IMPROVE ClinicalTrials.gov number, NCT01282996.).},
  langid = {english},
  pmid = {23902482},
  keywords = {Abdomen,Digestive System Surgical Procedures,Double-Blind Method,Female,Humans,Intention to Treat Analysis,Male,Middle Aged,Operative Time,Positive-Pressure Respiration,Postoperative Complications,Respiratory Insufficiency,Tidal Volume}
}

@article{gabiatti6967,
  title = {Myosteatosis in a Systemic Inflammation-Dependent Manner Predicts Favorable Survival Outcomes in Locally Advanced Esophageal Cancer},
  author = {Gabiatti, Camila T. B. and Martins, Mariane C. L. and Miyazaki, Daniela L. and Silva, Leandro P. and Lascala, Fabiana and Macedo, Ligia T. and Mendes, Maria Carolina Santos and Carvalheira, Jos{\'e} Barreto Campello},
  year = {2019},
  journal = {Cancer Medicine},
  volume = {8},
  number = {16},
  pages = {6967--6976},
  issn = {2045-7634},
  doi = {10.1002/cam4.2593},
  abstract = {Increased adiposity and its attendant metabolic features as well as systemic inflammation have been associated with prognosis in locally advanced esophageal cancer (LAEC). However, whether myosteatosis and its combination with systemic inflammatory markers are associated with prognosis of esophageal cancer is unknown. Our study aimed to investigate the influence of myosteatosis and its association with systemic inflammation on progression-free survival (PFS) and overall survival (OS) in LAEC patients treated with definitive chemoradiotherapy (dCRT). We retrospectively gathered information on 123 patients with LAEC submitted to dCRT at the University of Campinas Hospital. Computed tomography (CT) images at the level of L3 were analyzed to assess muscularity and adiposity. Systemic inflammation was mainly measured by calculating the neutrophil-to-lymphocyte ratio (NLR). Median PFS for patients with myosteatosis (n = 72) was 11.0 months vs 4.0 months for patients without myosteatosis (n = 51) (hazard ratio [HR]: 0.53; 95\% confidence interval [CI], 0.34-0.83; P = .005). Myosteatosis was also independently associated with a favorable OS. Systemic inflammation (NLR {$>$} 2.8) was associated with a worse prognosis. The combination of myosteatosis with systemic inflammation revealed that the subgroup of patients with myosteatosis and without inflammation presented less than half the risk of disease progression (HR: 0.47; 95\% CI: 0.26-0.85; P = .013) and death (HR: 0.39; 95\% CI, 0.21-0.72; P = .003) compared with patients with inflammation. This study demonstrated that myosteatosis without systemic inflammation was independently associated with favorable PFS and OS in LAEC patients treated with dCRT.},
  langid = {english},
  keywords = {cachexia,esophageal neoplasms,myosteatosis,Myosteatosis; GE,sarcopenia,survival analysis},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2593},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\U35RF4TC\\Gabiatti et al. - 2019 - Myosteatosis in a systemic inflammation-dependent .pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\EYY2IQDB\\cam4.html}
}

@article{gallagher21S,
  title = {Body Composition (Sarcopenia) in Obese Patients: Implications for Care in the Intensive Care Unit},
  shorttitle = {Body Composition (Sarcopenia) in Obese Patients},
  author = {Gallagher, Dympna and DeLegge, Mark},
  year = {2011},
  month = sep,
  journal = {JPEN. Journal of parenteral and enteral nutrition},
  volume = {35},
  number = {5 Suppl},
  pages = {21S-8S},
  issn = {1941-2444},
  doi = {10.1177/0148607111413773},
  abstract = {The study of body composition is a rapidly evolving science. In today's environment, there is a great deal of interest in assessing body composition, especially in the obese subject, as a guide to clinical and nutrition interventions. There are some strikingly different compartments of body composition between the obese and the lean patient. We do have the ability to measure body composition accurately, although these techniques can be labor intensive and expensive. The recognition of patients with sarcopenic obesity has identified a potential high-risk patient population. These body composition abnormalities may have even greater importance in the intensive care patient.},
  langid = {english},
  pmcid = {PMC3306216},
  pmid = {21807929},
  keywords = {Adipose Tissue,Body Composition,Energy Metabolism,Humans,Intensive Care Units,Muscle; Skeletal,Nutrition Assessment,Obesity,Obesity Paradox,Phenotype,Sarcopenia}
}

@article{gannon7,
  title = {Reduced Fitness and Physical Functioning Are Long-Term Sequelae after Curative Treatment for Esophageal Cancer: A Matched Control Study},
  author = {Gannon, J A and Guinan, E M and Doyle, S L and Beddy, P and Reynolds, J V and Hussey, J},
  pages = {7},
  abstract = {Reduced physical functioning is common following resections for esophageal cancer; however, objective data on physical performance outcomes in this cohort are rare. The aim of this study was to assess the physical performance and health related quality of life (HRQOL) of disease free survivors and compare findings in a case matched noncancer control group. Twenty-five males (mean ({$\pm$}SD) aged 63 ({$\pm$}6) years) who were over 6 months postesophagectomy and disease-free were compared with 25 controls (60 {$\pm$} 6 years). Physical functioning was assessed through hand grip strength (dynamometry), exercise capacity (incremental shuttle walk test), physical activity levels (RT3 accelerometer), and body composition (bio-electrical impedance analysis). Health-related quality of life was measured using the EORTC QLQ-C30 questionnaire. Esophageal cancer survivors demonstrated significantly lower fitness (P {$<$} 0.001) and time spent in moderate (P {$<$} 0.001) and vigorous (P {$<$} 0.001) intensity physical activity compared with controls. Global health status and quality of life were similar in both groups (P = 0.245); however, physical and role functioning domains were lower in the cancer survivors (P {$<$} 0.001, and P = 0.001, respectively). These data show that disease-free survivors of curative esophageal cancer treatment demonstrate a significant compromise in physical functioning compared with controls, thus highlighting the multiple, complex rehabilitative needs of this cohort.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NTBCJEMK\\Gannon et al. - Reduced fitness and physical functioning are long-.pdf}
}

@article{ganz35,
  title = {Circumferential Ablation of {{Barrett}}'s Esophagus That Contains High-Grade Dysplasia: A {{U}}.{{S}}. {{Multicenter Registry}}},
  shorttitle = {Circumferential Ablation of {{Barrett}}'s Esophagus That Contains High-Grade Dysplasia},
  author = {Ganz, Robert A. and Overholt, Bergein F. and Sharma, Virender K. and Fleischer, David E. and Shaheen, Nicholas J. and Lightdale, Charles J. and Freeman, Stephen R. and Pruitt, Ronald E. and Urayama, Shiro M. and Gress, Frank and Pavey, Darren A. and Branch, M. Stanley and Savides, Thomas J. and Chang, Kenneth J. and Muthusamy, V. Raman and Bohorfoush, Anthony G. and Pace, Samuel C. and DeMeester, Steven R. and Eysselein, Viktor E. and Panjehpour, Masoud and Triadafilopoulos, George and {U.S. Multicenter Registry}},
  year = {2008},
  month = jul,
  journal = {Gastrointestinal Endoscopy},
  volume = {68},
  number = {1},
  pages = {35--40},
  issn = {1097-6779},
  doi = {10.1016/j.gie.2007.12.015},
  abstract = {BACKGROUND: The management strategies for Barrett's esophagus (BE) that contains high-grade dysplasia (HGD) include intensive endoscopic surveillance, photodynamic therapy, thermal ablation, EMR, and esophagectomy. OBJECTIVE: To assess the safety and effectiveness of endoscopic circumferential balloon-based ablation by using radiofrequency energy for treating BE HGD. DESIGN: Multicenter U.S. registry. SETTING: Sixteen academic and community centers; treatment period from September 2004 to March 2007. PATIENTS: Patients with histologic evidence of intestinal metaplasia (IM) that contained HGD confirmed by at least 2 expert pathologists. A prior EMR was permitted, provided that residual HGD remained in the BE region for ablation. INTERVENTION: Endoscopic circumferential ablation with follow-up esophageal biopsies to assess the histologic response to treatment. OUTCOMES: Histologic complete response (CR) end points: (1) all biopsy specimen fragments obtained at the last biopsy session were negative for HGD (CR-HGD), (2) all biopsy specimens were negative for any dysplasia (CR-D), and (3) all biopsy specimens were negative for IM (CR-IM). RESULTS: A total of 142 patients (median age 66 years, interquartile range [IQR] 59-75 years) who had BE HGD (median length 6 cm, IQR 3-8 cm) underwent circumferential ablation (median 1 session, IQR 1-2). No serious adverse events were reported. There was 1 asymptomatic stricture and no buried glands. Ninety-two patients had at least 1 follow-up biopsy session (median follow-up 12 months, IQR 8-15 months). A CR-HGD was achieved in 90.2\% of patients, CR-D in 80.4\%, and CR-IM in 54.3\%. LIMITATIONS: A nonrandomized study design, without a control arm, a lack of centralized pathology review, ablation and biopsy technique not standardized, and a relatively short-term follow-up. CONCLUSIONS: Endoscopic circumferential ablation is a promising modality for the treatment of BE that contains HGD. In this multicenter registry, the intervention safely achieved a CR for HGD in 90.2\% of patients at a median of 12 months of follow-up.},
  langid = {english},
  pmid = {18355819},
  keywords = {Aged,Barrett Esophagus,Biopsy; Needle,Catheter Ablation,Education; Medical; Continuing,Esophageal Neoplasms,Esophagoscopy,Female,Follow-Up Studies,Humans,Immunohistochemistry,Male,Middle Aged,Precancerous Conditions,Registries,Risk Assessment,Sensitivity and Specificity,Treatment Outcome,United States}
}

@article{garcia-aguilarJCO2200032,
  title = {Organ {{Preservation}} in {{Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy}}},
  author = {{Garcia-Aguilar}, Julio and Patil, Sujata and Gollub, Marc J. and Kim, Jin K. and Yuval, Jonathan B. and Thompson, Hannah M. and Verheij, Floris S. and Omer, Dana M. and Lee, Meghan and Dunne, Richard F. and Marcet, Jorge and Cataldo, Peter and Polite, Blase and Herzig, Daniel O. and Liska, David and Oommen, Samuel and Friel, Charles M. and Ternent, Charles and Coveler, Andrew L. and Hunt, Steven and Gregory, Anita and Varma, Madhulika G. and Bello, Brian L. and Carmichael, Joseph C. and Krauss, John and Gleisner, Ana and Paty, Philip B. and Weiser, Martin R. and Nash, Garrett M. and Pappou, Emmanouil and Guillem, Jos{\'e} G. and Temple, Larissa and Wei, Iris H. and Widmar, Maria and Lin, Sabrina and Segal, Neil H. and Cercek, Andrea and Yaeger, Rona and Smith, J. Joshua and Goodman, Karyn A. and Wu, Abraham J. and Saltz, Leonard B.},
  year = {2022},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  pages = {JCO2200032},
  issn = {1527-7755},
  doi = {10.1200/JCO.22.00032},
  abstract = {PURPOSE: Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total neoadjuvant therapy are limited. METHODS: In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TME) or watch-and-wait on the basis of tumor response. Patients in both groups received 4 months of infusional fluorouracil-leucovorin-oxaliplatin or capecitabine-oxaliplatin and 5,000 to 5,600 cGy of radiation combined with either continuous infusion fluorouracil or capecitabine during radiotherapy. The trial was designed as two stand-alone studies with disease-free survival (DFS) as the primary end point for both groups, with a comparison to a null hypothesis on the basis of historical data. The secondary end point was TME-free survival. RESULTS: Median follow-up was 3 years. Three-year DFS was 76\% (95\% CI, 69 to 84) for the INCT-CRT group and 76\% (95\% CI, 69 to 83) for the CRT-CNCT group, in line with the 3-year DFS rate (75\%) observed historically. Three-year TME-free survival was 41\% (95\% CI, 33 to 50) in the INCT-CRT group and 53\% (95\% CI, 45 to 62) in the CRT-CNCT group. No differences were found between groups in local recurrence-free survival, distant metastasis-free survival, or overall survival. Patients who underwent TME after restaging and patients who underwent TME after regrowth had similar DFS rates. CONCLUSION: Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.},
  langid = {english},
  pmid = {35483010},
  keywords = {Rectal;TNT}
}

@article{gemmill173,
  type = {Journal {{Article}}},
  title = {Systematic Review of Enhanced Recovery after Gastro-Oesophageal Cancer Surgery},
  author = {Gemmill, E. H. and Humes, D. J. and Catton, J. A.},
  year = {2015},
  journal = {Ann R Coll Surg Engl},
  volume = {97},
  number = {3},
  pages = {173--9},
  issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
  doi = {10.1308/003588414X14055925061630}
}

@article{gerard12,
  title = {{{BODY COMPOSITION AND ANTI-NEOPLASTIC TREATMENT IN ADULT AND OLDER SUBJECTS}} - {{A SYSTEMATIC REVIEW}}},
  author = {G{\'e}rard, S and Br{\'e}chemier, D and Lefort, A and Lozano, S and Kan, G Abellan Van and Filleron, T and Mourey, L and {Bernard-Marty}, C and {Roug{\'e}-Bugat}, M E and Soler, V and Vellas, B and Cesari, M and Rolland, Y and Balardy, L},
  journal = {J Nutr Health Aging},
  pages = {12},
  abstract = {Background: The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that agerelated modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy. Method: We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition. Results: Our search identified 1879 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenic patients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancer patients. Conclusions: Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancer patients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ADAZ4FW6\\GÃ©rard et al. - BODY COMPOSITION AND ANTI-NEOPLASTIC TREATMENT IN .pdf}
}

@article{gharzaie0158916,
  title = {Radiation {{Therapy}} and {{Cardiac Death}} in {{Long-Term Survivors}} of {{Esophageal Cancer}}: {{An Analysis}} of the {{Surveillance}}, {{Epidemiology}}, and {{End Result Database}}},
  shorttitle = {Radiation {{Therapy}} and {{Cardiac Death}} in {{Long-Term Survivors}} of {{Esophageal Cancer}}},
  author = {Gharzai, Laila and Verma, Vivek and Denniston, Kyle A. and Bhirud, Abhijeet R. and Bennion, Nathan R. and Lin, Chi},
  year = {2016},
  journal = {PloS One},
  volume = {11},
  number = {7},
  pages = {e0158916},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0158916},
  abstract = {OBJECTIVE: Radiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined late cardiac death in survivors of esophageal cancer that had or had not received RT. METHODS: 5,630 patients were identified that were diagnosed with esophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) from 1973-2012, who were followed for at least 5 years after therapy. Examined risk factors for cardiac death included age ({$\leq$}55/56-65/66-75/{$>$}75), gender, race (white/non-white), stage (local/regional/distant), histology (SCC/AC), esophageal location ({$<$}18cm/18-24cm/25-32cm/33-40cm from incisors), diagnosis year (1973-1992/1993-2002/2003-2012), and receipt of surgery and/or RT. Time to cardiac death was evaluated using the Kaplan-Meier method. A Cox model was used to evaluate risk factors for cardiac death in propensity score matched data. RESULTS: Patients who received RT were younger, diagnosed more recently, had more advanced disease, SCC histology, and no surgery. The RT group had higher risk of cardiac death than the no-RT group (log-rank p{$<$}0.0001). The median time to cardiac death in the RT group was 289 months (95\% CI, 255-367) and was not reached in the no-RT group. The probability of cardiac death increased with age and decreased with diagnosis year, and this trend was more pronounced in the RT group. Multivariate analysis found RT to be associated with higher probability of cardiac death (OR 1.23, 95\% CI 1.03-1.47, HR 1.961, 95\% CI 1.466-2.624). Lower esophageal subsite (33-40 cm) was also associated with a higher risk of cardiac death. Other variables were not associated with cardiac death. CONCLUSIONS: Recognizing the limitations of a SEER analysis including lack of comorbidity accountability, these data should prompt more definitive study as to whether a possible associative effect of RT on cardiac death could potentially be a causative effect.},
  langid = {english},
  pmcid = {PMC4948887},
  pmid = {27428362},
  keywords = {Adenocarcinoma,Aged,Carcinoma; Squamous Cell,Death,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagus,Female,Follow-Up Studies,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Proportional Hazards Models,Survival Analysis,Survivors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FCIURAFT\\Gharzai et al. - 2016 - Radiation Therapy and Cardiac Death in Long-Term S.pdf}
}

@article{giaquinto202,
  title = {Cancer Statistics for {{African American}}/{{Black People}} 2022},
  author = {Giaquinto, Angela N. and Miller, Kimberly D. and Tossas, Katherine Y. and Winn, Robert A. and Jemal, Ahmedin and Siegel, Rebecca L.},
  year = {2022},
  month = may,
  journal = {CA: a cancer journal for clinicians},
  volume = {72},
  number = {3},
  pages = {202--229},
  issn = {1542-4863},
  doi = {10.3322/caac.21718},
  abstract = {African American/Black individuals have a disproportionate cancer burden, including the highest mortality and the lowest survival of any racial/ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2018), mortality (through 2019), survival, screening, and risk factors using population-based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2022, there will be approximately 224,080 new cancer cases and 73,680 cancer deaths among Black people in the United States. During the most recent 5-year period, Black men had a 6\% higher incidence rate but 19\% higher mortality than White men overall, including an approximately 2-fold higher risk of death from myeloma, stomach cancer, and prostate cancer. The overall cancer mortality disparity is narrowing between Black and White men because of a steeper drop in Black men for lung and prostate cancers. However, the decline in prostate cancer mortality in Black men slowed from 5\% annually during 2010 through 2014 to 1.3\% during 2015 through 2019, likely reflecting the 5\% annual increase in advanced-stage diagnoses since 2012. Black women have an 8\% lower incidence rate than White women but a 12\% higher mortality; further, mortality rates are 2-fold higher for endometrial cancer and 41\% higher for breast cancer despite similar or lower incidence rates. The wide breast cancer disparity reflects both later stage diagnosis (57\% localized stage vs 67\% in White women) and lower 5-year survival overall (82\% vs 92\%, respectively) and for every stage of disease (eg, 20\% vs 30\%, respectively, for distant stage). Breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in 2019. Targeted interventions are needed to reduce stark cancer inequalities in the Black community.},
  langid = {english},
  pmid = {35143040},
  keywords = {African Americans,American Cancer Society,Black people,Breast Neoplasms,cancer statistics,Female,Humans,incidence,Male,mortality,National Cancer Institute (U.S.),Prostatic Neoplasms,Race,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XLANDLXR\\Giaquinto et al. - 2022 - Cancer statistics for African AmericanBlack Peopl.pdf}
}

@article{gill1059,
  title = {Colon Cancer Treatment: Are There Racial Disparities in an Equal-Access Healthcare System?},
  shorttitle = {Colon Cancer Treatment},
  author = {Gill, Abegail A. and Enewold, Lindsey and Zahm, Shelia H. and Shriver, Craig D. and Stojadinovic, Alexander and McGlynn, Katherine A. and Zhu, Kangmin},
  year = {2014},
  month = sep,
  journal = {Diseases of the Colon and Rectum},
  volume = {57},
  number = {9},
  pages = {1059--1065},
  issn = {1530-0358},
  doi = {10.1097/DCR.0000000000000177},
  abstract = {BACKGROUND: In the general US population, blacks and whites have been shown to undergo colon cancer treatment at disproportionate rates. Accessibility to medical care may be the most important factor influencing differences in colon cancer treatment rates among whites and blacks. OBJECTIVE: We assessed whether racial disparities in colon cancer surgery and chemotherapy existed in an equal-access health care system. In addition, we sought to examine whether racial differences varied according to demographic and tumor characteristics. DESIGN AND SETTING: Database research using the Department of Defense Military Health System. PATIENTS: Patients included 2560 non-Hispanic whites (NHW) and non-Hispanic blacks (NHB) with colon cancer diagnosed from 1998 to 2007. MAIN OUTCOME MEASURES: Logistic regression was used to assess the associations between race and the receipt of colon cancer surgery or chemotherapy while controlling for available potential confounders, both overall and stratified by age at diagnosis, sex, and tumor stage. RESULTS: After multivariate adjustment, the odds of receiving colon cancer surgery or chemotherapy for NHBs versus NHWs were similar (OR, 0.75 [95\% CI, 0.37-1.53]; OR, 0.79 [95\% CI, 0.59-1.04]). In addition, no effect modifications by age at diagnosis, sex, and tumor stage were observed. LIMITATIONS: Treatment data might not be complete for beneficiaries who also had non-Department of Defense health insurance. CONCLUSIONS: When access to medical care is equal, racial disparities in the provision of colon cancer surgery and chemotherapy were not apparent. Thus, it is possible that the inequalities in access to care play a major role in the racial disparities seen in colon cancer treatment in the general population.},
  langid = {english},
  pmcid = {PMC4126203},
  pmid = {25101601},
  keywords = {Adenocarcinoma,Adult,Aged,Blacks,Colonic Neoplasms,Female,Health Services Accessibility,Healthcare Disparities,Humans,Male,Middle Aged,Race,United States,Whites}
}

@article{gille225155,
  title = {Population-{{Based Estimates}} of 1-{{Year Mortality After Major Surgery Among Community-Living Older US Adults}}},
  author = {Gill, Thomas M. and Vander Wyk, Brent and {Leo-Summers}, Linda and Murphy, Terrence E. and Becher, Robert D.},
  year = {2022},
  month = oct,
  journal = {JAMA surgery},
  pages = {e225155},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2022.5155},
  abstract = {IMPORTANCE: Despite their importance to guiding public health decision-making and policies and to establishing programs aimed at improving surgical care, contemporary nationally representative mortality data for geriatric surgery are lacking. OBJECTIVE: To calculate population-based estimates of mortality after major surgery in community-living older US adults and to determine how these estimates differ according to key demographic, surgical, and geriatric characteristics. DESIGN, SETTING, AND PARTICIPANTS: Prospective longitudinal cohort study with 1 year of follow-up in the continental US from 2011 to 2018. Participants included 5590 community-living fee-for-service Medicare beneficiaries, aged 65 years or older, from the National Health and Aging Trends Study (NHATS). Data analysis was conducted from February 22, 2021, to March 16, 2022. MAIN OUTCOMES AND MEASURES: Major surgeries and mortality over 1 year were identified through linkages with data from the Centers for Medicare \& Medicaid Services. Data on frailty and dementia were obtained from the annual NHATS assessments. RESULTS: From 2011 to 2017, of the 1193 major surgeries (from 992 community-living participants), the mean (SD) age was 79.2 (7.1) years; 665 were women (55.7\%), and 30 were Hispanic (2.5\%), 198 non-Hispanic Black (16.6\%), and 915 non-Hispanic White (76.7\%). Over the 1-year follow-up period, there were 206 deaths representing 872\,096 survey-weighted deaths and 13.4\% (95\% CI, 10.9\%-15.9\%) mortality. Mortality rates were 7.4\% (95\% CI, 4.9\%-9.9\%) for elective surgeries and 22.3\% (95\% CI, 17.4\%-27.1\%) for nonelective surgeries. For geriatric subgroups, 1-year mortality was 6.0\% (95\% CI, 2.6\%-9.4\%) for persons who were nonfrail, 27.8\% (95\% CI, 21.2\%-34.3\%) for those who were frail, 11.6\% (95\% CI, 8.8\%-14.4\%) for persons without dementia, and 32.7\% (95\% CI, 24.3\%-41.0\%) for those with probable dementia. The age- and sex-adjusted hazard ratios for 1-year mortality were 4.41 (95\% CI, 2.53-7.69) for frailty with a reduction in restricted mean survival time of 48.8 days and 2.18 (95\% CI, 1.40-3.40) for probable dementia with a reduction in restricted mean survival time of 44.9 days. CONCLUSIONS AND RELEVANCE: In this study, the population-based estimate of 1-year mortality after major surgery among community-living older adults in the US was 13.4\% but was 3-fold higher for nonelective than elective procedures. Mortality was considerably elevated among older persons who were frail or who had probable dementia, highlighting the potential prognostic value of geriatric conditions after major surgery.},
  langid = {english},
  pmcid = {PMC9582971},
  pmid = {36260323},
  keywords = {Geriatric}
}

@article{gillis391,
  title = {Effects of {{Nutritional Prehabilitation}}, {{With}} and {{Without Exercise}}, on {{Outcomes}} of {{Patients Who Undergo Colorectal Surgery}}: {{A~Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Effects of {{Nutritional Prehabilitation}}, {{With}} and {{Without Exercise}}, on {{Outcomes}} of {{Patients Who Undergo Colorectal Surgery}}},
  author = {Gillis, Chelsia and Buhler, Katherine and Bresee, Lauren and Carli, Francesco and Gramlich, Leah and {Culos-Reed}, Nicole and Sajobi, Tolulope T. and Fenton, Tanis R.},
  year = {2018},
  month = aug,
  journal = {Gastroenterology},
  volume = {155},
  number = {2},
  pages = {391-410.e4},
  issn = {1528-0012},
  doi = {10.1053/j.gastro.2018.05.012},
  abstract = {BACKGROUND \& AIMS: Although there have been meta-analyses of the effects of exercise-only prehabilitation on patients undergoing colorectal surgery, little is known about the effects of nutrition-only (oral nutritional supplements with and without counseling) and multimodal (oral nutritional supplements with and without counseling and with exercise) prehabilitation on clinical outcomes and patient function after surgery. We performed a systemic review and meta-analysis to determine the individual and combined effects of nutrition-only and multimodal prehabilitation compared with no prehabilitation (control) on outcomes of patients undergoing colorectal resection. METHODS: We searched Medline, EMBASE, CINAHL, CENTRAL, and ProQuest for cohort and randomized controlled studies of adults awaiting colorectal surgery who received at least 7 days of nutrition prehabilitation with or without exercise. We performed a random-effects meta-analysis to estimate the pooled risk ratio for categorical data and the weighted mean difference for continuous variables. The primary outcome was length of hospital stay; the secondary outcome was recovery of functional capacity based on results of a 6-minute walk test. RESULTS: We identified 9 studies (5~randomized controlled studies and 4 cohort studies) composed of 914 patients undergoing colorectal surgery (438 received prehabilitation and 476 served as controls). Receipt of any prehabilitation significantly decreased days spent in the hospital compared with controls (weighted mean difference of length of hospital stay~=~-2.2 days; 95\% confidence interval~=~-3.5 to~-0.9). Only 3 studies reported on functional outcomes but could not be pooled owing to methodologic heterogeneity. In the individual studies, multimodal prehabilitation significantly improved results of the 6-minute walk test at 4 and 8 weeks after surgery compared with standard Enhanced Recovery Pathway care and at 8 weeks compared with standard Enhanced Recovery Pathway care with added rehabilitation. The 4 observational studies had a high risk of bias. CONCLUSIONS: In a systematic review and meta-analysis, we found that nutritional prehabilitation alone or combined with an exercise program significantly decreased length of hospital stay by 2 days in patients undergoing colorectal surgery. There is some evidence that multimodal prehabilitation accelerated the return to presurgical functional capacity.},
  langid = {english},
  pmid = {29750973},
  keywords = {Combined Modality Therapy,Counseling,CRC,Diet Therapy,Digestive System Surgical Procedures,Enhanced Recovery After Surgery,Enhanced Recovery Pathway,Exercise Therapy,Humans,Length of Stay,Postoperative Complications,Prehab,Preoperative Care,Preoperative Nutrition,Recovery of Function,Surgery Preparation,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\N67ZJU7T\\Gillis et al_2018_Effects of Nutritional Prehabilitation, With and Without Exercise, on Outcomes.pdf}
}

@article{gillis937,
  title = {Prehabilitation versus Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer},
  shorttitle = {Prehabilitation versus Rehabilitation},
  author = {Gillis, Chelsia and Li, Chao and Lee, Lawrence and Awasthi, Rashami and Augustin, Berson and Gamsa, Ann and Liberman, A. Sender and Stein, Barry and Charlebois, Patrick and Feldman, Liane S. and Carli, Francesco},
  year = {2014},
  month = nov,
  journal = {Anesthesiology},
  volume = {121},
  number = {5},
  pages = {937--947},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000393},
  abstract = {BACKGROUND: The preoperative period (prehabilitation) may represent a more appropriate time than the postoperative period to implement an intervention. The impact of prehabilitation on recovery of function al exercise capacity was thus studied in patients undergoing colorectal resection for cancer. METHODS: A parallel-arm single-blind superiority randomized controlled trial was conducted. Seventy-seven patients were randomized to receive either prehabilitation (n = 38) or rehabilitation (n = 39). Both groups received a home-based intervention of moderate aerobic and resistance exercises, nutritional counseling with protein supplementation, and relaxation exercises initiated either 4 weeks before surgery (prehabilitation) or immediately after surgery (rehabilitation), and continued for 8 weeks after surgery. Patients were managed with an enhanced recovery pathway. Primary outcome was functional exercise capacity measured using the validated 6-min walk test. RESULTS: Median duration of prehabilitation was 24.5 days. While awaiting surgery, functional walking capacity increased ({$\geq$} 20 m) in a higher proportion of the prehabilitation group compared with the rehabilitation group (53 vs. 15\%, adjusted P = 0.006). Complication rates and duration of hospital stay were similar. The difference between baseline and 8-week 6-min walking test was significantly higher in the prehabilitation compared with the rehabilitation group (+23.7 m [SD, 54.8] vs. -21.8 m [SD, 80.7]; mean difference 45.4 m [95\% CI, 13.9 to 77.0]). A higher proportion of the prehabilitation group were also recovered to or above baseline exercise capacity at 8 weeks compared with the rehabilitation group (84 vs. 62\%, adjusted P = 0.049). CONCLUSION: Meaningful changes in postoperative functional exercise capacity can be achieved with a prehabilitation program.},
  langid = {english},
  pmid = {25076007},
  keywords = {Aged,Colorectal Neoplasms,Exercise,Exercise Therapy,Exercise Tolerance,Female,Humans,Male,Middle Aged,Nutrition Therapy,Postoperative Care,Prehab,Preoperative Care,Resistance Training,Single-Blind Method,Treatment Outcome,Walking}
}

@article{glantz1,
  title = {Biostatistics: How to Detect, Correct and Prevent Errors in the Medical Literature},
  shorttitle = {Biostatistics},
  author = {Glantz, S. A.},
  year = {1980},
  month = jan,
  journal = {Circulation},
  volume = {61},
  number = {1},
  pages = {1--7},
  issn = {0009-7322},
  doi = {10.1161/01.cir.61.1.1},
  abstract = {Approximately half the articles published in medical journals that use statistical methods use them incorrectly. These errors are so widespread that the present system of peer review has not been able to control them. This article presents a few rules of thumb to help readers identify questionable statistical analysis and estimate what the authors would have concluded had they used appropriate statistical methods. To prevent such errors from appearing, journals should secure review by someone knowledgeable in statistics before accepting a manuscript. In addition, human research committees should insist that an investigator define an appropriate strategy for data analysis before approving a protocol. Such policies should quickly and effectively increase the reliability of the clinical and scientific literature.},
  langid = {english},
  pmid = {7349923},
  keywords = {Humans,Peer Review,Research Design,Statistics as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VTABZC4W\\Glantz_1980_Biostatistics.pdf}
}

@article{glisch179,
  title = {Immune {{Checkpoint Inhibitor Use Near}} the {{End}} of {{Life Is Associated With Poor Performance Status}}, {{Lower Hospice Enrollment}}, and {{Dying}} in the {{Hospital}}},
  author = {Glisch, Chad and Hagiwara, Yuya and {Gilbertson-White}, Stephanie and Gao, Yubo and Lyckholm, Laurel},
  year = {2020},
  month = mar,
  journal = {American Journal of Hospice and Palliative Medicine\textregistered},
  volume = {37},
  number = {3},
  pages = {179--184},
  publisher = {{SAGE Publications Inc}},
  issn = {1049-9091},
  doi = {10.1177/1049909119862785},
  abstract = {Background:Immune checkpoint inhibitors have changed the landscape of cancer care by increasing progression-free and overall survival in some patients with cancer. We evaluated use and variables contributing to immune checkpoint inhibitor treatment near the end of life.Methods:We studied 157 patients who received immune checkpoint inhibitors and died between January 2015 and December 2018. All patients had a palliative care consult any time between starting an immune checkpoint inhibitor and death. Univariate and multivariate models were used to examine variables related to immune checkpoint inhibitor use near the end of life.Results:Among 157 patients studied, 42 (27\%) received a dose of immune checkpoint inhibitor in the last 30 days of life. Those who received treatment in the last 30 days of life had lower hospice enrollment (19 [45\%] vs 78 [69\%], P = .007) and higher rates of dying in the hospital (23 [56\%] vs 33 [29\%], P = .002). The percentage of patients with Eastern Cooperative Oncology Group (ECOG) {$\geq$}3 at the time of last immune checkpoint inhibitor dose was higher in the group that received immune checkpoint inhibitor treatment in the last 30 days of life (11 [26\%] vs 9 [8\%], P = .003). Lack of traditional chemotherapy after immune checkpoint inhibitor, ECOG {$\geq$}3, and lack of hospice enrollment were independently associated with receiving immune checkpoint inhibitor in the last 30 days of life.Conclusion:Immune checkpoint inhibitor use in the last 30 days of life is common and associated with poor performance status, lower hospice enrollment, and dying in the hospital.},
  langid = {english},
  keywords = {ICI}
}

@article{gomez-perez419,
  title = {Tutorial: {{A Step-by-Step Guide}} ({{Version}} 2.0) for {{Measuring Abdominal Circumference}} and {{Skeletal Muscle From}} a {{Single Cross-Sectional Computed-Tomography Image Using}} the {{National Institutes}} of {{Health ImageJ}}},
  shorttitle = {Tutorial},
  author = {{Gomez-Perez}, Sandra and McKeever, Liam and Sheean, Patricia},
  year = {2020},
  month = mar,
  journal = {JPEN. Journal of parenteral and enteral nutrition},
  volume = {44},
  number = {3},
  pages = {419--424},
  issn = {1941-2444},
  doi = {10.1002/jpen.1721},
  abstract = {BACKGROUND: In patients with acute and chronic illness, depleted skeletal muscle (SM) mass, also referred to as sarcopenia, is a condition associated with an underlying disease process and adverse outcomes. Because of software upgrades and errors related to installation, clarifications and a revised tutorial were needed for calculating SM cross-sectional area (CSA) using the National Institutes of Health (NIH) ImageJ. METHODS: A pilot study was conducted to determine the usability of the tutorial version 2.0. Eight adults ({$\geq$}18 years of age) who had no previous experience or background in body composition or computed-tomography imaging and owned a personal laptop computer (Mac or PC) were included in the pilot study. Participants were tested on the completion of 4 tasks: (1) installation of software, (2) updating the software, (3) following revised tutorial (version 2.0), and (4) transferring information from the software to a spreadsheet for calculation of SM CSA. RESULTS: All participants completed the tutorial and all assigned tasks, 4/4 (100\%). However, 38\% (3/8) of the participants made errors while cutting and pasting values from the ImageJ results box to a spreadsheet for calculating SM CSA. CONCLUSION: The tutorial version 2.0 was easy to follow and provided sufficient information for adults to install, update, and perform the steps of body composition for the NIH ImageJ software without major issues. Care should be taken when cutting and pasting results from the software as well as when using the Microsoft Excel spreadsheet for calculating SM CSA.},
  langid = {english},
  pmid = {31617218},
  keywords = {Adult,body composition,computed tomography,Humans,Muscle; Skeletal,National Institutes of Health (U.S.),NIH ImageJ,Pilot Projects,Sarcopenia,skeletal muscle,Tomography; X-Ray Computed,United States}
}

@article{gonzalez999,
  title = {Obesity Paradox in Cancer: New Insights Provided by Body Composition},
  shorttitle = {Obesity Paradox in Cancer},
  author = {Gonzalez, Maria Cristina and Pastore, Carla A. and Orlandi, Silvana P. and Heymsfield, Steven B.},
  year = {2014},
  month = may,
  journal = {The American Journal of Clinical Nutrition},
  volume = {99},
  number = {5},
  pages = {999--1005},
  issn = {1938-3207},
  doi = {10.3945/ajcn.113.071399},
  abstract = {BACKGROUND: Obesity, defined by body mass index (BMI), appears to have a paradoxical protective effect in several chronic diseases. OBJECTIVE: We investigated the obesity paradox in cancer patients by using body composition. DESIGN: The study was an observational study of 175 cancer patients assessed before chemotherapy. Obesity was defined as BMI (in kg/m(2)) {$\geq$}30 or fat mass index (FMI; fat mass divided by the square of height) {$\geq$}5.2 (men) and {$\geq$}8.2 (women) measured by using a bioelectrical impedance analysis. Low muscle mass (sarcopenia) was defined as fat-free mass index (fat-free mass divided by the square of height) {$<$}17.5 (men) and {$<$}15.1 (women). RESULTS: Most patients were women (65.7\%) and had a mean ({$\pm$}SD) age of 56.9 {$\pm$} 12.8 y. According to BMI criteria, 60\% of patients were overweight or obese. The median survival time for overweight (2.64 y; range: 0.23-3.16 y) and obese (2.61 y; range: 0.26-3.20 y) patients was significantly higher than for patients with a normal (2.04 y; range: 0.06-3.05 y) or low (0.52 y; range: 0.19-0.98 y) BMI (P {$<$} 0.001). Sarcopenic patients had shorter survival, regardless of their FMI. Obesity predicted higher survival rates only when sarcopenia was absent. In a multivariate Cox regression model, sarcopenia was an independent predictor of higher mortality (HR: 5.19; 95\% CI: 2.58, 10.43) after we controlled for BMI, age, and tumor stage. CONCLUSIONS: The obesity paradox is present in cancer patients only when obesity is defined by BMI. Patients with sarcopenic obesity had the poorest prognosis. Cancer patients with high mortality risk can be identified by a body-composition assessment.},
  langid = {english},
  pmid = {24572565},
  keywords = {Adiposity,Adult,Aged,Body Composition,Body Mass Index,Electric Impedance,Female,Follow-Up Studies,Humans,Male,Middle Aged,Multivariate Analysis,Neoplasms,Obesity,Prognosis,Proportional Hazards Models,Prospective Studies,Sarcopenia}
}

@article{goodpaster18,
  title = {Composition of Skeletal Muscle Evaluated with Computed Tomography},
  author = {Goodpaster, B. H. and Thaete, F. L. and Kelley, D. E.},
  year = {2000},
  month = may,
  journal = {Annals of the New York Academy of Sciences},
  volume = {904},
  pages = {18--24},
  issn = {0077-8923},
  doi = {10.1111/j.1749-6632.2000.tb06416.x},
  abstract = {Computed tomography (CT) can yield quantitative imaging data from detailed maps of linear attenuation coefficients within tissue. The attenuation characteristics of skeletal muscle and adipose tissue can be quantified in vivo to provide information about the composition of skeletal muscle and the distribution of adipose tissue within muscle. Several studies have taken advantage of this utility to quantify skeletal muscle composition and fatty infiltration of muscle, in particular to quantify the attenuation characteristics of muscle as a marker of its lipid content. In this manner we found that the mean muscle attenuation of skeletal muscle reflects an increase in its fat content in obesity, and that this regional body composition parameter is strongly related to insulin-resistant glucose metabolism. In addition, muscle composition and adipose tissue distribution within muscle may be altered with clinical weight-loss interventions. CT may also provide important information about the changes in muscle mass and composition with aging and disease, which may, in turn, affect the muscle's function. In summary, CT can provide important quantitative data on the composition of muscle, and the distribution of adipose tissue within it, and this may be important in examining the relationships among skeletal muscle metabolism, lipid accumulation within muscle, and muscle function.},
  langid = {english},
  pmid = {10865705},
  keywords = {Adipose Tissue,Body Composition,Humans,Methods,Muscle; Skeletal,Tomography; X-Ray Computed}
}

@article{goulde227S,
  title = {Prevention of {{VTE}} in Nonorthopedic Surgical Patients: {{Antithrombotic Therapy}} and {{Prevention}} of {{Thrombosis}}, 9th Ed: {{American College}} of {{Chest Physicians Evidence-Based Clinical Practice Guidelines}}},
  shorttitle = {Prevention of {{VTE}} in Nonorthopedic Surgical Patients},
  author = {Gould, Michael K. and Garcia, David A. and Wren, Sherry M. and Karanicolas, Paul J. and Arcelus, Juan I. and Heit, John A. and Samama, Charles M.},
  year = {2012},
  month = feb,
  journal = {Chest},
  volume = {141},
  number = {2 Suppl},
  pages = {e227S-e277S},
  issn = {1931-3543},
  doi = {10.1378/chest.11-2297},
  abstract = {BACKGROUND: VTE is a common cause of preventable death in surgical patients. METHODS: We developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by using systematic methods as described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. RESULTS: We describe several alternatives for stratifying the risk of VTE in general and abdominal-pelvic surgical patients. When the risk for VTE is very low ({$<$} 0.5\%), we recommend that no specific pharmacologic (Grade 1B) or mechanical (Grade 2C) prophylaxis be used other than early ambulation. For patients at low risk for VTE ({$\sim$}1.5\%), we suggest mechanical prophylaxis, preferably with intermittent pneumatic compression (IPC), over no prophylaxis (Grade 2C). For patients at moderate risk for VTE ({$\sim$}3\%) who are not at high risk for major bleeding complications, we suggest low-molecular-weight heparin (LMWH) (Grade 2B), low-dose unfractionated heparin (Grade 2B), or mechanical prophylaxis with IPC (Grade 2C) over no prophylaxis. For patients at high risk for VTE ({$\sim$}6\%) who are not at high risk for major bleeding complications, we recommend pharmacologic prophylaxis with LMWH (Grade 1B) or low-dose unfractionated heparin (Grade 1B) over no prophylaxis. In these patients, we suggest adding mechanical prophylaxis with elastic stockings or IPC to pharmacologic prophylaxis (Grade 2C). For patients at high risk for VTE undergoing abdominal or pelvic surgery for cancer, we recommend extended-duration, postoperative, pharmacologic prophylaxis (4 weeks) with LMWH over limited-duration prophylaxis (Grade 1B). For patients at moderate to high risk for VTE who are at high risk for major bleeding complications or those in whom the consequences of bleeding are believed to be particularly severe, we suggest use of mechanical prophylaxis, preferably with IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C). For patients in all risk groups, we suggest that an inferior vena cava filter not be used for primary VTE prevention (Grade 2C) and that surveillance with venous compression ultrasonography should not be performed (Grade 2C). We developed similar recommendations for other nonorthopedic surgical populations. CONCLUSIONS: Optimal thromboprophylaxis in nonorthopedic surgical patients will consider the risks of VTE and bleeding complications as well as the values and preferences of individual patients.},
  langid = {english},
  pmcid = {PMC3278061},
  pmid = {22315263},
  keywords = {Combined Modality Therapy,Evidence-Based Medicine,Fibrinolytic Agents,Hemorrhage,Heparin,Heparin; Low-Molecular-Weight,Intermittent Pneumatic Compression Devices,Postoperative Complications,Pulmonary Embolism,Risk Factors,Societies; Medical,Stockings; Compression,Surgical Procedures; Operative,United States,Venous Thromboembolism,VTE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KW7CUGGW\\Gould et al_2012_Prevention of VTE in nonorthopedic surgical patients.pdf}
}

@article{graffy20190327,
  title = {Deep Learning-Based Muscle Segmentation and Quantification at Abdominal {{CT}}: Application to a Longitudinal Adult Screening Cohort for Sarcopenia Assessment},
  shorttitle = {Deep Learning-Based Muscle Segmentation and Quantification at Abdominal {{CT}}},
  author = {Graffy, Peter M. and Liu, Jiamin and Pickhardt, Perry J. and Burns, Joseph E. and Yao, Jianhua and Summers, Ronald M.},
  year = {2019},
  month = aug,
  journal = {The British Journal of Radiology},
  volume = {92},
  number = {1100},
  pages = {20190327},
  issn = {1748-880X},
  doi = {10.1259/bjr.20190327},
  abstract = {OBJECTIVE: To investigate a fully automated abdominal CT-based muscle tool in a large adult screening population. METHODS: A fully automated validated muscle segmentation algorithm was applied to 9310 non-contrast CT scans, including a primary screening cohort of 8037 consecutive asymptomatic adults (mean age, 57.1{$\pm$}7.8 years; 3555M/4482F). Sequential follow-up scans were available in a subset of 1171 individuals (mean interval, 5.1 years). Muscle tissue cross-sectional area and attenuation (Hounsfield unit, HU) at the L3 level were assessed, including change over time. RESULTS: Mean values were significantly higher in males for both muscle area (190.6{$\pm$}33.6 vs 133.3{$\pm$}24.1 cm2, p{$<$}0.001) and density (34.3{$\pm$}11.1 HU vs 27.3{$\pm$}11.7 HU, p{$<$}0.001). Age-related losses were observed, with mean muscle area reduction of -1.5 cm2/year and attenuation reduction of -1.5 HU/year. Overall age-related muscle density (attenuation) loss was steeper than for muscle area for both sexes up to the age of 70 years. Between ages 50 and 70, relative muscle attenuation decreased significantly more in females (-30.6\% vs -18.0\%, p{$<$}0.001), whereas relative rates of muscle area loss were similar (-8\%). Between ages 70 and 90, males lost more density (-22.4\% vs -7.5\%) and area (-13.4\% vs -6.9\%, p{$<$}0.001). Of the 1171 patients with longitudinal follow-up, 1013 (86.5\%) showed a decrease in muscle attenuation, 739 (63.1\%) showed a decrease in area, and 1119 (95.6\%) showed a decrease in at least one of these measures. CONCLUSION: This fully automated CT muscle tool allows for both individualized and population-based assessment. Such data could be automatically derived at abdominal CT regardless of study indication, allowing for opportunistic sarcopenia detection. ADVANCES IN KNOWLEDGE: This fully automated tool can be applied to routine abdominal CT scans for prospective or retrospective opportunistic sarcopenia assessment, regardless of the original clinical indication. Mean values were significantly higher in males for both muscle area and muscle density. Overall age-related muscle density (attenuation) loss was steeper than for muscle area for both sexes, and therefore may be a more valuable predictor of adverse outcomes.},
  langid = {english},
  pmcid = {PMC6724622},
  pmid = {31199670},
  keywords = {Abdominal Muscles,Cohort Studies,Deep Learning,Female,Humans,Image Interpretation; Computer-Assisted,Longitudinal Studies,Male,Middle Aged,ML,Radiography; Abdominal,Retrospective Studies,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UI54QGUW\\Graffy et al_2019_Deep learning-based muscle segmentation and quantification at abdominal CT.pdf}
}

@article{grotenhuis2698,
  title = {Sarcopenia/{{Muscle Mass}} Is Not a {{Prognostic Factor}} for {{Short-}} and {{Long-Term Outcome After Esophagectomy}} for {{Cancer}}},
  author = {Grotenhuis, Brechtje A. and Shapiro, Jo{\"e}l and {van Adrichem}, Stefan and {de Vries}, Marianne and Koek, Marcel and Wijnhoven, Bas P. L. and {van Lanschot}, J. Jan B.},
  year = {2016},
  month = nov,
  journal = {World Journal of Surgery},
  volume = {40},
  number = {11},
  pages = {2698--2704},
  issn = {1432-2323},
  doi = {10.1007/s00268-016-3603-1},
  abstract = {BACKGROUND: Recent studies have suggested that sarcopenia is a prognostic risk indicator of postoperative complications and predicts survival in cancer patients. The aim of this study is to investigate whether sarcopenia is associated with postoperative short-term outcome (morbidity and mortality) and long-term survival in patients undergoing esophagectomy for cancer after neoadjuvant chemoradiotherapy. METHODS: All patients who underwent neoadjuvant chemoradiotherapy followed by esophagectomy for cancer, and of whom an adequate CT scan was available, were included in the current study. The presence of sarcopenia was defined by CT imaging using cut-off values of the total cross-sectional muscle tissue measured transversely at the third lumbar level. RESULTS: A total number of 120 patients were eligible for analysis. Almost half of the patients (N~=~54, 45~\%) were classified as having sarcopenia; 24 sarcopenic patients (44~\%) had overweight and 5 sarcopenic patients (9~\%) were obese. Overall morbidity and mortality rate did not differ significantly between sarcopenic and non-sarcopenic patients, nor did long-term overall or disease-free survival. Also sarcopenic obesity was not associated with worse outcome. CONCLUSION: The presence of sarcopenia was not associated with a negative short- and long-term outcome in this selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.},
  langid = {english},
  pmcid = {PMC5073118},
  pmid = {27272482},
  keywords = {Adult,Aged,Chemoradiotherapy,Cross-Sectional Studies,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Morbidity,Neoadjuvant Therapy,Overweight,Prognosis,Randomized Controlled Trials as Topic,Risk Factors,Sarcopenia,Tomography; X-Ray Computed,Treatment Outcome,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\42VZJ9UC\\Grotenhuis et al_2016_Sarcopenia-Muscle Mass is not a Prognostic Factor for Short- and Long-Term.pdf}
}

@article{gu3029,
  title = {Prognostic Significance of Combined Pretreatment Body Mass Index ({{BMI}}) and {{BMI}} Loss in Patients with Esophageal Cancer},
  author = {Gu, Wen-Shen and Fang, Wei-Zhen and Liu, Chun-Yue and Pan, Kun-Yi and Ding, Rui and Li, Xiao-Hui and Duan, Chao-Hui},
  year = {2019},
  journal = {Cancer Management and Research},
  volume = {11},
  pages = {3029--3041},
  issn = {1179-1322},
  doi = {10.2147/CMAR.S197820},
  abstract = {Background: Body mass index (BMI) has been associated with a risk of esophageal cancer. However, the influence of BMI and BMI loss on people with esophageal cancer that were treated with different therapies has not been described in China. Methods: In total, 615 consecutive patients that underwent esophagectomy and/or chemotherapy/radiotherapy were classified according to the Asian-specific BMI (kg/m2) cutoff values. The impact of BMI and BMI loss on long-term overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. Results: Multivariate analysis showed that overweight and obese patients had a more favorable survival than normal weight and underweight patients (p=0.017). Patients with a low BMI and high BMI loss before therapy had worse OS than others (p=0.001). Subgroup analysis showed that patients with a high BMI were more likely to suffer hypertension (p{$<$}0.001) and receive only surgery (p{$<$}0.001), and they were less likely to be smokers (p=0.007) and anemic (p{$<$}0.001). Conversely, patients with high BMI loss were more likely to be anemic (p=0.001), to have advanced pathological stage (p=0.012), and to receive chemotherapy and radiotherapy (p=0.001). Moreover, the mortality rate was higher when patients had a high BMI loss. There is no survival benefit of higher BMI in the non-esophageal squamous cell carcinoma (ESCC) group. Conclusion: Pretreatment BMI was an independent prognostic factor for long-term survival in esophageal cancer patients treated with different treatments. The overall survival was increased in esophageal cancer patients with a high pretreatment BMI and no BMI loss. There is no survival benefit of higher BMI in the non-ESCC group.},
  langid = {english},
  pmcid = {PMC6489636},
  pmid = {31114349},
  keywords = {BMI,BMI loss,esophageal cancer,long-term survival},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9XDY788Y\\Gu et al. - 2019 - Prognostic significance of combined pretreatment b.pdf}
}

@article{guerard894,
  title = {Frailty {{Index Developed From}} a {{Cancer-Specific Geriatric Assessment}} and the {{Association With Mortality Among Older Adults With Cancer}}},
  author = {Guerard, Emily J. and Deal, Allison M. and Chang, YunKyung and Williams, Grant R. and Nyrop, Kirsten A. and Pergolotti, Mackenzi and Muss, Hyman B. and Sanoff, Hanna K. and Lund, Jennifer L.},
  year = {2017},
  month = jul,
  journal = {Journal of the National Comprehensive Cancer Network: JNCCN},
  volume = {15},
  number = {7},
  pages = {894--902},
  issn = {1540-1413},
  doi = {10.6004/jnccn.2017.0122},
  abstract = {Background: An objective measure is needed to identify frail older adults with cancer who are at increased risk for poor health outcomes. The primary objective of this study was to develop a frailty index from a cancer-specific geriatric assessment (GA) and evaluate its ability to predict all-cause mortality among older adults with cancer. Patients and Methods: Using a unique and novel data set that brings together GA data with cancer-specific and long-term mortality data, we developed the Carolina Frailty Index (CFI) from a cancer-specific GA based on the principles of deficit accumulation. CFI scores (range, 0-1) were categorized as robust (0-0.2), pre-frail (0.2-0.35), and frail ({$>$}0.35). The primary outcome for evaluating predictive validity was all-cause mortality. The Kaplan-Meier method and log-rank tests were used to compare survival between frailty groups, and Cox proportional hazards regression models were used to evaluate associations. Results: In our sample of 546 older adults with cancer, the median age was 72 years, 72\% were women, 85\% were white, and 47\% had a breast cancer diagnosis. Overall, 58\% of patients were robust, 24\% were pre-frail, and 18\% were frail. The estimated 5-year survival rate was 72\% in robust patients, 58\% in pre-frail patients, and 34\% in frail patients (log-rank test, P{$<$}.0001). Frail patients had more than a 2-fold increased risk of all-cause mortality compared with robust patients (adjusted hazard ratio, 2.36; 95\% CI, 1.51-3.68). Conclusions: The CFI was predictive of all-cause mortality in older adults with cancer, a finding that was independent of age, sex, cancer type and stage, and number of medical comorbidities. The CFI has the potential to become a tool that oncologists can use to objectively identify frailty in older adults with cancer.},
  langid = {english},
  pmid = {28687577},
  keywords = {Aged,Aged; 80 and over,cFI,Comorbidity,Female,Follow-Up Studies,Frail Elderly,Frailty,Geriatric Assessment,Humans,Male,Mortality,Neoplasms,North Carolina,Registries},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QMMXDLY4\\Guerard et al_2017_Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the.pdf}
}

@article{guinan1569,
  type = {Journal {{Article}}},
  title = {Sarcopenia during Neoadjuvant Therapy for Oesophageal Cancer: Characterising the Impact on Muscle Strength and Physical Performance},
  author = {Guinan, E. M. and Doyle, S. L. and Bennett, A. E. and O'Neill, L. and Gannon, J. and Elliott, J. A. and O'Sullivan, J. and Reynolds, J. V. and Hussey, J.},
  year = {2018},
  journal = {Support Care Cancer},
  volume = {26},
  number = {5},
  pages = {1569--1576},
  issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
  doi = {10.1007/s00520-017-3993-0}
}

@article{guo68,
  title = {A Comparative Study of the Therapeutic Effect in Two Protocols: Video-Assisted Thoracic Surgery Combined with Laparoscopy versus Right Open Transthoracic Esophagectomy for Esophageal Cancer Management},
  shorttitle = {A Comparative Study of the Therapeutic Effect in Two Protocols},
  author = {Guo, Ming and Xie, Baiyi and Sun, Xiaoyan and Hu, Meng and Yang, Qingjie and Lei, Yunhong},
  year = {2013},
  month = feb,
  journal = {The Chinese-German Journal of Clinical Oncology},
  volume = {12},
  number = {2},
  pages = {68--71},
  issn = {1613-9089},
  doi = {10.1007/s10330-012-0966-0},
  abstract = {The aim was to evaluate the best intra-thoracoscopic surgery technique between video-assisted thoracic surgery (VATS) combined with laparoscopy and right open transthoracic esophagectomy, in patients with esophageal cancer.},
  langid = {english},
  keywords = {MIE}
}

@article{guralnikM221,
  type = {Journal {{Article}}},
  title = {Lower Extremity Function and Subsequent Disability: Consistency across Studies, Predictive Models, and Value of Gait Speed Alone Compared with the Short Physical Performance Battery},
  author = {Guralnik, J. M. and Ferrucci, L. and Pieper, C. F. and Leveille, S. G. and Markides, K. S. and Ostir, G. V. and Studenski, S. and Berkman, L. F. and Wallace, R. B.},
  year = {2000},
  journal = {J Gerontol A Biol Sci Med Sci},
  volume = {55},
  number = {4},
  pages = {M221-31},
  issn = {1079-5006 (Print) 1079-5006 (Linking)}
}

@article{gurtner1620,
  type = {Journal {{Article}}},
  title = {Two-Team Synchronous Oesophagectomy},
  author = {Gurtner, G. C. and Robertson, C. S. and Chung, S. C. and Li, A. K.},
  year = {1994},
  journal = {Br J Surg},
  volume = {81},
  number = {11},
  pages = {1620--2},
  issn = {0007-1323 (Print) 0007-1323 (Linking)}
}

@article{guttmann1131,
  title = {Improved {{Overall Survival}} with {{Aggressive Primary Tumor Radiotherapy}} for {{Patients}} with {{Metastatic Esophageal Cancer}}},
  author = {Guttmann, David M. and Mitra, Nandita and Bekelman, Justin and Metz, James M. and Plastaras, John and Feng, Weiwei and {Swisher-McClure}, Samuel},
  year = {2017},
  month = jul,
  journal = {Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer},
  volume = {12},
  number = {7},
  pages = {1131--1142},
  issn = {1556-1380},
  doi = {10.1016/j.jtho.2017.03.026},
  abstract = {OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer. METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy ({$<$}5040 cGy), chemotherapy plus definitive dose radiotherapy ({$\geq$}5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score. Potential unmeasured confounding was assessed through sensitivity analyses. RESULTS: The final cohort consisted of 12,683 patients: 57\% were treated with chemotherapy alone, 24\% were treated with chemotherapy plus palliative dose radiotherapy, and 19\% were treated with chemotherapy plus definitive dose radiotherapy. Compared with chemotherapy alone, chemotherapy plus definitive dose radiotherapy was associated with improved survival (median overall survival of 8.3 versus 11.3 months [hazard ratio~= 0.72, 95\% confidence interval: 0.70-0.74, p {$\leq$} 0.001]), whereas chemotherapy plus palliative dose radiotherapy was associated with slightly inferior outcomes (median overall survival of 8.3 months versus 7.5 months (hazard ratio~= 1.10, 95\% confidence interval 1.07-1.13, p {$\leq$} 0.001). These findings were robust to potential unmeasured confounding in sensitivity analyses. Additionally, landmark analyses confirmed these findings in patients surviving 12 months or longer. CONCLUSIONS: Definitive dose, but not conventional palliative dose, PTDRT is associated with improved overall survival in metastatic esophageal cancer, suggesting that local control may be important to prognosis. These findings support integrating PTDRT into future clinical trials aimed at refining personalized treatment for patients with metastatic esophageal cancer.},
  langid = {english},
  pmid = {28461255},
  keywords = {Aged,Aged; 80 and over,Cohort Studies,Esophageal neoplasms,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoplasm metastasis,Neoplasm Metastasis,Palliative care,Radiation,Radiotherapy,Survival Analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GJ9E6HED\\Guttmann et al. - 2017 - Improved Overall Survival with Aggressive Primary .pdf}
}

@article{haidry87,
  title = {Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the {{UK National Halo RFA Registry}}},
  shorttitle = {Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma},
  author = {Haidry, Rehan J. and Dunn, Jason M. and Butt, Mohammed A. and Burnell, Matthew G. and Gupta, Abhinav and Green, Sarah and Miah, Haroon and Smart, Howard L. and Bhandari, Pradeep and Smith, Lesley Ann and Willert, Robert and Fullarton, Grant and Morris, John and Di Pietro, Massimo and Gordon, Charles and Penman, Ian and Barr, Hugh and Patel, Praful and Boger, Philip and Kapoor, Neel and Mahon, Brinder and Hoare, Jonathon and Narayanasamy, Ravi and O'Toole, Dermot and Cheong, Edward and Direkze, Natalie C. and Ang, Yeng and Novelli, Marco and Banks, Matthew R. and Lovat, Laurence Bruce},
  year = {2013},
  month = jul,
  journal = {Gastroenterology},
  volume = {145},
  number = {1},
  pages = {87--95},
  issn = {1528-0012},
  doi = {10.1053/j.gastro.2013.03.045},
  abstract = {BACKGROUND \& AIMS: Patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) or early neoplasia increasingly receive endoscopic mucosal resection and radiofrequency ablation (RFA) therapy. We analyzed data from a UK registry that follows the outcomes of patients with BE who have undergone RFA for neoplasia. METHODS: We collected data on 335 patients with BE and neoplasia (72\% with HGD, 24\% with intramucosal cancer, 4\% with low-grade dysplasia [mean age, 69 years; 81\% male]), treated at 19 centers in the United Kingdom from July 2008 through August 2012. Mean length of BE segments was 5.8 cm (range, 1-20 cm). Patients' nodules were removed by endoscopic mucosal resection, and the patients then underwent RFA every 3 months until all areas of BE were ablated or cancer developed. Biopsies were collected 12 months after the first RFA; clearance of HGD, dysplasia, and BE were assessed. RESULTS: HGD was cleared from 86\% of patients, all dysplasia from 81\%, and BE from 62\% at the 12-month time point, after a mean of 2.5 (range, 2-6) RFA procedures. Complete reversal dysplasia was 15\% less likely for every 1-cm increment in BE length (odds ratio~= 1.156; SE~= 0.048; 95\% confidence interval: 1.07-1.26; P {$<$} .001). Endoscopic mucosal resection before RFA did not provide any benefit. Invasive cancer developed in 10 patients (3\%) by the 12-month time point and disease had progressed in 17 patients (5.1\%) after a median follow-up time of 19 months. Symptomatic strictures developed in 9\% of patients and were treated by endoscopic dilatation. Nineteen months after therapy began, 94\% of patients remained clear of dysplasia. CONCLUSIONS: We analyzed data from a large series of patients in the United Kingdom who underwent RFA for BE-related neoplasia and found that by 12 months after treatment, dysplasia was cleared from 81\%. Shorter segments of BE respond better to RFA; http://www.controlled-trials.com, number ISRCTN93069556.},
  langid = {english},
  pmid = {23542069},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Barrett Esophagus,Catheter Ablation,Disease Progression,Esophageal Neoplasms,Esophagoscopy,Female,Humans,Male,Middle Aged,Mucous Membrane,Neoplasm Staging,Registries,Treatment Outcome}
}

@article{haisleye162743,
  type = {Journal {{Article}}},
  title = {Association of {{Intervals Between Neoadjuvant Chemoradiation}} and {{Surgical Resection With Pathologic Complete Response}} and {{Survival}} in {{Patients With Esophageal Cancer}}},
  author = {Haisley, K. R. and Laird, A. E. and Nabavizadeh, N. and Gatter, K. M. and Holland, J. M. and Vaccaro, G. M. and Thomas, C. R., Jr. and Schipper, P. H. and Hunter, J. G. and Dolan, J. P.},
  year = {2016},
  journal = {JAMA Surg},
  volume = {151},
  number = {11},
  pages = {e162743},
  issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
  doi = {10.1001/jamasurg.2016.2743}
}

@article{hall970,
  title = {Transfusion {{Threshold Trials}}: {{The Need}} to {{Establish}} a {{Clear Difference}} in {{Transfusion Practice}} between {{Study Groups}}},
  shorttitle = {Transfusion {{Threshold Trials}}},
  author = {Hall, Suzanne M. and Desborough, Michael J.},
  year = {2015},
  month = oct,
  journal = {Anesthesiology},
  volume = {123},
  number = {4},
  pages = {970--971},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000802},
  langid = {english},
  pmid = {26372130},
  keywords = {Abdominal Neoplasms,Erythrocyte Transfusion,Female,Humans,Male,SurgOnc}
}

@article{hallet205,
  title = {The Impact of Perioperative Iron on the Use of Red Blood Cell Transfusions in Gastrointestinal Surgery: A Systematic Review and Meta-Analysis},
  shorttitle = {The Impact of Perioperative Iron on the Use of Red Blood Cell Transfusions in Gastrointestinal Surgery},
  author = {Hallet, Julie and Hanif, Asad and Callum, Jeannie and Pronina, Ioulia and Wallace, David and Yohanathan, Lavanya and McLeod, Robin and Coburn, Natalie},
  year = {2014},
  month = oct,
  journal = {Transfusion Medicine Reviews},
  volume = {28},
  number = {4},
  pages = {205--211},
  issn = {1532-9496},
  doi = {10.1016/j.tmrv.2014.05.004},
  abstract = {Perioperative anemia is common, yet detrimental, in surgical patients. However, red blood cell transfusions (RBCTs) used to treat anemia are associated with significant postoperative risks and worse oncologic outcomes. Perioperative iron has been suggested to mitigate perioperative anemia. This meta-analysis examined the impact of perioperative iron compared to no intervention on the need for RBCT in gastrointestinal surgery. We systematically searched Medline, Embase, Web of Science, Cochrane Central, and Scopus to identify relevant randomized controlled trials (RCTs) and nonrandomized studies (NRSs). We excluded studies investigating autologous RBCT or erythropoietin. Two independent reviewers selected the studies, extracted data, and assessed the risk of bias using the Cochrane tool and Newcastle-Ottawa scale. Primary outcomes were proportion of patients getting allogeneic RBCT and number of transfused patient. Secondary outcomes were hemoglobin change, 30-day postoperative morbidity and mortality, length of stay, and oncologic outcomes. A meta-analysis using random effects models was performed. The review was registered in PROSPERO (CRD42013004805). From 883 citations, we included 2 RCTs and 2 NRSs (n = 325 patients), all pertaining to colorectal cancer surgery. Randomized controlled trials were at high risk for bias and underpowered. One RCT and 1 NRS using preoperative oral iron reported a decreased proportion of patients needing RBCT. One RCT on preoperative intravenous iron and 1 NRS on postoperative PO iron did not observe a difference. Only 1 study revealed a difference in number of transfused patients. One RCT reported significantly increased postintervention hemoglobin. Among 3 studies reporting length of stay, none observed a difference. Other secondary outcomes were not reported. Meta-analysis revealed a trend toward fewer patients requiring RBCT with iron supplementation (risk ratio, 0.66 [0.42, 1.02]), but no benefit on the number of RBCT per patient (weighted mean difference, -0.91 [-1.61, -0.18]). Although preliminary evidence suggests that it may be a promising strategy, there is insufficient evidence to support the routine use of perioperative iron to decrease the need for RBCT in colorectal cancer surgery. Well-designed RCTs focusing on the need for RBCT and including long-term outcomes are warranted.},
  langid = {english},
  pmid = {24997001},
  keywords = {Anemia,Colorectal cancer,Erythrocyte Transfusion,Erythrocytes,Female,Gastrointestinal Tract,Hemoglobins,Humans,Iron,Male,Observational Studies as Topic,Perioperative,Perioperative Period,Randomized Controlled Trials as Topic,Surgery,Transfusion,Transplantation; Homologous,Treatment Outcome}
}

@article{hanna521,
  type = {Journal {{Article}}},
  title = {Minimally Invasive Esophagectomy in the Community Hospital Setting},
  author = {Hanna, E. M. and Norton, H. J. and Reames, M. K. and Salo, J. C.},
  year = {2011},
  journal = {Surg Oncol Clin N Am},
  volume = {20},
  number = {3},
  pages = {521--30, ix},
  issn = {1558-5042 (Electronic) 1055-3207 (Linking)},
  doi = {10.1016/j.soc.2011.01.009}
}

@article{harada7,
  title = {Prognostic and Clinical Impact of Sarcopenia in Esophageal Squamous Cell Carcinoma},
  author = {Harada, K and Ida, S and Baba, Y and Ishimoto, T and Kosumi, K and Tokunaga, R and Izumi, D and Ohuchi, M and Nakamura, K and Kiyozumi, Y and Imamura, Y and Iwatsuki, M and Iwagami, S and Miyamoto, Y and Sakamoto, Y and Yoshida, N and Watanabe, M and Baba, H},
  year = {2015},
  pages = {7},
  abstract = {Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor prognosis in several types of cancers, but has not been investigated in esophageal squamous cell carcinoma (ESCC). This retrospective study investigates the relationship between sarcopenia and clinical outcome in ESCC patients treated by surgical resection or definitive chemoradiation therapy (dCRT). The study was retrospectively conducted in a single academic hospital in Kumamoto, Japan, and involved 325 ESCC patients (256 surgical cases and 69 dCRT cases) treated between April 2005 and April 2011. Skeletal muscle mass was quantified by radiologic measures using standard computed tomography scans. The skeletal muscle tissue in the 325 ESCC patients was distributed as follows: mean: 47.10; median: 46.88; standard deviation (SD): 7.39; range: 31.48\textendash 71.11; interquartile range, 46.29\textendash 47.90. Skeletal muscle tissue was greater in male patients than in female patients (P {$<$} 0.0001), but was independent of other clinical and tumor features. Sarcopenia was not significantly associated with overall survival (log rank P = 0.54). Lymph node involvement significantly altered the relationship between sarcopenia and survival rate (P for interaction = 0.026). Sarcopenia significantly reduced the overall survival of patients without lymph node involvement (log rank P = 0.035), but was uncorrelated with overall survival in patients with lymph involvement (log rank, P = 0.31). The anastomosis leakage rate was significantly higher in the sarcopenia group than in the non-sarcopenia group (P = 0.032), but other surgical complications did not significantly differ between the two groups. Sarcopenia in ESCC patients without lymph node involvement is associated with poor prognosis, indicating sarcopenia as a potential biomarker for identifying patients likely to experience an inferior outcome. Moreover, sarcopenia was associated with anastomosis leakage but no other short-term surgical outcome.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VLT29CWL\\Harada et al. - 2015 - Prognostic and clinical impact of sarcopenia in es.pdf}
}

@article{hardacker3739,
  title = {Treatment of Clinical {{T2N0M0}} Esophageal Cancer},
  author = {Hardacker, Thomas J. and Ceppa, DuyKhanh and Okereke, Ikenna and Rieger, Karen M. and Jalal, Shadia I. and LeBlanc, Julia K. and DeWitt, John M. and Kesler, Kenneth A. and Birdas, Thomas J.},
  year = {2014},
  month = nov,
  journal = {Annals of Surgical Oncology},
  volume = {21},
  number = {12},
  pages = {3739--3743},
  issn = {1534-4681},
  doi = {10.1245/s10434-014-3929-6},
  abstract = {BACKGROUND: Management of clinical T2N0M0 (cT2N0M0) esophageal cancer remains controversial. We reviewed our institutional experience over 21~years (1990-2011) to determine clinical staging accuracy, optimal treatment approaches, and factors predictive of survival in this patient population. METHODS: Patients with cT2N0M0 esophageal cancer determined by endoscopic ultrasound (EUS) were identified through a prospectively collected database. Demographics, perioperative data, and outcomes were examined. Cox regression model and Kaplan-Meier plots were used for statistical survival analysis. RESULTS: A total of 731 patients underwent esophagectomy, of whom 68 cT2N0M0 patients (9~\%) were identified. Fifty-seven patients (84~\%) had adenocarcinoma. Thirty-three patients (48.5~\%) were treated with neoadjuvant chemoradiation followed by surgery, and 35 underwent surgical resection alone. All resections except one included a transthoracic approach with two-field lymph node dissection. Thirty-day operative mortality was 2.9~\%. Only 3 patients (8.5~\%) who underwent surgery alone had T2N0M0 disease identified by pathology: the disease of 15 (42.8~\%) was found to be overstaged and 17 (48.5~\%) understaged after surgery. Understaging was more common in poorly differentiated tumors (p~=~0.03). Nine patients (27.2~\%) had complete pathologic response after chemoradiotherapy. Absence of lymph node metastases (pN0) was significantly more frequent in the neoadjuvant group (29 of 33 vs. 21 of 35, p~=~0.01). Median follow-up was 44.2~months. Overall 5-year survival was 50.8~\%. On multivariate analysis, adenocarcinoma (p~=~0.001) and pN0 after resection (p~=~0.01) were significant predictors of survival. CONCLUSIONS: EUS was inaccurate in staging cT2N0M0 esophageal cancer in this study. Poorly differentiated tumors were more frequently understaged. Adenocarcinoma and absence of lymph node metastases (pN0) were independently predictive of long-term survival. pN0 status was significantly more common in patients undergoing neoadjuvant therapy, but long-term survival was not affected by neoadjuvant therapy. A strategy of neoadjuvant therapy followed by resection may be optimal in this group, especially in patients with disease likely to be understaged.},
  langid = {english},
  pmid = {25047477},
  keywords = {Adenocarcinoma,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Combined Modality Therapy,Endosonography,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Lymph Node Excision,Lymphatic Metastasis,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Prognosis,Prospective Studies,Radiotherapy,Survival Rate}
}

@article{hardiman1302,
  type = {Journal {{Article}}},
  title = {Patient Autonomy-Centered Self-Care Checklist Reduces Hospital Readmissions after Ileostomy Creation},
  author = {Hardiman, K. M. and Reames, C. D. and McLeod, M. C. and Regenbogen, S. E.},
  year = {2016},
  journal = {Surgery},
  volume = {160},
  number = {5},
  pages = {1302--1308},
  issn = {1532-7361 (Electronic) 0039-6060 (Linking)},
  doi = {10.1016/j.surg.2016.05.007}
}

@article{harrell361,
  title = {Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors},
  shorttitle = {Multivariable Prognostic Models},
  author = {Harrell, F. E. and Lee, K. L. and Mark, D. B.},
  year = {1996},
  month = feb,
  journal = {Statistics in Medicine},
  volume = {15},
  number = {4},
  pages = {361--387},
  issn = {0277-6715},
  doi = {10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4},
  abstract = {Multivariable regression models are powerful tools that are used frequently in studies of clinical outcomes. These models can use a mixture of categorical and continuous variables and can handle partially observed (censored) responses. However, uncritical application of modelling techniques can result in models that poorly fit the dataset at hand, or, even more likely, inaccurately predict outcomes on new subjects. One must know how to measure qualities of a model's fit in order to avoid poorly fitted or overfitted models. Measurement of predictive accuracy can be difficult for survival time data in the presence of censoring. We discuss an easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities. Both types of predictive accuracy should be unbiasedly validated using bootstrapping or cross-validation, before using predictions in a new data series. We discuss some of the hazards of poorly fitted and overfitted regression models and present one modelling strategy that avoids many of the problems discussed. The methods described are applicable to all regression models, but are particularly needed for binary, ordinal, and time-to-event outcomes. Methods are illustrated with a survival analysis in prostate cancer using Cox regression.},
  langid = {english},
  pmid = {8668867},
  keywords = {C-statistic,Clinical Trials as Topic,Computer Graphics,Computer Simulation,Data Interpretation; Statistical,Discriminant Analysis,Humans,Linear Models,Male,Mathematical Computing,Models; Statistical,Multivariate Analysis,Prostatic Neoplasms,Regression Analysis,Software,Survival Analysis,Treatment Outcome}
}

@article{harris377,
  type = {Journal {{Article}}},
  title = {Research Electronic Data Capture ({{REDCap}})\textendash a Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support},
  author = {Harris, P. A. and Taylor, R. and Thielke, R. and Payne, J. and Gonzalez, N. and Conde, J. G.},
  year = {2009},
  journal = {J Biomed Inform},
  volume = {42},
  number = {2},
  pages = {377--81},
  issn = {1532-0480 (Electronic) 1532-0464 (Linking)},
  doi = {10.1016/j.jbi.2008.08.010}
}

@article{harter2525,
  type = {Journal {{Article}}},
  title = {Nutritional and Functional Factors as Prognostic of Surgical Cancer Patients},
  author = {Harter, J. and Orlandi, S. P. and Gonzalez, M. C.},
  year = {2017},
  journal = {Support Care Cancer},
  volume = {25},
  number = {8},
  pages = {2525--2530},
  issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
  doi = {10.1007/s00520-017-3661-4}
}

@article{hategan612,
  title = {Trimodality Therapy and Definitive Chemoradiotherapy for Esophageal Cancer: A Single-Center Experience and Review of the Literature},
  shorttitle = {Trimodality Therapy and Definitive Chemoradiotherapy for Esophageal Cancer},
  author = {Hategan, M. and Cook, N. and Prewett, S. and Hindmarsh, A. and Qian, W. and Gilligan, D.},
  year = {2015},
  month = oct,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {28},
  number = {7},
  pages = {612--618},
  issn = {1442-2050},
  doi = {10.1111/dote.12242},
  abstract = {In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups. Chemoradiotherapy followed by surgery (trimodality therapy) has not been widely adopted. The outcomes of patients undergoing dCRT or trimodality therapy at our cancer center between 2004 and 2012 were restrospectively analyzed. Trimodality therapy was offered to selected patients of good performance status (World Health Organisation performance status 0/1), with squamous cell carcinoma or bulky adenocarcinoma. dCRT was offered to patients of good PS but with comorbidities, upper third tumors or at patient's request. Patients received four cycles of chemotherapy with a platinum agent (mostly cisplatin) and a fluoropyrimidine (mostly 5-fluorouracil) over a total of 11 weeks. Cycles 3 and 4 were given concurrently with radiotherapy: 50 Gy in 25 fractions for dCRT and 45 Gy in 25 fractions in the trimodality group. Surgery occurred 8-10 weeks following the completion of chemoradiotherapy. The cut-off length for maximum gross tumor volume length was 10 cm. One hundred two patients were included (47 received dCRT, and 55 received trimodality treatment). The majority of tumors were stage III (80.4\%), and two-thirds were located in the distal esophagus (64.7\%). Median follow-up was 44 months. The 2-year overall survival (OS) was 57.3\% (median OS 39.7 months) for the dCRT group and 77.8\% (median not reached) for the trimodality group. The 5-year OS rates were 38\% and 58\%, respectively. Postoperative mortality rate was low at 1.8\%, and the pathological complete response rate was 23.6\%. In conclusion, trimodality treatment for patients with esophageal and junctional gastroesophageal tumors offers high rates of 2-year survival, and the potential for long-term cure. dCRT is an established alternative for patients that are not fit or suitable for surgery.},
  langid = {english},
  pmid = {24863560},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Agents,Antineoplastic Protocols,Carcinoma; Adenosquamous,Carcinoma; Squamous Cell,Chemoradiotherapy,chemotherapy,Chemotherapy; Adjuvant,Cisplatin,Combined Modality Therapy,England,esophageal cancer,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Fluorouracil,Humans,Male,Middle Aged,Neoplasm Staging,Patient Selection,radiotherapy,Remission Induction,Retrospective Studies,surgery,Survival Rate,Treatment Outcome,trimodality therapy}
}

@article{hayashi6,
  title = {Low Skeletal Muscle Density Is Associated with Poor Survival in Patients Who Receive Chemotherapy for Metastatic Gastric Cancer},
  author = {Hayashi, Naomi and Ando, Yuichi and Gyawali, Bishal and Shimokata, Tomoya and Maeda, Osamu and Fukaya, Masahide and Goto, Hidemi and Nagino, Masato and Kodera, Yasuhiro},
  year = {2016},
  journal = {ONCOLOGY REPORTS},
  pages = {6},
  abstract = {Low skeletal muscle density (SMD) and low skeletal muscle index (SMI) are associated with poor overall survival (OS) in patients with various types of cancer. We retrospectively studied SMD and SMI using computed tomographic (CT) scans in patients with gastric cancer receiving chemotherapy to evaluate its prognostic significance. SMD and SMI were obtained from CT-based analysis using Slice-O-Matic\textregistered{} medical imaging software in patients who received S-1 plus cisplatin chemotherapy for metastatic gastric cancer. The CT images taken within 1 month before starting chemotherapy were used. The cut-off values for determining low SMD [{$<$}33 Hounsfield units (HU) in obese and {$<$}41 HU in non-obese patients] and low SMI ({$<$}41 cm2/m2 in females, {$<$}43 cm2/m2 in non-obese males and {$<$}53 cm2/m2 in obese males) were referenced from a large population based study. The CT images of 53 patients were reviewed. The median SMD was 36.8 HU (range, 19.5-59.3 HU), and the median SMI was 39.8 cm2/m2 (range, 23.7-60.0 cm2/m2). Patients with low SMD had significantly shorter OS compared with patients having normal SMD (8.9 vs. 12.8 months, P=0.03). However, OS did not differ significantly between patients with low and normal SMI (11.1 and 14.3 months, P= 0.18). Multivariate analyses confirmed that low SMD was an independent predictor of poor outcomes (P{$<$}0.01). SMD is an important prognosticator of survival in patients with metastatic gastric cancer receiving chemotherapy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\67BG8IY8\\Hayashi et al. - 2016 - Low skeletal muscle density is associated with poo.pdf}
}

@article{hayes95,
  type = {Journal {{Article}}},
  title = {Comparison of Conventional {{Lewis-Tanner}} Two-Stage Oesophagectomy with the Synchronous Two-Team Approach},
  author = {Hayes, N. and Shaw, I. H. and Raimes, S. A. and Griffin, S. M.},
  year = {1995},
  journal = {Br J Surg},
  volume = {82},
  number = {1},
  pages = {95--7},
  issn = {0007-1323 (Print) 0007-1323 (Linking)}
}

@article{he794969,
  title = {Three-{{Dimensional Liver Image Segmentation Using Generative Adversarial Networks Based}} on {{Feature Restoration}}},
  author = {He, Runnan and Xu, Shiqi and Liu, Yashu and Li, Qince and Liu, Yang and Zhao, Na and Yuan, Yongfeng and Zhang, Henggui},
  year = {2021},
  journal = {Frontiers in Medicine},
  volume = {8},
  pages = {794969},
  issn = {2296-858X},
  doi = {10.3389/fmed.2021.794969},
  abstract = {Medical imaging provides a powerful tool for medical diagnosis. In the process of computer-aided diagnosis and treatment of liver cancer based on medical imaging, accurate segmentation of liver region from abdominal CT images is an important step. However, due to defects of liver tissue and limitations of CT imaging procession, the gray level of liver region in CT image is heterogeneous, and the boundary between the liver and those of adjacent tissues and organs is blurred, which makes the liver segmentation an extremely difficult task. In this study, aiming at solving the problem of low segmentation accuracy of the original 3D U-Net network, an improved network based on the three-dimensional (3D) U-Net, is proposed. Moreover, in order to solve the problem of insufficient training data caused by the difficulty of acquiring labeled 3D data, an improved 3D U-Net network is embedded into the framework of generative adversarial networks (GAN), which establishes a semi-supervised 3D liver segmentation optimization algorithm. Finally, considering the problem of poor quality of 3D abdominal fake images generated by utilizing random noise as input, deep convolutional neural networks (DCNN) based on feature restoration method is designed to generate more realistic fake images. By testing the proposed algorithm on the LiTS-2017 and KiTS19 dataset, experimental results show that the proposed semi-supervised 3D liver segmentation method can greatly improve the segmentation performance of liver, with a Dice score of 0.9424 outperforming other methods.},
  langid = {english},
  pmcid = {PMC8777029},
  pmid = {35071275},
  keywords = {3D segmentation of liver,CT image,feature restoration,generative adversarial networks,ML,semi-supervised},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WCIBD8AV\\He et al_2021_Three-Dimensional Liver Image Segmentation Using Generative Adversarial.pdf}
}

@article{heald1479,
  title = {Recurrence and Survival after Total Mesorectal Excision for Rectal Cancer},
  author = {Heald, R. J. and Ryall, R. D.},
  year = {1986},
  month = jun,
  journal = {Lancet (London, England)},
  volume = {1},
  number = {8496},
  pages = {1479--1482},
  issn = {0140-6736},
  doi = {10.1016/s0140-6736(86)91510-2},
  abstract = {A 7 1/2-year consecutive series is presented from a district hospital with a policy of referring all rectal carcinomas to one surgical firm. The performance of lower anterior resections has limited the rate of abdominoperineal excision with permanent colostomy to 11\%. Of 115 patients in whom curative resection was attempted, 69 had anastomoses below 5 cm and 39 had mural resection margins of less than 2.5 cm. Surgical priority, however, was given to complete excision of the visceral rectal mesentery or mesorectum. At an average of 4.2 years postoperatively, three pelvic recurrences have developed but there have been no staple-line recurrences in patients who had "curative" surgery. The corrected cumulative probability of survival at 5 years is 87\% and the tumour-free survival by Dukes stage is A 94\%, B 87\%, and C 58\%. Patients with low tumours did no less well than those with high tumours, when treated by anterior resection. On this evidence, it is often safe to limit mural clearance and thus preserve the anal sphincters, provided that the mesorectum is excised intact with the cancer.},
  langid = {english},
  pmid = {2425199},
  keywords = {Follow-Up Studies,Humans,Methods,Neoplasm Recurrence; Local,Neoplasm Staging,Palliative Care,Postoperative Complications,Rectal Neoplasms,Rectal; TME,Rectum,Surgical Staplers}
}

@article{hemke387,
  title = {Deep Learning for Automated Segmentation of Pelvic Muscles, Fat, and Bone from {{CT}} Studies for Body Composition Assessment},
  author = {Hemke, Robert and Buckless, Colleen G. and Tsao, Andrew and Wang, Benjamin and Torriani, Martin},
  year = {2020},
  month = mar,
  journal = {Skeletal Radiology},
  volume = {49},
  number = {3},
  pages = {387--395},
  issn = {1432-2161},
  doi = {10.1007/s00256-019-03289-8},
  abstract = {OBJECTIVE: To develop a deep convolutional neural network (CNN) to automatically segment an axial CT image of the pelvis for body composition measures. We hypothesized that a deep CNN approach would achieve high accuracy when compared to manual segmentations as the reference standard. MATERIALS AND METHODS: We manually segmented 200 axial CT images at the supra-acetabular level in 200 subjects, labeling background, subcutaneous adipose tissue (SAT), muscle, inter-muscular adipose tissue (IMAT), bone, and miscellaneous intra-pelvic content. The dataset was randomly divided into training (180/200) and test (20/200) datasets. Data augmentation was utilized to enlarge the training dataset and all images underwent preprocessing with histogram equalization. Our model was trained for 50 epochs using the U-Net architecture with batch size of 8, learning rate of 0.0001, Adadelta optimizer and a dropout of 0.20. The Dice (F1) score was used to assess similarity between the manual segmentations and the CNN predicted segmentations. RESULTS: The CNN model with data augmentation of N\,=\,3000 achieved accurate segmentation of body composition for all classes. The Dice scores were as follows: background (1.00), miscellaneous intra-pelvic content (0.98), SAT (0.97), muscle (0.95), IMAT (0.91), and bone (0.92). Mean time to automatically segment one CT image was 0.07~s (GPU) and 2.51~s (CPU). CONCLUSIONS: Our CNN-based model enables accurate automated segmentation of multiple tissues on pelvic CT images, with promising implications for body composition studies.},
  langid = {english},
  pmcid = {PMC6980503},
  pmid = {31396667},
  keywords = {Adipose Tissue,Body composition,Body Composition,Computed tomography,Contrast Media,Datasets as Topic,Deep learning,Female,Humans,Male,Middle Aged,ML,Muscle,Muscle; Skeletal,Neural Networks; Computer,Pelvis,Retrospective Studies,Segmentation,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\34DISEU8\\Hemke et al_2020_Deep learning for automated segmentation of pelvic muscles, fat, and bone from.pdf}
}

@article{heneghan8,
  title = {Can {{CT-PET}} and {{Endoscopic Assessment PostNeoadjuvant Chemoradiotherapy Predict Residual Disease}} in {{Esophageal Cancer}}?},
  author = {Heneghan, Helen M and Donohoe, Claire and Elliot, Jessie and Ahmed, Zuhair and Malik, Vinod and Ravi, Narayamasamy and Reynolds, John V},
  year = {2016},
  journal = {Annals of Surgery},
  volume = {264},
  number = {5},
  pages = {8},
  abstract = {Objective: The aim of this study is to assess CT-PET and endoscopic assessment postneoadjuvant chemoradiotherapy (nCRT) in predicting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC). Design: A prospective cohort study. Background: nCRT is increasingly standard of care in LAEC, with pCR a surrogate for excellent outcome. Predicting pCR before surgery, with metabolic imaging and endoscopy, may spare patients' operative intervention. Methods: One hundred thirty-eight consecutive patients [mean age 61 \AE{} 8, 99 male (72\%), 103 (75\%) adenocarcinoma] underwent nCRT with CT-PET and endoscopy 4 to 6 weeks later, and surgery subsequently. A complete metabolic response (cMR) was defined as SUVmax of {$<$}4. A complete endoscopic response (cER) was no residual mucosal abnormality. The association of pCR with cMR and cER was analyzed. Results: pCR was achieved in 30 patients (22\%); 37\% SCC and 17\% adenocarcinoma. A cMR was evident in 63 (46\%), of whom 17 (27\%) had a pCR and 17(27\%) were ypN\th. A cER was observed in 45 (33\%). The Spearman correlation for cER and cMR was 0.066 (P {$\frac{1}{4}$} 0.479), for cER and pCR was 0.004 (P {$\frac{1}{4}$} 0.969), and cMR and pCR \textendash 0.120 (P {$\frac{1}{4}$} 0.160). The sensitivity, specificity, positive predictive value, and negative predictive value of cMR was 57\%, 57\%, 27\%, and 82\%, respectively, and for combined cMR and cER was 24\%, 83\%, 28\%, and 79\%, respectively. Conclusions: The prediction of pCR through CT-PET and endoscopy independently or combined is limited by low sensitivity and poor positive predictive value. Protocols to avoid surgery in patients with apparent complete clinical complete based on these criteria should be adopted with considerable caution.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5428HY6V\\Heneghan et al. - 2016 - Can CT-PET and Endoscopic Assessment PostNeoadjuva.pdf}
}

@article{hershman313,
  title = {Delay of Adjuvant Chemotherapy Initiation Following Breast Cancer Surgery among Elderly Women},
  author = {Hershman, Dawn L. and Wang, Xiaoyan and McBride, Russell and Jacobson, Judith S. and Grann, Victor R. and Neugut, Alfred I.},
  year = {2006},
  month = oct,
  journal = {Breast Cancer Research and Treatment},
  volume = {99},
  number = {3},
  pages = {313--321},
  issn = {0167-6806},
  doi = {10.1007/s10549-006-9206-z},
  abstract = {BACKGROUND: Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood. METHODS: To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. Among women {$>$} or = 65 years diagnosed between 1992 and 1999 with stages I-II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival. RESULTS: Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47\% initiated chemotherapy within 1 month, 37\% between 1 and 2 months, 6\% between 2 and 3 months and 10\% {$>$}3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95\% CI 1.31-2.19) and overall mortality (HR 1.46; 95\% CI 1.21-1.75). CONCLUSIONS: Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays ({$>$}3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.},
  langid = {english},
  pmid = {16583264},
  keywords = {Age Factors,Aged,Aged; 80 and over,Antineoplastic Agents,Breast Neoplasms,Chemotherapy; Adjuvant,DoseIntensity,Drug Administration Schedule,Evaluation Studies as Topic,Female,Humans,Kaplan-Meier Estimate,Linear Models,Medicare,Prognosis,Proportional Hazards Models,Risk Factors,SEER Program,Time Factors,United States}
}

@article{hibbard1918,
  type = {Journal {{Article}}},
  title = {Development and Testing of a Short Form of the Patient Activation Measure},
  author = {Hibbard, J. H. and Mahoney, E. R. and Stockard, J. and Tusler, M.},
  year = {2005},
  journal = {Health Serv Res},
  volume = {40},
  number = {6 Pt 1},
  pages = {1918--30},
  issn = {0017-9124 (Print) 0017-9124 (Linking)},
  doi = {10.1111/j.1475-6773.2005.00438.x}
}

@article{hibbard207,
  type = {Journal {{Article}}},
  title = {What the Evidence Shows about Patient Activation: Better Health Outcomes and Care Experiences; Fewer Data on Costs},
  author = {Hibbard, J. H. and Greene, J.},
  year = {2013},
  journal = {Health Aff (Millwood)},
  volume = {32},
  number = {2},
  pages = {207--14},
  issn = {1544-5208 (Electronic) 0278-2715 (Linking)},
  doi = {10.1377/hlthaff.2012.1061}
}

@article{hoeppner503,
  title = {{{ESOPEC}}: Prospective Randomized Controlled Multicenter Phase {{III}} Trial Comparing Perioperative Chemotherapy ({{FLOT}} Protocol) to Neoadjuvant Chemoradiation ({{CROSS}} Protocol) in Patients with Adenocarcinoma of the Esophagus ({{NCT02509286}})},
  shorttitle = {{{ESOPEC}}},
  author = {Hoeppner, Jens and Lordick, Florian and Brunner, Thomas and Glatz, Torben and Bronsert, Peter and R{\"o}thling, Nadine and Schmoor, Claudia and Lorenz, Dietmar and Ell, Christian and Hopt, Ulrich T. and Siewert, J. R{\"u}diger},
  year = {2016},
  month = jul,
  journal = {BMC cancer},
  volume = {16},
  pages = {503},
  issn = {1471-2407},
  doi = {10.1186/s12885-016-2564-y},
  abstract = {BACKGROUND: Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of neoadjuvant chemoradiation and perioperative chemotherapy applying contemporary treatment protocols are lacking. The present trial was initiated to obtain valid information whether neoadjuvant chemoradiation or perioperative chemotherapy yields better survival in the treatment of localized esophageal adenocarcinoma. METHODS/DESIGN: The ESOPEC trial is an investigator-initiated multicenter prospective randomized controlled two-arm trial, comparing the efficacy of neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery versus perioperative chemotherapy and surgery (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) for the curative treatment of localized esophageal adenocarcinoma. Patients with cT1cN\,+\,cM0 and cT2-4acNxcM0 esophageal and junctional adenocarcinoma are eligible. The trial aims to include 438 participants who are centrally randomized to one of the two treatment groups in a 1:1 ratio stratified by N-stage and study site. The primary endpoint of the trial is overall survival assessed with a minimum follow-up of 36~months. Secondary objectives are progression-free survival, recurrence-free survival, site of failure, postoperative morbidity and mortality, duration of hospitalization as well as quality of life. DISCUSSION: The ESOPEC trial compares perioperative chemotherapy according to the FLOT protocol to neoadjuvant chemoradiation according to the CROSS protocol in multimodal treatment of non-metastasized recectable adenocarcinoma of the esophagus and the gastroesophageal junction. The goal of the trial is identify the superior protocol with regard to patient survival, treatment morbidity and quality of life. TRIAL REGISTRATION: NCT02509286 (July 22, 2015).},
  langid = {english},
  pmcid = {PMC4952147},
  pmid = {27435280},
  keywords = {Adenocarcinoma,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy,Disease-Free Survival,Drug Therapy,Esophageal cancer,Esophageal Neoplasms,Esophagus,Female,Humans,Male,Middle Aged,Neoadjuvant chemoradiation,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Perioperative chemotherapy,Prospective Studies,Quality of Life,Radiotherapy,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WEA45JGV\\Hoeppner et al. - 2016 - ESOPEC prospective randomized controlled multicen.pdf}
}

@article{hollis1114,
  title = {Prognostic Significance of Tumor Length in Patients Receiving Esophagectomy for Esophageal Cancer},
  author = {Hollis, Alexander C. and Quinn, Lauren M. and Hodson, James and Evans, Emily and Plowright, James and Begum, Ruksana and Mitchell, Harriet and Hallissey, Mike T. and Whiting, John L. and Griffiths, Ewen A.},
  year = {2017},
  month = dec,
  journal = {Journal of Surgical Oncology},
  volume = {116},
  number = {8},
  pages = {1114--1122},
  issn = {1096-9098},
  doi = {10.1002/jso.24789},
  abstract = {AIMS: We investigated the prognostic value of tumor length measurements acquired both from pre-operative imaging and post-operative pathology in esophageal cancer. METHODS: Tumor lengths were examined retrospectively for 389 esophagectomy patients with respect to Endoscopy, EUS (Endoscopic Ultrasound), CT and PET-CT, and pathology. Correlations between the measurements on the different approaches were assessed, and associations between tumor length and survival were analyzed. RESULTS: Only the tumor lengths assessed on pathology were found to be significantly associated with overall (P\,=\,0.001) and recurrence free (P\,{$<$}\,0.001) survival on univariable analysis. The median overall survival was 47.1 months in those patients with tumor lengths {$<$}3.0\,cm, falling to 19.6 and 18.0 months in those with 3.0-4.4 and 4.5+\,cm tumors, respectively, demonstrating a reduction in patient survival at a tumor length of around 3\,cm. Tumor length on pathology was significantly correlated with tumor differentiation and both T- and N-categories. After accounting for these factors, tumor length on pathology was a significant independent predictor of recurrence-free (P\,=\,0.016), but not overall (P\,=\,0.128) survival. CONCLUSIONS: Tumor lengths on pathology were found to be the most predictive of patient outcome. However, after accounting for other tumor-related factors, tumor length only resulted in a marginal improvement in predictive accuracy.},
  langid = {english},
  pmid = {28767142},
  keywords = {Aged,Endosonography,esophageal cancer,Esophageal Neoplasms,esophagectomy,Esophagectomy,Female,Humans,Male,Middle Aged,Prognosis,recurrence,Retrospective Studies,survival,tumor length}
}

@article{holsth1354,
  title = {Restrictive versus Liberal Transfusion Strategy for Red Blood Cell Transfusion: Systematic Review of Randomised Trials with Meta-Analysis and Trial Sequential Analysis},
  shorttitle = {Restrictive versus Liberal Transfusion Strategy for Red Blood Cell Transfusion},
  author = {Holst, Lars B. and Petersen, Marie W. and Haase, Nicolai and Perner, Anders and Wetterslev, J{\o}rn},
  year = {2015},
  month = mar,
  journal = {BMJ (Clinical research ed.)},
  volume = {350},
  pages = {h1354},
  issn = {1756-1833},
  doi = {10.1136/bmj.h1354},
  abstract = {OBJECTIVE: To compare the benefit and harm of restrictive versus liberal transfusion strategies to guide red blood cell transfusions. DESIGN: Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. DATA SOURCES: Cochrane central register of controlled trials, SilverPlatter Medline (1950 to date), SilverPlatter Embase (1980 to date), and Science Citation Index Expanded (1900 to present). Reference lists of identified trials and other systematic reviews were assessed, and authors and experts in transfusion were contacted to identify additional trials. TRIAL SELECTION: Published and unpublished randomised clinical trials that evaluated a restrictive compared with a liberal transfusion strategy in adults or children, irrespective of language, blinding procedure, publication status, or sample size. DATA EXTRACTION: Two authors independently screened titles and abstracts of trials identified, and relevant trials were evaluated in full text for eligibility. Two reviewers then independently extracted data on methods, interventions, outcomes, and risk of bias from included trials. random effects models were used to estimate risk ratios and mean differences with 95\% confidence intervals. RESULTS: 31 trials totalling 9813 randomised patients were included. The proportion of patients receiving red blood cells (relative risk 0.54, 95\% confidence interval 0.47 to 0.63, 8923 patients, 24 trials) and the number of red blood cell units transfused (mean difference -1.43, 95\% confidence interval -2.01 to -0.86) were lower with the restrictive compared with liberal transfusion strategies. Restrictive compared with liberal transfusion strategies were not associated with risk of death (0.86, 0.74 to 1.01, 5707 patients, nine lower risk of bias trials), overall morbidity (0.98, 0.85 to 1.12, 4517 patients, six lower risk of bias trials), or fatal or non-fatal myocardial infarction (1.28, 0.66 to 2.49, 4730 patients, seven lower risk of bias trials). Results were not affected by the inclusion of trials with unclear or high risk of bias. Using trial sequential analyses on mortality and myocardial infarction, the required information size was not reached, but a 15\% relative risk reduction or increase in overall morbidity with restrictive transfusion strategies could be excluded. CONCLUSIONS: Compared with liberal strategies, restrictive transfusion strategies were associated with a reduction in the number of red blood cell units transfused and number of patients being transfused, but mortality, overall morbidity, and myocardial infarction seemed to be unaltered. Restrictive transfusion strategies are safe in most clinical settings. Liberal transfusion strategies have not been shown to convey any benefit to patients. TRIAL REGISTRATION: PROSPERO CRD42013004272.},
  langid = {english},
  pmcid = {PMC4372223},
  pmid = {25805204},
  keywords = {Erythrocyte Transfusion,Humans,Models; Statistical,Odds Ratio,Randomized Controlled Trials as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QZWTVURM\\Holst et al_2015_Restrictive versus liberal transfusion strategy for red blood cell transfusion.pdf}
}

@article{hong8,
  title = {Total {{Lesion Glycolysis Using 18F-FDG PET}}/{{CT}} as a {{Prognostic Factor}} for {{Locally Advanced Esophageal Cancer}}},
  author = {Hong, Ji Hyung and Kim, Hyon Ho and Han, Eun Ji and Byun, Jae Ho and Jang, Hong Seok and Choi, Eun Kyoung and Kang, Jin Hyoung and Yoo, Ie Ryung},
  pages = {8},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4HDVN345\\Hong et al. - Total Lesion Glycolysis Using 18F-FDG PETCT as a .pdf}
}

@article{honmaClinicalOutcomesResectable2017,
  title = {Clinical {{Outcomes}} of {{Resectable Esophageal Cancer}} with {{Supraclavicular Lymph Node Metastases Treated}} with {{Curative Intent}}},
  author = {Honma, Yoshitaka and Hokamura, Nobukazu and Nagashima, Kengo and Sudo, Kazuki and Shoji, Hirokazu and Iwasa, Satoru and Takashima, Atsuo and Kato, Ken and Hamaguchi, Tetsuya and Boku, Narikazu and Umezawa, Rei and Ito, Yoshinori and Itami, Jun and Koyanagi, Kazuo and Igaki, Hiroyasu and Tachimori, Yuji},
  year = {2017},
  month = jul,
  journal = {Anticancer Research},
  volume = {37},
  number = {7},
  pages = {3741--3749},
  issn = {1791-7530},
  doi = {10.21873/anticanres.11748},
  abstract = {BACKGROUND: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. PATIENTS AND METHODS: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. RESULTS: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. CONCLUSION: Over 30\% of patients with resectable M1LYM treated with curative intent achieved long-term survival.},
  langid = {english},
  pmid = {28668869},
  keywords = {80 and over,Adult,Aged,Antimetabolites,Antineoplastic,chemoradiotherapy,Chemoradiotherapy,Cisplatin,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Female,Fluorouracil,Humans,Kaplan-Meier Estimate,Lymph Nodes,Lymphatic Metastasis,Male,Middle Aged,supraclavicular lymph node metastases,surgery,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WRQXFW6P\\Honma et al. - 2017 - Clinical Outcomes of Resectable Esophageal Cancer .pdf}
}

@article{hopkins1381,
  title = {Barriers to the {{Interpretation}} of {{Body Composition}} in {{Colorectal Cancer}}: {{A Review}} of the {{Methodological Inconsistency}} and {{Complexity}} of the {{CT-Defined Body Habitus}}},
  shorttitle = {Barriers to the {{Interpretation}} of {{Body Composition}} in {{Colorectal Cancer}}},
  author = {Hopkins, Jessica J. and Skubleny, Daniel and Bigam, David L. and Baracos, Vickie E. and Eurich, Dean T. and Sawyer, Michael B.},
  year = {2018},
  month = may,
  journal = {Annals of Surgical Oncology},
  volume = {25},
  number = {5},
  pages = {1381--1394},
  issn = {1534-4681},
  doi = {10.1245/s10434-018-6395-8},
  abstract = {BACKGROUND: Measurement of body composition by computed tomography (CT) is an advancing field. Sarcopenia, myosteatosis, and visceral obesity (VO) have been identified as predictive of survival in colorectal cancer (CRC). We performed a systematic review of contemporary studies to characterize this association and highlight methodological inconsistencies. METHODS: MEDLINE and PubMed were queried for articles published from January 2000 on, with populations of resectable CRC and with CT-measured body composition and survival data. The study quality was assessed by two independent reviewers using the Newcastle-Ottawa Scale. RESULTS: Twenty studies met inclusion criteria, with a total of 8895 patients. Only two of the studies scored as high quality and nine as moderate quality. The remaining nine studies scored as low quality. Ten studies considered sarcopenia and 12 considered visceral obesity (VO). Cutoff points to define sarcopenia, myosteatosis, and VO were identified by optimal stratification, quartiles, or median values. The prevalence of sarcopenia varied from 15 to 60\%, which based on study population and cutoff value used. Sarcopenia was associated with worse overall and disease-free survival in eight of the included studies. Myosteatosis was considered in three studies with a prevalence of 19-78\%. It was significantly predictive of worse overall and disease-free survival in all three studies. VO had a prevalence of 14-70\% and was inconsistently predictive of survival outcomes. CONCLUSIONS: There is a lack of methodological consistency within the currently published literature. Despite this, sarcopenia and myosteatosis, but not VO, are consistently associated with worse survival outcomes, when population and cancer-specific cutoffs are utilized.},
  langid = {english},
  pmid = {29488190},
  keywords = {Body Composition,Colorectal Neoplasms,Disease-Free Survival,Humans,Methods,Muscular Diseases,Obesity; Abdominal,Review,Sarcopenia,Survival Rate,Tomography; X-Ray Computed}
}

@article{hovaguimian46,
  title = {Restrictive versus {{Liberal Transfusion Strategy}} in the {{Perioperative}} and {{Acute Care Settings}}: {{A Context-specific Systematic Review}} and {{Meta-analysis}} of {{Randomized Controlled Trials}}},
  shorttitle = {Restrictive versus {{Liberal Transfusion Strategy}} in the {{Perioperative}} and {{Acute Care Settings}}},
  author = {Hovaguimian, Fr{\'e}d{\'e}rique and Myles, Paul S.},
  year = {2016},
  month = jul,
  journal = {Anesthesiology},
  volume = {125},
  number = {1},
  pages = {46--61},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000001162},
  abstract = {BACKGROUND: Blood transfusions are associated with morbidity and mortality. However, restrictive thresholds could harm patients less able to tolerate anemia. Using a context-specific approach (according to patient characteristics and clinical settings), the authors conducted a systematic review to quantify the effects of transfusion strategies. METHODS: The authors searched MEDLINE, EMBASE, CENTRAL, and grey literature sources to November 2015 for randomized controlled trials comparing restrictive versus liberal transfusion strategies applied more than 24\,h in adult surgical or critically ill patients. Data were independently extracted. Risk ratios were calculated for 30-day complications, defined as inadequate oxygen supply (myocardial, cerebral, renal, mesenteric, and peripheral ischemic injury; arrhythmia; and unstable angina), mortality, composite of both, and infections. Statistical combination followed a context-specific approach. Additional analyses explored transfusion protocol heterogeneity and cointerventions effects. RESULTS: Thirty-one trials were regrouped into five context-specific risk strata. In patients undergoing cardiac/vascular procedures, restrictive strategies seemed to increase the risk of events reflecting inadequate oxygen supply (risk ratio [RR], 1.09; 95\% CI, 0.97 to 1.22), mortality (RR, 1.39; 95\% CI, 0.95 to 2.04), and composite events (RR, 1.12; 95\% CI, 1.01 to 1.24-3322, 3245, and 3322 patients, respectively). Similar results were found in elderly orthopedic patients (inadequate oxygen supply: RR, 1.41; 95\% CI, 1.03 to 1.92; mortality: RR, 1.09; 95\% CI, 0.80 to 1.49; composite outcome: RR, 1.24; 95\% CI, 1.00 to 1.54-3465, 3546, and 3749 patients, respectively), but not in critically ill patients. No difference was found for infections, although a protective effect may exist. Risk estimates varied with successful/unsuccessful transfusion protocol implementation. CONCLUSIONS: Restrictive transfusion strategies should be applied with caution in high-risk patients undergoing major surgery.},
  langid = {english},
  pmid = {27167445},
  keywords = {Acute Disease,Blood Transfusion,Humans,Perioperative Care,Randomized Controlled Trials as Topic,Surgery,Treatment Outcome}
}

@article{howard-anderson1870,
  type = {Journal {{Article}}},
  title = {Readmissions in the Era of Patient Engagement},
  author = {{Howard-Anderson}, J. and Lonowski, S. and Vangala, S. and Tseng, C. H. and Busuttil, A. and {Afsar-Manesh}, N.},
  year = {2014},
  journal = {JAMA Intern Med},
  volume = {174},
  number = {11},
  pages = {1870--2},
  issn = {2168-6114 (Electronic) 2168-6106 (Linking)},
  doi = {10.1001/jamainternmed.2014.4782}
}

@article{hoyo1706,
  title = {Body Mass Index in Relation to Oesophageal and Oesophagogastric Junction Adenocarcinomas: A Pooled Analysis from the {{International BEACON Consortium}}},
  shorttitle = {Body Mass Index in Relation to Oesophageal and Oesophagogastric Junction Adenocarcinomas},
  author = {Hoyo, Cathrine and Cook, Michael B. and Kamangar, Farin and Freedman, Neal D. and Whiteman, David C. and Bernstein, Leslie and Brown, Linda M. and Risch, Harvey A. and Ye, Weimin and Sharp, Linda and Wu, Anna H. and Ward, Mary H. and Casson, Alan G. and Murray, Liam J. and Corley, Douglas A. and Nyr{\'e}n, Olof and Pandeya, Nirmala and Vaughan, Thomas L. and Chow, Wong-Ho and Gammon, Marilie D.},
  year = {2012},
  month = dec,
  journal = {International Journal of Epidemiology},
  volume = {41},
  number = {6},
  pages = {1706--1718},
  issn = {1464-3685},
  doi = {10.1093/ije/dys176},
  abstract = {BACKGROUND: Previous studies suggest an association between obesity and oesophageal (OA) and oesophagogastric junction adenocarcinomas (OGJA). However, these studies have been limited in their ability to assess whether the effects of obesity vary by gender or by the presence of gastro-oesophageal reflux (GERD) symptoms. METHODS: Individual participant data from 12 epidemiological studies (8 North American, 3 European and 1 Australian) comprising 1997 OA cases, 1900 OGJA cases and 11 159 control subjects were pooled. Logistic regression was used to estimate study-specific odds ratios (ORs) and 95\% confidence intervals (CIs) for the association between body mass index (BMI, kg/m(2)) and the risk of OA and OGJA. Random-effects meta-analysis was used to combine these ORs. We also investigated effect modification and synergistic interaction of BMI with GERD symptoms and gender. RESULTS: The association of OA and OGJA increased directly with increasing BMI (P for trend {$<$}0.001). Compared with individuals with a BMI {$<$}25, BMI {$\geq$}40 was associated with both OA (OR 4.76, 95\% CI 2.96-7.66) and OGJA (OR 3.07, 95\% CI 1.89-4.99). These associations were similar when stratified by gender and GERD symptoms. There was evidence for synergistic interaction between BMI and GERD symptoms in relation to OA/OGJA risk. CONCLUSIONS: These data indicate that BMI is directly associated with OA and OGJA risk in both men and women and in those with and without GERD symptoms. Disentangling the relationship between BMI and GERD will be important for understanding preventive efforts for OA and OGJA.},
  langid = {english},
  pmcid = {PMC3535758},
  pmid = {23148106},
  keywords = {Adenocarcinoma,Adult,Aged,Body Mass Index,Esophageal Neoplasms,Esophagogastric Junction,Female,Gastroesophageal Reflux,GE,Humans,Logistic Models,Male,Middle Aged,Sex Distribution},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QPVEQMFU\\Hoyo et al. - 2012 - Body mass index in relation to oesophageal and oes.pdf}
}

@article{hu1062,
  title = {Assessing the Initiation and Completion of Adjuvant Chemotherapy in a Large Nationwide and Population-Based Cohort of Elderly Patients with Stage-{{III}} Colon Cancer},
  author = {Hu, Chung-Yuan and Delclos, George L. and Chan, Wenyaw and Du, Xianglin L.},
  year = {2011},
  month = dec,
  journal = {Medical Oncology (Northwood, London, England)},
  volume = {28},
  number = {4},
  pages = {1062--1074},
  issn = {1559-131X},
  doi = {10.1007/s12032-010-9644-7},
  abstract = {Randomized trials conducted in the 1980s have established the effectiveness of 5-fluorouracil-based adjuvant chemotherapy in treating stage-III colon cancer. However, the initiation of adjuvant chemotherapy is just the first step for survival improvement. Little is known about the actual completion rate of such a therapy in the community. The objectives of this study were to measure the initiation and completion rate of adjuvant chemotherapy and to identify the associated factors. We studied 12,265 patients aged 65+ diagnosed with stage-III colon cancer between 1991 and 2005 who were identified from the Surveillance, Epidemiology, and End Results-Medicare linked database. Chemotherapy initiation was defined as at least one claim indicating the use of chemotherapy. The first and last claims were used to measure the length of chemotherapy. A complete course of chemotherapy was defined as 8-13~months for 1991-1995 cohort and 5-7~months for 1996-2005 cohort according to clinical guideline. Of the 12,265 patients, 64.4\% received adjuvant chemotherapy within 3~months after tumor resection. Among those who had chemotherapy initiated, 62.2\% (or 38.0\% of 12,265 patients) received a complete course of chemotherapy. Patient's age at diagnosis, marital status, and comorbidity score were the significant predictors for chemotherapy initiation. These variables remained significant in predicting chemotherapy completion after adjusting for year of diagnosis and other factors. In conclusion, initiation and completion of chemotherapy was largely influenced by patient's age, marital status and comorbidity. Further investigation is needed to explore the cause of these differences in adherence to standard treatment that is essential for better quality of cancer care.},
  langid = {english},
  pmid = {20714945},
  keywords = {Age Factors,Aged,Aged; 80 and over,Antineoplastic Agents,Chemotherapy; Adjuvant,Cohort Studies,Colonic Neoplasms,Comorbidity,DoseIntensity,Female,Fluorouracil,Humans,Male,Neoplasm Staging,SEER Program}
}

@article{hu38,
  title = {Neoadjuvant {{PD-1}} Blockade with Toripalimab, with or without Celecoxib, in Mismatch Repair-Deficient or Microsatellite Instability-High, Locally Advanced, Colorectal Cancer ({{PICC}}): A Single-Centre, Parallel-Group, Non-Comparative, Randomised, Phase 2 Trial},
  shorttitle = {Neoadjuvant {{PD-1}} Blockade with Toripalimab, with or without Celecoxib, in Mismatch Repair-Deficient or Microsatellite Instability-High, Locally Advanced, Colorectal Cancer ({{PICC}})},
  author = {Hu, Huabin and Kang, Liang and Zhang, Jianwei and Wu, Zehua and Wang, Hui and Huang, Meijin and Lan, Ping and Wu, Xiaojian and Wang, Chao and Cao, Wuteng and Hu, Jiancong and Huang, Yan and Huang, Liang and Wang, Huaiming and Shi, Lishuo and Cai, Yue and Shen, Cailu and Ling, Jiayu and Xie, Xiaoyu and Cai, Yonghua and He, Xiaowen and Dou, Ruoxu and Zhou, Jiaming and Ma, Tenghui and Zhang, Xingwei and Luo, Shuangling and Deng, Weihao and Ling, Li and Liu, Hao and Deng, Yanhong},
  year = {2022},
  month = jan,
  journal = {The Lancet. Gastroenterology \& Hepatology},
  volume = {7},
  number = {1},
  pages = {38--48},
  issn = {2468-1253},
  doi = {10.1016/S2468-1253(21)00348-4},
  abstract = {BACKGROUND: PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting for resectable mismatch repair-deficient or microsatellite instability-high colorectal cancer remains unclear. We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers. METHODS: The PD-1 Inhibitor in Microsatellite Instability Colorectal Cancer (PICC) trial was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study undertaken at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Eligible patients were aged 18-75 years, had histologically confirmed mismatch repair-deficient or microsatellite instability-high colorectal cancer, had clinical stage T3-T4 or any T with lymph node positivity (N+), Eastern Cooperative Oncology Group performance score of 0 or 1, and adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1), without any stratification or balanced blocking, to receive toripalimab 3 mg/kg intravenously on day 1, with or without celecoxib 200 mg orally twice daily from day 1 to 14 of each 14-day cycle, for six cycles before surgical resection. Adjuvant treatment with toripalimab with or without celecoxib was permitted at the investigators' discretion. The primary endpoint was the proportion of patients with pathological complete response, defined as tumours without any viable tumour cells in the resected primary tumour sample and all sampled regional lymph nodes. All efficacy and safety analyses were assessed in the modified intention-to-treat population, which included all patients who were randomly assigned to treatment and who received at least one dose of toripalimab. This trial is registered with ClinicalTrials.gov, NCT03926338, and is ongoing. FINDINGS: Between May 1, 2019, and April 1, 2021, 53 patients were screened, of whom 34 were randomly assigned to either the toripalimab plus celecoxib group (n=17) or the toripalimab monotherapy group (n=17). As of data cutoff (Aug 10, 2021), median follow-up was 14{$\cdot$}9 months (IQR 8{$\cdot$}8-17{$\cdot$}0). All patients received study treatment and underwent surgical resection; there were no treatment-related surgical delays. All 34 patients had an R0 resection ({$>$}1 mm resection margin). 15 of 17 patients (88\% [95\% CI 64-99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65\% [38-86]) in the toripalimab monotherapy group had a pathological complete response. All patients continued to receive adjuvant toripalimab with or without celecoxib for a total perioperative duration of 6 months and were alive and free of recurrence at data cutoff. During neoadjuvant treatment, ten (59\%) patients in the toripalimab plus celecoxib group and ten (59\%) in the toripalimab monotherapy group had grade 1-2 treatment-related adverse events. Only one (3\%) of 34 patients, who was in the toripalimab plus celecoxib group, had a grade 3 or higher treatment-related adverse event during the neoadjuvant phase, which was grade 3 increased aspartate aminotransferase levels. In the adjuvant phase, only one (3\%) of 34 patients, who was in the toripalimab monotherapy group, had a grade 3 or higher treatment-related adverse events, which was grade 3 increased aspartate aminotransferase and alanine aminotransferase levels. INTERPRETATION: Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints. FUNDING: The National Key R\&D Program of China, the National Natural Science Foundation of China, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.},
  langid = {english},
  pmid = {34688374},
  keywords = {Adult,Aged,Antibodies; Monoclonal; Humanized,Antineoplastic Combined Chemotherapy Protocols,Celecoxib,Chemotherapy; Adjuvant,Colectomy,Colorectal Neoplasms,DNA Mismatch Repair,DNA-Binding Proteins,Female,Humans,Lymph Node Excision,Lymphatic Metastasis,Male,Microsatellite Instability,Middle Aged,Mismatch Repair Endonuclease PMS2,MutL Protein Homolog 1,MutS Homolog 2 Protein,Neoadjuvant Therapy,Programmed Cell Death 1 Receptor,Young Adult}
}

@article{huange0210055,
  title = {Post-Chemoradiotherapy {{FDG PET}} with Qualitative Interpretation Criteria for Outcome Stratification in Esophageal Squamous Cell Carcinoma},
  author = {Huang, Yung-Cheng and Li, Shau-Hsuan and Lu, Hung-I. and Hsu, Chien-Chin and Wang, Yu-Ming and Lin, Wei-Che and Chen, Chao-Jung and Ho, Kuo-Wei and Chiu, Nan-Tsing},
  year = {2019},
  journal = {PloS One},
  volume = {14},
  number = {1},
  pages = {e0210055},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0210055},
  abstract = {OBJECTIVES: Post-chemoradiotherapy (CRT) FDG PET is a useful prognosticator of esophageal cancer. However, debate on the diverse criteria of previous publications preclude worldwide multicenter comparisons, and even a universal practice guide. We aimed to validate a simple qualitative interpretation criterion of post-CRT FDG PET for outcome stratification and compare it with other criteria. METHODS: The post-CRT FDG PET of 114 patients with esophageal squamous cell carcinoma (ESCC) were independently interpreted using a qualitative 4-point scale (Qual4PS) that identified focal esophageal FDG uptake greater than liver uptake as residual tumor. Cohen's {$\kappa$} coefficient ({$\kappa$}) was used to measure interobserver agreement of Qual4PS. The Kaplan-Meier method and Cox proportional hazards regression analyses were used for survival analysis. Other criteria included a different qualitative approach (QualBK), maximal standardized uptake values (SUVmax3.4, SUVmax2.5), relative change of SUVmax between pre- and post-CRT FDG PET ({$\Delta$}SUVmax), mean standardized uptake values (SUVmean), metabolic volume (MV) and total lesion glycolysis (TLG). RESULTS: Overall interobserver agreement on the Qual4PS criterion was excellent ({$\kappa$}: 0.95). Except the QualBK, SUVmax2.5, and TLG, all the other criteria were significant predictors for overall survival (OS). Multivariable analysis showed only Qual4PS (HR: 15.41; P = 0.005) and AJCC stage (HR: 2.47; P = 0.007) were significant independent variables. The 2-year OS rates of Qual4PS(-) patients undergoing CRT alone (68.4\%) and patients undergoing trimodality therapy (62.5\%) were not significant different, but the 2-year OS rates of Qual4PS(+) patients undergoing CRT alone (10.0\%) were significantly lower than in patients undergoing trimodality therapy (42.1\%). CONCLUSIONS: The Qual4PS criterion is reproducible for assessing the response of ESCC to CRT, and valuable for predicting survival. It may add value to response-adapted treatment for ESCC patients, and help to decide whether surgery is warranted after CRT.},
  langid = {english},
  pmcid = {PMC6322736},
  pmid = {30615636},
  keywords = {Adult,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Chemoradiotherapy,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Outcome Assessment; Health Care,Positron Emission Tomography Computed Tomography,Proportional Hazards Models,Retrospective Studies,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6CMDDZQS\\Huang et al. - 2019 - Post-chemoradiotherapy FDG PET with qualitative in.pdf}
}

@article{huerter948,
  title = {Enteral {{Access}} Is Not {{Required}} for {{Esophageal Cancer Patients Undergoing Neoadjuvant Therapy}}},
  author = {Huerter, Mary E. and Charles, Eric J. and Downs, Emily A. and Hu, Yinin and Lau, Christine L. and Isbell, James M. and McMurry, Timothy L. and Kozower, Benjamin D.},
  year = {2016},
  month = sep,
  journal = {The Annals of Thoracic Surgery},
  volume = {102},
  number = {3},
  pages = {948--954},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2016.03.041},
  abstract = {BACKGROUND: The nutritional status of esophageal cancer patients during neoadjuvant therapy remains a challenging problem. The objective of this study was to determine whether routine enteral feeding tube placement improved nutritional status and perioperative outcomes for patients undergoing neoadjuvant therapy for esophageal cancer. METHODS: The Society of Thoracic Surgeons database was used to identify patients who underwent neoadjuvant therapy and esophagectomy at our institution between 2010 and 2014. Nutritional status before and after neoadjuvant therapy was determined through standardized nutrition consultations. Predictors of change in nutrition and adverse events were evaluated with multivariable and univariate logistic regressions. RESULTS: Two hundred thirty-four esophagectomy patients were identified, and 127 (54\%) received neoadjuvant therapy. Of those receiving neoadjuvant therapy, 80\% (102/127) presented with dysphagia, and 48\% (61/127) received enteral feeding access (EA). Multivariable regression revealed that high initial albumin level, high initial body mass index, and presence of EA were associated with nutritional stability during neoadjuvant therapy. However, 27.9\% (17/61) of patients who received EA did not use their access at all or did not use it consistently during the course of preoperative treatment. The preoperative grades of malnutrition and esophagectomy outcomes were similar between groups (EA vs no EA). CONCLUSIONS: EA is associated with improved nutritional status for patients undergoing neoadjuvant therapy for esophageal cancer. However, adverse events and suboptimal use are common. Esophagectomy outcomes were similar for patients with and without EA. These results support judicious patient selection for EA, expedited neoadjuvant therapy, and close collaboration with nutritionists.},
  langid = {english},
  pmid = {27209608},
  keywords = {Aged,Enteral Nutrition,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Nutritional Status,Stents}
}

@article{hulscher1662,
  title = {Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus},
  author = {Hulscher, Jan B. F. and {van Sandick}, Johanna W. and {de Boer}, Angela G. E. M. and Wijnhoven, Bas P. L. and Tijssen, Jan G. P. and Fockens, Paul and Stalmeier, Peep F. M. and {ten Kate}, Fiebo J. W. and {van Dekken}, Herman and Obertop, Huug and Tilanus, Hugo W. and {van Lanschot}, J. Jan B.},
  year = {2002},
  month = nov,
  journal = {The New England Journal of Medicine},
  volume = {347},
  number = {21},
  pages = {1662--1669},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa022343},
  abstract = {BACKGROUND: Controversy exists about the best surgical treatment for esophageal carcinoma. METHODS: We randomly assigned 220 patients with adenocarcinoma of the mid-to-distal esophagus or adenocarcinoma of the gastric cardia involving the distal esophagus either to transhiatal esophagectomy or to transthoracic esophagectomy with extended en bloc lymphadenectomy. Principal end points were overall survival and disease-free survival. Early morbidity and mortality, the number of quality-adjusted life-years gained, and cost effectiveness were also determined. RESULTS: A total of 106 patients were assigned to undergo transhiatal esophagectomy, and 114 to undergo transthoracic esophagectomy. Demographic characteristics and characteristics of the tumor were similar in the two groups. Perioperative morbidity was higher after transthoracic esophagectomy, but there was no significant difference in in-hospital mortality (P=0.45). After a median follow-up of 4.7 years, 142 patients had died--74 (70 percent) after transhiatal resection and 68 (60 percent) after transthoracic resection (P=0.12). Although the difference in survival was not statistically significant, there was a trend toward a survival benefit with the extended approach at five years: disease-free survival was 27 percent in the transhiatal-esophagectomy group, as compared with 39 percent in the transthoracic-esophagectomy group (95 percent confidence interval for the difference, -1 to 24 percent [the negative value indicates better survival with transhiatal resection]), whereas overall survival was 29 percent as compared with 39 percent (95 percent confidence interval for the difference, -3 to 23 percent). CONCLUSIONS: Transhiatal esophagectomy was associated with lower morbidity than transthoracic esophagectomy with extended en bloc lymphadenectomy. Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term survival at five years with the extended transthoracic approach.},
  langid = {english},
  pmid = {12444180},
  keywords = {Adenocarcinoma,Adult,Aged,Cost-Benefit Analysis,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Health Care Costs,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Quality-Adjusted Life Years,Survival Analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MBHERUZX\\Hulscher et al. - 2002 - Extended transthoracic resection compared with lim.pdf}
}

@article{humbert347,
  type = {Journal {{Article}}},
  title = {Swallowing Intentional Off-State in Aging and {{Alzheimer}}'s Disease: Preliminary Study},
  author = {Humbert, I. A. and McLaren, D. G. and Malandraki, G. and Johnson, S. C. and Robbins, J.},
  year = {2011},
  journal = {J Alzheimers Dis},
  volume = {26},
  number = {2},
  pages = {347--54},
  issn = {1875-8908 (Electronic) 1387-2877 (Linking)},
  doi = {10.3233/JAD-2011-110380}
}

@article{hurria1708,
  title = {Reply to {{N}}. {{Lowy}} et al and to {{J}}. {{Dhanda}} et Al},
  author = {Hurria, Arti and Levit, Laura A. and Dale, William and Mohile, Supriya G. and Muss, Hyman B. and Fehrenbacher, Louis and Magnuson, Allison and Lichtman, Stuart M. and Bruinooge, Suanna S. and {Soto-Perez-de-Celis}, Enrique and Tew, William P. and Postow, Michael A. and Cohen, Harvey J.},
  year = {2016},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {34},
  number = {14},
  pages = {1708--1709},
  issn = {1527-7755},
  doi = {10.1200/JCO.2015.66.3740},
  langid = {english},
  pmid = {27001583},
  keywords = {Chemo}
}

@article{hurria3826,
  title = {Improving the {{Evidence Base}} for {{Treating Older Adults With Cancer}}: {{American Society}} of {{Clinical Oncology Statement}}},
  shorttitle = {Improving the {{Evidence Base}} for {{Treating Older Adults With Cancer}}},
  author = {Hurria, Arti and Levit, Laura A. and Dale, William and Mohile, Supriya G. and Muss, Hyman B. and Fehrenbacher, Louis and Magnuson, Allison and Lichtman, Stuart M. and Bruinooge, Suanna S. and {Soto-Perez-de-Celis}, Enrique and Tew, William P. and Postow, Michael A. and Cohen, Harvey J. and {American Society of Clinical Oncology}},
  year = {2015},
  month = nov,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {33},
  number = {32},
  pages = {3826--3833},
  issn = {1527-7755},
  doi = {10.1200/JCO.2015.63.0319},
  abstract = {The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is that clinicians have less evidence on how to treat older adults, who represent the majority of patients with cancer. Clinicians and patients are forced to extrapolate from trials conducted in younger, healthier populations when developing treatment plans. This has created a dearth of knowledge regarding the risk of toxicity in the average older patient and about key end points of importance to older adults. ASCO makes five recommendations to improve evidence generation in this population: (1) Use clinical trials to improve the evidence base for treating older adults with cancer, (2) leverage research designs and infrastructure for generating evidence on older adults with cancer, (3) increase US Food and Drug Administration authority to incentivize and require research involving older adults with cancer, (4) increase clinicians' recruitment of older adults with cancer to clinical trials, and (5) use journal policies to improve researchers' reporting on the age distribution and health risk profiles of research participants.},
  langid = {english},
  pmid = {26195697},
  keywords = {Aged,Aged; 80 and over,Aging,Chemo,Clinical Trials as Topic,Editorial Policies,Evidence-Based Medicine,Humans,Medical Oncology,Neoplasms,Patient Selection,Periodicals as Topic,Research Design,Research Report,Societies; Medical,United States,United States Food and Drug Administration}
}

@article{hutcheson62,
  type = {Journal {{Article}}},
  title = {Dynamic {{Imaging Grade}} of {{Swallowing Toxicity}} ({{DIGEST}}): {{Scale}} Development and Validation},
  author = {Hutcheson, K. A. and Barrow, M. P. and Barringer, D. A. and Knott, J. K. and Lin, H. Y. and Weber, R. S. and Fuller, C. D. and Lai, S. Y. and Alvarez, C. P. and Raut, J. and Lazarus, C. L. and May, A. and Patterson, J. and Roe, J. W. and Starmer, H. M. and Lewin, J. S.},
  year = {2017},
  journal = {Cancer},
  volume = {123},
  number = {1},
  pages = {62--70},
  issn = {1097-0142 (Electronic) 0008-543X (Linking)},
  doi = {10.1002/cncr.30283}
}

@article{hutchesonEatExerciseRadiotherapy2013,
  type = {Journal {{Article}}},
  title = {Eat and Exercise during Radiotherapy or Chemoradiotherapy for Pharyngeal Cancers: Use It or Lose It},
  author = {Hutcheson, K. A. and Bhayani, M. K. and Beadle, B. M. and Gold, K. A. and Shinn, E. H. and Lai, S. Y. and Lewin, J.},
  year = {2013},
  journal = {JAMA Otolaryngol Head Neck Surg},
  volume = {139},
  number = {11},
  pages = {1127--34},
  issn = {2168-619X (Electronic) 2168-6181 (Linking)},
  doi = {10.1001/jamaoto.2013.4715}
}

@article{hynes1559,
  title = {The Impact of Pre- and Post-Operative Weight Loss and Body Mass Index on Prognosis in Patients with Oesophageal Cancer},
  author = {Hynes, O. and Anandavadivelan, P. and Gossage, J. and Johar, A. M. and Lagergren, J. and Lagergren, P.},
  year = {2017},
  month = aug,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {43},
  number = {8},
  pages = {1559--1565},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2017.05.023},
  abstract = {BACKGROUND: Weight loss is a cardinal symptom of oesophageal cancer and is often continued after surgery. High body mass index (BMI) is a strong risk factor for oesophageal adenocarcinoma. This study aimed to assess the impact of pre- and post-operative weight loss and BMI on long-term mortality after resection for oesophageal cancer. METHODS: This prospective and nationwide cohort study included 390 patients, operated on for oesophageal cancer in Sweden in 2001-2005 with follow-up until 2016, who responded to a questionnaire on weight history 6 months after surgery. Multivariable Cox proportional hazard models provided hazard ratios (HRs) and 95\% confidence intervals (95\% CIs) of mortality while adjusting for several prognostic factors, including tumour stage. RESULTS: Compared to weight stable patients, pre-surgery weight loss indicated increased HRs of overall all-cause mortality (HR~=~1.32, 95\% CI 0.94-1.86) and disease-specific mortality (HR~=~1.36, 95\% CI 0.93-1.98). Patients with {$>$}20\% weight loss post-surgery had worse overall all-cause mortality (HR~=~1.71, 95\% CI 1.01-2.88) and disease-specific mortality (HR~=~2.20, 95\% CI 1.24-3.89). Compared to patients with normal BMI, decreased HRs were indicated for patients who were obese at the time of surgery (overall all-cause mortality HR 0.87 95\% CI, 0.58-1.31 and disease-specific mortality HR~=~0.89, 95\% CI 0.57-1.40), while patients with BMI {$\leq$}19.9~at 6 months post-surgery had increased all-cause mortality (HR~=~1.41, 95\% CI 1.03-1.95) and disease-specific mortality (HR~=~1.55, 95\% CI 1.09-2.21). CONCLUSION: Post-operative weight loss and low BMI at 6 months post-surgery are independent markers of poor prognosis in patients who undergo surgery for oesophageal cancer.},
  langid = {english},
  pmid = {28655483},
  keywords = {Aged,BMI,Body Mass Index,Esophageal Neoplasms,Female,GE,Humans,Male,Mortality,Neoplasm Staging,Oesophageal neoplasm,Prospective Studies,Risk Factors,Surveys and Questionnaires,Survival,Sweden,Weight change,Weight Loss}
}

@article{hyun115,
  title = {Prognostic Value of Metabolic Tumor Volume Measured by {{18F-fluorodeoxyglucose}} Positron Emission Tomography in Patients with Esophageal Carcinoma},
  author = {Hyun, Seung Hyup and Choi, Joon Young and Shim, Young Mog and Kim, Kwhanmien and Lee, Su Jin and Cho, Young Seok and Lee, Ji Young and Lee, Kyung-Han and Kim, Byung-Tae},
  year = {2010},
  month = jan,
  journal = {Annals of Surgical Oncology},
  volume = {17},
  number = {1},
  pages = {115--122},
  issn = {1534-4681},
  doi = {10.1245/s10434-009-0719-7},
  abstract = {PURPOSE: The aim of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) in patients with esophageal carcinoma. METHODS: We retrospectively reviewed 151 patients with pathologically proven esophageal carcinoma (146 squamous cell carcinomas and 5 adenocarcinomas) who underwent pretreatment (18)F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by (18)F-FDG PET. The prognostic significance of MTV, SUVmax, and other clinicopathological variables was assessed by Cox proportional hazards regression analysis. To further evaluate and compare the predictive performance of PET parameters, MTV and SUVmax, time-dependent receiver operating characteristic curve (ROC) analysis was used. RESULTS: In the univariate analysis, age, American Joint Committee on Cancer (AJCC) stage, tumor-node-metastasis (TNM) factors, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis adjusted for age, sex, and treatment modality, independent predictive factors associated with decreased overall survival were T stage [hazard ratio (HR) 4.325, P = 0.006], M stage (HR 2.009, P = 0.007), and MTV (HR 1.013, P = 0.021). SUVmax was not a significant factor (HR 0.97, P = 0.061). On time-dependent ROC analysis, MTV showed good predictive performance for overall survival consistently better than SUVmax. CONCLUSION: MTV, a volumetric parameter of (18)F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with esophageal carcinoma.},
  langid = {english},
  pmid = {19826877},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Cohort Studies,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Follow-Up Studies,Humans,Male,Middle Aged,Neoplasm Staging,Positron-Emission Tomography,Prognosis,Radiopharmaceuticals,Retrospective Studies,Survival Rate,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Q5F78DQZ\\Hyun et al. - 2010 - Prognostic value of metabolic tumor volume measure.pdf}
}

@article{ida4432,
  title = {Sarcopenia Is a {{Predictor}} of {{Postoperative Respiratory Complications}} in {{Patients}} with {{Esophageal Cancer}}},
  author = {Ida, Satoshi and Watanabe, Masayuki and Yoshida, Naoya and Baba, Yoshifumi and Umezaki, Naoki and Harada, Kazuto and Karashima, Ryuichi and Imamura, Yu and Iwagami, Shiro and Baba, Hideo},
  year = {2015},
  month = dec,
  journal = {Annals of Surgical Oncology},
  volume = {22},
  number = {13},
  pages = {4432--4437},
  issn = {1534-4681},
  doi = {10.1245/s10434-015-4559-3},
  abstract = {BACKGROUND: Depletion of skeletal muscle mass (sarcopenia) indicates a poor prognosis for patients with several kinds of cancer, but it remains unclear whether esophageal squamous cell carcinoma (ESCC) is among these cancers. The aim of this study was to clarify the relationship between sarcopenia and postoperative outcome in patients with ESCC treated by esophagectomy. METHODS: Skeletal muscle mass was assessed in 138 patients who underwent esophagectomy from August 2009 to May 2014. A multifrequency bioelectrical impedance analysis (InBody 720; Biospace, Tokyo, Japan) was used to assess skeletal muscle mass just before surgery. Postoperative complications were graded according to the Clavien-Dindo classification, and univariate and multivariate analyses were performed for postoperative respiratory complications. RESULTS: Sarcopenia was determined in 61 patients (44.2 \%). Preoperative pulmonary function was significantly lower and the rate of respiratory complications significantly higher in the sarcopenia group than in the non-sarcopenia group (p {$<$} 0.01). For other complications, the differences were not significant. Multivariate analysis showed that sarcopenia [odds ratio (OR) 5.82; p = 0.0001] and longer operation time (OR 3.09; p = 0.04) were risk factors for the occurrence of respiratory complications. CONCLUSIONS: Sarcopenia may be a predictor of pulmonary complications after esophagectomy. Further analysis is needed to clarify whether nutritional intervention improves skeletal muscle mass and thus contributes to reducing postoperative respiratory complications in sarcopenic patients.},
  langid = {english},
  pmid = {25862583},
  keywords = {Aged,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Neoplasm Staging,Postoperative Complications,Prognosis,Prospective Studies,Risk Factors,Sarcopenia}
}

@article{iida753,
  title = {Risk Factors for Non-Gastric-Cancer-Related Death after Gastrectomy in Elderly Patients},
  author = {Iida, Michihisa and Takeda, Shigeru and Nakashima, Chiyo and Nishiyama, Mitsuo and Watanabe, Yusaku and Suzuki, Nobuaki and Yoshino, Shigefumi and Nakagami, Yuki and Tanabe, Tsuyoshi and Nagano, Hiroaki},
  year = {2022},
  month = nov,
  journal = {Annals of Gastroenterological Surgery},
  volume = {6},
  number = {6},
  pages = {753--766},
  issn = {2475-0328},
  doi = {10.1002/ags3.12588},
  abstract = {AIM: To identify preoperative factors, especially other diseases that cause death, that are associated with the prognosis of gastrectomy in elderly patients with gastric cancer. METHODS: This retrospective study included a total of 211 consecutive patients aged {$\geq$}75\,years who underwent radical gastrectomy due to gastric cancer. Time-dependent receiver operating characteristic curve analysis was performed to determine the optimal cutoff values for various perioperative factors. Risk factors for the overall survival and death from other diseases were analyzed using the Cox proportional hazards model. RESULTS: Among the all perioperative factors, sex, neutrophil-to-lymphocyte ratio, skeletal muscle mass index, and lymph node dissection in accordance with guidelines or not extracted as independent risk factors for death from other diseases. In an analysis restricted to the preoperative factors, sex, neutrophil-to-lymphocyte ratio, and skeletal muscle mass index of the patients were extracted as independent risk factors for death from other diseases and overall survival. We divided the patients into four groups according to the number of preoperative risk factors for death from other diseases and found that the 5-year non-gastric-cancer-related survival was different among the four groups (risk factor 0, 91.7\%; risk factor 1, 83.3\%; risk factor 2, 56.3\%; risk factor 3, 27.2\%; P\,{$<$}\,0.001). CONCLUSION: Male sex, low skeletal muscle mass index, and high neutrophil-to-lymphocyte ratio are risk factors for non-gastric-cancer-related death and the overall survival of elderly patients undergoing gastrectomy. Cautious treatment strategies are needed for elderly gastric cancer patients with many risk factors.},
  langid = {english},
  pmcid = {PMC9628222},
  pmid = {36338595},
  keywords = {elderly,gastrectomy,gastric cancer,NLR,prognosis,risk factors,Sarcopenia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RF5M57D7\\Iida et al_2022_Risk factors for non-gastric-cancer-related death after gastrectomy in elderly.pdf}
}

@article{inoue34,
  type = {Journal {{Article}}},
  title = {Changes in Exercise Capacity, Muscle Strength, and Health-Related Quality of Life in Esophageal Cancer Patients Undergoing Esophagectomy},
  author = {Inoue, T. and Ito, S. and Ando, M. and Nagaya, M. and Aso, H. and Mizuno, Y. and Hattori, K. and Nakajima, H. and Nishida, Y. and Niwa, Y. and Kodera, Y. and Koike, M. and Hasegawa, Y.},
  year = {2016},
  journal = {BMC Sports Sci Med Rehabil},
  volume = {8},
  pages = {34},
  issn = {2052-1847 (Print) 2052-1847 (Linking)},
  doi = {10.1186/s13102-016-0060-y}
}

@article{inoue68,
  type = {Journal {{Article}}},
  title = {Prevention of Postoperative Pulmonary Complications through Intensive Preoperative Respiratory Rehabilitation in Patients with Esophageal Cancer},
  author = {Inoue, J. and Ono, R. and Makiura, D. and {Kashiwa-Motoyama}, M. and Miura, Y. and Usami, M. and Nakamura, T. and Imanishi, T. and Kuroda, D.},
  year = {2013},
  journal = {Dis Esophagus},
  volume = {26},
  number = {1},
  pages = {68--74},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1111/j.1442-2050.2012.01336.x}
}

@article{inouedoz050a,
  title = {Preoperative Six-Minute Walk Distance as a Predictor of Postoperative Complication in Patients with Esophageal Cancer},
  author = {Inoue, Takayuki and Ito, Satoru and Kanda, Mitsuro and Niwa, Yukiko and Nagaya, Motoki and Nishida, Yoshihiro and Hasegawa, Yoshinori and Koike, Masahiko and Kodera, Yasuhiro},
  year = {2020},
  month = mar,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {33},
  number = {2},
  pages = {doz050},
  issn = {1442-2050},
  doi = {10.1093/dote/doz050},
  abstract = {Surgery for esophageal cancer is associated with high morbidity and mortality. Reduced pulmonary functions and exercise capacity are known as risk factors for complications after esophagectomy. The 6-minute walk distance (6MWD) measured by the 6-minute walk test (6MWT) is a simple field test that can be used to evaluate the functional exercise capacity of patients who undergo thoracic surgery. The aim of this study was to evaluate the association of the preoperative 6MWD with postoperative complications in patients with esophageal cancer. Records of a total of 111 patients who underwent thoracic surgery followed by postoperative rehabilitation from January 2013 to December 2015 were retrospectively reviewed. Data of patients who experienced Clavien-Dindo grade II or severer (grade~{$\geq~$}II) complications were compared with those who experienced grade~{$\leq$}I complications. The 6MWD was significantly correlated with age, serum albumin concentration, hemoglobin concentration, and hand grip strength. A total of 42 patients experienced grade~{$\geq$}II. The 6MWD of patients with grade~{$\geq~$}II complications was significantly shorter than that of those with grade~{$\leq$}I complications. In receiver operating characteristic analysis, 6MWD~{$\leq~$}454 m was a threshold for predicting grade~{$\geq$}II complications with 71.0\% sensitivity and 54.8\% specificity. The incidence of grade~{$\geq$}II complications led to delayed ambulation and longer stays in hospital. In the multiple regression analysis, the preoperative risk factors for incidence of grade~{$\geq$}II complications included lower levels of preoperative 6MWD and \% of the predicted value of forced expiratory volume in 1~second. Our results indicate that the 6MWT is useful to assess preoperative physical status in patients with esophageal cancer.},
  langid = {english},
  pmid = {31111872},
  keywords = {Aged,Carcinoma,complications,esophageal cancer surgery,Esophageal Neoplasms,Esophagectomy,Female,Health Status Indicators,Humans,Incidence,Male,Middle Aged,Physical Fitness,Postoperative Complications,Preoperative Care,rehabilitation,Retrospective Studies,Risk Factors,Sensitivity and Specificity,surgery,Walk Test}
}

@article{internullo1096,
  title = {Outcome after Esophagectomy for Cancer of the Esophagus and {{GEJ}} in Patients Aged over 75 Years},
  author = {Internullo, Eveline and Moons, Johnny and Nafteux, Philippe and Coosemans, Willy and Decker, Georges and De Leyn, Paul and Van Raemdonck, Dirk and Lerut, Toni},
  year = {2008},
  month = jun,
  journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
  volume = {33},
  number = {6},
  pages = {1096--1104},
  issn = {1010-7940},
  doi = {10.1016/j.ejcts.2008.03.004},
  abstract = {OBJECTIVE: Though the surgical treatment of esophageal cancer is increasingly accepted for elderly people defined as aged over 70 years, less is reported about the results in patients over 75. This study is a single institution retrospective analysis of outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years. METHODS: All consecutive patients 76 years old and over undergoing curative esophagectomy for cancer in the period 1991-2006 were analyzed as to comorbidities, outcome and long-term survival. All the data had been prospectively collected in a database. Postoperative mortality risk was assessed by P-POSSUM and O-POSSUM score for in-hospital mortality and by the recently published Steyerberg's score system [Steyerberg EW, Neville BA, Koppert LB, Lemmens VEPP, Tilanus HW, Coebergh JWW, Weeks JC, Earle CC. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277-84.] for 30-day mortality. Five-year survival was compared to the standardized survival in the general population. RESULTS: One hundred and eight patients fulfilling the abovementioned criteria were found (76 males and 32 females, mean age 79.5 years, mean standardized life-expectancy: 7.36 years). Among them, 69\% had esophageal tumors and 31\% GEJ tumors. The predominant histology was adenocarcinoma (74\%). Eighty-six (79.6\%) presented with one or more major comorbidities or a history of previous major upper-GI surgery, potentially affecting the surgical outcome. All underwent resection with curative intent (R(0) 83.3\%, R(1) 12\%, R(2) 4.6\%). The overall postoperative morbidity rate was 51.9\%, pulmonary complications (37\%) being the most frequent. Postoperative mortality, mainly due to cardiopulmonary complications, was 7.4\%, which was consistent with that predicted by P-POSSUM score (7.2\%) and lower than that predicted by O-POSSUM score (15.1\%). Thirty-day mortality was 5.5\%, being consistent with that predicted by the Steyerberg's score (6.8\%). Overall 5-year survival was 35.7\%, while R(0) overall survival 42\% and cancer specific R(0) survival 51.7\%. CONCLUSIONS: Patients 76 years old and over with esophageal or GEJ cancer should not be denied surgery solely on the basis of age. Outcome and long-term results in the selected elderly are not differing from those reported for younger patients. However, despite thorough preoperative assessment being applied in the selection of the candidates for surgery, a practical and reliable individual risk-analysis stratification is still lacking.},
  langid = {english},
  pmid = {18407509},
  keywords = {Adenocarcinoma,Age Distribution,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Epidemiologic Methods,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Humans,Male,Neoadjuvant Therapy,Neoplasm Staging,Severity of Illness Index,Sex Distribution,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\E8QB3TKK\\Internullo et al. - 2008 - Outcome after esophagectomy for cancer of the esop.pdf}
}

@article{iqbal,
  type = {Journal {{Article}}},
  title = {Cost {{Effectiveness}} of a {{Novel Attempt}} to {{Reduce Readmission}} after {{Ileostomy Creation}}},
  author = {Iqbal, A. and Raza, A. and Huang, E. and Goldstein, L. and Hughes, S. J. and Tan, S. A.},
  year = {2017},
  journal = {JSLS},
  volume = {21},
  number = {1},
  issn = {1938-3797 (Electronic) 1086-8089 (Linking)},
  doi = {10.4293/JSLS.2016.00082}
}

@article{irving370,
  type = {Journal {{Article}}},
  title = {{{NIH ImageJ}} and {{Slice-O-Matic}} Computed Tomography Imaging Software to Quantify Soft Tissue},
  author = {Irving, B. A. and Weltman, J. Y. and Brock, D. W. and Davis, C. K. and Gaesser, G. A. and Weltman, A.},
  year = {2007},
  journal = {Obesity (Silver Spring)},
  volume = {15},
  number = {2},
  pages = {370--6},
  issn = {1930-7381 (Print) 1930-7381 (Linking)},
  doi = {10.1038/oby.2007.573}
}

@article{islame363,
  title = {Fully Automated Deep-Learning Section-Based Muscle Segmentation from {{CT}} Images for Sarcopenia Assessment},
  author = {Islam, S. and Kanavati, F. and Arain, Z. and Da Costa, O. Fadeeva and Crum, W. and Aboagye, E. O. and Rockall, A. G.},
  year = {2022},
  month = may,
  journal = {Clinical Radiology},
  volume = {77},
  number = {5},
  pages = {e363-e371},
  issn = {1365-229X},
  doi = {10.1016/j.crad.2022.01.036},
  abstract = {AIM: To develop a fully automated deep-learning-based approach to measure muscle area for assessing sarcopenia on standard-of-care computed tomography (CT) of the abdomen without any case exclusion criteria, for opportunistic screening for frailty. MATERIALS AND METHODS: This ethically approved retrospective study used publicly available and institutional unselected abdominal CT images (n=1,070 training, n=31 testing). The method consisted of two sequential steps: section detection from CT volume followed by muscle segmentation on single-section. Both stages used fully convolutional neural networks (FCNN), based on a UNet-like architecture. Input data consisted of CT volumes with a variety of fields of view, section thicknesses, occlusions, artefacts, and anatomical variations. Output consisted of segmented muscle area on a CT section at the L3 vertebral level. The muscle was segmented into erector spinae, psoas, and rectus abdominus muscle groups. Output was tested against expert manual segmentation. RESULTS: Threefold cross-validation was used to evaluate the model. Section detection cross-validation error was 1.41~{$\pm~$}5.02 (in sections). Segmentation cross-validation Dice overlaps were 0.97~{$\pm~$}0.02, 0.95~{$\pm~$}0.04, and 0.94~{$\pm~$}0.04 for erector spinae, psoas, and rectus abdominus, respectively, and 0.96~{$\pm~$}0.02 for the combined muscle area, with R2~=~0.95/0.98 for muscle attenuation/area in 28/31 hold-out test cases. No statistical difference was found between the automated output and a second annotator. Fully automated processing took {$<$}1 second per CT examination. CONCLUSIONS: A FCNN pipeline accurately and efficiently automates muscle segmentation at the L3 vertebral level from unselected abdominal CT volumes, with no manual processing step. This approach is promising as a generalisable tool for opportunistic screening for frailty on standard-of-care CT.},
  langid = {english},
  pmid = {35260232},
  keywords = {Deep Learning,Frailty,Humans,Image Processing; Computer-Assisted,L3,ML,Muscles,Retrospective Studies,Sarcopenia,Tomography; X-Ray Computed}
}

@article{jack1313,
  title = {The Effect of Neoadjuvant Chemotherapy on Physical Fitness and Survival in Patients Undergoing Oesophagogastric Cancer Surgery},
  author = {Jack, S. and West, M. A. and Raw, D. and Marwood, S. and Ambler, G. and Cope, T. M. and Shrotri, M. and Sturgess, R. P. and Calverley, P. M. A. and Ottensmeier, C. H. and Grocott, M. P. W.},
  year = {2014},
  month = oct,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {40},
  number = {10},
  pages = {1313--1320},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2014.03.010},
  abstract = {BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by surgery for resectable oesophageal or gastric cancer improves outcome when compared with surgery alone. However NAC has adverse effects. We assess here whether NAC adversely affects physical fitness and whether such an effect is associated with impaired survival following surgery. METHODS: We prospectively studied 116 patients with oesophageal or gastric cancer to assess the effect of NAC on physical fitness, of whom 89 underwent cardiopulmonary exercise testing (CPET) before NAC and proceeded to surgery. 39 patients were tested after all cycles of NAC but prior to surgery. Physical fitness was assessed by measuring oxygen uptake (VO{$_2$} in ml kg(-1) min(-1)) at the estimated lactate threshold (\texttheta L) and at peak exercise (VO{$_2$} peak in ml kg(-1) min(-1)). RESULTS: VO{$_2$} at \texttheta L and at peak were significantly lower after NAC compared to pre-NAC values: VO{$_2$} at \texttheta L 14.5 {$\pm$} 3.8 (baseline) vs. 12.3 {$\pm$} 3.0 (post-NAC) ml kg(-1) min(-1); p {$\leq$} 0.001; VO{$_2$} peak 20.8 {$\pm$} 6.0 vs. 18.3 {$\pm$} 5.1 ml kg(-1) min(-1); p {$\leq$} 0.001; absolute VO{$_2$} (ml min(-1)) at \texttheta L and peak were also lower post-NAC; p {$\leq$} 0.001. Decreased baseline VO{$_2$} at \texttheta L and peak were associated with increased one year mortality in patients who completed a full course of NAC and had surgery; p = 0.014. CONCLUSION: NAC before cancer surgery significantly reduced physical fitness in the overall cohort. Lower baseline fitness was associated with reduced one-year-survival in patients completing NAC and surgery, but not in patients who did not complete NAC. It is possible that in some patients the harms of NAC may outweigh the benefits. Trials Registry Number: NCT01335555.},
  langid = {english},
  pmid = {24731268},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Agents,Cancer surgery,Cardiopulmonary exercise testing,Chemotherapy; Adjuvant,Cohort Studies,CPT,Esophageal Neoplasms,Exercise Test,Exercise Tolerance,Female,Humans,Male,Middle Aged,Neoadjuvant chemotherapy,Neoadjuvant Therapy,Oesphagogastric,Oxygen Consumption,Physical fitness,Physical Fitness,Prospective Studies,Stomach Neoplasms,Survival}
}

@article{james516,
  title = {Mitomycin or Cisplatin Chemoradiation with or without Maintenance Chemotherapy for Treatment of Squamous-Cell Carcinoma of the Anus ({{ACT II}}): A Randomised, Phase 3, Open-Label, 2 \texttimes{} 2 Factorial Trial},
  shorttitle = {Mitomycin or Cisplatin Chemoradiation with or without Maintenance Chemotherapy for Treatment of Squamous-Cell Carcinoma of the Anus ({{ACT II}})},
  author = {James, Roger D. and {Glynne-Jones}, Robert and Meadows, Helen M. and Cunningham, David and Myint, Arthur Sun and Saunders, Mark P. and Maughan, Timothy and McDonald, Alec and Essapen, Sharadah and Leslie, Martin and Falk, Stephen and Wilson, Charles and Gollins, Simon and Begum, Rubina and Ledermann, Jonathan and Kadalayil, Latha and {Sebag-Montefiore}, David},
  year = {2013},
  month = may,
  journal = {The Lancet. Oncology},
  volume = {14},
  number = {6},
  pages = {516--524},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(13)70086-X},
  abstract = {BACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50\%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival. METHODS: In this 2 \texttimes{} 2 factorial trial, we enrolled patients with histologically confirmed squamous-cell carcinoma of the anus without metastatic disease from 59 centres in the UK. Patients were randomly assigned to one of four groups, to receive either mitomycin (12 mg/m(2) on day 1) or cisplatin (60 mg/m(2) on days 1 and 29), with fluorouracil (1000 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); with or without two courses of maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14). The random allocation was generated by computer and patients assigned by telephone. Randomisation was done by minimisation and stratified by tumour site, T and N stage, sex, age, and renal function. Neither patients nor investigators were masked to assignment. Primary endpoints were complete response at 26 weeks and acute toxic effects (for chemoradiation), and progression-free survival (for maintenance). The primary analyses were done by intention to treat. This study is registered at controlled-trials.com, number 26715889. FINDINGS: We enrolled 940 patients: 472 were assigned to mitomycin, of whom 246 were assigned to no maintenance, 226 to maintenance; 468 were assigned to cisplatin, of whom 246 were assigned to no maintenance, 222 to maintenance. Median follow-up was 5.1 years (IQR 3.9-6.9). 391 of 432 (90.5\%) patients in the mitomycin group versus 386 of 431 (89.6\%) in the cisplatin group had a complete response at 26 weeks (difference -0.9\%, 95\% CI -4.9 to 3.1; p=0.64). Overall, toxic effects were similar in each group (334/472 [71\%] for mitomycin vs 337/468 [72\%] for cisplatin). The most common grade 3-4 toxic effects were skin (228/472 [48\%] vs 222/468 [47\%]), pain (122/472 [26\%] vs 135/468 [29\%]), haematological (124/472 [26\%] vs 73/468 [16\%]), and gastrointestinal (75/472 [16\%] vs 85/468 [18\%]). 3-year progression-free survival was 74\% (95\% CI 69-77; maintenance) versus 73\% (95\% CI 68-77; no maintenance; hazard ratio 0.95, 95\% CI 0.75-1.21; p=0.70). INTERPRETATION: The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK. FUNDING: Cancer Research UK.},
  langid = {english},
  pmid = {23578724},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Anus Neoplasms,Carcinoma; Squamous Cell,Chemoradiotherapy,Cisplatin,Disease-Free Survival,Dose Fractionation; Radiation,Drug Administration Schedule,Female,Fluorouracil,Humans,Intention to Treat Analysis,Kaplan-Meier Estimate,Male,Middle Aged,Mitomycin,Neoplasm Recurrence; Local,Proportional Hazards Models,Time Factors,Treatment Outcome,United Kingdom},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JL7GB5PV\\James et al_2013_Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy.pdf}
}

@article{jang360,
  title = {Opportunistic {{Osteoporosis Screening}} at {{Routine Abdominal}} and {{Thoracic CT}}: {{Normative L1 Trabecular Attenuation Values}} in {{More}} than 20 000 {{Adults}}},
  shorttitle = {Opportunistic {{Osteoporosis Screening}} at {{Routine Abdominal}} and {{Thoracic CT}}},
  author = {Jang, Samuel and Graffy, Peter M. and Ziemlewicz, Timothy J. and Lee, Scott J. and Summers, Ronald M. and Pickhardt, Perry J.},
  year = {2019},
  month = may,
  journal = {Radiology},
  volume = {291},
  number = {2},
  pages = {360--367},
  issn = {1527-1315},
  doi = {10.1148/radiol.2019181648},
  abstract = {Background Abdominal and thoracic CT provide a valuable opportunity for osteoporosis screening regardless of the clinical indication for imaging. Purpose To establish reference normative ranges for first lumbar vertebra (L1) trabecular attenuation values across all adult ages to measure bone mineral density (BMD) at routine CT. Materials and Methods Reference data were constructed from 20 374 abdominal and/or thoracic CT examinations performed at 120 kV. Data were derived from adults (mean age, 60 years {$\pm$} 12 [standard deviation]; 56.1\% [11 428 of 20 374] women). CT examinations were performed with (n = 4263) or without (n = 16 111) intravenous contrast agent administration for a variety of unrelated clinical indications between 2000 and 2018. L1 Hounsfield unit measurement was obtained either with a customized automated tool (n = 11 270) or manually by individual readers (n = 9104). The effects of patient age, sex, contrast agent, and manual region-of-interest versus fully automated L1 Hounsfield unit measurement were assessed using multivariable logistic regression analysis. Results Mean L1 attenuation decreased linearly with age at a rate of 2.5 HU per year, averaging 226 HU {$\pm$} 44 for patients younger than 30 years and 89 HU {$\pm$} 38 for patients 90 years or older. Women had a higher mean L1 attenuation compared with men (P {$<$} .008) until menopause, after which both groups had similar values. Administration of intravenous contrast agent resulted in negligible differences in mean L1 attenuation values except in patients younger than 40 years. The fully automated method resulted in measurements that were average 21 HU higher compared with manual measurement (P {$<$} .004); at intrapatient subanalysis, this difference was related to the level of transverse measurement used (midvertebra vs off-midline level). Conclusion Normative ranges of L1 vertebra trabecular attenuation were established across all adult ages, and these can serve as a quick reference at routine CT to identify adults with low bone mineral density who are at risk for osteoporosis. \textcopyright{} RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Smith in this issue.},
  langid = {english},
  pmcid = {PMC6492986},
  pmid = {30912719},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Cancellous Bone,Contrast Media,Female,Humans,Male,Mass Screening,Middle Aged,ML,Osteoporosis,Radiography; Abdominal,Radiography; Thoracic,Retrospective Studies,Tomography; X-Ray Computed,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9IUZ2KWC\\Jang et al_2019_Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT.pdf}
}

@article{jang557,
  title = {Skeletal {{Muscle Mass Loss During Cancer Treatment}}: {{Differences}} by {{Race}} and {{Cancer Site}}},
  shorttitle = {Skeletal {{Muscle Mass Loss During Cancer Treatment}}},
  author = {Jang, Min Kyeong and Park, Chang Gi and Hong, Susan and Laddu, Deepika and Li, Hongjin and Rhee, Esther and Doorenbos, Ardith Z.},
  year = {2020},
  month = sep,
  journal = {Oncology nursing forum},
  volume = {47},
  number = {5},
  pages = {557--566},
  issn = {0190-535X},
  doi = {10.1188/20.ONF.557-566},
  abstract = {OBJECTIVES: To examine skeletal muscle mass change in a racially diverse sample of patients undergoing cancer treatment, determine significant predictors of muscle mass loss, and explore the interaction of race and cancer site. SAMPLE \& SETTING: A retrospective analysis was conducted for 212 patients seeking treatment at a university hospital clinic. METHODS \& VARIABLES: Skeletal muscle mass index (SMI) was determined by computed tomography at the time of cancer diagnosis and with cancer treatment. RESULTS: One hundred thirty-four patients (63\%) had SMI loss with cancer treatment. Race and cancer site were found to be significant predictors of SMI loss. Compared to other racial groups, non-Hispanic Black (NHB) patients had the greatest SMI loss (p {$<$} 0.001) with cancer treatment. NHB patients with rectal cancer experienced the greatest SMI loss compared to patients of other races and cancer types. IMPLICATIONS FOR NURSING: To improve survivorship care for patients with cancer, it is essential to develop strategies for assessing and managing skeletal muscle mass loss throughout treatment, particularly for NHB patients with rectal cancer.},
  pmcid = {PMC7793555},
  pmid = {32830799},
  keywords = {Disparities},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XPYEZ4H8\\Jang et al. - 2020 - Skeletal Muscle Mass Loss During Cancer Treatment.pdf}
}

@article{jang8,
  title = {Characteristics of Sarcopenia by {{European}} Consensuses and a Phenotype Score},
  author = {Jang, Il-Young and Lee, Eunju and Lee, Heayon and Park, Hyungchul and Kim, Sunyoung and Kim, Kwang-il and Jung, Hee-Won and Kim, Dae Hyun},
  pages = {8},
  abstract = {Background We aimed to assess the clinical characteristics of sarcopenia by the original and revised European Working Group on Sarcopenia in Older People (EWGSOP 1 and 2), and to propose a new sarcopenia phenotype score (SPS) to improve relevance of clinical outcomes. Methods Analyses were performed in 1408 older adults of the Aging Study of PyeongChang Rural Area, a community-based cohort in Korea. For sarcopenia definitions, we used EWGSOP 1, EWGSOP 2, and SPS, a new index counting number of abnormal domains among components of grip strength, gait speed, or muscle mass. Frailty status by the frailty index and the Cardiovascular Health Study frailty score was compared with sarcopenia measures. Prediction ability for composite outcome combining death and institutionalization due to functional decline was assessed among sarcopenia measures. Results Generally, sarcopenia spectrum by both EWGSOP 1 and 2 was associated with worse functional status in parameters of geriatric assessments. However, population who were considered as sarcopenic by EWGSOP 1, but not by EWGSOP 2, showed increased risk of composite outcome and worse frailty status, compared with people who were classified as not sarcopenic by both EWGSOP 1 and 2. With SPS, dose\textendash response relationship was observed with both frailty status and outcome prediction. Prediction for composite outcome was better in SPS than in EWGSOP 2 classification. Conclusions A new SPS might be used to classify sarcopenic burden in older adults to resolve possible inconsistencies in phenotype correlation and outcome prediction of EWGSOP 2 criteria.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CWYCPDHX\\Jang et al. - Characteristics of sarcopenia by European consensu.pdf}
}

@article{jarvinen27,
  title = {Loss of Skeletal Muscle Mass during Neoadjuvant Treatments Correlates with Worse Prognosis in Esophageal Cancer: A Retrospective Cohort Study},
  shorttitle = {Loss of Skeletal Muscle Mass during Neoadjuvant Treatments Correlates with Worse Prognosis in Esophageal Cancer},
  author = {J{\"a}rvinen, Tommi and Ilonen, Ilkka and Kauppi, Juha and Salo, Jarmo and R{\"a}s{\"a}nen, Jari},
  year = {2018},
  month = feb,
  journal = {World Journal of Surgical Oncology},
  volume = {16},
  number = {1},
  pages = {27},
  issn = {1477-7819},
  doi = {10.1186/s12957-018-1327-4},
  abstract = {BACKGROUND: Nutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis of esophageal cancer patients. METHODS: Esophageal cancer patients (N~=\,115) undergoing neoadjuvant therapy and surgery between 2010 and 2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which defined sarcopenia (SMI\,{$<$}\,52.4~cm2/m2 for men and {$<$}\,38.5~cm2/m2 for women). Images were collected before and after neoadjuvant treatments. RESULTS: Sarcopenia in preoperative imaging was prevalent in 92 patients (80\%). Median overall survival was 900~days (interquartile range 334-1447) with no difference between sarcopenic (median\,=\,900) and non-sarcopenic (median\,=\,914) groups (p~=\,0.872). Complication rates did not differ (26.1\% vs 32.6\%, p~=\,0.725). A 2.98\% decrease in skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p~=\,0.04). CONCLUSION: Loss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.},
  langid = {english},
  pmcid = {PMC5809976},
  pmid = {29433514},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Body composition,Cachexia,Combined Modality Therapy,Cross-Sectional Studies,Esophageal neoplasms,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Malnutrition,Middle Aged,Muscle; Skeletal,Neoadjuvant Therapy,Prognosis,Retrospective Studies,Risk Factors,Sarcopenia,Survival Rate,Thoracic surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QZEDQJTX\\JÃ¤rvinen et al. - 2018 - Loss of skeletal muscle mass during neoadjuvant tr.pdf}
}

@article{javeri624,
  title = {Influence of the Baseline {{18F-fluoro-2-deoxy-D-glucose}} Positron Emission Tomography Results on Survival and Pathologic Response in Patients with Gastroesophageal Cancer Undergoing Chemoradiation},
  author = {Javeri, Heta and Xiao, Lianchun and Rohren, Eric and Komaki, Ritsuko and Hofstetter, Wayne and Lee, Jeffrey H. and Maru, Dipen and Bhutani, Manoop S. and Swisher, Stephen G. and Wang, Xuemei and Ajani, Jaffer A.},
  year = {2009},
  month = feb,
  journal = {Cancer},
  volume = {115},
  number = {3},
  pages = {624--630},
  issn = {0008-543X},
  doi = {10.1002/cncr.24056},
  abstract = {BACKGROUND: In patients with esophageal cancer who receive chemoradiation, tools to predict/prognosticate outcome before administering therapy are lacking. The authors evaluated initial standardized unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography and its association with overall survival and the degree of pathologic response after surgery. METHODS: The authors analyzed 161 patients with esophageal adenocarcinoma who had chemoradiation followed by surgery. The log-rank test, univariate Cox proportional hazards model, Kaplan-Meier survival plot, and Fisher exact test were used to analyze dichotomized iSUV and its association with overall survival and pathologic response. RESULTS: The median age of 161 patients was 61 years (range, 26-80 years) and the majority of patients had lower esophageal or gastroesophageal junction involvement. All patients received fluoropyrimidine and, most commonly, a taxane or platinum compound with concomitant radiation. The median radiation dose was 45 grays (Gy) (range, 45 Gy-50.4 Gy). The median iSUV for all patients was 10.1 (range, 0-58). Using the Fisher exact test, iSUV was not found to be associated with the location of the primary cancer. iSUV higher than the median (10.1) was associated with a better pathologic response (P = .06). Patients with primary cancer with iSUV {$>$}10.1 had a lower risk for death (hazards ratio of 0.56) compared with those with iSUV {$<$} or = 10.1. Higher iSUV was nonsignificantly associated with improved survival (P = .07). CONCLUSIONS: Data from the current study suggest that lower iSUV is associated with poor survival and lower probability of response to chemoradiation. iSUV needs to be further evaluated because it may be used to complement other imaging or biomarker assessments to individualize therapy.},
  langid = {english},
  pmid = {19130466},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antineoplastic Agents,CHemoRT,Combined Modality Therapy,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm; Residual,Outcome Assessment; Health Care,PET,Positron-Emission Tomography,Predictive Value of Tests,Prognosis,Survival Rate,Treatment Outcome}
}

@article{jensen32,
  title = {{{GLIM Criteria}} for the {{Diagnosis}} of {{Malnutrition}}: {{A Consensus Report From}} the {{Global Clinical Nutrition Community}}},
  shorttitle = {{{GLIM Criteria}} for the {{Diagnosis}} of {{Malnutrition}}},
  author = {Jensen, Gordon L. and Cederholm, Tommy and Correia, M. Isabel T. D. and Gonzalez, M. Christina and Fukushima, Ryoji and Higashiguchi, Takashi and {de Baptista}, Gertrudis Adrianza and Barazzoni, Rocco and Blaauw, Ren{\'e}e and Coats, Andrew J. S. and Crivelli, Adriana and Evans, David C. and Gramlich, Leah and {Fuchs-Tarlovsky}, Vanessa and Keller, Heather and Llido, Luisito and Malone, Ainsley and Mogensen, Kris M. and Morley, John E. and Muscaritoli, Maurizio and Nyulasi, Ibolya and Pirlich, Matthias and Pisprasert, Veeradej and {de van der Schueren}, Marian and Siltharm, Soranit and Singer, Pierre and Tappenden, Kelly A. and Velasco, Nicolas and Waitzberg, Dan L. and Yamwong, Preyanuj and Yu, Jianchun and Compher, Charlene and Van Gossum, Andre},
  year = {2019},
  month = jan,
  journal = {JPEN. Journal of parenteral and enteral nutrition},
  volume = {43},
  number = {1},
  pages = {32--40},
  issn = {1941-2444},
  doi = {10.1002/jpen.1440},
  abstract = {BACKGROUND: This initiative aims to build a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS: The Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS: A 2-step approach for the malnutrition diagnosis was selected, that is, first screening to identify at risk status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among GLIM participants that selected 3 phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and 2 etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least 1 phenotypic criterion and 1 etiologic criterion should be present. Phenotypic metrics for grading severity are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSIONS: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The construct should be re-considered every 3-5 years.},
  langid = {english},
  pmid = {30175461},
  keywords = {Adult,Aged,assessment,Body Mass Index,Cachexia,Consensus,diagnosis,Female,GLIM,Humans,Leadership,Male,malnutrition,Malnutrition,Mass Screening,Middle Aged,Muscles,Nutrition Assessment,Nutritional Status,Phenotype,Practice Guidelines as Topic,Sarcopenia,screening,Societies; Scientific,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BWFUQQV2\\Jensen et al_2019_GLIM Criteria for the Diagnosis of Malnutrition.pdf}
}

@article{jensendoac050,
  title = {Neoadjuvant versus Definitive Chemoradiation in Locally Advanced Esophageal Cancer for Patients of Advanced Age or Significant Comorbidities},
  author = {Jensen, Garrett L. and Hammonds, Kendall P. and Haque, Waqar},
  year = {2022},
  month = jul,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  pages = {doac050},
  issn = {1442-2050},
  doi = {10.1093/dote/doac050},
  abstract = {The addition of surgery to chemoradiation for esophageal cancer has not shown a survival benefit in randomized trials. Patients with more comorbidities or advanced age are more likely to be given definitive chemoradiation due to surgical risk. We aimed to identify subsets of patients in whom the addition of surgery to chemoradiation does not provide an overall survival (OS) benefit. The National Cancer Database was queried for patients with locally advanced esophageal cancer who received either definitive chemoradiation or neoadjuvant chemoradiation followed by surgery. Bivariate analysis was used to assess the association between patient characteristics and treatment groups. Log-rank tests and Cox proportional hazards models were performed to assess for differences in survival. A total of 15,090 with adenocarcinoma and 5,356 with squamous cell carcinoma met the inclusion criteria. Patients treated with neoadjuvant chemoradiation and surgery had significantly improved survival by Cox proportional hazards model regardless of histology if {$<$}50, 50-60, 61-70, or 71-80~years old. There was no significant benefit or detriment in patients 81-90~years old. Survival advantage was also significant with a Charlson/Deyo comorbidity condition score of 0, 1, 2, and {$\geq$}3 in adenocarcinoma squamous cell carcinoma with scores of 2 or {$\geq$}3 had no significant benefit or detriment. Patients 81-90~years old or with squamous cell carcinoma and a Charlson/Deyo comorbidity score\,{$\geq$}\,2 lacked an OS benefit from neoadjuvant chemoradiation followed by surgery compared with definitive chemoradiation. Careful consideration of esophagectomy-specific surgical risks should be used when recommending treatment for these patients.},
  langid = {english},
  pmid = {35901451},
  keywords = {elderly,esophagectomy,performance status}
}

@article{jiao278,
  title = {Clinical Significance of Micrometastasis in Lung and Esophageal Cancer: A New Paradigm in Thoracic Oncology},
  shorttitle = {Clinical Significance of Micrometastasis in Lung and Esophageal Cancer},
  author = {Jiao, Xiaolong and Krasna, Mark J.},
  year = {2002},
  month = jul,
  journal = {The Annals of Thoracic Surgery},
  volume = {74},
  number = {1},
  pages = {278--284},
  issn = {0003-4975},
  doi = {10.1016/s0003-4975(01)03376-8},
  abstract = {In the past decade, detection of micrometastatic disease in different clinical samples including pleural lavage, lymph node, bone marrow, and blood has become a rapidly growing area of interest in research of non-small cell lung cancer and esophageal cancer. The results of these studies support the concept that, just as in many other solid malignancies, systemic spread may happen at an early stage in non-small cell lung cancer and esophageal cancer. Such systemic spread is often occult (micrometastases) at the time of primary diagnosis, which may have adverse effects on survival. Improved staging can be expected with information on micrometastases, and a subgroup of patients who will benefit most from adjuvant therapy might be identified. Although reliable and standard methods need to be developed before detection of micrometastasis is incorporated in the routine clinical practice, we suggest that it be considered an important correlate in clinical trials in non-small cell lung cancer and esophageal cancer.},
  langid = {english},
  pmid = {12118789},
  keywords = {Bone Marrow Neoplasms,Carcinoma; Non-Small-Cell Lung,Esophageal Neoplasms,Humans,Immunohistochemistry,Lung Neoplasms,Lymph Nodes,Lymphatic Metastasis,Neoplastic Cells; Circulating,Pleural Neoplasms,Prognosis}
}

@article{jin1681,
  title = {Multicenter, {{Randomized}}, {{Phase III Trial}} of {{Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy}} in {{Locally Advanced Rectal Cancer}} ({{STELLAR}})},
  author = {Jin, Jing and Tang, Yuan and Hu, Chen and Jiang, Li-Ming and Jiang, Jun and Li, Ning and Liu, Wen-Yang and Chen, Si-Lin and Li, Shuai and Lu, Ning-Ning and Cai, Yong and Li, Yong-Heng and Zhu, Yuan and Cheng, Guang-Hui and Zhang, Hong-Yan and Wang, Xin and Zhu, Su-Yu and Wang, Jun and Li, Gao-Feng and Yang, Jia-Lin and Zhang, Kuan and Chi, Yihebali and Yang, Lin and Zhou, Hai-Tao and Zhou, Ai-Ping and Zou, Shuang-Mei and Fang, Hui and Wang, Shu-Lian and Zhang, Hai-Zeng and Wang, Xi-Shan and Wei, Li-Chun and Wang, Wen-Ling and Liu, Shi-Xin and Gao, Yuan-Hong and Li, Ye-Xiong},
  year = {2022},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {40},
  number = {15},
  pages = {1681--1692},
  issn = {1527-7755},
  doi = {10.1200/JCO.21.01667},
  abstract = {PURPOSE: To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. MATERIALS AND METHODS: Patients with distal or middle-third, clinical primary tumor stage 3-4 and/or regional lymph node-positive rectal cancer were randomly assigned (1:1) to short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiotherapy (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [chemoradiotherapy; CRT]). Total mesorectal excision was undertaken 6-8 weeks after preoperative treatment, with two additional cycles of CAPOX (intravenous oxaliplatin [130 mg/m2, once a day] on day 1 and capecitabine [1,000 mg/m2, twice a day] from days 1 to 14) in the TNT group and six cycles of CAPOX in the CRT group. The primary end point was 3-year disease-free survival (DFS). RESULTS: Between August 2015 and August 2018, a total of 599 patients were randomly assigned to receive TNT (n = 302) or CRT (n = 297). At a median follow-up of 35.0 months, 3-year DFS was 64.5\% and 62.3\% in TNT and CRT groups, respectively (hazard ratio, 0.883; one-sided 95\% CI, not applicable to 1.11; P {$<$} .001 for noninferiority). There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5\% v 75.1\%; P = .033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III-V toxicities during preoperative treatment was 26.5\% in the TNT group versus 12.6\% in the CRT group (P {$<$} .001). CONCLUSION: Short-term radiotherapy with preoperative chemotherapy followed by surgery was efficacious with acceptable toxicity and could be used as an alternative to CRT for locally advanced rectal cancer.},
  langid = {english},
  pmcid = {PMC9113208},
  pmid = {35263150},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Chemoradiotherapy,Fluorouracil,Humans,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Neoplasm Staging,Neoplasms; Second Primary,Rectal Neoplasms,Rectal;TNT},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7RFWGVDJ\\Jin et al. - 2022 - Multicenter, Randomized, Phase III Trial of Short-.pdf}
}

@article{jine035031,
  title = {Association of the Neutrophil to Lymphocyte Ratio and Clinical Outcomes in Patients with Lung Cancer Receiving Immunotherapy: A Meta-Analysis},
  shorttitle = {Association of the Neutrophil to Lymphocyte Ratio and Clinical Outcomes in Patients with Lung Cancer Receiving Immunotherapy},
  author = {Jin, Jing and Yang, Lan and Liu, Dan and Li, Weimin},
  year = {2020},
  month = jun,
  journal = {BMJ open},
  volume = {10},
  number = {6},
  pages = {e035031},
  issn = {2044-6055},
  doi = {10.1136/bmjopen-2019-035031},
  abstract = {OBJECTIVES: To explore the relationship between the pretreatment or post-treatment neutrophil to lymphocyte ratio (NLR) and overall survival (OS)/progression-free survival (PFS) in patients with lung cancer receiving immunotherapy. DESIGN: We searched several databases to collect relevant studies conducted until July 2019. We carefully reviewed the full text of the included publications and combined the HRs and 95\% CIs to assess the association between the NLR and survival time in patients with lung cancer receiving immunotherapy. DATA SOURCES: PubMed, the Cochrane Library, Embase and Web of Science ELIGIBILITY CRITERIA: Studies reporting the prognostic value of the NLR in patients with lung cancer receiving immunotherapy were enrolled. DATA EXTRACTION AND SYNTHESIS: Basic information on the articles and patients (NLR cut-off value, NLR at baseline and HRs with 95\% CIs for OS and PFS) was extracted by two authors independently. The pooled HRs of OS and PFS were synthesised using the random effects or fixed effects model. RESULTS: Twenty-three studies with 2068 patients were enrolled. Among all patients, 1305 (64.0\%) were men and 643 (31.4\%) were diagnosed with squamous cell carcinoma (SCC). In a pooled analysis of OS and PFS from all studies, an elevated NLR predicted poor OS (HR=1.62; 95\%\,CI: 1.41 to 1.87; p{$<$}0.001) and PFS (HR=1.47; 95\%\,CI: 1.25 to 1.72; p{$<$}0.001). Subgroup analyses stratified showed that the post-treatment NLR was not significantly related to OS and that patients in Asia had significantly higher HRs than those in Europe and America. Furthermore, the proportion of SCC and baseline NLR could affect the prognostic value of the NLR. CONCLUSIONS: Our study found that an elevated NLR was associated with poor OS and PFS in patients with lung cancer receiving immunotherapy and that several clinical factors might have an impact on the predictive value of the NLR in the survival of patients with lung cancer.},
  langid = {english},
  pmcid = {PMC7282333},
  pmid = {32499266},
  keywords = {Carcinoma; Squamous Cell,Correlation of Data,epidemiology,Humans,immunology,Immunotherapy,Leukocyte Count,Lung,Lung Neoplasms,Lymphocyte Count,Neutrophils,NLR,Prognosis,respiratory tract tumours,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KJ9A9V7C\\Jin et al_2020_Association of the neutrophil to lymphocyte ratio and clinical outcomes in.pdf}
}

@article{johansson667,
  title = {Impact of Proton Pump Inhibitors on Benign Anastomotic Stricture Formations after Esophagectomy and Gastric Tube Reconstruction: Results from a Randomized Clinical Trial},
  shorttitle = {Impact of Proton Pump Inhibitors on Benign Anastomotic Stricture Formations after Esophagectomy and Gastric Tube Reconstruction},
  author = {Johansson, Jan and Oberg, Stefan and Wenner, J{\"o}rgen and Zilling, Thomas and Johnsson, Folke and {von Holstein}, Christer Sta{\"e}l and Walther, Bruno},
  year = {2009},
  month = nov,
  journal = {Annals of Surgery},
  volume = {250},
  number = {5},
  pages = {667--673},
  issn = {1528-1140},
  doi = {10.1097/SLA.0b013e3181bcb139},
  abstract = {OBJECTIVE: The primary aim of this study was to evaluate if the use of proton pump inhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses. SUMMARY BACKGROUND DATA: Benign anastomotic strictures are associated with anastomotic leaks or conduit ischemia. Also patients without those complications develop benign anastomotic strictures. We hypothesize that patients without postoperative anastomotic complications may develop benign anastomotic strictures due to exposure of acid gastric tube contents to the anastomotic area, and that the formation of such strictures may be reduced by prophylactic use of PPIs. METHODS: Eighty patients without preoperative chemo- or radiotherapy, without clinical or radiological signs of anastomotic leaks were included in this clinical trial. The patients were randomized to b.i.d. PPIs or no treatment for 1 year. Benign anastomotic strictures were defined as anastomotic narrowing not allowing a standard diagnostic endoscope to pass without dilatation. The study was registered in the EudraCT database (2009-009997-28) for clinical trials. RESULTS: : Seventy-nine patients were evaluated. Benign anastomotic strictures developed in 5/39 (13\%) patients in the PPI group and in 18/40 (45\%) in the control group (RR 5.6, 95\% CI: 2.0-15.9, P = 0.001). The use of a narrower 25 mm cartridge as compared to a wider 28 or 31 mm cartridge significantly increased stricture formations (RR 2.9, 95\% CI: 1.1-7.6, P = 0.025). CONCLUSIONS: Prophylactic PPI treatment reduced the prevalence of benign anastomotic strictures following esophagectomy with gastric tube reconstruction and circular stapled anastomoses. Larger sized circular staple cartridges additionally reduced the stricture prevalence.},
  langid = {english},
  pmid = {19801933},
  keywords = {Anastomosis; Surgical,Dilatation,Esophageal Neoplasms,Esophageal pH Monitoring,Esophageal Stenosis,Esophagectomy,Esophagus,Female,Humans,Male,Proton Pump Inhibitors,Stomach,Surgical Stapling}
}

@article{jones245,
  type = {Journal {{Article}}},
  title = {Patient-{{Reported Outcomes Measurement Information System}} ({{PROMIS}}) {{Use}} in {{Surgical Care}}: {{A Scoping Study}}},
  author = {Jones, R. S. and Stukenborg, G. J.},
  year = {2017},
  journal = {J Am Coll Surg},
  volume = {224},
  number = {3},
  pages = {245-254 e1},
  issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
  doi = {10.1016/j.jamcollsurg.2016.11.015}
}

@article{jones327,
  type = {Journal {{Article}}},
  title = {Transitional Care Interventions and Hospital Readmissions in Surgical Populations: A Systematic Review},
  author = {Jones, C. E. and Hollis, R. H. and Wahl, T. S. and Oriel, B. S. and Itani, K. M. and Morris, M. S. and Hawn, M. T.},
  year = {2016},
  journal = {Am J Surg},
  volume = {212},
  number = {2},
  pages = {327--35},
  issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
  doi = {10.1016/j.amjsurg.2016.04.004}
}

@article{jonesO20,
  type = {Journal {{Article}}},
  title = {Simple Psoas Cross-Sectional Area Measurement Is a Quick and Easy Method to Assess Sarcopenia and Predicts Major Surgical Complications},
  author = {Jones, K. I. and Doleman, B. and Scott, S. and Lund, J. N. and Williams, J. P.},
  year = {2015},
  journal = {Colorectal Dis},
  volume = {17},
  number = {1},
  pages = {O20-6},
  issn = {1463-1318 (Electronic) 1462-8910 (Linking)},
  doi = {10.1111/codi.12805}
}

@article{jordanNutritionalTherapyPatients2018,
  title = {Nutritional {{Therapy}} for {{Patients}} with {{Esophageal Cancer}}},
  author = {Jordan, Taja and Mastnak, Denis Mlakar and Palamar, Nizra and Kozjek, Nada Rotovnik},
  year = {2018},
  month = jan,
  journal = {Nutrition and Cancer-an International Journal},
  volume = {70},
  number = {1},
  pages = {23--29},
  issn = {1532-7914},
  doi = {10.1080/01635581.2017.1374417},
  abstract = {Malnutrition develops in 79\% patients with esophageal cancer. Thus, these patients represent a group of cancer patients, which is the most nutritionally compromised. Dysphagia and more than 10\% loss of body weight are already present at the time of diagnosis. Treatments for esophageal cancer contribute significantly to the development of malnutrition. This paper describes the nutritional treatment of patients and nutritional strategies in patients with dysphagia and other nutritional problems that accompany the treatment of patients with esophageal cancer. Here are shown the types and methods of nutritional support, which are suitable for this group of patients. Nutritional support of patients with esophageal cancer is performed as a parallel therapeutic route.},
  langid = {english},
  pmid = {29016197},
  keywords = {Body Composition,Deglutition Disorders,Dietary Supplements,Enteral Nutrition,Esophageal Neoplasms,Esophagectomy,Humans,Nutrition Assessment,Nutritional Status,Nutritional Support,Parenteral Nutrition}
}

@article{joshi1026,
  title = {A Systematic Review of Randomized Trials Evaluating Regional Techniques for Postthoracotomy Analgesia},
  author = {Joshi, Girish P. and Bonnet, Francis and Shah, Rajesh and Wilkinson, Roseanne C. and Camu, Frederic and Fischer, Barrie and Neugebauer, Edmund A. M. and Rawal, Narinder and Schug, Stephan A. and Simanski, Christian and Kehlet, Henrik},
  year = {2008},
  month = sep,
  journal = {Anesthesia and Analgesia},
  volume = {107},
  number = {3},
  pages = {1026--1040},
  issn = {1526-7598},
  doi = {10.1213/01.ane.0000333274.63501.ff},
  abstract = {BACKGROUND: Thoracotomy induces severe postoperative pain and impairment of pulmonary function, and therefore regional analgesia has been intensively studied in this procedure. Thoracic epidural analgesia is commonly considered the "gold standard" in this setting; however, evaluation of the evidence is needed to assess the comparative benefits of alternative techniques, guide clinical practice and identify areas requiring further research. METHODS: In this systematic review of randomized trials we evaluated thoracic epidural, paravertebral, intrathecal, intercostal, and interpleural analgesic techniques, compared to each other and to systemic opioid analgesia, in adult thoracotomy. Postoperative pain, analgesic use, and complications were analyzed. RESULTS: Continuous paravertebral block was as effective as thoracic epidural analgesia with local anesthetic (LA) but was associated with a reduced incidence of hypotension. Paravertebral block reduced the incidence of pulmonary complications compared with systemic analgesia, whereas thoracic epidural analgesia did not. Thoracic epidural analgesia was superior to intrathecal and intercostal techniques, although these were superior to systemic analgesia; interpleural analgesia was inadequate. CONCLUSIONS: Either thoracic epidural analgesia with LA plus opioid or continuous paravertebral block with LA can be recommended. Where these techniques are not possible, or are contraindicated, intrathecal opioid or intercostal nerve block are recommended despite insufficient duration of analgesia, which requires the use of supplementary systemic analgesia. Quantitative meta-analyses were limited by heterogeneity in study design, and subject numbers were small. Further well designed studies are required to investigate the optimum components of the epidural solution and to rigorously evaluate the risks/benefits of continuous infusion paravertebral and intercostal techniques compared with thoracic epidural analgesia.},
  langid = {english},
  pmid = {18713924},
  keywords = {Analgesia,Analgesia; Epidural,Analgesics; Opioid,Humans,Hypotension,Nerve Block,Odds Ratio,Pain; Postoperative,Randomized Controlled Trials as Topic,Thoracotomy,Treatment Outcome}
}

@article{kadouhdgz140,
  title = {{{GLP-1 Analog Modulates Appetite}}, {{Taste Preference}}, {{Gut Hormones}}, and {{Regional Body Fat Stores}} in {{Adults}} with {{Obesity}}},
  author = {Kadouh, Hoda and Chedid, Victor and Halawi, Houssam and Burton, Duane D. and Clark, Matthew M. and Khemani, Disha and Vella, Adrian and Acosta, Andres and Camilleri, Michael},
  year = {2020},
  month = may,
  journal = {The Journal of Clinical Endocrinology and Metabolism},
  volume = {105},
  number = {5},
  pages = {dgz140},
  issn = {1945-7197},
  doi = {10.1210/clinem/dgz140},
  abstract = {PURPOSE: Obesity is associated with alterations in appetite, gastrointestinal hormone levels and excessive fat mass. We previously published a double-blind, placebo-controlled, randomized, 16-week trial on effects of once-daily glucagon-like peptide-1 (GLP-1) analog, liraglutide on weight, satiation, and gastric functions in obese volunteers. The aim of this substudy is to compare to placebo the effects of liraglutide on appetite, taste preference, regional body fat stores, and anthropometric measurements. METHODS: Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily). At baseline and 16 weeks, the following were measured: appetite and taste preferences rated every 30 min for 5 h after ingesting 300 mL Ensure\textregistered; maximal tolerated volume (MTV) with a nutrient drink test; fasting and postprandial bioactive GLP-1 (7-36) and peptide YY (PYY) levels; total and regional body fat with dual-energy X-ray absorptiometry, and waist and hip circumference. RESULTS: Thirty-five participants (17 liraglutide; 18 placebo) completed the trial. Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness. Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide relative to baseline. Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed. CONCLUSION: Liraglutide 3 mg SQ modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity without reduction in lean body mass.},
  langid = {english},
  pmcid = {PMC7105351},
  pmid = {31665455},
  keywords = {Adipose Tissue,Adolescent,Adult,Aged,appetite,Appetite,Body Composition,body fat,Double-Blind Method,Female,Food Preferences,Gastrointestinal Hormones,GLP-1,GLP-1 analog,Glucagon-Like Peptide 1,Humans,Hypoglycemic Agents,liraglutide,Liraglutide,Male,Middle Aged,obesity,Obesity,Placebos,Satiation,Taste,taste preference,Young Adult}
}

@article{kalff,
  title = {Long-{{Term Survival After Minimally Invasive Versus Open Esophagectomy}} for {{Esophageal Cancer}}: {{A Nationwide Propensity-Score Matched Analysis}}},
  shorttitle = {Long-{{Term Survival After Minimally Invasive Versus Open Esophagectomy}} for {{Esophageal Cancer}}},
  author = {Kalff, Marianne C. and Fransen, Laura F. C. and {de Groot}, Eline M. and Gisbertz, Suzanne S. and Nieuwenhuijzen, Grard A. P. and Ruurda, Jelle P. and Verhoeven, Rob H. A. and Luyer, Misha D. P. and {van Hillegersberg}, Richard and {van Berge Henegouwen}, Mark I. and {Dutch Upper Gastrointestinal Cancer Audit group}},
  year = {2020},
  month = dec,
  journal = {Annals of Surgery},
  volume = {Publish Ahead of Print},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000004708},
  abstract = {OBJECTIVES: This study aimed to compare long-term survival following minimally invasive esophagectomy (MIE) versus open esophagectomy (OE) for esophageal cancer using a nationwide propensity-score matched cohort. SUMMARY BACKGROUND DATA: MIE provides lower postoperative morbidity and mortality, and similar short-term oncological quality compared to OE. METHODS: Data was acquired from the Dutch Upper Gastrointestinal Cancer Audit. Patients undergoing minimally invasive or open, transthoracic or transhiatal esophagectomy for primary esophageal cancer between 2011-2015 were included. A propensity-score matching analysis for MIE versus OE was performed separately for transthoracic and transhiatal esophagectomies. RESULTS: A total of 1036 transthoracic MIE and OE patients, and 582 transhiatal MIE and OE patients were matched. Long-term survival was comparable for MIE and OE for both transthoracic and transhiatal procedures (5-year overall survival: transthoracic MIE 49.2\% vs. OE 51.1\%, p 0.695; transhiatal MIE 48.4\% vs. OE 50.7\%, p 0.832). For both procedures, MIE yielded more lymph nodes (transthoracic median 21 vs. 18, p {$<$} 0.001; transhiatal 15 vs. 13, p 0.007). Post-operative morbidity was comparable after transthoracic MIE and OE (60.8\% vs. 64.9\%, p 0.177), with a reduced length of stay after transthoracic MIE (median 12 vs. 15 days, p {$<$} 0.001). After transhiatal MIE, more postoperative complications (64.9\% vs. 56.4\%, p 0.034) were observed, without subsequent difference in length of stay. CONCLUSION: Long-term survival after minimally invasive esophagectomy was equivalent to open in both propensity-score matched cohorts of patients undergoing transthoracic or transhiatal esophageal resections. Transhiatal minimally invasive esophagectomy was accompanied with more post-operative morbidity. Both transthoracic and transhiatal minimally invasive esophagectomy resulted in a more extended lymphadenectomy.},
  langid = {english},
  pmid = {33378310},
  keywords = {MIE}
}

@article{kaneoka,
  type = {Journal {{Article}}},
  title = {Presentation of Oropharyngeal Dysphagia and Rehabilitative Intervention Following Esophagectomy: A Systematic Review},
  author = {Kaneoka, A. and Yang, S. and Inokuchi, H. and Ueha, R. and Yamashita, H. and Nito, T. and Seto, Y. and Haga, N.},
  year = {2018},
  journal = {Dis Esophagus},
  volume = {31},
  number = {8},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1093/dote/doy050}
}

@article{kangaspunta449,
  title = {Preoperative Intravenous Iron Treatment Reduces Postoperative Complications and Postoperative Anemia in Preoperatively Anemic Patients with Colon Carcinoma},
  author = {Kangaspunta, Mikael and M{\"a}kij{\"a}rvi, Jorma and Koskensalo, Selja and Kokkola, Arto and Arkkila, Perttu and Scheinin, Tom and Rasilainen, Suvi},
  year = {2022},
  month = feb,
  journal = {International Journal of Colorectal Disease},
  volume = {37},
  number = {2},
  pages = {449--455},
  issn = {1432-1262},
  doi = {10.1007/s00384-021-04080-9},
  abstract = {PURPOSE: Anemia is common among patients with colorectal cancer and is associated with an increased risk of complications and poorer survival rate. The main objective of our study was to determine the effect of preoperative intravenous iron supplementation therapy on the need for red blood cell transfusions, other postoperative complications, and length of hospital stay in colon cancer patients undergoing colon resection. METHODS: In this retrospective cohort study, data were collected from medical records of all 549 colon carcinoma patients who underwent a colon resection in Helsinki University Hospital during the years 2017 and 2018. The patients were divided into two cohorts: one with anemic patients treated with preoperative intravenous iron supplementation therapy (180 patients) and one with anemic patients without preoperative intravenous iron supplementation therapy (138 patients). Non-anemic patients and patients requiring emergency surgery were excluded (231 patients). RESULTS: Patients treated with intravenous iron had less postoperative complications (33.9\% vs. 45.9\%, p\,=\,0.045) and a lower prevalence of anemia at 1~month after surgery (38.7\% vs. 65.3\%, p\,{$<$}\,0.01) when compared with patients without preoperative iv iron treatment. No difference was found in the amount of red blood cell transfusions, length of stay, or mortality between the groups. CONCLUSION: This is the first study demonstrating a significant decrease in postoperative complications in anemic colon cancer patients receiving preoperative intravenous iron supplementation therapy. This treatment also diminishes the rate of postoperative anemia, which is often associated with a facilitated recovery.},
  langid = {english},
  pmcid = {PMC8803765},
  pmid = {34931280},
  keywords = {Anemia,Carcinoma,Colon cancer,Colonic Neoplasms,Colorectal surgery,Hemoglobins,Humans,Intravenous iron,Iron,Postoperative Complications,Preoperative Care,Retrospective Studies,Surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QJHBV5VX\\Kangaspunta et al_2022_Preoperative intravenous iron treatment reduces postoperative complications and.pdf}
}

@article{kapiteijn638,
  title = {Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer},
  author = {Kapiteijn, E. and Marijnen, C. A. and Nagtegaal, I. D. and Putter, H. and Steup, W. H. and Wiggers, T. and Rutten, H. J. and Pahlman, L. and Glimelius, B. and {van Krieken}, J. H. and Leer, J. W. and {van de Velde}, C. J. and {Dutch Colorectal Cancer Group}},
  year = {2001},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {345},
  number = {9},
  pages = {638--646},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa010580},
  abstract = {BACKGROUND: Short-term preoperative radiotherapy and total mesorectal excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of total mesorectal excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by total mesorectal excision (924 patients) or to total mesorectal excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P{$<$}0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized total mesorectal excision.},
  langid = {english},
  pmid = {11547717},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Analysis of Variance,Colorectal Surgery,Female,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Preoperative Care,Proportional Hazards Models,Prospective Studies,Radiotherapy; Adjuvant,Rectal Neoplasms,Rectal; RT,Rectum,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BLAENGIA\\Kapiteijn et al. - 2001 - Preoperative radiotherapy combined with total meso.pdf}
}

@article{kaplan457,
  title = {Nonparametric {{Estimation}} from {{Incomplete Observations}}},
  author = {Kaplan, E. L. and Meier, Paul},
  year = {1958},
  month = jun,
  journal = {Journal of the American Statistical Association},
  volume = {53},
  number = {282},
  pages = {457--481},
  issn = {0162-1459, 1537-274X},
  doi = {10.1080/01621459.1958.10501452},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LPCAEQT5\\Kaplan and Meier - 1958 - Nonparametric Estimation from Incomplete Observati.pdf}
}

@article{kapoore25115,
  title = {Immune Checkpoint Inhibitors in Patients with Solid Tumors and Poor Performance Status: {{A}} Prospective Data from the Real-World Settings},
  shorttitle = {Immune Checkpoint Inhibitors in Patients with Solid Tumors and Poor Performance Status},
  author = {Kapoor, Akhil and Noronha, Vanita and Patil, Vijay M. and Menon, Nandini and Joshi, Amit and Abraham, George and Prabhash, Kumar},
  year = {2021},
  month = apr,
  journal = {Medicine},
  volume = {100},
  number = {13},
  pages = {e25115},
  issn = {1536-5964},
  doi = {10.1097/MD.0000000000025115},
  abstract = {Immune checkpoint inhibitors (ICIs) are rapidly being incorporated as treatment option either alone or in combination with chemotherapy in most of the solid tumors. Since there is very limited data of ICI in patients with poor performance status (PS) from the real world settings, we performed a retrospective audit of patients who received ICI and report the analysis based on ECOG PS of these patients.This study is a retrospective audit of a prospectively collected database of patients receiving ICIs for advanced solid tumors in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. All statistical calculations were performed using SPSS statistical software for windows version 20.0.A total of 155 patients who received ICIs during the specified period were evaluated for this study. Baseline ECOG PS 0-1 (n{$\mkern1mu$}={$\mkern1mu$}103, 66.4\%) patients was associated with median OS 9.1 (95\% CI [confidence interval], 4.4-NR) months when compared to ECOG 2-4 (n{$\mkern1mu$}={$\mkern1mu$}52, 33.5\%) which had a median OS of 2.9 (95\% CI; 1.8-5.5) months (HR, 1.7, 95\% CI, 1.1-2.7, log rank P{$\mkern1mu$}={$\mkern1mu$}.017). The disease control rate for the poor PS group was 34.6\%. However, 27.3\% patients (95\% CI: 20.3-34.3) were still alive at 1{$\mkern1mu$}year. Median OS in patients with PS 2 was 3.7{$\mkern1mu$}months (95\% CI: 0-11.6) as compared to 1.8{$\mkern1mu$}months (95\% CI: 0.2-3.4) for those with PS 3-4 (HR-2.0; 95\% CI: 1.0-3.9, P{$\mkern1mu$}={$\mkern1mu$}.041). The tolerance to ICIs was good with no grade 3/4 toxicities in 44 (84.6\%) patients.Immune checkpoint inhibitors are a safe and effective therapeutic option even in solid tumor patients with poor performance status.},
  langid = {english},
  pmcid = {PMC8021372},
  pmid = {33787593},
  keywords = {Antineoplastic Agents; Immunological,Databases; Factual,Female,Humans,ICI,Immune Checkpoint Inhibitors,Kaplan-Meier Estimate,Male,Medical Audit,Medical Oncology,Middle Aged,Neoplasms,Outcome Assessment; Health Care,Prospective Studies,Retrospective Studies,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\E92M2JPM\\Kapoor et al_2021_Immune checkpoint inhibitors in patients with solid tumors and poor performance.pdf}
}

@article{kato4249,
  type = {Journal {{Article}}},
  title = {Videofluoroscopic Evaluation in Oropharyngeal Swallowing after Radical Esophagectomy with Lymphadenectomy for Esophageal Cancer},
  author = {Kato, H. and Miyazaki, T. and Sakai, M. and Sano, A. and Tanaka, N. and Kimura, H. and Inose, T. and Faried, A. and Saito, K. and Sohda, M. and Nakajima, M. and Fukai, Y. and Masuda, N. and Fukuchi, M. and Manda, R. and Ojima, H. and Tsukada, K. and Kuwano, H.},
  year = {2007},
  journal = {Anticancer Res},
  volume = {27},
  number = {6C},
  pages = {4249--54},
  issn = {0250-7005 (Print) 0250-7005 (Linking)}
}

@article{kato921,
  ids = {kato921a},
  title = {Comparison between Positron Emission Tomography and Computed Tomography in the Use of the Assessment of Esophageal Carcinoma},
  author = {Kato, Hiroyuki and Kuwano, Hiroyuki and Nakajima, Masanobu and Miyazaki, Tatsuya and Yoshikawa, Minako and Ojima, Hitoshi and Tsukada, Katsuhiko and Oriuchi, Noboru and Inoue, Tomio and Endo, Keigo},
  year = {2002},
  month = feb,
  journal = {Cancer},
  volume = {94},
  number = {4},
  pages = {921--928},
  issn = {0008-543X},
  abstract = {BACKGROUND: The role and potential value of positron emission tomography (PET) scanning in certain tumors has been widely investigated in recent years. The authors retrospectively assessed the performance of 18-F-fluorodeoxyglucose (FDG)-PET in the assessment of esophageal squamous cell carcinoma (SCC). METHODS: The results using PET were compared with those using computed tomography (CT), and these were correlated with the pathologic findings. The authors studied 32 patients with thoracic esophageal SCC who had undergone radical esophagectomy. RESULTS: Uptake of FDG in the primary tumor was found in 25 of the 32 (78.1\%) cases. Comparison of the FDG uptake and the clinicopathologic findings showed that there was a significant association between the FDG uptake and each of the depth of tumor invasion (P {$<$} 0.05), occurrence of lymph node metastasis (P {$<$} 0.01), and lymphatic invasion (P {$<$} 0.01). The survival rate in cases with high FDG uptake (standardized uptake value [SUV], {$>$}3) was significantly lower than that in cases with low FDG uptake (SUV, {$<$} 3; P {$<$} 0.05). In the evaluation of lymph node staging by the detection of lymph node metastasis, FDG-PET showed 77.8\% sensitivity, 92.9\% specificity, and 84.4\% accuracy, and CT scanning showed 61.1\% sensitivity, 71.4\% specificity, and 65.6\% accuracy. Positron emission tomography scanning showed a high degree of accuracy in the neck, upper thoracic, and abdominal regions. However, in the mid- and lower thoracic regions, the sensitivity was very low. The smallest lymph node metastasis that was detected by FDG-PET imaging was 6 mm. The average size of lymph node metastasis that was undetected by FDG-PET scanning was 7.3 mm (range, 1-17 mm). CONCLUSIONS: In conclusion, FDG-PET may be used as a noninvasive diagnostic technique in assessing the aggressiveness of the tumor and the prognosis in patients with esophageal SCC. During the preoperative diagnostic procedures, the sensitivity, specificity, and accuracy of lymph node staging is higher with FDG-PET than with CT imaging. In view of the high specificity of FDG-PET, it also gives useful information to guide the choice of treatment of esophageal carcinoma.},
  langid = {english},
  pmid = {11920459},
  keywords = {Adult,Aged,Carcinoma,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Lymphatic Metastasis,Male,Middle Aged,Neoplasm Staging,Prognosis,Radiopharmaceuticals,Reproducibility of Results,Retrospective Studies,Sensitivity and Specificity,Tomography; Emission-Computed,Tomography; X-Ray Computed}
}

@article{katoh20,
  title = {Prediction Models for Patients with Esophageal or Gastric Cancer: {{A}} Systematic Review and Meta-Analysis},
  author = {Katoh, Masaru},
  pages = {20},
  abstract = {Background Clinical prediction models are increasingly used to predict outcomes such as survival in cancer patients. The aim of this study was threefold. First, to perform a systematic review to identify available clinical prediction models for patients with esophageal and/or gastric cancer. Second, to evaluate sources of bias in the included studies. Third, to investigate the predictive performance of the prediction models using meta-analysis.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DF5QDYU7\\Katoh - Prediction models for patients with esophageal or .pdf}
}

@article{kaufnerCD012451,
  title = {Erythropoietin plus Iron versus Control Treatment Including Placebo or Iron for Preoperative Anaemic Adults Undergoing Non-Cardiac Surgery},
  author = {Kaufner, Lutz and {von Heymann}, Christian and Henkelmann, Anne and Pace, Nathan L. and Weibel, Stephanie and Kranke, Peter and Meerpohl, Joerg J. and Gill, Ravi},
  year = {2020},
  month = aug,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {8},
  pages = {CD012451},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD012451.pub2},
  abstract = {BACKGROUND: Approximately 30\% of adults undergoing non-cardiac surgery suffer from preoperative anaemia. Preoperative anaemia is a risk factor for mortality and adverse outcomes in different surgical specialties and is frequently the reason for blood transfusion. The most common causes are renal, chronic diseases, and iron deficiency. International guidelines recommend that the cause of anaemia guide preoperative anaemia treatment. Recombinant human erythropoietin (rHuEPO) with iron supplementation has frequently been used to increase preoperative haemoglobin concentrations in patients in order to avoid the need for perioperative allogeneic red blood cell (RBC) transfusion. OBJECTIVES: To evaluate the efficacy of preoperative rHuEPO therapy (subcutaneous or parenteral) with iron (enteral or parenteral) in reducing the need for allogeneic RBC transfusions in preoperatively anaemic adults undergoing non-cardiac surgery. SEARCH METHODS: We searched CENTRAL, Ovid MEDLINE(R), Ovid Embase, ISI Web of Science: SCI-EXPANDED and CPCI-S, and clinical trial registries WHO ICTRP and ClinicalTrials.gov on 29 August 2019. SELECTION CRITERIA: We included all randomized controlled trials (RCTs) that compared preoperative rHuEPO + iron therapy to control treatment (placebo, no treatment, or standard of care with or without iron) for preoperatively anaemic adults undergoing non-cardiac surgery. We used the World Health Organization (WHO) definition of anaemia: haemoglobin concentration (g/dL) less than 13 g/dL for males, and 12 g/dL for non-pregnant females (decision of inclusion based on mean haemoglobin concentration). We defined two subgroups of rHuEPO dosage: 'low' for 150 to 300 international units (IU)/kg body weight, and 'high' for 500 to 600 IU/kg body weight. DATA COLLECTION AND ANALYSIS: Two review authors collected data from the included studies. Our primary outcome was the need for RBC transfusion (no autologous transfusion, fresh frozen plasma or platelets), measured in transfused participants during surgery (intraoperative) and up to five days after surgery. Secondary outcomes of interest were: haemoglobin concentration (directly before surgery), number of RBC units (where one unit contains 250 to 450 mL) transfused per participant (intraoperative and up to five days after surgery), mortality (within 30 days after surgery), length of hospital stay, and adverse events (e.g. renal dysfunction, thromboembolism, hypertension, allergic reaction, headache, fever, constipation). MAIN RESULTS: Most of the included trials were in orthopaedic, gastrointestinal, and gynaecological surgery and included participants with mild and moderate preoperative anaemia (haemoglobin from 10 to 12 g/dL). The duration of preoperative rHuEPO treatment varied across the trials, ranging from once a week to daily or a 5-to-10-day period, and in one trial preoperative rHuEPO was given on the morning of surgery and for five days postoperatively. We included 12 trials (participants = 1880) in the quantitative analysis of the need for~RBC transfusion following preoperative treatment with rHuEPO + iron to correct preoperative anaemia in non-cardiac surgery; two studies were multiarmed trials with two different dose regimens. Preoperative rHuEPO + iron given to anaemic adults reduced the need RBC transfusion (risk ratio (RR) 0.55, 95\% confidence interval (CI) 0.38 to 0.80; participants = 1880; studies = 12; I2 = 84\%; moderate-quality~evidence due to inconsistency). This analysis suggests that on average, the combined administration of rHuEPO + iron~will mean 231 fewer individuals will need transfusion for every 1000 individuals compared to the control group. Preoperative high-dose rHuEPO + iron given to anaemic adults increased the haemoglobin concentration (mean difference (MD) 1.87 g/dL, 95\% CI 1.26 to 2.49; participants = 852; studies = 3; I2 = 89\%; low-quality evidence due to inconsistency and risk of bias) but not low-dose rHuEPO + iron~(MD 0.11 g/dL, 95\% CI -0.46 to 0.69; participants = 334; studies = 4; I2 = 69\%; low-quality evidence due to inconsistency and risk of bias). There was probably little or no difference in the number of RBC units when rHuEPO + iron was given preoperatively (MD -0.09, 95\% CI -0.23 to 0.05; participants = 1420; studies = 6; I2 = 2\%; moderate-quality evidence due to imprecision).~ There was probably little or no difference in the risk of mortality within 30 days of surgery (RR 1.19, 95\% CI 0.39 to 3.63; participants = 230; studies = 2; I2 = 0\%; moderate-quality evidence due to imprecision) or of adverse events including local rash, fever, constipation, or transient hypertension (RR 0.93, 95\% CI 0.68 to 1.28; participants = 1722; studies = 10; I2 = 0\%; moderate-quality evidence due to imprecision). The administration of rHuEPO + iron~before non-cardiac surgery did not clearly~reduce the length of hospital stay of preoperative anaemic adults (MD -1.07, 95\% CI -4.12 to 1.98; participants = 293; studies = 3; I2 = 87\%; low-quality evidence due to inconsistency and imprecision). AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that preoperative rHuEPO + iron therapy for anaemic adults prior to non-cardiac surgery reduces the need for RBC transfusion and, when given at higher doses, increases the haemoglobin concentration preoperatively. The administration of rHuEPO + iron treatment did not decrease the mean number of units of RBC transfused per patient. There were no important differences in the risk of adverse events or mortality within 30 days, nor in length of hospital stay. Further, well-designed, adequately powered RCTs are required to estimate the impact of this combined treatment more precisely.},
  langid = {english},
  pmcid = {PMC8095002},
  pmid = {32790892},
  keywords = {Adult,Anemia,Digestive System Surgical Procedures,Epo,Erythrocyte Transfusion,Erythropoietin,Female,Gynecologic Surgical Procedures,Hemoglobin A,Humans,Iron,Length of Stay,Male,Orthopedic Procedures,Placebos,Preoperative Care,Randomized Controlled Trials as Topic,Recombinant Proteins,Surgery,Surgical Procedures; Operative}
}

@article{kauppila1131,
  title = {Meta-Analysis of Health-Related Quality of Life after Minimally Invasive versus Open Oesophagectomy for Oesophageal Cancer},
  author = {Kauppila, J. H. and Xie, S. and Johar, A. and Markar, S. R. and Lagergren, P.},
  year = {2017},
  month = aug,
  journal = {The British Journal of Surgery},
  volume = {104},
  number = {9},
  pages = {1131--1140},
  issn = {1365-2168},
  doi = {10.1002/bjs.10577},
  abstract = {BACKGROUND: The aim of this systematic review and meta-analysis was to compare health-related quality of life (HRQoL) outcomes between minimally invasive and open oesophagectomy for cancer at different postoperative time points. METHODS: A search of PubMed (MEDLINE), Web of Science, Embase, Scopus, CINAHL and the Cochrane Library was performed for studies that compared open with minimally invasive oesophagectomy. A random-effects meta-analysis was conducted for studies that measured HRQoL scores using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-OES18 questionnaires. Mean differences (MDs) greater than 10 in scores were considered clinically relevant. Pooled effects of MDs with 95 per cent confidence intervals were estimated to assess statistical significance. RESULTS: Nine studies were included in the qualitative analysis, involving 1157 patients who had minimally invasive surgery and 907 patients who underwent open surgery. Minimally invasive surgery resulted in better scores for global quality of life (MD 11{$\cdot$}61, 95 per cent c.i. 3{$\cdot$}84 to 19{$\cdot$}39), physical function (MD 11{$\cdot$}88, 3{$\cdot$}92 to 19{$\cdot$}84), fatigue (MD -13{$\cdot$}18, -17{$\cdot$}59 to -8{$\cdot$}76) and pain (MD -15{$\cdot$}85, -20{$\cdot$}45 to -11{$\cdot$}24) compared with open surgery at 3 months after surgery. At 6 and 12 months, no significant differences remained. CONCLUSION: Patients report better global quality of life, physical function, fatigue and pain 3 months after minimally invasive surgery compared with open surgery. No such differences remain at longer follow-up of 6 and 12 months.},
  langid = {english},
  pmid = {28632926},
  keywords = {Esophageal Neoplasms,Esophagectomy,Esophagoscopy,Fatigue,Humans,Laparoscopy,Pain; Postoperative,Quality of Life},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UNBYRPTV\\Kauppila et al_2017_Meta-analysis of health-related quality of life after minimally invasive versus.pdf}
}

@article{kawata,
  type = {Journal {{Article}}},
  title = {Multidisciplinary Team Management for Prevention of Pneumonia and Long-Term Weight Loss after Esophagectomy: A Single-Center Retrospective Study},
  author = {Kawata, S. and Hiramatsu, Y. and Shirai, Y. and Watanabe, K. and Nagafusa, T. and Matsumoto, T. and Kikuchi, H. and Kamiya, K. and Takeuchi, H.},
  year = {2020},
  journal = {Esophagus},
  issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
  doi = {10.1007/s10388-020-00721-0}
}

@article{kaya707,
  type = {Journal {{Article}}},
  title = {Patients' Readiness for Discharge: {{Predictors}} and Effects on Unplanned Readmissions, Emergency Department Visits and Death},
  author = {Kaya, S. and Sain Guven, G. and Aydan, S. and Kar, A. and Teles, M. and Yildiz, A. and Koca, G. S. and Kartal, N. and Korku, C. and Urek, D. and Demir, I. B. and Toka, O.},
  year = {2018},
  journal = {J Nurs Manag},
  volume = {26},
  number = {6},
  pages = {707--716},
  issn = {1365-2834 (Electronic) 0966-0429 (Linking)},
  doi = {10.1111/jonm.12605}
}

@article{keating2532,
  title = {Adjuvant Chemotherapy for Stage {{III}} Colon Cancer: Do Physicians Agree about the Importance of Patient Age and Comorbidity?},
  shorttitle = {Adjuvant Chemotherapy for Stage {{III}} Colon Cancer},
  author = {Keating, Nancy L. and Landrum, Mary Beth and Klabunde, Carrie N. and Fletcher, Robert H. and Rogers, Selwyn O. and Doucette, William R. and Tisnado, Diana and Clauser, Steven and Kahn, Katherine L.},
  year = {2008},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {26},
  number = {15},
  pages = {2532--2537},
  issn = {1527-7755},
  doi = {10.1200/JCO.2007.15.9434},
  abstract = {PURPOSE: We surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations. METHODS: National survey of surgeons and medical oncologists caring for patients with colorectal cancer regarding whether they would recommend adjuvant chemotherapy for hypothetical patients with stage III colon cancer who varied by age (55 v 80 years) and comorbid illness (none, moderate, severe congestive heart failure [CHF]). Repeated measures logistic regression was used to assess the influence of patient, physician, and practice characteristics on chemotherapy recommendations. RESULTS: Of 1,096 physicians, nearly all recommended chemotherapy for patients who were 55 years old with no comorbidity (99.0\%), 55-years old with moderate CHF (88.6\%), or 80 years old with no comorbidity (92.6\%); many fewer recommended chemotherapy for 55-year-old patients with severe CHF (24.9\%) or 80-year-old patients with moderate (47.2\%) or severe (9.0\%) CHF (P {$<$} .001). Younger physicians (P {$<$} .001) were more likely than others to recommend adjuvant chemotherapy overall, although physician factors explained little of the variability in recommendations. CONCLUSION: Physicians agree with guidelines recommending adjuvant chemotherapy for young, healthy patients with stage III colon cancer but differ widely on recommendations for patients who are older and sicker. Few physician or practice characteristics were associated with recommendations. For older and sicker patients, the individual physicians seen may have a substantial impact on the likelihood of receiving chemotherapy. Understanding better the sources of variation not explained by patients' clinical characteristics may allow improved tailoring of therapy to patients most likely to benefit.},
  langid = {english},
  pmid = {18487570},
  keywords = {Adult,Age Factors,Aged,Aged; 80 and over,Antineoplastic Agents,Chemotherapy; Adjuvant,Colonic Neoplasms,Comorbidity,CRC,Decision Making,Female,Humans,Lung Neoplasms,Male,Middle Aged,Neoplasm Staging,Physicians}
}

@article{keeler214,
  title = {Randomized Clinical Trial of Preoperative Oral versus Intravenous Iron in Anaemic Patients with Colorectal Cancer},
  author = {Keeler, B. D. and Simpson, J. A. and Ng, O. and Padmanabhan, H. and Brookes, M. J. and Acheson, A. G. and {IVICA Trial Group}},
  year = {2017},
  month = feb,
  journal = {The British Journal of Surgery},
  volume = {104},
  number = {3},
  pages = {214--221},
  issn = {1365-2168},
  doi = {10.1002/bjs.10328},
  abstract = {BACKGROUND: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery. METHODS: Anaemic patients with non-metastatic colorectal adenocarcinoma were recruited at least 2 weeks before surgery and randomized to receive oral (ferrous sulphate) or intravenous (ferric carboxymaltose) iron. Perioperative changes in haemoglobin, ferritin, transferrin saturation and blood transfusion use were recorded until postoperative outpatient review. RESULTS: Some 116 patients were included in the study. There was no difference in blood transfusion use from recruitment to trial completion in terms of either volume of blood administered (P\,=\,0{$\cdot$}841) or number of patients transfused (P\,=\,0{$\cdot$}470). Despite this, increases in haemoglobin after treatment were higher with intravenous iron (median 1{$\cdot$}55 (i.q.r. 0{$\cdot$}93-2{$\cdot$}58) versus 0{$\cdot$}50 (-0{$\cdot$}13 to 1{$\cdot$}33) g/dl; P\,{$<$}\,0{$\cdot$}001), which was associated with fewer anaemic patients at the time of surgery (75 versus 90 per cent; P\,=\,0{$\cdot$}048). Haemoglobin levels were thus higher at surgery after treatment with intravenous than with oral iron (mean 11{$\cdot$}9 (95 per cent c.i. 11{$\cdot$}5 to 12{$\cdot$}3) versus 11{$\cdot$}0 (10{$\cdot$}6 to 11{$\cdot$}4) g/dl respectively; P\,=\,0{$\cdot$}002), as were ferritin (P\,{$<$}\,0{$\cdot$}001) and transferrin saturation (P\,{$<$}\,0{$\cdot$}001) levels. CONCLUSION: Intravenous iron did not reduce the blood transfusion requirement but was more effective than oral iron at treating preoperative anaemia and iron deficiency in patients undergoing colorectal cancer surgery.},
  langid = {english},
  pmid = {28092401},
  keywords = {Adenocarcinoma,Administration; Oral,Adult,Aged,Aged; 80 and over,Anemia; Iron-Deficiency,Colorectal Neoplasms,Elective Surgical Procedures,Erythrocyte Transfusion,Female,Ferric Compounds,Ferrous Compounds,Follow-Up Studies,Hematinics,Humans,Injections; Intravenous,Iron,Male,Maltose,Middle Aged,Postoperative Complications,Preoperative Care,Prospective Studies,Surgery,Treatment Outcome}
}

@article{kelsen1979,
  type = {Journal {{Article}}},
  title = {Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer},
  author = {Kelsen, D. P. and Ginsberg, R. and Pajak, T. F. and Sheahan, D. G. and Gunderson, L. and Mortimer, J. and Estes, N. and Haller, D. G. and Ajani, J. and Kocha, W. and Minsky, B. D. and Roth, J. A.},
  year = {1998},
  journal = {N Engl J Med},
  volume = {339},
  number = {27},
  pages = {1979--84},
  issn = {0028-4793 (Print) 0028-4793 (Linking)},
  doi = {10.1056/NEJM199812313392704},
  keywords = {Adenocarcinoma,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Cisplatin,Esophageal Neoplasms,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Survival Analysis,Treatment Failure}
}

@article{kemeny786,
  title = {Prognostic Factors in Advanced Colorectal Carcinoma. {{Importance}} of Lactic Dehydrogenase Level, Performance Status, and White Blood Cell Count},
  author = {Kemeny, N. and Braun, D. W.},
  year = {1983},
  month = may,
  journal = {The American Journal of Medicine},
  volume = {74},
  number = {5},
  pages = {786--794},
  issn = {0002-9343},
  doi = {10.1016/0002-9343(83)91066-5},
  abstract = {In 220 patients with advanced colorectal carcinoma, objective tumor response to chemotherapy and survival were related to the following parameters: age, sex, performance status, time interval from diagnosis to metastases, initial site of metastases, and initial white blood cell count, lactic dehydrogenase, alkaline phosphatase, and carcinoembryonic antigen levels. Each variable was first evaluated separately. By conventional statistical methods, none of the variables significantly predicted response, although the following parameters significantly (p less than 0.01) predicted survival: Patients with an initially normal level of lactic dehydrogenase versus those with an abnormal level of lactic dehydrogenase had median survivals of 16 and 7.0 months, respectively; normal versus abnormal carcinoembryonic antigen levels, 23 and 9.2 months, respectively; white blood cell count of less than 10,000 versus greater than 10,000 cells/mm3, 11 and 7.0 months, respectively; performance status of greater than 70 versus less than 60, 11 and 6.6 months, respectively; and lung versus liver metastases, 12 and 8.0 months, respectively. By studying the variables together with multivariate analysis, we found that the most important variables in predicting response were the lactic dehydrogenase level and the white blood cell count. In predicting survival, the most important variables were the lactic dehydrogenase level, performance status, and lung involvement. We recommend that future randomized therapeutic trials for advanced colorectal carcinoma should delineate and perhaps stratify for the lactic dehydrogenase level, performance status, white blood cell count, and/or the presence of lung involvement.},
  langid = {english},
  pmid = {6837602},
  keywords = {Adult,Aged,Carcinoembryonic Antigen,Colonic Neoplasms,Female,Humans,L-Lactate Dehydrogenase,Leukocyte Count,Lung Neoplasms,Male,Middle Aged,Neoplasm Metastasis,Prognosis,Rectal Neoplasms}
}

@article{khalil2013,
  type = {Journal {{Article}}},
  title = {Operative {{Intercostal Nerve Blocks With Long-Acting Bupivacaine Liposome}} for {{Pain Control After Thoracotomy}}},
  author = {Khalil, K. G. and Boutrous, M. L. and Irani, A. D. and Miller, C. C., 3rd and Pawelek, T. R. and Estrera, A. L. and Safi, H. J.},
  year = {2015},
  journal = {Ann Thorac Surg},
  volume = {100},
  number = {6},
  pages = {2013--8},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2015.08.017}
}

@article{khan97,
  title = {How {{I Treat Vitamin D Deficiency}}},
  author = {Khan, Qamar J. and Fabian, Carol J.},
  year = {2010},
  month = mar,
  journal = {Journal of Oncology Practice},
  volume = {6},
  number = {2},
  pages = {97--101},
  issn = {1554-7477},
  doi = {10.1200/JOP.091087},
  abstract = {Vitamin D plays an important role in the homeostasis of a variety of organ systems, but its role in prevention of cancer and recurrence\textemdash along with necessary blood levels\textemdash has yet to be defined.},
  pmcid = {PMC2835491},
  pmid = {20592785},
  keywords = {Survivorship},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8K769C79\\Khan and Fabian - 2010 - How I Treat Vitamin D Deficiency.pdf}
}

@article{kharrazi1499,
  title = {The {{Value}} of {{Unstructured Electronic Health Record Data}} in {{Geriatric Syndrome Case Identification}}},
  author = {Kharrazi, Hadi and Anzaldi, Laura J. and Hernandez, Leilani and Davison, Ashwini and Boyd, Cynthia M. and Leff, Bruce and Kimura, Joe and Weiner, Jonathan P.},
  year = {2018},
  month = aug,
  journal = {Journal of the American Geriatrics Society},
  volume = {66},
  number = {8},
  pages = {1499--1507},
  issn = {1532-5415},
  doi = {10.1111/jgs.15411},
  abstract = {OBJECTIVES: To examine the value of unstructured electronic health record (EHR) data (free-text notes) in identifying a set of geriatric syndromes. DESIGN: Retrospective analysis of unstructured EHR notes using a natural language processing (NLP) algorithm. SETTING: Large multispecialty group. PARTICIPANTS: Older adults (N=18,341; average age 75.9, 58.9\% female). MEASUREMENTS: We compared the number of geriatric syndrome cases identified using structured claims and structured and unstructured EHR data. We also calculated these rates using a population-level claims database as a reference and identified comparable epidemiological rates in peer-reviewed literature as a benchmark. RESULTS: Using insurance claims data resulted in a geriatric syndrome prevalence ranging from 0.03\% for lack of social support to 8.3\% for walking difficulty. Using structured EHR data resulted in similar prevalence rates, ranging from 0.03\% for malnutrition to 7.85\% for walking difficulty. Incorporating unstructured EHR notes, enabled by applying the NLP algorithm, identified considerably higher rates of geriatric syndromes: absence of fecal control (2.1\%, 2.3 times as much as structured claims and EHR data combined), decubitus ulcer (1.4\%, 1.7 times as much), dementia (6.7\%, 1.5 times as much), falls (23.6\%, 3.2 times as much), malnutrition (2.5\%, 18.0 times as much), lack of social support (29.8\%, 455.9 times as much), urinary retention (4.2\%, 3.9 times as much), vision impairment (6.2\%, 7.4 times as much), weight loss (19.2\%, 2.9 as much), and walking difficulty (36.34\%, 3.4 as much). The geriatric syndrome rates extracted from structured data were substantially lower than published epidemiological rates, although adding the NLP results considerably closed this gap. CONCLUSION: Claims and structured EHR data give an incomplete picture of burden related to geriatric syndromes. Geriatric syndromes are likely to be missed if unstructured data are not analyzed. Pragmatic NLP algorithms can assist with identifying individuals at high risk of experiencing geriatric syndromes and improving coordination of care for older adults.},
  langid = {english},
  pmid = {29972595},
  keywords = {Aged,Aged; 80 and over,Algorithms,case identification,Databases; Factual,electronic health records,Electronic Health Records,Female,Frail Elderly,Frailty,geriatric syndromes,Humans,Male,Mobility Limitation,Natural Language Processing,natural language processing and text-mining,Prevalence,Retrospective Studies,Social Support,Syndrome,unstructured free-text data}
}

@article{kim207,
  type = {Journal {{Article}}},
  title = {Does the Timing of Esophagectomy after Chemoradiation Affect Outcome?},
  author = {Kim, J. Y. and Correa, A. M. and Vaporciyan, A. A. and Roth, J. A. and Mehran, R. J. and Walsh, G. L. and Rice, D. C. and Ajani, J. A. and Maru, D. M. and Bhutani, M. S. and Welsh, J. and Marom, E. M. and Swisher, S. G. and Hofstetter, W. L.},
  year = {2012},
  journal = {Ann Thorac Surg},
  volume = {93},
  number = {1},
  pages = {207-12; discussion 212-3},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2011.05.021}
}

@article{kim403,
  title = {Multimodality Assessment of Esophageal Cancer: Preoperative Staging and Monitoring of Response to Therapy},
  shorttitle = {Multimodality Assessment of Esophageal Cancer},
  author = {Kim, Tae Jung and Kim, Hyae Young and Lee, Kyung Won and Kim, Moon Soo},
  year = {2009 Mar-Apr},
  journal = {Radiographics: A Review Publication of the Radiological Society of North America, Inc},
  volume = {29},
  number = {2},
  pages = {403--421},
  issn = {1527-1323},
  doi = {10.1148/rg.292085106},
  abstract = {Esophageal cancer is a leading cause of cancer mortality worldwide. Complete resection of esophageal cancer and adjacent malignant lymph nodes is the only potentially curative treatment. Accurate preoperative staging and assessment of therapeutic response after neoadjuvant therapy are crucial in determining the most suitable therapy and avoiding inappropriate attempts at curative surgery. Computed tomography (CT) is recommended for initial imaging following confirmation of malignancy at pathologic analysis, primarily to rule out unresectable or distant metastatic disease. With the advent of multidetector CT, use of thin sections and multiplanar reformation allows more accurate staging of esophageal cancer. Endoscopic ultrasonography (US) is the best modality for determining the depth of tumor invasion and presence of regional lymph node involvement. Combined use of fine-needle aspiration and endoscopic US can improve assessment of lymph node involvement. Positron emission tomography (PET) is useful for assessment of distant metastases but is not appropriate for detecting and staging primary tumors. PET may also be helpful in restaging after neoadjuvant therapy, since it allows identification of early response to treatment and detection of interval distant metastases. Each imaging modality has its advantages and disadvantages; therefore, CT, endoscopic US, and PET should be considered complementary modalities for preoperative staging and therapeutic monitoring of patients with esophageal cancer.},
  langid = {english},
  pmid = {19325056},
  keywords = {Aged,Endosonography,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoplasm Staging,Outcome Assessment; Health Care,Positron-Emission Tomography,Preoperative Care,Prognosis,Tomography; X-Ray Computed,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BQSG8IXG\\Kim et al. - 2009 - Multimodality assessment of esophageal cancer pre.pdf}
}

@article{kim4721,
  title = {Evaluation of Sarcopenia in Small-Cell Lung Cancer Patients by Routine Chest {{CT}}},
  author = {Kim, Eun Young and Kim, Young Saing and Park, Inkeun and Ahn, Hee Kyung and Cho, Eun Kyung and Jeong, Yu Mi and Kim, Jeong Ho},
  year = {2016},
  month = nov,
  journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
  volume = {24},
  number = {11},
  pages = {4721--4726},
  issn = {1433-7339},
  doi = {10.1007/s00520-016-3321-0},
  abstract = {BACKGROUND: Single cross-sectional area of muscle at the third lumbar vertebra (L3MA) is gold standard to estimate skeletal muscle mass (SMM), and L3 muscle index (L3MI, L3MA/height(2)) is used to determine sarcopenia. The purposes of this study were to evaluate the relationship between SMM indices determined by routine chest CT and L3MI in patients with small-cell lung cancer (SCLC) and to suggest chest CT-derived diagnostic criteria for sarcopenia. METHODS: Area of pectoralis muscles at the aortic arch (PMA) and at L1 (L1MA) was retrospectively measured on chest CT images of 90 consecutive SCLC patients. Pearson's correlation and multiple linear regression analysis were used to assess relationships between L3MI determined by PET/CT and pectoralis muscle index (PMI) and L1 muscle index (L1MI) determined by chest CT. RESULTS: The correlation between L1MI and L3MI was stronger than that between PMI and L3MI (r~=~0.851 vs. r~=~0.447, p~{$<~$}0.001). Multivariable regression analysis showed that L1MI was the only significant predictor of L3MI; L3MI~=~0.963~\texttimes ~L1MI~+~10.336 (R (2) ~=~0.689, p~{$<~$}0.001) for male and L3MI~=~0.772~\texttimes ~L1MI~+~16.518 (R (2) ~=~0.777, p~{$<~$}0.001) for female. Using this relationship, estimated cutoffs of L1MI for sarcopenia were 46~cm(2)/m(2) for male and 29~cm(2)/m(2) for female (L3MI cutoffs for sarcopenia are 55~cm(2)/m(2) for male and 39~cm(2)/m(2) for female). The sensitivity and specificity of L1MI cutoffs to determine sarcopenia were 98.2 and 100~\%, respectively. CONCLUSIONS: Chest CT-determined L1MI is highly correlated with L3MI in SCLC patients. L1MI, as determined by chest CT, could be used to determine the presence of sarcopenia with suggested cutoffs of 46~cm(2)/m(2) for men and 29~cm(2)/m(2) for women.},
  langid = {english},
  pmid = {27364150},
  keywords = {Aged,Cancer cachexia,Female,Humans,Lung,Lung Neoplasms,Male,Retrospective Studies,Sarcopenia,Skeletal muscle mass,Small Cell Lung Carcinoma,Small-cell lung cancer,Tomography,Tomography; X-Ray Computed,X-ray computed}
}

@article{kim5,
  title = {Prognostic {{Significance}} of {{CT-Determined Sarcopenia}} in {{Patients}} with {{Small-Cell Lung Cancer}}},
  author = {Kim, Eun Young},
  year = {2015},
  journal = {Journal of Thoracic Oncology},
  volume = {10},
  number = {12},
  pages = {5},
  abstract = {Introduction: The primary objective of this study was to determine the prognostic significance of computed tomography (CT)determined sarcopenia in small-cell lung cancer (SCLC) patients. Methods: This retrospective study consisted of a total of 149 consecutive SCLC patients. The cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using baseline CT images. Sarcopenia was defined as a L3 muscle index of less than 55\,cm2/m2 for men and of less than 39\,cm2/m2 for women as proposed by international consensus of cancer cachexia. In addition, Korean-specific cutoffs for sarcopenia was also applied (49\,cm2/m2 for men and 31\,cm2/m2 for women). Overall survival (OS) and clinical characteristics of patients with or without sarcopenia were compared. Results: Mean patient age was 68.6\,{$\pm$}\,9.5 years. Most were male (85.3\%) and 67.8\% had extensive disease at time of diagnosis. Sarcopenia was present in 118 patients (79.2\%) and was significantly related to an advanced age (p = 0.028), male sex (p {$<$} 0.001), lower body mass index (p {$<$} 0.001), and poor performance status (p = 0.049). Sarcopenic patients had shorter OS than nonsarcopenic patients (median: 8.6 months versus 16.8 months; p = 0.031). Multivariable analysis revealed that sarcopenia was an independent prognostic factor of poor survival (hazards ratio: 1.68; 95\% confidence interval: 1.04\textendash 2.72; p = 0.034), along with extensive stage (p {$<$} 0.001), supportive care only (p {$<$} 0.001), and an elevated lactate dehydrogenase level (p = 0.020). Using Korean sarcopenia cutoffs, sarcopenic patients were also found to have poorer OS than nonsarcopenic patients, however, the survival difference was not statistically significant (median: 8.4 months versus 12.7 months; p = 0.144 by the log-rank test). Conclusions: Sarcopenia as determined by CT could be used to predict prognosis in patients with SCLC. Optimum reference values},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CSSRKH2Y\\Kim - 2015 - Prognostic Significance of CT-Determined Sarcopeni.pdf}
}

@article{kim77,
  title = {Clinical Significance of Skeletal Muscle Density and Sarcopenia in Patients with Pancreatic Cancer Undergoing First-Line Chemotherapy: A Retrospective Observational Study},
  shorttitle = {Clinical Significance of Skeletal Muscle Density and Sarcopenia in Patients with Pancreatic Cancer Undergoing First-Line Chemotherapy},
  author = {Kim, In-Ho and Choi, Moon Hyung and Lee, In Seok and Hong, Tae Ho and Lee, Myung Ah.},
  year = {2021},
  month = jan,
  journal = {BMC Cancer},
  volume = {21},
  pages = {77},
  issn = {1471-2407},
  doi = {10.1186/s12885-020-07753-w},
  abstract = {Background To investigate the clinical impact of sarcopenia and skeletal muscle density (SMD) among patients with metastatic pancreatic adenocarcinoma who underwent palliative first line gemcitabine-based chemotherapy. Methods A total of 330 patients treated with first line gemcitabine-based chemotherapy between January 2010 and March 2017 were included. CT scans before chemotherapy and after 8{$\pm$}2\,weeks were evaluated. The L3 skeletal muscle index (SMI) was used to detect sarcopenia and calculated as the total area of the L3 skeletal muscle divided by the height-squared (cm2/m2). SMD was quantified as the mean muscle radiation attenuation of the muscle cross-sectional area across the L3 vertebral body level and was assessed between -\,29 and +\,150 Hounsfield units. Results A SMI to SMD comparison revealed a positive correlation (R2 = 0.058, P {$<$}\,0.001). Compared with high SMD, the risks of low SMI were 1.516 (95\% confidence interval [CI]: 1.164\textendash 1.973) among patients with low SMD. Kaplan\textendash Meier analysis showed that the low SMD was related to poor overall survival (OS, median, 6.1 versus [vs.] 7.9\,months, P = 0.010). Multivariate analysis using Cox regression showed that low SMI (hazard ratio [HR]: 1.35, 95\% CI: 1.03\textendash 1.78, P = 0.032) and low SMD (HR: 1.45, 95\% CI: 1.09\textendash 1.93, P = 0.011) were poor prognostic factors for OS, respectively. Co-presence of low SMI and low SMD had more powerful prognostic implication for OS (HR: 1.58, 95\% CI: 1.12\textendash 2.23, P = 0.010). Grade 3 or higher toxicity of chemotherapy was more frequently observed in patients who have a low SMI (43\% vs. 59\%, P = 0.019) and low SMD (44\% vs. 60\%, P = 0.023). OS was not related to SMD status among patients who were chemotherapy responders (complete or partial responses). However, among non-responders (stable or progressive disease), low SMD groups had significantly poorer OS in comparison with high SMD groups (median, 5.6 vs 7.4\,months, P = 0.006). Conclusions Sarcopenia and SMD status can be considered a prognostic factor in patients with metastatic pancreatic adenocarcinoma who received palliative first line gemcitabine-based chemotherapy. Severe chemotherapy toxicity occurred in the sarcopenia and low SMD groups. Our data suggest that a comprehensive assessment of skeletal muscle parameters may be more useful prognostic factors. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-020-07753-w.},
  pmcid = {PMC7814715},
  pmid = {33461517},
  keywords = {Pancreatic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5AB24AE6\\Kim et al_2021_Clinical significance of skeletal muscle density and sarcopenia in patients.pdf}
}

@article{kitagawa5409,
  title = {Analysis of {{Factors Associated}} with {{Weight Loss After Esophagectomy}} for {{Esophageal Cancer}}},
  author = {Kitagawa, Hiroyuki and Namikawa, Tsutomu and Munekage, Masaya and Fujisawa, Kazune and Munekage, Eri and Kawanishi, Yasuhiro and Kobayashi, Michiya and Hanazaki, Kazuhiro},
  year = {2016},
  month = oct,
  journal = {Anticancer Research},
  volume = {36},
  number = {10},
  pages = {5409--5412},
  issn = {1791-7530},
  doi = {10.21873/anticanres.11117},
  abstract = {AIM: To investigate the factors associated with weight loss (WL) after esophagectomy for esophageal cancer. PATIENTS AND METHODS: We retrospectively reviewed 136 patients who underwent esophagectomy for esophageal cancer. Preoperative characteristics, surgical methods, postoperative outcomes and weight changes at 6 months after surgery were analyzed. RESULTS: Seventy-eight patients had more than 10\% WL compared to their weight at surgery. On univariate analysis, higher body mass index [(BMI): {$\geq$}20.8; p=0.012] and shorter length of hospitalization [(LOH); p=0.041] demonstrated an association with more than 10\% WL. On multivariate analysis, higher BMI [odds ratio (OR)=2.821; 95\% confidence interval (CI)=1.238-6.426; p=0.014] and shorter LOH (OR=2.953; 95\% CI=1.009-8.646; p=0.048) were independently associated with more than 10\% WL. CONCLUSION: Higher BMI and shorter LOH were unfavorable risk factors for WL after esophagectomy for esophageal cancer.},
  langid = {english},
  pmid = {27798907},
  keywords = {Aged,esophageal cancer,Esophageal Neoplasms,esophagectomy,Esophagectomy,Female,GE,Humans,Male,Middle Aged,Retrospective Studies,Weight loss,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SCKE2TPH\\Kitagawa et al. - 2016 - Analysis of Factors Associated with Weight Loss Af.pdf}
}

@article{klevebroS692,
  title = {Application of Standardized Hemodynamic Protocols within Enhanced Recovery after Surgery Programs to Improve Outcomes Associated with Anastomotic Leak and Conduit Necrosis in Patients Undergoing Esophagectomy},
  author = {Klevebro, Fredrik and Boshier, Piers R. and Low, Donald E.},
  year = {2019},
  month = apr,
  journal = {Journal of Thoracic Disease},
  volume = {11},
  number = {Suppl 5},
  pages = {S692-S701},
  issn = {2072-1439},
  doi = {10.21037/jtd.2018.11.141},
  abstract = {Esophagectomy for cancer is associated with high risk for postoperative morbidity. The most serious regularly encountered complication is anastomotic leak and the most feared individual complication is conduit necrosis. Both of these complications affect the length of stay, mortality, quality of life, and survival for patients undergoing esophageal resection. The maintenance of conduit viability is of primary importance in the perioperative care of patients following esophageal resection. It has been shown that restrictive fluid management may be associated with improved postoperative outcomes in abdominal and other types of surgery, but many factors can affect the incidence of anastomotic leak and the viability of the gastric conduit. We have performed a comprehensive review with the aim to give an overview of the available evidence for the use of standardized hemodynamic protocols (SHPs) for esophagectomy and review the hemodynamic protocol, which has been applied within a standardized clinical pathway (SCP) at the Department of Thoracic surgery at the Virginia Mason Medical Center between 2004-2018 where the anastomotic leak rate over the period has been 5.2\% and the incidence of conduit necrosis requiring surgical management is zero. The literature review demonstrates that there are few high quality studies that provide scientific evidence for the use of a SHP. The evidence indicates that the use of goal-directed hemodynamic monitoring might be associated with a reduced risk for postoperative complications, shortened length of stay, and decreased need for intensive care unit stay. We propose that the routine application of a SHP can provide a uniform infrastructure to optimize conduit perfusion and decrease the incidence of anastomotic leak.},
  langid = {english},
  pmcid = {PMC6503292},
  pmid = {31080646},
  keywords = {Esophageal cancer,esophagectomy,goal-directed therapy,hemodynamic protocol,perioperative care,postoperative complications},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NEGVSAKX\\Klevebro et al_2019_Application of standardized hemodynamic protocols within enhanced recovery.pdf}
}

@article{knyrim1302,
  title = {A Controlled Trial of an Expansile Metal Stent for Palliation of Esophageal Obstruction Due to Inoperable Cancer},
  author = {Knyrim, K. and Wagner, H. J. and Bethge, N. and Keymling, M. and Vakil, N.},
  year = {1993},
  month = oct,
  journal = {The New England Journal of Medicine},
  volume = {329},
  number = {18},
  pages = {1302--1307},
  issn = {0028-4793},
  doi = {10.1056/NEJM199310283291803},
  abstract = {BACKGROUND: Esophageal obstruction due to cancer can produce debilitating dysphagia. Rapid palliation is usually possible with endoscopic placement of a plastic esophageal prosthesis, but this device has a high rate of complications. A new alternative is a metal-mesh stent that collapses to 3 mm in diameter at placement but can then expand up to 16 mm. METHODS: Patients with esophageal carcinoma (39 patients) or malignant extrinsic obstruction (3 patients) were randomly assigned to treatment with either a plastic prosthesis (16 mm in diameter) or an expansile metal-mesh stent. The patients were evaluated every six weeks until death. The degree of palliation was expressed as a dysphagia score and a Karnofsky performance score. RESULTS: Complications were significantly less frequent with the metal stents than with the plastic prostheses (no complications vs. nine; P {$<$} 0.001). The dysphagia and Karnofsky scores improved significantly and to a similar degree in both treatment groups. The most common causes of recurrent dysphagia were migration of the plastic prostheses (five patients) and ingrowth or overgrowth of the metal stents by tumor (five patients). The rates of reintervention were similar in both treatment groups, as were the 30-day mortality rates. The period of hospitalization after placement of a prosthesis was significantly longer in the group given plastic prostheses than in the group given metal stents (mean +/- SE, 12.5 +/- 2.1 vs. 5.4 +/- 1.0 days; P = 0.005). Despite their higher initial cost, the metal stents were cost effective because of the absence of fatal complications and the decrease in the hospital stay. CONCLUSIONS: Expansile metal stents are a safe and cost-effective alternative to conventional plastic endoprostheses in the treatment of esophageal obstruction due to inoperable cancer.},
  langid = {english},
  pmid = {7692297},
  keywords = {Aged,Cost-Benefit Analysis,Deglutition Disorders,Esophageal Neoplasms,Esophageal Stenosis,Female,Follow-Up Studies,Humans,Male,Metals,Middle Aged,Palliative Care,Plastics,Prosthesis Design,Recurrence,Stents,Treatment Outcome}
}

@article{ko,
  title = {Low {{Rates}} of {{Medical Oncology Consultation}} for {{Older Women}} ({$\geq~$}70~{{Years}}) with {{Newly Diagnosed}}, {{Non-Metastatic Breast Cancer}}: {{A Population-Based Study}}},
  shorttitle = {Low {{Rates}} of {{Medical Oncology Consultation}} for {{Older Women}} ({$\geq~$}70~{{Years}}) with {{Newly Diagnosed}}, {{Non-Metastatic Breast Cancer}}},
  author = {Ko, Gary and Hallet, Julie and Jerzak, Katarzyna J. and Chan, Wing and Coburn, Natalie and Barabash, Victoria and Wright, Frances C. and Look Hong, Nicole J.},
  year = {2022},
  month = oct,
  journal = {Annals of Surgical Oncology},
  issn = {1534-4681},
  doi = {10.1245/s10434-022-12640-8},
  abstract = {BACKGROUND: Curative intent cancer treatment needs to be balanced with patient comorbidities and quality of life when treating older women with breast cancer. We examined consultation patterns and association of age at diagnosis with lack of specialist cancer consultations for older women with breast cancer. METHODS: We conducted a population-based retrospective cohort study of older women ({$\geq$} 70~years of age) with incident, non-metastatic breast cancer (2010-2018) by linking administrative databases in Ontario, Canada. The outcomes of interest were lack of specialist cancer consultation (surgeon, medical oncology, or radiation oncology) within 12 months of diagnosis. Association of age with lack of specialist cancer consultation was examined using Poisson regression modeling. RESULTS: Of 21,849 older women, 2.4\% (n~=~517) did not have any specialist cancer consultation within 12 months of diagnosis; lack of any specialist cancer consultation increased with age (0.8\% for age 70-74~years, 1.3\% for age 75-79~years, 2.5\% for age 80-84~years, and 7.0\% for age {$\geq$} 85~years; p~{$<~$}0.001). The proportion of patients who did not have consultations with surgeons, medical oncologists, and radiation oncologists was 8.6\% (n~=~1888), 34.4\% (n~=~7510), and 24.7\% (n~=~5404), respectively. Older age group was independently associated with an increased likelihood of lacking any specialist consultation, as well as not receiving surgical and medical oncology consultations. CONCLUSION: More than one-third of women {$\geq$} 70~years of age with non-metastatic breast cancer did not have a consultation with a medical oncologist, with women aged {$\geq$} 85~years least likely to have a medical oncology consultation.},
  langid = {english},
  pmid = {36255513},
  keywords = {BreastCancer}
}

@article{kofoed26,
  title = {Survival after Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal Junction},
  author = {Kofoed, S. C. and Muhic, A. and Baeksgaard, L. and Jendresen, M. and Gustafsen, J. and Holm, J. and Bardram, L. and Brandt, B. and Bren{\o}, J. and Svendsen, L. B.},
  year = {2012},
  journal = {Scandinavian journal of surgery: SJS: official organ for the Finnish Surgical Society and the Scandinavian Surgical Society},
  volume = {101},
  number = {1},
  pages = {26--31},
  issn = {1799-7267},
  doi = {10.1177/145749691210100106},
  abstract = {BACKGROUND AND AIMS: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18\% and 50\%. In the pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adeno-carcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradio-therapy. METHODS: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 pa-tients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol. RESULTS: Patients with positive node status in the resected specimen, the 3-year disease-free survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24\% and 37\%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival. CONCLUSION: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.},
  langid = {english},
  pmid = {22414465},
  keywords = {Adenocarcinoma,Aged,Chemoradiotherapy; Adjuvant,Disease-Free Survival,Esophagogastric Junction,Female,Humans,Lymphatic Metastasis,Male,Middle Aged,Radiotherapy Dosage,Stomach Neoplasms}
}

@article{koh480,
  type = {Journal {{Article}}},
  title = {Functional Assessment of the Cervical Esophagus after Gastric Transposition and Cervical Esophagogastrostomy},
  author = {Koh, P. and Turnbull, G. and Attia, E. and LeBrun, P. and Casson, A. G.},
  year = {2004},
  journal = {Eur J Cardiothorac Surg},
  volume = {25},
  number = {4},
  pages = {480--5},
  issn = {1010-7940 (Print) 1010-7940 (Linking)},
  doi = {10.1016/j.ejcts.2003.12.034}
}

@article{kohne10259,
  title = {Creating Learning Health Systems and the Emerging Role of Biomedical Informatics},
  author = {Kohn, Martin S. and Topaloglu, Umit and Kirkendall, Eric S. and Dharod, Ajay and Wells, Brian J. and Gurcan, Metin},
  year = {2022},
  journal = {Learning Health Systems},
  volume = {6},
  number = {1},
  pages = {e10259},
  issn = {2379-6146},
  doi = {10.1002/lrh2.10259},
  abstract = {Introduction The nature of information used in medicine has changed. In the past, we were limited to routine clinical data and published clinical trials. Today, we deal with massive, multiple data streams and easy access to new tests, ideas, and capabilities to process them. Whereas in the past getting information for decision-making was a challenge, now, it is how to analyze, evaluate and prioritize all that is readily available through the multitude of data-collecting devices. Clinicians must become adept with the tools needed to deal with the era of big data, requiring a major change in how we learn to make decisions. Major change is often met with resistance and questions about value. A Learning Health System is an enabler to encourage the development of such tools and demonstrate value in improved decision-making. Methods We describe how we are developing a Biomedical Informatics program to help our medical institution's evolution as an academic Learning Health System, including strategy, training for house staff and examples of the role of informatics from operations to research. Results We described an array of learning health system implementations and educational programs to improve healthcare and prepare a cadre of physicians with basic information technology skills. The programs have been well accepted with, for example, increasing interest and enrollment in the educational programs. Conclusions We are now in an era when large volumes of a wide variety of data are readily available. The challenge is not so much in the acquisition of data, but in assessing the quality, relevance and value of the data. The data we can get may not be the data we need. In the past, sources of data were limited, and trial results published in journals were the major source of evidence for decision making. The advent of powerful analytics systems has changed the concept of evidence. Clinicians will have to develop the skills necessary to work in the era of big data. It is not reasonable to expect that all clinicians will also be data scientists. However, understanding the role of AI and predictive analytics, and how to apply them, will become progressively more important. Programs such as the one being implemented at Wake Forest fill that need.},
  langid = {english},
  keywords = {aLHS,biomedical informatics,eFI,learning health systems,physician education},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/lrh2.10259},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LT6S2IZC\\Kohn et al_2021_Creating learning health systems and the emerging role of biomedical informatics.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\TCJ6PACL\\Kohn et al_2022_Creating learning health systems and the emerging role of biomedical informatics.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\BWWFGBFN\\lrh2.html}
}

@article{kohne308,
  title = {Clinical Determinants of Survival in Patients with 5-Fluorouracil-Based Treatment for Metastatic Colorectal Cancer: Results of a Multivariate Analysis of 3825 Patients},
  shorttitle = {Clinical Determinants of Survival in Patients with 5-Fluorouracil-Based Treatment for Metastatic Colorectal Cancer},
  author = {K{\"o}hne, C. H. and Cunningham, D. and Di Costanzo, F. and Glimelius, B. and Blijham, G. and Aranda, E. and Scheithauer, W. and Rougier, P. and Palmer, M. and Wils, J. and Baron, B. and Pignatti, F. and Sch{\"o}ffski, P. and Micheel, S. and Hecker, H.},
  year = {2002},
  month = feb,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {13},
  number = {2},
  pages = {308--317},
  issn = {0923-7534},
  doi = {10.1093/annonc/mdf034},
  abstract = {BACKGROUND: Patients with metastatic colorectal cancer are usually offered systemic chemotherapy as palliative treatment. A multivariate analysis was performed in order to identify predictors and their constellation that allow a valid prediction of the outcome in patients treated with 5-fluorouracil (5-FU)-based therapy. PATIENTS AND METHODS: A total of 3825 patients treated with 5-FU within 19 prospective randomised and three phase II trials were separated into learning (n = 2549) and validation (n = 1276) samples. Data were analysed by tree analysis using the recursive partition and amalgamation method (RECPAM). A predictor could only enter the RECPAM analysis if the number of patients with missing values was {$<$} 33.3\% within a node, and the minimal node size was set to 50 patients. Twenty-three potential predictors were grouped into subsets of laboratory variables (11 parameters), tumour-related variables (seven parameters) and clinical variables (five parameters). In the first step, tree analysis was performed separately for each predictor subset. The selected prognostic parameters of the resulting partial models (the 'winners') were entered into the general model. The classification rule from the data of the learning set was applied to the independent validation set. RESULTS: Winners of the subgroup analysis for laboratory variables were: platelets {$>$} or = 400 x 10(9)/l, alkaline phosphatase {$>$} or = 300 U/l, white blood cell (WBC) count {$>$} or = 10 x 10(9)/l and haemoglobin {$<$} 11 x 10(9)/l, and all predicted a worse outcome. Negative predictors within the subgroup of tumour parameters were: number of tumour sites more than one or more than two, presence of liver metastases or peritoneal carcinomatosis, which predicted a worse outcome. Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting. Among the clinical parameters only performance status of ECOG 0 or 1 predicted better outcome. In the final regression tree, three risk groups could be identified: low risk group (n = 1111) with a median survival of 15 months for patients with ECOG 0/1 and only one tumour site; intermediate risk group (n = 904) with a median survival of 10.7 months for patients with ECOG 0/1 and more than one tumour site and alkaline phosphatase {$<$} 300 U/l or patients with ECOG {$>$} 1, WBC count {$<$} 10 x 10(9)/l and only one tumour site; high risk group (n = 534) with a median survival of 6.1 months for patients with ECOG 0/1 and more than one tumour site and alkaline phosphatase of {$>$} or = 300 U/l or patients with ECOG {$>$} 1 and more than one tumour site or WBC count {$>$} 10 x 10(9)/l. The median survival times for the good, intermediate and high risk groups in the validation sample were 14.7, 10.5 and 6.4 months, respectively. CONCLUSIONS: Patients can be divided into at least three risk groups depending on the four baseline clinical parameters: performance status, WBC count, alkaline phosphatase and number of metastatic sites. Any molecular or biological marker should be validated against these clinical parameters and decisions for more or less intensive treatments may be studied separately in these three risk groups. Also, clinical trials should be stratified according to the three risk groups.},
  langid = {english},
  pmid = {11886010},
  keywords = {Alkaline Phosphatase,Antineoplastic Combined Chemotherapy Protocols,Colorectal Neoplasms,CRC,Fluorouracil,Humans,Leukocyte Count,Multivariate Analysis,Neoplasm Metastasis,Prospective Studies}
}

@article{komatsu14922,
  title = {Night Home Enteral Nutrition as a Novel Enforced and Physiologically Effective Nutrition Therapy Following Total Gastrectomy for Gastric Cancer},
  author = {Komatsu, Shuhei and Konishi, Tomoki and Matsubara, Daiki and Soga, Koji and Shimomura, Katsumi and Ikeda, Jun and Taniguchi, Fumihiro and Iwase, Hiroya and Kubota, Takeshi and Shioaki, Yasuhiro and Otsuji, Eigo},
  year = {2022},
  month = sep,
  journal = {Scientific Reports},
  volume = {12},
  number = {1},
  pages = {14922},
  issn = {2045-2322},
  doi = {10.1038/s41598-022-17420-8},
  abstract = {Enteral nutrition has been reported to be safe and effective in malnourished patients undergoing upper gastrointestinal surgery. In this study, we devised night home enteral nutrition (N-HEN) as a novel nutritional strategy and evaluated the efficacy in gastric cancer patients following total gastrectomy. Between January 2017 and March 2021, 24 patients were prospectively included in the protocol and supported by N-HEN for three postoperative months through a jejunostomy during the night (Elental:1200~kcal/day), and 22 patients without N-HEN were followed as a control group (CG). Body weight loss, nutritional indicators and tolerance to chemotherapy were evaluated. After 3 and 6~months, patients with N-HEN had significantly less body weight loss than CG (3~months P\,\&lt;\,0.0001: N-HEN 4.0\% vs. CG 15.2\%, 6~months P\,\&lt;\,0.0001: N-HEN 7.7\% vs. CG 17.7\%). Prealbumin was significantly higher in patients with N-HEN than CG after 3 and 6~months (3~months P\,\&lt;\,0.0001, 6~months P\,=\,0.0037). Albumin, total protein and hemoglobin, tended to be higher after 3 and 6~months in patients with N-HEN than CG, and total cholesterol after 6~months. Concerning the tolerance to adjuvant chemotherapy in Stage II-III patients, patients with N-HEN significantly had a higher completion rate (P\,=\,0.0420: N-HEN 70\% vs. CG 29\%) and longer duration (P\,=\,0.0313: N-HEN 458~days vs. CG 261~days) as planned. Continuous monitoring of blood glucose concentration in patients with N-HEN did not show nocturnal hypoglycemia or hyperglycemia. N-HEN could be a novel enforced and physiologically effective nutritional strategy to support potentially malnourished patients following total gastrectomy.},
  langid = {english},
  pmcid = {PMC9440117},
  pmid = {36056110},
  keywords = {Enteral,Enteral Nutrition,Gastrectomy,Humans,Jejunostomy,Malnutrition,Stomach Neoplasms,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WFPZLQKE\\Komatsu et al_2022_Night home enteral nutrition as a novel enforced and physiologically effective.pdf}
}

@article{komici485,
  title = {Frailty in {{Patients With Lung Cancer}}: {{A Systematic Review}} and {{Meta-Analysis}}},
  shorttitle = {Frailty in {{Patients With Lung Cancer}}},
  author = {Komici, Klara and Bencivenga, Leonardo and Navani, Neal and D'Agnano, Vito and Guerra, Germano and Bianco, Andrea and Rengo, Giuseppe and Perrotta, Fabio},
  year = {2022},
  month = aug,
  journal = {Chest},
  volume = {162},
  number = {2},
  pages = {485--497},
  issn = {0012-3692},
  doi = {10.1016/j.chest.2022.02.027},
  abstract = {Background Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification. Research Question What is the prevalence and impact of frailty in patients with lung cancer? Study Design and Methods This systematic review and meta-analysis used a combination of free-text terms and medical subject headings terms, according to the database requirements in MEDLINE/PubMed, Scopus, and Cochrane Library from inception until November 15,~2020. Results A total of 2,571 articles were identified, and 16 articles involving 4,183 patients were included for study. The prevalence of frailty in lung cancer was 45\%~(95\%~CI, 28-61; I2~= 99.5\%; P~{$<$} .0001). In patients with lung cancer, frailty was associated with an increased hazard ratio for mortality (hazard ratio, 3.01; 95\%~CI, 1.77-5.10; P~{$<$} .001). Interpretation The prevalence of frailty in lung cancer is 45\%, which has a significant negative impact on survival of patients with lung cancer. These results highlight the importance of measuring frailty, which provides important prognostic information, and may provide opportunities for interventions to improve outcomes in patients with lung cancer.},
  langid = {english},
  keywords = {elderly,frailty,Lung,lung cancer,mortality,outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JUULQIFY\\S0012369222003919.html}
}

@article{koo913,
  title = {A Prognostic Model in Patients Who Receive Chemotherapy for Metastatic or Recurrent Gastric Cancer: Validation and Comparison with Previous Models},
  shorttitle = {A Prognostic Model in Patients Who Receive Chemotherapy for Metastatic or Recurrent Gastric Cancer},
  author = {Koo, Dong Hoe and Ryoo, Baek-Yeol and Kim, Hwa Jung and Ryu, Min-Hee and Lee, Sung-Sook and Moon, Jung-Hwa and Chang, Heung-Moon and Lee, Jae-Lyun and Kim, Tae Won and Kang, Yoon-Koo},
  year = {2011},
  month = oct,
  journal = {Cancer Chemotherapy and Pharmacology},
  volume = {68},
  number = {4},
  pages = {913--921},
  issn = {1432-0843},
  doi = {10.1007/s00280-011-1561-8},
  abstract = {To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models.},
  langid = {english},
  keywords = {Stage4}
}

@article{koster2520,
  title = {Snakemake--a Scalable Bioinformatics Workflow Engine},
  author = {K{\"o}ster, Johannes and Rahmann, Sven},
  year = {2012},
  month = oct,
  journal = {Bioinformatics (Oxford, England)},
  volume = {28},
  number = {19},
  pages = {2520--2522},
  issn = {1367-4811},
  doi = {10.1093/bioinformatics/bts480},
  abstract = {SUMMARY: Snakemake is a workflow engine that provides a readable Python-based workflow definition language and a powerful execution environment that scales from single-core workstations to compute clusters without modifying the workflow. It is the first system to support the use of automatically inferred multiple named wildcards (or variables) in input and output filenames. AVAILABILITY: http://snakemake.googlecode.com. CONTACT: johannes.koester@uni-due.de.},
  langid = {english},
  pmid = {22908215},
  keywords = {Computational Biology,Electronic Data Processing,Methods,ML,Programming Languages,Software,Workflow},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VHPQ529N\\KÃ¶ster_Rahmann_2012_Snakemake--a scalable bioinformatics workflow engine.pdf}
}

@article{koterazawa407,
  title = {Severe Weight Loss after Minimally Invasive Oesophagectomy Is Associated with Poor Survival in Patients with Oesophageal Cancer at 5~Years},
  author = {Koterazawa, Yasufumi and Oshikiri, Taro and Takiguchi, Gosuke and Urakawa, Naoki and Hasegawa, Hiroshi and Yamamoto, Masashi and Kanaji, Shingo and Yamashita, Kimihiro and Matsuda, Takeru and Nakamura, Tetsu and Suzuki, Satoshi and Kakeji, Yoshihiro},
  year = {2020},
  month = dec,
  journal = {BMC gastroenterology},
  volume = {20},
  number = {1},
  pages = {407},
  issn = {1471-230X},
  doi = {10.1186/s12876-020-01543-1},
  abstract = {BACKGROUND: Patients often experience severe weight loss after oesophagectomy. Enteral nutrition via a feeding jejunostomy tube (FT) is commonly practised. This study aimed to assess the effect of severe weight loss postoperatively and enteral nutrition via an FT on long-term prognosis after oesophagectomy. METHODS: This study analysed 317 patients who underwent minimally invasive oesophagectomy at Kobe University Hospital and Hyogo Cancer Center from 2010 to 2015. The patients' body weight was evaluated at 3~months postoperatively. They were organised into the severe weight loss (n\,=\,65) and moderate weight loss (n\,=\,252) groups. Furthermore, they were categorised into the FT group (184 patients who had an FT placed during oesophagectomy) and no-FT group (133 patients without FT). Patients (119 per group) matched for the FT and no-FT groups were identified via propensity score matching. RESULTS: The 5-year overall survival (OS) rate in the severe weight loss group was significantly lower (p\,=\,0.024). In the multivariate analysis, tumour invasion depth (pT3-4), preoperative therapy and severe weight loss had a worse OS (hazard ratio\,=\,1.89; 95\% confidence interval\,=\,1.12-3.17, hazard ratio\,=\,2.11; 95\% confidence interval\,=\,1.25-3.54, hazard ratio\,=\,1.82; 95\% confidence interval\,=\,1.02-3.524, respectively). No significant differences in the number of severe weight loss patients and OS were found between the FT and no-FT groups. CONCLUSION: Severe weight loss is significantly associated with poor OS. In addition, enteral nutrition via an FT did not improve the severe weight loss and OS.},
  langid = {english},
  pmcid = {PMC7713340},
  pmid = {33272220},
  keywords = {Enteral nutrition,Enteral Nutrition,Esophageal Neoplasms,Esophagectomy,Humans,Minimally invasive oesophagectomy,Severe weight loss,Treatment Outcome,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2WAK4ZTF\\Koterazawa et al. - 2020 - Severe weight loss after minimally invasive oesoph.pdf}
}

@article{krishnane175,
  title = {Impact of {{Performance Status}} on {{Response}} and {{Survival Among Patients Receiving Checkpoint Inhibitors}} for {{Advanced Solid Tumors}}},
  author = {Krishnan, Mridula and Kasinath, Pooja and High, Robin and Yu, Fang and Teply, Benjamin A.},
  year = {2022},
  month = jan,
  journal = {JCO oncology practice},
  volume = {18},
  number = {1},
  pages = {e175-e182},
  issn = {2688-1535},
  doi = {10.1200/OP.20.01055},
  abstract = {PURPOSE: Clinical trials, which led to the approval of immune checkpoint inhibitors (ICI), have been almost exclusively performed in patients with good Eastern Cooperative Oncology Group performance status (ECOG PS of 0-1). However, ICI remains an attractive option for patients with advanced tumors and poor PS. We hypothesized that patients with ECOG PS {$\geq$} 2 would have worse outcomes with ICI. METHODS: We retrospectively identified patients with advanced solid tumors who were treated with ICI at our institution. The log-rank test compared the survival among patients with different ECOG PS. We used a proportional hazards model to assess association between ECOG PS and overall survival (OS) with adjustment for covariates including age, sex, malignancy type, time from advance disease diagnosis, and line of therapy. We compared overall response rates between groups with Pearson chi-square exact test. We also analyzed in-hospital mortality and hospice referral rates. RESULTS: We identified 257 patients treated with ICI. One hundred eighty-two patients had ECOG PS 0-1, and 75 had ECOG PS {$\geq$} 2. The median overall survival was 12.6 months for the ECOG PS 0-1 group compared with 3.1 months for the ECOG PS {$\geq$} 2 group (P {$<$} .001). The overall response rate for patients with ECOG PS 0-1 was 23\% compared with 8\% for those with poor PS (P = .005). Patients with poor PS treated with ICI had similar hospice referral rates (67\% for ECOG PS {$\geq$} 2 v 61.9\% for ECOG PS 0-1, P = .50) but were more likely to have in-hospital death as compared with the good PS group (28.6\% v 15.1\%, P = .035). CONCLUSION: Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.},
  langid = {english},
  pmid = {34351819},
  keywords = {Cohort Studies,Hospital Mortality,Humans,ICI,Neoplasms,Prospective Studies,Retrospective Studies}
}

@article{kroenke3008,
  title = {Muscle Radiodensity and Mortality in Patients with Colorectal Cancer},
  author = {Kroenke, Candyce H. and Prado, Carla M. and Meyerhardt, Jeffrey A. and Weltzien, Erin K. and Xiao, Jingjie and Cespedes Feliciano, Elizabeth M. and Caan, Bette J.},
  year = {2018},
  month = jul,
  journal = {Cancer},
  volume = {124},
  number = {14},
  pages = {3008--3015},
  issn = {1097-0142},
  doi = {10.1002/cncr.31405},
  abstract = {BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear. METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all-cause and CRC-specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross-classification of categories of low versus normal SMD and muscle mass (MM) with outcomes. RESULTS: The median follow-up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate-adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95\% confidence interval [95\% CI], 1.36-1.90) and CRC-specific (HR, 1.74; 95\% CI, 1.38-2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95\% CI, 1.65-2.47) and CRC-specific (HR, 2.54; 95\% CI, 1.91-3.37) mortality rates. CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease-specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008-15. \textcopyright{} 2018 American Cancer Society.},
  langid = {english},
  pmcid = {PMC6033621},
  pmid = {29797673},
  keywords = {adiposity,Aged,body composition,Body Composition,Body Mass Index,colorectal cancer (CRC),Colorectal Neoplasms,Female,Follow-Up Studies,Humans,Male,Middle Aged,mortality,muscle,muscle radiodensity,Muscle; Skeletal,myosteatosis,Myosteatosis,Neoplasm Staging,North Carolina,Prognosis,Risk Factors,Sarcopenia,survival,Survival Rate,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FZGRQJEF\\Kroenke et al. - 2018 - Muscle radiodensity and mortality in patients with.pdf}
}

@article{kubo184,
  title = {Prognostic {{Implication}} of {{Postoperative Weight Loss After Esophagectomy}} for {{Esophageal Squamous Cell Cancer}}},
  author = {Kubo, Yuto and Miyata, Hiroshi and Sugimura, Keijiro and Shinno, Naoki and Asukai, Kei and Hasegawa, Shinitiro and Yanagimoto, Yoshitomo and Yamada, Daisaku and Yamamoto, Kazuyoshi and Nishimura, Junichi and Wada, Hiroshi and Takahashi, Hidenori and Yasui, Masayoshi and Omori, Takeshi and Ohue, Masayuki and Yano, Masahiko},
  year = {2021},
  month = jan,
  journal = {Annals of Surgical Oncology},
  volume = {28},
  number = {1},
  pages = {184--193},
  issn = {1534-4681},
  doi = {10.1245/s10434-020-08762-6},
  abstract = {Preoperative weight loss in esophageal cancer is reported to be associated with a poor prognosis. However, the impact of postoperative weight loss on the prognosis of patients with esophageal cancer remains unclear.},
  langid = {english}
}

@article{kubo7173,
  title = {Influences of the {{Charlson Comorbidity Index}} and {{Nutrition Status}} on {{Prognosis After Esophageal Cancer Surgery}}},
  author = {Kubo, Yuto and Tanaka, Koji and Yamasaki, Makoto and Yamashita, Kotaro and Makino, Tomoki and Saito, Takuro and Yamamoto, Kazuyoshi and Takahashi, Tsuyoshi and Kurokawa, Yukinori and Motoori, Masaaki and Kimura, Yutaka and Nakajima, Kiyokazu and Eguchi, Hidetoshi and Doki, Yuichiro},
  year = {2021},
  month = nov,
  journal = {Annals of Surgical Oncology},
  volume = {28},
  number = {12},
  pages = {7173--7182},
  issn = {1534-4681},
  doi = {10.1245/s10434-021-09779-1},
  abstract = {BACKGROUND: The Charlson Comorbidity Index (CCI), an indicator that objectively quantifies comorbidities, reduces nutritional status; however, the impact of the CCI on the postoperative nutrition indexes of patients with esophageal cancer remains unclear. METHODS: In total, 336 patients with esophageal cancer who underwent surgery between January 2011 and April 2017 were included in this study. We investigated the relationship between the CCI and postoperative nutrition indexes. RESULTS: Patients were divided into two groups: CCI {$\leq$}1 (low CCI group) and CCI {$\geq$}2 (high CCI group). A high CCI was significantly associated with shortened overall survival (OS; 3-year OS rate of 77.9\% in the low CCI group versus 59.7\% in the high CCI group; p~=~0.008). Nutritional indexes, such as the Prognostic Nutritional Index (PNI), at 1~month after esophagectomy were significantly lower in the high CCI group than in the low CCI group (p~=~0.031); however, the PNI at 6 months after surgery was similar between the high and low CCI groups. Multivariate analysis identified high CCI as an independent risk factor associated with PNI {$<$}45 in esophageal cancer patients at 1 month after esophagectomy (p~=~0.047). CONCLUSION: This study showed that CCI {$\geq$}2 was significantly associated with poor PNI at 1 month after surgery for esophageal cancer, indicating that it is necessary to administer effective nutritional interventions for patients with postoperative malnutrition, especially those with multiple comorbidities.},
  langid = {english},
  pmid = {33835302},
  keywords = {CCI,Comorbidity,Esophageal Neoplasms,Humans,Nutrition Assessment,Nutritional Status,Prognosis,Retrospective Studies,Survival}
}

@article{kukreja242,
  type = {Journal {{Article}}},
  title = {Patient-{{Reported Outcomes Are Associated With Enhanced Recovery Status}} in {{Patients With Bladder Cancer Undergoing Radical Cystectomy}}},
  author = {Kukreja, J. B. and Shi, Q. and Chang, C. M. and Seif, M. A. and Sterling, B. M. and Chen, T. Y. and Creel, K. M. and Kamat, A. M. and Dinney, C. P. and Navai, N. and Shah, J. B. and Wang, X. S.},
  year = {2018},
  journal = {Surg Innov},
  volume = {25},
  number = {3},
  pages = {242--250},
  issn = {1553-3514 (Electronic) 1553-3506 (Linking)},
  doi = {10.1177/1553350618764218}
}

@article{kullberg10425,
  title = {Automated Analysis of Liver Fat, Muscle and Adipose Tissue Distribution from {{CT}} Suitable for Large-Scale Studies},
  author = {Kullberg, Joel and Hedstr{\"o}m, Anders and Brandberg, John and Strand, Robin and Johansson, Lars and Bergstr{\"o}m, G{\"o}ran and Ahlstr{\"o}m, H{\aa}kan},
  year = {2017},
  month = sep,
  journal = {Scientific Reports},
  volume = {7},
  number = {1},
  pages = {10425},
  issn = {2045-2322},
  doi = {10.1038/s41598-017-08925-8},
  abstract = {Computed Tomography (CT) allows detailed studies of body composition and its association with metabolic and cardiovascular disease. The purpose of this work was to develop and validate automated and manual image processing techniques for detailed and efficient analysis of body composition from CT data. The study comprised 107 subjects examined in the Swedish CArdioPulmonary BioImage Study (SCAPIS) using a 3-slice CT protocol covering liver, abdomen, and thighs. Algorithms were developed for automated assessment of liver attenuation, visceral (VAT) and subcutaneous (SAT) abdominal adipose tissue, thigh muscles, subcutaneous, subfascial (SFAT) and intermuscular adipose tissue. These were validated using manual reference measurements. SFAT was studied in selected subjects were the fascia lata could be visually identified (approx. 5\%). In addition, precision of manual measurements of intra- (IPAT) and retroperitoneal adipose tissue (RPAT) and deep- and superficial SAT was evaluated using repeated measurements. Automated measurements correlated strongly to manual reference measurements. The SFAT depot showed the weakest correlation (r\,=\,0.744). Automated VAT and SAT measurements were slightly, but significantly overestimated ({$\leq$}4.6\%, p\,{$\leq$}\,0.001). Manual segmentation of abdominal sub-depots showed high repeatability (CV\,{$\leq$}\,8.1\%, r\,{$\geq$}\,0.930). We conclude that the low dose CT-scanning and automated analysis makes the setup suitable for large-scale studies.},
  langid = {english},
  pmcid = {PMC5585405},
  pmid = {28874743},
  keywords = {Abdominal Fat,Adipose Tissue,Adiposity,Automation,Body Composition,Female,Humans,Image Processing; Computer-Assisted,Liver,Male,Middle Aged,ML,Muscles,Reproducibility of Results,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\3ARKMCXK\\Kullberg et al_2017_Automated analysis of liver fat, muscle and adipose tissue distribution from CT.pdf}
}

@article{kumar6,
  title = {Muscle Composition Measured by {{CT}} Scan Is a Measurable Predictor of Overall Survival in Advanced Ovarian Cancer},
  author = {Kumar, Amanika and Moynagh, Michael R and Multinu, Francesco and Cliby, William A and McGree, Michaela E and Weaver, Amy L and Young, Phillip M and {Bakkum-Gamez}, Jamie N and Langstraat, Carrie L and Dowdy, Sean C and Jatoi, Aminah and Mariani, Andrea},
  year = {2016},
  journal = {Gynecologic Oncology},
  pages = {6},
  abstract = {Objectives. To assess the impact of muscle composition and sarcopenia on overall survival in advanced epithelial ovarian cancer (EOC) after primary debulking surgery (PDS). Methods. Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/1/2006 and 12/ 31/2012 were included. Patient variables and vital status were abstracted. Body composition was evaluated in a semi-automated process using Slice-O-Matic software v4.3 (TomoVision). Skeletal muscle area and mean skeletal muscle attenuation were recorded. Associations with overall survival were evaluated using Cox proportional hazards models and recursive partitioning. Results. We identified 296 patients and 132 (44.6\%) were classified as sarcopenic. The average mean skeletal muscle attenuation of the entire cohort was 33.4 Hounsfield units (HU). A multivariate model of overall risk of death included histology, residual disease, and mean skeletal attenuation. Among patients without residual disease, overall survival, but not progression free survival was significantly different between patients with low versus high mean skeletal attenuation (median survival, 2.8 vs. 3.3 years). Among patients with residual disease, overall survival was significantly different between patients with low versus high mean skeletal attenuation {$\geq$}36.40 vs. b36.40 HU (median survival, 2.0 vs. 3.3 years). Conclusions. Sarcopenia and low mean skeletal muscle attenuation are common in women undergoing PDS for advanced EOC. These factors are associated with poorer outcomes, and can be used in preoperative risk stratification and patient counseling. Further research into body composition and whether this risk factor can be altered via nutrition or fitness in this population is warranted.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CHXJVTHP\\Kumar et al. - 2016 - Muscle composition measured by CT scan is a measur.pdf}
}

@article{kurita127,
  title = {Sarcopenia Is a Reliable Prognostic Factor in Patients with Advanced Pancreatic Cancer Receiving {{FOLFIRINOX}} Chemotherapy},
  author = {Kurita, Yusuke and Kobayashi, Noritoshi and Tokuhisa, Motohiko and Goto, Ayumu and Kubota, Kensuke and Endo, Itaru and Nakajima, Atsushi and Ichikawa, Yasushi},
  year = {2019},
  month = jan,
  journal = {Pancreatology},
  volume = {19},
  number = {1},
  pages = {127--135},
  issn = {1424-3903},
  doi = {10.1016/j.pan.2018.11.001},
  abstract = {Background/objectives FOLFIRINOX is the reliable treatments for pancreatic cancer, but it has a relatively high toxicity and the selection of suitable patients for this regimen remains challenge. On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer. The aim of this study was to investigate the effect of sarcopenia on overall survival (OS) and time to treatment failure (TTF) in patients with pancreatic cancer who received FOLFIRINOX. Methods Clinical data of consecutive patients treated with FOLFIRINOX at our institution from 2011 to 2017 was retrospectively reviewed. Skeletal muscle index (SMI) and adipose tissue index (ATI) at the third lumbar spine level was calculated from computed tomography (CT) images. The association between clinical factors (SMI and ATI), and OS and TTF were determined using univariate and multivariate analyses. Results We assessed 82 patients. The median OS of sarcopenia and the non-sarcopenia patients were 11.3 and 17.0 months, respectively (hazard ratio [HR], 2.49; 95\% confidence interval [CI], 1.43\textendash 4.32; p\,=\,0.001). Median TTF was 3.0 and 6.1 months in the sarcopenia and the non-sarcopenia patients, respectively (HR, 1.67; 95\% CI, 1.03\textendash 2.71; p\,=\,0.032). Multivariate analyses revealed that sarcopenia (HR, 1.37; 95\% CI, 1.01\textendash 1.87; p\,=\,0.045) was an independent prognostic factor of OS. High ATI (p\,=\,0.022) and sarcopenic obesity (p\,=\,0.008) were significantly associated with hematologic toxicity. Conclusions Sarcopenia is an independent indicator of poor prognosis in patients with pancreatic cancer who received FOLFIRINOX, while ATI and sarcopenic obesity predicted severe hematologic toxicity.},
  langid = {english},
  keywords = {FOLFIRINOX,Pancreatic,Pancreatic cancer,Sarcopenia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\P8G5AN68\\S1424390318307464.html}
}

@article{kurita9,
  title = {Handgrip {{Strength Predicts Postoperative Pneumonia After Thoracoscopic}}\textendash{{Laparoscopic Esophagectomy}} for {{Patients}} with {{Esophageal Cancer}}},
  author = {Kurita, Daisuke},
  pages = {9},
  abstract = {Background. Despite advances in minimally invasive surgery, postoperative pneumonia after esophagectomy remains a frequent complication. Sarcopenia, defined as low muscle strength and quantity, has been associated with adverse surgical outcomes in numerous cancers. The recent definition and diagnostic criteria for sarcopenia have emphasized muscle strength rather than muscle quantity as the primary indicator of sarcopenia, although most studies have focused only on muscle quantity. This study aimed to determine the association of muscle strength and quantity with postoperative pneumonia after thoracoscopic\textendash laparoscopic esophagectomy (TLE).},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\E896VHXT\\Kurita - Handgrip Strength Predicts Postoperative Pneumonia.pdf}
}

@article{kurk1033,
  title = {Loss of Skeletal Muscle Index and Survival in Patients with Metastatic Colorectal Cancer: {{Secondary}} Analysis of the Phase 3 {{CAIRO3}} Trial},
  shorttitle = {Loss of Skeletal Muscle Index and Survival in Patients with Metastatic Colorectal Cancer},
  author = {Kurk, Sophie A. and Peeters, Petra H. M. and Dorresteijn, Bram and {de Jong}, Pim A. and Jourdan, Marion and Creemers, Geert-Jan M. and Erdkamp, Frans L. G. and {de Jongh}, Felix E. and Kint, Peter A. M. and Poppema, Boelo J. and Radema, Sandra A. and Simkens, Lieke H. J. and Tanis, Bea C. and {Tjin-A-Ton}, Manuel L. R. and Van Der Velden, Ankie and Punt, Cornelis J. A. and Koopman, Miriam and May, Anne M.},
  year = {2020},
  month = feb,
  journal = {Cancer Medicine},
  volume = {9},
  number = {3},
  pages = {1033--1043},
  issn = {2045-7634},
  doi = {10.1002/cam4.2787},
  abstract = {BACKGROUND: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. METHODS: This is a~retrospective analysis~of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine~+~bevacizumab (CAP-B) or observation, after six cycles capecitabine~+~oxaliplatin~+~bevacizumab (CAPOX-B). Upon first disease progression (PD1), CAPOX-B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time-periods; p1: during initial CAPOX-B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1-p3, with PD1, PD2, and survival was studied by Cox regression models. RESULTS: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean -0.6 SMI units [95\% CI -1.07;-0.26] and p3: -2.2 units [-2.7;-1.8], whereas during p2, SMI increased~+~1.2 units [0.8-1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09-1.35]; 1.54 [1.31-1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10-1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14-1.63]). CONCLUSIONS: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines.},
  langid = {english},
  pmcid = {PMC6997070},
  pmid = {31850687},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Body composition,body mass index,Body Mass Index,chemo,chemotherapy,Clinical Trials; Phase III as Topic,Colorectal Neoplasms,crc,Disease Progression,Female,Humans,Longitudinal Studies,Maintenance Chemotherapy,Male,metastatic colorectal cancer,Middle Aged,Muscle; Skeletal,Palliative Care,Prognosis,Progression-Free Survival,Randomized Controlled Trials as Topic,Retrospective Studies,Risk Factors,sarcopenia,Sarcopenia,skeletal muscle mass,survival,Time Factors,Tomography; X-Ray Computed}
}

@article{kurk803,
  title = {Skeletal Muscle Mass Loss and Dose-Limiting Toxicities in Metastatic Colorectal Cancer Patients},
  author = {Kurk, Sophie and Peeters, Petra and Stellato, Rebecca and Dorresteijn, B. and {de Jong}, Pim and Jourdan, Marion and Creemers, Geert-Jan and Erdkamp, Frans and {de Jongh}, Felix and Kint, Peter and Simkens, Lieke and Tanis, Bea and {Tjin-A-Ton}, Manuel and Van Der Velden, Ankie and Punt, Cornelis and Koopman, Miriam and May, Anne},
  year = {2019},
  month = aug,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {10},
  number = {4},
  pages = {803--813},
  issn = {2190-6009},
  doi = {10.1002/jcsm.12436},
  abstract = {BACKGROUND: Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine~+~bevacizumab (CAP-B) or observation and during more intensive capecitabine~+~oxaliplatin~+~bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B. METHODS: Sarcopenia status and SMI loss were assessed by using consecutive computed tomography scans. DLTs were defined as any dose delay/reduction/discontinuation of systemic treatment because of reported CTCAE (version 3.0) toxicities at the start or during treatment. Poisson regression models were used to study whether sarcopenia and body mass index (BMI) at the start of treatment and SMI and BMI loss during treatment were associated with DLTs. RESULTS: One hundred eighty-two patients (mean age 63.0~{$\pm~$}8.8~years, 37\% female) received CAP-B, and 232 patients (mean age 63.0~{$\pm~$}9.0~years, 34\% female) received CAPOX-B. At the start of CAP-B and CAPOX-B, 54\% and 46\% of patients were sarcopenic, respectively. Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic at the start of CAP-B 25.0~{$\pm~$}3.9 vs. 26.7~{$\pm~$}4.1 and CAPOX-B 25.8~{$\pm~$}3.8 vs. 27.1~{$\pm~$}3.8~kg/m2 ). Sarcopenia at the start of CAP-B was not associated with DLTs [relative risk 0.87 (95\% confidence interval 0.64-1.19)], whereas patients with {$>$}2\% SMI loss had a significantly higher risk of DLTs [1.29 (1.01-1.66)]. At the start of subsequent CAPOX-B, 25\% of patients received a dose reduction, and the risk of dose reduction was significantly higher for patients with preceding SMI loss [1.78 (1.06-3.01)] or sarcopenia [1.75 (1.08-2.86)]. After the received dose reductions, sarcopenia or SMI loss was not significantly associated with a higher risk of DLTs during CAPOX-B [sarcopenia vs. non-sarcopenic: 0.86 (0.69-1.08) and SMI loss vs. stable/gain: 0.83 (0.65-1.07)]. In contrast, BMI (loss) at the start or during either treatment was not associated with an increased risk of DLTs. CONCLUSIONS: In this large longitudinal study in metastatic colorectal cancer patients during palliative systemic treatment, sarcopenia and/or muscle loss was associated with an increased risk of DLTs. BMI was not associated with DLTs and could not detect sarcopenia or SMI loss. Prospective (randomized) studies should reveal whether normalizing chemotherapeutic doses to muscle mass or muscle mass preservation (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.},
  langid = {english},
  pmcid = {PMC6711417},
  pmid = {31094083},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Body composition,chemo,Chemotherapy,Colorectal Neoplasms,crc,Dose-limiting toxicity,Dose-Response Relationship; Drug,Female,Humans,Longitudinal Studies,Male,Metastatic colorectal cancer,Middle Aged,Neoplasm Metastasis,Sarcopenia,Skeletal muscle mass},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\L5PMBGBE\\Kurk et al. - Skeletal muscle mass loss and dose-limiting toxici.pdf}
}

@article{kurk909,
  title = {Impact of Different Palliative Systemic Treatments on Skeletal Muscle Mass in Metastatic Colorectal Cancer Patients},
  author = {Kurk, Sophie A. and Peeters, Petra H. M. and Dorresteijn, Bram and {de Jong}, Pim A. and Jourdan, Marion and Kuijf, Hugo J. and Punt, Cornelis J. A. and Koopman, Miriam and May, Anne M.},
  year = {2018},
  month = oct,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {9},
  number = {5},
  pages = {909--919},
  issn = {2190-6009},
  doi = {10.1002/jcsm.12337},
  abstract = {BACKGROUND: Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy-related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy. We investigated changes in SMM during various consecutive palliative systemic treatment regimens using repeated abdominal computed tomography scans of mCRC patients who participated in the randomized phase 3 CAIRO3 study. METHODS: In the CAIRO3 study, mCRC patients with stable disease or better after 6~cycles of first-line treatment with capecitabine~+~oxaliplatin~+~bevacizumab (CAPOX-B) were randomized between maintenance treatment with capecitabine~+~bevacizumab (CAP-B) or observation. Upon first disease progression, in both groups, CAPOX-B or other treatment was reintroduced until the second disease progression, which was the primary study endpoint. We analysed 1355 computed tomography scans of 450 (81\%) CAIRO3 patients (64~{$\pm~$}9.0~years, CAP-B n~=~223; observation n~=~227) for SMM at four time points (i.e. prior to the start of pre-randomization initial treatment, at randomization, and at first and at second disease progression) using the Slice-o-matic software and single slice evaluation at the lumbar 3 level. By using accepted and widely used formulas, whole body SMM was calculated. A linear mixed effects model, adjusted for relevant confounders, was used to assess SMM changes for the total group and within and between study arms. RESULTS: During 6~cycles of initial treatment with CAPOX-B prior to randomization, SMM decreased significantly in all patients [CAP-B arm: -0.53~kg (95\% CI -1.12; -0.07) and observation arm: -0.85~kg (-1.45; -0.25)]. After randomization, SMM recovered during CAP-B treatment by 1.32~kg (0.73; 1.90) and observation by 1.20~kg (0.63; 1.78) (median time from randomization to first disease progression 8.6 and 4.1~months for CAP-B arm and observation arm, respectively). After first progression and during reintroduction treatment with CAPOX-B or other treatment, SMM again decreased significantly and comparable in both arms, CAP-B: -2.71~kg (-3.37; -2.03), and observation: -2.01~kg (-2.64; -1.41) (median time from first progression until second progression CAP-B arm: 4.7~months and observation arm: 6.6~months). CONCLUSIONS: This longitudinal study provides a unique insight in SMM changes in mCRC patients during palliative systemic treatment regimens, including observation. Our data show that muscle loss is reversible and may be influenced by the intensity of systemic regimens. Although studies have shown prognostic capacity for SMM, the effects of subsequent changes in SMM are unknown and may be clues for new future therapeutic interventions.},
  langid = {english},
  pmcid = {PMC6204584},
  pmid = {30144305},
  keywords = {Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Body composition,Body Weights and Measures,Chemotherapy,Colorectal Neoplasms,Female,Humans,Male,Metastatic colorectal cancer,Middle Aged,Muscle; Skeletal,Neoplasm Metastasis,Neoplasm Staging,Organ Size,Palliative Care,Sarcopenia,Skeletal muscle,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IPHQ9FXU\\Kurk et al. - 2018 - Impact of different palliative systemic treatments.pdf}
}

@article{kuwano328,
  type = {Journal {{Article}}},
  title = {Gastric Involvement of Oesophageal Squamous Cell Carcinoma},
  author = {Kuwano, H. and Baba, K. and Ikebe, M. and Kitamura, K. and Adachi, Y. and Mori, M. and Sugimachi, K.},
  year = {1992},
  journal = {Br J Surg},
  volume = {79},
  number = {4},
  pages = {328--30},
  issn = {0007-1323 (Print) 0007-1323 (Linking)}
}

@article{laboratories111,
  type = {Journal {{Article}}},
  title = {{{ATS}} Statement: Guidelines for the Six-Minute Walk Test},
  author = {Laboratories, A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function},
  year = {2002},
  journal = {Am J Respir Crit Care Med},
  volume = {166},
  number = {1},
  pages = {111--7},
  issn = {1073-449X (Print) 1073-449X (Linking)},
  doi = {10.1164/ajrccm.166.1.at1102}
}

@article{laermans224,
  title = {Adverse Events of Iron and/or Erythropoiesis-Stimulating Agent Therapy in Preoperatively Anemic Elective Surgery Patients: A Systematic Review},
  shorttitle = {Adverse Events of Iron and/or Erythropoiesis-Stimulating Agent Therapy in Preoperatively Anemic Elective Surgery Patients},
  author = {Laermans, Jorien and Van Remoortel, Hans and Avau, Bert and Bekkering, Geertruida and Georgsen, J{\o}rgen and Manzini, Paola Maria and Meybohm, Patrick and Ozier, Yves and De Buck, Emmy and Compernolle, Veerle and Vandekerckhove, Philippe},
  year = {2022},
  month = oct,
  journal = {Systematic Reviews},
  volume = {11},
  number = {1},
  pages = {224},
  issn = {2046-4053},
  doi = {10.1186/s13643-022-02081-5},
  abstract = {BACKGROUND: Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anemia treatment, as reflected in a set of evidence-based treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs. METHODS: Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until 23 May 2022. Randomized controlled trials (RCTs), cohort, and case-control studies investigating any AE during or after iron and/or ESA administration in adult elective surgery patients with preoperative anemia were eligible for inclusion and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence. RESULTS: Data from 26 RCTs and 16 cohort studies involving a total of 6062 patients were extracted, on 6 treatment comparisons: (1) intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low certainty evidence was assigned to all but one outcome category. This uncertainty results from both the low quantity and quality of AE data due to the high risk of bias caused by limitations in the study design, data collection, and reporting. CONCLUSIONS: It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documentation, and reporting of AE data.},
  langid = {english},
  pmcid = {PMC9578279},
  pmid = {36253838},
  keywords = {Adult,Adverse events,Anemia,Blood transfusion,Elective surgery,Elective Surgical Procedures,Epo,Erythropoiesis,Erythropoiesis-stimulating agents,Ferric Oxide; Saccharated,Hematinics,Humans,Iron,Preoperative care,Surgery,Systematic review},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\HTZ6C3MX\\Laermans et al_2022_Adverse events of iron and-or erythropoiesis-stimulating agent therapy in.pdf}
}

@article{lakenman652,
  type = {Journal {{Article}}},
  title = {Handgrip {{Strength Is Associated With Treatment Modifications During Neoadjuvant Chemoradiation}} in {{Patients With Esophageal Cancer}}},
  author = {Lakenman, P. and {Ottens-Oussoren}, K. and {Witvliet-van Nierop}, J. and {van der Peet}, D. and {de van der Schueren}, M.},
  year = {2017},
  journal = {Nutr Clin Pract},
  volume = {32},
  number = {5},
  pages = {652--657},
  issn = {1941-2452 (Electronic) 0884-5336 (Linking)},
  doi = {10.1177/0884533617700862}
}

@article{lauretani1851,
  title = {Age-Associated Changes in Skeletal Muscles and Their Effect on Mobility: An Operational Diagnosis of Sarcopenia},
  shorttitle = {Age-Associated Changes in Skeletal Muscles and Their Effect on Mobility},
  author = {Lauretani, Fulvio and Russo, Cosimo Roberto and Bandinelli, Stefania and Bartali, Benedetta and Cavazzini, Chiara and Di Iorio, Angelo and Corsi, Anna Maria and Rantanen, Taina and Guralnik, Jack M. and Ferrucci, Luigi},
  year = {2003},
  month = nov,
  journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
  volume = {95},
  number = {5},
  pages = {1851--1860},
  issn = {8750-7587},
  doi = {10.1152/japplphysiol.00246.2003},
  abstract = {Sarcopenia, the reduction of muscle mass and strength that occurs with aging, is widely considered one of the major causes of disability in older persons. Surprisingly, criteria that may help a clinician to identify persons with impaired muscle function are still lacking. Using data from a large representative sample of the general population, we examined how muscle function and calf muscle area change with aging and affect mobility in men and women free of neurological conditions. We tested several putative indicators of sarcopenia, including knee extension isometric torque, handgrip, lower extremity muscle power, and calf muscle area. For each indicator, sarcopenia was considered to be present when the measure was {$>$}2 SDs below the mean. For all four measures, the prevalence of sarcopenia increased with age, both in men and women. The age-associated gradient in prevalence was maximum for muscle power and minimum for calf-muscle area. However, lower extremity muscle power was no better than knee-extension torque or handgrip in the early identification of poor mobility, defined either as walking speed {$<$}0.8 m/s or inability to walk at least 1 km without difficulty and without developing symptoms. Optimal cutoff values that can be used in the clinical practice to identify older persons with poor mobility were developed. The findings of the study lay the basis for a cost-effective, clinical marker of sarcopenia based on a measure of isometric handgrip strength. Our findings should be verified in a longitudinal study.},
  langid = {english},
  pmid = {14555665},
  keywords = {Adult,Age Distribution,Aged,Aged; 80 and over,Aging,Female,Grip,Hand Strength,Humans,Male,Middle Aged,Muscle Contraction,Muscle; Skeletal,Muscular Atrophy,Sex Distribution,Torque,Walking}
}

@article{lavin1536,
  title = {Survival and Response to Chemotherapy for Advanced Colorectal Adenocarcinoma: An {{Eastern Cooperative Oncology Group}} Report},
  shorttitle = {Survival and Response to Chemotherapy for Advanced Colorectal Adenocarcinoma},
  author = {Lavin, P. and Mittelman, A. and Douglass, H. and Engstrom, P. and Klaassen, D.},
  year = {1980},
  month = oct,
  journal = {Cancer},
  volume = {46},
  number = {7},
  pages = {1536--1543},
  issn = {0008-543X},
  doi = {10.1002/1097-0142(19801001)46:7<1536::aid-cncr2820460707>3.0.co;2-k},
  abstract = {A series of 1,314 cases of advanced measurable colon or rectal cancer were evaluated for objective tumor response and survival. All patients received chemotherapy according to protocols conducted by the Eastern Cooperative Oncology Group during the period between 1974 and 1977. For those patients who had not received chemotherapy prior to study entry, no therapy program under evaluations was significantly more active than the oral or intravenous 5-fluorouracil treatment programs with respect to survival or objective tumor response. The survival and response rates therapy programs under study, including methyl-CCNU, appeared to be comparable. Initial performance status (P {$<$} 0.01), weight loss in the six months prior to study entry (P {$<$} 0.001), and prior chemotherapy status were shown to be most prognostic for survival, and thus merit inclusion as stratification factors in any comparative trial involving this population. These factors were shown to have a cumulatively greater influence upon survival than the treatment program. Treatment differences were most accentuated within the favorable subgroups of the leading prognostic factors. The location of the primary tumor had a significant effect upon the eventual sites of metastatic disease involvement at the time of study entry (P {$<$} 0.001). The consequences of this analysis suggest that investigators need to address characteristics of the population under study. It is also noted that patients with chemotherapy prior to study entry are best suited for survival studies, while patients with no chemotherapy prior to study entry are well suited for both objective tumor response and survival studies.},
  langid = {english},
  pmid = {6998557},
  keywords = {Antineoplastic Agents,Clinical Trials as Topic,Colonic Neoplasms,Drug Administration Schedule,Drug Therapy; Combination,ECOG,Humans,Neoplasm Metastasis,Neoplasm Recurrence; Local,Prognosis,Rectal Neoplasms}
}

@article{law205,
  title = {Resistance {{Exercise}} to {{Prevent}} and {{Manage Sarcopenia}} and {{Dynapenia}}},
  author = {Law, Timothy D. and Clark, Leatha A. and Clark, Brian C.},
  year = {2016},
  journal = {Annual Review of Gerontology \& Geriatrics},
  volume = {36},
  number = {1},
  pages = {205--228},
  issn = {0198-8794},
  doi = {10.1891/0198-8794.36.205},
  abstract = {For well over twenty centuries the muscle wasting (sarcopenia) and weakness (dynapenia) that occurs with old age has been a predominant concern of mankind. Exercise has long been suggested as a treatment to combat sarcopenia and dynapenia, as it exerts effects on both the nervous and muscular systems that are critical to positive physiological and functional adaptations (e.g., enhanced muscle strength). For more than two decades scientists have recognized the profound role that progressive resistance exercise training can have on increasing muscle strength, muscle size and functional capacity in older adults. In this review article we discuss how resistance exercise training can be used in the management and prevention of sarcopenia and dynapenia. We first provide an overview of the evidence for this notion and highlight certain critical factors- namely exercise intensity, volume and progression- that are key to optimizing the resistance exercise prescription. We then highlight how many, if not most, of the commonly prescribed exercise programs for seniors are not the 'best practices', and subsequently present easy-to-read guidelines for a well-rounded resistance exercise training program designed for the management and prevention of sarcopenia and dynapenia, including example training programs for the beginner through the advanced senior resistance exerciser. These guidelines have been written for the academician as well as the student and health care provider across a variety of disciplines, including those in the long term care industry, such as wellness instructors or activity directors.},
  langid = {english},
  pmcid = {PMC4849483},
  pmid = {27134329},
  keywords = {Aging,Dynapenia,Exercise,Muscle,Sarcopenia,Strength,Weakness},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5KKIZ9HE\\Law et al_2016_Resistance Exercise to Prevent and Manage Sarcopenia and Dynapenia.pdf}
}

@article{lee268,
  title = {Phase {{III}} Trial Comparing Capecitabine plus Cisplatin versus Capecitabine plus Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with {{D2}} Lymph Node Dissection: The {{ARTIST}} Trial},
  shorttitle = {Phase {{III}} Trial Comparing Capecitabine plus Cisplatin versus Capecitabine plus Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with {{D2}} Lymph Node Dissection},
  author = {Lee, Jeeyun and Lim, Do Hoon and Kim, Sung and Park, Se Hoon and Park, Joon Oh and Park, Young Suk and Lim, Ho Yeong and Choi, Min Gew and Sohn, Tae Sung and Noh, Jae Hyung and Bae, Jae Moon and Ahn, Yong Chan and Sohn, Insuk and Jung, Sin Ho and Park, Cheol Keun and Kim, Kyoung-Mee and Kang, Won Ki},
  year = {2012},
  month = jan,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {30},
  number = {3},
  pages = {268--273},
  issn = {1527-7755},
  doi = {10.1200/JCO.2011.39.1953},
  abstract = {PURPOSE: The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge to investigate the role of postoperative chemoradiotherapy therapy in patients with curatively resected gastric cancer with D2 lymph node dissection. This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP). PATIENTS AND METHODS: The XP arm received six cycles of XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy. The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and two cycles of XP. RESULTS: Of 458 patients, 228 were randomly assigned to the XP arm and 230 to the XP/XRT/XP arm. Treatment was completed as planned by 75.4\% of patients (172 of 228) in the XP arm and 81.7\% (188 of 230) in the XP/XRT/XP arm. Overall, the addition of XRT to XP chemotherapy did not significantly prolong disease-free survival (DFS; P = .0862). However, in the subgroup of patients with pathologic lymph node metastasis at the time of surgery (n = 396), patients randomly assigned to the XP/XRT/XP arm experienced superior DFS when compared with those who received XP alone (P = .0365), and the statistical significance was retained at multivariate analysis (estimated hazard ratio, 0.6865; 95\% CI, 0.4735 to 0.9952; P = .0471). CONCLUSION The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in gastric cancer. A subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.},
  langid = {english},
  pmid = {22184384},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Chemoradiotherapy; Adjuvant,Cisplatin,Deoxycytidine,Disease-Free Survival,Female,Fluorouracil,Humans,Lymph Node Excision,Male,Middle Aged,Neoplasm Recurrence; Local,Stomach Neoplasms,Young Adult}
}

@article{lee487,
  title = {Pixel-{{Level Deep Segmentation}}: {{Artificial Intelligence Quantifies Muscle}} on {{Computed Tomography}} for {{Body Morphometric Analysis}}},
  shorttitle = {Pixel-{{Level Deep Segmentation}}},
  author = {Lee, Hyunkwang and Troschel, Fabian M. and Tajmir, Shahein and Fuchs, Georg and Mario, Julia and Fintelmann, Florian J. and Do, Synho},
  year = {2017},
  month = aug,
  journal = {Journal of Digital Imaging},
  volume = {30},
  number = {4},
  pages = {487--498},
  issn = {1618-727X},
  doi = {10.1007/s10278-017-9988-z},
  abstract = {Pretreatment risk stratification is key for personalized medicine. While many physicians rely on an "eyeball test" to assess whether patients will tolerate major surgery or chemotherapy, "eyeballing" is inherently subjective and difficult to quantify. The concept of morphometric age derived from cross-sectional imaging has been found to correlate well with outcomes such as length of stay, morbidity, and mortality. However, the determination of the morphometric age is time intensive and requires highly trained experts. In this study, we propose a fully automated deep learning system for the segmentation of skeletal muscle cross-sectional area (CSA) on an axial computed tomography image taken at the third lumbar vertebra. We utilized a fully automated deep segmentation model derived from an extended implementation of a fully convolutional network with weight initialization of an ImageNet pre-trained model, followed by post processing to eliminate intramuscular fat for a more accurate analysis. This experiment was conducted by varying window level (WL), window width (WW), and bit resolutions in order to better understand the effects of the parameters on the model performance. Our best model, fine-tuned on 250 training images and ground truth labels, achieves 0.93~{$\pm~$}0.02 Dice similarity coefficient (DSC) and 3.68~{$\pm~$}2.29\% difference between predicted and ground truth muscle CSA on 150 held-out test cases. Ultimately, the fully automated segmentation system can be embedded into the clinical environment to accelerate the quantification of muscle and expanded to volume analysis of 3D datasets.},
  langid = {english},
  pmcid = {PMC5537099},
  pmid = {28653123},
  keywords = {Adipose Tissue,Age Factors,Artificial intelligence,Artificial Intelligence,Body Mass Index,Computed tomography,Computer-aided diagnosis (CAD),Convolutional neural networks,Deep learning,Female,Humans,Length of Stay,Machine Learning,Male,Middle Aged,ML,Muscle segmentation,Muscle; Skeletal,Obesity,Sex Factors,Time Factors,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MITDUUA3\\Lee et al_2017_Pixel-Level Deep Segmentation.pdf}
}

@article{leichman4555,
  title = {S0356: A Phase {{II}} Clinical and Prospective Molecular Trial with Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy before Surgery for Patients with Esophageal Adenocarcinoma},
  shorttitle = {S0356},
  author = {Leichman, Lawrence P. and Goldman, Bryan H. and Bohanes, Pierre O. and Lenz, Heinz J. and Thomas, Charles R. and Billingsley, Kevin G. and Corless, Christopher L. and Iqbal, Syma and Gold, Philip J. and Benedetti, Jacqueline K. and Danenberg, Kathleen D. and Blanke, Charles D.},
  year = {2011},
  month = dec,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {29},
  number = {34},
  pages = {4555--4560},
  issn = {1527-7755},
  doi = {10.1200/JCO.2011.36.7490},
  abstract = {PURPOSE: Pathologic complete response (pCR) after neoadjuvant therapy for locally advanced esophageal adenocarcinoma is associated with improved survival. The Southwest Oncology Group designed a trimodality, phase II, single-arm trial with objectives of achieving a pCR rate of 40\% with prospective exploratory analyses of intratumoral molecular markers postulated to affect response and survival. PATIENTS AND METHODS: Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions; surgery was performed 28 to 42 days after neoadjuvant therapy. Chemotherapy was planned after surgery. Tumors were analyzed for mRNA expression and polymorphisms in genes involved in drug metabolism and DNA repair. RESULTS: Ninety-three patients were evaluable. Two deaths (2.2\%) were attributable to preoperative therapy, and two deaths (2.2\%) were attributable to surgery. Grade 3 and 4 toxicities were recorded for 47.3\% and 19.4\% of patients, respectively. Seventy-nine patients (84.9\%) underwent surgery; 67.7\% of patients had R0 resections. Twenty-six patients (28.0\%) had confirmed pCR (95\% CI, 19.1\% to 38.2\%). At a median follow-up of 39.2 months, estimates of median and 3-year overall survival (OS) were 28.3 months and 45.1\%, respectively. Intratumoral ERCC-1 gene expression was inversely related to progression-free survival and OS. CONCLUSION: Neoadjuvant oxaliplatin, PI-FU, and EBRT for esophageal adenocarcinoma is active and tolerable. Because the regimen failed to meet the primary end point, it does not define a new standard. However, future trials can be built on this platform to validate the role of ERCC-1 in determining the best systemic regimen for individual patients.},
  langid = {english},
  pmcid = {PMC3236655},
  pmid = {22025151},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Combined Modality Therapy,Disease-Free Survival,Drug Administration Schedule,Esophageal Neoplasms,Esophagectomy,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Organoplatinum Compounds,Oxaliplatin,Radiotherapy; Adjuvant},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UZJAFIUX\\Leichman et al. - 2011 - S0356 a phase II clinical and prospective molecul.pdf}
}

@article{lenchik1695,
  title = {Automated {{Segmentation}} of {{Tissues Using CT}} and {{MRI}}: {{A Systematic Review}}},
  shorttitle = {Automated {{Segmentation}} of {{Tissues Using CT}} and {{MRI}}},
  author = {Lenchik, Leon and Heacock, Laura and Weaver, Ashley A. and Boutin, Robert D. and Cook, Tessa S. and Itri, Jason and Filippi, Christopher G. and Gullapalli, Rao P. and Lee, James and Zagurovskaya, Marianna and Retson, Tara and Godwin, Kendra and Nicholson, Joey and Narayana, Ponnada A.},
  year = {2019},
  month = dec,
  journal = {Academic Radiology},
  volume = {26},
  number = {12},
  pages = {1695--1706},
  issn = {1878-4046},
  doi = {10.1016/j.acra.2019.07.006},
  abstract = {RATIONALE AND OBJECTIVES: The automated segmentation of organs and tissues throughout the body using computed tomography and magnetic resonance imaging has been rapidly increasing. Research into many medical conditions has benefited greatly from these approaches by allowing the development of more rapid and reproducible quantitative imaging markers. These markers have been used to help diagnose disease, determine prognosis, select patients for therapy, and follow responses to therapy. Because some of these tools are now transitioning from research environments to clinical practice, it is important for radiologists to become familiar with various methods used for automated segmentation. MATERIALS AND METHODS: The Radiology Research Alliance of the Association of University Radiologists convened an Automated Segmentation Task Force to conduct a systematic review of the peer-reviewed literature on this topic. RESULTS: The systematic review presented here includes 408 studies and discusses various approaches to automated segmentation using computed tomography and magnetic resonance imaging for neurologic, thoracic, abdominal, musculoskeletal, and breast imaging applications. CONCLUSION: These insights should help prepare radiologists to better evaluate automated segmentation tools and apply them not only to research, but eventually to clinical practice.},
  langid = {english},
  pmcid = {PMC6878163},
  pmid = {31405724},
  keywords = {Algorithms,Automation,CT,Humans,Machine learning,Magnetic Resonance Imaging,ML,MRI,Quantitative imaging,Review,Segmentation,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AUTXIM6A\\Lenchik et al_2019_Automated Segmentation of Tissues Using CT and MRI.pdf}
}

@article{lenchik277,
  ids = {lenchik277a},
  title = {Automated {{Muscle Measurement}} on {{Chest CT Predicts All-Cause Mortality}} in {{Older Adults From}} the {{National Lung Screening Trial}}},
  author = {Lenchik, Leon and Barnard, Ryan and Boutin, Robert D. and Kritchevsky, Stephen B. and Chen, Haiying and Tan, Josh and Cawthon, Peggy M. and Weaver, Ashley A. and Hsu, Fang-Chi},
  year = {2021},
  month = jan,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {76},
  number = {2},
  pages = {277--285},
  issn = {1758-535X},
  doi = {10.1093/gerona/glaa141},
  abstract = {BACKGROUND: Muscle metrics derived from computed tomography (CT) are associated with adverse health events in older persons, but obtaining these metrics using current methods is not practical for large datasets. We developed a fully automated method for muscle measurement on CT images. This study aimed to determine the relationship between muscle measurements on CT with survival in a large multicenter trial of older adults. METHOD: The relationship between baseline paraspinous skeletal muscle area (SMA) and skeletal muscle density (SMD) and survival over 6 years was determined in 6,803 men and 4,558 women (baseline age: 60-69 years) in the National Lung Screening Trial (NLST). The automated machine learning pipeline selected appropriate CT series, chose a single image at T12, and segmented left paraspinous muscle, recording cross-sectional area and density. Associations between SMA and SMD with all-cause mortality were determined using sex-stratified Cox proportional hazards models, adjusted for age, race, height, weight, pack-years of smoking, and presence of diabetes, chronic lung disease, cardiovascular disease, and cancer at enrollment. RESULTS: After a mean 6.44 {$\pm$} 1.06 years of follow-up, 635 (9.33\%) men and 265 (5.81\%) women died. In men, higher SMA and SMD were associated with a lower risk of all-cause mortality, in fully adjusted models. A one-unit standard deviation increase was associated with a hazard ratio (HR) = 0.85 (95\% confidence interval [CI] = 0.79, 0.91; p {$<$} .001) for SMA and HR = 0.91 (95\% CI = 0.84, 0.98; p = .012) for SMD. In women, the associations did not reach significance. CONCLUSION: Higher paraspinous SMA and SMD, automatically derived from CT exams, were associated with better survival in a large multicenter cohort of community-dwelling older men.},
  langid = {english},
  pmcid = {PMC7812435},
  pmid = {32504466},
  keywords = {Aged,Aging,Cohort Studies,Computed tomography,Female,Humans,Lung,Machine learning,Machine Learning,Male,Middle Aged,ML,Mortality,Muscle; Skeletal,Myosteatosis,Proportional Hazards Models,Retrospective Studies,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BGQ68WQY\\Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\LQC3QFIB\\Lenchik et al. - 2021 - Automated Muscle Measurement on Chest CT Predicts .pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\MP9P8BFH\\Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf}
}

@article{li539,
  title = {Peritoneal {{Metastases}} from {{Malignant Mesothelioma}}},
  author = {Li, Claire Yue and Alexander, H. Richard},
  year = {2018},
  month = jul,
  journal = {Surgical Oncology Clinics of North America},
  volume = {27},
  number = {3},
  pages = {539--549},
  issn = {1558-5042},
  doi = {10.1016/j.soc.2018.02.010},
  abstract = {Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly present with nonspecific abdominal symptoms that usually lead to diagnosis when the condition is relatively advanced. MPM is considered a chemotherapy-resistant malignancy.},
  langid = {english},
  pmid = {29935688},
  keywords = {Combined Modality Therapy,Diffuse malignant peritoneal mesothelioma,Early postoperative intraperitoneal chemotherapy,Humans,Hyperthermic intraoperative peritoneal chemotherapy,Lung Neoplasms,Mesothelioma,Mesothelioma; Malignant,Operative cytoreduction,Peritoneal metastases,Peritoneal Neoplasms,Treatment Outcome}
}

@article{lieffers1173,
  title = {A Viscerally Driven Cachexia Syndrome in Patients with Advanced Colorectal Cancer: Contributions of Organ and Tumor Mass to Whole-Body Energy Demands},
  shorttitle = {A Viscerally Driven Cachexia Syndrome in Patients with Advanced Colorectal Cancer},
  author = {Lieffers, Jessica R. and Mourtzakis, Marina and Hall, Kevin D. and McCargar, Linda J. and Prado, Carla M. M. and Baracos, Vickie E.},
  year = {2009},
  month = apr,
  journal = {The American Journal of Clinical Nutrition},
  volume = {89},
  number = {4},
  pages = {1173--1179},
  issn = {1938-3207},
  doi = {10.3945/ajcn.2008.27273},
  abstract = {BACKGROUND: Cancer cachexia-associated weight loss is poorly understood; energetically demanding tissues (eg, organ and tumor mass) and resting energy expenditure (REE) are reported to increase with advanced cancer. OBJECTIVE: The objective was to quantify the potential contribution of increasing masses of energetically demanding tissues to REE with colorectal cancer cachexia progression. DESIGN: A longitudinal computed tomography (CT) image review was performed to quantify organ size (liver, including metastases, and spleen) and peripheral tissues (skeletal muscle and adipose tissue) during colorectal cancer cachexia progression (n = 34). Body composition was prospectively evaluated by CT and dual-energy X-ray absorptiometry, and REE was determined by indirect calorimetry in advanced colorectal cancer patients (n = 18). RESULTS: Eleven months from death, the liver (2.3 +/- 0.7 kg) and spleen (0.32 +/- 0.2 kg) were larger than reference values. One month from death, liver weight increased to 3.0 +/- 1.5 kg (P = 0.010), spleen showed a trend to increase (P = 0.077), and concurrent losses of muscle (4.2 kg) and fat (3.5 kg) (P {$<$} 0.05) were observed. The estimated percentage of fat-free mass (FFM) occupied by the liver increased from 4.5\% to 7.0\% (P {$<$} 0.001). The most rapid loss of peripheral tissues and liver and metastases gain occurred within 3 mo of death. A positive linear relation existed between liver mass and measured whole-body REE (r(2) = 0.35, P = 0.010); because liver accounted for a larger percentage of FFM, measured REE . kg FFM(-1) . d(-1) increased (r(2) = 0.35, P = 0.010). CONCLUSIONS: Increases in mass and in the proportion of high metabolic rate tissues, including liver and tumor, represented a cumulative incremental REE of approximately 17,700 kcal during the last 3 mo of life and may contribute substantially to cachexia-associated weight loss.},
  langid = {english},
  pmid = {19244378},
  keywords = {Absorptiometry; Photon,Adipose Tissue,Basal Metabolism,Body Composition,Cachexia,Calorimetry; Indirect,Cohort Studies,Colorectal Neoplasms,CRC,Disease Progression,Female,Humans,Liver,Longitudinal Studies,Male,Middle Aged,Muscle; Skeletal,Neoplasm Metastasis,Organ Size,Prospective Studies,Retrospective Studies,Spleen,Tomography; X-Ray Computed,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RWRGXGW8\\Lieffers et al_2009_A viscerally driven cachexia syndrome in patients with advanced colorectal.pdf}
}

@article{lieffers931,
  title = {Sarcopenia Is Associated with Postoperative Infection and Delayed Recovery from Colorectal Cancer Resection Surgery},
  author = {Lieffers, J. R. and Bathe, O. F. and Fassbender, K. and Winget, M. and Baracos, V. E.},
  year = {2012},
  month = sep,
  journal = {British Journal of Cancer},
  volume = {107},
  number = {6},
  pages = {931--936},
  issn = {1532-1827},
  doi = {10.1038/bjc.2012.350},
  abstract = {BACKGROUND: Skeletal muscle depletion (sarcopenia) predicts morbidity and mortality in the elderly and cancer patients. METHODS: We tested whether sarcopenia predicts primary colorectal cancer resection outcomes in stage II-IV patients (n=234). Sarcopenia was assessed using preoperative computed tomography images. Administrative hospitalisation data encompassing the index surgical admission, direct transfers for inpatient rehabilitation care and hospital re-admissions within 30 days was searched for International Classification of Disease (ICD)-10 codes for postoperative infections and inpatient rehabilitation care and used to calculate length of stay (LOS). RESULTS: Overall, 38.9\% were sarcopenic; 16.7\% had an infection and 9.0\% had inpatient rehabilitation care. Length of stay was longer for sarcopenic patients overall (15.9 {$\pm$} 14.2 days vs 12.3 {$\pm$} 9.8 days, P=0.038) and especially in those {$\geq$} 65 years (20.2 {$\pm$} 16.9 days vs 13.1 {$\pm$} 8.3 days, P=0.008). Infection risk was greater for sarcopenic patients overall (23.7\% vs 12.5\%; P=0.025), and especially those {$\geq$} 65 years (29.6\% vs 8.8\%, P=0.005). Most (90\%) inpatient rehabilitation care was in patients {$\geq$} 65 years. Inpatient rehabilitation was more common in sarcopenic patients overall (14.3\% vs 5.6\%; P=0.024) and those {$\geq$} 65 years (24.1\% vs 10.7\%, P=0.06). In a multivariate model in patients {$\geq$} 65 years, sarcopenia was an independent predictor of both infection (odds ratio (OR) 4.6, (95\% confidence interval (CI) 1.5, 13.9) P{$<$}0.01) and rehabilitation care (OR 3.1 (95\% CI 1.04, 9.4) P{$<$}0.04). CONCLUSION: Sarcopenia predicts postoperative infections, inpatient rehabilitation care and consequently a longer LOS.},
  langid = {english},
  pmcid = {PMC3464761},
  pmid = {22871883},
  keywords = {Adult,Aged,Canada,Colectomy,Colorectal Neoplasms,Comorbidity,Female,Humans,Length of Stay,Logistic Models,Male,Middle Aged,Multivariate Analysis,Neoplasm Staging,Odds Ratio,Patient Readmission,Postoperative Complications,Predictive Value of Tests,Risk Factors,Sarcopenia,Surgical Wound Infection,Survival Analysis,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K67862EQ\\Lieffers et al_2012_Sarcopenia is associated with postoperative infection and delayed recovery from.pdf}
}

@article{ligthart-melis587,
  title = {Dietician-Delivered Intensive Nutritional Support Is Associated with a Decrease in Severe Postoperative Complications after Surgery in Patients with Esophageal Cancer},
  author = {{Ligthart-Melis}, G. C. and Weijs, P. J. M. and {te Boveldt}, N. D. and Buskermolen, S. and Earthman, C. P. and Verheul, H. M. W. and {de Lange-de Klerk}, E. S. M. and {van Weyenberg}, S. J. B. and {van der Peet}, D. L.},
  year = {2013},
  month = aug,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {26},
  number = {6},
  pages = {587--593},
  issn = {1442-2050},
  doi = {10.1111/dote.12008},
  abstract = {The aim of this study was to evaluate the effect of dietician-delivered intensive nutritional support (INS) on postoperative outcome in patients with esophageal cancer. Approximately 50-80\% of patients with esophageal cancer are malnourished at the time of diagnosis. Malnutrition enhances the risk of postoperative complications, resulting in delay of postoperative recovery and impairment of quality of life. Sixty-five patients with esophageal cancer were included. All patients who received surgery (n = 28) in the time frame between March 2009 and April 2010, the first year after the start of INS, were included in the INS intervention group. The control group (n = 37) consisted of patients who received surgery during the 3 years before the start of INS. Logistic regression analysis was used to compare differences in severity of postoperative complications using the Dindo classification. Linear regression was applied to evaluate differences in preoperative weight change. The adjusted odds ratio for developing serious complications after surgery of INS compared with the control group was 0.23 (95\% confidence interval: 0.053-0.97; P = 0.045). Benefit was mainly observed in patients who received neoadjuvant therapy before esophagectomy (n = 35). The INS program furthermore resulted in a relative preoperative weight gain in comparison with the control group of +4.8\% (P = 0.009, adjusted) in these neoadjuvant-treated patients. This study shows that dietician-delivered INS preserves preoperative weight and decreases severe postoperative complications in patients with esophageal cancer.},
  langid = {english},
  pmid = {23237356},
  keywords = {Cause of Death,complication,Counseling,Critical Care,Dietary Proteins,Dietetics,dietician,Energy Intake,Enteral Nutrition,esophageal cancer,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Hospitalization,Humans,Length of Stay,Male,Malnutrition,Meals,Middle Aged,Neoadjuvant Therapy,nutrition,Nutritional Support,Postoperative Complications,surgery,Treatment Outcome,Weight Gain,weight loss,Weight Loss}
}

@article{lin1107,
  type = {Journal {{Article}}},
  title = {Increasing the Interval between Neoadjuvant Chemoradiotherapy and Surgery in Esophageal Cancer: A Meta-Analysis of Published Studies},
  author = {Lin, G. and Han, S. Y. and Xu, Y. P. and Mao, W. M.},
  year = {2016},
  journal = {Dis Esophagus},
  volume = {29},
  number = {8},
  pages = {1107--1114},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1111/dote.12432}
}

@article{lin115,
  title = {Impact of Sarcopenia on the Prognosis and Treatment of Lung Cancer: An Umbrella Review},
  shorttitle = {Impact of Sarcopenia on the Prognosis and Treatment of Lung Cancer},
  author = {Lin, Ting-Yu and Chen, Yen-Fu and Wu, Wei-Ting and Han, Der-Sheng and Tsai, I.-Chen and Chang, Ke-Vin and {\"O}z{\c c}akar, Levent},
  year = {2022},
  month = oct,
  journal = {Discover. Oncology},
  volume = {13},
  number = {1},
  pages = {115},
  issn = {2730-6011},
  doi = {10.1007/s12672-022-00576-0},
  abstract = {BACKGROUND: Lung cancer is the leading cause of cancer-related mortality worldwide. Sarcopenia, defined as the loss of muscle mass and function, is known to cause adverse health outcomes. The purpose of this umbrella review was to integrate published systematic reviews and meta-analyses exploring sarcopenia and lung cancer to provide comprehensive knowledge on their relationship. METHODS: Eligible studies were searched from scientific databases until June 28, 2022. Critical appraisal was performed using A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2. The impact of sarcopenia on the pathophysiology, prevalence, and prognosis of lung cancer is summarized at the level of systematic reviews or meta-analyses. RESULTS: Fourteen reviews and meta-analyses were conducted. The methodological quality was high for one review, low for nine, and critically low for four. The most common standard for diagnosing sarcopenia in the lung cancer population is computed tomography (CT) to measure the skeletal muscle index at the third lumbar vertebra (L3). Sarcopenia was highly prevalent among patients with lung cancer, with a pooled prevalence ranging from 42.8\% to 45.0\%. The association between sarcopenia and increased postoperative complications and decreased disease control rates with immune checkpoint inhibitors has been demonstrated. Mortality was significantly higher in sarcopenic patients than in non-sarcopenic patients with lung cancer, regardless of the stage of disease or type of treatment. CONCLUSIONS: Sarcopenia is a poor prognostic factor for lung cancer. Future studies are necessary to clarify the pathophysiology of sarcopenia and develop effective interventions for sarcopenia in patients with lung cancer.},
  langid = {english},
  pmcid = {PMC9616989},
  pmid = {36307591},
  keywords = {Frailty,Lung,Malignancy,Muscle loss,Prognosis,Pulmonary},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FUHFIZE3\\Lin et al_2022_Impact of sarcopenia on the prognosis and treatment of lung cancer.pdf}
}

@article{lin221,
  title = {Efficacy and Safety of Erythropoietin and Intravenous Iron in Perioperative Blood Management: A Systematic Review},
  shorttitle = {Efficacy and Safety of Erythropoietin and Intravenous Iron in Perioperative Blood Management},
  author = {Lin, David M. and Lin, Estelle S. and Tran, Minh-Ha},
  year = {2013},
  month = oct,
  journal = {Transfusion Medicine Reviews},
  volume = {27},
  number = {4},
  pages = {221--234},
  issn = {1532-9496},
  doi = {10.1016/j.tmrv.2013.09.001},
  abstract = {The use of erythropoietin (EPO) and intravenous (IV) iron as bloodless therapeutic modalities is being explored in the current era of restrictive transfusion strategies and perioperative blood management. It is unclear, however, whether the evidence in the literature supports their safety and efficacy in reducing perioperative red cell transfusions. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, we conducted a systematic review to evaluate their use in a variety of perioperative settings. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Only studies with a comparator group were eligible for inclusion. Twenty-four randomized controlled trials (RCTs) and 15 nonrandomized studies were included in the final review. Using the Cochrane risk of bias tool, 8 RCTs were assessed to be at low risk for methodological bias. Of these, however, only 4 RCTs were adequately powered to detect a reduction in transfusion rates. Patients with preoperative iron deficiency anemia may have an earlier and more robust hemoglobin recovery with preoperative IV iron therapy than with oral iron supplementation. A short preoperative regimen of EPO, or a single dose of EPO plus IV iron in the preoperative or intraoperative period, may significantly reduce transfusion rates (number needed to treat to avoid any transfusion ranged from 3 to 6). With regard to the safety of erythropoietin-stimulating agent therapy, IV iron appears to be as well tolerated as oral iron; however, the incidence of severe anaphylactic-type reactions attributable to IV iron is difficult to estimate in prospective trials because of its relatively infrequent occurrence. Furthermore, EPO may increase the risk of thromboembolism in spinal surgery patients who receive mechanical antithrombotic prophylaxis in the perioperative period so pharmacological thromboprophylaxis is advised. Future low risk of bias, adequately powered prospective efficacy, and safety trials in various surgical settings that traditionally require red cell transfusions would be required to make evidenced-based conclusions about the clinical significance of erythropoietin-stimulating agent as a transfusion avoidance strategy in perioperative blood management.},
  langid = {english},
  pmid = {24135037},
  keywords = {Clinical Trials as Topic,Erythrocyte Transfusion,Erythropoietin,Humans,Infusions; Intravenous,Iron,Multicenter Studies as Topic,Patient Safety,Perioperative Period,Randomized Controlled Trials as Topic,Risk,Surgery,Surgical Procedures; Operative,Thromboembolism,Treatment Outcome}
}

@article{linden1794,
  title = {Drain {{Amylase}}: {{A Simple}} and {{Versatile Method}} of {{Detecting Esophageal Anastomotic Leaks}}},
  shorttitle = {Drain {{Amylase}}},
  author = {Linden, Philip A. and Towe, Christopher W. and Worrell, Stephanie G. and Jiang, Boxiang and Ho, Vanessa P. and {Argote-Greene}, Luis and Bachman, Katelynn and Perry, Yaron},
  year = {2022},
  month = jun,
  journal = {The Annals of Thoracic Surgery},
  volume = {113},
  number = {6},
  pages = {1794--1800},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2021.07.062},
  abstract = {BACKGROUND: Anastomotic leak after esophagectomy is a significant cause of morbidity. Perianastomotic drain amylase is accurate in detecting leaks, but it is unclear whether its accuracy is affected by comorbid conditions, anastomotic method, or anastomotic location. We hypothesized that drain amylase would accurately discriminate leak in a variety of settings. METHODS: We reviewed 290 consecutive patients undergoing esophagectomy with gastric conduit reconstruction. Patient comorbidities, operative variables, and drain amylase were collected. The diagnosis of a leak was based on the level of intervention required, and was characterized as clinically significant if it required wound opening or endoscopic or surgical intervention. Receiver-operating characteristic curves analysis was performed to determine the accuracy of amylase to detect leak for each patient variable. RESULTS: A total of 53 (18.3\%) of 290 esophagectomies had an anastomotic leak, of which 33 (11.4\%) of 290 were clinically significant. Drain amylase was a strong predictor of anastomotic leak on postoperative day (POD) 3 to POD 7, regardless of patient comorbidities, location of anastomosis, or technique of anastomosis, but was less accurate in the diagnosis of leak in current smokers (area under the receiver-operating characteristic curve, 0.530 vs 0.752; P~= .006). A maximum drain amylase value no higher than 35 on POD 3, POD 4, or POD 5 was 88\% sensitive in detecting leak at any point postoperatively. A value greater than or equal to 150 was 88\% specific in diagnosing leak. CONCLUSIONS: Drain amylase is a versatile method for early detection of anastomotic leaks. Its accuracy is unaffected by neoadjuvant treatment, location or type of anastomosis, or patient comorbidities but may be less accurate in active smokers.},
  langid = {english},
  pmcid = {PMC8863952},
  pmid = {34437855},
  keywords = {Amylases,Anastomosis; Surgical,Anastomotic Leak,Drainage,Esophageal Neoplasms,Esophagectomy,Humans,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\J5BFW7WU\\Linden et al_2022_Drain Amylase.pdf}
}

@article{lindstrom739,
  title = {Effects of a Perioperative Smoking Cessation Intervention on Postoperative Complications: A Randomized Trial},
  shorttitle = {Effects of a Perioperative Smoking Cessation Intervention on Postoperative Complications},
  author = {Lindstr{\"o}m, David and Sadr Azodi, Omid and Wladis, Andreas and T{\o}nnesen, Hanne and Linder, Stefan and N{\aa}sell, Hans and Ponzer, Sari and Adami, Johanna},
  year = {2008},
  month = nov,
  journal = {Annals of Surgery},
  volume = {248},
  number = {5},
  pages = {739--745},
  issn = {1528-1140},
  doi = {10.1097/SLA.0b013e3181889d0d},
  abstract = {OBJECTIVE: To determine whether an intervention with smoking cessation starting 4 weeks before general and orthopedic surgery would reduce the frequency of postoperative complications. SUMMARY BACKGROUND DATA: Complications are a major concern after elective surgery and smokers have an increased risk. There is insufficient evidence concerning how the duration of preoperative smoking intervention affects postoperative complications. METHODS: A randomized controlled trial, conducted between February 2004 and December 2006 at 4 university-affiliated hospitals in the Stockholm region, Sweden. The outcome assessment was blinded. The follow-up period for the primary outcome was 30 days. Eligibility criteria were active daily smokers, aged 18 to 79 years. Of the 238 patients assessed, 76 refused participating, and 117 men and women undergoing surgery for primary hernia repair, laparoscopic cholecystectomy, or a hip or knee prosthesis were enrolled. INTERVENTION: Smoking cessation therapy with individual counseling and nicotine substitution started 4 weeks before surgery and continued 4 weeks postoperatively. The control group received standard care. The main outcome measure was frequency of any postoperative complication. RESULTS: An intention-to-treat analysis showed that the overall complication rate in the control group was 41\%, and in the intervention group, it was 21\% (P = 0.03). Relative risk reduction for the primary outcome of any postoperative complication was 49\% and number needed to treat was 5 (95\% CI, 3-40). An analysis per protocol showed that abstainers had fewer complications (15\%) than those who continued to smoke or only reduced smoking (35\%), although this difference was not statistically significant. CONCLUSION: Perioperative smoking cessation seems to be an effective tool to reduce postoperative complications even if it is introduced as late as 4 weeks before surgery.},
  langid = {english},
  pmid = {18948800},
  keywords = {Aged,Arthroplasty; Replacement; Hip,Arthroplasty; Replacement; Knee,Cholecystectomy; Laparoscopic,Clinical Protocols,Female,Hernia; Inguinal,Hernia; Umbilical,Humans,Male,Middle Aged,Postoperative Complications,Preoperative Care,Smoking Cessation,Time Factors}
}

@article{liu525421,
  title = {Oncologic {{Outcome}} and {{Efficacy}} of {{Chemotherapy}} in {{Colorectal Cancer Patients Aged}} 80 {{Years}} or {{Older}}},
  author = {Liu, Wenting and Zhang, Mengyuan and Wu, Jun and Tang, Ran and Hu, Liqun},
  year = {2020},
  journal = {Frontiers in Medicine},
  volume = {7},
  pages = {525421},
  issn = {2296-858X},
  doi = {10.3389/fmed.2020.525421},
  abstract = {Purpose: The present study aimed to evaluate the oncologic outcomes of patients 80 years or older compared with younger patients, and we then further investigated the efficacy of chemotherapy in individuals 80 years or older. Methods: A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results database. The {$\chi$}2 test was used to analyze the different clinicopathologic and demographic variables between 65- and 79-year and {$\geq$}80-year groups. Kaplan-Meier analysis and log-rank testing were used to compare colorectal cancer (CRC)-specific survival (CCSS) curves between different groups. Multivariate and univariate Cox proportional hazards models with hazard ratios (HRs) and 95\% confidence intervals (CIs) were also used to assess CCSS and OS. Results: A total of 189,926 patients were included in our study. Compared with 65- to 79-year-old patients, age 80 years or older was associated with 48.4\% increased CRC-specific mortality (HR = 1.484, 95\% CI = 1.453-1.516, P {$<$} 0.0001; using 65-79 years old as the reference). Moreover, not receiving chemotherapy was significantly associated with an increased risk of CRC-related death, independent of other prognostic factors (HR = 0.615, 95\% CI = 0.589-0.643, P {$<$} 0.0001) in individuals 80 years or older. Conclusions: This large population-based study showed that older age was associated with worse oncologic outcomes compared to younger age. Chemotherapy could offer survival benefit for very old patients diagnosed with CRC, and we strongly believed that very old patients were undertreated in the present medical practices.},
  langid = {english},
  pmcid = {PMC7645236},
  pmid = {33195291},
  keywords = {80 years,chemotherapy,colorectal cancer,Elderly,population-based,survival},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K5KDFHXW\\Liu et al_2020_Oncologic Outcome and Efficacy of Chemotherapy in Colorectal Cancer Patients.pdf}
}

@article{liuS11,
  title = {Data {{That Drive}}: {{Closing}} the {{Loop}} in the {{Learning Hospital System}}},
  shorttitle = {Data {{That Drive}}},
  author = {Liu, Vincent X. and Morehouse, John W. and Baker, Jennifer M. and Greene, John D. and Kipnis, Patricia and Escobar, Gabriel J.},
  year = {2016},
  month = nov,
  journal = {Journal of hospital medicine},
  volume = {11},
  number = {Suppl 1},
  pages = {S11-S17},
  issn = {1553-5592},
  doi = {10.1002/jhm.2651},
  abstract = {The learning healthcare system describes a vision of US healthcare that capitalizes on science, information technology, incentives, and care culture to drive improvements in the quality of health care. The inpatient setting, one of the most costly and impactful domains of healthcare, is an ideal setting in which to use data and information technology to foster continuous learning and quality improvement. The rapid digitization of inpatient medicine offers incredible new opportunities to use data from routine care to generate new discovery and thus close the virtuous cycle of learning. We use an object lesson\textemdash sepsis care within the 21 hospitals of the Kaiser Permanente Northern California integrated healthcare delivery system\textemdash to offer insight into the critical elements necessary for developing a learning hospital system. We then describe how a hospital-wide data-driven approach to inpatient care can facilitate improvements in the quality of hospital care.},
  pmcid = {PMC5510651},
  pmid = {27805797},
  keywords = {Sepsis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZDN8NLS7\\Liu et al_2016_Data That Drive.pdf}
}

@article{lorimer177,
  type = {Journal {{Article}}},
  title = {Quality {{Improvement}} in {{Minimally Invasive Esophagectomy}}: {{Outcome Improvement Through Data Review}}},
  author = {Lorimer, P. D. and Motz, B. M. and Boselli, D. M. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
  year = {2019},
  journal = {Ann Surg Oncol},
  volume = {26},
  number = {1},
  pages = {177--187},
  issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
  doi = {10.1245/s10434-018-6938-z}
}

@article{low299,
  title = {Guidelines for {{Perioperative Care}} in {{Esophagectomy}}: {{Enhanced Recovery After Surgery}} ({{ERAS}}\textregistered ) {{Society Recommendations}}},
  shorttitle = {Guidelines for {{Perioperative Care}} in {{Esophagectomy}}},
  author = {Low, Donald E. and Allum, William and De Manzoni, Giovanni and Ferri, Lorenzo and Immanuel, Arul and Kuppusamy, MadhanKumar and Law, Simon and Lindblad, Mats and Maynard, Nick and Neal, Joseph and Pramesh, C. S. and Scott, Mike and Mark Smithers, B. and Addor, Val{\'e}rie and Ljungqvist, Olle},
  year = {2019},
  month = feb,
  journal = {World Journal of Surgery},
  volume = {43},
  number = {2},
  pages = {299--330},
  issn = {1432-2323},
  doi = {10.1007/s00268-018-4786-4},
  abstract = {INTRODUCTION: Enhanced recovery after surgery (ERAS) programs provide a format for multidisciplinary care and has been shown to predictably improve short term outcomes associated with surgical procedures. Esophagectomy has historically been associated with significant levels of morbidity and mortality and as a result routine application and audit of ERAS guidelines specifically designed for esophageal resection has significant potential to improve outcomes associated with this complex procedure. METHODS: A team of international experts in the surgical management of esophageal cancer was assembled and the existing literature was identified and reviewed prior to the production of the guidelines. Well established procedure specific components of ERAS were reviewed and updated with changes relevant to esophagectomy. Procedure specific, operative and technical sections were produced utilizing the best current level of evidence. All sections were rated regarding the level of evidence and overall recommendation according to the evaluation (GRADE) system. RESULTS: Thirty-nine sections were ultimately produced and assessed for quality of evidence and recommendations. Some sections were completely new to ERAS programs due to the fact that esophagectomy is the first guideline with a thoracic component to the procedure. CONCLUSIONS: The current ERAS society guidelines should be reviewed and applied in all centers looking to improve outcomes and quality associated with esophageal resection.},
  langid = {english},
  pmid = {30276441},
  keywords = {Enteral Nutrition,ERAS,Esophageal Neoplasms,Esophagectomy,Humans,Lymph Node Excision,Minimally Invasive Surgical Procedures,Perioperative Care,Practice Guidelines as Topic,Recovery of Function},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XD88I55Q\\Low et al_2019_Guidelines for Perioperative Care in Esophagectomy.pdf}
}

@article{ludmir1769,
  title = {Factors {{Associated With Age Disparities Among Cancer Clinical Trial Participants}}},
  author = {Ludmir, Ethan B. and Mainwaring, Walker and Lin, Timothy A. and Miller, Austin B. and Jethanandani, Amit and Espinoza, Andres F. and Mandel, Jacob J. and Lin, Steven H. and Smith, Benjamin D. and Smith, Grace L. and VanderWalde, Noam A. and Minsky, Bruce D. and Koong, Albert C. and Stinchcombe, Thomas E. and Jagsi, Reshma and Gomez, Daniel R. and Thomas, Charles R. and Fuller, C. David},
  year = {2019},
  month = dec,
  journal = {JAMA oncology},
  volume = {5},
  number = {12},
  pages = {1769--1773},
  issn = {2374-2445},
  doi = {10.1001/jamaoncol.2019.2055},
  abstract = {IMPORTANCE: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. OBJECTIVE: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. DATA SOURCES: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. STUDY SELECTION: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. DATA EXTRACTION AND SYNTHESIS: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. MAIN OUTCOMES AND MEASURES: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. RESULTS: Three hundred two trials met inclusion criteria. The trials collectively enrolled 262\,354 participants; 249 trials (82.5\%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95\% CI, -7.17 to -5.81 years; P\,{$<$}\,.001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P\,=\,.002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95\% CI, -0.37 to -0.01 years; P\,=\,.04). CONCLUSIONS AND RELEVANCE: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access.},
  langid = {english},
  pmcid = {PMC6547133},
  pmid = {31158272},
  keywords = {Age Factors,Clinical Trials; Phase III as Topic,Humans,Linear Models,Neoplasms,Randomized Controlled Trials as Topic,Risk Assessment},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NMYIPWRQ\\Ludmir et al_2019_Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.pdf}
}

@article{ludwig1886,
  title = {Prevalence of Iron Deficiency across Different Tumors and Its Association with Poor Performance Status, Disease Status and Anemia},
  author = {Ludwig, H. and M{\"u}ld{\"u}r, E. and Endler, G. and H{\"u}bl, W.},
  year = {2013},
  month = jul,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {24},
  number = {7},
  pages = {1886--1892},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdt118},
  abstract = {BACKGROUND: Only limited data on the prevalence of iron deficiency (ID) and its correlation with clinical parameters are available in cancer. ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue. PATIENTS AND METHODS: Parameters of iron status and clinical parameters were evaluated in 1528 patients with cancer who presented consecutively within a four-month period at our center. One thousand fifty-three patients had solid tumors and 475 hematological malignancies. RESULTS: ID [transferrin saturation (TSAT) {$<$} 20\%] was noted in 645 (42.6\%) of the 1513 patients with TSAT tests available and 500 (33.0\%) were anemic. ID rates were highest in pancreatic (63.2\%), colorectal (51.9\%) and lung cancers (50.7\%). Of the 409 iron-deficient patients in whom serum ferritin levels were available additionally to TSAT, 335 (81.9\%) presented with functional ID (FID) (TSAT {$<$} 20\%, serum ferritin {$\geq$}30 ng/ml) and 74 (18.1\%) with absolute ID. In patients with solid tumors, prevalence of ID correlated with cancer stage at diagnosis (P = 0.001), disease status (P = 0.001) and ECOG performance status (P = 0.005). CONCLUSIONS: ID was frequently noted in cancer and was associated with advanced disease, close proximity to cancer therapy, and poor performance status in patients with solid tumors.},
  langid = {english},
  pmcid = {PMC3690908},
  pmid = {23567147},
  keywords = {absolute iron deficiency,Adult,Aged,Aged; 80 and over,Anemia Diagnosis,Anemia; Iron-Deficiency,cancer-related anemia,chemotherapy-induced anemia,CRC,Female,functional iron deficiency,Humans,iron deficiency,iron deficiency anemia,Male,Middle Aged,Neoplasms,Prevalence,Severity of Illness Index,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RZRNQTK7\\Ludwig et al_2013_Prevalence of iron deficiency across different tumors and its association with.pdf}
}

@article{luketich486,
  type = {Journal {{Article}}},
  title = {Minimally Invasive Esophagectomy: Outcomes in 222 Patients},
  author = {Luketich, J. D. and {Alvelo-Rivera}, M. and Buenaventura, P. O. and Christie, N. A. and McCaughan, J. S. and Litle, V. R. and Schauer, P. R. and Close, J. M. and Fernando, H. C.},
  year = {2003},
  journal = {Ann Surg},
  volume = {238},
  number = {4},
  pages = {486-94; discussion 494-5},
  issn = {0003-4932 (Print) 0003-4932 (Linking)},
  doi = {10.1097/01.sla.0000089858.40725.68}
}

@article{luketich95,
  type = {Journal {{Article}}},
  title = {Outcomes after Minimally Invasive Esophagectomy: Review of over 1000 Patients},
  author = {Luketich, J. D. and Pennathur, A. and Awais, O. and Levy, R. M. and Keeley, S. and Shende, M. and Christie, N. A. and Weksler, B. and Landreneau, R. J. and Abbas, G. and Schuchert, M. J. and Nason, K. S.},
  year = {2012},
  journal = {Ann Surg},
  volume = {256},
  number = {1},
  pages = {95--103},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0b013e3182590603}
}

@article{luporsi225,
  title = {Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: {{French}} Healthcare Payer Perspective},
  shorttitle = {Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion},
  author = {Luporsi, Elisabeth and Mahi, Lamine and Morre, Camille and Wernli, Jorge and {de Pouvourville}, G{\'e}rard and Bugat, Roland},
  year = {2012},
  journal = {Journal of Medical Economics},
  volume = {15},
  number = {2},
  pages = {225--232},
  issn = {1941-837X},
  doi = {10.3111/13696998.2011.639823},
  abstract = {OBJECTIVE: To evaluate the economic impact of intravenous iron (in the form of intravenous iron preparation of ferric carboxymaltose) in three different clinical settings of iron deficiency anemia: chemotherapy-induced anemia in breast cancer, chemotherapy-induced anemia in digestive cancer, and perioperative anemia in knee and hip surgery. METHODS: The economic model compared the usual therapeutic strategies of anemia without intravenous iron and strategies including intravenous iron, in each of the three clinical settings selected. Costs related to anemia treatment by erythropoiesis-stimulating agents (ESA), blood transfusion, and intravenous iron were estimated and compared inside each setting. Cost savings were calculated from the French healthcare payer perspective. Data included in the economic model were obtained from scientific literature, public health agencies, and medical experts. RESULTS: The most prominent annual cost savings were observed in chemotherapy-induced anemia in breast cancer (\texteuro 997 and \texteuro 360 per patient for metastatic and non-metastatic breast cancers, respectively; global cost saving, \texteuro 33.6 million). This large impact of intravenous iron on costs was mainly explained by both a lower number of women treated and lower ESA dosing. Mean annual cost saving in digestive cancers and knee and hip surgery were estimated to \texteuro 168 and \texteuro 216 per patient and global cost savings of \texteuro 7.5 and \texteuro 12.1 million, respectively. Overall, annual cost savings in these three settings were estimated to \texteuro 53 million including \texteuro 39 million for ESA cost savings. Sensitivity analysis showed that strategies including intravenous iron remained cost-effective even with wide variations in the assumptions, particularly for cost savings on ESA. LIMITATIONS: Economic model based on literature data and expert opinions. CONCLUSIONS: The present economic model suggests that use of intravenous iron, according to recommendations of international guidelines, is cost saving, particularly in chemotherapy-induced anemia in breast cancers.},
  langid = {english},
  pmid = {22077267},
  keywords = {Anemia,Blood Transfusion,Cost Savings,Costs and Cost Analysis,Dose-Response Relationship; Drug,EPO,Erythropoiesis,Female,Ferric Compounds,France,Hematinics,Humans,Iron,Maltose,Models; Economic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\L434LRFZ\\Luporsi et al_2012_Evaluation of cost savings with ferric carboxymaltose in anemia treatment.pdf}
}

@article{lv6751,
  title = {Minimally Invasive Esophagectomy versus Open Esophagectomy for Esophageal Cancer: A Meta-Analysis},
  shorttitle = {Minimally Invasive Esophagectomy versus Open Esophagectomy for Esophageal Cancer},
  author = {Lv, Lu and Hu, Weidong and Ren, Yanchen and Wei, Xiaoxuan},
  year = {2016},
  journal = {OncoTargets and Therapy},
  volume = {9},
  pages = {6751--6762},
  issn = {1178-6930},
  doi = {10.2147/OTT.S112105},
  abstract = {BACKGROUND AND OBJECTIVES: The safety and effectiveness of minimally invasive esophagectomy (MIE) in comparison with the open esophagectomy (OE) remain uncertain in esophageal cancer treatment. The purpose of this meta-analysis is to compare the outcomes of the two surgical modalities. METHODS: Searches were conducted in MEDLINE, EMBASE, and ClinicalTrials.gov with the following index words: "esophageal cancer", "VATS", "MIE", "thoracoscopic esophagectomy", and "open esophagectomy" for relative studies that compared the effects between MIE and OE. Random-effect models were used, and heterogeneity was assessed. RESULTS: A total of 20 studies were included in the analysis, consisting of four randomized controlled trials and 16 prospective studies. MIE has reduced operative blood loss (P=0.0009) but increased operation time (P=0.009) in comparison with OE. Patients get less respiratory complications (risk ratio =0.74, 95\% CI =0.58-0.94, P=0.01) and better overall survival (hazard ratio =0.54, 95\% CI =0.42-0.70, P{$<$}0.00001) in the MIE group than the OE group. No statistical difference was observed between the two groups in terms of lymph node harvest, R0 resection, and other major complications. CONCLUSION: MIE is a better choice for esophageal cancer because patients undergoing MIE may benefit from reduced blood loss, less respiratory complications, and also improved overall survival condition compared with OE. However, more randomized controlled trials are still needed to verify these differences.},
  langid = {english},
  pmcid = {PMC5096744},
  pmid = {27826201},
  keywords = {laparoscopic esophagectomy,postoperative prognosis,thoracoscopic esophagectomy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UVHUUYSB\\Lv et al_2016_Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer.pdf}
}

@article{lv8483,
  title = {The Effect of Surgery plus Chemoradiotherapy on Survival of Elderly Patients with Stage II-III Esophageal Cancer: A {{SEER-based}} Demographic Analysis},
  shorttitle = {The Effect of Surgery plus Chemoradiotherapy on Survival of Elderly Patients with Stage II-III Esophageal Cancer},
  author = {Lv, Hao and Chao, Ce and Wang, Bin and Wang, Zhigang and Qian, Yongxiang and Zhang, Xiaoying},
  year = {2021},
  month = dec,
  journal = {Cancer Medicine},
  volume = {10},
  number = {23},
  pages = {8483--8496},
  issn = {2045-7634},
  doi = {10.1002/cam4.4352},
  abstract = {BACKGROUND: The optimal treatment for elderly patients with esophageal cancer (EC) remains controversial. In the present study, we aimed to investigate whether elderly patients with stage II-III EC could benefit from trimodal therapy. METHODS: The selected elderly patients with stage II-III EC between 2004 and 2015 were included in a retrospective cohort study from the Surveillance, Epidemiology, and End Results database. The patients were divided into two groups based on whether or not they underwent surgery. The inverse probability of treatment weighting (IPTW) analysis was used to balance the confounding factors between the two groups. The Cox regression analysis, the log-rank test, and the Kaplan-Meier curves were conducted to identify the survival benefits of different treatment regimes. RESULTS: A total of 1596 patients were included in this cohort study, in which 278 patients underwent surgery. In the combination of chemoradiotherapy and surgery group, there were more male patients, more patients aged between 75 and 79~years, and more married patients in the surgery group. Moreover, there were more patients with adenomatous carcinoma, more patients with a tumor size of less than 5~cm, and more patients with a T3~stage in the combination group. In the survival analysis, patients in the combination group had a longer overall survival (OS) and EC-specific survival (ECSS). After IPTW analysis, the survival analysis generated similar results. The competitive risk model found that our results were stable. There was still a significant difference in OS and ECSS between the combination group and chemoradiotherapy alone group for esophageal adenocarcinoma (p~{$<~$}0.001). CONCLUSIONS: Elderly patients with stage II-III EC, especially those with adenocarcinoma, could benefit from the combination of surgery and chemoradiotherapy.},
  langid = {english},
  pmcid = {PMC8633220},
  pmid = {34800005},
  keywords = {Aged,chemoradiotherapy,Chemoradiotherapy,Combined Modality Therapy,elderly patients,esophageal cancer,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Neoplasm Staging,Prognosis,Retrospective Studies,SEER Program,surgery,survival,Survival Rate,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QGGW6JV5\\Lv et al_2021_The effect of surgery plus chemoradiotherapy on survival of elderly patients.pdf}
}

@article{lyu839516,
  title = {Effects of {{Enteral Nutrition}} on {{Patients With Oesophageal Carcinoma Treated With Concurrent Chemoradiotherapy}}: {{A Prospective}}, {{Multicentre}}, {{Randomised}}, {{Controlled Study}}},
  shorttitle = {Effects of {{Enteral Nutrition}} on {{Patients With Oesophageal Carcinoma Treated With Concurrent Chemoradiotherapy}}},
  author = {Lyu, Jiahua and Shi, Anhui and Li, Tao and Li, Jie and Zhao, Ren and Zhu, Shuchai and Wang, Jianhua and Xing, Ligang and Yang, Daoke and Xie, Conghua and Shen, Liangfang and Zhang, Hailin and Zhu, Guangying and Wang, Jing and Pan, Wenyan and Li, Fang and Lang, Jinyi and Shi, Hanping},
  year = {2022},
  journal = {Frontiers in Oncology},
  volume = {12},
  pages = {839516},
  issn = {2234-943X},
  doi = {10.3389/fonc.2022.839516},
  abstract = {BACKGROUND: The oesophageal carcinoma patients show high incidence of malnutrition, which negatively affects their therapy outcome. Moreover, benefits of enteral nutrition remain to be studied in details in these patients. Therefore, we set to assess the effects of enteral nutrition on the nutritional status, treatment toxicities and survival in the oesophageal carcinoma patients treated with concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Eligible patients were randomly assigned to either the experimental or control group. The patients in the experimental group were treated with a whole-course enteral nutrition management, while the control group were provided a unsystematic nutrition without setting intake goals for energy and protein. The primary endpoint was a change in body weight, while the secondary endpoints included nutrition-related haematological indicators, toxicities, completion rate of treatment and survival. RESULTS: A total of 222 patients were randomised to either the experimental (n=148) or control (n=74) group. Patients in the experimental group showed significantly less decrease in body weight, serum albumin and haemoglobin levels, a lower incidence rates of grade {$\geq$}3 myelosuppression and infection, and a higher completion rate of CCRT than those in the control group. While analyses of the 2 and 3 year overall survival (OS) and progression-free survival (PFS) did not reveal differences between these groups, we observed a significantly higher OS at 1 year (83.6\% vs. 70.0\%). In the subgroup analysis, patients with patient-generated subjective global assessment (PG-SGA)=C were likely to have better OS and PFS with enteral nutrition. CONCLUSIONS: In EC patients treated with CCRT, enteral nutrition conferred positive effects on the nutritional status, treatment toxicities and prognosis, which mandate its inclusion in clinical practice. CLINICAL TRIAL REGISTRATION: This prospective trial has been registered with www.clinicaltrials.gov as NCT02399306.},
  langid = {english},
  pmcid = {PMC8914079},
  pmid = {35280748},
  keywords = {chemoradiotherapy,EN,enteral nutrition,nutritional status,oesophageal carcinoma,prognosis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BR9PQRWG\\Lyu et al_2022_Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated.pdf}
}

@article{ma307,
  title = {A Retrospective Study Evaluating Single-Unit Red Blood Cell Transfusions in Reducing Allogeneic Blood Exposure},
  author = {Ma, M. and Eckert, K. and Ralley, F. and {Chin-Yee}, I.},
  year = {2005},
  month = aug,
  journal = {Transfusion Medicine (Oxford, England)},
  volume = {15},
  number = {4},
  pages = {307--312},
  issn = {0958-7578},
  doi = {10.1111/j.0958-7578.2005.00592.x},
  abstract = {Although guidelines recommend the use of single-unit red blood cell (RBC) transfusions to minimize allogeneic blood exposure, clinical practice remains dominated by two-unit transfusions. This study assesses the potential impact of a single-unit transfusion policy on reducing RBC utilization. We performed a retrospective analysis of adult patients admitted to a tertiary care hospital who received one or two RBC units. In subjects transfused two units, the effect of one unit was estimated by dividing the change in haemoglobin by 2. The proportion of patients reaching a haemoglobin threshold of 70, 75, 80, 85 and 90 g L(-1) with a single RBC unit was estimated. Of 302 included patients, only 65 received a one-unit transfusion. Based on thresholds of {$>$} or = 90, {$>$} or = 80 and {$>$} or = 70 g L(-1), a single-unit transfusion would be sufficient in 42.0\% (RRR = 0.54), 79.6\% (RRR = 0.23) and 98.0\% (RRR = 0.02) of cases, respectively. This corresponds to 0.21, 0.57 and 0.82 mean RBC units saved per patient. In the orthopaedic subpopulation, the mean RBC units saved are 0.53, 0.88 and 1.00 for the same haemoglobin targets. Adopting a policy of transfusing RBC in single-unit aliquots could significantly improve RBC utilization and decrease patient exposure to allogeneic blood.},
  langid = {english},
  pmid = {16101808},
  keywords = {Erythrocyte Transfusion,Guideline Adherence,Health Care Rationing,Hemoglobins,Humans,Medical Audit,Orthopedic Procedures,Retrospective Studies}
}

@article{maas1986,
  title = {Quality of {{Life}} and {{Late Complications After Minimally Invasive Compared}} to {{Open Esophagectomy}}: {{Results}} of a {{Randomized Trial}}},
  shorttitle = {Quality of {{Life}} and {{Late Complications After Minimally Invasive Compared}} to {{Open Esophagectomy}}},
  author = {Maas, K. W. and Cuesta, M. A. and {van Berge Henegouwen}, M. I. and Roig, J. and Bonavina, L. and Rosman, C. and Gisbertz, S. S. and Biere, S. S. A. Y. and {van der Peet}, D. L.},
  year = {2015},
  month = aug,
  journal = {World Journal of Surgery},
  volume = {39},
  number = {8},
  pages = {1986--1993},
  issn = {1432-2323},
  doi = {10.1007/s00268-015-3100-y},
  abstract = {The minimally invasive esophagectomy (MIE) is widely being implemented for esophageal cancer in order to reduce morbidity and improve quality of life. Non-randomized studies investigating the mid-term quality of life after MIE show conflicting results at 1-year follow-up. Therefore, the aim of this study is to determine whether MIE has a continuing better mid-term 1-year quality of life than open esophagectomy (OE) indicating both a faster recovery and less procedure-related symptoms.},
  langid = {english},
  keywords = {MIE}
}

@article{macdonald342,
  title = {The Advantages and Limitations of Cross-Sectional Body Composition Analysis},
  author = {MacDonald, Alisdair J. and Greig, Carolyn A. and Baracos, Vickie},
  year = {2011},
  month = dec,
  journal = {Current Opinion in Supportive and Palliative Care},
  volume = {5},
  number = {4},
  pages = {342--349},
  issn = {1751-4266},
  doi = {10.1097/SPC.0b013e32834c49eb},
  abstract = {PURPOSE OF REVIEW: Cross-sectional (C-S) imaging is now commonly used to measure body composition in clinical studies. This review highlights the advantages, limitations and suggested future directions for this technique. RECENT FINDINGS: Current understanding of C-S imaging reproducibility, tissue identification and segmentation methods, comparison between imaging techniques and estimates of whole body composition using a single image are described. SUMMARY: C-S imaging can reliably measure muscle and fat distribution and uniquely discriminate between intra-abdominal organ and muscle component of fat-free mass. It precisely tracks changes within an individual, but is less able to distinguish true differences in whole body estimates between individuals.},
  langid = {english},
  pmid = {21986910},
  keywords = {Abdomen,Adipose Tissue,Adiposity,Body Composition,Humans,Magnetic Resonance Imaging,Muscle; Skeletal,Tomography; X-Ray Computed}
}

@article{macdonald725,
  title = {Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction},
  author = {Macdonald, J. S. and Smalley, S. R. and Benedetti, J. and Hundahl, S. A. and Estes, N. C. and Stemmermann, G. N. and Haller, D. G. and Ajani, J. A. and Gunderson, L. L. and Jessup, J. M. and Martenson, J. A.},
  year = {2001},
  month = sep,
  journal = {The New England Journal of Medicine},
  volume = {345},
  number = {10},
  pages = {725--730},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa010187},
  abstract = {BACKGROUND: Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction. METHODS: A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart. RESULTS: The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P{$<$}0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent. CONCLUSIONS: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.},
  langid = {english},
  pmid = {11547741},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antimetabolites; Antineoplastic,Combined Modality Therapy,Disease-Free Survival,Esophagogastric Junction,Female,Fluorouracil,Gastrectomy,Humans,Leucovorin,Lymph Node Excision,Male,Middle Aged,Radiation Dosage,Stomach Neoplasms,Survival Rate}
}

@article{mackenzie88,
  title = {National Proficiency-Gain Curves for Minimally Invasive Gastrointestinal Cancer Surgery},
  author = {Mackenzie, H. and Markar, S. R. and Askari, A. and Ni, M. and Faiz, O. and Hanna, G. B.},
  year = {2016},
  month = jan,
  journal = {The British Journal of Surgery},
  volume = {103},
  number = {1},
  pages = {88--96},
  issn = {1365-2168},
  doi = {10.1002/bjs.9963},
  abstract = {BACKGROUND: Minimal access surgery for gastrointestinal cancer has short-term benefits but is associated with a proficiency-gain curve. The aim of this study was to define national proficiency-gain curves for minimal access colorectal and oesophagogastric surgery, and to determine the impact on clinical outcomes. METHODS: All adult patients undergoing minimal access oesophageal, colonic and rectal surgery between 2002 and 2012 were identified from the Hospital Episode Statistics database. Proficiency-gain curves were created using risk-adjusted cumulative sum analysis. Change points were identified, and bootstrapping was performed with 1000 iterations to identify a confidence level. The primary outcome was 30-day mortality; secondary outcomes were 90-day mortality, reintervention, conversion and length of hospital stay. RESULTS: Some 1696, 15\,008 and 16\,701 minimal access oesophageal, rectal and colonic cancer resections were performed during the study period. The change point in the proficiency-gain curve for 30-day mortality for oesophageal, rectal and colonic surgery was 19 (confidence level 98{$\cdot$}4 per cent), 20 (99{$\cdot$}2 per cent) and three (99{$\cdot$}5 per cent) procedures; the mortality rate fell from 4{$\cdot$}0 to 2{$\cdot$}0 per cent (relative risk reduction (RRR) 0{$\cdot$}50, P\,=\,0{$\cdot$}033), from 2{$\cdot$}1 to 1{$\cdot$}2 per cent (RRR 0{$\cdot$}43, P\,{$<$}\,0{$\cdot$}001) and from 2{$\cdot$}4 to 1{$\cdot$}8 per cent (RRR 0{$\cdot$}25, P\,=\,0{$\cdot$}058) respectively. The change point in the proficiency-gain curve for reintervention in oesophageal, rectal and colonic resection was 19 (98{$\cdot$}1 per cent), 32 (99{$\cdot$}5 per cent) and 26 (99{$\cdot$}2 per cent) procedures respectively. There were also significant proficiency-gain curves for 90-day mortality, conversion and length of stay. CONCLUSION: The introduction of minimal access gastrointestinal cancer surgery has been associated with a proficiency-gain curve for mortality and major morbidity at a national level. Unnecessary patient harm should be avoided by appropriate training and monitoring of new surgical techniques.},
  langid = {english},
  pmid = {26578089},
  keywords = {Adult,Aged,Clinical Competence,Colectomy,Conversion to Open Surgery,Digestive System Surgical Procedures,Esophagectomy,Female,Gastrectomy,Gastrointestinal Neoplasms,Humans,Learning Curve,Length of Stay,Male,Middle Aged,Minimally Invasive Surgical Procedures,Rectum,Retrospective Studies,Treatment Outcome,United Kingdom}
}

@article{maeda515,
  type = {Journal {{Article}}},
  title = {Sarcopenia Is an Independent Risk Factor of Dysphagia in Hospitalized Older People},
  author = {Maeda, K. and Akagi, J.},
  year = {2016},
  journal = {Geriatr Gerontol Int},
  volume = {16},
  number = {4},
  pages = {515--21},
  issn = {1447-0594 (Electronic) 1447-0594 (Linking)},
  doi = {10.1111/ggi.12486}
}

@article{magudia319,
  title = {Population-{{Scale CT-based Body Composition Analysis}} of a {{Large Outpatient Population Using Deep Learning}} to {{Derive Age-}}, {{Sex-}}, and {{Race-specific Reference Curves}}},
  author = {Magudia, Kirti and Bridge, Christopher P. and Bay, Camden P. and Babic, Ana and Fintelmann, Florian J. and Troschel, Fabian M. and Miskin, Nityanand and Wrobel, William C. and Brais, Lauren K. and Andriole, Katherine P. and Wolpin, Brian M. and Rosenthal, Michael H.},
  year = {2021},
  month = feb,
  journal = {Radiology},
  volume = {298},
  number = {2},
  pages = {319--329},
  issn = {1527-1315},
  doi = {10.1148/radiol.2020201640},
  abstract = {Background Although CT-based body composition (BC) metrics may inform disease risk and outcomes, obtaining these metrics has been too resource intensive for large-scale use. Thus, population-wide distributions of BC remain uncertain. Purpose To demonstrate the validity of fully automated, deep learning BC analysis from abdominal CT examinations, to define demographically adjusted BC reference curves, and to illustrate the advantage of use of these curves compared with standard methods, along with their biologic significance in predicting survival. Materials and Methods After external validation and equivalency testing with manual segmentation, a fully automated deep learning BC analysis pipeline was applied to a cross-sectional population cohort that included any outpatient without a cardiovascular disease or cancer who underwent abdominal CT examination at one of three hospitals in 2012. Demographically adjusted population reference curves were generated for each BC area. The z scores derived from these curves were compared with sex-specific thresholds for sarcopenia by using {$\chi$}2 tests and used to predict 2-year survival in multivariable Cox proportional hazards models that included weight and body mass index (BMI). Results External validation showed excellent correlation (R = 0.99) and equivalency (P {$<$} .001) of the fully automated deep learning BC analysis method with manual segmentation. With use of the fully automated BC data from 12\,128 outpatients (mean age, 52 years; 6936 [57\%] women), age-, race-, and sex-normalized BC reference curves were generated. All BC areas varied significantly with these variables (P {$<$} .001 except for subcutaneous fat area vs age [P = .003]). Sex-specific thresholds for sarcopenia demonstrated that age and race bias were not present if z scores derived from the reference curves were used (P {$<$} .001). Skeletal muscle area z scores were significantly predictive of 2-year survival (P = .04) in combined models that included BMI. Conclusion Fully automated body composition (BC) metrics vary significantly by age, race, and sex. The z scores derived from reference curves for BC parameters better capture the demographic distribution of BC compared with standard methods and can help predict survival. \textcopyright{} RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Summers in this issue.},
  langid = {english},
  pmcid = {PMC8128280},
  pmid = {33231527},
  keywords = {Age Distribution,Body Composition,Cohort Studies,Cross-Sectional Studies,Deep Learning,Female,Humans,Image Processing; Computer-Assisted,Male,Middle Aged,Outpatients,Racial Groups,Radiography; Abdominal,Reference Values,Reproducibility of Results,Sex Distribution,Tomography; X-Ray Computed}
}

@article{maish1777,
  title = {Endoscopic Mucosal Resection as a Staging Technique to Determine the Depth of Invasion of Esophageal Adenocarcinoma},
  author = {Maish, Mary S. and DeMeester, Steven R.},
  year = {2004},
  month = nov,
  journal = {The Annals of Thoracic Surgery},
  volume = {78},
  number = {5},
  pages = {1777--1782},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2004.04.064},
  abstract = {BACKGROUND: Endoscopic ablation and vagal-sparing esophagectomy offer the potential for reduced morbidity in patients with high-grade dysplasia or early esophageal adenocarcinoma, but neither includes a lymphadenectomy. Although adequate for intramucosal tumors, both are potentially inadequate for patients with submucosal tumor invasion given the high prevalence of nodal metastases with these lesions. Currently there is no test including endoscopic ultrasound that can accurately determine whether a small tumor is confined to the mucosa or has penetrated into the submucosa. The aim of this study was to compare the pathologic depth of invasion by endoscopic mucosal resection with findings and outcome after surgical resection to assess the accuracy and reliability of endoscopic mucosal resection for staging early esophageal adenocarcinoma. METHODS: From 2001 to 2003, 7 patients presented with small, endoscopically visible adenocarcinomas. All underwent endoscopic mucosal resection followed by surgical resection. RESULTS: Analysis of the resected specimens confirmed that the endoscopic mucosal resection had accurately determined the depth of tumor invasion in all patients, and had completely excised the lesion in all but 1 patient (86\%). Lymph node dissection was included as part of the resection in 2 patients with submucosal invasion by endoscopic mucosal resection, and a vagal-sparing esophagectomy was used in the 5 patients with only intramucosal tumors. All patients are alive and disease-free at a median follow-up of 7 months. CONCLUSIONS: Endoscopic mucosal resection accurately determines the depth of tumor invasion, and should be used as a staging procedure in patients with early esophageal cancer when therapies that do not include a lymphadenectomy are considered.},
  langid = {english},
  pmid = {15511474},
  keywords = {Adenocarcinoma,Aged,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Esophagoscopy,Female,Follow-Up Studies,Gastrectomy,Humans,Lymph Node Excision,Male,Middle Aged,Mucous Membrane,Neoplasm Invasiveness,Neoplasm Staging,Remission Induction,Retrospective Studies,Treatment Outcome,Vagus Nerve}
}

@article{makiura430,
  title = {Preoperative Sarcopenia Is a Predictor of Postoperative Pulmonary Complications in Esophageal Cancer Following Esophagectomy: {{A}} Retrospective Cohort Study},
  shorttitle = {Preoperative Sarcopenia Is a Predictor of Postoperative Pulmonary Complications in Esophageal Cancer Following Esophagectomy},
  author = {Makiura, Daisuke and Ono, Rei and Inoue, Junichiro and Kashiwa, Miyuki and Oshikiri, Taro and Nakamura, Tetsu and Kakeji, Yoshihiro and Sakai, Yoshitada and Miura, Yasushi},
  year = {2016},
  month = nov,
  journal = {Journal of Geriatric Oncology},
  volume = {7},
  number = {6},
  pages = {430--436},
  issn = {1879-4076},
  doi = {10.1016/j.jgo.2016.07.003},
  abstract = {OBJECTIVES: The number of geriatric patients with esophageal cancer has been increasing. Geriatric syndromes such as sarcopenia might adversely affect postoperative recovery. The aim of this study was to evaluate the relationships between sarcopenia and postoperative complications, and the associations between sarcopenia and perioperative functional changes in patients with esophageal cancer following esophagectomy. MATERIALS AND METHODS: Participants comprised 104 patients who underwent esophagectomy from July 2011 to April 2015. Preoperative sarcopenia was diagnosed by the presence of low muscle mass and low physical functions according to Asian Working Group for Sarcopenia criteria. Low physical function was defined by loss of grip strength and/or slow walking speed. Postoperative pulmonary, cardiac, infectious, and surgical complications were extracted. Perioperative functional changes were calculated (value at postoperative day 30-value before surgery). For statistical analyses, both uni- and multivariate logistic regression analyses were performed. RESULTS: Twenty-nine patients (27.9\%) were diagnosed with sarcopenia. The incidence of postoperative pulmonary complications was significantly higher in the sarcopenia group (37.9\%) than in the non-sarcopenia group (17.3\%; P=0.04). There was no relationship between sarcopenia and other complications or perioperative functional changes. Multivariate analysis identified sarcopenia (odds ratio (OR), 3.13; 95\% confidence interval (CI), 1.12-8.93) and high Brinkman index (OR, 3.46; 95\% CI, 1.20-11.77) as independent risk factors for the development of pulmonary complications. CONCLUSION: The assessment of sarcopenia may be useful to predict the postoperative pulmonary complications following esophagectomy. On the other hand, sarcopenia does not predict cardiac, infectious, and surgical complications or perioperative function.},
  langid = {english},
  pmid = {27452909},
  keywords = {Aged,Blood Loss; Surgical,Body Composition,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Fatigue,Female,Functional status,Humans,Length of Stay,Lung Diseases,Male,Muscle Strength,Muscle; Skeletal,Operative Time,Postoperative Complications,Postoperative pulmonary complications,Preoperative Care,Quality of Life,Rehabilitation,Retrospective Studies,Risk Factors,Sarcopenia,Treatment Outcome}
}

@article{makiura456,
  title = {Impact of {{Sarcopenia}} on {{Unplanned Readmission}} and {{Survival After Esophagectomy}} in {{Patients}} with {{Esophageal Cancer}}},
  author = {Makiura, Daisuke and Ono, Rei and Inoue, Junichiro and Fukuta, Akimasa and Kashiwa, Miyuki and Miura, Yasushi and Oshikiri, Taro and Nakamura, Tetsu and Kakeji, Yoshihiro and Sakai, Yoshitada},
  year = {2018},
  month = feb,
  journal = {Annals of Surgical Oncology},
  volume = {25},
  number = {2},
  pages = {456--464},
  issn = {1534-4681},
  doi = {10.1245/s10434-017-6294-4},
  abstract = {BACKGROUND: Although sarcopenia increases postoperative complications following esophagectomy, its effects on prognosis remain unclear. This study was performed to identify the effect of sarcopenia on 90-day unplanned readmission and overall survival (OS) after esophagectomy. METHODS: Ninety-eight patients with esophageal cancer who underwent esophagectomy were enrolled in this study. Unplanned readmission was defined as any emergent hospitalization within 90~days after discharge. Sarcopenia, defined as low muscle mass plus low muscle strength and/or low physical performance according to the Asian consensus definition, was assessed prior to esophagectomy. Multivariate logistic regression analysis was performed to identify factors that contributed to 90-day unplanned readmission. OS was estimated using the Kaplan-Meier method, and a Cox proportional hazards model was used to assess the relationship between sarcopenia and OS. RESULTS: Thirty-one patients (31.6\%) were diagnosed with sarcopenia. The 90-day unplanned readmission rate was significantly higher in patients with sarcopenia than those without (42.9\% vs. 16.4\%, respectively; p~=~0.01). Multivariable logistic regression analysis showed that sarcopenia was an independent predictor of 90-day unplanned readmission [odds ratio 3.71, 95\% confidence interval (CI) 1.29-11.05; p~=~0.02], and the log-rank test showed that sarcopenia was associated with OS (p~=~0.01). Moreover, sarcopenia was a significant predictor of OS after adjustment for age, sex, and pathological stage (hazard ratio 2.35, 95\% CI 1.21-4.54; p~=~0.01). CONCLUSIONS: Sarcopenia is a risk factor for 90-day unplanned readmission and OS following esophagectomy. Assessment of sarcopenia could help to identify patients at higher risk of a poor prognosis after esophagectomy.},
  langid = {english},
  pmid = {29214454},
  keywords = {Aged,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Muscle Strength,Patient Discharge,Patient Readmission,Prognosis,Retrospective Studies,Risk Factors,Sarcopenia,Survival Rate}
}

@article{malietzis320,
  title = {Low {{Muscularity}} and {{Myosteatosis Is Related}} to the {{Host Systemic Inflammatory Response}} in {{Patients Undergoing Surgery}} for {{Colorectal Cancer}}},
  author = {Malietzis, George and Johns, Neil and {Al-Hassi}, Hafid O. and Knight, Stella C. and Kennedy, Robin H. and Fearon, Kenneth C. H. and Aziz, Omer and Jenkins, John T.},
  year = {2016},
  month = feb,
  journal = {Annals of Surgery},
  volume = {263},
  number = {2},
  pages = {320--325},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000001113},
  abstract = {OBJECTIVE: We examined the relationships between computed tomography (CT)-defined skeletal muscle parameters and the systemic inflammatory response (SIR) in patients with operable primary colorectal cancer (CRC). BACKGROUND: Muscle depletion is characterized by a reduced muscle mass (myopenia) and increased infiltration by inter- and intramuscular fat (myosteatosis). It is recognized as a poor prognostic indicator in patients with cancer, but the underlying factors remain unclear. METHODS: A total of 763 patients diagnosed with CRC undergoing elective surgical resection between 2006 and 2013 were included. Image analysis of CT scans was used to calculate Lumbar skeletal muscle index (LSMI), and mean muscle attenuation (MA). The SIR was quantified by the preoperative neutrophil to lymphocyte ratio (NLR) and albumin levels. Correlation and multivariate regression analysis was performed to identify independent relationships between patient SIR and muscle characteristics. RESULTS: Patients with NLR {$>$} 3 had significantly lower LSMI and lower MA than those with NLR {$<$} 3 [LSMI = 42.07{$\mkern1mu$}cmm vs 44.27{$\mkern1mu$}cmm (P = 0.002) and MA = 30.04 Hounsfield unit (HU) vs 28.36 HU (P = 0.016)]. Multivariate logistic regression analysis showed that high NLR [odds ratio (OR) = 1.78 (95\% confidence interval [CI]: 1.29-2.45), P {$<$} 0.001] and low albumin [OR = 1.80 (95\% CI: 1.17-2.74), P = 0.007] were independent predictors of reduced muscle mass. High NLR was significantly related with a low mean MA and hence myosteatosis [OR = 1.60 (95\% CI: 1.03-2.49), P = 0.038]. CONCLUSIONS: These results highlight a direct association between myopenia, myosteatosis, and the host SIR in patients with operable CRC. A better understanding of factors that regulate muscle changes such as myopenia and myosteatosis may lead to the development of novel therapies that influence a more metabolically "healthy" skeletal muscle and potentially alter cancer outcomes.},
  langid = {english},
  pmid = {25643288},
  keywords = {Adult,Aged,Aged; 80 and over,Body Composition,Colorectal Neoplasms,Elective Surgical Procedures,Female,Humans,Male,Middle Aged,Multivariate Analysis,Muscle; Skeletal,Muscular Diseases,Myosteatosis,Prognosis,Systemic Inflammatory Response Syndrome,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\M7CCILI7\\Malietzis et al. - 2015 - Low Muscularity and Myosteatosis Is Related to the.pdf}
}

@article{malik1,
  title = {Metabolic Tumor Volume Provides Complementary Prognostic Information to {{EUS}} Staging in Esophageal and Junctional Cancer},
  author = {Malik, Vinod and Johnston, Ciaran and O'Toole, Dermot and Lucey, Julie and O'Farrell, Naoimh and Claxton, Zieta and Reynolds, John V.},
  year = {2017},
  month = feb,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {30},
  number = {3},
  pages = {1--8},
  issn = {1442-2050},
  doi = {10.1111/dote.12505},
  abstract = {To determine the correlation between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) derived esophageal tumor parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV)] and endoscopic ultrasound (EUS) derived tumor parameters (T stage, N stage) and their prognostic implications. 150 consecutive patients with cancer of the esophagus or esophagogastric junction underwent staging PET-CT and staging EUS. PET-CT derived SUVmax and MTV of the primary tumor was recorded. EUS evaluated T and N stage. Relationships between parameters were investigated using the Mann-Whitney U tests, survival analysis performed using Kaplan-Meier and independent prognostic factors determined using Cox regression multivariate analysis. A significant difference in MTV was noted between EUS T1/T2 tumors (median 6.7~cm3) and EUS T3/T4 tumors (median 35.7~cm3; P\,{$<$}\,0.0001). An MTV of {$<$}23.4~cm3 (P\,=\,0.0001), SUVmax\,{$<$}\,4.1 (P\,=\,0014), EUS T stage (P\,{$<$}\,0.0001), EUS N stage (P\,{$<$}\,0.0001), and clinical stage (P\,{$<$}\,0.0001) were all significantly associated with survival, with MTV {$<$}23.4~cm3 (P\,=\,0.004), EUS T stage (P\,=\,0.01), and EUS N stage (P\,=\,0.01) significant in multivariate analysis. MTV, a volumetric parameter of PET-CT, has more prognostic importance than SUVmax and provides valuable prognostic information in esophageal and junctional cancer, along with EUS T and N stage. MTV provides complementary information to EUS and should be included in the staging of esophageal and junctional cancer.},
  langid = {english},
  pmid = {27862622},
  keywords = {18F-FDG PET-CT,Adult,Aged,Aged; 80 and over,endoscopic ultrasound,Endosonography,esophageal cancer,Esophageal Neoplasms,Esophagogastric Junction,Esophagoscopy,Female,Fluorodeoxyglucose F18,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Neoplasm Staging,PET,Positron Emission Tomography Computed Tomography,Prognosis,Proportional Hazards Models,Prospective Studies,Radiopharmaceuticals,Regression Analysis,staging,Statistics; Nonparametric,Tumor Burden,Young Adult}
}

@article{mantziari2104,
  title = {Esophageal {{Cancer}} in {{Elderly Patients}}, {{Current Treatment Options}} and {{Outcomes}}; {{A Systematic Review}} and {{Pooled Analysis}}},
  author = {Mantziari, Styliani and Teixeira Farinha, Hugo and Bouygues, Vianney and Vignal, Jean-Charles and Deswysen, Yannick and Demartines, Nicolas and Sch{\"a}fer, Markus and Piessen, Guillaume},
  year = {2021},
  month = apr,
  journal = {Cancers},
  volume = {13},
  number = {9},
  pages = {2104},
  issn = {2072-6694},
  doi = {10.3390/cancers13092104},
  abstract = {Esophageal cancer, despite its tendency to increase among younger patients, remains a disease of the elderly, with the peak incidence between 70-79 years. In spite of that, elderly patients are still excluded from major clinical trials and they are frequently offered suboptimal treatment even for curable stages of the disease. In this review, a clear survival benefit is demonstrated for elderly patients treated with neoadjuvant treatment, surgery, and even definitive chemoradiation compared to palliative or no treatment. Surgery in elderly patients is often associated with higher morbidity and mortality compared to younger patients and may put older frail patients at increased risk of autonomy loss. Definitive chemoradiation is the predominant modality offered to elderly patients, with very promising results especially for squamous cell cancer, although higher rates of acute toxicity might be encountered. Based on the all the above, and although the best available evidence comes from retrospective studies, it is not justified to refrain from curative treatment for elderly patients based on their age alone. Thorough assessment and an adapted treatment plan as well as inclusion of elderly patients in ongoing clinical trials will allow better understanding and management of esophageal cancer in this heterogeneous and often frail population.},
  langid = {english},
  pmcid = {PMC8123886},
  pmid = {33925512},
  keywords = {Age,definitive chemoradiation,elderly,esophageal cancer,esophagectomy,surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LW8XQPX3\\Mantziari et al_2021_Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes\;.pdf}
}

@article{mao-de-ferro409,
  title = {Stents in Patients with Esophageal Cancer before Chemoradiotherapy: High Risk of Complications and No Impact on the Nutritional Status},
  shorttitle = {Stents in Patients with Esophageal Cancer before Chemoradiotherapy},
  author = {{M{\~a}o-de-Ferro}, S. and Serrano, M. and Ferreira, S. and Rosa, I. and Lage, P. and Alexandre, D. P. and Freire, J. and Mirones, L. and Casaca, R. and Bettencourt, A. and Pereira, A. D.},
  year = {2016},
  month = mar,
  journal = {European Journal of Clinical Nutrition},
  volume = {70},
  number = {3},
  pages = {409--410},
  issn = {1476-5640},
  doi = {10.1038/ejcn.2015.206},
  abstract = {Preoperative chemoradiotherapy is the standard of care for locally advanced esophageal cancer, causing persistent deterioration in the nutritional status. We performed a prospective study to evaluate the safety and efficacy of esophageal double-covered self-expandable metal stents in patients with esophageal cancer before chemoradiotherapy. The nutritional status and dysphagia were prospectively recorded. Eleven patients were included: eight were moderate and three were severely malnourished. After stent placement, dysphagia improved in all patients. With regard to complications, one patient developed an esophageal perforation that required urgent esophagectomy. Four patients presented stent migration. Three of these patients required enteral nutrition and none was submitted to surgery because of poor nutritional status. Of the other six patients, only four were operated upon. Stent placement presented a high complication rate and did not prevent weight loss or malnutrition. Other alternatives, including naso-gastric tube placement or endoscopic percutaneous gastrostomy or jejunostomy, should be considered.},
  langid = {english},
  pmid = {26669568},
  keywords = {Aged,Chemoradiotherapy,Deglutition Disorders,Enteral Nutrition,Esophageal Neoplasms,Female,Humans,Male,Malnutrition,Middle Aged,Nutritional Status,Prospective Studies,Stent; Stage IV,Stents}
}

@article{margolis1694,
  title = {Percutaneous Endoscopic Gastrostomy before Multimodality Therapy in Patients with Esophageal Cancer},
  author = {Margolis, Marc and Alexander, Pendleton and Trachiotis, Gregory D and Gharagozloo, Farid and Lipman, Timothy},
  year = {2003},
  month = nov,
  journal = {The Annals of Thoracic Surgery},
  volume = {76},
  number = {5},
  pages = {1694--1698},
  issn = {0003-4975},
  doi = {10.1016/S0003-4975(02)04890-7},
  abstract = {Background Percutaneous endoscopic gastrostomy (PEG) has not been widely used in esophageal cancer because of concerns about safety of dilatation, suitability of the stomach as an esophageal replacement, and potential for inoculation metastasis. Methods Experience with PEG in consecutive patients presenting with new esophageal cancer from March 1991 to March 2001 was reviewed retrospectively. PEG was planned in 119 of 179 (66\%) of these patients excluding those presenting moribund and those for whom early resection was planned. The PEG was placed using an endoscopic method with wire-guided endoscopic bougienage or laser ablation or both as needed. Success of placement, requirement for dilatation and ablation, PEG-related complications, tolerance of enteral feeds, and impact on therapy were evaluated. Results PEG placement was possible in 87\% of patients (103 of 119). Dilatation or laser ablation or both was required in 46\% (47 of 103). There was no procedure-related mortality. Thirty-day mortality was 13.5\%. Major PEG-related complications were observed in 4\% (4 of 103) and minor PEG-related complications in 12\% (12 of 103). PEG removal was required in 4 patients and interruption of enteral feeds required in 33 (32\%). No instances of esophageal disruption or tumor inoculation metastasis were noted. PEG takedown and site closure at the time of operation was uncomplicated and use of the stomach as an esophageal substitute was possible in all 61 resected patients. Rates of anastomotic leak, stricture, and gastric emptying delay were similar to those for patients proceeding to resection without prior PEG (leak: PEG = 8\% [5 of 61] versus non-PEG = 10.5\% [2 of 19]), (stricture: PEG = 37\% [22 of 61] versus non-PEG = 32.5\% [6 of 19]), (delay: PEG = 9.8\% [6 of 61] versus non-PEG = 10.5\% [2 of 19]). Analysis of variables showed PEG to be significantly related to attainment of target doses of chemoradiotherapy (p = 0.034), and survival at 12 months (p = 0.02). Conclusions PEG in esophageal cancer is safe and useful and does not compromise the stomach or esophagogastric anastomosis. Further study is required to define the efficacy of PEG as a means of nutritional support and its impact on survival.},
  langid = {english},
  keywords = {7,PEG},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DA43D6D8\\S0003497502048907.html}
}

@article{mariette152,
  title = {Hybrid {{Minimally Invasive Esophagectomy}} for {{Esophageal Cancer}}},
  author = {Mariette, Christophe and Markar, Sheraz R. and {Dabakuyo-Yonli}, Tienhan S. and Meunier, Bernard and Pezet, Denis and Collet, Denis and D'Journo, Xavier B. and Brigand, C{\'e}cile and Perniceni, Thierry and Carr{\`e}re, Nicolas and Mabrut, Jean-Yves and Msika, Simon and Peschaud, Fr{\'e}d{\'e}rique and Prudhomme, Michel and Bonnetain, Franck and Piessen, Guillaume},
  year = {2019},
  month = jan,
  journal = {New England Journal of Medicine},
  volume = {380},
  number = {2},
  pages = {152--162},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa1805101},
  abstract = {Hybrid Minimally Invasive Surgery for Esophageal Cancer Open esophagectomy involves laparotomy and thoracotomy. Laparoscopic abdominal surgery may be useful for reducing complications, but does it control the cancer? A trial suggests that morbidity is lower and cancer outcomes are at least as good with the hybrid procedure as with the open procedure.},
  pmid = {30625052},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa1805101},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Z6BR96XI\\NEJMoa1805101.html}
}

@article{mariette2416,
  type = {Journal {{Article}}},
  title = {Surgery Alone versus Chemoradiotherapy Followed by Surgery for Stage {{I}} and {{II}} Esophageal Cancer: Final Analysis of Randomized Controlled Phase {{III}} Trial {{FFCD}} 9901},
  author = {Mariette, C. and Dahan, L. and Mornex, F. and Maillard, E. and Thomas, P. A. and Meunier, B. and Boige, V. and Pezet, D. and Robb, W. B. and {Le Brun-Ly}, V. and Bosset, J. F. and Mabrut, J. Y. and Triboulet, J. P. and Bedenne, L. and Seitz, J. F.},
  year = {2014},
  journal = {J Clin Oncol},
  volume = {32},
  number = {23},
  pages = {2416--22},
  issn = {1527-7755 (Electronic) 0732-183X (Linking)},
  doi = {10.1200/JCO.2013.53.6532}
}

@article{markar1,
  title = {Component Analysis of Enhanced Recovery Pathways for Esophagectomy},
  author = {Markar, S. R. and Naik, R. and Malietzis, G. and Halliday, L. and Athanasiou, T. and Moorthy, K.},
  year = {2017},
  month = oct,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {30},
  number = {10},
  pages = {1--10},
  issn = {1442-2050},
  doi = {10.1093/dote/dox090},
  abstract = {The objective of this systematic review is to identify key components of enhanced recovery protocols (ERP) that lead to improved length of hospital stay (LOS) following esophagectomy. Relevant electronic databases were searched for studies comparing clinical outcome from esophagectomy followed by a conventional pathway versus ERP. Relevant outcome measures were compared and metaregression was performed to identify the key ERP components associated with reduced in LOS. Thirteen publications were included, ERP was associated with no changes in in-hospital mortality, total complications, anastomotic leak, or pulmonary complications compared with a conventional pathway, however LOS was reduced in the ERP group. Metaregression identified that immediate extubation was associated with reduced LOS (OR = -0.51, 95\%CI -0.77 to -0.25; P~{$<~$}0.01). Several postoperative factors were associated with a significant reduction in length of hospital stay, and in order of most important were (i) gastrograffin swallow {$\leq$}5 days (OR = -4.27, 95\%CI -4.50 to -4.03); (ii) mobilization on postoperative day {$\leq$}1 (OR = -2.49, 95\%CI -2.63 to -2.34); (iii) removal of urinary catheter {$\leq$}2 days (OR = -0.99, 95\%CI -1.15 to -0.84); (iv) oral intake with at least sips of fluid {$\leq$}1 day (OR = -0.96, 95\%CI -1.24 to -0.68); (v) enteral diet with feeding jejunostomy or gastrostomy {$\leq~$}1 day (OR = -0.57, 95\%CI -0.80 to -0.35) and (vi) epidural removal {$\leq~$}4 days (OR = -0.17, 95\%CI -0.27 to -0.07). Several core ERP components and principles appear to be associated with LOS reduction. These elements should form a part of the core ERP for the specialty, while surgical teams incorporate other elements through an iterative process.},
  langid = {english},
  pmid = {28859398},
  keywords = {Airway Extubation,Analgesia; Epidural,Contrast Media,Diatrizoate Meglumine,Drinking,Early Ambulation,Enteral Nutrition,esophageal cancer,esophageal cancer surgery,Esophagectomy,Hospital Mortality,Humans,Length of Stay,Postoperative Care,Postoperative Complications,supportive care,Time Factors,Urinary Catheterization},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\3F7I6J9K\\Markar et al_2017_Component analysis of enhanced recovery pathways for esophagectomy.pdf}
}

@article{markar1528,
  title = {Surgical {{Proficiency Gain}} and {{Survival After Esophagectomy}} for {{Cancer}}},
  author = {Markar, Sheraz R. and Mackenzie, Hugh and Lagergren, Pernilla and Hanna, George B. and Lagergren, Jesper},
  year = {2016},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {34},
  number = {13},
  pages = {1528--1536},
  issn = {1527-7755},
  doi = {10.1200/JCO.2015.65.2875},
  abstract = {PURPOSE: We aimed to identify the presence and length of esophagectomy proficiency gain curves in terms of short- and long-term mortality for esophageal cancer. PATIENTS AND METHODS: Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with follow-up until 2014 were identified from a well-established, population-based, nationwide Swedish cohort study. Proficiency gain curves were created by using risk-adjusted cumulative sum analysis for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-specific mortality measures. Similarly, the proficiency gain curves for lymph node harvest, resection margin status, and reoperation incidence were assessed as performance-contributing factors to the observed changes in long-term survival. RESULTS: Esophagectomies in 1,821 patients with esophageal cancer were conducted by 139 surgeons. The change-point in proficiency gain curve for all-cause 30-day mortality was early, at 15 cases, when mortality decreased from 7.9\% to 3.1\% (P {$<$} .001). Later change-points, which ranged from 35 to 59 cases, were observed for 1-, 3- and 5-year mortality rates, for which all-cause mortality decreased from 34.9\% to 27.7\% (P = .011), from 47.4\% to 41.5\% (P = .049), and from 31.4\% to 19.1\% (P = .009), respectively. Similar change-points were observed in disease-specific mortality at 1 and 3 years. There was a continuous increase in lymph node harvest, which did not plateau. Also, change-points were observed for resection margin with tumor involvement at 17 cases, with a reduction from 20.9\% to 15.2\% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6\% to 5.0\% (P {$<$} .001). CONCLUSION: The gain of proficiency in esophagectomy for cancer is associated with measurable changes in short- and long-term mortality results. These findings indicate a need for structured national training and mentorship programs for esophageal cancer surgery.},
  langid = {english},
  pmid = {26951311},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Cohort Studies,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Registries,Sweden,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8BPPVD93\\Markar et al. - 2016 - Surgical Proficiency Gain and Survival After Esoph.pdf}
}

@article{markar250,
  type = {Journal {{Article}}},
  title = {Systematic Review and Pooled Analysis Assessing the Association between Elderly Age and Outcome Following Surgical Resection of Esophageal Malignancy},
  author = {Markar, S. R. and Karthikesalingam, A. and Thrumurthy, S. and Ho, A. and Muallem, G. and Low, D. E.},
  year = {2013},
  journal = {Dis Esophagus},
  volume = {26},
  number = {3},
  pages = {250--62},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1111/j.1442-2050.2012.01353.x}
}

@article{markar59,
  title = {Role of Neoadjuvant Treatment in Clinical {{T2N0M0}} Oesophageal Cancer: Results from a Retrospective Multi-Center {{European}} Study},
  shorttitle = {Role of Neoadjuvant Treatment in Clinical {{T2N0M0}} Oesophageal Cancer},
  author = {Markar, Sheraz R. and Gronnier, Caroline and Pasquer, Arnaud and Duhamel, Alain and Beal, H{\'e}l{\`e}ne and Th{\'e}reaux, J{\'e}r{\'e}mie and Gagni{\`e}re, Johan and Lebreton, Gil and Brigand, C{\'e}cile and Meunier, Bernard and Collet, Denis and Mariette, Christophe and {FREGAT working group \textendash{} FRENCH \textendash{} AFC}},
  year = {2016},
  month = mar,
  journal = {European Journal of Cancer (Oxford, England: 1990)},
  volume = {56},
  pages = {59--68},
  issn = {1879-0852},
  doi = {10.1016/j.ejca.2015.11.024},
  abstract = {AIMS: The aims of this study were to compare short- and long-term outcomes for clinical T2N0 oesophageal cancer with analysis of (i) primary surgery (S) versus neoadjuvant therapy plus surgery (NS), (ii) squamous cell carcinoma and adenocarcinoma subsets; and (iii) neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy. METHODS: Data were collected from 30 European centres from 2000 to 2010. Among 2944 included patients, 355 patients (12.1\%) had cT2N0 disease; 285 (S) and 70 (NS), were compared in terms of short- and long-term outcomes. Propensity score matching analyses were used to compensate for differences in baseline characteristics. RESULTS: No significant differences between the groups were shown in terms of in hospital morbidity and mortality. Nodal disease was observed in 50\% of S-group at the time of surgery, with 20\% pN2/N3. Utilisation of neoadjuvant therapy was associated with significant tumour downstaging as reflected by increases in pT0, pN0 and pTNM stage 0 disease, this effect was further enhanced with neoadjuvant chemoradiotherapy. After adjustment on propensity score and confounding factors, for all patients and subset analysis of squamous cell and adenocarcinoma, neoadjuvant therapy had no significant effect upon survival or recurrence (overall, loco-regional, distant or mixed) compared to surgery alone. There were no significant differences between neoadjuvant chemotherapy and chemoradiotherapy in short- or long-term outcomes. CONCLUSION: The results of this study suggest that a surgery alone treatment approach should be recommended as the primary treatment approach for cT2N0 oesophageal cancer despite 50\% of patients having nodal disease at the time of surgery.},
  langid = {english},
  pmid = {26808298},
  keywords = {Adenocarcinoma,Carcinoma; Squamous Cell,Chemoradiotherapy; Adjuvant,Chemotherapy; Adjuvant,Chi-Square Distribution,cT2N0M0,Disease-Free Survival,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Europe,Female,Humans,Incidence,Kaplan-Meier Estimate,Logistic Models,Lymphatic Metastasis,Male,Middle Aged,Neoadjuvant Therapy,Neoadjuvant treatment,Neoplasm Staging,Oesophageal cancer,Propensity Score,Retrospective Studies,Review,Risk Factors,Surgery,Survival,Time Factors,Treatment Outcome}
}

@article{markar922,
  title = {Assessment of Short-Term Clinical Outcomes Following Salvage Esophagectomy for the Treatment of Esophageal Malignancy: Systematic Review and Pooled Analysis},
  shorttitle = {Assessment of Short-Term Clinical Outcomes Following Salvage Esophagectomy for the Treatment of Esophageal Malignancy},
  author = {Markar, Sheraz R. and Karthikesalingam, Alan and Penna, Marta and Low, Donald E.},
  year = {2014},
  month = mar,
  journal = {Annals of Surgical Oncology},
  volume = {21},
  number = {3},
  pages = {922--931},
  issn = {1534-4681},
  doi = {10.1245/s10434-013-3364-0},
  abstract = {BACKGROUND: Combined chemoradiotherapy is increasingly being used as definitive treatment for locoregional esophageal malignancy. Patients with residual or recurrent localized cancer are often selectively considered for salvage esophagectomy (SALV). The aim of this pooled analysis was to compare short-term clinical outcomes from SALV following definitive chemoradiotherapy with those from planned esophagectomy following neoadjuvant chemoradiotherapy (NCRS). METHODS: MEDLINE, EMBASE, Cochrane, trial registries, conference proceedings and reference lists were searched for relevant comparative studies. Primary outcome measures were in-hospital mortality, anastomotic leak and pulmonary complications. Secondary outcomes were length of hospital stay, negative (R0) resection margin, and estimated blood loss. RESULTS: Eight studies comprising 954 patients; 242 (SALV) and 712 (NCRS) were included. SALV was associated with a significantly increased incidence of post-operative mortality (9.50 vs. 4.07 \%; pooled odds ratio [POR] = 3.02; p {$<$} 0.001), anastomotic leak (23.97 vs. 14.47 \%; POR = 1.99; p = 0.005), pulmonary complications (29.75 vs. 16.99 \%; POR = 2.12; p {$<$} 0.001), and an increased length of hospital stay (weighted mean difference = 8.29 days; 95 \% CI 7.08-9.5; p {$<$} 0.001). There were no significant differences between the groups in the incidence of negative resection margins or estimated blood loss. CONCLUSIONS: SALV has poorer short-term outcomes when compared with planned esophagectomy following neoadjuvant chemoradiotherapy. Patients and multidisciplinary tumor boards should be made aware of these differences in outcomes and SALV should be reserved for practice in high-volume institutions.},
  langid = {english},
  pmid = {24212722},
  keywords = {Esophageal Neoplasms,Esophagectomy,Humans,Prognosis,Salvage Therapy,Survival Rate}
}

@article{martin-harris136,
  type = {Journal {{Article}}},
  title = {Clinical Utility of the Modified Barium Swallow},
  author = {{Martin-Harris}, B. and Logemann, J. A. and McMahon, S. and Schleicher, M. and Sandidge, J.},
  year = {2000},
  journal = {Dysphagia},
  volume = {15},
  number = {3},
  pages = {136--41},
  issn = {0179-051X (Print) 0179-051X (Linking)},
  doi = {10.1007/s004550010015}
}

@article{martin1,
  type = {Journal {{Article}}},
  title = {The Association of Swallowing Dysfunction and Aspiration Pneumonia},
  author = {Martin, B. J. and Corlew, M. M. and Wood, H. and Olson, D. and Golopol, L. A. and Wingo, M. and Kirmani, N.},
  year = {1994},
  journal = {Dysphagia},
  volume = {9},
  number = {1},
  pages = {1--6},
  issn = {0179-051X (Print) 0179-051X (Linking)},
  doi = {10.1007/BF00262751}
}

@article{martin1308,
  title = {Long-Term Weight Change after Oesophageal Cancer Surgery},
  author = {Martin, L. and Lagergren, P.},
  year = {2009},
  month = nov,
  journal = {The British Journal of Surgery},
  volume = {96},
  number = {11},
  pages = {1308--1314},
  issn = {1365-2168},
  doi = {10.1002/bjs.6723},
  abstract = {BACKGROUND: Malnutrition is common after oesophageal cancer surgery. This study investigated weight changes and the risk of malnutrition among long-term survivors. METHODS: A nationwide cohort study was conducted in Sweden in 2001-2004, with follow-up to 2008. Weight was assessed before oesophagectomy, after 6 months and at 3 years. Logistic regression was performed with adjustment for confounders. Odds ratios (ORs) for postoperative weight loss of at least 15 per cent were estimated. RESULTS: Some 203 patients survived at least 3 years after oesophagectomy. Continuous weight loss occurred for up to 3 years. Women and men had a similar risk of malnutrition after 3 years (OR 0.85 (95 per cent confidence interval 0.24 to 2.98)). In overweight patients (preoperative body mass index at least 25 kg/m(2)) the risk of malnutrition was increased almost fivefold at 6 months (OR 4.90 (2.27 to 10.59)) and 3 years (OR 4.60 (1.80 to 11.78)). There was no difference in weight loss at 6 months between survivors and those who died between 6 months and 3 years after surgery (OR 1.11 (0.64 to 1.94)). CONCLUSION: Weight loss can be long lasting after oesophagectomy; overweight patients are at particularly increased risk of malnutrition.},
  langid = {english},
  pmid = {19847871},
  keywords = {Adult,Aged,Body Mass Index,Epidemiologic Methods,Esophageal Neoplasms,Female,Humans,Male,Malnutrition,Middle Aged,Postoperative Complications,Stomach Neoplasms,Survivors,Survivorship,Weight Loss,Weight Loss;GE}
}

@article{martin1362,
  title = {Risk Factors for Malnutrition after Oesophageal and Cardia Cancer Surgery},
  author = {Martin, L. and Jia, C. and Rouvelas, I. and Lagergren, P.},
  year = {2008},
  month = nov,
  journal = {The British Journal of Surgery},
  volume = {95},
  number = {11},
  pages = {1362--1368},
  issn = {1365-2168},
  doi = {10.1002/bjs.6374},
  abstract = {BACKGROUND: Oesophageal cancer surgery is often followed by malnutrition, but the factors causing weight loss are unknown. The aim of this population-based study was to identify such risk factors. METHODS: Data were collected from a nationwide Swedish organization for research on surgery for oesophageal cancer. A total of 340 patients (75.9 per cent of those eligible) responded to a study-specific questionnaire concerning height and weight, just before and 6 months after surgery. Factors influencing malnutrition, defined as loss of body mass index of at least 15 per cent 6 months after operation, were identified by logistic regression. RESULTS: Neoadjuvant therapy (received by 10.6 per cent of all patients) and female sex were associated with at least a twofold increased risk of weight loss (odds ratio (OR) 2.41 (95 per cent confidence interval 1.01 to 5.77) and 2.14 (1.07 to 4.28) respectively), whereas preoperative weight loss was associated with a decreased risk (OR 0.13 (0.03 to 0.65)). Age, tumour stage and location, type of oesophageal substitute, suture technique and postoperative complications did not influence the risk. CONCLUSION: Neoadjuvant therapy and female sex appear to be associated with an increased risk of malnutrition after oesophageal cancer surgery.},
  langid = {english},
  pmid = {18844265},
  keywords = {Aged,Cardia,Cohort Studies,Esophageal Neoplasms,Esophagectomy,Female,Gastrectomy,GE,Humans,Male,Malnutrition,Middle Aged,Neoadjuvant Therapy,Postoperative Complications,Prospective Studies,Regression Analysis,Risk Factors,Sex Factors,Stomach Neoplasms,Weight Loss}
}

@article{martin1496,
  title = {Malnutrition after Oesophageal Cancer Surgery in {{Sweden}}},
  author = {Martin, L. and Lagergren, J. and Lindblad, M. and Rouvelas, I. and Lagergren, P.},
  year = {2007},
  month = dec,
  journal = {The British Journal of Surgery},
  volume = {94},
  number = {12},
  pages = {1496--1500},
  issn = {1365-2168},
  doi = {10.1002/bjs.5881},
  abstract = {BACKGROUND: Oesophageal cancer resection carries a risk of nutritional disorders. The aim of this study was to estimate weight change after surgery in a population-based setting and to identify nutritional problems that might correlate with weight loss. METHODS: Data were collected through the Swedish Esophageal and Cardia Cancer Register, a nationwide registry of oesophageal cancer surgery. Patients who underwent oesophageal cancer surgery between 2001 and 2004 were followed up until April 2005, and data on patient and tumour characteristics and surgical treatment were collected. Six months after surgery the patients were asked to complete a questionnaire about weight and a health-related quality of life questionnaire (European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) with an oesophageal-specific module (EORTC QLQ-OES18)). RESULTS: The response rate to the questionnaire was 76.9 per cent and weight change in 226 patients was analysed. Six months after operation 63.7 per cent had lost more than 10 per cent of their preoperative BMI, and 20.4 per cent had lost more than 20 per cent. Appetite loss, eating difficulties and odynophagia were significantly linked to postoperative weight loss, whereas dysphagia or reflux did not correlate with malnutrition. CONCLUSION: Malnutrition is a considerable problem after oesophagectomy, and is linked to appetite loss, eating difficulties and odynophagia.},
  langid = {english},
  pmid = {17668914},
  keywords = {Adult,Aged,Aged; 80 and over,Body Mass Index,Deglutition Disorders,Esophageal Neoplasms,Feeding and Eating Disorders,Female,Humans,Male,Malnutrition,Middle Aged,Postoperative Complications,Prognosis,Sweden,Weight Gain}
}

@article{martin1539a,
  title = {Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index},
  shorttitle = {Cancer Cachexia in the Age of Obesity},
  author = {Martin, Lisa and Birdsell, Laura and Macdonald, Neil and Reiman, Tony and Clandinin, M. Thomas and McCargar, Linda J. and Murphy, Rachel and Ghosh, Sunita and Sawyer, Michael B. and Baracos, Vickie E.},
  year = {2013},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {31},
  number = {12},
  pages = {1539--1547},
  issn = {1527-7755},
  doi = {10.1200/JCO.2012.45.2722},
  abstract = {PURPOSE: Emerging evidence suggests muscle depletion predicts survival of patients with cancer. PATIENTS AND METHODS: At a cancer center in Alberta, Canada, consecutive patients with cancer (lung or GI; N = 1,473) were assessed at presentation for weight loss history, lumbar skeletal muscle index, and mean muscle attenuation (Hounsfield units) by computed tomography (CT). Univariate and multivariate analyses were conducted. Concordance (c) statistics were used to test predictive accuracy of survival models. RESULTS: Body mass index (BMI) distribution was 17\% obese, 35\% overweight, 36\% normal weight, and 12\% underweight. Patients in all BMI categories varied widely in weight loss, muscle index, and muscle attenuation. Thresholds defining associations between these three variables and survival were determined using optimal stratification. High weight loss, low muscle index, and low muscle attenuation were independently prognostic of survival. A survival model containing conventional covariates (cancer diagnosis, stage, age, performance status) gave a c statistic of 0.73 (95\% CI, 0.67 to 0.79), whereas a model ignoring conventional variables and including only BMI, weight loss, muscle index, and muscle attenuation gave a c statistic of 0.92 (95\% CI, 0.88 to 0.95; P {$<$} .001). Patients who possessed all three of these poor prognostic variables survived 8.4 months (95\% CI, 6.5 to 10.3), regardless of whether they presented as obese, overweight, normal weight, or underweight, in contrast to patients who had none of these features, who survived 28.4 months (95\% CI, 24.2 to 32.6; P {$<$} .001). CONCLUSION: CT images reveal otherwise occult muscle depletion. Patients with cancer who are cachexic by the conventional criterion (involuntary weight loss) and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight.},
  langid = {english},
  pmid = {23530101},
  keywords = {Adult,Age Factors,Aged,Body Composition,Body Mass Index,Cachexia,Canada,Cancer Care Facilities,Female,Follow-Up Studies,Gastrointestinal Neoplasms,Humans,Lung Neoplasms,Male,Middle Aged,Muscle; Skeletal,Neoplasm Staging,Obesity,Prognosis,Risk Factors,Survival Rate}
}

@article{martin227,
  title = {Cancer-{{Associated Malnutrition}} and {{CT-Defined Sarcopenia}} and {{Myosteatosis Are Endemic}} in {{Overweight}} and {{Obese Patients}}},
  author = {Martin, Lisa and Gioulbasanis, Ioannis and Senesse, Pierre and Baracos, Vickie E.},
  year = {2020},
  month = feb,
  journal = {JPEN. Journal of parenteral and enteral nutrition},
  volume = {44},
  number = {2},
  pages = {227--238},
  issn = {1941-2444},
  doi = {10.1002/jpen.1597},
  abstract = {BACKGROUND: Overweight/obese patients' large fat mass can mask the loss of skeletal muscle, which is associated with mortality in the oncology setting. We investigated the prevalence of computed tomography (CT)-defined sarcopenia and myosteatosis across different levels of nutrition risk assessed by the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF). We also evaluated whether the PG-SGA SF, sarcopenia, and myosteatosis were prognostic of overall survival. METHODS: This was a prospective, observational study. Consecutive patients with body mass index {$\geq$}25.0 kg/m2 with newly diagnosed head and neck cancer (any stage) or lung and gastrointestinal tract cancer (locally recurrent or metastatic) were screened at presentation to oncology clinics. Nutrition risk was assigned based on PG-SGA SF triage recommendations. Based on CT, patients were classified with sarcopenia and/or myosteatosis using published cutoffs. Survival analyses were conducted. RESULTS: Patients (n=1157) were 63.6 {$\pm$} 11.4 years, 64\% male, and 61\% had stage IV disease. Sarcopenia and myosteatosis were prevalent across PG-SGA SF nutrition risk categories (scores 0-1 [no risk; 36\% sarcopenic; 44\% myosteatotic], scores 2-3 [37\%; 37\%], scores 4-8 [40\%; 41\%], and scores {$\geq$}9 [high risk; 50\%; 49\%]). In multivariable survival analysis, PG-SGA SF scores {$\geq$}9 (hazard ratio [HR] 2.08, 95\% confidence interval [CI] 1.66-2.60, P{$<$}0.001), sarcopenia (HR 1.25, 95\% CI 1.06-1.46, P=0.006), and myosteatosis (HR 1.25, 95\% CI 1.07-1.46, P{$<$}0.001) independently predicted reduced survival. CONCLUSION: CT-defined sarcopenia and myosteatosis are prevalent across different levels of nutrition risk in overweight/obese patients with cancer. Assessment of skeletal muscle using CT adds prognostic value to the PG-SGA SF.},
  langid = {english},
  pmid = {31012128},
  keywords = {Female,Humans,Male,Malnutrition,Myosteatosis,Neoplasms,Obesity,Overweight,Prospective Studies,Sarcopenia,Tomography; X-Ray Computed}
}

@article{martin2669,
  title = {Assessment of {{Computed Tomography}} ({{CT}})-{{Defined Muscle}} and {{Adipose Tissue Features}} in {{Relation}} to {{Short-Term Outcomes After Elective Surgery}} for {{Colorectal Cancer}}: {{A Multicenter Approach}}},
  shorttitle = {Assessment of {{Computed Tomography}} ({{CT}})-{{Defined Muscle}} and {{Adipose Tissue Features}} in {{Relation}} to {{Short-Term Outcomes After Elective Surgery}} for {{Colorectal Cancer}}},
  author = {Martin, Lisa and Hopkins, Jessica and Malietzis, Georgios and Jenkins, J. T. and Sawyer, Michael B. and Brisebois, Ron and MacLean, Anthony and Nelson, Gregg and Gramlich, Leah and Baracos, Vickie E.},
  year = {2018},
  month = sep,
  journal = {Annals of Surgical Oncology},
  volume = {25},
  number = {9},
  pages = {2669--2680},
  issn = {1534-4681},
  doi = {10.1245/s10434-018-6652-x},
  abstract = {BACKGROUND: Sarcopenia, visceral obesity (VO), and reduced muscle radiodensity (myosteatosis) are suggested risk factors for postoperative morbidity in colorectal cancer (CRC), but usually are not concurrently assessed. Published thresholds used to define these features are not CRC-specific and are defined in relation to mortality, not postoperative outcomes. This study aimed to evaluate body composition in relation to length of hospital stay (LOS) and postoperative outcomes. METHODS: Pre-surgical computed tomography (CT) images were assessed for total area and radiodensity of skeletal muscle and visceral adipose tissue in a pooled Canadian and UK cohort (n\,=\,2100). Sex- and age-specific values for these features were calculated. For 1139 of 2100 patients, LOS data were available, and sex- and age-specific thresholds for sarcopenia, myosteatosis, and VO were defined on the basis of LOS. Association of CT-defined features with LOS and readmissions was explored using negative binomial and logistic regression models, respectively. RESULTS: In the multivariable analysis, the predictors of LOS (P\,{$<$}\,0.001) were age, surgical approach, major complications (incidence rate ratio [IRR] 2.42; 95\% confidence interval [CI] 2.18-2.68), study cohort, and three body composition profiles characterized by myosteatosis combined with either sarcopenia (IRR, 1.27; 95\% CI 1.12-1.43) or VO (IRR, 1.25; 95\% CI 1.10-1.42), and myosteatosis combined with both sarcopenia and VO (IRR, 1.58; 95\% CI 1.29-1.93). In the multivariable analysis, risk of readmission was associated with VO alone (odds ratio [OR] 2.66; 95\% CI 1.18-6.00); P\,=\,0.018), VO combined with myosteatosis (OR, 2.72; 95\% CI 1.36-5.46; P\,=\,0.005), or VO combined with myosteatosis and sarcopenia (OR, 2.98; 95\% CI 1.06-5.46; P\,=\,0.038). Importantly, the effect of body composition profiles on LOS and readmission was independent of major complications. CONCLUSION: The findings showed that CT-defined multidimensional body habitus is independently associated with LOS and hospital readmission.},
  langid = {english},
  pmid = {30006691},
  keywords = {Body Composition,Colorectal,ICC,LOS,Patient Readmission,Postoperative Complications,Sarcopenia,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FRZBACYT\\Martin et al_2018_Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue.pdf}
}

@article{martin4376,
  title = {Prognostic Factors in Patients with Advanced Cancer: Use of the Patient-Generated Subjective Global Assessment in Survival Prediction},
  shorttitle = {Prognostic Factors in Patients with Advanced Cancer},
  author = {Martin, Lisa and Watanabe, Sharon and Fainsinger, Robin and Lau, Francis and Ghosh, Sunita and Quan, Hue and Atkins, Marlis and Fassbender, Konrad and Downing, G. Michael and Baracos, Vickie},
  year = {2010},
  month = oct,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {28},
  number = {28},
  pages = {4376--4383},
  issn = {1527-7755},
  doi = {10.1200/JCO.2009.27.1916},
  abstract = {PURPOSE: To determine whether elements of a standard nutritional screening assessment are independently prognostic of survival in patients with advanced cancer. PATIENTS AND METHODS: A prospective nested cohort of patients with metastatic cancer were accrued from different units of a Regional Palliative Care Program. Patients completed a nutritional screen on admission. Data included age, sex, cancer site, height, weight history, dietary intake, 13 nutrition impact symptoms, and patient- and physician-reported performance status (PS). Univariate and multivariate survival analyses were conducted. Concordance statistics (c-statistics) were used to test the predictive accuracy of models based on training and validation sets; a c-statistic of 0.5 indicates the model predicts the outcome as well as chance; perfect prediction has a c-statistic of 1.0. RESULTS: A training set of patients in palliative home care (n = 1,164) was used to identify prognostic variables. Primary disease site, PS, short-term weight change (either gain or loss), dietary intake, and dysphagia predicted survival in multivariate analysis (P {$<$} .05). A model including only patients separated by disease site and PS with high c-statistics between predicted and observed responses for survival in the training set (0.90) and validation set (0.88; n = 603). The addition of weight change, dietary intake, and dysphagia did not further improve the c-statistic of the model. The c-statistic was also not altered by substituting physician-rated palliative PS for patient-reported PS. CONCLUSION: We demonstrate a high probability of concordance between predicted and observed survival for patients in distinct palliative care settings (home care, tertiary inpatient, ambulatory outpatient) based on patient-reported information.},
  langid = {english},
  pmid = {20805456},
  keywords = {Aged,Female,Home Care Services,Humans,Male,Middle Aged,Neoplasms,Nutrition Assessment,Palliative Care,Predictive Value of Tests,Prognosis,Prospective Studies,Regression Analysis,Risk Assessment,Risk Factors,Survival Analysis}
}

@article{martin610,
  title = {Risk Factors for Weight Loss among Patients Surviving 5~Years after Esophageal Cancer Surgery},
  author = {Martin, Lena and Lagergren, Pernilla},
  year = {2015},
  month = feb,
  journal = {Annals of Surgical Oncology},
  volume = {22},
  number = {2},
  pages = {610--616},
  issn = {1534-4681},
  doi = {10.1245/s10434-014-3973-2},
  abstract = {BACKGROUND: This study aimed to identify factors influencing postoperative weight loss {$\geq$}15~\% in long-term survivors after esophageal cancer surgery. METHODS: A population-based study was conducted in Sweden between 2001 and 2005, with regular follow-up for 5~years. Current weight, weight at operation, and average weight were assessed and dichotomized as weight loss of {$\geq$}15~\%. Logistic regression estimated relative risks of weight loss between pre- and 5~years postoperatively, expressed as odds ratios (ORs) with 95~\% confidence intervals (CIs). Statistically significant differences in nutritional symptoms between weight loss groups were analyzed using linear regression models to likewise test as risk factors. Body mass index (BMI) at operation ({$<$} or {$\geq$}25), sex, and preoperative weight loss ({$<$} or {$\geq$}10~\%) were tested as risk factors. Nutritional symptoms were selected from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-OES18, including fatigue, nausea and vomiting, dyspnoea, appetite loss, diarrhea, and dysphagia, eating difficulties, reflux and pain. RESULTS: A total of 117 patients were included. Patients with preoperative BMI {$\geq$}25 were at a threefold increased risk (OR 3.2; 95~\% CI 1.4-7.3) for postoperative weight loss of {$\geq$}15~\% 5~years after operation. Moreover, eating difficulties, pain, fatigue, nausea and vomiting, and appetite loss were clinically relevant and statistically significantly worse symptoms experienced among those with a weight loss of {$\geq$}15~\% (all at p~{$<~$}0.05). CONCLUSIONS: Overweight at the time of operation is associated with postoperative weight loss from a long-term perspective. Several nutritional symptoms are associated with weight loss of {$>$}15~\% 5~years postoperatively.},
  langid = {english},
  pmid = {25120247},
  keywords = {Aged,Case-Control Studies,Esophageal Neoplasms,Esophagectomy,Female,GE,Humans,Male,Middle Aged,Prospective Studies,Quality of Life,Risk Factors,Survivors,Weight Loss}
}

@article{martin90,
  title = {Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss},
  author = {Martin, Lisa and Senesse, Pierre and Gioulbasanis, Ioannis and Antoun, Sami and Bozzetti, Federico and Deans, Chris and Strasser, Florian and Thoresen, Lene and Jagoe, R. Thomas and Chasen, Martin and Lundholm, Kent and Bosaeus, Ingvar and Fearon, Kenneth H. and Baracos, Vickie E.},
  year = {2015},
  month = jan,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {33},
  number = {1},
  pages = {90--99},
  issn = {1527-7755},
  doi = {10.1200/JCO.2014.56.1894},
  abstract = {PURPOSE: Existing definitions of clinically important weight loss (WL) in patients with cancer are unclear and heterogeneous and do not consider current trends toward obesity. METHODS: Canadian and European patients with cancer (n = 8,160) formed a population-based data set. Body mass index (BMI) and percent WL (\%WL) were recorded, and patients were observed prospectively until death. Data were entered into a multivariable analysis controlling for age, sex, cancer site, stage, and performance status. Relationships for BMI and \%WL to overall survival were examined to develop a grading system. RESULTS: Mean overall \%WL was -9.7\% {$\pm$} 8.4\% and BMI was 24.4 {$\pm$} 5.1 kg/m(2), and both \%WL and BMI independently predicted survival (P {$<$} .01). Differences in survival were observed across five categories of BMI ({$<$} 20.0, 20.0 to 21.9, 22.0 to 24.9, 25.0 to 27.9, and {$\geq$} 28.0 kg/m(2); P {$<$} .001) and five categories of \%WL (-2.5\% to -5.9\%, -6.0\% to -10.9\%, -11.0\% to -14.9\%, {$\geq$} -15.0\%, and weight stable ({$\pm$} 2.4\%); P {$<$} .001). A 5 \texttimes{} 5 matrix representing the five \%WL categories within each of the five BMI categories was graded based on median survival and prognostic significance. Weight-stable patients with BMI {$\geq$} 25.0 kg/m(2) (grade 0) had the longest survival (20.9 months; 95\% CI, 17.9 to 23.9 months), and \%WL values associated with lowered categories of BMI were related to shorter survival (P {$<$} .001), as follows: grade 1, 14.6 months (95\% CI, 12.9 to 16.2 months); grade 2, 10.8 months (95\% CI, 9.7 to 11.9 months); grade 3, 7.6 months (95\% CI, 7.0 to 8.2 months); and grade 4, 4.3 months (95\% CI, 4.1 to 4.6 months). Survival discrimination by grade was observed within specific cancers, stages, ages, and performance status and in an independent validation sample (n = 2,963). CONCLUSION: A robust grading system incorporating the independent prognostic significance of both BMI and \%WL was developed.},
  langid = {english},
  pmid = {25422490},
  keywords = {Aged,Body Mass Index,Cachexia,Canada,Databases; Factual,Europe,Female,Humans,Male,Middle Aged,Multivariate Analysis,Neoplasm Staging,Neoplasms,Population Surveillance,Prognosis,Prospective Studies,Survival Analysis,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KQYVQ29S\\Martin et al. - Diagnostic Criteria for the Classification of Canc.pdf}
}

@article{matsui6378,
  title = {Relationship {{Between Early Postoperative Change}} in {{Total Psoas Muscle Area}} and {{Long-term Prognosis}} in {{Esophagectomy}} for {{Patients}} with {{Esophageal Cancer}}},
  author = {Matsui, Kazuaki and Kawakubo, Hirofumi and Hirata, Yuki and Matsuda, Satoru and Mayanagi, Shuhei and Irino, Tomoyuki and Fukuda, Kazumasa and Nakamura, Rieko and Wada, Norihito and Kitagawa, Yuko},
  year = {2021},
  month = oct,
  journal = {Annals of Surgical Oncology},
  volume = {28},
  number = {11},
  pages = {6378--6387},
  issn = {1534-4681},
  doi = {10.1245/s10434-021-09623-6},
  abstract = {PURPOSE: Postoperative sarcopenia following esophagectomy for esophageal cancer has become a severe problem due to the increasing number of elderly patients undergoing surgery. This study aimed to clarify the relationship between early postoperative skeletal muscle change and cancer prognosis, and propose effective interventions to prevent sarcopenia. METHODS: This study retrospectively analyzed 152 patients who underwent esophagectomy for esophageal cancer. Total psoas muscle area (TPA) was measured before surgery as baseline and on postoperative day 7 ({$\pm~$}2). The effect of early postoperative skeletal muscle loss on 5-year survival was investigated. Moreover, 5-year survival in patients with postoperative complications and a high inflammatory status, which were previously reported as poor prognostic factors of esophageal cancer, was also investigated. RESULTS: Among the 152 patients, 52 (34.2\%) showed a decrease in TPA, while 100 (65.8\%) maintained their TPA. The TPA decreasing group exhibited poor 5-year overall survival (OS) (p~=~0.003) and 5-year recurrence-free survival (RFS) (p~{$<~$}0.001). The TPA decreasing group also showed a poor 5-year OS in patients who developed severe postoperative complications (p~=~0.015). Multivariate analyses showed that decreased TPA was found to be independently associated with OS (p~=~0.017) as well as RFS (p~=~0.002). CONCLUSIONS: Our findings suggested a relationship between decreased TPA within 1~week after esophagectomy and long-term prognosis among patients with esophageal cancer. If TPA can be maintained, the prognosis was better even in cases with serious complications.},
  langid = {english},
  pmid = {33786679},
  keywords = {Aged,Esophageal Neoplasms,Esophagectomy,GE,Humans,Postoperative Complications,Prognosis,Psoas,Psoas Muscles,Retrospective Studies,Risk Factors,Sarcopenia,Survival Rate}
}

@article{mattioli255,
  type = {Journal {{Article}}},
  title = {Patient Position for a Synchronous Cervicothoracoabdominal Two-Team Esophagectomy},
  author = {Mattioli, S. and D'Ovidio, F. and Di Simone, M. P. and Lazzari, A. and Paladini, R. and Begliomini, B.},
  year = {1997},
  journal = {Ann Thorac Surg},
  volume = {63},
  number = {1},
  pages = {255--7},
  issn = {0003-4975 (Print) 0003-4975 (Linking)}
}

@article{mauricio11,
  title = {Nutritional {{Status Parameters}} as {{Risk Factors}} for {{Mortality}} in {{Cancer Patients}}},
  author = {Mauricio, S{\'i}lvia Fernandes},
  pages = {11},
  abstract = {The aim of this study was to verify the relationship between weight loss, handgrip strength (HGS) and phase angle (PA) before the beginning of chemotherapy with overall survival in cancer patients. Patients diagnosed with gastrointestinal and breast cancer who were over 18 years old and were scheduled to undergo adjuvant treatment at Hospital Borges da Costa/Brazil were evaluated. The exclusion criteria were neoadjuvant treatment, patients with kidney and liver disease and using diuretics. Weight, HGS and PA tests were performed by trained dietitians. The KaplanMeier survival method and the log-rank test, cox regression and ROC curve were used and p {$<$} 0.05 was considered significant. Two-hundred and twenty-eight patients were evaluated.The median survival time was higher among the patients who showed weight loss of less than 10\% of usual body weight (p {$<$} 0.05). Regarding HGS, patients with decreased HGS had a 22.0 month survival versus 34.2 months for those with normal values (p {$<$} 0.05). 146 patients had normal PA values, and these patients had increased survival time compared to those with inappropriate values (p {$<$} 0.05). In the Cox regression, weight loss and PA were predictors of mortality, HGS wasn't significantly associated with mortality. ROC analysis revealed that weight loss was the nutritional status parameter with the most predictive power.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ME7BI6E8\\Mauricio - Nutritional Status Parameters as Risk Factors for .pdf}
}

@article{mayanagi3741,
  title = {Negative {{Impact}} of {{Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed}} by {{Surgery}} on {{Survival}} for {{Patients}} with {{Thoracic Esophageal Cancer}}},
  author = {Mayanagi, Shuhei and Tsubosa, Yasuhiro and Omae, Katsuhiro and Niihara, Masahiro and Uchida, Tsuneyuki and Tsushima, Takahiro and Yokota, Tomoya and Sato, Hiroshi and Naito, Tateaki and Yasui, Hirofumi},
  year = {2017},
  month = nov,
  journal = {Annals of Surgical Oncology},
  volume = {24},
  number = {12},
  pages = {3741--3747},
  issn = {1534-4681},
  doi = {10.1245/s10434-017-6020-2},
  abstract = {BACKGROUND: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery. METHODS: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4~months after surgery as well as the postoperative recurrence and overall survival (OS). RESULTS: Of the 66 patients, 39 (59\%) showed a skeletal muscle decrease from baseline to 4~months after esophagectomy. The change in the skeletal muscle index from baseline to 4~months after surgery was -1.2~cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p~=~0.029), pathologic stage (HR 5.73; p~{$<~$}0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p~=~0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p~{$<~$}0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p~=~0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival. CONCLUSIONS: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.},
  langid = {english},
  pmcid = {PMC5658455},
  pmid = {28861809},
  keywords = {Adenocarcinoma,Carcinoma; Squamous Cell,Combined Modality Therapy,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Muscle; Skeletal,Prognosis,Retrospective Studies,Survival Rate,Thoracic Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\HQ97KUUU\\Mayanagi et al_2017_Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy.pdf}
}

@article{mcisaac538,
  title = {Association of {{Frailty}} and 1-{{Year Postoperative Mortality Following Major Elective Noncardiac Surgery}}: {{A Population-Based Cohort Study}}},
  shorttitle = {Association of {{Frailty}} and 1-{{Year Postoperative Mortality Following Major Elective Noncardiac Surgery}}},
  author = {McIsaac, Daniel I. and Bryson, Gregory L. and {van Walraven}, Carl},
  year = {2016},
  month = jun,
  journal = {JAMA surgery},
  volume = {151},
  number = {6},
  pages = {538--545},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2015.5085},
  abstract = {IMPORTANCE: Single-center studies identify frailty as a risk factor for 30-day postoperative mortality. The long-term and population-level effect of frailty on postoperative mortality is, to our knowledge, poorly described, as are the interactions of frailty with important predictors of mortality. OBJECTIVE: To measure the population-level effect of patient frailty on, and its association with, 1-year postoperative mortality. DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study in Ontario, Canada, with data collected between April 1, 2002 and March 31, 2012. Analysis was performed from December 2014 to March 2015. All patients were community-dwelling individuals aged 65 years or older on the day of elective, major noncardiac surgery. EXPOSURE: Frailty, as defined by the Johns Hopkins Adjusted Clinical Groups (ACG) frailty-defining diagnoses indicator. The ACG frailty-defining diagnoses indicator is a binary variable that uses 12 clusters of frailty-defining diagnoses. MAIN OUTCOMES AND MEASURES: One-year all-cause postoperative mortality. RESULTS: Of 202 811 patients, 6289 (3.1\%) were frail (mean [SD] age, 77 [7] years). Within 1 year, 13.6\% (n\,=\,855) of frail and 4.8\% (n\,=\,9433) of nonfrail patients died. Adjustment for sociodemographic and surgical confounders resulted in a hazard ratio of 2.23 (95\% CI, 2.08-2.40). The interaction between frailty and postoperative time demonstrated an increased relative hazard for death in frail patients (hazard ratio, 35.58; 95\% CI, 29.78-40.19) on postoperative day 3. The association between frailty and increased risk of death decreased with patient age (HR, 2.66; 95\% CI, 2.28-3.10 at age 65; HR, 1.63; 95\% CI, 1.36-1.95 at age 90). Significant variations in the increased risk for death in frail patients existed between different surgery types and was strongest after total joint arthroplasty (HR, 3.79; 95\% CI, 3.21-4.47 for hip replacement; HR, 2.68; 95\% CI, 2.10-3.42 for knee replacement). CONCLUSIONS AND RELEVANCE: At a population level, preoperative frailty-defining diagnoses were associated with a significantly increased risk of 1-year mortality that was particularly notable in the early postoperative period, in younger patients, and after joint arthroplasty.},
  langid = {english},
  pmid = {26791334},
  keywords = {Age Factors,Aged,Aged; 80 and over,Arthroplasty; Replacement; Hip,Arthroplasty; Replacement; Knee,Cause of Death,Elective Surgical Procedures,Female,Frail Elderly,Frailty,Health Status,Humans,Male,Ontario,Postoperative Period,Retrospective Studies,Risk Factors,Surgical Procedures; Operative,Time Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6AVYJM2F\\McIsaac et al_2016_Association of Frailty and 1-Year Postoperative Mortality Following Major.pdf}
}

@article{mckeown259,
  title = {Total Three-Stage Oesophagectomy for Cancer of the Oesophagus},
  author = {McKeown, K. C.},
  year = {1976},
  month = apr,
  journal = {The British Journal of Surgery},
  volume = {63},
  number = {4},
  pages = {259--262},
  issn = {0007-1323},
  doi = {10.1002/bjs.1800630403},
  abstract = {The technique of total three-stage oesophagectomy is described fully. Points of detail in the procedure of the abdominal, thoracic and cervical phases are emphasized. A brief note is made regarding the management of the respiratory situation at the end of the operation.},
  langid = {english},
  pmid = {1276657},
  keywords = {Esophageal Neoplasms,Esophagus,Humans,Methods,Stomach}
}

@article{mehrane595,
  type = {Journal {{Article}}},
  title = {Pain {{Management}} in an {{Enhanced Recovery Pathway After Thoracic Surgical Procedures}}},
  author = {Mehran, R. J. and Martin, L. W. and Baker, C. M. and Mena, G. E. and Rice, D. C.},
  year = {2016},
  journal = {Ann Thorac Surg},
  volume = {102},
  number = {6},
  pages = {e595-e596},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2016.05.050}
}

@article{melis114,
  title = {Correlations between Neoadjuvant Treatment, Anemia, and Perioperative Complications in Patients Undergoing Esophagectomy for Cancer},
  author = {Melis, Marcovalerio and McLoughlin, James M. and Dean, E. Michelle and Siegel, Erin M. and Weber, Jill M. and Shah, Nilay and Kelley, Scott T. and Karl, Richard C.},
  year = {2009},
  month = may,
  journal = {The Journal of Surgical Research},
  volume = {153},
  number = {1},
  pages = {114--120},
  issn = {1095-8673},
  doi = {10.1016/j.jss.2008.06.005},
  abstract = {INTRODUCTION: The influence of preoperative hemoglobin levels on outcomes of patients undergoing esophagectomy for cancer is not clearly defined. The goal of this article was to explore the association between combined modality therapy, preoperative anemia status, and perioperative blood transfusion and risk of postoperative complications among patients undergoing esophageal resection. METHODS: From a retrospective esophageal database, 413 patients were identified. Anemia was defined according to the World Health Organization classification of {$<$}13 g/dL or {$<$}12 g/dL for men or women, respectively. Statistical analysis was performed with analysis of variance, Pearson's chi(2), or Fisher exact test as appropriate. The independent association of anemia, blood transfusion, and combined modality treatment on risk of postoperative complications were examined using multiple logistic regression. RESULTS: Information on combined modality treatment, preoperative hemoglobin levels, and blood transfusion was available for 413 patients, of whom 57\% received combined modality treatment. Overall 197 (47.6\%) patients were preoperatively found to be anemic, and those who had received combined modality treatment were more likely to be anemic (60.6\% versus 30.7\%, P {$<$} 0.001). Anemic patients required more blood transfusions than nonanemic patients (46.7\% versus 29.6\%, P {$<$} 0.001). Seventy-five percent of patients who required transfusion during the hospital stay had received combined modality treatment (P = 0.01). Combined modality treatment and anemia were not associated with increased risk of complications. Patients with any perioperative complication and surgical site infections were more likely to have received blood transfusion compared to patients without complications (OR = 1.73; 95\% CI 1.04-2.87 and OR = 2.98; 95\% CI 1.04-8.55; respectively). CONCLUSIONS: Overall, we determined that administration of neoadjuvant treatment to esophageal cancer patients was not associated with an increased rate of perioperative complications. Preoperative anemia did not predict worsened short-term outcomes, but increased the chances of red blood cell transfusion, which were significantly associated with higher overall complications and increased risk of surgical site infections. These data confirm previous studies that allogenic red blood cell transfusions are independent risk factors for increased morbidity and mortality and should be minimized during surgery for esophageal cancer.},
  langid = {english},
  pmid = {19201421},
  keywords = {Aged,Anemia,Esophageal Neoplasms,Esophagectomy,Female,Hemoglobins,Humans,Male,Middle Aged,Neoadjuvant Therapy,Postoperative Complications,Transfusion Reaction},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\83DHIY9N\\Melis et al_2009_Correlations between neoadjuvant treatment, anemia, and perioperative.pdf}
}

@article{mendoza1186,
  type = {Journal {{Article}}},
  title = {The Rapid Assessment of Fatigue Severity in Cancer Patients: Use of the {{Brief Fatigue Inventory}}},
  author = {Mendoza, T. R. and Wang, X. S. and Cleeland, C. S. and Morrissey, M. and Johnson, B. A. and Wendt, J. K. and Huber, S. L.},
  year = {1999},
  journal = {Cancer},
  volume = {85},
  number = {5},
  pages = {1186--96},
  issn = {0008-543X (Print) 0008-543X (Linking)}
}

@article{mercurystudygroup779,
  title = {Diagnostic Accuracy of Preoperative Magnetic Resonance Imaging in Predicting Curative Resection of Rectal Cancer: Prospective Observational Study},
  shorttitle = {Diagnostic Accuracy of Preoperative Magnetic Resonance Imaging in Predicting Curative Resection of Rectal Cancer},
  author = {{MERCURY Study Group}},
  year = {2006},
  month = oct,
  journal = {BMJ (Clinical research ed.)},
  volume = {333},
  number = {7572},
  pages = {779},
  issn = {1756-1833},
  doi = {10.1136/bmj.38937.646400.55},
  abstract = {OBJECTIVE: To assess the accuracy of preoperative staging of rectal cancer with magnetic resonance imaging to predict surgical circumferential resection margins. DESIGN: Prospective observational study of rectal cancers treated by colorectal multidisciplinary teams between January 2002 and October 2003. SETTING: 11 colorectal units in four European countries. PARTICIPANTS: 408 consecutive patients presenting with all stages of rectal cancer and undergoing magnetic resonance imaging before total mesorectal excision surgery and histopathological assessment of the surgical specimen. MAIN OUTCOME MEASURES: Accuracy of magnetic resonance imaging in predicting a curative resection based on the histological yardstick of presence or absence of tumour at the margins of the specimen. RESULTS: 354 of the 408 patients had a clear circumferential resection margin (87\%, 95\% confidence interval 83\% to 90\%). Specificity for prediction of a clear margin by magnetic resonance imaging was 92\% (327/354, 90\% to 95\%). High resolution scans were technically satisfactory in 93\% (379/408). Surgical specimens were histopathologically graded as complete or moderate in 80\% (328/408), and the median lymph node harvest was 12 (range 0-49). Magnetic resonance imaging predicted clear margins in 349 patients. At surgery 327 had clear margins (94\%, 91\% to 96\%). CONCLUSION: High resolution magnetic resonance imaging accurately predicts whether the surgical resection margins will be clear or affected by tumour. This technique can be reproduced accurately in multiple centres to predict curative resection and warns the multidisciplinary team of potential failure of surgery, thus enabling selection of patients for preoperative treatment.},
  langid = {english},
  pmcid = {PMC1602032},
  pmid = {16984925},
  keywords = {Adult,Aged,Aged; 80 and over,Feasibility Studies,Female,Humans,Magnetic Resonance Imaging,Male,Middle Aged,Neoplasm Staging,Preoperative Care,Prospective Studies,Rectal Neoplasms,Rectal;MRI,Sensitivity and Specificity},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\W7VK8YBZ\\MERCURY Study Group - 2006 - Diagnostic accuracy of preoperative magnetic reson.pdf}
}

@article{messager318,
  title = {Preoperative Chemoradiation with Paclitaxel-Carboplatin or with Fluorouracil-Oxaliplatin-Folinic Acid ({{FOLFOX}}) for Resectable Esophageal and Junctional Cancer: The {{PROTECT-1402}}, Randomized Phase 2 Trial},
  shorttitle = {Preoperative Chemoradiation with Paclitaxel-Carboplatin or with Fluorouracil-Oxaliplatin-Folinic Acid ({{FOLFOX}}) for Resectable Esophageal and Junctional Cancer},
  author = {Messager, Mathieu and Mirabel, Xavier and Tresch, Emmanuelle and Paumier, Amaury and Vendrely, V{\'e}ronique and Dahan, Laetitia and Glehen, Olivier and Vasseur, Frederique and Lacornerie, Thomas and Piessen, Guillaume and El Hajbi, Farid and Robb, William B. and Clisant, St{\'e}phanie and Kramar, Andrew and Mariette, Christophe and Adenis, Antoine},
  year = {2016},
  month = may,
  journal = {BMC cancer},
  volume = {16},
  pages = {318},
  issn = {1471-2407},
  doi = {10.1186/s12885-016-2335-9},
  abstract = {BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemotherapeutic regimens (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid) when each is combined with the radiation regime utilized in the CROSS trial. METHODS/DESIGN: PROTECT is a prospective, randomized, multicenter, open arms, phase II trial. Eligible patients will have a histologically confirmed adenocarcinoma or squamous cell carcinoma and be treated with neoadjuvant radiochemotherapy followed by surgery for stage IIB or stage III resectable esophageal cancer. A total of 106 patients will be randomized to receive either 3~cycles of FOLFOX combined to concurrent radiotherapy (41.4 Grays) or carboplatin and paclitaxel with the same radiation regimen, using a 1:1 allocation ratio. DISCUSSION: This ongoing trial offers the unique opportunity to compare two standards of chemotherapy delivered with a common regimen of preoperative radiation, in the setting of operable locally advanced esophageal or gastro-esophageal junctional tumors. TRIAL REGISTRATION: NCT02359968 (ClinicalTrials.gov) (registration date: 9 FEB 2015), EudraCT: 2014-000649-62 (registration date: 10 FEB 2014).},
  langid = {english},
  pmcid = {PMC4872363},
  pmid = {27194176},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,Chemoradiotherapy,Cisplatin,Dose Fractionation; Radiation,Esophageal cancer,Esophageal Neoplasms,Female,Fluorouracil,FOLFOX,Humans,Leucovorin,Male,Middle Aged,Neoadjuvant Therapy,Organoplatinum Compounds,Paclitaxel,Paclitaxel-carboplatin,Prospective Studies,Randomized trial,Survival Analysis,Treatment Outcome,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2H5DG8SX\\Messager et al. - 2016 - Preoperative chemoradiation with paclitaxel-carbop.pdf}
}

@article{mhaskarCD009624,
  title = {The Role of Iron in the Management of Chemotherapy-Induced Anemia in Cancer Patients Receiving Erythropoiesis-Stimulating Agents},
  author = {Mhaskar, Rahul and Wao, Hesborn and Miladinovic, Branko and Kumar, Ambuj and Djulbegovic, Benjamin},
  year = {2016},
  month = feb,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {2},
  pages = {CD009624},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD009624.pub2},
  abstract = {BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat chemotherapy-induced anemia (CIA). However, about half of patients do not benefit. OBJECTIVES: To evaluate the benefits and harms related to the use of iron as a supplement to ESA and iron alone compared with ESA alone in the management of CIA. SEARCH METHODS: We searched for relevant trials from the Cochrane Central Register of Controlled Trials (CENTRAL) (issue 1 January 2016), MEDLINE (1950 to February 2016), and www.clinicaltrials.gov without using any language limits. SELECTION CRITERIA: All randomized controlled trials (RCTs) comparing 'iron plus ESA' or 'iron alone' versus 'ESA alone' in people with CIA were eligible for inclusion. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included eight RCTs (12 comparisons) comparing ESA plus iron versus ESA alone enrolling 2087 participants. We did not find any trial comparing iron alone versus ESAs alone in people with CIA. None of the included RCTs reported overall survival. There was a beneficial effect of iron supplementation to ESAs compared with ESAs alone on hematopoietic response (risk ratio (RR) 1.17, 95\% confidence interval (CI) 1.09 to 1.26; P {$<$} 0.0001; 1712 participants; 11 comparisons; high-quality evidence). Assuming a baseline risk of 35\% to 80\% for hematopoietic response without iron supplementation, between seven and 16 patients should be treated to achieve hematopoietic response in one patient. In subgroup analyses, RCTs that used intravenous (IV) iron favored ESAs and iron (RR 1.20 (95\% CI 1.10 to 1.31); P {$<$} 0.00001; 1321 participants; eight comparisons), whereas we found no evidence for a difference in hematopoietic response in RCTs using oral iron (RR 1.04 (95\% CI 0.87 to 1.24); P = 0.68; 391 participants; three comparisons). There was no evidence for a difference between the subgroups of IV and oral iron (P = 0.16). There was no evidence for a difference between the subgroups of types of iron (P = 0.31) and types of ESAs (P = 0.16) for hematopoietic response.The iron supplementation to ESAs might be beneficial as fewer participants treated with iron supplementation required red blood cell (RBC) transfusions compared to the number of participants treated with ESAs alone (RR 0.74 (95\% CI 0.60 to 0.92); P = 0.007; 1719 participants; 11 comparisons; moderate-quality evidence). Assuming a baseline risk of 7\% to 40\% for RBC transfusion without iron supplementation, between 10 and 57 patients should be treated to avoid RBC transfusion in one patient.We found no evidence for a difference in the median time to hematopoietic response with addition of iron to ESAs (hazard ratio (HR) 0.93 (95\% CI 0.67 to 1.28); P = 0.65; 1042 participants; seven comparisons; low-quality evidence). In subgroup analyses, RCTs in which dextran (HR 0.95 (95\% CI 0.36 to 2.52); P = 0.92; 340 participants; three comparisons), sucrose iron (HR 1.15 (95\% CI 0.60 to 2.21); P = 0.67; 102 participants; one comparison) and sulfate iron (HR 1.24 (95\% CI 0.99 to 1.56); P = 0.06; 55 participants; one comparison) were used showed no evidence for difference between iron supplementation versus ESAs alone compared with RCTs in which gluconate (HR 0.78 (95\% CI 0.65 to 0.94); P = 0.01; 464 participants; two comparisons) was used for median time to hematopoietic response (P = 0.02). There was no evidence for a difference between the subgroups of route of iron administration (P = 0.13) and types of ESAs (P = 0.46) for median time to hematopoietic response.Our results indicated that there could be improvement in the hemoglobin (Hb) levels with addition of iron to ESAs (mean difference (MD) 0.48 (95\% CI 0.10 to 0.86); P = 0.01; 827 participants; seven comparisons; low-quality evidence). In RCTs in which IV iron was used there was evidence for a difference (MD 0.84 (95\% CI 0.21 to 1.46); P = 0.009; 436 participants; four comparisons) compared with oral iron (MD 0.07 (95\% CI -0.19 to 0.34); P = 0.59; 391 participants; three comparisons) for mean change in Hb level (P = 0.03). RCTs in which dextran (MD 1.55 (95\% CI 0.62 to 2.47); P = 0.001; 102 participants; two comparisons) was used showed evidence for a difference with iron supplementation versus ESAs alone compared with RCTs in which gluconate (MD 0.54 (95\% CI -0.15 to 1.22); P = 0.12; 334 participants; two comparisons) and sulfate iron (MD 0.07 (95\% CI -0.19 to 0.34); P = 0.59; 391 participants; three comparisons) were used for mean change in Hb level (P = 0.007). RCTs in which epoetin was used showed evidence for a difference with iron supplementation versus ESAs alone (MD 0.77 (95\% CI 0.25 to 1.29); P = 0.004; 337 participants; five comparisons) compared with darbepoetin use (MD 0.10 (95\% CI -0.13 to 0.33); P = 0.38; 490 participants; two comparisons) for mean change in Hb level (P = 0.02).We found no evidence for a difference in quality of life with addition of iron to ESAs (standardized mean difference 0.01 (95\% CI -0.10 to 0.12); P = 0.88; 1124 participants; three RCTs; high-quality evidence).We found no evidence for a difference in risk of grade III-IV thromboembolic events (RR 0.95 (95\% CI 0.54 to 1.65); P = 0.85; 783 participants; three RCTs; moderate-quality evidence). The incidence of treatment-related mortality (TRM) was 0\% (997 participants; four comparisons; high-quality evidence).Other common adverse events included vomiting, asthenia, and leukopenia, and were similar in both arms.Overall the risk of bias across outcomes was high to low. Since the included RCTs had shorter follow-up duration (up to 20 weeks), the long-term effects of iron supplementation are unknown. Our main reasons for downgrading the quality of evidence were inconsistency across the included studies and imprecision of results. AUTHORS' CONCLUSIONS: Our systematic review shows that addition of iron to ESAs offers superior hematopoietic response, reduces the risk of RBC transfusions, and improves Hb levels, and appears to be well tolerated. None of the included RCTs reported overall survival. We found no evidence for a difference in quality of life with iron supplementation.},
  langid = {english},
  pmcid = {PMC8765740},
  pmid = {26845108},
  keywords = {Administration; Oral,Anemia,Antineoplastic Agents,Epo,Erythrocyte Transfusion,Hematinics,Hematopoiesis,Humans,Injections; Intravenous,Iron,Neoplasms,Oncology,Randomized Controlled Trials as Topic}
}

@article{michelet911,
  title = {Protective Ventilation Influences Systemic Inflammation after Esophagectomy: A Randomized Controlled Study},
  shorttitle = {Protective Ventilation Influences Systemic Inflammation after Esophagectomy},
  author = {Michelet, Pierre and D'Journo, Xavier-Beno{\^i}t and Roch, Antoine and Doddoli, Christophe and Marin, Valerie and Papazian, Laurent and Decamps, Isabelle and Bregeon, Fabienne and Thomas, Pascal and Auffray, Jean-Pierre},
  year = {2006},
  month = nov,
  journal = {Anesthesiology},
  volume = {105},
  number = {5},
  pages = {911--919},
  issn = {0003-3022},
  doi = {10.1097/00000542-200611000-00011},
  abstract = {BACKGROUND: Esophagectomy induces a systemic inflammatory response whose extent has been recognized as a predictive factor of postoperative respiratory morbidity. The aim of this study was to determine the effectiveness of a protective ventilatory strategy to reduce systemic inflammation in patients undergoing esophagectomy. METHODS: The authors prospectively investigated 52 patients undergoing planned esophagectomy for cancer. Patients were randomly assigned to a conventional ventilation strategy (n = 26; tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure) or a protective ventilation strategy (n = 26; tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time). RESULTS: Plasmatic levels of interleukin (IL)-1beta, IL-6, IL-8, and tumor necrosis factor alpha were measured perioperatively and postoperatively. Pulmonary function and postoperative evolution were also evaluated. Patients who received protective strategy had lower blood levels of IL-1beta, IL-6, and IL-8 at the end of one-lung ventilation (0.24 [0.15-0.40] vs. 0.56 [0.38-0.89] pg/ml, P {$<$} 0.001; 91 [61-117] vs. 189 [127-294] pg/ml, P {$<$} 0.001; and 30 [22-45] vs. 49 [29-69] pg/ml, P {$<$} 0.05, respectively) and 18 h postoperatively (0.18 [0.13-0.30] vs. 0.43 [0.34-0.54] pg/ml, P {$<$} 0.001; 54 [36-89] vs. 116 [78-208] pg/ml, P {$<$} 0.001; 16 [11-24] vs. 35 [28-53] pg/ml, P {$<$} 0.001, respectively). Protective strategy resulted in higher oxygen partial pressure to inspired oxygen fraction ratio during one-lung ventilation and 1 h postoperatively and in a reduction of postoperative mechanical ventilation duration (115 +/- 38 vs. 171 +/- 57 min, P {$<$} 0.001). CONCLUSION: A protective ventilatory strategy decreases the proinflammatory systemic response after esophagectomy, improves lung function, and results in earlier extubation.},
  langid = {english},
  pmid = {17065884},
  keywords = {Aged,Esophageal Neoplasms,Esophagectomy,Female,Humans,Inflammation Mediators,Interleukin-1beta,Interleukin-6,Interleukin-8,Male,Middle Aged,Positive-Pressure Respiration,Prospective Studies,Respiration; Artificial,Systemic Inflammatory Response Syndrome,Tidal Volume,Tumor Necrosis Factor-alpha}
}

@article{miholic73,
  title = {Postprandial Release of Glucagon-like Peptide-1, Pancreatic Glucagon, and Insulin after Esophageal Resection},
  author = {Miholic, J. and Orskov, C. and Holst, J. J. and Kotzerke, J. and Pichlmayr, R.},
  year = {1993},
  journal = {Digestion},
  volume = {54},
  number = {2},
  pages = {73--78},
  issn = {0012-2823},
  doi = {10.1159/000201016},
  abstract = {Postprandial concentrations of glucose and the immunoreactivity of insulin, glucagon-like peptide-1 (GLP-1), and pancreatic glucagon were measured in 10 patients who had undergone esophageal resection (ER) and replacement by the stomach. Emptying of the esophageal substitute was assessed by scintigraphy using a 99Tc-labeled solid test meal. The data were compared with measurements performed in 14 controls, in 7 of whom gastric emptying was measured. The gastric emptying half time was 6.8 +/- 6.2 min (median 144 s) in ER cases, significantly shorter than in controls: 70 +/- 29 min (median 51 min). The early integrated (first 30 min) and total integrated insulin and GLP-1 concentrations were significantly higher than in controls. In 3 of 10 esophagectomy patients the blood glucose concentration fell below 3.8 mmol/l postprandially. High GLP-1 concentrations in the first 30 min were associated with low serum glucose during the 2nd h postprandially when all the hypoglycemic episodes occurred. It is concluded that rapid emptying of the esophageal substitute induces the exaggerated GLP-1 response, which is a main factor for reactive hypoglycemia.},
  langid = {english},
  pmid = {8319842},
  keywords = {Blood Glucose,Eating,Esophageal Neoplasms,Esophagoplasty,Esophagus,Female,Gastric Emptying,GLP-1,Glucagon,Glucagon-Like Peptide 1,Humans,Insulin,Male,Middle Aged,Pancreas,Peptide Fragments,Protein Precursors,Stomach}
}

@article{miki,
  title = {Loss of Adipose Tissue or Skeletal Muscle during First-Line Gemcitabine/Nab-Paclitaxel Therapy Is Associated with Worse Survival after Second-Line Therapy of Advanced Pancreatic Cancer},
  author = {Miki, Masami and Lee, Lingaku and Hisano, Terumasa and Sugimoto, Rie and Furukawa, Masayuki},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  volume = {n/a},
  number = {n/a},
  issn = {1743-7563},
  doi = {10.1111/ajco.13669},
  abstract = {Aim Progression of cachexia indicated by decreased body weight and composition is associated with poor survival of advanced pancreatic cancer (APC). There are limited data concerning the prognostic effect of cachexia on second-line chemotherapy (L2). We aimed to assess the impact of cachexia progression during first-line therapy (L1) on survival after L2. Methods We reviewed patients with gemcitabine/nab-paclitaxel (GEM/nabPTX)-refractory APC who underwent L2 with modified FOLFIRINOX or S-1 between 2015 and 2019 in our institution. We determined clinicopathological data including body composition parameters: subcutaneous fat area (SFA), visceral fat area (VFA), and skeletal muscle index (SMI). Correlations of changes in these parameters, as well as their effect on overall survival after L2 (OS2), were examined. Results Median rates of change in SMI, SFA, and VFA were 0.19\%, -4.17\%, and -18.39\%, respectively, in 59 patients during L1. Although there was moderate correlation in rate of change between SFA and VFA, there was no correlation between SMI and other parameters. We defined loss of SFA, VFA, and SMI as decreases greater than 8.5\%, 34.1\%, and 8.7\%, respectively. Median OS2 of patients with loss in any of these parameters was significantly shorter than in patients without loss (3.83 vs. 8.73 months). Multivariate analysis revealed that loss in any parameters, performance status, and C-reactive protein/albumin ratio were independent negative prognostic factors. Conclusion Loss of adipose tissue or skeletal muscle during L1 had a considerable impact on OS2 in APC refractory to GEM/nabPTX.},
  langid = {english},
  keywords = {adipose tissue,cachexia,chemotherapy,Pancreas,pancreatic cancer,skeletal muscle},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13669},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IAQJIE7L\\Miki et al. - Loss of adipose tissue or skeletal muscle during f.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\SQ4A79LR\\ajco.html}
}

@article{mine0179522,
  title = {Comparison between Gastrostomy Feeding and Self-Expandable Metal Stent Insertion for Patients with Esophageal Cancer and Dysphagia},
  author = {Min, Yang Won and Jang, Eun Young and Jung, Ji Hey and Lee, Hyuk and Min, Byung-Hoon and Lee, Jun Haeng and Rhee, Poong-Lyul and Kim, Jae J.},
  year = {2017},
  month = jun,
  journal = {PLOS ONE},
  volume = {12},
  number = {6},
  pages = {e0179522},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0179522},
  abstract = {Background Self-expandable metal stent (SEMS) insertion and percutaneous gastrostomy (PG) feeding are commonly used for patients with esophageal cancer and dysphagia. This study aimed to compare outcomes between SEMS insertion and PG feeding for them. Methods We retrospectively analyzed 308 patients with esophageal cancer who underwent fully covered SEMS insertion (stent group) or PG (gastrostomy group) for dysphagia due to tumor. Patients with other causes of dysphagia, such as radiation-induced or postoperative stricture, were excluded from the study. Clinical outcomes were compared between the two groups, including overall survival and need for additional intervention and postprocedural nutritional status. Results At baseline, the stent group (n = 169) had more stage IV patients, less cervical cancers, and received radiotherapy and esophagectomy less often than the gastrostomy group (n = 64). The Kaplan-Meier curves showed higher overall survival in the gastrostomy group than in the stent group. Multivariate analysis revealed that PG was associated with better survival compared with SEMS insertion (hazard ratio 0.541, 95\% confidence interval 0.346\textendash 0.848, p = 0.007). In addition, the gastrostomy group needed additional intervention less often (3.1\% vs. 21.9\%, p {$<$} 0.001) and experienced less decrease in serum albumin levels (-0.15 {$\pm$} 0.56 g/dL vs. -0.39 {$\pm$} 0.58 g/dL, p = 0.011) than the stent group after procedure. Conclusions Our data suggested that, compared with SEMS insertion, PG is associated with better overall survival in patients with esophageal cancer and dysphagia. Stabilized nutritional status by PG may play a role in improving patient survival.},
  langid = {english},
  keywords = {Cancer treatment,Dysphagia,Esophageal cancer,Esophagectomy,Nutrition,Patients,Radiation therapy,Serum albumin},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\E4M8HUSX\\Min et al. - 2017 - Comparison between gastrostomy feeding and self-ex.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\CT6QPIDD\\article.html}
}

@article{minnella1081a,
  title = {Effect of {{Exercise}} and {{Nutrition Prehabilitation}} on {{Functional Capacity}} in {{Esophagogastric Cancer Surgery}}: {{A Randomized Clinical Trial}}},
  shorttitle = {Effect of {{Exercise}} and {{Nutrition Prehabilitation}} on {{Functional Capacity}} in {{Esophagogastric Cancer Surgery}}},
  author = {Minnella, Enrico M. and Awasthi, Rashami and Loiselle, Sarah-Eve and Agnihotram, Ramanakumar V. and Ferri, Lorenzo E. and Carli, Francesco},
  year = {2018},
  month = dec,
  journal = {JAMA surgery},
  volume = {153},
  number = {12},
  pages = {1081--1089},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2018.1645},
  abstract = {Importance: Preserving functional capacity is a key element in the care continuum for patients with esophagogastric cancer. Prehabilitation, a preoperative conditioning intervention aiming to optimize physical status, has not been tested in upper gastrointestinal surgery to date. Objective: To investigate whether prehabilitation is effective in improving functional status in patients undergoing esophagogastric cancer resection. Design, Setting, and Participants: A randomized clinical trial (available-case analysis based on completed assessments) was conducted at McGill University Health Centre (Montreal, Quebec, Canada) comparing prehabilitation with a control group. Intervention consisted of preoperative exercise and nutrition optimization. Participants were adults awaiting elective esophagogastric resection for cancer. The study dates were February 13, 2013, to February 10, 2017. Main Outcomes and Measures: The primary outcome was change in functional capacity, measured with absolute change in 6-minute walk distance (6MWD). Preoperative (end of the prehabilitation period) and postoperative (from 4 to 8 weeks after surgery) data were compared between groups. Results: Sixty-eight patients were randomized, and 51 were included in the primary analysis. The control group were a mean (SD) age, 68.0 (11.6) years and 20 (80\%) men. Patients in the prehabilitation group were a mean (SD) age, 67.3 (7.4) years and 18 (69\%) men. Compared with the control group, the prehabilitation group had improved functional capacity both before surgery (mean [SD] 6MWD change, 36.9 [51.4] vs -22.8 [52.5] m; P\,{$<$}\,.001) and after surgery (mean [SD] 6MWD change, 15.4 [65.6] vs -81.8 [87.0] m; P\,{$<$}\,.001). Conclusions and Relevance: Prehabilitation improves perioperative functional capacity in esophagogastric surgery. Keeping patients from physical and nutritional status decline could have a significant effect on the cancer care continuum. Trial Registration: ClinicalTrials.gov Identifier: NCT01666158.},
  langid = {english},
  pmcid = {PMC6583009},
  pmid = {30193337},
  keywords = {Aged,Esophageal Neoplasms,Exercise,Female,Humans,Male,Middle Aged,Nutritional Status,Prehabilitation,Preoperative Care,Stomach Neoplasms,Walking},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H8ZDI237\\Minnella et al_2018_Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in.pdf}
}

@article{minsky1167,
  title = {{{INT}} 0123 ({{Radiation Therapy Oncology Group}} 94-05) Phase {{III}} Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose versus Standard-Dose Radiation Therapy},
  shorttitle = {{{INT}} 0123 ({{Radiation Therapy Oncology Group}} 94-05) Phase {{III}} Trial of Combined-Modality Therapy for Esophageal Cancer},
  author = {Minsky, Bruce D. and Pajak, Thomas F. and Ginsberg, Robert J. and Pisansky, Thomas M. and Martenson, James and Komaki, Ritsuko and Okawara, Gordon and Rosenthal, Seth A. and Kelsen, David P.},
  year = {2002},
  month = mar,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {20},
  number = {5},
  pages = {1167--1174},
  issn = {0732-183X},
  doi = {10.1200/JCO.2002.20.5.1167},
  abstract = {PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer. PATIENTS AND METHODS: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m(2)/24 hours for 4 days) and cisplatin (75 mg/m(2) bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive. RESULTS: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31\% v 40\%), or local/regional failure and local/regional persistence of disease (56\% v 52\%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less. CONCLUSION: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.},
  langid = {english},
  pmid = {11870157},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Combined Modality Therapy,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Radiotherapy,Radiotherapy Dosage,Treatment Outcome}
}

@article{mitchell325,
  type = {Journal {{Article}}},
  title = {Health Literacy and 30-Day Postdischarge Hospital Utilization},
  author = {Mitchell, S. E. and Sadikova, E. and Jack, B. W. and {Paasche-Orlow}, M. K.},
  year = {2012},
  journal = {J Health Commun},
  volume = {17 Suppl 3},
  pages = {325--38},
  issn = {1087-0415 (Electronic) 1081-0730 (Linking)},
  doi = {10.1080/10810730.2012.715233}
}

@article{mitsiopoulos115,
  title = {Cadaver Validation of Skeletal Muscle Measurement by Magnetic Resonance Imaging and Computerized Tomography},
  author = {Mitsiopoulos, N. and Baumgartner, R. N. and Heymsfield, S. B. and Lyons, W. and Gallagher, D. and Ross, R.},
  year = {1998},
  month = jul,
  journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
  volume = {85},
  number = {1},
  pages = {115--122},
  issn = {8750-7587},
  doi = {10.1152/jappl.1998.85.1.115},
  abstract = {Magnetic resonance imaging (MRI) and computerized tomography (CT) are promising reference methods for quantifying whole body and regional skeletal muscle mass. Earlier MRI and CT validation studies used data-acquisition techniques and data-analysis procedures now outdated, evaluated anatomic rather than adipose tissue-free skeletal muscle (ATFSM), studied only the relatively large thigh, or found unduly large estimation errors. The aim of the present study was to compare arm and leg ATFSM cross-sectional area estimates (cm2) by using standard MRI and CT acquisition and image-analysis methods with corresponding cadaver estimates. A second objective was to validate MRI and CT measurements of adipose tissue embedded within muscle (interstitial adipose tissue) and surrounding muscle (subcutaneous adipose tissue). ATFSM area (n = 119) by MRI [38.9 +/- 22.3 (SD) cm2], CT (39.7 +/- 22.8 cm2), and cadaver (39.5 +/- 23.0 cm2) were not different (P {$>$} 0.001), and both MRI and CT estimates of ATFSM were highly correlated with corresponding cadaver values [MRI: r = 0.99, SE of estimate (SEE) 3.9 cm2, P {$<$} 0.001; and CT: r = 0.99, SEE = 3.8 cm2, P {$<$} 0.001]. Similarly good results were observed between MRI- and CT-measured vs. cadaver-measured interstitial and subcutaneous adipose tissue. For MRI-ATFSM the intraobserver correlation for duplicate measurements in vivo was 0. 99 [SEE = 8.7 cm2 (2.9\%), P {$<$} 0.001]. These findings strongly support the use of MRI and CT as reference methods for appendicular skeletal muscle, interstitial and subcutaneous adipose tissue measurement in vivo.},
  langid = {english},
  pmid = {9655763},
  keywords = {Adipose Tissue,Aged,Aged; 80 and over,Body Composition,Cadaver,Humans,Image Processing; Computer-Assisted,L3,Leg,Magnetic Resonance Imaging,Middle Aged,Muscle; Skeletal,Obesity,Reproducibility of Results,Tomography; X-Ray Computed}
}

@article{miyamoto12,
  title = {Negative {{Impact}} of {{Skeletal Muscle Loss}} after {{Systemic Chemotherapy}} in {{Patients}} with {{Unresectable Colorectal Cancer}}},
  author = {Miyamoto, Yuji and Baba, Yoshifumi and Sakamoto, Yasuo and Ohuchi, Mayuko and Tokunaga, Ryuma and Kurashige, Junji and Hiyoshi, Yukiharu and Iwagami, Shiro and Yoshida, Naoya and Watanabe, Masayuki and Baba, Hideo},
  year = {2015},
  journal = {PLOS ONE},
  pages = {12},
  abstract = {Background OPEN ACCESS Citation: Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. (2015) Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS ONE 10(6): e0129742. doi:10.1371/journal.pone.0129742 Academic Editor: Akinobu Taketomi, Hokkaido University, JAPAN Received: January 17, 2015 Accepted: May 12, 2015 Skeletal muscle depletion (sarcopenia) is closely associated with limited physical ability and high mortality. This study evaluated the prognostic significance of skeletal muscle status before and after chemotherapy in patients with unresectable colorectal cancer (CRC). Methods We conducted a retrospective analysis of 215 consecutive patients with unresectable CRC who underwent systemic chemotherapy. Skeletal muscle cross-sectional area was measured by computed tomography. We evaluated the prognostic value of skeletal muscle mass before chemotherapy and the rate of skeletal muscle change in cross-sectional area after chemotherapy. Published: June 12, 2015 Copyright: \textcopyright{} 2015 Miyamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: This work was supported by the Japan Society for the Promotion of Science (JSPS) Grantin-Aid for Scientific Research (C), grant number 26462020. Competing Interests: The authors have declared that no competing interests exist. Results One-hundred-eighty-two patients met our inclusion criteria. There were no significant differences in progression-free survival (PFS) or overall survival (OS) associated with skeletal muscle mass before chemotherapy. However, 22 patients with skeletal muscle loss ({$>$}5\%) after chemotherapy showed significantly shorter PFS and OS compared with those without skeletal muscle loss (PFS, log-rank p = 0.029; OS, log-rank p = 0.009). Multivariate Cox regression analysis revealed that skeletal muscle loss after chemotherapy (hazard ratio, 2.079; 95\% confidence interval, 1.194\textendash 3.619; p = 0.010) was independently associated with OS. Conclusions Skeletal muscle loss after chemotherapy was an independent, negative prognostic factor in unresectable CRC.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\HL6QSRIR\\Miyamoto et al. - 2015 - Negative Impact of Skeletal Muscle Loss after Syst.pdf}
}

@article{miyata3053,
  title = {Clinical {{Assessment}} of {{Sarcopenia}} and {{Changes}} in {{Body Composition During Neoadjuvant Chemotherapy}} for {{Esophageal Cancer}}},
  author = {Miyata, Hiroshi and Sugimura, Keijiro and Motoori, Masaaki and Fujiwara, Yoshiyuki and Omori, Takeshi and Yanagimoto, Yoshitomo and Ohue, Masayuki and Yasui, Masayoshi and Miyoshi, Norikatsu and Tomokuni, Akira and Akita, Hirofumi and Kobayashi, Shogo and Takahashi, Hidenori and Yano, Masahiko},
  year = {2017},
  month = jun,
  journal = {Anticancer Research},
  volume = {37},
  number = {6},
  pages = {3053--3059},
  issn = {1791-7530},
  doi = {10.21873/anticanres.11660},
  abstract = {AIM: The aim of this study was to assess changes in body composition during neoadjuvant chemotherapy (NAC) and investigate whether chemotherapy-related toxicities affect body composition in patients with esophageal cancer. PATIENTS AND METHODS: In ninety-four patients who underwent NAC for esophageal cancer, body composition was assessed before and after NAC. Associations between the incidence of toxicities and change in body composition during NAC were investigated. RESULTS: Forty-four (46.8\%) and 50 (53.2\%) out of 94 patients were defined as having sarcopenia before and after NAC, respectively. There was no significant difference in the incidence of any toxicity pre-treatment between patients with sarcopenia and those without sarcopenia. No significant reduction in skeletal muscle mass or fat mass was observed in the patients during NAC (p=0.501 and p=0.072). However, patients who experienced grade 4 neutropenia or febrile neutropenia during NAC showed a significantly larger decrease in change of skeletal muscle mass compared to patients who did not experience those toxicities (p=0.013 and 0.036, respectively). CONCLUSION: The incidence of serious adverse events such as febrile neutropenia and grade 4 neutropenia is associated with a significant reduction of skeletal muscle mass during NAC. We should make an effort to reduce the incidence of adverse events in order to maintain an appropriate body composition during NAC.},
  langid = {english},
  pmid = {28551644},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,bioelectrical impedance analysis,body composition,Body Composition,Carcinoma; Squamous Cell,chemotherapy,Cisplatin,Docetaxel,Doxorubicin,Esophageal cancer,Esophageal Neoplasms,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neutropenia,sarcopenia,Sarcopenia,Taxoids,toxicity},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KSWLZGQI\\Miyata et al_2017_Clinical Assessment of Sarcopenia and Changes in Body Composition During.pdf}
}

@article{mohile2326,
  title = {Practical {{Assessment}} and {{Management}} of {{Vulnerabilities}} in {{Older Patients Receiving Chemotherapy}}: {{ASCO Guideline}} for {{Geriatric Oncology}}},
  shorttitle = {Practical {{Assessment}} and {{Management}} of {{Vulnerabilities}} in {{Older Patients Receiving Chemotherapy}}},
  author = {Mohile, Supriya G. and Dale, William and Somerfield, Mark R. and Schonberg, Mara A. and Boyd, Cynthia M. and Burhenn, Peggy S. and Canin, Beverly and Cohen, Harvey Jay and Holmes, Holly M. and Hopkins, Judith O. and Janelsins, Michelle C. and Khorana, Alok A. and Klepin, Heidi D. and Lichtman, Stuart M. and Mustian, Karen M. and Tew, William P. and Hurria, Arti},
  year = {2018},
  month = aug,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {36},
  number = {22},
  pages = {2326--2347},
  issn = {1527-7755},
  doi = {10.1200/JCO.2018.78.8687},
  abstract = {Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients {$\geq$} 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments. Evidence supports, at a minimum, assessment of function, comorbidity, falls, depression, cognition, and nutrition. The Panel recommends instrumental activities of daily living to assess for function, a thorough history or validated tool to assess comorbidity, a single question for falls, the Geriatric Depression Scale to screen for depression, the Mini-Cog or the Blessed Orientation-Memory-Concentration test to screen for cognitive impairment, and an assessment of unintentional weight loss to evaluate nutrition. Either the CARG (Cancer and Aging Research Group) or CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) tools are recommended to obtain estimates of chemotherapy toxicity risk; the Geriatric-8 or Vulnerable Elders Survey-13 can help to predict mortality. Clinicians should use a validated tool listed at ePrognosis to estimate noncancer-based life expectancy {$\geq$} 4 years. GA results should be applied to develop an integrated and individualized plan that informs cancer management and to identify nononcologic problems amenable to intervention. Collaborating with caregivers is essential to implementing GA-guided interventions. The Panel suggests that clinicians take into account GA results when recommending chemotherapy and that the information be provided to patients and caregivers to guide treatment decision making. Clinicians should implement targeted, GA-guided interventions to manage nononcologic problems. Additional information is available at www.asco.org/supportive-care-guidelines .},
  langid = {english},
  pmcid = {PMC6063790},
  pmid = {29782209},
  keywords = {Age Factors,Aged,Aged; 80 and over,CGA;Elderly;Chemo,Female,Geriatric Assessment,Geriatrics,Humans,Male,Medical Oncology,Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RBILPA9A\\Mohile et al_2018_Practical Assessment and Management of Vulnerabilities in Older Patients.pdf}
}

@article{mojdehbakhsh101059,
  title = {Efficacy and Safety of a Restrictive Blood Transfusion Protocol in Gynecologic Surgical Patients},
  author = {Mojdehbakhsh, Rachel P. and {Al-Rubaye}, Rana and Huang, Dandi S. and Connor, Joseph and {Al-Niaimi}, Ahmed},
  year = {2022},
  month = oct,
  journal = {Gynecologic Oncology Reports},
  volume = {43},
  pages = {101059},
  issn = {2352-5789},
  doi = {10.1016/j.gore.2022.101059},
  abstract = {Objectives: This study sought to compare differences in blood transfusion and surgical complication rates before and after the implementation of a restrictive blood transfusion protocol. Methods: On July 1, 2018, our institution implemented a restrictive blood transfusion protocol utilizing a hemoglobin trigger of less than 7~g/dL. Retrospective chart review was completed to review patients undergoing major abdominal surgery by the gynecology and gynecologic oncology services 18~months before, and after initiation of the transfusion protocol. Outcomes included number of patients, units transfused and postoperative complication rates. Complications included reoperation on the day of admission, surgical site infections, wound disruptions, pulmonary, renal, central nervous system, and cardiovascular complications, as well as deep venous thromboses, readmissions, and 30-day mortality. Results: There were 290 people in the pre- and 449 patients in the post-protocol group. A similar number of patients received blood transfusions in both groups (9.3\% versus 10.6\% p~=~0.57). However, significantly fewer units of blood were given post-protocol initiation. For every patient who received a transfusion pre-protocol, 2.66 units were administered compared to 1.2 units after the protocol was initiated (p~=~0.003). All postoperative complications were not significantly different between groups (p~{$>~$}0.05). Individual postoperative complications were combined and analyzed using a clustered approach to detect rates of complications more conservatively. Both the 7-system (5.1\% versus 4.9\%, p~=~0.90) and 8-system (5.5\% versus 4.9\%, p~=~0.72) clustered analyses were not significantly different before and after the initiation of the transfusion protocol. Conclusions: A restrictive transfusion protocol is effective in decreasing the number of units of blood transfused without affecting postoperative complication rates in gynecologic surgery patients.},
  langid = {english},
  pmcid = {PMC9418048},
  pmid = {36039064},
  keywords = {Gynecologic oncology,Gynecology,GynSurgery,Mortality,Postoperative complications,Restrictive blood transfusion},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CAQHN2W2\\Mojdehbakhsh et al_2022_Efficacy and safety of a restrictive blood transfusion protocol in gynecologic.pdf}
}

@article{morley392,
  type = {Journal {{Article}}},
  title = {Frailty Consensus: A Call to Action},
  author = {Morley, J. E. and Vellas, B. and {van Kan}, G. A. and Anker, S. D. and Bauer, J. M. and Bernabei, R. and Cesari, M. and Chumlea, W. C. and Doehner, W. and Evans, J. and Fried, L. P. and Guralnik, J. M. and Katz, P. R. and Malmstrom, T. K. and McCarter, R. J. and Gutierrez Robledo, L. M. and Rockwood, K. and {von Haehling}, S. and Vandewoude, M. F. and Walston, J.},
  year = {2013},
  journal = {J Am Med Dir Assoc},
  volume = {14},
  number = {6},
  pages = {392--7},
  issn = {1538-9375 (Electronic) 1525-8610 (Linking)},
  doi = {10.1016/j.jamda.2013.03.022}
}

@article{morsbach50,
  title = {Body Composition Evaluation with Computed Tomography: {{Contrast}} Media and Slice Thickness Cause Methodological Errors},
  shorttitle = {Body Composition Evaluation with Computed Tomography},
  author = {Morsbach, Fabian and Zhang, Yi-Hua and Martin, Lena and Lindqvist, Catarina and Brismar, Torkel},
  year = {2019},
  month = mar,
  journal = {Nutrition (Burbank, Los Angeles County, Calif.)},
  volume = {59},
  pages = {50--55},
  issn = {1873-1244},
  doi = {10.1016/j.nut.2018.08.001},
  abstract = {OBJECTIVE: Although computed tomography (CT) is frequently used to determine body composition, the effects of using different CT protocols is not well known. The aim of this study was to determine whether contrast media phase, radiation dose, and slice thickness in CT affect body composition segmentation. METHODS: Clinically indicated perfusion CTs of the upper abdomen in 20 patients (seven women) between 40 and 87 y of age with high suspicion of hepatocellular carcinoma were analyzed retrospectively. Axial images from the L3 level with varying imaging delay were reconstructed after contrast media injection (18 images per patient), slice thickness (5 images, 2-10 mm), and radiation dose (4 images with one-third to four-thirds of standard dose). Muscle and fat areas were segmented semiautomatically by drawing regions of interests and using established cutoff thresholds. Skeletal muscle index (SMI), steatotic muscle area, and adipose tissue index, as well as muscle attenuation and fat attenuation, were evaluated. RESULTS: Average SMI increased by up to 2.8\% after contrast media injection. Steatotic muscle area decreased by {$\leq$}13.8\%, and adipose tissue index decreased by {$\leq$}6.5\%. Muscle attenuation increased after contrast media injection, whereas fat attenuation decreased (all P {$<$} 0.001). SMI decreased by 1.9\% on average when increasing slice thickness from 2 to 10 mm. Steatotic muscle area increased by {$\leq$}3.3\%, and adipose tissue index increased by {$\leq$}1.5\% (all P {$<$} 0.05). Muscle attenuation did not change significantly with reconstruction thickness. Radiation dose had no effect on estimated area of spinal muscle, fatty spinal muscle, or visceral fat. CONCLUSIONS: Contrast media have a strong effect on the evaluation of body composition, whereas the influence of slice thickness is less pronounced. Radiation dose can be reduced by {$\geq$}66\% without significantly affecting segmentation.},
  langid = {english},
  pmid = {30419500},
  keywords = {Adipose Tissue,Adult,Aged,Aged; 80 and over,Body composition,Body Composition,Carcinoma; Hepatocellular,Computed tomography,Contrast,Contrast Media,Diagnostic Errors,Fat,Female,Humans,Liver Neoplasms,Male,Methods,Middle Aged,Muscle,Muscle; Skeletal,Radiation Dosage,Retrospective Studies,Segmentation,Skeletal muscle index,Tomography; X-Ray Computed}
}

@article{mosquera272,
  title = {Impact of Frailty on Surgical Outcomes: {{The}} Right Patient for the Right Procedure},
  shorttitle = {Impact of Frailty on Surgical Outcomes},
  author = {Mosquera, Catalina and Spaniolas, Konstantinos and Fitzgerald, Timothy L.},
  year = {2016},
  month = aug,
  journal = {Surgery},
  volume = {160},
  number = {2},
  pages = {272--280},
  issn = {1532-7361},
  doi = {10.1016/j.surg.2016.04.030},
  abstract = {BACKGROUND: Measuring frailty may improve patient selection for high-risk procedures. METHODS: Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program for patients who underwent elective high-risk operative procedures, and a frailty index was used to classify the patients. RESULTS: Our study analyzed 232,352 patients with a mean age of 65~years; the majority of patients were males (54\%) and white (78\%). The most common procedure was colectomy (41\%), followed by lower extremity bypass (25\%), gastrectomy (8\%), endovascular abdominal aneurism repair (7\%), pancreatectomy (7\%), cardiac operation (6\%), nephrectomy (3\%), and pulmonary resection (2\%). A majority of the patients were classified as mildly frail (34\%), followed by nonfrail (29\%), moderately frail (21\%), and severely frail (15\%). On univariate analysis, age, race, procedure, sex, and frailty scores were associated with complications, prolonged duration of stay, and 30-day mortality (P~{$<~$}.0001). On multivariate analysis, frailty was associated with complications, prolonged duration of stay, and 30-day mortality. Increasing frailty disproportionately impacted mortality; colectomy showed the greatest mortality in severely frail patients (9.36\%), followed by esophagectomy (8.2\%), pulmonary resection (6.4\%), pancreatectomy (5.8\%), cardiac procedures (4.4\%), gastrectomy (4.3\%), nephrectomy (3.32\%), endovascular abdominal aneurism repair (2.49\%), and lower extremity bypass (2.41\%; P~=~.0001). A similar association between duration of stay and morbidity with frailty was noted. CONCLUSION: Frailty has a significant impact on postoperative outcomes that varies with type of procedure.},
  langid = {english},
  pmid = {27267548},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Databases; Factual,Elective Surgical Procedures,Female,Frail Elderly,Frailty,Health Status,Hospital Mortality,Humans,Length of Stay,Male,Middle Aged,Patient Selection,Postoperative Complications,Quality Improvement,Retrospective Studies,Risk Factors,United States,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\77RH7365\\Mosquera et al_2016_Impact of frailty on surgical outcomes.pdf}
}

@article{motz,
  type = {Journal {{Article}}},
  title = {Minimally {{Invasive Ivor Lewis Esophagectomy Without Patient Repositioning}}},
  author = {Motz, B. M. and Lorimer, P. D. and Boselli, D. and Symanowski, J. T. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
  year = {2019},
  journal = {J Gastrointest Surg},
  issn = {1873-4626 (Electronic) 1091-255X (Linking)},
  doi = {10.1007/s11605-018-4063-8}
}

@article{mourtzakis997,
  title = {A Practical and Precise Approach to Quantification of Body Composition in Cancer Patients Using Computed Tomography Images Acquired during Routine Care},
  author = {Mourtzakis, Marina and Prado, Carla M. M. and Lieffers, Jessica R. and Reiman, Tony and McCargar, Linda J. and Baracos, Vickie E.},
  year = {2008},
  month = oct,
  journal = {Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme},
  volume = {33},
  number = {5},
  pages = {997--1006},
  issn = {1715-5312},
  doi = {10.1139/H08-075},
  abstract = {Human body composition is important in numerous cancer research domains. Our objective was to evaluate clinically accessible methods to achieve practical and precise measures of body composition in cancer patients. Dual-energy X-ray absorptiometry (DXA)-based analysis of fat and fat-free mass was performed in 50 cancer patients and compared with bioelectrical impedance analysis (BIA) and with regional computed tomography (CT) images available in the patients' medical records. BIA overestimated or underestimated fat-free mass substantially compared with DXA as the method of reference (up to 9.3 kg difference). Significant changes in fat-free mass over time detected with DXA in a subset of 21 patients (+2.2 +/- 3.2\%/100 days, p = 0.003), was beyond the limits of detection of BIA. Regional analysis of fat and fat-free tissue at the 3rd lumbar vertebra with either DXA or CT strongly predicted whole-body fat and fat-free mass (r = 0.86-0.94; p {$<$} 0.001). CT images provided detail on specific muscles, adipose tissues and organs, not provided by DXA or BIA. CT presents great practical significance due to the prevalence of these images in patient diagnosis and follow-up, thus marrying clinical accessibility with high precision to quantify specific tissues and to predict whole-body composition.},
  langid = {english},
  pmid = {18923576},
  keywords = {Absorptiometry; Photon,Adipose Tissue,Aged,Body Composition,Electric Impedance,Female,Humans,Image Processing; Computer-Assisted,Magnetic Resonance Imaging,Male,Methods,Middle Aged,Muscle; Skeletal,Neoplasms,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FINVIYVE\\Mourtzakis et al_2008_A practical and precise approach to quantification of body composition in.pdf}
}

@article{moyes125,
  type = {Journal {{Article}}},
  title = {Cardiopulmonary Exercise Testing as a Predictor of Complications in Oesophagogastric Cancer Surgery},
  author = {Moyes, L. H. and McCaffer, C. J. and Carter, R. C. and Fullarton, G. M. and Mackay, C. K. and Forshaw, M. J.},
  year = {2013},
  journal = {Ann R Coll Surg Engl},
  volume = {95},
  number = {2},
  pages = {125--30},
  issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
  doi = {10.1308/003588413X13511609954897}
}

@article{mueller983,
  title = {Patient {{Blood Management}}: {{Recommendations From}} the 2018 {{Frankfurt Consensus Conference}}},
  shorttitle = {Patient {{Blood Management}}},
  author = {Mueller, Markus M. and Van Remoortel, Hans and Meybohm, Patrick and Aranko, Kari and Aubron, C{\'e}cile and Burger, Reinhard and Carson, Jeffrey L. and Cichutek, Klaus and De Buck, Emmy and Devine, Dana and Fergusson, Dean and Foll{\'e}a, Gilles and French, Craig and Frey, Kathrine P. and Gammon, Richard and Levy, Jerrold H. and Murphy, Michael F. and Ozier, Yves and Pavenski, Katerina and {So-Osman}, Cynthia and Tiberghien, Pierre and Volmink, Jimmy and Waters, Jonathan H. and Wood, Erica M. and Seifried, Erhard and {ICC PBM Frankfurt 2018 Group}},
  year = {2019},
  month = mar,
  journal = {JAMA},
  volume = {321},
  number = {10},
  pages = {983--997},
  issn = {1538-3598},
  doi = {10.1001/jama.2019.0554},
  abstract = {IMPORTANCE: Blood transfusion is one of the most frequently used therapies worldwide and is associated with benefits, risks, and costs. OBJECTIVE: To develop a set of evidence-based recommendations for patient blood management (PBM) and for research. EVIDENCE REVIEW: The scientific committee developed 17 Population/Intervention/Comparison/Outcome (PICO) questions for red blood cell (RBC) transfusion in adult patients in 3 areas: preoperative anemia (3 questions), RBC transfusion thresholds (11 questions), and implementation of PBM programs (3 questions). These questions guided the literature search in 4 biomedical databases (MEDLINE, EMBASE, Cochrane Library, Transfusion Evidence Library), searched from inception to January 2018. Meta-analyses were conducted with the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology and the Evidence-to-Decision framework by 3 panels including clinical and scientific experts, nurses, patient representatives, and methodologists, to develop clinical recommendations during a consensus conference in Frankfurt/Main, Germany, in April 2018. FINDINGS: From 17\,607 literature citations associated with the 17 PICO questions, 145 studies, including 63 randomized clinical trials with 23\,143 patients and 82 observational studies with more than 4 million patients, were analyzed. For preoperative anemia, 4 clinical and 3 research recommendations were developed, including the strong recommendation to detect and manage anemia sufficiently early before major elective surgery. For RBC transfusion thresholds, 4 clinical and 6 research recommendations were developed, including 2 strong clinical recommendations for critically ill but clinically stable intensive care patients with or without septic shock (recommended threshold for RBC transfusion, hemoglobin concentration {$<$}7 g/dL) as well as for patients undergoing cardiac surgery (recommended threshold for RBC transfusion, hemoglobin concentration {$<$}7.5 g/dL). For implementation of PBM programs, 2 clinical and 3 research recommendations were developed, including recommendations to implement comprehensive PBM programs and to use electronic decision support systems (both conditional recommendations) to improve appropriate RBC utilization. CONCLUSIONS AND RELEVANCE: The 2018 PBM International Consensus Conference defined the current status of the PBM evidence base for practice and research purposes and established 10 clinical recommendations and 12 research recommendations for preoperative anemia, RBC transfusion thresholds for adults, and implementation of PBM programs. The relative paucity of strong evidence to answer many of the PICO questions supports the need for additional research and an international consensus for accepted definitions and hemoglobin thresholds, as well as clinically meaningful end points for multicenter trials.},
  langid = {english},
  pmid = {30860564},
  keywords = {Anemia,Anemia; Iron-Deficiency,Blood Loss; Surgical,Blood Transfusion,Cardiac Surgical Procedures,Critical Care,Erythrocyte Transfusion,Gastrointestinal Hemorrhage,Guidelines,Hematinics,Hemoglobins,Hip Fractures,Humans,Iron,Preoperative Care}
}

@article{mulligan313,
  type = {Journal {{Article}}},
  title = {Margin Involvement and Outcome in Oesophageal Carcinoma: A 10-Year Experience in a Specialist Unit},
  author = {Mulligan, E. D. and Dunne, B. and Griffin, M. and Keeling, N. and Reynolds, J. V.},
  year = {2004},
  journal = {Eur J Surg Oncol},
  volume = {30},
  number = {3},
  pages = {313--7},
  issn = {0748-7983 (Print) 0748-7983 (Linking)},
  doi = {10.1016/j.ejso.2003.11.009}
}

@article{munoz233,
  title = {International Consensus Statement on the Peri-Operative Management of Anaemia and Iron Deficiency},
  author = {Mu{\~n}oz, M. and Acheson, A. G. and Auerbach, M. and Besser, M. and Habler, O. and Kehlet, H. and Liumbruno, G. M. and Lasocki, S. and Meybohm, P. and Rao Baikady, R. and Richards, T. and Shander, A. and {So-Osman}, C. and Spahn, D. R. and Klein, A. A.},
  year = {2017},
  month = feb,
  journal = {Anaesthesia},
  volume = {72},
  number = {2},
  pages = {233--247},
  issn = {1365-2044},
  doi = {10.1111/anae.13773},
  abstract = {Despite current recommendations on the management of pre-operative anaemia, there is no pragmatic guidance for the diagnosis and management of anaemia and iron deficiency in surgical patients. A number of experienced researchers and clinicians took part in an expert workshop and developed the following consensus statement. After presentation of our own research data and local policies and procedures, appropriate relevant literature was reviewed and discussed. We developed a series of best-practice and evidence-based statements to advise on patient care with respect to anaemia and iron deficiency in the peri-operative period. These statements include: a diagnostic approach for anaemia and iron deficiency in surgical patients; identification of patients appropriate for treatment; and advice on practical management and follow-up. We urge anaesthetists and peri-operative physicians to embrace these recommendations, and hospital administrators to enable implementation of these concepts by allocating adequate resources.},
  langid = {english},
  pmid = {27996086},
  keywords = {anaemia,Anemia,Consensus,Guidelines,Health Care Costs,Humans,Injections; Intravenous,iron,Iron,Iron Deficiencies,Perioperative Care,pre-operative assessment,transfusion},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XMZNS5GQ\\MuÃ±oz et al_2017_International consensus statement on the peri-operative management of anaemia.pdf}
}

@article{murnane2295,
  title = {Myosteatosis Predicts Higher Complications and Reduced Overall Survival Following Radical Oesophageal and Gastric Cancer Surgery},
  author = {Murnane, Lisa C. and Forsyth, Adrienne K. and Koukounaras, Jim and Pilgrim, Charles Hc and Shaw, Kalai and Brown, Wendy A. and Mourtzakis, Marina and Tierney, Audrey C. and Burton, Paul R.},
  year = {2021},
  month = sep,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {47},
  number = {9},
  pages = {2295--2303},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2021.02.008},
  abstract = {INTRODUCTION: Low muscle attenuation, as governed by increased intramuscular fat infiltration (myosteatosis), may associate with adverse surgical outcomes. We aimed to determine whether myosteatosis is associated with an increased risk of postoperative complications and reduced long-term survival after oesophago-gastric (OG) cancer surgery. METHODS: Patients who underwent radical OG cancer surgery with preoperative abdominal computed tomography (CT) imaging were included. Myosteatosis was evaluated using previously defined cut-points for low skeletal muscle attenuation measured by CT. Oncological, surgical, complications, and outcome data were obtained from a prospective database. RESULTS: Of 108 patients, 56\% (n\,=\,61) had myosteatosis. Patients with myosteatosis were older (69.1\,{$\pm$}\,9.1 vs. 62.8\,{$\pm$}\,9.8 years, p\,=\,0.001) and had a similar body mass index (BMI) (23.4\,{$\pm$}\,5.3 vs. 25.9\,{$\pm$}\,6.7\,kg/m2, p\,=\,0.766) compared to patients with normal muscle attenuation. Patients with myosteatosis had a higher rate of anastomotic leaks (15\% vs. 2\%, p\,=\,0.041). On multivariate analysis, myosteatosis was an independent predictor of overall (OR 3.03, 95\% CI 1.31-6.99, p\,=\,0.009) and severe complications (OR 4.33, 95\% CI 1.26-14.9, p\,=\,0.020). Patients with myosteatosis had reduced 5 year overall (54.1\% vs. 83\%, p\,=\,0.004) and disease-free (55.2\% vs. 87.2\%, p\,=\,0.007) survival. CONCLUSION: Myosteatosis is associated with a significantly increased risk of overall and severe complications as well as substantially reduced long-term survival. Assessment of muscle attenuation provides analysis beyond standard anthropometrics and may form part of preoperative physiological staging tools used to improve surgical outcomes.},
  langid = {english},
  pmid = {33640171},
  keywords = {Adenocarcinoma,Adipose Tissue,Adiposity,Aged,Anastomotic Leak,Complications,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Gastrectomy,GE,Humans,Length of Stay,Male,Middle Aged,Muscle attenuation,Muscle; Skeletal,Myosteatosis,Postoperative Complications,Preoperative Period,Retrospective Studies,Risk Factors,Stomach Neoplasms,Survival Rate,Tomography; X-Ray Computed}
}

@article{murphydoaa098,
  title = {Exaggerated Postprandial {{GLP-1}} Secretion Following Esophagectomy Is Not Associated with Gastric Emptying and Intestinal Transit},
  author = {Murphy, C. F. and Elliott, J. A. and Docherty, N. G. and Mohamed, A. A. and Vincent, R. P. and Ravi, N. and Reynolds, J. V. and {le Roux}, C. W.},
  year = {2021},
  month = jul,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {34},
  number = {7},
  pages = {doaa098},
  issn = {1442-2050},
  doi = {10.1093/dote/doaa098},
  abstract = {Esophagectomy causes postprandial symptoms associated with an exaggerated postprandial gut hormone response. This study aimed to compare the gastrointestinal transit time of patients 1~year after esophagectomy with unoperated controls, including its relation to satiety gut hormone release. In this cross-sectional study, consecutive, disease-free patients after esophagectomy with pyloroplasty were compared with unoperated control subjects to assess gastric emptying (GE) and cecal arrival time (CAT). Serial plasma samples were collected before, and for 300~minutes after, a mixed-meal challenge. Body composition was assessed, and symptom scores were calculated. Eleven patients 1~year post-esophagectomy (age: 62.6\,{$\pm$}\,9.8, male: 82\%) did not show a significantly different GE pattern compared with 10 control subjects (P\,=\,0.245). Rather, patients could be categorized bimodally as exhibiting either rapid or slow GE relative to controls. Those with rapid GE trended toward a higher postprandial symptom burden (P\,=\,0.084) without higher postprandial glucagon-like peptide-1 (GLP-1) secretion (P\,=\,0.931). CAT was significantly shorter after esophagectomy (P\,=\,0.043) but was not significantly associated with GE, GLP-1 secretion, or symptom burden. Neither early nutrient delivery to the proximal small intestine nor to the colon explains the exaggerated postprandial GLP-1 response after esophagectomy. GE varies significantly in these patients despite consistent pyloric management.},
  langid = {english},
  pmid = {32944747},
  keywords = {Cross-Sectional Studies,enteroendocrine signaling,esophageal cancer surgery,esophagectomy,Esophagectomy,Gastric Emptying,gastrointestinal transit,GLP-1,Glucagon-Like Peptide 1,gut hormones,health-related quality of life,Humans,Male,Postprandial Period,survivorship,weight loss}
}

@article{nagai2995,
  title = {Skeletal {{Muscle Mass Reduction Velocity}} as a {{Simple Prognostic Indicator}} for {{Patients}} with {{Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy}}},
  author = {Nagai, Takashi and Naiki, Taku and Iida, Keitaro and Nozaki, Satoshi and Etani, Toshiki and Sugiyama, Yosuke and Ando, Ryosuke and Yanase, Takahiro and Chaya, Ryosuke and Moritoki, Yoshinobu and Kobayashi, Daichi and Akita, Hidetoshi and Okamura, Takehiko and Yasui, Takahiro},
  year = {2019},
  month = oct,
  journal = {Asian Pacific journal of cancer prevention: APJCP},
  volume = {20},
  number = {10},
  pages = {2995--3000},
  issn = {2476-762X},
  doi = {10.31557/APJCP.2019.20.10.2995},
  abstract = {BACKGROUND: Patients with metastatic urothelial carcinoma (mUC) have an uncertain prognosis. The aim of the current study was to evaluate the prognostic potential of a skeletal muscle mass reduction index measured by computed tomography (CT) for mUC patients undergoing second-line gemcitabine and docetaxel (GD) chemotherapy. METHODS: We retrospectively reviewed 44 patients with mUC who received second-line GD chemotherapy between 2006 and 2015 in our hospital. Skeletal muscle area (SMA) at the third lumbar vertebra was measured using CT images obtained from medical records, and a skeletal muscle index (SMI) was calculated for each patient as: SMI = SMA / height2. Changes in SMI across timepoints (SMI inclination) were calculated as: SMI inclination = [( SMI/SMI)/duration of the interval between imaging visits]. Patients were then divided into two groups: a "steep" group (SMI inclination {$<$} -0.01) and a "gentle" group (SMI inclination {$\geq$} -0.01). Kaplan-Meier curves and multivariate Cox proportional hazards regression models were used to evaluate the relationship between SMI inclination and overall survival (OS). RESULTS: There were no differences in patient characteristics between the two groups with respect to median age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), disease control rate or first-line treatment regimen. OS from the start of second-line GD therapy group was significantly shorter in the "steep" group relative to the "gentle" group. The multivariate analysis revealed that "steep" SMI inclination and presence of anemia were strong predictors of poor prognosis. CONCLUSION: Higher values of SMI inclination, indicating a faster rate of skeletal muscle mass reduction, may serve as a useful predictive marker for OS in mUC patients undergoing second-line GD chemotherapy.},
  langid = {english},
  pmcid = {PMC6982681},
  pmid = {31653146},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Transitional Cell,Deoxycytidine,Docetaxel,Female,Follow-Up Studies,Humans,Male,metastatic urothelial carcinoma,Methods,Middle Aged,Muscle; Skeletal,Prognosis,Prognostic factor,Retrospective Studies,sarcopenia,Sarcopenia,second-line chemotherapy,skeletal mass index,Survival Rate,Urologic Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\M3CU2EJN\\Nagai et al. - 2019 - Skeletal Muscle Mass Reduction Velocity as a Simpl.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\SU3RZQZU\\Nagai et al. - Skeletal Muscle Mass Reduction Velocity as a Simpl.pdf}
}

@article{nagamatsu1064,
  type = {Journal {{Article}}},
  title = {Preoperative Evaluation of Cardiopulmonary Reserve with the Use of Expired Gas Analysis during Exercise Testing in Patients with Squamous Cell Carcinoma of the Thoracic Esophagus},
  author = {Nagamatsu, Y. and Shima, I. and Yamana, H. and Fujita, H. and Shirouzu, K. and Ishitake, T.},
  year = {2001},
  journal = {J Thorac Cardiovasc Surg},
  volume = {121},
  number = {6},
  pages = {1064--8},
  issn = {0022-5223 (Print) 0022-5223 (Linking)},
  doi = {10.1067/mtc.2001.113596}
}

@article{nagpal1621,
  title = {Is Minimally Invasive Surgery Beneficial in the Management of Esophageal Cancer? {{A}} Meta-Analysis},
  shorttitle = {Is Minimally Invasive Surgery Beneficial in the Management of Esophageal Cancer?},
  author = {Nagpal, Kamal and Ahmed, Kamran and Vats, Amit and Yakoub, Danny and James, David and Ashrafian, Hutan and Darzi, Ara and Moorthy, Krishna and Athanasiou, Thanos},
  year = {2010},
  month = jul,
  journal = {Surgical Endoscopy},
  volume = {24},
  number = {7},
  pages = {1621--1629},
  issn = {1432-2218},
  doi = {10.1007/s00464-009-0822-7},
  abstract = {INTRODUCTION: Open esophagectomy for cancer is a major oncological procedure, associated with significant morbidity and mortality. Recently, thoracoscopic procedures have offered a potentially advantageous alternative because of less operative trauma compared with thoracotomy. The aim of this study was to utilize meta-analysis to compare outcomes of open esophagectomy with those of minimally invasive esophagectomy (MIE) and hybrid minimally invasive esophagectomy (HMIE). METHODS: Literature search was performed using Medline, Embase, Cochrane Library, and Google Scholar databases for comparative studies assessing different techniques of esophagectomy. A random-effects model was used for meta-analysis, and heterogeneity was assessed. Primary outcomes of interest were 30-day mortality and anastomotic leak. Secondary outcomes included operative outcomes, other postoperative outcomes, and oncological outcomes in terms of lymph nodes retrieved. RESULTS: A total of 12 studies were included in the analysis. Studies included a total of 672 patients for MIE and HMIE, and 612 for open esophagectomy. There was no significant difference in 30-day mortality; however, MIE had lower blood loss, shorter hospital stay, and reduced total morbidity and respiratory complications. For all other outcomes, there was no significant difference between the two groups. CONCLUSION: Minimally invasive esophagectomy is a safe alternative to the open technique. Patients undergoing MIE may benefit from shorter hospital stay, and lower respiratory complications and total morbidity compared with open esophagectomy. Multicenter, prospective large randomized controlled trials are required to confirm these findings in order to base practice on sound clinical evidence.},
  langid = {english},
  pmid = {20108155},
  keywords = {Aged,Esophageal Neoplasms,Esophagectomy,Female,Humans,Laparoscopy,Male,Middle Aged,Minimally Invasive Surgical Procedures,Thoracoscopy}
}

@article{nagtegaal303,
  title = {What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?},
  author = {Nagtegaal, Iris D. and Quirke, Phil},
  year = {2008},
  month = jan,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {26},
  number = {2},
  pages = {303--312},
  issn = {1527-7755},
  doi = {10.1200/JCO.2007.12.7027},
  abstract = {PURPOSE: Treatment of rectal cancer has changed dramatically over the last decade. The worldwide introduction of total mesorectal excision in combination with the increasing use of radio(chemo)-therapy has led to an improved prognosis. One of the main prognostic factors in rectal cancer is the circumferential resection margin (CRM). Since the initial description of its clinical importance in 1986, the involvement of this margin (also called lateral or radial resection margin) has been associated with a poor prognosis. METHODS: In the current review, the evidence for the importance of the CRM in more than 17,500 patients is reviewed, and the relevance of this assessment to modern treatment is assessed. RESULTS: We demonstrate that, after neoadjuvant therapy (both radiotherapy and radiochemotherapy), the predictive value of the CRM for local recurrence is significantly higher than when no preoperative therapy has been applied (hazard ratio [HR] = 6.3 v 2.0, respectively; P {$<$} .05). Furthermore, involvement of the CRM is a powerful predictor of both development of distant metastases (HR = 2.8; 95\% CI, 1.9 to 4.3) and survival (HR = 1.7; 95\% CI, 1.3 to 2.3). In addition to the prognostic data, this review describes different modes of margin involvement, exact definitions, and factors influencing its presence. CONCLUSION: CRM involvement is one of the key factors in rectal cancer treatment.},
  langid = {english},
  pmid = {18182672},
  keywords = {Chemotherapy; Adjuvant,Combined Modality Therapy,Humans,Laparoscopy,Logistic Models,Neoadjuvant Therapy,Neoplasm Metastasis,Neoplasm Recurrence; Local,Neoplasm Staging,Neoplasm; Residual,Prognosis,Radiotherapy; Adjuvant,Rectal Neoplasms,Survival Rate}
}

@article{nakajo10,
  title = {Texture Analysis of {{18F-FDG PET}}/{{CT}} to Predict Tumour Response and Prognosis of Patients with Esophageal Cancer Treated by Chemoradiotherapy},
  author = {Nakajo, Masatoyo},
  year = {2017},
  journal = {Eur J Nucl Med Mol Imaging},
  pages = {10},
  abstract = {Purpose This retrospective study was done to examine whether the heterogeneity in primary tumour F-18fluorodeoxyglucose (18F-FDG) distribution can predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy (CRT).},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZPPWMRID\\Nakajo - 2017 - Texture analysis of 18F-FDG PETCT to predict tumo.pdf}
}

@article{nakashima1100,
  title = {Assessment of {{Sarcopenia}} as a {{Predictor}} of {{Poor Outcomes After Esophagectomy}} in {{Elderly Patients With Esophageal Cancer}}},
  author = {Nakashima, Yuichiro and Saeki, Hiroshi and Nakanishi, Ryota and Sugiyama, Masahiko and Kurashige, Junji and Oki, Eiji and Maehara, Yoshihiko},
  year = {2018},
  month = jun,
  journal = {Annals of Surgery},
  volume = {267},
  number = {6},
  pages = {1100--1104},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002252},
  abstract = {OBJECTIVE: The objective of the study was to elucidate the impact of sarcopenia in elderly patients with esophageal cancer on postoperative complications and long-term survival after surgery for esophageal cancer. SUMMARY BACKGROUND DATA: Sarcopenia, defined as loss of skeletal muscle mass with age, has been identified as a poor prognostic factor for malignancies. This retrospective study investigated the effect of sarcopenia on surgical outcomes among young and elderly patients with esophageal cancer. METHODS: Data were collected for 341 consecutive patients who underwent esophagectomy for esophageal cancer. Patients were assigned to 2 groups according to age (younger than 65 years and 65 years or older) and the presence of sarcopenia. RESULTS: Sarcopenia was present in 170 of 341 patients (49.9\%) with esophageal cancer and in 74 of 166 elderly patients (44.6\%). The incidence of anastomotic leak and in-hospital death was significantly higher in the elderly sarcopenia group than in the elderly nonsarcopenia group (31.5\% vs 15.2\%, P = 0.015, 6.8 vs 0.0\%, P = 0.037, respectively), and the overall survival rate in patients with sarcopenia correlated with a significantly poor prognosis in the elderly group (P {$<$} 0.001). Multivariate analysis revealed that sarcopenia was a risk factor for an anastomotic leak (P = 0.034) and was an unfavorable prognostic factor for survival (P {$<$} 0.001). Those correlations between sarcopenia and surgical outcomes were not observed in the young group. CONCLUSIONS: Sarcopenia and worse surgical outcomes were significantly associated patients with in esophageal cancer aged 65 years and older but not in those younger than 65 years.},
  langid = {english},
  pmid = {28437312},
  keywords = {Age Factors,Aged,Anastomotic Leak,Esophageal Neoplasms,Esophagectomy,Female,Hospital Mortality,Humans,Male,Middle Aged,Postoperative Complications,Prognosis,Retrospective Studies,Risk Factors,Sarcopenia,Survival Rate}
}

@article{nakashima492,
  title = {Skeletal {{Muscle Loss After Esophagectomy Is}} an {{Independent Risk Factor}} for {{Patients}} with {{Esophageal Cancer}}},
  author = {Nakashima, Yuichiro and Saeki, Hiroshi and Hu, Qingjiang and Tsuda, Yasuo and Zaitsu, Yoko and Hisamatsu, Yuichi and Ando, Koji and Kimura, Yasue and Oki, Eiji and Mori, Masaki},
  year = {2020},
  month = feb,
  journal = {Annals of Surgical Oncology},
  volume = {27},
  number = {2},
  pages = {492--498},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07850-6},
  abstract = {BACKGROUND: Postoperative changes in skeletal muscle and their influence on outcomes after esophagectomy for patients with esophageal cancer have not been fully investigated. This study aimed to confirm that postoperative skeletal muscle decrease influences long-term patient outcomes. METHODS: Data were collected from 218 patients who underwent curative esophagectomy for esophageal cancer whose data were available before and 6~months after surgery. The skeletal muscle index (SMI) was measured at the level of the L3 vertebrae, and the postoperative change in the SMI compared with preoperative values was calculated as the delta SMI. RESULTS: The mean SMI value was -\,11.64\%, and the median delta SMI value was -\,11.88\%. The first and third quartiles were defined as cutoffs, and 218 patients were classified as the mild-loss group (54 patients), moderate-loss group (110 patients), and severe-loss group (54 patients). The patients with a more severely reduced SMI had a worse prognosis (5-year overall survival rates: mild loss, 66.6\%; moderate loss, 58.8\%; and severe loss, 48.5\%; p\,=\,0.0314). This correlation between reduced SMI and prognosis also was observed for the patients with preoperative sarcopenia (p\,{$<$}\,0.0001), but not for those without preoperative sarcopenia. CONCLUSIONS: Postoperative reduced SMI and worse prognosis were significantly associated in esophageal cancer patients.},
  langid = {english},
  pmid = {31549319},
  keywords = {Adenocarcinoma,Aged,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Female,Follow-Up Studies,GE,Humans,Male,Middle Aged,Muscle; Skeletal,Neoplasm Recurrence; Local,Postoperative Complications,Prognosis,Retrospective Studies,Risk Factors,Sarcopenia,Survival Rate}
}

@article{nakata7,
  title = {Outcomes of {{Cervical End-to-Side Triangulating Esophagogastric Anastomosis}} with {{Minimally Invasive Esophagectomy}}},
  author = {Nakata, Kohei and Nagai, Eishi and Ohuchida, Kenoki and Nakamura, Katsuya and Tanaka, Masao},
  year = {2015},
  journal = {World J Surg},
  pages = {7},
  abstract = {Background Esophagogastric anastomosis after esophagectomy has been performed with a variety of techniques during the past decade. However, anastomotic leakage and stricture are still important clinical problems after esophagogastric anastomosis, causing burdensome symptoms and poor quality of life. Herein, we describe a novel cervical end-to-side triangulating esophagogastric anastomoasis using linear stapler. Methods A total of 90 patients (85 \% male; mean age 63 years) with thoracic esophageal cancer who underwent cervical end-to-side esophagogastric triangular anastomosis using a linear stapler after minimally invasive esophagectomy between November 2006 and April 2013 were retrospectively reviewed. Results The median operation time was 602 min (range 424\textendash 936 min). The volume of blood loss during the entire operative procedure was 127 ml (range 0\textendash 700 ml). There were no cases of anastomotic leakage in this study, although four patients (4.4 \%) developed dysphagia associated with benign anastomotic stricture formation. All patients with a benign anastomotic stricture underwent balloon dilation, which resulted in improvement in their symptoms. Conclusions Considering the absence of anastomotic leakage and low rate of anastomotic stricture formation in this study, our modified triangular esophagogastric anastomosis technique appears promising and may contribute to reduced morbidity and mortality rates following esophagectomy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MJS25W4S\\Nakata et al. - 2015 - Outcomes of Cervical End-to-Side Triangulating Eso.pdf}
}

@article{nanson340,
  type = {Journal {{Article}}},
  title = {Synchronous Combined Abdomino- Thoraco-Cervical (Oesophagectomy)},
  author = {Nanson, E. M.},
  year = {1975},
  journal = {Aust N Z J Surg},
  volume = {45},
  number = {4},
  pages = {340--8},
  issn = {0004-8682 (Print) 0004-8682 (Linking)}
}

@article{narita52,
  title = {Establishment and Validation of Prognostic Nomograms in First-Line Metastatic Gastric Cancer Patients},
  author = {Narita, Yukiya and Kadowaki, Shigenori and Oze, Isao and Kito, Yosuke and Kawakami, Takeshi and Machida, Nozomu and Taniguchi, Hiroya and Ura, Takashi and Ando, Masashi and Ito, Seiji and Tajika, Masahiro and Yatabe, Yasushi and Yasui, Hirofumi and Muro, Kei},
  year = {2018},
  month = feb,
  journal = {Journal of Gastrointestinal Oncology},
  volume = {9},
  number = {1},
  pages = {52--63},
  issn = {2078-6891},
  doi = {10.21037/jgo.2017.11.08},
  abstract = {Background It remains unclear whether human epidermal growth factor receptor 2 (HER2) status is an outcome-associated biomarker independent of known prognostic factors for metastatic gastric cancer. Moreover, there are few reports about nomograms in inoperable locally advanced or metastatic gastric cancer (AGC), although several studies have been reported regarding other cancer types. This retrospective study aimed to develop nomograms that combine HER2 status and other prognostic factors to predict the survival outcomes of AGC patients starting first-line treatment. Methods In this study, 838 consecutive AGC patients starting first-line chemotherapy at the Aichi Cancer Center Hospital (ACC) were included to establish the nomograms that calculated the predicted probability of survival at different time points, 6 months and 1 and 2 years for overall survival (OS) and 3 and 6 months, and 1 year for progression free survival (PFS). Nomograms were independently validated with 269 consecutive AGC patients at the Cancer Center Hospital (SCC) who underwent first-line chemotherapy. The discriminatory ability and accuracy of the models were assessed using Harrell's c-index. IHC3+ or IHC2+/ISH+ tumors were defined as HER2 positive. Results At a median follow-up of 12.3 (ACC) and 11.6 (SCC) months, the median OS was 12.5 and 12.4 months (P=1.00), and the median PFS was 4.8 and 5.8 months (P=0.03), respectively. The nomograms showed good C-index values: OS was respectively 0.688 and 0.576 and PFS was respectively for 0.643 and 0.544. Conclusions The nomograms including HER2 status as covariate are crucial determinants of clinical care.},
  pmcid = {PMC5848026},
  pmid = {29564171},
  keywords = {Stage4},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4HMEJ8Y2\\Narita et al. - 2018 - Establishment and validation of prognostic nomogra.pdf}
}

@article{nattenmueller4131,
  title = {{{CT-based}} Compartmental Quantification of Adipose Tissue versus Body Metrics in Colorectal Cancer Patients},
  author = {Nattenmueller, Johanna and Hoegenauer, Hanna and Boehm, Juergen and Scherer, Dominique and Paskow, Michael and Gigic, Biljana and {Schrotz-King}, Petra and Grenacher, Lars and Ulrich, Cornelia and Kauczor, Hans-Ulrich},
  year = {2016},
  month = nov,
  journal = {European Radiology},
  volume = {26},
  number = {11},
  pages = {4131--4140},
  issn = {1432-1084},
  doi = {10.1007/s00330-016-4231-8},
  abstract = {PURPOSE: While obesity is considered a prognostic factor in colorectal cancer (CRC), there is increasing evidence that not simply body mass index (BMI) alone but specifically abdominal fat distribution is what matters. As part of the ColoCare study, this study measured the distribution of adipose tissue compartments in CRC patients and aimed to identify the body metric that best correlates with these measurements as a useful proxy for adipose tissue distribution. MATERIALS AND METHODS: In 120 newly-diagnosed CRC patients who underwent multidetector computed tomography (CT), densitometric quantification of total (TFA), visceral (VFA), intraperitoneal (IFA), retroperitoneal (RFA), and subcutaneous fat area (SFA), as well as the M. erector spinae and psoas was performed to test the association with gender, age, tumor stage, metabolic equivalents, BMI, waist-to-height (WHtR) and waist-to-hip ratio (WHR). RESULTS: VFA was 28.8 \% higher in men (pVFA{$<$}0.0001) and 30.5 \% higher in patients older than 61 years (pVFA{$<$}0.0001). WHtR correlated best with all adipose tissue compartments (rVFA=0.69, rTFA=0.84, p{$<$}0.0001) and visceral-to-subcutaneous-fat-ratio (VFR, rVFR=0.22, p={$<$}0.05). Patients with tumor stages III/IV showed significantly lower overall adipose tissue than I/II. Increased M. erector spinae mass was inversely correlated with all compartments. CONCLUSION: Densitometric quantification on CT is a highly reproducible and reliable method to show fat distribution across adipose tissue compartments. This distribution might be best reflected by WHtR, rather than by BMI or WHR. KEY POINTS: \textbullet{} Densitometric quantification of adipose tissue on CT is highly reproducible and reliable. \textbullet{} Waist-to-height ratio better correlates with adipose tissue compartments and VFR than BMI or waist-to-hip ratio. \textbullet{} Men have higher a higher visceral fat area than women. \textbullet{} Patients older than 61 years have higher visceral fat area. \textbullet{} Patients with tumor stages III/IV have significantly lower adipose tissue than those in stages I/II.},
  langid = {english},
  pmcid = {PMC5587125},
  pmid = {26852215},
  keywords = {Abdominal Fat,Adipose Tissue,Adult,Aged,Body mass index,Body Mass Index,Colorectal neoplasms,Colorectal Neoplasms,Female,Humans,Intra-Abdominal Fat,Male,Methods,Middle Aged,Multidetector computed tomography,Multidetector Computed Tomography,Obesity,Subcutaneous Fat,Tomography; X-Ray Computed,Waist-Hip Ratio,Waist-to-height ratio},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\J3PKC9MC\\Nattenmueller et al. - 2016 - CT-based compartmental quantification of adipose t.pdf}
}

@article{nelson1092,
  title = {Implementation of {{Enhanced Recovery After Surgery}} ({{ERAS}}) {{Across}} a {{Provincial Healthcare System}}: {{The ERAS Alberta Colorectal Surgery Experience}}},
  shorttitle = {Implementation of {{Enhanced Recovery After Surgery}} ({{ERAS}}) {{Across}} a {{Provincial Healthcare System}}},
  author = {Nelson, Gregg and Kiyang, Lawrence N. and Crumley, Ellen T. and Chuck, Anderson and Nguyen, Thanh and Faris, Peter and Wasylak, Tracy and {Basualdo-Hammond}, Carlota and McKay, Susan and Ljungqvist, Olle and Gramlich, Leah M.},
  year = {2016},
  month = may,
  journal = {World Journal of Surgery},
  volume = {40},
  number = {5},
  pages = {1092--1103},
  issn = {1432-2323},
  doi = {10.1007/s00268-016-3472-7},
  abstract = {BACKGROUND: Enhanced recovery after surgery (ERAS) colorectal guideline implementation has occurred primarily in standalone institutions worldwide. We implemented the guideline in a single provincial healthcare system, and our study examined the effect of the guideline on patient outcomes [length of stay (LOS), complications, and 30-day post-discharge readmissions] across a healthcare system. METHODS: We compared pre- and post-guideline implementation in consecutive elective colorectal patients, {$\geq$} 18 years, from six Alberta hospitals between February 2013 and December 2014. Participants were followed up to 30 days post discharge. We used summary statistics, to assess the LOS and complications, and multivariate regression methods to assess readmissions and to estimate cost impacts. RESULTS: A total of 1333 patients (350 pre- and 983 post-ERAS) were analysed. Of this number, 55 \% were males. Median overall guideline compliance was 39 \% in pre- and 60 \% in post-ERAS patients. Median LOS was 6 days for pre-ERAS compared to 4.5 days in post-ERAS patients with the longest implementation (p value {$<$}0.0001). Adjusted risk ratio (RR) was 1.71, 95 \% CI 1.09-2.68 for 30-day readmission, comparing pre- to post-ERAS patients. The proportion of patients who developed at least one complication was significantly reduced, from pre- to post-ERAS, difference in proportions = 11.7 \%, 95 \% CI 2.5-21.0, p value: 0.0139. The net cost savings attributable to guideline implementation ranged between \$2806 and \$5898 USD per patient. CONCLUSION: The findings in our study have shown that ERAS colorectal guideline implementation within a healthcare system resulted in patient outcome improvements, similar to those obtained in smaller standalone implementations. There was a significant beneficial impact of ERAS on scarce health system resources.},
  langid = {english},
  pmid = {26928854},
  keywords = {Aged,Alberta,Clinical Protocols,Colon,ERAS,Female,Guideline Adherence,Humans,Length of Stay,Male,Middle Aged,Patient Readmission,Perioperative Care,Postoperative Complications,Rectum}
}

@article{neto272,
  title = {Association between Driving Pressure and Development of Postoperative Pulmonary Complications in Patients Undergoing Mechanical Ventilation for General Anaesthesia: A Meta-Analysis of Individual Patient Data},
  shorttitle = {Association between Driving Pressure and Development of Postoperative Pulmonary Complications in Patients Undergoing Mechanical Ventilation for General Anaesthesia},
  author = {Neto, Ary Serpa and Hemmes, Sabrine N. T. and Barbas, Carmen S. V. and Beiderlinden, Martin and {Fernandez-Bustamante}, Ana and Futier, Emmanuel and Gajic, Ognjen and {El-Tahan}, Mohamed R. and Ghamdi, Abdulmohsin A. Al and G{\"u}nay, Ersin and Jaber, Samir and Kokulu, Serdar and Kozian, Alf and Licker, Marc and Lin, Wen-Qian and Maslow, Andrew D. and Memtsoudis, Stavros G. and Reis Miranda, Dinis and Moine, Pierre and Ng, Thomas and Paparella, Domenico and Ranieri, V. Marco and Scavonetto, Federica and Schilling, Thomas and Selmo, Gabriele and Severgnini, Paolo and Sprung, Juraj and Sundar, Sugantha and Talmor, Daniel and Treschan, Tanja and Unzueta, Carmen and Weingarten, Toby N. and Wolthuis, Esther K. and Wrigge, Hermann and Amato, Marcelo B. P. and Costa, Eduardo L. V. and {de Abreu}, Marcelo Gama and Pelosi, Paolo and Schultz, Marcus J. and {PROVE Network Investigators}},
  year = {2016},
  month = apr,
  journal = {The Lancet. Respiratory Medicine},
  volume = {4},
  number = {4},
  pages = {272--280},
  issn = {2213-2619},
  doi = {10.1016/S2213-2600(16)00057-6},
  abstract = {BACKGROUND: Protective mechanical ventilation strategies using low tidal volume or high levels of positive end-expiratory pressure (PEEP) improve outcomes for patients who have had surgery. The role of the driving pressure, which is the difference between the plateau pressure and the level of positive end-expiratory pressure is not known. We investigated the association of tidal volume, the level of PEEP, and driving pressure during intraoperative ventilation with the development of postoperative pulmonary complications. METHODS: We did a meta-analysis of individual patient data from randomised controlled trials of protective ventilation during general anesthaesia for surgery published up to July 30, 2015. The main outcome was development of postoperative pulmonary complications (postoperative lung injury, pulmonary infection, or barotrauma). FINDINGS: We included data from 17 randomised controlled trials, including 2250 patients. Multivariate analysis suggested that driving pressure was associated with the development of postoperative pulmonary complications (odds ratio [OR] for one unit increase of driving pressure 1{$\cdot$}16, 95\% CI 1{$\cdot$}13-1{$\cdot$}19; p{$<$}0{$\cdot$}0001), whereas we detected no association for tidal volume (1{$\cdot$}05, 0{$\cdot$}98-1{$\cdot$}13; p=0{$\cdot$}179). PEEP did not have a large enough effect in univariate analysis to warrant inclusion in the multivariate analysis. In a mediator analysis, driving pressure was the only significant mediator of the effects of protective ventilation on development of pulmonary complications (p=0{$\cdot$}027). In two studies that compared low with high PEEP during low tidal volume ventilation, an increase in the level of PEEP that resulted in an increase in driving pressure was associated with more postoperative pulmonary complications (OR 3{$\cdot$}11, 95\% CI 1{$\cdot$}39-6{$\cdot$}96; p=0{$\cdot$}006). INTERPRETATION: In patients having surgery, intraoperative high driving pressure and changes in the level of PEEP that result in an increase of driving pressure are associated with more postoperative pulmonary complications. However, a randomised controlled trial comparing ventilation based on driving pressure with usual care is needed to confirm these findings. FUNDING: None.},
  langid = {english},
  pmid = {26947624},
  keywords = {Adult,Aged,Anesthesia; General,Female,Humans,Intraoperative Period,Lung Diseases,Male,Middle Aged,Positive-Pressure Respiration,Postoperative Complications,Randomized Controlled Trials as Topic,Tidal Volume},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2TY49VEY\\Neto et al_2016_Association between driving pressure and development of postoperative pulmonary.pdf}
}

@article{newman6,
  title = {Strength, {{But Not Muscle Mass}}, {{Is Associated With Mortality}} in the {{Health}}, {{Aging}} and {{Body Composition Study Cohort}}},
  author = {Newman, Anne B and Kupelian, Varant and Visser, Marjolein and Simonsick, Eleanor M and Goodpaster, Bret H and Kritchevsky, Stephen B and Tylavsky, Frances A and Rubin, Susan M and Harris, Tamara B},
  pages = {6},
  abstract = {Background. Although muscle strength and mass are highly correlated, the relationship between direct measures of low muscle mass (sarcopenia) and strength in association with mortality has not been examined. Methods. Total mortality rates were examined in the Health, Aging and Body Composition (Health ABC) Study in 2292 participants (aged 70\textendash 79 years, 51.6\% women, and 38.8\% black). Knee extension strength was measured with isokinetic dynamometry, grip strength with isometric dynamometry. Thigh muscle area was measured by computed tomography (CT) scan, and leg and arm lean soft tissue mass were determined by dual energy x-ray absorptiometry (DXA). Both strength and muscle size were assessed as in gender-specific Cox proportional hazards models, with age, race, comorbidities, smoking status, level of physical activity, fat area by CT or fat mass by DXA, height, and markers of inflammation, including interleukin-6, C-reactive protein, and tumor necrosis factor-a considered as potential confounders. Results. There were 286 deaths over an average of 4.9 (standard deviation {$\frac{1}{4}$} 0.9) years of follow-up. Both quadriceps and grip strength were strongly related to mortality. For quadriceps strength (per standard deviation of 38 Nm), the crude hazard ratio for men was 1.51 (95\% confidence interval, 1.28\textendash 1.79) and 1.65 (95\% confidence interval, 1.19\textendash 2.30) for women. Muscle size, determined by either CT area or DXA regional lean mass, was not strongly related to mortality. In the models of quadriceps strength and mortality, adjustment for muscle area or regional lean mass only slightly attenuated the associations. Further adjustment for other factors also had minimal effect on the association of quadriceps strength with mortality. Associations of grip strength with mortality were similar. Conclusion. Low muscle mass did not explain the strong association of strength with mortality, demonstrating that muscle strength as a marker of muscle quality is more important than quantity in estimating mortality risk. Grip strength provided risk estimates similar to those of quadriceps strength.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UIIHSED4\\Newman et al. - Strength, But Not Muscle Mass, Is Associated With .pdf}
}

@article{ngCD011588,
  title = {Iron Therapy for Pre-Operative Anaemia},
  author = {Ng, Oliver and Keeler, Barrie D. and Mishra, Amitabh and Simpson, Alastair and Neal, Keith and Brookes, Matthew J. and Acheson, Austin G.},
  year = {2015},
  month = dec,
  journal = {The Cochrane Database of Systematic Reviews},
  number = {12},
  pages = {CD011588},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD011588.pub2},
  abstract = {BACKGROUND: Pre-operative anaemia is common and occurs in up to 76\% of patients. It is associated with increased peri-operative allogeneic blood transfusions, longer hospital lengths of stay and increased morbidity and mortality. Iron deficiency is one of the most common causes of this anaemia. Oral iron therapy has traditionally been used to treat anaemia but newer, safer parenteral iron preparations have been shown to be more effective in other conditions such as inflammatory bowel disease, chronic heart failure and post-partum haemorrhage. A limited number of studies look at iron therapy for the treatment of pre-operative anaemia. The aim of this Cochrane review is to summarise the evidence for use of iron supplementation, both enteral and parenteral, for the management of pre-operative anaemia. OBJECTIVES: The objective of this review is to evaluate the effects of pre-operative iron therapy (enteral or parenteral) in reducing the need for allogeneic blood transfusions in anaemic patients undergoing surgery. SEARCH METHODS: We ran the search on 25 March 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process \& Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R), EMBASE Classic and EMBASE (Ovid), CINAHL Plus (EBSCO), PubMed, clinical trials registries, conference abstracts, and we screened reference lists. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) which compared pre-operative iron monotherapy to placebo, no treatment, standard of care or another form of iron therapy for anaemic adults undergoing surgery. Anaemia was defined by haemoglobin values less than 13 g/dL for males and 12 g/dL for non-pregnant females. DATA COLLECTION AND ANALYSIS: Data were collected by two authors on the proportion of patients who receive a blood transfusion, amount of blood transfused per patient (units) and haemoglobin measured as continuous variables at pre-determined time-points: pre-treatment, pre-operatively but post-treatment, and post-operatively. Statistical analysis was performed using the Cochrane statistical software, Review Manager 2014. Outcome data were summarised in tables and a forest plot. MAIN RESULTS: Three prospective randomised controlled studies evaluated pre-operative iron therapy to correct anaemia (two in colorectal and one in gynaecological surgery) and included 114 patients in total. One compared oral iron versus standard care (Lidder 2007); one intravenous iron versus control (Edwards 2009); and one study compared oral versus intravenous iron (Kim 2009). Both colorectal trials reported the primary outcome (proportion of patients who received allogeneic blood transfusions) and meta-analysis showed a reduction in blood transfusions with the administration of iron therapy, but the reduction was not statistically significant (risk ratio (RR) 0.56, 95\% confidence interval (CI) 0.27 to 1.18). All studies reported haemoglobin change but data for the anaemic patients were only available for two studies (Edwards 2009 and Kim 2009). Edwards 2009 showed no difference in haemoglobin at the end of treatment pre-operatively. The intravenous versus oral iron study showed an increase in haemoglobin with intravenous iron at the end of treatment pre-operatively (MD 1.90 g/dL, 95\% CI 1.16 to 2.64; participants = 56), but the results are at high risk of bias because participants with less than 80\% compliance with therapy were excluded from the analysis and compliance was lower in the oral iron group due to the side-effects of treatment (Kim 2009).None of the studies reported quality of life, short- or long-term mortality or post-operative morbidity. AUTHORS' CONCLUSIONS: The use of iron therapy for pre-operative anaemia does not show a statistically significant reduction in the proportion of patients who received an allogeneic blood transfusion compared to no iron therapy. However, the 38 patients in our analysis falls far short of the 819 patients our information size calculation recommended to detect a 30\% reduction in blood transfusions. Intravenous iron may be more effective than oral iron at increasing haemoglobin. However, all these conclusions are drawn from only three small randomised controlled studies. Further well designed, adequately powered randomised controlled studies are required to determine the true effectiveness of iron therapy for pre-operative anaemia.},
  langid = {english},
  pmid = {26694949},
  keywords = {Administration; Oral,Adult,Anemia,Blood Transfusion,Ferritins,Hematocrit,Hemoglobin A,Humans,Injections; Intravenous,Iron,Preoperative Care,Randomized Controlled Trials as Topic,Reticulocyte Count,Surgery,Surgical Procedures; Operative},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VBHAEZDZ\\Ng et al_2015_Iron therapy for pre-operative anaemia.pdf}
}

@article{nguyen253,
  type = {Journal {{Article}}},
  title = {Minimally Invasive Intrathoracic Esophagogastric Anastomosis: Circular Stapler Technique with Transoral Placement of the Anvil},
  author = {Nguyen, N. T. and Nguyen, X. M. and Masoomi, H.},
  year = {2010},
  journal = {Semin Thorac Cardiovasc Surg},
  volume = {22},
  number = {3},
  pages = {253--5},
  issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
  doi = {10.1053/j.semtcvs.2010.10.012}
}

@article{niels1812,
  title = {Does {{VO2peak Provide}} a {{Prognostic Value}} in {{Esophagectomy}} and {{Gastrectomy}} for {{Post-operative Outcomes}}?},
  author = {Niels, Timo and Baltin, Christoph T. and Kosanke, Guido and Fetzner, Ulrich K. and Hoelscher, Arnulf H. and Bollschweiler, Elfriede and Naendrup, Jan-Hendrik and Baumann, Freerk T.},
  year = {2022 Jul-Aug},
  journal = {In Vivo (Athens, Greece)},
  volume = {36},
  number = {4},
  pages = {1812--1819},
  issn = {1791-7549},
  doi = {10.21873/invivo.12897},
  abstract = {BACKGROUND/AIM: Esophagectomy and gastrectomy are procedures with considerable physical burden and intense post-operative care of which the patient's physical condition seems to be a relevant predictor. The gold standard of the cardiorespiratory fitness is the peak oxygen consumption (VO2peak). This pilot study examined the prognostic value of VO2peak on post-surgery outcomes in esophageal and gastric cancer patients. PATIENTS AND METHODS: In this prospective cross-sectional study, patients scheduled for esophagectomy or gastrectomy were examined 24 h before the surgery regarding their VO2peak. The post-operative complications according to Clavien-Dindo grade IIIb/IV/V, Intensive-Care-Unit days, and overall hospital stay were documented following surgery. In a subset, body weight changes from surgery until hospital discharge and first aftercare visit were recorded. RESULTS: The functional capacity was significantly reduced in 34/35 of the included patients compared to matched norm-values (p{$<$}0.01). The only significant correlation was found between VO2peak values and body weight change from surgery to the first aftercare visit. A subgroup comparison of patients with a VO2peak {$<$}17 ml/min/kg and {$\geq$}17 ml/min/kg suggested small, non-significant differences in post-surgery outcomes and significant differences in the body weight change from surgery to hospital discharge, favoring the higher-VO2peak subgroup. CONCLUSION: The impaired functional capacity following esophagectomy or gastrectomy may strengthen the rational for exercise programs during neoadjuvant and pre-surgery phases. The prognostic value of VO2peak on post-operative outcomes remains uncertain due to noticeable descriptive differences, but no significant correlations, potentially limited by the smallsized population. Nonetheless, a correlation between VO2peak and body weight change post-surgery was observed and indicates a potential prognostic value of VO2peak.},
  langid = {english},
  pmcid = {PMC9301424},
  pmid = {35738612},
  keywords = {Body Weight,cardiopulmonary fitness,Cross-Sectional Studies,Esophageal Neoplasms,Esophagectomy,Gastrectomy,Humans,Pilot Projects,post-surgery outcomes,Prognosis,Prospective Studies,Stomach Neoplasms,tumor surgery,VO2peak},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZE5Q9CFR\\Niels et al_2022_Does VO2peak Provide a Prognostic Value in Esophagectomy and Gastrectomy for.pdf}
}

@article{nielsone1609,
  title = {Relative {{Dose Intensity}} of {{Chemotherapy}} and {{Survival}} in {{Patients}} with {{Advanced Stage Solid Tumor Cancer}}: {{A Systematic Review}} and {{Meta-Analysis}}},
  shorttitle = {Relative {{Dose Intensity}} of {{Chemotherapy}} and {{Survival}} in {{Patients}} with {{Advanced Stage Solid Tumor Cancer}}},
  author = {Nielson, Carrie M. and Bylsma, Lauren C. and Fryzek, Jon P. and Saad, Hossam A. and Crawford, Jeffrey},
  year = {2021},
  month = sep,
  journal = {The Oncologist},
  volume = {26},
  number = {9},
  pages = {e1609-e1618},
  issn = {1549-490X},
  doi = {10.1002/onco.13822},
  abstract = {BACKGROUND: Chemotherapy-induced toxicities lead to therapy dose reduction or delay, affecting patient outcomes. This systematic review and meta-analysis evaluated the impact of relative dose intensity (RDI) on survival in adult patients with solid tumor cancer on nonadjuvant-based chemotherapy regimens. METHODS: PubMed, Embase, and Web of Science databases were searched for peer-reviewed English journal articles or congress abstracts evaluating association between RDI and survival; observational studies, case series of {$\geq$}20 patients, and clinical trials published between 2013 and 2020 were eligible. Meta-analyses were conducted to quantify the association between RDI levels and overall survival (OS) among studies reporting a hazard ratio (HR) for OS by similar tumor types, regimens, and RDI. Forest plots represented summary HR and 95\% confidence interval (CI); Cochran's Q and I2 tests evaluated study heterogeneity. RESULTS: Overall, 919 articles were reviewed and 22 included; seven were eligible for meta-analysis. Significantly shorter OS at RDI {$<$}80\% versus {$\geq$}80\% and~{$<$}85\% versus {$\geq$}85\% was observed upon meta-analysis of four carboplatin-based studies for breast, non-small cell lung, or ovarian cancer (HR 1.17; 95\% CI: 1.07-1.27) and three FOLFOX-, FOLFIRI-, or FOLFIRINOX-based studies for colorectal or pancreatic cancer (HR 1.39; 95\% CI: 1.03-1.89). Grade 3 or higher hematologic toxicities were higher for carboplatin-based regimens (thrombocytopenia: 14\%-22\%; anemia: 15\%-19\%; neutropenia: 24\%-58\%) than FOLFOX-, FOLFIRI-, or FOLFIRINOX-based regimens (thrombocytopenia: 1\%-4\%; anemia: 5\%-19\%; neutropenia: 19\%-47\%). CONCLUSION: The results suggested longer OS with RDI {$\geq$}80\% or~{$\geq$}85\% for both regimens, indicating that management of toxicities across treatment modalities may contribute to maintenance of higher RDI and benefit survival for patients with advanced solid tumors. IMPLICATIONS FOR PRACTICE: Chemotherapy-induced toxicities lead to dose reduction and/or treatment delay, thus affecting patient outcomes. Results of this systematic review and meta-analysis, evaluating the impact of relative dose intensity (RDI) on survival of patients with solid tumors on nonadjuvant-based chemotherapy regimens, demonstrate a longer overall survival with RDI levels of at least 80\% for patients with solid tumors on carboplatin-based and FOLFOX-, FOLFIRI-, or FOLFIRINOX-based chemotherapy regimens, suggesting a protective effect of maintaining RDI {$\geq$}80\% or~{$\geq$}\,-85\%. Although grade 3 or higher hematologic toxicities occurred more in carboplatin-based studies, managing toxicities across treatment regimens may contribute to maintenance of higher RDI and ultimately benefit overall survival.},
  langid = {english},
  pmcid = {PMC8417866},
  pmid = {33973301},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Carboplatin,Carboplatin-based regimens,DoseIntensity,FOLFOX/FOLFIRI-based regimens,Humans,Meta-analysis,Overall survival,Pancreatic Neoplasms,Progression-free survival,Relative dose intensity},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FBIUYJ9J\\Nielson et al_2021_Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced.pdf}
}

@article{nigro1826,
  title = {Combined Preoperative Radiation and Chemotherapy for Squamous Cell Carcinoma of the Anal Canal},
  author = {Nigro, Nd and Seydel, Hg and Considine, B and Vaitkevicius, Vk and Leichman, L and Kinzie, Jj},
  year = {1983},
  month = may,
  journal = {Cancer},
  volume = {51},
  number = {10},
  pages = {1826},
  publisher = {{Cancer}},
  issn = {0008-543X},
  doi = {10.1002/1097-0142(19830515)51:10<1826::aid-cncr2820511012>3.0.co;2-l},
  abstract = {Twenty-eight patients with squamous cell carcinoma of the anal canal were treated by preoperative radiation therapy and chemotherapy. The radiation therapy was given for 3000 rad (30 Gy) at 200 rad per day, 5 days a week, to the primary tumor with margin and to the pelvic and inguinal lymph nodes. C \ldots},
  langid = {english},
  pmid = {6831348},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\EQP65KFK\\6831348.html}
}

@article{nishigori678,
  type = {Journal {{Article}}},
  title = {Sarcopenia as a Predictor of Pulmonary Complications after Esophagectomy for Thoracic Esophageal Cancer},
  author = {Nishigori, T. and Okabe, H. and Tanaka, E. and Tsunoda, S. and Hisamori, S. and Sakai, Y.},
  year = {2016},
  journal = {J Surg Oncol},
  volume = {113},
  number = {6},
  pages = {678--84},
  issn = {1096-9098 (Electronic) 0022-4790 (Linking)},
  doi = {10.1002/jso.24214}
}

@article{noh1389,
  title = {Adjuvant Capecitabine plus Oxaliplatin for Gastric Cancer after {{D2}} Gastrectomy ({{CLASSIC}}): 5-Year Follow-up of an Open-Label, Randomised Phase 3 Trial},
  shorttitle = {Adjuvant Capecitabine plus Oxaliplatin for Gastric Cancer after {{D2}} Gastrectomy ({{CLASSIC}})},
  author = {Noh, Sung Hoon and Park, Sook Ryun and Yang, Han-Kwang and Chung, Hyun Cheol and Chung, Ik-Joo and Kim, Sang-Woon and Kim, Hyung-Ho and Choi, Jin-Hyuk and Kim, Hoon-Kyo and Yu, Wansik and Lee, Jong Inn and Shin, Dong Bok and Ji, Jiafu and Chen, Jen-Shi and Lim, Yunni and Ha, Stella and Bang, Yung-Jue and {CLASSIC trial investigators}},
  year = {2014},
  month = nov,
  journal = {The Lancet. Oncology},
  volume = {15},
  number = {12},
  pages = {1389--1396},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(14)70473-5},
  abstract = {BACKGROUND: The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The planned interim analysis of CLASSIC (median follow-up 34 months) showed that adjuvant capecitabine plus oxaliplatin significantly improved disease-free survival, the primary endpoint, compared with observation after D2 gastrectomy. We report the 5-year follow-up data from the trial. METHODS: CLASSIC was a phase 3, randomised, open-label study done at 35 cancer centres, medical centres, and hospitals in China, South Korea, and Taiwan. Patients with stage II-IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m(2) twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m(2) on day 1) for 6 months or observation alone. Randomisation was stratified by country and disease stage with a permuted block (size four) design. Neither patients nor investigators were masked to treatment assignment. The primary outcome was 3-year disease-free survival in the intention-to-treat population. This analysis presents the final preplanned assessment of outcomes after 5 years. The study is registered with ClinicalTrials.gov, NCT00411229. FINDINGS: We enrolled 1035 patients: 520 were randomly assigned to adjuvant capecitabine and oxaliplatin, and 515 to observation. Median follow-up for this analysis in the intention-to-treat population was 62{$\cdot$}4 months (IQR 54-70). 139 (27\%) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus 203 (39\%) patients in the observation group (stratified hazard ratio [HR] 0{$\cdot$}58, 95\% CI 0{$\cdot$}47-0{$\cdot$}72; p{$<$}0{$\cdot$}0001). Estimated 5-year disease-free survival was 68\% (95\% CI 63-73) in the adjuvant capecitabine and oxaliplatin group versus 53\% (47-58) in the observation alone group. By the clinical cutoff date, 103 patients (20\%) had died in the adjuvant capecitabine and oxaliplatin group versus 141 patients (27\%) in the observation group (stratified HR 0{$\cdot$}66, 95\% CI 0{$\cdot$}51-0{$\cdot$}85; p=0{$\cdot$}0015). Estimated 5-year overall survival was 78\% (95\% CI 74-82) in the adjuvant capecitabine and oxaliplatin group versus 69\% (64-73) in the observation group. Adverse event data were not collected after the primary analysis. INTERPRETATION: Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer. FUNDING: F Hoffmann La-Roche and Sanofi.},
  langid = {english},
  pmid = {25439693},
  keywords = {Aged,Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Chemotherapy; Adjuvant,Deoxycytidine,Disease-Free Survival,Drug-Related Side Effects and Adverse Reactions,Female,Fluorouracil,Follow-Up Studies,Gastrectomy,Humans,Male,Middle Aged,Neoplasm Staging,Organoplatinum Compounds,Oxaliplatin,Stomach Neoplasms}
}

@article{noordman142,
  title = {Neoadjuvant Chemoradiotherapy plus Surgery versus Active Surveillance for Oesophageal Cancer: A Stepped-Wedge Cluster Randomised Trial},
  shorttitle = {Neoadjuvant Chemoradiotherapy plus Surgery versus Active Surveillance for Oesophageal Cancer},
  author = {Noordman, Bo Jan and Wijnhoven, Bas P. L. and Lagarde, Sjoerd M. and Boonstra, Jurjen J. and Coene, Peter Paul L. O. and Dekker, Jan Willem T. and Doukas, Michael and {van der Gaast}, Ate and Heisterkamp, Joos and Kouwenhoven, Ewout A. and Nieuwenhuijzen, Grard A. P. and Pierie, Jean-Pierre E. N. and Rosman, Camiel and {van Sandick}, Johanna W. and {van der Sangen}, Maurice J. C. and Sosef, Meindert N. and Spaander, Manon C. W. and Valkema, Roelf and {van der Zaag}, Edwin S. and Steyerberg, Ewout W. and {van Lanschot}, J. Jan B. and {SANO-study group}},
  year = {2018},
  month = feb,
  journal = {BMC cancer},
  volume = {18},
  number = {1},
  pages = {142},
  issn = {1471-2407},
  doi = {10.1186/s12885-018-4034-1},
  abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced oesophageal cancer. With this treatment, 29\% of patients have a pathologically complete response in the resection specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer. METHODS: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15\%, intra-correlation coefficient 0.02, power 80\%, 2-sided {$\alpha$} 0.05, 12\% drop-out). Patients will undergo a first clinical response evaluation (CRE-I) 4-6~weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second CRE (CRE-II), 6-8~weeks after CRE-I. CRE-II will include 18F-FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance (second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/12/16/20/24/30/36/48 and 60~months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life, clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy. DISCUSSION: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.},
  langid = {english},
  pmcid = {PMC5801846},
  pmid = {29409469},
  keywords = {Active surveillance,Chemoradiotherapy,Clinical Trials; Phase III as Topic,Cost-Benefit Analysis,Disease-Free Survival,Endoscopic Ultrasound-Guided Fine Needle Aspiration,Esophageal Neoplasms,Esophagectomy,Humans,Multicenter Studies as Topic,Neoadjuvant chemoradiotherapy,Neoadjuvant Therapy,Oesophageal cancer,Outcome Assessment; Health Care,Positron Emission Tomography Computed Tomography,Randomized Controlled Trials as Topic,Research Design,Standard oesophagectomy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JPM8RE68\\Noordman et al. - 2018 - Neoadjuvant chemoradiotherapy plus surgery versus .pdf}
}

@article{noordman965,
  title = {Detection of Residual Disease after Neoadjuvant Chemoradiotherapy for Oesophageal Cancer ({{preSANO}}): A Prospective Multicentre, Diagnostic Cohort Study},
  shorttitle = {Detection of Residual Disease after Neoadjuvant Chemoradiotherapy for Oesophageal Cancer ({{preSANO}})},
  author = {Noordman, Bo Jan and Spaander, Manon C. W. and Valkema, Roelf and Wijnhoven, Bas P. L. and {van Berge Henegouwen}, Mark I. and Shapiro, Jo{\"e}l and Biermann, Katharina and {van der Gaast}, Ate and {van Hillegersberg}, Richard and Hulshof, Maarten C. C. M. and Krishnadath, Kausilia K. and Lagarde, Sjoerd M. and Nieuwenhuijzen, Grard A. P. and Oostenbrug, Liekele E. and Siersema, Peter D. and Schoon, Erik J. and Sosef, Meindert N. and Steyerberg, Ewout W. and {van Lanschot}, J. Jan B. and {SANO study group}},
  year = {2018},
  month = jul,
  journal = {The Lancet. Oncology},
  volume = {19},
  number = {7},
  pages = {965--974},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(18)30201-8},
  abstract = {BACKGROUND: After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have a pathological complete response of the primary tumour before surgery. Thus, the necessity of standard oesophagectomy after neoadjuvant chemoradiotherapy should be reconsidered for patients who respond sufficiently to neoadjuvant treatment. In this study, we aimed to establish the accuracy of detection of residual disease after neoadjuvant chemoradiotherapy with different diagnostic approaches, and the optimal combination of diagnostic techniques for clinical response evaluations. METHODS: The preSANO trial was a prospective, multicentre, diagnostic cohort study at six centres in the Netherlands. Eligible patients were aged 18 years or older, had histologically proven, resectable, squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric junction, and were eligible for potential curative therapy with neoadjuvant chemoradiotherapy (five weekly cycles of carboplatin [area under the curve 2 mg/mL per min] plus paclitaxel [50 mg/m2 of body-surface area] combined with 41{$\cdot$}4 Gy radiotherapy in 23 fractions) followed by oesophagectomy. 4-6 weeks after completion of neoadjuvant chemoradiotherapy, patients had oesophagogastroduodenoscopy with biopsies and endoscopic ultrasonography with measurement of maximum tumour thickness. Patients with histologically proven locoregional residual disease or no-pass during endoscopy and without distant metastases underwent immediate surgical resection. In the remaining patients a second clinical response evaluation was done (PET-CT, oesophagogastroduodenoscopy with biopsies, endoscopic ultrasonography with measurement of maximum tumour thickness, and fine-needle aspiration of suspicious lymph nodes), followed by surgery 12-14 weeks after completion of neoadjuvant chemoradiotherapy. The primary endpoint was the correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens, as shown by the proportion of tumour regression grade (TRG) 3 or 4 ({$>$}10\% residual carcinoma in the resection specimen) residual tumours that was missed during clinical response evaluations. This study was registered with the Netherlands Trial Register (NTR4834), and has been completed. FINDINGS: Between July 22, 2013, and Dec 28, 2016, 219 patients were included, 207 of whom were included in the analyses. Eight of 26 TRG3 or TRG4 tumours (31\% [95\% CI 17-50]) were missed by endoscopy with regular biopsies and fine-needle aspiration. Four of 41 TRG3 or TRG4 tumours (10\% [95\% CI 4-23]) were missed with bite-on-bite biopsies and fine-needle aspiration. Endoscopic ultrasonography with maximum tumour thickness measurement missed TRG3 or TRG4 residual tumours in 11 of 39 patients (28\% [95\% CI 17-44]). PET-CT missed six of 41 TRG3 or TRG4 tumours (15\% [95\% CI 7-28]). PET-CT detected interval distant histologically proven metastases in 18 (9\%) of 190 patients (one squamous cell carcinoma, 17 adenocarcinomas). INTERPRETATION: After neoadjuvant chemoradiotherapy for oesophageal cancer, clinical response evaluation with endoscopic ultrasonography, bite-on-bite biopsies, and fine-needle aspiration of suspicious lymph nodes was adequate for detection of locoregional residual disease, with PET-CT for detection of interval metastases. Active surveillance with this combination of diagnostic modalities is now being assessed in a phase 3 randomised controlled trial (SANO trial; Netherlands Trial Register NTR6803). FUNDING: Dutch Cancer Society.},
  langid = {english},
  pmid = {29861116},
  keywords = {Area Under Curve,Biopsy; Fine-Needle,Chemoradiotherapy,Cohort Studies,Disease-Free Survival,Endosonography,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Invasiveness,Neoplasm Staging,Neoplasm; Residual,Positron Emission Tomography Computed Tomography,Prognosis,Prospective Studies,Risk Assessment,Survival Rate}
}

@article{noordmanImpactSurgicalApproach2018,
  title = {Impact of {{Surgical Approach}} on {{Long-Term Survival}} in {{Esophageal Adenocarcinoma Patients With}} or {{Without Neoadjuvant Chemoradiotherapy}}},
  author = {Noordman, Bo Jan and {van Klaveren}, David and {van Berge Henegouwen}, Mark I. and Wijnhoven, Bas P. L. and Gisbertz, Suzanne S. and Lagarde, Sjoerd M. and {van der Gaast}, Ate and Hulshof, Maarten C. C. M. and Biermann, Katharina and Steyerberg, Ewout W. and {van Lanschot}, J. Jan B. and {also on behalf of the CROSS-study group}},
  year = {2018},
  month = may,
  journal = {Annals of Surgery},
  volume = {267},
  number = {5},
  pages = {892--897},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002240},
  abstract = {OBJECTIVE: To compare overall survival in patients with esophageal adenocarcinoma who underwent transhiatal esophagectomy (THE) with limited lymphadenectomy or transthoracic esophagectomy (TTE) with extended lymphadenectomy with or without neoadjuvant chemoradiotherapy (nCRT). BACKGROUND: The application of neoadjuvant therapy might change the association between the extent of lymphadenectomy and survival in patients with esophageal adenocarcinoma. This may influence the choice of surgical approach in patients treated with nCRT. METHODS: Patients with potentially curable subcarinal esophageal adenocarcinoma treated with surgery alone or nCRT followed by surgery in 7 centers were included. The effect of surgical approach on overall survival, differentiated by the addition or omission of nCRT, was analyzed using a multivariable Cox regression model that included well-known prognostic factors and factors that might have influenced the choice of surgical approach. RESULTS: In total, 701 patients were included, of whom 318 had TTE with extended lymphadenectomy and 383 had THE with limited lymphadenectomy. TTE had differential effects on survival (P for interaction = 0.02), with a more favorable prognostic effect in patients who were treated with surgery alone [hazard ratio (HR) = 0.77, 95\% confidence interval (CI) 0.58-1.03]. This association was statistically significant in a subgroup of patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 0.62, 95\% CI 0.43-0.90). The favorable prognostic effect of TTE over THE was absent in the nCRT and surgery group (HR = 1.16, 95\% CI 0.80-1.66) and in the subgroup of nCRT patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 1.00, 95\% CI 0.61-1.68). CONCLUSIONS: Compared to surgery alone, the addition of nCRT may reduce the need for TTE with extended lymphadenectomy to improve long-term survival in patients with esophageal adenocarcinoma.},
  langid = {english},
  pmid = {28350565},
  keywords = {Adenocarcinoma,Adjuvant,Aged,Chemoradiotherapy,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Netherlands,Positron-Emission Tomography,Retrospective Studies,Survival Rate,Time Factors,Treatment Outcome,Ultrasonography}
}

@article{norman8,
  title = {Hand Grip Strength: {{Outcome}} Predictor and Marker of Nutritional Status},
  author = {Norman, Kristina},
  year = {2011},
  journal = {Clinical Nutrition},
  pages = {8},
  abstract = {Background \& aims: Among all muscle function tests, measurement of hand grip strength has gained attention as a simple, non-invasive marker of muscle strength of upper extremities, well suitable for clinical use. This review outlines the prognostic relevance of grip strength in various clinical and epidemiologic settings and investigates its suitability as marker of nutritional status in cross-sectional as well as intervention studies.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QURQCWPL\\Norman - 2011 - Hand grip strength Outcome predictor and marker o.pdf}
}

@article{normann948,
  title = {Effect of Comprehensive Geriatric Assessment for Frail Elderly Patients Operated for Colorectal Cancer-the Colorectal Cancer Frailty Study: Study Protocol for a Randomized, Controlled, Multicentre Trial},
  shorttitle = {Effect of Comprehensive Geriatric Assessment for Frail Elderly Patients Operated for Colorectal Cancer-the Colorectal Cancer Frailty Study},
  author = {Normann, Maria and Ekerstad, Niklas and Angenete, Eva and Prytz, Mattias},
  year = {2022},
  month = nov,
  journal = {Trials},
  volume = {23},
  number = {1},
  pages = {948},
  issn = {1745-6215},
  doi = {10.1186/s13063-022-06883-9},
  abstract = {BACKGROUND: Colorectal cancer (CRC) is the third most common cancer worldwide, with a median age of 72-75 years at diagnosis. Curative treatment usually involves surgery; if left untreated, symptoms may require emergency surgery. Therefore, most patients will be accepted for surgery, despite of high age or comorbidity. It is known that elderly patients suffer higher risks after surgery than younger patients, in terms of complications and mortality. Assessing frailty and offering frail elderly patients individualized treatment according to the comprehensive geriatric assessment (CGA) and care concept has been shown to improve the outcome for frail elderly patients in other clinical contexts. METHODS: This randomized controlled multicentre trial aims to investigate if CGA and care prior to curatively intended surgery for CRC in frail elderly patients will improve postoperative outcome. All patients {$\geq$} 70 years with surgically curable CRC will be screened for frailty using the Clinical Frailty Scale (CFS-9). Frail patients will be offered inclusion. Randomization is stratified for colon or rectal cancer. Patients in the intervention group are, in addition to standard protocol, treated according to CGA and care. This consists of individualized assessments and interventions, established by a multiprofessional team. Patients in the control group are treated according to best known practice as stipulated by Swedish colorectal cancer treatment guidelines, within an enhanced recovery after surgery (ERAS) setting. The primary outcome is 90-day mortality. Secondary outcomes are the length of hospital stay and total number of hospital days within 3 months, discharge destination, 30-day readmission, ADL, safe medication assessment, CFS-9 score, complications, Health-Related Quality of Life (HRQoL) at 2-month follow-up in comparison to baseline measurements, health economical calculations including cost-effectiveness analysis based on costs of hospital care and primary care, mortality and HRQoL at baseline, 2- and 12-month follow-up and all-cause 1-year mortality. DISCUSSION: The trial is the first of its size and extent to investigate intervention with CGA and care prior to surgery for CRC in frail elderly patients. If this addition proves to be favourable, it could have implications on future care of frail elderly patients with CRC. TRIAL REGISTRATION: ClinicalTrials.gov NCT04358328. Registered on 4 February 2020.},
  langid = {english},
  pmcid = {PMC9670054},
  pmid = {36397083},
  keywords = {Aged,CGA,CGA and care,Colorectal neoplasm,Colorectal Neoplasms,Elderly,ERAS,Fatigue Syndrome; Chronic,Frail Elderly,Frailty,Geriatric Assessment,Humans,Multicenter Studies as Topic,PICO (patient-intervention-comparison-outcome),Quality of Life,Randomized Controlled Trials as Topic,RCT (randomised controlled trial),Sarcopenia,Surgery},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7VAEXG3L\\Normann et al_2022_Effect of comprehensive geriatric assessment for frail elderly patients.pdf}
}

@article{nowak3142,
  title = {End-to-End Automated Body Composition Analyses with Integrated Quality Control for Opportunistic Assessment of Sarcopenia in {{CT}}},
  author = {Nowak, Sebastian and Theis, Maike and Wichtmann, Barbara D. and Faron, Anton and Froelich, Matthias F. and Tollens, Fabian and Gei{\ss}ler, Helena L. and Block, Wolfgang and Luetkens, Julian A. and Attenberger, Ulrike I. and Sprinkart, Alois M.},
  year = {2022},
  month = may,
  journal = {European Radiology},
  volume = {32},
  number = {5},
  pages = {3142--3151},
  issn = {1432-1084},
  doi = {10.1007/s00330-021-08313-x},
  abstract = {OBJECTIVES: To develop a pipeline for automated body composition analysis and skeletal muscle assessment with integrated quality control for large-scale application in opportunistic imaging. METHODS: First, a convolutional neural network for extraction of a single slice at the L3/L4 lumbar level was developed on CT scans of 240 patients applying the nnU-Net framework. Second, a 2D competitive dense fully convolutional U-Net for segmentation of visceral and subcutaneous adipose tissue (VAT, SAT), skeletal muscle (SM), and subsequent determination of fatty muscle fraction (FMF) was developed on single CT slices of 1143 patients. For both steps, automated quality control was integrated by a logistic regression model classifying the presence of L3/L4 and a linear regression model predicting the segmentation quality in terms of Dice score. To evaluate the performance of the entire pipeline end-to-end, body composition metrics, and FMF were compared to manual analyses including 364 patients from two centers. RESULTS: Excellent results were observed for slice extraction (z-deviation\,=\,2.46\,{$\pm$}\,6.20~mm) and segmentation (Dice score for SM\,=\,0.95\,{$\pm$}\,0.04, VAT\,=\,0.98\,{$\pm$}\,0.02, SAT\,=\,0.97\,{$\pm$}\,0.04) on the dual-center test set excluding cases with artifacts due to metallic implants. No data were excluded for end-to-end performance analyses. With a restrictive setting of the integrated segmentation quality control, 39 of 364 patients were excluded containing 8 cases with metallic implants. This setting ensured a high agreement between manual and fully automated analyses with mean relative area deviations of {$\Delta$}SM\,=\,3.3\,{$\pm$}\,4.1\%, {$\Delta$}VAT\,=\,3.0\,{$\pm$}\,4.7\%, {$\Delta$}SAT\,=\,2.7\,{$\pm$}\,4.3\%, and {$\Delta$}FMF\,=\,4.3\,{$\pm$}\,4.4\%. CONCLUSIONS: This study presents an end-to-end automated deep learning pipeline for large-scale opportunistic assessment of body composition metrics and sarcopenia biomarkers in clinical routine. KEY POINTS: \textbullet{} Body composition metrics and skeletal muscle quality can be opportunistically determined from routine abdominal CT scans. \textbullet{} A pipeline consisting of two convolutional neural networks allows an end-to-end automated analysis. \textbullet{} Machine-learning-based quality control ensures high agreement between manual and automatic analysis.},
  langid = {english},
  pmcid = {PMC9038788},
  pmid = {34595539},
  keywords = {Body composition,Body Composition,Deep learning,Humans,MacineLearning,Muscle; Skeletal,Quality control,Quality Control,Sarcopenia,Tomography; X-ray computed,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8TZDSZS5\\Nowak et al. - 2022 - End-to-end automated body composition analyses wit.pdf}
}

@article{nurkin1090,
  title = {Outcomes of Endoscopic Resection for High-Grade Dysplasia  and Esophageal Cancer},
  author = {Nurkin, Steven J. and Nava, Hector R. and Yendamuri, Sai and LeVea, Charles M. and Nwogu, Chumy E. and Groman, Adrienne and Wilding, Gregory and Bain, Andrew J. and Hochwald, Steven N. and Khushalani, Nikhil I.},
  year = {2014},
  month = apr,
  journal = {Surgical Endoscopy},
  volume = {28},
  number = {4},
  pages = {1090--1095},
  issn = {1432-2218},
  doi = {10.1007/s00464-013-3270-3},
  abstract = {BACKGROUND: Endoscopic resection (ER) is an important advance in the management of esophageal tumors. It has been used successfully for superficial esophageal cancer and high-grade dysplasia (HGD) arising out of Barrett epithelium. METHODS: From a single institution within the Department of Surgery, patients who underwent ER for esophageal tumors between December 2001 and January 2012 were evaluated. Demographic, clinical, and pathologic variables were collected and reviewed. RESULTS: We identified 81 patients who underwent ER for esophageal lesions. Median patient age was 69 years, and the median follow-up was 3.25 years. In patients with HGD, at the time of last endoscopy, the complete eradication rate of HGD was 84 \% and cancer-specific survival was 100 \%. During surveillance, one patient developed an invasive carcinoma that required endoscopic therapy. Patients with T1a and negative deep margins on ER had a recurrence-free and cancer-specific survival of 100 \%. There were seven patients with T1b and negative margins on ER. Three patients underwent esophagectomy; final pathology revealed no residual malignancy or lymph node metastasis. Two patients had definitive chemoradiation, and two patients were observed. To date, there has been no cancer recurrence. In all patients who underwent ER, there was one episode of bleeding that required endoscopic treatment and admission for observation. CONCLUSIONS: ER can be performed safely and can adequately stage and often treat patients with HGD and superficial cancers. Patients with HGD and T1a disease with negative margins are cured with ER alone. Observation and surveillance may be an option for select patients with low-risk, early submucosal disease (T1b) and negative margins.},
  langid = {english},
  pmid = {24232046},
  keywords = {Adult,Aged,Aged; 80 and over,Barrett Esophagus,Disease-Free Survival,Endoscopy; Gastrointestinal,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Incidence,Lymphatic Metastasis,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,New York,Retrospective Studies,Risk Assessment,Survival Rate,Time Factors,Treatment Outcome}
}

@article{nuytens232,
  title = {Five-{{Year Survival Outcomes}} of {{Hybrid Minimally Invasive Esophagectomy}} in {{Esophageal Cancer}}: {{Results}} of the {{MIRO Randomized Clinical Trial}}},
  shorttitle = {Five-{{Year Survival Outcomes}} of {{Hybrid Minimally Invasive Esophagectomy}} in {{Esophageal Cancer}}},
  author = {Nuytens, Frederiek and {Dabakuyo-Yonli}, Tienhan S. and B, Meunier and J, Gagni{\`e}re and D, Collet and Xb, D'Journo and C, Brigand and T, Perniceni and N, Carr{\`e}re and Jy, Mabrut and S, Msika and F, Peschaud and M, Prudhomme and Sr, Markar and G, Piessen},
  year = {2021},
  month = apr,
  journal = {JAMA surgery},
  volume = {156},
  number = {4},
  pages = {232--332},
  publisher = {{JAMA Surg}},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2020.7081},
  abstract = {ClinicalTrials.gov Identifier: NCT00937456.},
  langid = {english},
  pmid = {33595631},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DL86WLQB\\F et al_2021_Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\2YZCBT2K\\33595631.html}
}

@article{ohnmacht311,
  ids = {ohnmacht311a},
  title = {Percutaneous Endoscopic Gastrostomy Risks Rendering the Gastric Conduit Unusable for Esophagectomy},
  author = {Ohnmacht, G. A. and Allen, M. S. and Cassivi, S. D. and Deschamps, C. and Nichols, F. C. and Pairolero, P. C.},
  year = {2006},
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {19},
  number = {4},
  pages = {311--312},
  issn = {1120-8694},
  doi = {10.1111/j.1442-2050.2006.00588.x},
  abstract = {Surgical treatment for cancer of the esophagus most often involves replacement of the esophagus with a gastric conduit. This gastric tube relies upon the continuity of the gastroepiploic artery for its blood supply. This case report involves a patient whose gastroepiploic artery became thrombosed by a percutaneous endoscopic gastrostomy, rendering his gastric conduit unusable.},
  langid = {english},
  pmid = {16866867},
  keywords = {Adenocarcinoma,Aged,Deglutition Disorders,Enteral Nutrition,Equipment Failure,Esophageal Neoplasms,Esophagectomy,Gastroepiploic Artery,Gastrostomy,Humans,Intubation; Gastrointestinal,Jejunostomy,Male,PEG},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\D2SVM7QF\\Ohnmacht et al_2006_Percutaneous endoscopic gastrostomy risks rendering the gastric conduit.pdf}
}

@article{okerekedoab083,
  title = {Disparities in Esophageal Cancer Care Based on Race: A {{National Cancer Database}} Analysis},
  shorttitle = {Disparities in Esophageal Cancer Care Based on Race},
  author = {Okereke, Ikenna C. and Westra, Jordan and Tyler, Douglas and Klimberg, Suzanne and Jupiter, Daniel and Venkatesan, Rohit and Brooks, Kaelyn and Kuo, Yong-Fang},
  year = {2021},
  month = dec,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  pages = {doab083},
  issn = {1442-2050},
  doi = {10.1093/dote/doab083},
  abstract = {Esophageal cancer is one of the most common cancer killers in our country. The effects of racial disparities on care for esophageal cancer patients are incompletely understood. Using the National Cancer Database, we investigated racial disparities in treatment and outcome of esophageal cancer patients. The National Cancer Database was queried from 2004 to 2017. Logistic regression and survival analysis were used to determine racial differences in access, treatment and outcome. A total of 127,098 patients were included. All minority groups were more likely to be diagnosed at advanced stages versus Caucasians after adjusting for covariates (African American OR-1.64 [95\% confidence interval 1.53-1.76], Hispanic OR-1.19 [1.08-1.32], Asian OR-1.78 [1.55-2.06]). After adjustment, all minorities were less likely at every stage to receive surgery. Despite these disparities, Hispanics and Asians had improved survival compared with Caucasians. African Americans had worse survival. Racial disparities for receiving surgery were present in both academic and community institutions, and at high-volume and low-volume institutions. Surgery partially mediated the survival difference between African Americans and Caucasians (HR-1.13 [1.10-1.16] and HR-1.04 [1.02-1.07], without and with adjustment of surgery).There are racial disparities in the treatment of esophageal cancer. Despite these disparities, Hispanics and Asians have improved overall survival versus Caucasians. African Americans have the worst overall survival. Racial disparities likely affect outcome in esophageal cancer. But other factors, such as epigenetics and tumor biology, may correlate more strongly with outcome for patients with esophageal cancer.},
  langid = {english},
  pmid = {34918057},
  keywords = {cancer epidemiology,cancer treatment,esophageal cancer,Race}
}

@article{okumura11,
  title = {Impact of Preoperative Quality as Well as Quantity of Skeletal Muscle on Survival after Resection of Pancreatic Cancer},
  author = {Okumura, Shinya},
  year = {2015},
  volume = {157},
  number = {6},
  pages = {11},
  abstract = {Background. Skeletal muscle depletion, referred to as sarcopenia, is predictive of mortality in patients undergoing digestive operations. The impact of muscle quality on outcomes, however, is unclear. This retrospective study investigated the impact of preoperative skeletal muscle quantity and quality on survival in patients undergoing resection of pancreatic cancer. Methods. We investigated 230 patients who underwent resection of pancreatic cancer between 2004 and 2013. The quantity and quality of skeletal muscle, indicated by psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC), were measured in preoperative computed tomography images. Overall survival (OS) and recurrence-free survival (RFS) rates were compared according to PMI and IMAC, and prognostic factors after pancreatic resection were assessed. Results. The OS and RFS rates in patients with low PMI were lesser than in those with normal/high PMI (P {$<$} .001, P {$<$} .001), with a mean survival time of 17.7 and 33.2 months, respectively. The OS and RFS rates in patients with high IMAC also were less than in those with normal/low IMAC (P {$<$} .001, P = .003) (mean survival time = 21.5 and 56.5 months, respectively). Low PMI (low muscle mass) and high IMAC (low muscle quality) were independent prognostic factors of poor OS (hazard ratio [HR] = 1.999, P {$<$} .001; HR = 2.527, P {$<$} .001) and RFS (HR = 1.607, P = .007; HR = 1.640, P = .004), respectively. Conclusion. Preoperative sarcopenia, indicating low quality and quantity of skeletal muscle, is closely related to mortality after resection of pancreatic cancer. (Surgery 2015;157:1088-98.)},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KZ38Y8W4\\Okumura - 2015 - Impact of preoperative quality as well as quantity.pdf}
}

@article{okumura13,
  title = {Impact of the Preoperative Quantity and Quality of Skeletal Muscle on Outcomes after Resection of Extrahepatic Biliary Malignancies},
  author = {Okumura, Shinya},
  year = {2016},
  volume = {159},
  number = {3},
  pages = {13},
  abstract = {Background. Skeletal muscle depletion, referred to as sarcopenia, predicts mortality after major surgery. This study investigated the impact of preoperative skeletal muscle quantity and quality on outcomes in patients undergoing resection of extrahepatic biliary cancer. Methods. We performed a retrospective analysis of 207 patients undergoing resection for biliary cancer between 2004 and 2013. The quantity and quality of skeletal muscle, indicated by the psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC), were measured on preoperative images of computed tomography. Overall survival (OS) and recurrence-free survival (RFS) rates were compared by PMI and IMAC, and prognostic factors after operation were assessed. Results. The OS and RFS rates were less in patients with low PMI (low muscle quantity) than in those with normal PMI (P {$<$} .001 and P {$<$} .001; 5-year OS, 15.7 vs 53.5\%). The OS and RFS rates were also less in patients with high IMAC (low muscle quality) than in those with normal IMAC (P {$<$} .001 and P {$<$} .001; 5-year OS, 23.8 vs 55.9\%). Low PMI and high IMAC were independent factors predictive of poor OS (hazard ratio [HR], 2.921 [95\% CI, 1.920\textendash 4.470; P {$<$} .001] and HR, 1.725 [95\% CI, 1.159\textendash 2.590; P = .007]) and RFS (HR, 2.141 [95\% CI, 1.464\textendash 3.129, P {$<$} .001] and HR, 1.492 [95\% CI, 1.032\textendash 2.166, P = .034]). Conclusion. Preoperative sarcopenia, indicating a low quantity and quality of skeletal muscle, is related closely to mortality after resection of biliary cancer. (Surgery 2016;159:821-33.)},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MFBWBYC2\\Okumura - 2016 - Impact of the preoperative quantity and quality of.pdf}
}

@article{okumura543,
  type = {Journal {{Article}}},
  title = {Functional Outcome Assessment of Swallowing ({{FOAMS}}) Scoring and Videofluoroscopic Evaluation of Perioperative Swallowing Rehabilitation in Radical Esophagectomy},
  author = {Okumura, T. and Shimada, Y. and Watanabe, T. and Nakamichi, N. and Nagata, T. and Tsukada, K.},
  year = {2016},
  journal = {Surg Today},
  volume = {46},
  number = {5},
  pages = {543--51},
  issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
  doi = {10.1007/s00595-015-1203-6}
}

@article{older355,
  title = {Cardiopulmonary Exercise Testing as a Screening Test for Perioperative Management of Major Surgery in the Elderly},
  author = {Older, P. and Hall, A. and Hader, R.},
  year = {1999},
  month = aug,
  journal = {Chest},
  volume = {116},
  number = {2},
  pages = {355--362},
  issn = {0012-3692},
  doi = {10.1378/chest.116.2.355},
  abstract = {STUDY OBJECTIVE: To develop an integrated strategy for the identification and subsequent management of high-risk patients in order to reduce both morbidity and mortality. DESIGN: Prospective consecutive series in which all patients underwent cardiopulmonary exercise (CPX) testing. SETTING: CPX laboratory and level 3 ICU and high-dependency unit (HDU) of a metropolitan teaching hospital. PATIENTS: Five hundred forty-eight patients {$>$}60 years of age (or younger with known cardiopulmonary disease) scheduled for major intra-abdominal surgery. INTERVENTIONS: The patients were assigned to one of three management strategies (ICU, HDU, or ward) based on the anaerobic threshold (deltaT) and ECG evidence of myocardial ischemia as determined by CPX testing that was performed as part of the presurgery evaluation, and by the expected oxygen demand stress of the surgical procedure. RESULTS: Overall mortality was 3.9\%. Forty-three percent of deaths were attributed to poor cardiopulmonary function, as detected preoperatively. There were no deaths related to cardiopulmonary complications in any patient deemed fit for major abdominal surgery and ward management, as determined by CPX testing. CONCLUSIONS: In elderly patients undergoing major intra-abdominal surgery, the AT, as determined by CPX testing, is an excellent predictor of mortality from cardiopulmonary causes in the postoperative period. Preoperative screening using CPX testing allowed the identification of high-risk patients and the appropriate selection of perioperative management.},
  langid = {english},
  pmid = {10453862},
  keywords = {Aged,Aged; 80 and over,Anaerobic Threshold,Aortic Aneurysm; Abdominal,Digestive System Surgical Procedures,Exercise Test,Humans,Middle Aged,Postoperative Care,Postoperative Complications,Predictive Value of Tests,Risk Assessment}
}

@article{omloo992,
  title = {Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus: Five-Year Survival of a Randomized Clinical Trial},
  shorttitle = {Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus},
  author = {Omloo, Jikke M. T. and Lagarde, Sjoerd M. and Hulscher, Jan B. F. and Reitsma, Johannes B. and Fockens, Paul and {van Dekken}, Herman and Ten Kate, Fiebo J. W. and Obertop, Huug and Tilanus, Hugo W. and {van Lanschot}, J. Jan B.},
  year = {2007},
  month = dec,
  journal = {Annals of Surgery},
  volume = {246},
  number = {6},
  pages = {992-1000; discussion 1000-1001},
  issn = {0003-4932},
  doi = {10.1097/SLA.0b013e31815c4037},
  abstract = {OBJECTIVE: To determine whether extended transthoracic esophagectomy for adenocarcinoma of the mid/distal esophagus improves long-term survival. BACKGROUND: A randomized trial was performed to compare surgical techniques. Complete 5-year survival data are now available. METHODS: A total of 220 patients with adenocarcinoma of the distal esophagus (type I) or gastric cardia involving the distal esophagus (type II) were randomly assigned to limited transhiatal esophagectomy or to extended transthoracic esophagectomy with en bloc lymphadenectomy. Patients with peroperatively irresectable/incurable cancer were excluded from this analysis (n = 15). A total of 95 patients underwent transhiatal esophagectomy and 110 patients underwent transthoracic esophagectomy. RESULTS: After transhiatal and transthoracic resection, 5-year survival was 34\% and 36\%, respectively (P = 0.71, per protocol analysis). In a subgroup analysis, based on the location of the primary tumor according to the resection specimen, no overall survival benefit for either surgical approach was seen in 115 patients with a type II tumor (P = 0.81). In 90 patients with a type I tumor, a survival benefit of 14\% was seen with the transthoracic approach (51\% vs. 37\%, P = 0.33). There was evidence that the treatment effect differed depending on the number of positive lymph nodes in the resection specimen (test for interaction P = 0.06). In patients (n = 55) without positive nodes locoregional disease-free survival after transhiatal esophagectomy was comparable to that after transthoracic esophagectomy (86\% and 89\%, respectively). The same was true for patients (n = 46) with more than 8 positive nodes (0\% in both groups). Patients (n = 104) with 1 to 8 positive lymph nodes in the resection specimen showed a 5-year locoregional disease-free survival advantage if operated via the transthoracic route (23\% vs. 64\%, P = 0.02). CONCLUSION: There is no significant overall survival benefit for either approach. However, compared with limited transhiatal resection extended transthoracic esophagectomy for type I esophageal adenocarcinoma shows an ongoing trend towards better 5-year survival. Moreover, patients with a limited number of positive lymph nodes in the resection specimen seem to benefit from an extended transthoracic esophagectomy.},
  langid = {english},
  pmid = {18043101},
  keywords = {Adenocarcinoma,Adult,Aged,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Laparotomy,Male,Middle Aged,Neoplasm Staging,Retrospective Studies,Survival Rate,Thoracotomy,Time Factors,Treatment Outcome}
}

@article{onishi14,
  title = {Prognostic {{Impact}} of {{Sarcopenic Obesity}} after {{Neoadjuvant Chemotherapy Followed}} by {{Surgery}} in {{Elderly Patients}} with {{Esophageal Squamous Cell Carcinoma}}},
  author = {Onishi, Sachiyo and Tajika, Masahiro and Tanaka, Tsutomu and Yamada, Keisaku and Abe, Tetsuya and Higaki, Eiji and Hosoi, Takahiro and Inaba, Yoshitaka and Muro, Kei and Shimizu, Masahito and Niwa, Yasumasa},
  year = {2020},
  pages = {14},
  abstract = {We evaluated the impact of body composition on clinical outcomes after neoadjuvant chemotherapy (NAC) followed by surgery for elderly cStage II/III esophageal squamous cell carcinoma (ESCC). Ninety-one patients {$\geq$}70 years old and 116 patients {$<$}70 years old with ECSS who underwent NAC between January 2013 and June 2018 at the Aichi Cancer Center were included. Body composition as assessed from computed tomography (CT), American Society of Anesthesiologists physical status (ASA-PS), and subjective global assessment (SGA) was assessed before initiation of NAC. Although elderly patients showed significantly poorer ASA-PS (p {$<$} 0.01) and SGA (p {$<$} 0.01), and significantly more frequent history of malignancy (p {$<$} 0.05), no significant differences were identified in the frequencies of adverse events, postoperative complications, or in cancer-specific survival (p = 0.65, hazard ratio 1.15), or overall survival (p = 0.42, hazard ratio 1.26). However, multivariate analysis identified sarcopenic obesity as the only independent predictor of prognosis in elderly patients. Sarcopenic obesity was associated with higher body mass index (p = 0.04), better SGA (p {$<$} 0.01), and lower pre-treatment weight loss (p = 0.03). NAC was as effective and safe for elderly patients without sarcopenic obesity as for young patients. However, diagnosing sarcopenic obesity based on clinical findings is difficult, so the preoperative CT assessment of sarcopenic obesity is important.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QCFYGJZA\\Onishi et al. - 2020 - Prognostic Impact of Sarcopenic Obesity after Neoa.pdf}
}

@article{oppedijk385,
  title = {Patterns of Recurrence after Surgery Alone versus Preoperative Chemoradiotherapy and Surgery in the {{CROSS}} Trials},
  author = {Oppedijk, Vera and {van der Gaast}, Ate and {van Lanschot}, Jan J. B. and {van Hagen}, Pieter and {van Os}, Rob and {van Rij}, Caroline M. and {van der Sangen}, Maurice J. and Beukema, Jannet C. and R{\"u}tten, Heidi and Spruit, Patty H. and Reinders, Janny G. and Richel, Dick J. and {van Berge Henegouwen}, Mark I. and Hulshof, Maarten C. C. M.},
  year = {2014},
  month = feb,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {32},
  number = {5},
  pages = {385--391},
  issn = {1527-7755},
  doi = {10.1200/JCO.2013.51.2186},
  abstract = {PURPOSE: To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone. PATIENTS AND METHODS: Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin. RESULTS: Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75\%). Of the 374 patients who underwent resection, 86\% were allocated to surgery and 92\% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58\% versus 35\% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34\% to 14\% (P {$<$} .001) and peritoneal carcinomatosis from 14\% to 4\% (P {$<$} .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35\% v 29\%; P = .025). LRR occurred in 5\% within the target volume, in 2\% in the margins, and in 6\% outside the radiation target volume. In 1\%, the exact site in relation to the target volume was unclear. Only 1\% had an isolated infield recurrence after CRT plus surgery. CONCLUSION: Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5\%, mostly combined with outfield failures.},
  langid = {english},
  pmid = {24419108},
  keywords = {Adenocarcinoma,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Carboplatin,Carcinoma; Squamous Cell,Chemotherapy; Adjuvant,Dose Fractionation; Radiation,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Gastrectomy,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Multivariate Analysis,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Paclitaxel,Proportional Hazards Models,Risk Factors,Stomach Neoplasms,Time Factors,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\M4JZC4RT\\Oppedijk et al. - 2014 - Patterns of recurrence after surgery alone versus .pdf}
}

@article{orkaby1257,
  title = {The {{Burden}} of {{Frailty Among U}}.{{S}}. {{Veterans}} and {{Its Association With Mortality}}, 2002-2012},
  author = {Orkaby, Ariela R. and Nussbaum, Lisa and Ho, Yuk-Lam and Gagnon, David and Quach, Lien and Ward, Rachel and Quaden, Rachel and Yaksic, Enzo and Harrington, Kelly and Paik, Julie M. and Kim, Dae H. and Wilson, Peter W. and Gaziano, J. Michael and Djousse, Luc and Cho, Kelly and Driver, Jane A.},
  year = {2019},
  month = jul,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {74},
  number = {8},
  pages = {1257--1264},
  issn = {1758-535X},
  doi = {10.1093/gerona/gly232},
  abstract = {BACKGROUND: Frailty is a key determinant of clinical outcomes. We sought to describe frailty among U.S. Veterans and its association with mortality. METHODS: Nationwide retrospective cohort study of regular Veterans Affairs (VA) users, aged at least 65 years in 2002-2012, followed through 2014, using national VA administrative and Medicare and Medicaid data. A frailty index (FI) for VA (VA-FI) was calculated using the cumulative deficit method. Thirty-one age-related deficits in health from diagnostic and procedure codes were included and were updated biennially. Survival analysis assessed associations between VA-FI and mortality. RESULTS: A VA-FI was calculated for 2,837,152 Veterans over 10 years. In 2002, 35.5\% were non-frail (FI = 0-0.10), 32.6\% were pre-frail (FI = 0.11-0.20), 18.9\% were mildly frail (FI = 0.21-0.30), 8.7\% were moderately frail (FI = 0.31-0.40), and 4.3\% were severely frail (FI {$>$} 0.40). From 2002 to 2012, the prevalence of moderate frailty increased to 12.7\%and severe frailty to 14.1\%. Frailty was strongly associated with survival and was independent of age, sex, race, and smoking; the VA-FI better predicted mortality than age alone. Although prevalence of frailty rose over time, compared to non-frail Veterans, 2 years' hazard ratios (95\% confidence intervals) for mortality declined from a peak in 2004 of 2.01 (1.97-2.04), 3.49 (3.44-3.55), 5.88 (5.79-5.97), and 10.39 (10.23-10.56) for pre-frail, mildly, moderately, and severely frail, respectively, to 1.51 (1.49-1.53), 2.36 (2.33-2.39), 3.68 (3.63-3.73), 6.62 (6.53-6.71) in 2012. At every frailty level, risk of mortality was lower for women versus men and higher for blacks versus whites. CONCLUSIONS: Frailty affects at least 3 of every 10 U.S. Veterans aged 65 years and older, and is strongly associated with mortality. The VA-FI could be used to more accurately estimate life expectancy and individualize care for Veterans.},
  langid = {english},
  pmcid = {PMC6625596},
  pmid = {30307533},
  keywords = {Aged,Epidemiology,Female,Frail Elderly,Frailty,Geriatric Assessment,Humans,Male,Mortality,Retrospective Studies,United States,Veterans},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XL3ANP4N\\Orkaby et al_2019_The Burden of Frailty Among U.pdf}
}

@article{orringer282,
  title = {Transhiatal Esophagectomy without Thoracotomy for Carcinoma of the Thoracic Esophagus},
  author = {Orringer, M. B.},
  year = {1984},
  month = sep,
  journal = {Annals of Surgery},
  volume = {200},
  number = {3},
  pages = {282--288},
  issn = {0003-4932},
  doi = {10.1097/00000658-198409000-00005},
  abstract = {Transhiatal esophagectomy (THE) without thoracotomy was performed in 100 patients with carcinoma of the thoracic esophagus (7 upper, 45 mid, and 48 lower third). The esophagus was replaced with stomach (96) or colon (4). Intraoperative complications included pneumothorax requiring a chest tube(s) (63) and membranous tracheal tear (2). Blood loss averaged 880 ml. Postoperative complications included transient recurrent laryngeal nerve paresis (31), anastomotic leak (5), and chylothorax (2). There were no intraoperative deaths or re-explorations for postoperative bleeding. Six hospital deaths resulted from aspiration pneumonia (2), retroperitoneal or mediastinal abscess (2), pulmonary embolus (1), and respiratory insufficiency (1). Postoperative hospitalization averaged 14 days. Actuarial survival among the 94 operative survivors is 82\% at 6 months, 52\% at 12 months, 32\% at 24 months, 22\% at 36 months, and 17\% at 48 months. Of the operative survivors, 15\% have lived 2 years or more and 10\% are clinically disease free. THE is safe, associated with a low morbidity, and achieves excellent palliation and survival at least as good as that reported in many series of transthoracic esophagectomies for esophageal carcinoma.},
  langid = {english},
  pmcid = {PMC1250471},
  pmid = {6465981},
  keywords = {Chylothorax,Esophageal Neoplasms,Follow-Up Studies,Humans,Intraoperative Complications,Ligation,Methods,Postoperative Complications,Prognosis,Thoracic Duct,Trachea,Vocal Cord Paralysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\J4R2GSJ3\\Orringer - 1984 - Transhiatal esophagectomy without thoracotomy for .pdf}
}

@article{orringer363,
  title = {Two Thousand Transhiatal Esophagectomies: Changing Trends, Lessons Learned},
  shorttitle = {Two Thousand Transhiatal Esophagectomies},
  author = {Orringer, Mark B. and Marshall, Becky and Chang, Andrew C. and Lee, Julia and Pickens, Allan and Lau, Christine L.},
  year = {2007},
  month = sep,
  journal = {Annals of Surgery},
  volume = {246},
  number = {3},
  pages = {363-372; discussion 372-374},
  issn = {0003-4932},
  doi = {10.1097/SLA.0b013e31814697f2},
  abstract = {OBJECTIVE: "Rediscovered" in 1976, transhiatal esophagectomy (THE) has been applicable in most situations requiring esophageal resection and reconstruction. The objective of this study was to review the authors' 30-year experience with THE and changing trends in its use. METHODS: Using the authors' prospective Esophagectomy Database, this single institution experience with THE was analyzed retrospectively. RESULTS: Two thousand and seven THEs were performed-1063 (previously reported) between 1976 and 1998 (group I) and 944 from 1998 to 2006 (group II), 24\% for benign disease, 76\%, cancer. THE was possible in 98\%. Stomach was the esophageal substitute in 97\%. Comparing outcomes between group I and group II, statistically significant differences (P {$<$} 0.001) were observed in hospital mortality (4\% vs. 1\%); adenocarcinoma histology (69\% vs. 86\%); use of neoadjuvant chemoradiation (28\% vs. 52\%); mean blood loss (677 vs. 368 mL); anastomotic leak (14\% vs. 9\%); and discharge within 10 days (52\% vs. 78\%). Major complications remain infrequent: wound infection/dehiscence, 3\%, atelectasis/pneumonia, 2\%, intrathoracic hemorrhage, recurrent laryngeal nerve paralysis, chylothorax, and tracheal laceration, {$<$}1\% each. Late functional results have been good or excellent in 73\%. Aggressive preoperative conditioning, avoiding the ICU, improved pain management, and early ambulation reduce length of stay, with 50\% in group II discharged within 1 week. CONCLUSION: THE refinements have reduced the historic morbidity and mortality of esophageal resection. This largest reported THE experience reinforces the value of consistent technique and a clinical pathway in managing these high acuity esophageal patients.},
  langid = {english},
  pmcid = {PMC1959358},
  pmid = {17717440},
  keywords = {Aged,Chi-Square Distribution,Early Ambulation,Esophageal Diseases,Esophageal Neoplasms,Esophagectomy,Female,Humans,Length of Stay,Logistic Models,Male,Middle Aged,Postoperative Complications,Proportional Hazards Models,Retrospective Studies,Stomach,Survival Rate,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6NS7F4WJ\\Orringer et al. - 2007 - Two thousand transhiatal esophagectomies changing.pdf}
}

@article{orringer643,
  title = {Esophagectomy without Thoracotomy},
  author = {Orringer, M. B. and Sloan, H.},
  year = {1978},
  month = nov,
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  volume = {76},
  number = {5},
  pages = {643--654},
  issn = {0022-5223},
  abstract = {Blunt esophagectomy without thoracotomy has been performed in 26 patients: four with benign disease and 22 with carcinomas involving various levels of the esophagus (10 cervicothoracic, one upper third, five middle third, and six distal third). Continuity of the alimentary tract was restored by anastomosing the pharynx or cervical esophagus either to stomach (19 patients) or to a colonic graft (seven patients). Esophageal resection and reconstruction were performed in a single stage in 25 patients, and the esophageal substitute was positioned in the posterior mediastinum in the original esophageal bed in 24 patients. There were no deaths directly related to the technique of blunt esophagectomy. Average intraoperative blood loss was 1,350 ml. for the entire group, 1,650 ml. for those requiring concomitant laryngectomy and 1,050 ml. for those undergoing esophagectomy without laryngectomy. Complications in these patients included pneumothorax (eight), transient hoarseness (five), pleural effusion (five), anastomotic leak (four), subphrenic abscess (one), and cerebrovascular accident (one). The five deaths were due to pheumonia (two), innominate artery rupture (two), and pulmonary embolus (one). Blunt esophagectomy without thoracotomy is safe and is far better tolerated physiologically than the combined transthoracic and abdominal operations more traditionally used for exophageal resection and reconstruction.},
  langid = {english},
  pmid = {703369},
  keywords = {Adenocarcinoma,Esophageal Diseases,Esophageal Neoplasms,Esophagoplasty,Esophagus,Follow-Up Studies,Humans,Methods,Postoperative Complications}
}

@article{ouattara1088,
  title = {Body Mass Index Kinetics and Risk Factors of Malnutrition One Year after Radical Oesophagectomy for Cancer},
  author = {Ouattara, Moussa and D'Journo, Xavier Benoit and Loundou, Anderson and Trousse, Delphine and Dahan, Laetitia and Doddoli, Christophe and Seitz, Jean Francois and Thomas, Pascal-Alexandre},
  year = {2012},
  month = may,
  journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
  volume = {41},
  number = {5},
  pages = {1088--1093},
  issn = {1873-734X},
  doi = {10.1093/ejcts/ezr182},
  abstract = {OBJECTIVE: Malnutrition is common after oesophageal cancer surgery. This study aims to investigate body mass index (BMI) kinetics and the risk factors of malnutrition among 1-year disease-free survivors after radical transthoracic oesophagectomy for cancer. METHODS: From a prospective single-institution database, 118 1-year disease-free survivors having undergone a R0 transthoracic oesophagectomy with gastric tubulization between 2000 and 2008 were identified retrospectively. BMI values were collected at the onset of the disease (pre-treatment BMI), at the time of surgery (preoperative BMI), at postoperative 6 months and 1 year after oesophagectomy (1-year BMI). Logistic regression was performed with adjustment for confounders to estimate odds ratios of the factors associated with a 1-year weight loss (WL) of at least 15\% of the pre-treatment body weight (BW). RESULTS: At the onset of the disease, 5 patients (4\%) were underweighted (BMI {$<$} 8.5 kg/m\&sup2;), 65 (55\%) were normal (BMI = 18.5-24.9 kg/m\&sup2;), 36 (31\%) were overweighted (BMI {$>$} 25 kg/m\&sup2;) and 12 (10\%) were obese (BMI {$>$} 30 kg/m\&sup2;). Mean pre-treatment, preoperative, postoperative 6-month and 1-year BMI values were 24.64 {$\pm$} 4 kg/m\&sup2;, 23.55 {$\pm$} 3.8 kg/m\&sup2;, 21.7 {$\pm$} 3 kg/m\&sup2; and 21.97 {$\pm$} 4 kg/m\&sup2;, respectively. One-year WL {$\geq$} 15\% of the pre-treatment BW was present in 29 patients (25\%): 18 among the 48 patients (37\%) with a pre-treatment BMI {$\geq$} 25 and 11 among the 70 patients (15\%) with pre-treatment BMI {$<$} 25 (P = 0.006). On logistic regression, initial overweighting was the sole independent prognosticator of 1-year postoperative WL of at least 15\% of the pre-treatment BW (P = 0.039; OR: 2.96, [1.06-8.32]). CONCLUSIONS: Postoperative malnutrition remains a severe problem after oesophageal cancer resection, even in long-term disease-free survivors. Overweight and obese patients are the segment population most exposed to this postoperative malnutrition, suggesting that such surgery could have substantial bariatric effect. A special vigilance programme on the nutritional status of this sub-group of patients should be the rule.},
  langid = {english},
  pmid = {22334635},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Body Mass Index,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Malnutrition,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Overweight,Retrospective Studies,Risk Factors,Sex Factors,Weight Loss,Weight Loss; GE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2QH3LMTC\\Ouattara et al. - 2012 - Body mass index kinetics and risk factors of malnu.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\T8SMT8EF\\Ouattara et al. - 2012 - Body mass index kinetics and risk factors of malnu.pdf}
}

@incollection{oxenberg29,
  type = {Book {{Section}}},
  title = {Prevention and {{Management}} of {{Complications}} from {{Esophagectomy}}},
  booktitle = {Esophageal {{Cancer}} and {{Beyond}}},
  author = {Oxenberg, Jacqueline},
  editor = {Chai, Jianyuan},
  year = {2018},
  pages = {29--47},
  publisher = {{IntechOpen}},
  address = {{London}}
}

@article{paireder478,
  title = {Impact of Sarcopenia on Outcome in Patients with Esophageal Resection Following Neoadjuvant Chemotherapy for Esophageal Cancer},
  author = {Paireder, M. and Asari, R. and Kristo, I. and Rieder, E. and Tamandl, D. and {Ba-Ssalamah}, A. and Schoppmann, S. F.},
  year = {2017},
  month = feb,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {43},
  number = {2},
  pages = {478--484},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2016.11.015},
  abstract = {BACKGROUND: Nutritional status and body composition parameters such as sarcopenia are important risk factors for impaired outcome in patients with esophageal cancer. This study was conducted to evaluate the effect of sarcopenia on long-term outcome after esophageal resection following neoadjuvant treatment. METHODS: Skeletal muscle index (SMI) and body composition parameters were measured in patients receiving neoadjuvant treatment for locally advanced esophageal cancer. Endpoints included relapse-free survival (RFS) and overall survival (OS). RESULTS: The study included 130 patients. Sarcopenia was found in 80 patients (61.5\%). Patients with squamous-cell cancer (SCC) showed a decreased median SMI of 48 (range 28.4-60.8) cm/m2 compared with that of patients with adenocarcinoma (AC) of 52 (range 34.4-74.2) cm/m2, P~{$<~$}0.001. The presence of sarcopenia had a significant impact on patient outcome: HR 1.69 (1.04-2.75), P~=~0.036. Median OS was 20.5 (7.36-33.64) versus 52.1 (13.55-90.65) months in sarcopenic and non-sarcopenic patients, respectively. Sarcopenia was identified as an independent risk factor: HR 1.72 (1.049-2.83), P~=~0.032. CONCLUSION: Our data provide evidence that sarcopenia impacts long-term outcome after esophageal resection in patients who have undergone neoadjuvant therapy. Assessment of the body composition parameter can be a reasonable part of patient selection and may influence treatment methods.},
  langid = {english},
  pmid = {28024944},
  keywords = {Adult,Aged,Body Composition,Body composition parameter,Carcinoma; Squamous Cell,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Risk Factors,Sarcopenia,Survival Rate,Treatment Outcome}
}

@article{pajewski1771,
  title = {Frailty {{Screening Using}} the {{Electronic Health Record Within}} a {{Medicare Accountable Care Organization}}},
  author = {Pajewski, Nicholas M. and Lenoir, Kristin and Wells, Brian J. and Williamson, Jeff D. and Callahan, Kathryn E.},
  year = {2019},
  month = oct,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {74},
  number = {11},
  pages = {1771--1777},
  issn = {1758-535X},
  doi = {10.1093/gerona/glz017},
  abstract = {BACKGROUND: The accumulation of deficits model for frailty has been used to develop an electronic health record (EHR) frailty index (eFI) that has been incorporated into British guidelines for frailty management. However, there have been limited applications of EHR-based approaches in the United States. METHODS: We constructed an adapted eFI for patients in our Medicare Accountable Care Organization (ACO, N = 12,798) using encounter, diagnosis code, laboratory, medication, and Medicare Annual Wellness Visit (AWV) data from the EHR. We examined the association of the eFI with mortality, health care utilization, and injurious falls. RESULTS: The overall cohort was 55.7\% female, 85.7\% white, with a mean age of 74.9 (SD = 7.3) years. In the prior 2 years, 32.1\% had AWV data. The eFI could be calculated for 9,013 (70.4\%) ACO patients. Of these, 46.5\% were classified as prefrail (0.10 {$<$} eFI {$\leq$} 0.21) and 40.1\% frail (eFI {$>$} 0.21). Accounting for age, comorbidity, and prior health care utilization, the eFI independently predicted all-cause mortality, inpatient hospitalizations, emergency department visits, and injurious falls (all p {$<$} .001). Having at least one functional deficit captured from the AWV was independently associated with an increased risk of hospitalizations and injurious falls, controlling for other components of the eFI. CONCLUSIONS: Construction of an eFI from the EHR, within the context of a managed care population, is feasible and can help to identify vulnerable older adults. Future work is needed to integrate the eFI with claims-based approaches and test whether it can be used to effectively target interventions tailored to the health needs of frail patients.},
  langid = {english},
  pmcid = {PMC6777083},
  pmid = {30668637},
  keywords = {Accidental Falls,Accountable Care Organizations,Age Factors,Aged,Aged; 80 and over,Cohort Studies,eFI,Electronic Health Records,Falls,Female,Frailty,Health Services,Hospitalization,Humans,Longitudinal Studies,Male,Mass Screening,Medicare,Multimorbidities,Patient Acceptance of Health Care,Prevalence,Risk Assessment,Sex Factors,Survival Analysis,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4MQIHMNF\\glz017_suppl_supplementary_table_1c.docx;C\:\\Users\\jsalo01\\Zotero\\storage\\68FSF4B4\\glz017_suppl_supplementary_table_1b.docx;C\:\\Users\\jsalo01\\Zotero\\storage\\6QVKPTEP\\Pajewski et al_2019_Frailty Screening Using the Electronic Health Record Within a Medicare.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\SU3YIXI5\\glz017_suppl_supplementary_table_1a.docx;C\:\\Users\\jsalo01\\Zotero\\storage\\VVSGU93L\\glz017_suppl_supplementary_figures_and_tables.docx}
}

@article{palanivelu7,
  type = {Journal {{Article}}},
  title = {Minimally Invasive Esophagectomy: Thoracoscopic Mobilization of the Esophagus and Mediastinal Lymphadenectomy in Prone Position\textendash Experience of 130 Patients},
  author = {Palanivelu, C. and Prakash, A. and Senthilkumar, R. and Senthilnathan, P. and Parthasarathi, R. and Rajan, P. S. and Venkatachlam, S.},
  year = {2006},
  journal = {J Am Coll Surg},
  volume = {203},
  number = {1},
  pages = {7--16},
  issn = {1072-7515 (Print) 1072-7515 (Linking)},
  doi = {10.1016/j.jamcollsurg.2006.03.016}
}

@article{palazzo1683,
  type = {Journal {{Article}}},
  title = {Minimally Invasive Esophagectomy with Extracorporeal Gastric Conduit Creation\textendash How {{I}} Do It},
  author = {Palazzo, F. and Evans, N. R., 3rd and Rosato, E. L.},
  year = {2013},
  journal = {J Gastrointest Surg},
  volume = {17},
  number = {9},
  pages = {1683--8},
  issn = {1873-4626 (Electronic) 1091-255X (Linking)},
  doi = {10.1007/s11605-013-2272-8}
}

@article{pamoukdjian13,
  title = {Frailty {{Parameters}}, {{Morbidity}} and {{Mortality}} in {{Older Adults}} with {{Cancer}}: {{A Structural Equation Modelling Approach Based}} on the {{Fried Phenotype}}},
  author = {Pamoukdjian, Frederic and Laurent, Marie and {Martinez-Tapia}, Claudia and Rolland, Yves and Paillaud, Elena and {Canoui-Poitrine}, Florence},
  year = {2020},
  pages = {13},
  abstract = {Background: to distinguish direct and indirect pathways to frailty phenotype, and quantify associations between two frailty components (i.e., sarcopenia and cachexia) regarding mortality and morbidity in older adults with cancer. Methods: all consecutive older outpatients with cancer were included in a prospective two-centre cohort study between 2013 and 2017 and had geriatric assessment. We used the frailty phenotype. Sarcopenia and cachexia were built as latent variables by including observed variables related to physical performances and related to nutrition and inflammation respectively. Structural equation modelling was used to distinguish between direct and indirect effects of the frailty parameters on the risk of death (Model 1) and the risk of morbidity (defined by unplanned hospitalization and/or disability and/or a fall; Model 2). The root mean square error of approximation (RMSEA) and the comparative fit index (CFI) were used to assess the model fit. Results: 603 older outpatients were included (mean age: 81.2 {$\pm$} 6.1; women: 54\%; frailty phenotype: 58\%). The 6-month mortality and morbidity rates were 18\% and 64\%, respectively. The fit was good for both models (RMSEA and CFI = 0.029 [0.017\textendash 0.039] and 0.99 for Model 1, and 0.028 [0.017\textendash 0.039] and 0.99 for Model 2, respectively). Sarcopenia and cachexia were both directly and significantly associated with 6-month mortality ({$\beta$}sarcopenia = 0.18, p = 0.01; {$\beta$}cachexia = 0.52, p {$<$} 0.0001) and morbidity ({$\beta$}sarcopenia = 0.37, p {$<$} 0.0001; {$\beta$}cachexia = 0.19, p {$<$} 0.02). Conclusions: sarcopenia and cachexia had a direct pathway with 6-month mortality and morbidity in older cancer patients.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4LWPLMHM\\Pamoukdjian et al. - 2020 - Frailty Parameters, Morbidity and Mortality in Old.pdf}
}

@article{paniaguacruze498,
  title = {Association {{Between Marital Status}} and {{Racial Disparities}} in {{Esophageal Cancer Care}}},
  author = {Paniagua Cruz, Alan and Haug, Karlie L. and Zhao, Lili and Reddy, Rishindra M.},
  year = {2020},
  month = jun,
  journal = {JCO oncology practice},
  volume = {16},
  number = {6},
  pages = {e498-e506},
  issn = {2688-1535},
  doi = {10.1200/JOP.19.00561},
  abstract = {PURPOSE: This study was designed to examine the impact of marital status on racial disparities in esophageal cancer care. PATIENTS AND METHODS: We performed a secondary analysis of data collected from the state cancer registry maintained by the Michigan Department of Health and Human Services. We identified patients with an esophageal cancer diagnosis between January 1, 2000, and December 31, 2013. {$\chi$}2 test and logistics regression were used to analyze 6,809 patients who met our eligibility criteria. Statistical significance was defined as P {$\leq$} .05. RESULTS: Approximately 88.4\% of our patients were White and 11.6\% were Black. A significantly higher number of White patients were married when compared with Blacks (62.9\% v 31.8\%, respectively; P {$<$} .0001). There was no significant difference in cancer staging between the 2 groups (P = .0671). Married Blacks had similar rates of esophagectomy, chemotherapy, and radiation as married Whites. Both single groups had lower rates of esophagectomy and chemotherapy than married Whites, but single Blacks were the least likely to undergo esophagectomy. Single patients were more likely to refuse treatment. CONCLUSION: Marital status differs significantly in Black and White patients with esophageal cancer and may help explain racial disparities in cancer care. Further research is needed to explore reasons for care underutilization in single patients and whether these differences translate into clinical outcomes.},
  langid = {english},
  pmcid = {PMC7291542},
  pmid = {32369408},
  keywords = {African Americans,Esophageal Neoplasms,Humans,Marital Status,Michigan,Race,Whites},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\EDRHBJEI\\Paniagua Cruz et al. - 2020 - Association Between Marital Status and Racial Disp.pdf}
}

@article{park1137,
  title = {Risk {{Factors}} for {{Weight Loss}} 1~{{Year After Esophagectomy}} and {{Gastric Pull-up}} for {{Esophageal Cancer}}},
  author = {Park, Seong Yong and Kim, Dae Joon and Suh, Jee Won and Byun, Go Eun},
  year = {2018},
  month = jul,
  journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
  volume = {22},
  number = {7},
  pages = {1137--1143},
  issn = {1873-4626},
  doi = {10.1007/s11605-018-3749-2},
  abstract = {BACKGROUND: Loss of body weight is regarded as a marker of malnutrition after esophagectomy. This study investigated changes in body weight and risk factors for weight loss after esophagectomy for esophageal cancer. METHODS: We retrospectively reviewed records of 181 patients who underwent esophagectomy and gastric pull-up from 2012 to June 2016. Patients with operative mortality and recurrences were excluded. Percent change in body weight was defined as change in body weight (\%)\,=\,(1-year body weight\,-\,preoperative body weight)\,\texttimes\,100/preoperative body weight. RESULTS: Mean age of patients was 62.98\,{$\pm$}\,8.23~years with 164 men (90.6\%). Mean preoperative body weight was 63.12\,{$\pm$}\,9.42~kg, and body weight at 1~year was 56.04\,{$\pm$}\,8.59~kg. Mean change in body weight was -\,10.95\,{$\pm$}\,7.50\%, and 98 (54.1\%) patients showed weight loss more than 10\% compared to initial body weight. Univariable analysis showed that initial body weight, narrow gastric tube, thoracotomy, laparotomy, and postoperative vocal cord palsy (VCP) were related to more than 10\% weight loss. Multivariable analysis showed that initial body weight (odds ratio [OR]\,=\,1.041, p\,=\,0.031) and postoperative VCP (OR\,=\,2.772, p\,=\,0.025) were adverse risk factors for weight loss 1~year after esophagectomy, whereas conduit type, route of reconstruction, postoperative complications, anastomotic complications, minimally invasive esophagectomy, and adjuvant therapy were not. CONCLUSIONS: Initial body weight and postoperative VCP were related to weight loss. Patients with VCP need additional nutritional monitoring and support.},
  langid = {english},
  pmid = {29611091},
  keywords = {Body Weight,Esophageal Squamous Cell Carcinoma,Esophagectomy,Esophagus,Female,Gastrostomy,GE,Humans,Laparotomy,Male,Malnutrition,Middle Aged,Neoplasm Staging,Postoperative Complications,Republic of Korea,Retrospective Studies,Risk Factors,Weight Loss}
}

@article{park13,
  type = {Journal {{Article}}},
  title = {Prognostic Value of Preoperative Total Psoas Muscle Area on Long-Term Outcome in Surgically Treated Oesophageal Cancer Patients},
  author = {Park, S. Y. and Yoon, J. K. and Lee, S. J. and Haam, S. and Jung, J.},
  year = {2017},
  journal = {Interact Cardiovasc Thorac Surg},
  volume = {24},
  number = {1},
  pages = {13--19},
  issn = {1569-9285 (Electronic) 1569-9285 (Linking)},
  doi = {10.1093/icvts/ivw274}
}

@article{park17683,
  title = {Loss of Skeletal Muscle Mass during Palliative Chemotherapy Is a Poor Prognostic Factor in Patients with Advanced Gastric Cancer},
  author = {Park, Song Ee and Choi, Jin Hwa and Park, Jae Yong and Kim, Beom Jin and Kim, Jae Gyu and Kim, Jong Won and Park, Joong-Min and Chi, Kyong-Choun and Hwang, In Gyu},
  year = {2020},
  month = oct,
  journal = {Scientific Reports},
  volume = {10},
  number = {1},
  pages = {17683},
  issn = {2045-2322},
  doi = {10.1038/s41598-020-74765-8},
  abstract = {Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively reviewed 111 consecutive AGC patients who underwent first-line palliative chemotherapy. Skeletal muscle area was measured before and after chemotherapy at the third lumbar vertebra level using computed tomography scans. We compared skeletal muscle index (SMI), body mass index (BMI), and body weight changes to chemotherapy response and survival. The 80 male and 31 female patients' median age was 65 (range 31-87) years, and 46.8\% had sarcopenia at baseline. Median pre-chemotherapy to post-chemotherapy SMI, BMI, and body weight decreases were -\,4.5~cm2/m2 (-\,11.3\%) (P\,{$<$}\,0.001); -\,0.7~kg/m2 (-\,3.2\%) (P\,{$<$}\,0.001); and -\,2.0~kg (-\,3.5\%) (P\,{$<$}\,0.001), respectively. Median SMI decreases for patients with objective response, stable disease, and disease progression were -\,4.0 cm2/m2 (range -\,20.1\,\textasciitilde\,9.5); -\,4.5 cm2/m2 (range -\,19.8\,\textasciitilde\,0.8); and -\,3.8 cm2/m2 (range: -\,17.6\,\textasciitilde\,0.1), respectively. Response to chemotherapy was not associated with SMI decrease (P\,=\,0.463). In multivariable analysis, sarcopenia at baseline (HR 1.681; 95\% CI 1.083-2.609, P\,=\,0.021), decreased SMI (HR 1.620; 95\% CI 1.041-2.520; P\,=\,0.032) were significant poor prognostic factors for survival. Skeletal muscle mass decreased significantly during chemotherapy in AGC patients, but was not associated with chemotherapy response. Decreased SMI was a poor prognostic factor in AGC patients during first-line palliative chemotherapy.},
  langid = {english},
  pmcid = {PMC7573603},
  pmid = {33077864},
  keywords = {Adult,Aged,Aged; 80 and over,Antineoplastic Agents,chemo,Female,gastric,Humans,Male,Middle Aged,Muscle; Skeletal,Organ Size,Palliative Care,Prognosis,Sarcopenia,Stomach Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GPQ3897L\\Park - 2020 - Loss of skeletal muscle mass during palliative che.pdf}
}

@article{participants156,
  type = {Journal {{Article}}},
  title = {Shall We Operate? {{Preoperative}} Assessment in Elderly Cancer Patients ({{PACE}}) Can Help. {{A SIOG}} Surgical Task Force Prospective Study},
  author = {{participants}, Pace and Audisio, R. A. and Pope, D. and Ramesh, H. S. and Gennari, R. and {van Leeuwen}, B. L. and West, C. and Corsini, G. and Maffezzini, M. and Hoekstra, H. J. and Mobarak, D. and Bozzetti, F. and Colledan, M. and Wildiers, H. and Stotter, A. and Capewell, A. and Marshall, E.},
  year = {2008},
  journal = {Crit Rev Oncol Hematol},
  volume = {65},
  number = {2},
  pages = {156--63},
  issn = {1040-8428 (Print) 1040-8428 (Linking)},
  doi = {10.1016/j.critrevonc.2007.11.001}
}

@article{pasquali481,
  title = {Survival {{After Neoadjuvant}} and {{Adjuvant Treatments Compared}} to {{Surgery Alone}} for {{Resectable Esophageal Carcinoma}}: {{A Network Meta-analysis}}},
  shorttitle = {Survival {{After Neoadjuvant}} and {{Adjuvant Treatments Compared}} to {{Surgery Alone}} for {{Resectable Esophageal Carcinoma}}},
  author = {Pasquali, Sandro and Yim, Guang and Vohra, Ravinder S. and Mocellin, Simone and Nyanhongo, Donald and Marriott, Paul and Geh, Ju Ian and Griffiths, Ewen A.},
  year = {2017},
  month = mar,
  journal = {Annals of Surgery},
  volume = {265},
  number = {3},
  pages = {481--491},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000001905},
  abstract = {OBJECTIVE: This network meta-analysis compared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the most effective approach. SUMMARY BACKGROUND DATA: The optimal treatment for resectable esophageal cancer is unknown. METHODS: A search for randomized controlled trials reporting on neoadjuvant and adjuvant therapies was conducted. Using a network meta-analysis, treatments were ranked based on their effectiveness for improving survival. RESULTS: In 33 eligible randomized controlled trials, 6072 patients were randomized to receive either surgery alone (N = 2459) or neoadjuvant CT (N = 1332), RT (N = 58), and CRT (N = 1196) followed by surgery or surgery followed by adjuvant CT (N = 542), RT (N = 383), and CRT (N = 102). Twenty-one comparisons were generated. Neoadjuvant CRT followed by surgery compared with surgery alone was the only treatment to significantly improve survival [hazard ratio (HR) = 0.77, 95\% confidence interval (CI): 0.68-0.87]. When trials were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared with surgery alone showed a survival advantage (HR = 0.83, 95\% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advantage (HR = 0.87, 95\% CI 0.67-1.14). A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR = 0.77, 95\% CI 0.68-0.87). CONCLUSIONS: This network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effective strategy in improving survival of resectable esophageal cancer. Resources should be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.},
  langid = {english},
  pmid = {27429017},
  keywords = {Carcinoma; Squamous Cell,Chemotherapy; Adjuvant,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Neoadjuvant Therapy,Network Meta-Analysis,Prognosis,Radiotherapy; Adjuvant,Randomized Controlled Trials as Topic,Risk Assessment,Survival Analysis}
}

@article{paty365,
  title = {Treatment of Rectal Cancer by Low Anterior Resection with Coloanal Anastomosis},
  author = {Paty, P. B. and Enker, W. E. and Cohen, A. M. and Lauwers, G. Y.},
  year = {1994},
  month = apr,
  journal = {Annals of Surgery},
  volume = {219},
  number = {4},
  pages = {365--373},
  issn = {0003-4932},
  doi = {10.1097/00000658-199404000-00007},
  abstract = {OBJECTIVE: Our institution's experience with low anterior resection in combination with coloanal anastomosis (LAR/CAA) for primary rectal cancer was reviewed (1) to determine cancer treatment results, 2) to identify risk factors for pelvic recurrence, and 3) to assess the long-term success of sphincter preservation. SUMMARY BACKGROUND DATA: Use of sphincter-preserving resection for mid-rectal and selected distal-rectal cancers continues to increase. As surgical techniques and adjuvant therapy evolve, treatment results must be carefully assessed. METHODS: One hundred thirty-four patients treated for primary rectal cancer by LAR/CAA between 1977 and 1990 were studied retrospectively. All pathologic slides were reviewed. Median follow-up was 4 years. RESULTS: Actuarial 5-year survival for all patients was 73\%. Among 36 patients who relapsed, distant metastatic disease had developed at the time of first clinical relapse in most (86\%). Pelvic recurrence was detected in 13 patients, an actuarial rate of 11\% at 5 years. Mesenteric implants, positive microscopic resection margin, T3 tumor, perineural invasion, blood vessel invasion, and high tumor grade were associated with increased risk for pelvic recurrence. Eleven patients ultimately required permanent colostomy, and in eight instances the cause was pelvic recurrence. CONCLUSIONS: Low anterior resection combined with coloanal anastomosis provides good treatment for mid-rectal cancers and for some distal rectal cancers. Pelvic recurrence is not associated with short distal resection margins but is correlated with the presence of histopathologic markers of aggressive disease in the primary tumor. Long-term preservation of anal sphincter function depends primarily on control of pelvic tumor and can be achieved in more than 90\% of patients.},
  langid = {english},
  pmcid = {PMC1243153},
  pmid = {8161262},
  keywords = {Adult,Aged,Aged; 80 and over,Anal Canal,Anastomosis; Surgical,Colon,Colostomy,Combined Modality Therapy,Female,Humans,LAR,Male,Middle Aged,Neoplasm Recurrence; Local,Prognosis,Rectal Neoplasms,Retrospective Studies,Risk Factors,Treatment Outcome}
}

@article{pech1200,
  title = {Long-Term Results and Risk Factor Analysis for Recurrence after Curative Endoscopic Therapy in 349 Patients with High-Grade Intraepithelial Neoplasia and Mucosal Adenocarcinoma in {{Barrett}}'s Oesophagus},
  author = {Pech, O. and Behrens, A. and May, A. and Nachbar, L. and Gossner, L. and Rabenstein, T. and Manner, H. and Guenter, E. and Huijsmans, J. and Vieth, M. and Stolte, M. and Ell, C.},
  year = {2008},
  month = sep,
  journal = {Gut},
  volume = {57},
  number = {9},
  pages = {1200--1206},
  issn = {1468-3288},
  doi = {10.1136/gut.2007.142539},
  abstract = {OBJECTIVE: Endoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus. This report provides 5 year follow-up data from a large prospective study investigating the efficacy and safety of endoscopic treatment in these patients and analysing risk factors for recurrence. DESIGN: Prospective case series. SETTING: Academic tertiary care centre. PATIENTS: Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia. Patients with submucosal or more advanced cancer were excluded. INTERVENTIONS: Endoscopic therapy. MAIN OUTCOME MEASURES: Rate of complete remission and recurrence rate, tumour-associated death. RESULTS: Endoscopic resection was performed in 279 patients, photodynamic therapy in 55, and both procedures in 13; two patients received argon plasma coagulation. The mean follow-up period was 63.6 (SD 23.1) months. Complete response (CR) was achieved in 337 patients (96.6\%); surgery was necessary in 13 (3.7\%) after endoscopic therapy failed. Metachronous lesions developed during the follow-up in 74 patients (21.5\%); 56 died of concomitant disease, but none died of BC. The calculated 5 year survival rate was 84\%. The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved {$>$}10 months and multifocal neoplasia. CONCLUSIONS: This study showed that endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. The risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.},
  langid = {english},
  pmid = {18460553},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Barrett Esophagus,Carcinoma in Situ,Epidemiologic Methods,Esophageal Neoplasms,Esophagoscopy,Female,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,Precancerous Conditions,Treatment Outcome}
}

@article{pech652,
  ids = {pechLongtermEfficacySafety2014},
  title = {Long-Term Efficacy and Safety of Endoscopic Resection for Patients with Mucosal Adenocarcinoma of the Esophagus},
  author = {Pech, Oliver and May, Andrea and Manner, Hendrik and Behrens, Angelika and Pohl, J{\"u}rgen and Weferling, Maren and Hartmann, Urs and Manner, Nicola and Huijsmans, Josephus and Gossner, Liebwin and Rabenstein, Thomas and Vieth, Michael and Stolte, Manfred and Ell, Christian},
  year = {2014},
  month = mar,
  journal = {Gastroenterology},
  volume = {146},
  number = {3},
  pages = {652-660.e1},
  issn = {1528-0012},
  doi = {10.1053/j.gastro.2013.11.006},
  abstract = {BACKGROUND \& AIMS: Barrett's esophagus-associated high-grade dysplasia is commonly treated by endoscopy. However, most guidelines offer no recommendations for endoscopic treatment of mucosal adenocarcinoma of the esophagus (mAC). We investigated the efficacy and safety of endoscopic resection in a large series of patients with mAC. METHODS: We collected data from 1000 consecutive patients (mean age, 69.1 {$\pm$} 10.7 years; 861 men) with mAC (481 with short-segment and 519 with long-segment Barrett's esophagus) who presented at a tertiary care center from October 1996 to September 2010. Patients with low-grade and high-grade dysplasia and submucosal or more advanced cancer were excluded. All patients underwent endoscopic resection of mACs. Patients found to have submucosal cancer at their first endoscopy examination were excluded from the analysis. RESULTS: After a mean follow-up period of 56.6 {$\pm$} 33.4 months, 963 patients (96.3\%) had achieved a complete response; surgery was necessary in 12 patients (3.7\%) after endoscopic therapy failed. Metachronous lesions or recurrence of cancer developed during the follow-up period in 140 patients (14.5\%) but endoscopic re-treatment was successful in 115, resulting in a long-term complete remission rate of 93.8\%; 111 died of concomitant disease and 2 of Barrett's esophagus-associated cancer. The calculated 10-year survival rate of patients who underwent endoscopic resection of mACs was 75\%. Major complications developed in 15 patients (1.5\%) but could be managed conservatively. CONCLUSIONS: Endoscopic therapy is highly effective and safe for patients with mAC, with excellent long-term results. In an almost 5-year follow-up of 1000 patients treated with endoscopic resection, there was no mortality and less than 2\% had major complications. Endoscopic therapy should become the standard of care for patients with mAC.},
  langid = {english},
  pmid = {24269290},
  keywords = {Adenocarcinoma,Aged,Barrettâs Esophagus,Endoscopic Mucosal Resection,Endoscopy,Esophageal Cancer,Esophageal Neoplasms,Esophagus,Female,Follow-Up Studies,Humans,Incidence,Local,Male,Middle Aged,Mucous Membrane,Neoplasm Recurrence,Neoplasm Recurrence; Local,Prospective Studies,Retrospective Studies,Survival Rate,T1,Treatment Outcome}
}

@article{peng439,
  type = {Journal {{Article}}},
  title = {Sarcopenia Negatively Impacts Short-Term Outcomes in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis},
  author = {Peng, P. D. and {van Vledder}, M. G. and Tsai, S. and {de Jong}, M. C. and Makary, M. and Ng, J. and Edil, B. H. and Wolfgang, C. L. and Schulick, R. D. and Choti, M. A. and Kamel, I. and Pawlik, T. M.},
  year = {2011},
  journal = {HPB (Oxford)},
  volume = {13},
  number = {7},
  pages = {439--46},
  issn = {1477-2574 (Electronic) 1365-182X (Linking)},
  doi = {10.1111/j.1477-2574.2011.00301.x}
}

@article{pennathurS2159,
  type = {Journal {{Article}}},
  title = {Technique of Minimally Invasive {{Ivor Lewis}} Esophagectomy},
  author = {Pennathur, A. and Awais, O. and Luketich, J. D.},
  year = {2010},
  journal = {Ann Thorac Surg},
  volume = {89},
  number = {6},
  pages = {S2159-62},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2010.03.069}
}

@article{penniment114,
  title = {Palliative Chemoradiotherapy versus Radiotherapy Alone for Dysphagia in Advanced Oesophageal Cancer: A Multicentre Randomised Controlled Trial ({{TROG}} 03.01)},
  shorttitle = {Palliative Chemoradiotherapy versus Radiotherapy Alone for Dysphagia in Advanced Oesophageal Cancer},
  author = {Penniment, Michael G. and De Ieso, Paolo B. and Harvey, Jennifer A. and Stephens, Sonya and Au, Heather-Jane and O'Callaghan, Christopher J. and Kneebone, Andrew and Ngan, Samuel Y. and Ward, Iain G. and Roy, Rajarshi and Smith, Jennifer G. and Nijjar, Tirath and Biagi, James J. and Mulroy, Liam A. and Wong, Rebecca and {TROG 03.01/CCTG ES.2 group}},
  year = {2018},
  month = feb,
  journal = {The Lancet. Gastroenterology \& Hepatology},
  volume = {3},
  number = {2},
  pages = {114--124},
  issn = {2468-1253},
  doi = {10.1016/S2468-1253(17)30363-1},
  abstract = {BACKGROUND: A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. We compared chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting. METHODS: This multicentre randomised controlled trial included patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) through a computer-generated adaptive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zealand, and the UK. Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological and renal function. Patients were stratified by hospital, dysphagia score (Mellow scale 1-4), and presence of metastases. The radiotherapy dose was 35 Gy in 15 fractions over 3 weeks for patients in Australia and New Zealand and 30 Gy in ten fractions over 2 weeks for patients in Canada and the UK. Chemotherapy consisted of one cycle of intravenous cisplatin (either 80 mg/m2 on day 1 or 20 mg/m2 per day on days 1-4 of radiotherapy at clinician's discretion) and intravenous fluorouracil 800 mg/m2 per day on days 1-4 of radiotherapy in week 1. Patients were assessed weekly during treatment. The primary endpoint was dysphagia relief (defined as {$\geq$}1 point reduction on the Mellow scale at 9 weeks and maintained 4 weeks later), and key secondary endpoints were dysphagia progression-free survival (defined as a worsening of at least 1 point on the Mellow scale from baseline or best response) and overall survival. These endpoints were analysed in the intention-to-treat population. This study is registered at ClinicalTrials.gov, number NCT00193882. This trial is closed. FINDINGS: Between July 7, 2003, and March 21, 2012, 111 patients were randomly assigned to chemoradiotherapy and 109 patients to radiotherapy. One patient in the chemoradiotherapy group was omitted from analysis because of ineligibility. 50 (45\%, 95\% CI 36-55) patients in the chemoradiotherapy group and 38 (35\%, 26-44) in the radiotherapy group obtained dysphagia relief (difference 10{$\cdot$}6\%, 95\% CI -2 to 23; p=0{$\cdot$}13). Median dysphagia progression-free survival was 4{$\cdot$}1 months (95\% CI 3{$\cdot$}5-4{$\cdot$}8) versus 3{$\cdot$}4 months (3{$\cdot$}1-4{$\cdot$}3) in the chemoradiotherapy and radiotherapy groups, respectively (p=0{$\cdot$}58), and median overall survival was 6{$\cdot$}9 months (95\% CI 5{$\cdot$}1-8{$\cdot$}3) versus 6{$\cdot$}7 months (4{$\cdot$}9-8{$\cdot$}0), respectively (p=0{$\cdot$}88). Of the 211 patients who commenced radiotherapy, grade 3-4 acute toxicity occurred in 38 (36\%) patients in the chemoradiotherapy group and in 17 (16\%) patients in the radiotherapy group (p=0{$\cdot$}0017). Anaemia, thrombocytopenia, neutropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in patients who had chemoradiotherapy than in patients who had radiotherapy. INTERPRETATION: Palliative chemoradiotherapy showed a modest, but not statistically significant, increase in dysphagia relief compared with radiotherapy alone, with minimal improvement in dysphagia progression-free survival and overall survival with chemoradiotherapy but at a cost of increased toxicity. A short course of radiotherapy alone should be considered a safe and well tolerated treatment for malignant dysphagia in the palliative setting. FUNDING: National Health and Medical Research Council, Canadian Cancer Society Research Institute, Canadian Cancer Trials Group, Trans Tasman Radiation Oncology Group, and Cancer Australia.},
  langid = {english},
  pmid = {29248399},
  keywords = {Aged,Aged; 80 and over,Antineoplastic Agents,Chemoradiotherapy,Cisplatin,Deglutition Disorders,Esophageal Neoplasms,Female,Fluorouracil,Humans,Intention to Treat Analysis,Male,Middle Aged,Neoplasm Metastasis,Palliative Care,Radiotherapy,Survival Analysis}
}

@article{perez-de-acha1377,
  title = {All-{{Cause Mortality Risk Prediction}} in {{Older Adults}} with {{Cancer}}: {{Practical Approaches}} and {{Limitations}}},
  shorttitle = {All-{{Cause Mortality Risk Prediction}} in {{Older Adults}} with {{Cancer}}},
  author = {{Perez-de-Acha}, Andrea and Pilleron, Sophie and {Soto-Perez-de-Celis}, Enrique},
  year = {2022},
  month = nov,
  journal = {Current Oncology Reports},
  volume = {24},
  number = {11},
  pages = {1377--1385},
  issn = {1534-6269},
  doi = {10.1007/s11912-022-01303-2},
  abstract = {PURPOSE OF REVIEW: The prediction of all-cause mortality is an important component of shared decision-making across the cancer care continuum, particularly in older adults with limited life expectancy, for whom there is an increased risk of over-diagnosis and treatment. RECENT FINDINGS: Currently, several international societies recommend the use of all-cause mortality risk prediction tools when making decisions regarding screening and treatment in geriatric oncology. Here, we review some practical aspects of the utilization of those tools and dissect the characteristics of those most employed in geriatric oncology, highlighting both their advantages and their limitations.},
  langid = {english},
  pmid = {35648341},
  keywords = {Aged,Cancer,Clinical decision rules,Decision Making,Decision Making; Shared,Decision-making,Geriatric Assessment,Humans,Life expectancy,Life Expectancy,Mass Screening,Mortality,Neoplasms,Older adults,Prognosis}
}

@article{persinger1632,
  type = {Journal {{Article}}},
  title = {Consistency of the Talk Test for Exercise Prescription},
  author = {Persinger, R. and Foster, C. and Gibson, M. and Fater, D. C. and Porcari, J. P.},
  year = {2004},
  journal = {Med Sci Sports Exerc},
  volume = {36},
  number = {9},
  pages = {1632--6},
  issn = {0195-9131 (Print) 0195-9131 (Linking)}
}

@article{perthen142,
  title = {Intra- and Interobserver Variability in Skeletal Muscle Measurements Using Computed Tomography Images},
  author = {Perthen, Joanna E. and Ali, Tamir and McCulloch, David and Navidi, Maziar and Phillips, Alexander W. and Sinclair, Rhona C. F. and Griffin, S. Michael and Greystoke, Alastair and Petrides, George},
  year = {2018},
  month = dec,
  journal = {European Journal of Radiology},
  volume = {109},
  pages = {142--146},
  issn = {1872-7727},
  doi = {10.1016/j.ejrad.2018.10.031},
  abstract = {PURPOSE: The progressive loss of skeletal muscle and function (known as sarcopenia) has been shown to be associated with various adverse outcome measures. Sophisticated measurements of body composition are increasingly being incorporated into research studies to stratify patients into those with or without sarcopenia, monitor treatment effects, and predict complications. A typical approach is to select axial image(s) at the mid-lumbar level and use semi-automated software to identify and quantify the skeletal muscle area. This area is then used to estimate whole-body parameters. This approach is somewhat subjective, and in this study we investigate its reproducibility, both within and between observers. MATERIALS AND METHODS: Repeated muscle measurements were performed on a cohort of 29 patients by 3 radiologists, to examine their intra- and interobserver reproducibility. RESULTS AND DISCUSSION: Mean muscle area for the cohort was 156\,cm2, with a wide range (98 - 261\,cm2). There was good intraobserver agreement between measurements, with a mean absolute difference between repeated measurements on the same patient of 0.98\,cm2, and a measurement variability of 2.92\,cm2. Much of the variability was shown to be due to the choice of a different slice when performing the repeated measurement. Averaging two slices provided a small but non-significant improvement in comparison to the single slice approach. Interobserver results showed good agreement, though there was a small bias for one observer, who measured slightly larger volumes compared to the other two. We conclude that the approach described provides reproducible skeletal muscle area measurements, and offer three specific recommendations to minimise variability.},
  langid = {english},
  pmid = {30527297},
  keywords = {Aged,Body composition,Body Composition,Body mass index,Chemotherapy; Adjuvant,Cohort Studies,CT,Esophageal Neoplasms,Esophagogastric Junction,Female,Humans,ICC,Male,Methods,Middle Aged,Muscle; Skeletal,Observer Variation,Prospective Studies,Reproducibility of Results,Sarcopenia,Skeletal muscle,Software,Stomach Neoplasms,Tomography; X-Ray Computed}
}

@article{petrelli179,
  title = {Addition of Iron to Erythropoiesis-Stimulating Agents in Cancer Patients: A Meta-Analysis of Randomized Trials},
  shorttitle = {Addition of Iron to Erythropoiesis-Stimulating Agents in Cancer Patients},
  author = {Petrelli, Fausto and Borgonovo, Karen and Cabiddu, Mary and Lonati, Veronica and Barni, Sandro},
  year = {2012},
  month = feb,
  journal = {Journal of Cancer Research and Clinical Oncology},
  volume = {138},
  number = {2},
  pages = {179--187},
  issn = {1432-1335},
  doi = {10.1007/s00432-011-1072-3},
  abstract = {BACKGROUND: Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia. METHODS: We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity. RESULTS: A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation. CONCLUSION: Overall parenteral iron reduces the risk of transfusions by 23\% and increases the chance of hematopoietic response by 29\% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.},
  langid = {english},
  pmid = {21972052},
  keywords = {Anemia,Antineoplastic Agents,Blood Transfusion,Hematinics,Humans,Iron,Neoplasms,Randomized Controlled Trials as Topic}
}

@article{petrillo2288,
  title = {Performance Status and End-of-Life Care among Adults with Non\textendash Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors},
  author = {Petrillo, Laura A. and {El-Jawahri}, Areej and Nipp, Ryan D. and Lichtenstein, Morgan R. L. and Durbin, Sienna M. and Reynolds, Kerry L. and Greer, Joseph A. and Temel, Jennifer S. and Gainor, Justin F.},
  year = {2020},
  journal = {Cancer},
  volume = {126},
  number = {10},
  pages = {2288--2295},
  issn = {1097-0142},
  doi = {10.1002/cncr.32782},
  abstract = {Background Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non\textendash small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. Methods This was a retrospective, single-site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS ({$\geq$}2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end-of-life health care. Results The patient mean age at ICI initiation was 67 years (range, 37-91 years), and 35.4\% of patients had PS {$\geq$}2. Most patients (80.8\%) received ICI as second-line or later therapy. The median OS was 4.5 months in patients with PS {$\geq$}2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P {$<$} .0001). Among the patients who died (n = 184), 28.8\% who had PS {$\geq$}2 received ICIs in their last 30 days of life compared with 10.8\% of those who had PS 0 or 1 (P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) and increased in-hospital deaths (odds ratio, 6.8; P = .001), independent of PS. Conclusions Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high-quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second-line or later therapy.},
  langid = {english},
  keywords = {hospice care,ICI,immunotherapy,nonâsmall cell lung carcinoma,supportive care,terminal care},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32782},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5SMH5LAE\\Petrillo et al_2020_Performance status and end-of-life care among adults with nonâsmall cell lung.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\P97CYENQ\\cncr.html}
}

@article{pettersson972,
  title = {Tumour Regression in the Randomized {{Stockholm III Trial}} of~Radiotherapy Regimens for Rectal Cancer},
  author = {Pettersson, D. and L{\"o}rinc, E. and Holm, T. and Iversen, H. and Cedermark, B. and Glimelius, B. and Martling, A.},
  year = {2015},
  month = jul,
  journal = {The British Journal of Surgery},
  volume = {102},
  number = {8},
  pages = {972-978; discussion 978},
  issn = {1365-2168},
  doi = {10.1002/bjs.9811},
  abstract = {BACKGROUND: The Stockholm III Trial randomized patients with primary operable rectal cancers to either short-course radiotherapy (RT) with immediate surgery (SRT), short-course RT with surgery delayed 4-8 weeks (SRT-delay) or long-course RT with surgery delayed 4-8 weeks. This preplanned interim analysis examined the pathological outcome of delaying surgery. METHODS: Patients randomized to the SRT and SRT-delay arms in the Stockholm III Trial between October 1998 and November 2010 were included, and data were collected in a prospective register. Additional data regarding tumour regression grade, according to Dworak, and circumferential margin were obtained by reassessment of histopathological slides. RESULTS: A total of 462 of 545 randomized patients had specimens available for reassessment. Patients randomized to SRT-delay had earlier ypT categories, and a higher rate of pathological complete responses (11{$\cdot$}8 versus 1{$\cdot$}7 per cent; P\,=\,0{$\cdot$}001) and Dworak grade 4 tumour regression (10{$\cdot$}1 versus 1{$\cdot$}7 per cent; P\,{$<$}\,0{$\cdot$}001) than patients randomized to SRT without delay. Positive circumferential resection margins were uncommon (6{$\cdot$}3 per cent) and rates did not differ between the two treatment arms. CONCLUSION: Short-course RT induces tumour downstaging if surgery is performed after an interval of 4-8 weeks.},
  langid = {english},
  pmcid = {PMC4744683},
  pmid = {26095256},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Female,Humans,Male,Middle Aged,Neoplasm Staging,Preoperative Care,Prospective Studies,Radiotherapy; Adjuvant,Rectal Neoplasms,Rectal;RT,Time Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RZ32I59E\\Pettersson et al. - 2015 - Tumour regression in the randomized Stockholm III .pdf}
}

@article{phoa1209,
  ids = {phoa1209a},
  title = {Radiofrequency Ablation vs Endoscopic Surveillance for Patients with {{Barrett}} Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial},
  shorttitle = {Radiofrequency Ablation vs Endoscopic Surveillance for Patients with {{Barrett}} Esophagus and Low-Grade Dysplasia},
  author = {Phoa, K. Nadine and {van Vilsteren}, Frederike G. I. and Weusten, Bas L. A. M. and Bisschops, Raf and Schoon, Erik J. and Ragunath, Krish and Fullarton, Grant and Di Pietro, Massimiliano and Ravi, Narayanasamy and Visser, Mike and Offerhaus, G. Johan and Seldenrijk, Cees A. and Meijer, Sybren L. and {ten Kate}, Fiebo J. W. and Tijssen, Jan G. P. and Bergman, Jacques J. G. H. M.},
  year = {2014},
  month = mar,
  journal = {JAMA},
  volume = {311},
  number = {12},
  pages = {1209--1217},
  issn = {1538-3598},
  doi = {10.1001/jama.2014.2511},
  abstract = {IMPORTANCE: Barrett esophagus containing low-grade dysplasia is associated with an increased risk of developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the western world. OBJECTIVE: To investigate whether endoscopic radiofrequency ablation could decrease the rate of neoplastic progression. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial that enrolled 136 patients with a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia at 9 European sites between June 2007 and June 2011. Patient follow-up ended May 2013. INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to either endoscopic treatment with radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with the balloon device for circumferential ablation of the esophagus or the focal device for targeted ablation, with a maximum of 5 sessions allowed. MAIN OUTCOMES AND MEASURES: The primary outcome was neoplastic progression to high-grade dysplasia or adenocarcinoma during a 3-year follow-up since randomization. Secondary outcomes were complete eradication of dysplasia and intestinal metaplasia and adverse events. RESULTS: Sixty-eight patients were randomized to receive ablation and 68 to receive control. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0\% (1.5\% for ablation vs 26.5\% for control; 95\% CI, 14.1\%-35.9\%; P\,{$<$}\,.001) and the risk of progression to adenocarcinoma by 7.4\% (1.5\% for ablation vs 8.8\% for control; 95\% CI, 0\%-14.7\%; P\,=\,.03). Among patients in the ablation group, complete eradication occurred in 92.6\% for dysplasia and 88.2\% for intestinal metaplasia compared with 27.9\% for dysplasia and 0.0\% for intestinal metaplasia among patients in the control group (P\,{$<$}\,.001). Treatment-related adverse events occurred in 19.1\% of patients receiving ablation (P\,{$<$}\,.001). The most common adverse event was stricture, occurring in 8 patients receiving ablation (11.8\%), all resolved by endoscopic dilation (median, 1 session). The data and safety monitoring board recommended early termination of the trial due to superiority of ablation for the primary outcome and the potential for patient safety issues if the trial continued. CONCLUSIONS AND RELEVANCE: In this randomized trial of patients with Barrett esophagus and a confirmed diagnosis of low-grade dysplasia, radiofrequency ablation resulted in a reduced risk of neoplastic progression over 3 years of follow-up. TRIAL REGISTRATION: trialregister.nl Identifier: NTR1198.},
  langid = {english},
  pmid = {24668102},
  keywords = {Adenocarcinoma,Aged,Barrett Esophagus,Catheter Ablation,Disease Progression,Esophageal Neoplasms,Esophagoscopy,Esophagus,Female,Humans,Male,Middle Aged,Treatment Outcome,Watchful Waiting},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2MJ8Z3LW\\Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\XK5ED99S\\Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf}
}

@article{phua488,
  type = {Journal {{Article}}},
  title = {Patients with Gastro-Oesophageal Reflux Disease and Cough Have Impaired Laryngopharyngeal Mechanosensitivity},
  author = {Phua, S. Y. and McGarvey, L. P. and Ngu, M. C. and Ing, A. J.},
  year = {2005},
  journal = {Thorax},
  volume = {60},
  number = {6},
  pages = {488--91},
  issn = {0040-6376 (Print) 0040-6376 (Linking)},
  doi = {10.1136/thx.2004.033894}
}

@article{pisarskae0174382,
  title = {Enhanced Recovery after Surgery Protocol in Oesophageal Cancer Surgery: {{Systematic}} Review and Meta-Analysis},
  shorttitle = {Enhanced Recovery after Surgery Protocol in Oesophageal Cancer Surgery},
  author = {Pisarska, Magdalena and Ma{\l}czak, Piotr and Major, Piotr and Wysocki, Micha{\l} and Budzy{\'n}ski, Andrzej and P{\k{e}}dziwiatr, Micha{\l}},
  year = {2017},
  journal = {PloS One},
  volume = {12},
  number = {3},
  pages = {e0174382},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0174382},
  abstract = {BACKGROUND: Enhanced Recovery After Surgery (ERAS) protocol are well established in many surgical disciplines, leading to decrease in morbidity and length of hospital stay. These multi-modal protocols have been also introduced to oesophageal cancer surgery. This review aimed to evaluate current literature on ERAS in oesophageal cancer surgery and conduct a meta-analysis on primary and secondary outcomes. METHODS: MEDLINE, Embase, Scopus and Cochrane Library were searched for eligible studies. We analyzed data up to May 2016. Eligible studies had to contain four described ERAS protocol elements. The primary outcome was overall morbidity. Secondary outcomes included length of hospital stay, specific complications, mortality and readmissions. Random effect meta-analyses were undertaken. RESULTS: Initial search yielded 1,064 articles. Thorough evaluation resulted in 13 eligible articles which were analyzed. A total of 2,042 patients were included in the analysis (1,058 ERAS group and 984 treated with traditional protocols). Analysis of overall morbidity as well as complication rate did not show any significant reduction. Non-surgical complications and pulmonary complications were significantly lower in the ERAS group, RR = 0.71 95\% CI 0.62-0.80, p {$<$} 0.00001 and RR = 0.75, 95\% CI 0.60-0.94, p = 0.01, respectively. Meta-analysis on length of stay presented significant reduction Mean difference = -3.55, 95\% CI -4.41 to -2.69, p for effect{$<$}0.00001. CONCLUSIONS: This systematic review with a meta-analysis on ERAS in oesophageal surgery indicates a reduction of non-surgical complications and no negative influence on overall morbidity. Moreover, a reduction in the length of hospital stay was presented.},
  langid = {english},
  pmcid = {PMC5370110},
  pmid = {28350805},
  keywords = {Esophageal Neoplasms,Esophagus,Humans,Length of Stay,Postoperative Complications,Recovery of Function,Systematic Reviews as Topic,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SEJA9D4U\\Pisarska et al_2017_Enhanced recovery after surgery protocol in oesophageal cancer surgery.pdf}
}

@article{podsiadlo142,
  title = {The Timed "{{Up}} \& {{Go}}": A Test of Basic Functional Mobility for Frail Elderly Persons},
  shorttitle = {The Timed "{{Up}} \& {{Go}}"},
  author = {Podsiadlo, D. and Richardson, S.},
  year = {1991},
  month = feb,
  journal = {Journal of the American Geriatrics Society},
  volume = {39},
  number = {2},
  pages = {142--148},
  issn = {0002-8614},
  doi = {10.1111/j.1532-5415.1991.tb01616.x},
  abstract = {This study evaluated a modified, timed version of the "Get-Up and Go" Test (Mathias et al, 1986) in 60 patients referred to a Geriatric Day Hospital (mean age 79.5 years). The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The results indicate that the time score is (1) reliable (inter-rater and intra-rater); (2) correlates well with log-transformed scores on the Berg Balance Scale (r = -0.81), gait speed (r = -0.61) and Barthel Index of ADL (r = -0.78); and (3) appears to predict the patient's ability to go outside alone safely. These data suggest that the timed "Up \& Go" test is a reliable and valid test for quantifying functional mobility that may also be useful in following clinical change over time. The test is quick, requires no special equipment or training, and is easily included as part of the routine medical examination.},
  langid = {english},
  pmid = {1991946},
  keywords = {Activities of Daily Living,Aged,Aged; 80 and over,Canes,Female,Humans,Male,Parkinson Disease,Time Factors,Walking}
}

@article{popuri512,
  title = {Body {{Composition Assessment}} in {{Axial CT Images Using FEM-Based Automatic Segmentation}} of {{Skeletal Muscle}}},
  author = {Popuri, Karteek and Cobzas, Dana and Esfandiari, Nina and Baracos, Vickie and J{\"a}gersand, Martin},
  year = {2016},
  month = feb,
  journal = {IEEE transactions on medical imaging},
  volume = {35},
  number = {2},
  pages = {512--520},
  issn = {1558-254X},
  doi = {10.1109/TMI.2015.2479252},
  abstract = {The proportions of muscle and fat tissues in the human body, referred to as body composition is a vital measurement for cancer patients. Body composition has been recently linked to patient survival and the onset/recurrence of several types of cancers in numerous cancer research studies. This paper introduces a fully automatic framework for the segmentation of muscle and fat tissues from CT images to estimate body composition. We developed a novel finite element method (FEM) deformable model that incorporates a priori shape information via a statistical deformation model (SDM) within the template-based segmentation framework. The proposed method was validated on 1000 abdominal and 530 thoracic CT images and we obtained very good segmentation results with Jaccard scores in excess of 90\% for both the muscle and fat regions.},
  langid = {english},
  pmid = {26415164},
  keywords = {Body Composition,Finite Element Analysis,Humans,Image Processing; Computer-Assisted,ML,Muscle; Skeletal,Radiography; Abdominal,Radiography; Thoracic,Reproducibility of Results,Tomography; X-Ray Computed}
}

@article{porporatoe200,
  title = {Understanding Cachexia as a Cancer Metabolism Syndrome},
  author = {Porporato, P. E.},
  year = {2016},
  month = feb,
  journal = {Oncogenesis},
  volume = {5},
  pages = {e200},
  issn = {2157-9024},
  doi = {10.1038/oncsis.2016.3},
  abstract = {Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and metastasis, but as well at a systemic level affecting the whole organism, eventually leading to cancer cachexia. Indeed, as cancer cells rely on external sources of nitrogen and carbon skeleton to grow, systemic metabolic deregulation promoting tissue wasting and metabolites mobilization ultimately supports tumor growth. Cachectic patients experience a wide range of symptoms affecting several organ functions such as muscle, liver, brain, immune system and heart, collectively decreasing patients' quality of life and worsening their prognosis. Moreover, cachexia is estimated to be the direct cause of at least 20\% of cancer deaths. The main aspect of cachexia syndrome is the unstoppable skeletal muscle and fat storage wasting, even with an adequate caloric intake, resulting in nutrient mobilization - both directly as lipid and amino acids and indirectly as glucose derived from the exploitation of liver gluconeogenesis - that reaches the tumor through the bloodstream. From a metabolic standpoint, cachectic host develops a wide range of dysfunctions, from increased insulin and IGF-1 resistance to induction of mitochondrial uncoupling proteins and fat tissue browning resulting in an increased energy expenditure and heat generation, even at rest. For a long time, cachexia has been merely considered an epiphenomenon of end-stage tumors. However, in specific tumor types, such as pancreatic cancers, it is now clear that patients present markers of tissue wasting at a stage in which tumor is not yet clinically detectable, and that host amino acid supply is required for tumor growth. Indeed, tumor cells actively promote tissue wasting by secreting specific factors such as parathyroid hormone-related protein and micro RNAs. Understanding the molecular and metabolic mediators of cachexia will not only advance therapeutic approaches against cancer, but also improve patients' quality of life.},
  langid = {english},
  pmcid = {PMC5154342},
  pmid = {26900952},
  keywords = {Cachexia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9HWEI3C4\\Porporato - 2016 - Understanding cachexia as a cancer metabolism synd.pdf}
}

@article{porteous139,
  type = {Journal {{Article}}},
  title = {A Standardized Anesthetic and Surgical Clinical Pathway for Esophageal Resection: Impact on Length of Stay and Major Outcomes},
  author = {Porteous, G. H. and Neal, J. M. and Slee, A. and Schmidt, H. and Low, D. E.},
  year = {2015},
  journal = {Reg Anesth Pain Med},
  volume = {40},
  number = {2},
  pages = {139--49},
  issn = {1532-8651 (Electronic) 1098-7339 (Linking)},
  doi = {10.1097/AAP.0000000000000197}
}

@article{poultsides35,
  title = {Reassessing the Need for Primary Tumor Surgery in Unresectable Metastatic Colorectal Cancer: Overview and Perspective},
  shorttitle = {Reassessing the Need for Primary Tumor Surgery in Unresectable Metastatic Colorectal Cancer},
  author = {Poultsides, George A. and Paty, Phillip B.},
  year = {2011},
  month = jan,
  journal = {Therapeutic Advances in Medical Oncology},
  volume = {3},
  number = {1},
  pages = {35--42},
  issn = {1758-8359},
  doi = {10.1177/1758834010386283},
  abstract = {In the absence of symptoms, primary tumor resection in patients who present with unresectable metastatic colorectal cancer is of uncertain benefit. Prophylactic surgery has been traditionally considered in this setting in order to prevent subsequent complications of perforation, obstruction, or bleeding later during the treatment course, which may require urgent surgery associated with higher mortality. However, recent data have called into question the efficacy of this upfront surgical strategy. We provide a brief overview of how current combinations of systemic chemotherapy including fluorouracil, oxaliplatin, irinotecan, and targeted biologic agents have allowed improved local (in addition to distant) tumor control, significantly decreasing the incidence of late primary-related complications requiring surgery from roughly 20\% in the era of single-agent fluoropyrimidine chemotherapy to almost 7\% in the era of modern triple-drug chemotherapy. In addition, we attempt to highlight those factors most associated with subsequent primary tumor-related complications in an effort to identify the subset of patients with synchronous metastatic colorectal cancer who might benefit from a surgery-first approach. Finally, we discuss modern nonsurgical options available for palliation of the primary colorectal tumor and review the outcome of patients for which emergent surgery is eventually required to address primary-related symptoms.},
  langid = {english},
  pmcid = {PMC3126037},
  pmid = {21789154},
  keywords = {chemotherapy,colorectal cancer,primary tumor,stage IV,Stage4},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WKDH46VW\\Poultsides and Paty - 2011 - Reassessing the need for primary tumor surgery in .pdf}
}

@article{prado1012,
  title = {Central Tenet of Cancer Cachexia Therapy: Do Patients with Advanced Cancer Have Exploitable Anabolic Potential?},
  shorttitle = {Central Tenet of Cancer Cachexia Therapy},
  author = {Prado, Carla M. and Sawyer, Michael B. and Ghosh, Sunita and Lieffers, Jessica R. and Esfandiari, Nina and Antoun, Sami and Baracos, Vickie E.},
  year = {2013},
  month = oct,
  journal = {The American Journal of Clinical Nutrition},
  volume = {98},
  number = {4},
  pages = {1012--1019},
  issn = {1938-3207},
  doi = {10.3945/ajcn.113.060228},
  abstract = {BACKGROUND: Skeletal muscle wasting is considered the central feature of cachexia, but the potential for skeletal muscle anabolism in patients with advanced cancer is unproven. OBJECTIVE: We investigated the clinical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabolism. DESIGN: We conducted a quantitative analysis of computed tomography (CT) images for the loss and gain of muscle in population-based cohorts of advanced cancer patients (lung, colorectal, and pancreas cancer and cholangiocarcinoma) in a longitudinal observational study. RESULTS: Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39\% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4\%, and muscle was stable in 45.6\% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with {$>$}90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95\% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95\% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain. CONCLUSIONS: A window of anabolic potential exists at defined early phases of the disease trajectory ({$>$}90 d survival), creating an opportunity for nutritional intervention to stop or reverse cachexia. Cancer patients within 90 d of death have a low likelihood of anabolic potential.},
  langid = {english},
  pmid = {23966429},
  keywords = {Adipose Tissue,Aged,Body Composition,Cachexia,Cholangiocarcinoma,Colorectal Neoplasms,Female,Humans,Longitudinal Studies,Lung Neoplasms,Male,Metabolism,Middle Aged,Muscle; Skeletal,Muscular Atrophy,Neoplasm Staging,Neoplasms,Pancreatic Neoplasms,Survival Rate,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZMS2TIEE\\prado1012.pdf}
}

@article{prado269,
  title = {The Emerging Role of Computerized Tomography in Assessing Cancer Cachexia},
  author = {Prado, Carla M. M. and Birdsell, Laura A. and Baracos, Vickie E.},
  year = {2009},
  month = dec,
  journal = {Current Opinion in Supportive and Palliative Care},
  volume = {3},
  number = {4},
  pages = {269--275},
  issn = {1751-4266},
  doi = {10.1097/SPC.0b013e328331124a},
  abstract = {PURPOSE OF REVIEW: The present review represents an overview of the potential opportunistic use of computerized tomography (CT) to enhance our understanding of abnormal body composition, specifically lean and adipose tissue changes in cancer cachexia. RECENT FINDINGS: One of the characteristics of cancer cachexia is the depletion of muscle with or without adipose tissue loss. Therefore, a body composition tool that specifically distinguishes between these tissues is essential in assessing this syndrome. Cancer patients are routinely evaluated by high resolution imaging such as CT for the purpose of diagnosis and follow-up. Recent work exploiting CT images for body composition analysis has revealed the natural history of cancer cachexia, including progressive alterations in skeletal muscle, adipose tissue, organs, and tumor mass. CT-based quantification of skeletal muscle has permitted identification of individuals with sarcopenia, and links between sarcopenia and functional status, chemotherapy toxicity, time to tumor progression, and mortality. SUMMARY: CT images routinely acquired from health records of cancer patients can be used to quantify specific lean and adipose tissues, to interpret body composition in population-based studies, and to evaluate individual patients in a clinical and therapeutic decision-making setting.},
  langid = {english},
  pmid = {19667996},
  keywords = {Adipose Tissue,Body Composition,Cachexia,Disease Progression,Humans,Muscle; Skeletal,Neoplasms,Thinness,Tomography; X-Ray Computed}
}

@article{prado2920,
  type = {Journal {{Article}}},
  title = {Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment},
  author = {Prado, C. M. and Baracos, V. E. and McCargar, L. J. and Reiman, T. and Mourtzakis, M. and Tonkin, K. and Mackey, J. R. and Koski, S. and Pituskin, E. and Sawyer, M. B.},
  year = {2009},
  journal = {Clin Cancer Res},
  volume = {15},
  number = {8},
  pages = {2920--6},
  issn = {1078-0432 (Print) 1078-0432 (Linking)},
  doi = {10.1158/1078-0432.CCR-08-2242}
}

@article{prado3264,
  title = {Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity},
  author = {Prado, Carla M. M. and Baracos, Vickie E. and McCargar, Linda J. and Mourtzakis, Marina and Mulder, Karen E. and Reiman, Tony and Butts, Charles A. and Scarfe, Andrew G. and Sawyer, Michael B.},
  year = {2007},
  month = jun,
  journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
  volume = {13},
  number = {11},
  pages = {3264--3268},
  issn = {1078-0432},
  doi = {10.1158/1078-0432.CCR-06-3067},
  abstract = {PURPOSE: Evidence suggests that lean body mass (LBM) may be useful to normalize doses of chemotherapy. Data from a prospective study were used to determine if the highest doses of 5-fluorouracil (5-FU) per kilogram LBM would be associated with dose-limiting toxicity in stage II/III colon cancer patients treated with 5-FU and leucovorin. EXPERIMENTAL DESIGN: Toxicity after cycle 1 was graded according to National Cancer Institute Common Toxicity Criteria, version 2.0. Muscle tissue was measured by computerized tomography. An extrapolation to the LBM compartment of the whole body was employed. RESULTS: Mean values of 5-FU/LBM of the entire population were different in terms of presence or absence of toxicity (P = 0.036). A cut point of 20 mg 5-FU/kg LBM seemed to be a threshold for developing toxicity (P = 0.005). This observation was pertinent to women (odds ratio, 16.73; P = 0.021). Women in this study had a relatively low proportion of LBM relative to their body surface area. CONCLUSION: Our study shows that low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area. We conclude that variation in toxicity between females and males may be partially explained by this feature of body composition.},
  langid = {english},
  pmid = {17545532},
  keywords = {Adult,Aged,Antineoplastic Agents,Body Composition,Body Mass Index,Body Surface Area,chemo,crc,Dose-Response Relationship; Drug,Female,Fluorouracil,Humans,Leucovorin,Male,Middle Aged,Prospective Studies,Sex Factors}
}

@article{prado629,
  title = {Prevalence and Clinical Implications of Sarcopenic Obesity in Patients with Solid Tumours of the Respiratory and Gastrointestinal Tracts: A Population-Based Study},
  shorttitle = {Prevalence and Clinical Implications of Sarcopenic Obesity in Patients with Solid Tumours of the Respiratory and Gastrointestinal Tracts},
  author = {Prado, Carla M. M. and Lieffers, Jessica R. and McCargar, Linda J. and Reiman, Tony and Sawyer, Michael B. and Martin, Lisa and Baracos, Vickie E.},
  year = {2008},
  month = jul,
  journal = {The Lancet. Oncology},
  volume = {9},
  number = {7},
  pages = {629--635},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(08)70153-0},
  abstract = {BACKGROUND: Emerging evidence on body composition suggests that sarcopenic obesity (obesity with depleted muscle mass) might be predictive of morbidity and mortality in non-malignant disease and also of toxicity to chemotherapy. We aimed to assess the prevalence and clinical implications of sarcopenic obesity in patients with cancer. METHODS: Between Jan 13, 2004, and Jan 19, 2007, 2115 patients with solid tumours of the respiratory or gastrointestinal tract from a cancer treatment centre serving northern Alberta, Canada, were identified. Available lumbar CT images of the obese patients were analysed for total skeletal muscle cross-sectional area; these values were also used to estimate total body fat-free mass (FFM). FINDINGS: Of the 2115 patients initially identified, 325 (15\%) were classified as obese (body-mass index [BMI] {$>$} or =30). Of these obese patients, 250 had CT images that met the criteria for analysis. The remaining 75 patients were recorded as without assessable scans. Obese patients had a wide range of muscle mass. Sex-specific cut-offs that defined a significant association between low muscle mass with mortality were ascertained by optimum stratification analysis: 38 (15\%) of 250 patients who had assessable CT images that met the criteria for analysis were below these cut-offs and were classified as having sarcopenia. Sarcopenic obesity was associated with poorer functional status compared with obese patients who did not have sarcopenia (p=0.009), and was an independent predictor of survival (hazard ratio [HR] 4.2 [95\% CI 2.4-7.2], p{$<$}0.0001). Estimated FFM showed a poor association with body-surface area (r(2)=0.37). Assuming that FFM represents the volume of distribution of many cytotoxic chemotherapy drugs, we estimated that individual variation in FFM could account for up to three-times variation in effective volume of distribution for chemotherapy administered per unit body-surface area, in this population. INTERPRETATION: This study provides evidence of the great variability of body composition in patients with cancer and links body composition, especially sarcopenic obesity, to clinical implications such as functional status, survival, and potentially, chemotherapy toxicity.},
  langid = {english},
  pmid = {18539529},
  keywords = {Adult,Aged,Aged; 80 and over,Alberta,Body Composition,Cohort Studies,Female,Gastrointestinal Neoplasms,Humans,Lung Neoplasms,Male,Middle Aged,Muscle; Skeletal,Muscular Diseases,Obesity,Prevalence}
}

@article{prescott1,
  title = {How Low Should We Go: {{A}} Systematic Review and Meta-Analysis of the Impact of Restrictive Red Blood Cell Transfusion Strategies in Oncology},
  shorttitle = {How Low Should We Go},
  author = {Prescott, Lauren S. and Taylor, Jolyn S. and {Lopez-Olivo}, Maria A. and Munsell, Mark F. and VonVille, Helena M. and Lairson, David R. and Bodurka, Diane C.},
  year = {2016},
  month = may,
  journal = {Cancer Treatment Reviews},
  volume = {46},
  pages = {1--8},
  issn = {1532-1967},
  doi = {10.1016/j.ctrv.2016.03.010},
  abstract = {BACKGROUND: Most non-oncologic clinical practice guidelines recommend restrictive allogeneic blood transfusion practices; however, there is a lack of consensus regarding the best transfusion practice in oncology. We conducted a systematic review of the literature to compare the efficacy and safety of restrictive versus liberal transfusion strategies in patients with cancer. METHODS: A literature search using MEDLINE, PUBMED and EMBASE identified all controlled studies comparing the use of restrictive with liberal transfusion in adult oncology participants up to August 10, 2015. Two review authors independently assessed studies for inclusion, extracted data and appraised the quality of the included studies. The primary outcomes of interest were blood utilization and all-cause mortality. RESULTS: Out of 4241 citations, six studies (3 randomized and 3 non-randomized) involving a total of 983 patients were included in the final review. The clinical context of the studies varied with 3 chemotherapy and 3 surgical studies. The overall risk of bias in all studies was moderate to high. Restrictive transfusion strategies were associated with a 36\% reduced risk of receiving a perioperative transfusion (risk ratio (RR) 0.64, 95\% confidence interval (CI) 0.49-0.83). There was no difference in mortality between the strategies (RR 1.00, 95\% CI 0.32-3.18). There were no differences in adverse events reported between the restrictive and liberal transfusion strategies. CONCLUSION: Restrictive strategy appears to decrease blood utilization without increasing morbidity or mortality in oncology. This review is limited by a paucity of high quality studies on this topic. Better designed studies are warranted.},
  langid = {english},
  pmcid = {PMC4884540},
  pmid = {27046422},
  keywords = {Anemia,Blood,Cancer,Erythrocyte Transfusion,Humans,Medical Oncology,Neoplasms,Randomized Controlled Trials as Topic,SurgOnc,Systematic review,Transfusion,Transplantation; Homologous},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TXU7IVTA\\Prescott et al_2016_How low should we go.pdf}
}

@article{qin11,
  type = {Journal {{Article}}},
  title = {Does Timing of Esophagectomy Following Neoadjuvant Chemoradiation Affect Outcomes? {{A}} Meta-Analysis},
  author = {Qin, Q. and Xu, H. and Liu, J. and Zhang, C. and Xu, L. and Di, X. and Zhang, X. and Sun, X.},
  year = {2018},
  journal = {Int J Surg},
  volume = {59},
  pages = {11--18},
  issn = {1743-9159 (Electronic) 1743-9159 (Linking)},
  doi = {10.1016/j.ijsu.2018.09.013}
}

@article{quirke996,
  title = {Local Recurrence of Rectal Adenocarcinoma Due to Inadequate Surgical Resection. {{Histopathological}} Study of Lateral Tumour Spread and Surgical Excision},
  author = {Quirke, P. and Durdey, P. and Dixon, M. F. and Williams, N. S.},
  year = {1986},
  month = nov,
  journal = {Lancet (London, England)},
  volume = {2},
  number = {8514},
  pages = {996--999},
  issn = {0140-6736},
  doi = {10.1016/s0140-6736(86)92612-7},
  abstract = {In 52 patients with rectal adenocarcinoma whole-mount sections of the entire operative specimen were examined by transverse slicing. There was spread to the lateral resection margin in 14 of 52 (27\%) patients and 12 of these proceeded to local pelvic recurrence. The specificity, sensitivity, and positive predictive values were 92\%, 95\%, and 85\%, respectively. In a retrospective stage-matched and grade-matched control group there was local recurrence in the same proportion of patients, but in this series no patient had been shown by routine sampling to have lateral spread. In rectal adenocarcinoma, local recurrence is mainly due to lateral spread of the tumour and has previously been underestimated.},
  langid = {english},
  pmid = {2430152},
  keywords = {Adenocarcinoma,Female,Humans,Male,Methods,Neoplasm Recurrence; Local,Palliative Care,Prospective Studies,Rectal Neoplasms,Rectal; TME,Retrospective Studies}
}

@article{raber-durlacher433,
  type = {Journal {{Article}}},
  title = {Swallowing Dysfunction in Cancer Patients: {{Dysphagia Section}}, {{Oral Care Study Group Multinational Association}} of {{Supportive Care}} in {{Cancer International Society}} of {{Oral Oncology}}},
  author = {{Raber-Durlacher}, J. E. and Brennan, M. T. and {Verdonck-de Leeuw}, I. M. and Gibson, R. J. and Eilers, J. G. and Waltimo, T. and Bots, C. P. and Michelet, M. and Sollecito, T. P. and Rouleau, T. S. and Sewnaik, A. and Bensadoun, R. J. and Fliedner, M. C. and Silverman, S., Jr. and Spijkervet, F. K.},
  year = {2012},
  journal = {Support Care Cancer},
  volume = {20},
  number = {3},
  pages = {433--43},
  issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
  doi = {10.1007/s00520-011-1342-2}
}

@article{raymond207,
  type = {Journal {{Article}}},
  title = {Predictors of {{Major Morbidity}} or {{Mortality After Resection}} for {{Esophageal Cancer}}: {{A Society}} of {{Thoracic Surgeons General Thoracic Surgery Database Risk Adjustment Model}}},
  author = {Raymond, D. P. and Seder, C. W. and Wright, C. D. and Magee, M. J. and Kosinski, A. S. and Cassivi, S. D. and Grogan, E. L. and Blackmon, S. H. and Allen, M. S. and Park, B. J. and Burfeind, W. R. and Chang, A. C. and DeCamp, M. M. and Wormuth, D. W. and Fernandez, F. G. and Kozower, B. D.},
  year = {2016},
  journal = {Ann Thorac Surg},
  volume = {102},
  number = {1},
  pages = {207--14},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2016.04.055}
}

@article{rechinelli9,
  title = {Presence of Dynapenia and Association with Anthropometric Variables in Cancer Patients},
  author = {Rechinelli, Ana Beatriz},
  year = {2020},
  pages = {9},
  abstract = {Background: Dynapenia is defined as an age-related loss of muscle strength. There is little information on dynapenia in cancer patients and on how it relates to anthropometric variables. The aim of this study was to analyze the presence of dynapenia and its association with anthropometric variables in hospitalized cancer patients. Methods: Participants comprised adult and elderly cancer patients evaluated within the first 48 h of hospital admission to a tertiary public hospital, a referral center for gastrointestinal tract surgery. Anthropometric variables were measured according to standardized protocols. Dynapenia was identified based on handgrip strength (HGS), according to the cutoff points defined by the European Working Group on Sarcopenia in Older People (EWGSOP2), with values for women {$<$} 16 kg and for men {$<$} 27 kg. Statistical analysis was performed using SPSS software, version 22.0, with a significance level of 5\%.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Z8HV7N86\\Rechinelli - 2020 - Presence of dynapenia and association with anthrop.pdf}
}

@article{redelmeier1278,
  type = {Journal {{Article}}},
  title = {Interpreting Small Differences in Functional Status: The {{Six Minute Walk}} Test in Chronic Lung Disease Patients},
  author = {Redelmeier, D. A. and Bayoumi, A. M. and Goldstein, R. S. and Guyatt, G. H.},
  year = {1997},
  journal = {Am J Respir Crit Care Med},
  volume = {155},
  number = {4},
  pages = {1278--82},
  issn = {1073-449X (Print) 1073-449X (Linking)},
  doi = {10.1164/ajrccm.155.4.9105067}
}

@article{refai820,
  title = {The Impact of Chest Tube Removal on Pain and Pulmonary Function after Pulmonary Resection},
  author = {Refai, Majed and Brunelli, Alessandro and Salati, Michele and Xium{\`e}, Francesco and Pompili, Cecilia and Sabbatini, Armando},
  year = {2012},
  month = apr,
  journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
  volume = {41},
  number = {4},
  pages = {820-822; discussion 823},
  issn = {1873-734X},
  doi = {10.1093/ejcts/ezr126},
  abstract = {OBJECTIVE: The aim of this study was to assess the immediate influence of chest tube removal on chest pain and forced expiratory volume in 1 s (FEV1) after pulmonary resection. METHODS: Prospective longitudinal investigation on 104 consecutive patients (53 wedge/segmentectomies and 51 lobectomies; 69 muscle and nerve-sparing lateral thoracotomy and 35 video-assisted thoracoscopic surgery (VATS)). Post-operative chest pain was controlled in all patients by a standardized combination of oral and intravenous non-opioid analgesics. All patients had one chest tube (24 French). Static and dynamic (after forced expiratory effort) pain and FEV1 were assessed before and 1 h after the chest tube removal by the same operator. No additional analgesics were administered before or after the chest tube removal. The pain level was assessed by the numeric pain scale [range: 0 (no pain)-10 (excruciating pain)]. FEV1 was assessed by a portable spirometer. Bronchodilators were not used in these patients. Pre- and post-removal measurements were compared by the Wilcoxon signed rank test. RESULTS: The average pre-removal static and dynamic pain scores were 2.6 and 4.1, respectively. The static and dynamic pain scores decreased by 42 and 41\%, respectively, after the tube removal (P {$<$} 0.0001). The average FEV1 before the chest tube removal was 1.5 l or 53\% of the predicted value and increased by 13\% after the tube removal (P = 0.0004). In total, 56 and 78\% of patients reported static and dynamic pain scores improvement and 67\% showed an FEV1 improvement after the chest tube removal. Similar results were observed in patients operated on through VATS or thoracotomy. Compared with patients whose chest tube was removed later, those who had their chest tube removed before post operative day 3 (POD3), showed a greater reduction in the static pain score (41 vs. 31\%, P = 0.05) and greater improvement in FEV1 (18 vs. 0.01\%, P = 0.02). CONCLUSIONS: The removal of a chest tube reduces pain and improves ventilatory function, independent of surgical access and particularly in the early post-operative phase. A fast track chest tube removal policy may favour patients' recovery.},
  langid = {english},
  pmid = {22219425},
  keywords = {Aged,Analgesics,Chest Pain,Chest Tubes,Device Removal,Drug Administration Schedule,Female,Forced Expiratory Volume,Humans,Male,Middle Aged,Pain Measurement,Pain; Postoperative,Pneumonectomy,Postoperative Care,Postoperative Period,Prospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\F8845FXB\\Refai et al_2012_The impact of chest tube removal on pain and pulmonary function after pulmonary.pdf}
}

@article{reichert11856,
  type = {Journal {{Article}}},
  title = {Ivor {{Lewis}} Esophagectomy Patients Are Particularly Vulnerable to Respiratory Impairment - a Comparison to Major Lung Resection},
  author = {Reichert, M. and Schistek, M. and Uhle, F. and Koch, C. and Bodner, J. and Hecker, M. and Horbelt, R. and Grau, V. and Padberg, W. and Weigand, M. A. and Hecker, A.},
  year = {2019},
  journal = {Sci Rep},
  volume = {9},
  number = {1},
  pages = {11856},
  issn = {2045-2322 (Electronic) 2045-2322 (Linking)},
  doi = {10.1038/s41598-019-48234-w}
}

@article{rejeski629,
  title = {An Automated Electronic Health-Record Derived Frailty Index Is Associated with Adverse Events after Endoscopy},
  author = {Rejeski, Jared and Xiao, Ted and Wheless, William and Pajewski, Nicholas M. and Jensen, Elizabeth and Callahan, Kathryn E.},
  year = {2022},
  month = feb,
  journal = {Journal of the American Geriatrics Society},
  volume = {70},
  number = {2},
  pages = {629--631},
  issn = {1532-5415},
  doi = {10.1111/jgs.17537},
  langid = {english},
  pmcid = {PMC8979651},
  pmid = {34716701},
  keywords = {Aged,eFI,Electronic Health Records,Endoscopy; Gastrointestinal,Frailty,Geriatric Assessment,Humans,Retrospective Studies,Risk Assessment},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H5AX2KGH\\Rejeski et al_2022_An automated electronic health-record derived frailty index is associated with.pdf}
}

@article{repici715,
  title = {Endoscopic Submucosal Dissection in Patients with Early Esophageal Squamous Cell Carcinoma: Results from a Prospective {{Western}} Series},
  shorttitle = {Endoscopic Submucosal Dissection in Patients with Early Esophageal Squamous Cell Carcinoma},
  author = {Repici, Alessandro and Hassan, Cesare and Carlino, Alessandra and Pagano, Nico and Zullo, Angelo and Rando, Giacomo and Strangio, Giuseppe and Romeo, Fabio and Nicita, Rinaldo and Rosati, Riccardo and Malesci, Alberto},
  year = {2010},
  month = apr,
  journal = {Gastrointestinal Endoscopy},
  volume = {71},
  number = {4},
  pages = {715--721},
  issn = {1097-6779},
  doi = {10.1016/j.gie.2009.11.020},
  abstract = {BACKGROUND: Although endoscopic submucosal dissection (ESD) is becoming accepted as an established treatment for superficial esophageal squamous cell neoplasia, the majority of data on this endoscopic modality has been provided by Japanese series. OBJECTIVE: To assess the efficacy and safety of ESD for esophageal squamous cell neoplasia in a consecutive series of patients treated in a Western setting. DESIGN AND SETTING: Single-center, prospective observational study. PATIENTS AND INTERVENTION: From January 2005 to July 2008, 20 patients with superficial esophageal squamous cell neoplasia were treated by ESD. MAIN OUTCOME MEASUREMENTS: Rates of en bloc resection, complete resection, and complications were evaluated as short-term outcomes. Overall survival, local or distant recurrence, and postoperative stricture rates were evaluated as long-term outcomes. RESULTS: ESD was performed in 20 patients (mean age 64 years, range 46-81 years; 16 men). The mean size of the lesion was 32 mm (range 15-60 mm); it was 30 mm or larger in 14 patients (70\%). The mean time of ESD was 89 minutes (range 58-180 minutes). En bloc resection with resection-free margins was achieved in 18 patients (90\%), whereas 2 patients presented with incomplete or indeterminate resection. Two cases (10\%) of mediastinal emphysema without overt perforation and 1 case (5\%) of post-ESD symptomatic stricture were reported. No local or distant post-ESD recurrence occurred in those with resection-free margins at a median follow-up of 18 months. LIMITATIONS: Small number of patients and limited follow-up. CONCLUSION: This Western series study confirms that ESD is a potentially curative treatment for superficial esophageal squamous cell neoplasia. Early and late complication rates were comparable to those of Japanese series. ESD should be probably considered as the treatment of choice in all large lesions amenable to endoscopic treatment.},
  langid = {english},
  pmid = {20363414},
  keywords = {Aged,Aged; 80 and over,Animals,Carcinoma; Squamous Cell,Disease-Free Survival,Esophageal Neoplasms,Esophagoscopy,Esophagus,Female,Follow-Up Studies,Humans,Male,Middle Aged,Postoperative Complications,Prospective Studies}
}

@article{retornaz9,
  title = {Predicting {{Chemotherapy Toxicity}} and {{Death}} in {{Older Adults}} with {{Colon Cancer}}: {{Results}} of {{MOST Study}}},
  author = {Retornaz, Fr{\'e}d{\'e}rique and Guillem, Olivier and Rousseau, Fr{\'e}d{\'e}rique and Morvan, Francois and Rinaldi, Yves and Nahon, Sophie and Castagna, Chantal and Boulahssass, Rabia and Grino, Michel},
  year = {2019},
  pages = {9},
  abstract = {Purpose. Older patients with colon cancer (CC) are vulnerable to chemotherapy toxicity and death. Establishing simple scores specific for patients with CC to predict severe chemotoxicity or early death is needed to select the best treatment strategy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\A927ULY3\\Retornaz et al. - 2019 - Predicting Chemotherapy Toxicity and Death in Olde.pdf}
}

@article{revels1136,
  title = {Racial Disparities in Esophageal Cancer Outcomes},
  author = {Revels, Sha'Shonda L. and Morris, Arden M. and Reddy, Rishindra M. and Akateh, Clifford and Wong, Sandra L.},
  year = {2013},
  month = apr,
  journal = {Annals of surgical oncology},
  volume = {20},
  number = {4},
  pages = {1136},
  publisher = {{NIH Public Access}},
  doi = {10.1245/s10434-012-2807-3},
  abstract = {Racial disparities in outcomes have been documented among patients with esophageal cancer. The purpose of this study is to identify mechanisms for ethnicity/race-related differences in the use of cancer-directed surgery and mortality.Data from the Surveillance, ...},
  langid = {english},
  pmid = {23263780},
  keywords = {Disparities},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FMICPVWL\\Revels et al. - 2013 - Racial disparities in esophageal cancer outcomes.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\6HS43GGG\\PMC4547835.html}
}

@article{rice1953,
  type = {Journal {{Article}}},
  title = {Posterior {{Intercostal Nerve Block With Liposomal Bupivacaine}}: {{An Alternative}} to {{Thoracic Epidural Analgesia}}},
  author = {Rice, D. C. and Cata, J. P. and Mena, G. E. and {Rodriguez-Restrepo}, A. and Correa, A. M. and Mehran, R. J.},
  year = {2015},
  journal = {Ann Thorac Surg},
  volume = {99},
  number = {6},
  pages = {1953--60},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2015.02.074}
}

@article{rice317,
  type = {Journal {{Article}}},
  title = {{{T2N0M0}} Esophageal Cancer},
  author = {Rice, T. W. and Mason, D. P. and Murthy, S. C. and Zuccaro, G., Jr. and Adelstein, D. J. and Rybicki, L. A. and Blackstone, E. H.},
  year = {2007},
  journal = {J Thorac Cardiovasc Surg},
  volume = {133},
  number = {2},
  pages = {317--24},
  issn = {1097-685X (Electronic) 0022-5223 (Linking)},
  doi = {10.1016/j.jtcvs.2006.09.023}
}

@article{richards1,
  title = {Preoperative Intravenous Iron for Anaemia in Elective Major Open Abdominal Surgery: The {{PREVENTT RCT}}},
  shorttitle = {Preoperative Intravenous Iron for Anaemia in Elective Major Open Abdominal Surgery},
  author = {Richards, Toby and Baikady, Ravishankar Rao and Clevenger, Ben and Butcher, Anna and Abeysiri, Sandy and Chau, Marisa and Swinson, Rebecca and Collier, Tim and Dodd, Matthew and Dyck, Laura Van and Macdougall, Iain and Murphy, Gavin and Browne, John and Bradbury, Andrew and Klein, Andrew},
  year = {2021},
  month = feb,
  journal = {Health Technology Assessment (Winchester, England)},
  volume = {25},
  number = {11},
  pages = {1--58},
  issn = {2046-4924},
  doi = {10.3310/hta25110},
  abstract = {BACKGROUND: Anaemia affects 30-50\% of patients before they undergo major surgery. Preoperative anaemia is associated with increased need for blood transfusion, postoperative complications and worse patient outcomes after surgery. International guidelines support the use of intravenous iron to correct anaemia in patients before surgery. However, the use of preoperative intravenous iron for patient benefit has not been assessed in the setting of a formal clinical trial. OBJECTIVES: To assess if intravenous iron given to patients with anaemia before major abdominal surgery is beneficial by reducing transfusion rates, postoperative complications, hospital stay and re-admission to hospital, and improving quality of life outcomes. DESIGN: A multicentre, double-blinded, randomised, controlled, Phase III clinical trial, with 1 : 1 randomisation comparing placebo (normal saline) with intravenous iron (intravenous ferric carboxymaltose 1000\,mg). Randomisation and treatment allocation were by a secure web-based service. SETTING: The study was conducted across 46 hospitals in England, Scotland and Wales between September 2013 and September 2018. PARTICIPANTS: Patients aged {$>$}\,18 years, undergoing elective major open abdominal surgery, with anaemia [Hb level of {$>$}\,90\,g/l and {$<$}\,120\,g/l (female patients) and {$<$}\,130\,g/l (male patients)] who could undergo randomisation and treatment 10-42 days before their operation. INTERVENTION: Double-blinded study comparing placebo of normal saline with 1000\,mg of ferric carboxymaltose administered 10-42 days prior to surgery. MAIN OUTCOME MEASURES: Co-primary end points were risk of blood transfusion or death at 30 days postoperatively, and rate of blood transfusions at 30 days post operation. RESULTS: A total of 487 patients were randomised (243 given placebo and 244 given intravenous iron), of whom 474 completed the trial and provided data for the analysis of the co-primary end points. The use of intravenous iron increased preoperative Hb levels (mean difference 4.7\,g/l, 95\% confidence interval 2.7 to 6.8 g/l; p\,{$<$}\,0.0001), but had no effect compared with placebo on risk of blood transfusion or death (risk ratio 1.03, 95\% confidence interval 0.78 to 1.37; p\,=\,0.84; absolute risk difference +0.8\%, 95\% confidence interval -7.3\% to 9.0\%), or rates of blood transfusion (rate ratio 0.98, 95\% confidence interval 0.68 to 1.43; p\,=\,0.93; absolute rate difference 0.00, 95\% confidence interval -0.14 to 0.15). There was no difference in postoperative complications or hospital stay. The intravenous iron group had higher Hb levels at the 8-week follow-up (difference in mean 10.7\,g/l, 95\% confidence interval 7.8 to 13.7 g/l; p\,{$<$}\,0.0001). There were a total of 71 re-admissions to hospital for postoperative complications in the placebo group, compared with 38 re-admissions in the intravenous iron group (rate ratio 0.54, 95\% confidence interval 0.34 to 0.85; p\,=\,0.009). There were no differences between the groups in terms of mortality (two per group at 30 days post operation) or in any of the prespecified safety end points or serious adverse events. CONCLUSIONS: In patients with anaemia prior to elective major abdominal surgery, there was no benefit from giving intravenous iron before the operation. FUTURE WORK: The impact of iron repletion on recovery from postoperative anaemia, and the association with reduced re-admission to hospital for complications, should be investigated. LIMITATIONS: In the preoperative intravenous iron to treat anaemia in major surgery (PREVENTT) trial, all patients included had anaemia and only 20\% had their anaemia corrected before surgery. The definition and causality of iron deficiency in this setting is not clear. TRIAL REGISTRATION: Current Controlled Trials ISRCTN67322816 and ClinicalTrials.gov NCT01692418. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25 No. 11. See the NIHR Journals Library website for further project information.},
  langid = {english},
  pmcid = {PMC7957457},
  pmid = {33632377},
  keywords = {Abdomen,ANAEMIA,Anemia,BLOOD TRANSFUSION,Elective Surgical Procedures,Female,Humans,INTRAVENOUS IRON,Iron,Male,PATIENT BLOOD MANAGEMENT,Quality of Life,RANDOMISED CONTROLLED TRIAL,Surgery,SURGERY},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LYVNF8V9\\Richards et al_2021_Preoperative intravenous iron for anaemia in elective major open abdominal.pdf}
}

@article{richards1353,
  title = {Preoperative Intravenous Iron to Treat Anaemia before Major Abdominal Surgery ({{PREVENTT}}): A Randomised, Double-Blind, Controlled Trial},
  shorttitle = {Preoperative Intravenous Iron to Treat Anaemia before Major Abdominal Surgery ({{PREVENTT}})},
  author = {Richards, Toby and Baikady, Ravishankar Rao and Clevenger, Ben and Butcher, Anna and Abeysiri, Sandy and Chau, Marisa and Macdougall, Iain C. and Murphy, Gavin and Swinson, Rebecca and Collier, Tim and Van Dyck, Laura and Browne, John and Bradbury, Andrew and Dodd, Matthew and Evans, Richard and Brealey, David and Anker, Stefan D. and Klein, Andrew},
  year = {2020},
  month = oct,
  journal = {Lancet (London, England)},
  volume = {396},
  number = {10259},
  pages = {1353--1361},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(20)31539-7},
  abstract = {BACKGROUND: Preoperative anaemia affects a high proportion of patients undergoing major elective surgery and is associated with poor outcomes. We aimed to test the hypothesis that intravenous iron given to anaemic patients before major open elective abdominal surgery would correct anaemia, reduce the need for blood transfusions, and improve patient outcomes. METHODS: In a double-blind, parallel-group randomised trial, we recruited adult participants identified with anaemia at preoperative hospital visits before elective major open abdominal surgery at 46 UK tertiary care centres. Anaemia was defined as haemoglobin less than 130 g/L for men and 120 g/L for women. We randomly allocated participants (1:1) via a secure web-based service to receive intravenous iron or placebo 10-42 days before surgery. Intravenous iron was administered as a single 1000 mg dose of ferric carboxymaltose in 100 mL normal saline, and placebo was 100 mL normal saline, both given as an infusion over 15 min. Unblinded study personnel prepared and administered the study drug; participants and other clinical and research staff were blinded to treatment allocation. Coprimary endpoints were risk of the composite outcome of blood transfusion or death, and number of blood transfusions from randomisation to 30 days postoperatively. The primary analysis included all randomly assigned patients with data available for the primary endpoints; safety analysis included all randomly assigned patients according to the treatment received. This study is registered, ISRCTN67322816, and is closed to new participants. FINDINGS: Of 487 participants randomly assigned to placebo (n=243) or intravenous iron (n=244) between Jan 6, 2014, and Sept 28, 2018, complete data for the primary endpoints were available for 474 (97\%) individuals. Death or blood transfusion occurred in 67 (28\%) of the 237 patients in the placebo group and 69 (29\%) of the 237 patients in the intravenous iron group (risk ratio 1{$\cdot$}03, 95\% CI 0{$\cdot$}78-1{$\cdot$}37; p=0{$\cdot$}84). There were 111 blood transfusions in the placebo group and 105 in the intravenous iron group (rate ratio 0{$\cdot$}98, 95\% CI 0{$\cdot$}68-1{$\cdot$}43; p=0{$\cdot$}93). There were no significant differences between the two groups for any of the prespecified safety endpoints. INTERPRETATION: Preoperative intravenous iron was not superior to placebo to reduce need for blood transfusion when administered to patients with anaemia 10-42 days before elective major abdominal surgery. FUNDING: UK National Institute of Health Research Health Technology Assessment Program.},
  langid = {english},
  pmcid = {PMC7581899},
  pmid = {32896294},
  keywords = {Abdomen,Administration; Intravenous,Aged,Anemia,Double-Blind Method,Elective Surgical Procedures,Female,Humans,Iron,Male,Preoperative Care,Surgery,Treatment Outcome,United Kingdom},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XZBBFKKA\\Richards et al_2020_Preoperative intravenous iron to treat anaemia before major abdominal surgery.pdf}
}

@article{rijssen9,
  title = {Skeletal {{Muscle Quality}} Is {{Associated}} with {{Worse Survival After Pancreatoduodenectomy}} for {{Periampullary}}, {{Nonpancreatic Cancer}}},
  author = {Rijssen, L B Van and Haverkort, E B and Nio, C Y and Busch, O R and Besselink, M G},
  pages = {9},
  abstract = {Background. Body composition measures may predict outcomes of cancer surgery. Whereas low muscle mass shown on preoperative computed tomography (CT) scans has been associated with worse outcomes after surgery for pancreatic cancer, less consideration has been given to low muscle attenuation, reflecting poor muscle quality. Studies relating muscle mass and muscle attenuation with outcomes for patients with periampullary, nonpancreatic cancer are lacking.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CR8ULY6I\\Rijssen et al. - Skeletal Muscle Quality is Associated with Worse S.pdf}
}

@article{rinninella2045,
  title = {Muscle Mass, Assessed at Diagnosis by {{L3-CT}} Scan as a Prognostic Marker of Clinical Outcomes in Patients with Gastric Cancer: {{A}}~Systematic Review and Meta-Analysis},
  shorttitle = {Muscle Mass, Assessed at Diagnosis by {{L3-CT}} Scan as a Prognostic Marker of Clinical Outcomes in Patients with Gastric Cancer},
  author = {Rinninella, Emanuele and Cintoni, Marco and Raoul, Pauline and Pozzo, Carmelo and Strippoli, Antonia and Bria, Emilio and Tortora, Giampaolo and Gasbarrini, Antonio and Mele, Maria Cristina},
  year = {2020},
  month = jul,
  journal = {Clinical Nutrition},
  volume = {39},
  number = {7},
  pages = {2045--2054},
  issn = {0261-5614},
  doi = {10.1016/j.clnu.2019.10.021},
  abstract = {Background \& aims Computed tomographic (CT) imaging at third lumbar vertebra (L3), routinely used by oncologists, represents a reliable tool to quantify muscle mass. A systematic review and meta-analysis was performed to assess the efficacy of CT scan to define muscle mass as a prognostic marker in gastric cancer (GC) patients undergoing gastrectomy and/or chemotherapy. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS) and the secondary outcomes included postoperative length of hospital stay (P-LOS), total and severe complications in GC patients undergoing gastrectomy. Methods Three electronic bibliographic databases \textemdash{} MEDLINE, Web of Science and Cochrane Central Register of Controlled Trials - were used to conduct a systematic literature search based on fixed inclusion and exclusion criteria, until April 2019. The adjusted and unadjusted hazard ratio (HR), odds ratio (OR) and mean difference (MD) with 95\% confidence interval (CI) were used to analyse the dichotomous variables (OS, RFS, total and severe complications) and continuous variables (P-LOS). Random- and fixed effects models were used according to the heterogeneity. Results A total of 5610~GC patients from 20 studies were identified. Low muscle mass at diagnosis was found in 32.7\% of GC patients and was significantly associated with poorer OS (HR 2.02, 95\% CI 1.71\textendash 2.38, p~{$<~$}0.00001, I2~=~47\%) and worse RFS (HR 1.97, 95\% CI 1.71\textendash 2.26, p~{$<~$}0.00001, I2~=~0\%). Meta-analysis of adjusted HR from multivariable analyses confirmed the association between OS and low muscle mass (HR 1.89, 95\% CI 1.68\textendash 2.12, p~{$<~$}0.00001, I2~=~36\%). Furthermore, low muscle mass and poorer OS were significantly associated in metastatic GC patients exclusively undergoing chemotherapy (HR 1.61, 95\% CI 1.23\textendash 2.11, p~{$<~$}0.0006, I2~=~18\%). Moreover, preoperative low muscle mass was significantly associated with longer P-LOS (MD 1.19, 95\% CI 0.68\textendash 1.71, p~{$<~$}0.00001, I2~=~0\%), higher risk of postoperative complications (OR 1.76, 95\% CI 1.17\textendash 2.66, p~=~0.007, I2~=~77\%) and severe complications (OR 1.54, 95\% CI 1.03\textendash 2.29, p~=~0.04, I2~=~49\%) in GC patients undergoing gastrectomy. Conclusions Low muscle mass, assessed by L3 CT-scan, affects almost 1/3 of GC patients at diagnosis and acts as a negative prognostic marker on many clinical outcomes. Therefore, identifying GC patients with low muscle mass at diagnosis or at follow-up visit should be recommendable. Clinical nutritionists should be part of tumor boards meetings to screen low muscle mass in order to prompt personalized nutritional support.},
  langid = {english},
  keywords = {Disease-related malnutrition,Gastric cancer,Muscle mass,Personalised medicine,Sarcopenia,Tumor boards},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IUBJ3T6B\\S0261561419331085.html}
}

@article{ripley226,
  title = {Pretreatment {{Dysphagia}} in {{Esophageal Cancer Patients May Eliminate}} the {{Need}} for {{Staging}} by {{Endoscopic Ultrasonography}}},
  author = {Ripley, R. Taylor and Sarkaria, Inderpal S. and Grosser, Rachel and Sima, Camelia S. and Bains, Manjit S. and Jones, David R. and Adusumilli, Prasad S. and Huang, James and Finley, David J. and Rusch, Valerie W. and Rizk, Nabil P.},
  year = {2016},
  month = jan,
  journal = {The Annals of Thoracic Surgery},
  volume = {101},
  number = {1},
  pages = {226--230},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2015.06.062},
  abstract = {BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancer patients with dysphagia. METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage. RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77\% (88 of 114) received neoadjuvant therapy, 18\% (20 of 114) did not, and 5\% (6 of 114) pursued treatment elsewhere. In total, 70\% (80 of 114) underwent esophagectomy; of these, 54\% (61 of 114) had dysphagia and 46\% (53 of 114) did not. Dysphagia scores were 66\% (40 of 61) grade 1, 25\% (15 of 61) grade 2, and 10\% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89\% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53\% (28 of 53) had T3-4 disease by EUS (p {$<$} 0.001). CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50\% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.},
  langid = {english},
  pmcid = {PMC4765728},
  pmid = {26603024},
  keywords = {Dysphonia,Endosonography,Esophageal Neoplasms,Female,Follow-Up Studies,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Prospective Studies,Unnecessary Procedures},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MY6K9FC9\\Ripley et al. - 2016 - Pretreatment Dysphagia in Esophageal Cancer Patien.pdf}
}

@article{rizzo974116,
  title = {Body Composition as a Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients: {{A}} Systematic Review},
  shorttitle = {Body Composition as a Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients},
  author = {Rizzo, Stefania and Scala, Isabel and Robayo, Angela Rodriguez and Cefal{\`i}, Marco and De Dosso, Sara and Cappio, Stefano and Xhepa, Genti and Del Grande, Filippo},
  year = {2022},
  month = sep,
  journal = {Frontiers in Oncology},
  volume = {12},
  pages = {974116},
  issn = {2234-943X},
  doi = {10.3389/fonc.2022.974116},
  abstract = {Objectives The objective of this systematic review was to assess associations between quantitative body composition measures extracted from imaging examinations and chemotherapy-related toxicity in pancreatic cancer patients. A secondary objective was to evaluate the different definitions of sarcopenia across included studies. Methods This systematic review was conducted according to the PRISMA statement. A comprehensive literature search of three electronic databases was performed by two authors. For each eligible article, information was collected concerning the clinical setting; basic study; population characteristics; technical; body composition features evaluated; CA 19.9 tumor marker levels; chemotherapy drugs administered; toxicities (hematologic, nausea/vomiting, diarrhea, neuropathy, reduction of number of cycles, overall toxicity); association of body composition values with toxicities. The overall quality of the included studies was critically evaluated. Results After the initial retrieval of 1137 articles, the systematic review included 12 articles (1/12 in the neo-adjuvant setting; 2/12 in the adjuvant setting; 3/12 in the metastatic setting; 2/12 in the unresectable setting; the other 4/12 included more than one clinical setting). The number of patients included ranged between 17 and 251; mean/median age ranged between 63 and 77 years; the percentage of sarcopenic patients ranged between 23 and 76\%. The most frequent body composition parameter evaluated was skeletal muscle index (11/12). Chemotherapy regimens included gemcitabine (as monotherapy or in combination with other drugs); FOLFIRINOX and S-1. Among the trials including gemcitabine, 2/9 demonstrated an association with toxicity, whereas 7/9 did not; among those including FOLFIRINOX, one demonstrated associated toxicity whereas the others did not. Altogether, 4/12 papers demonstrated an association between the body composition values and the development of chemotherapy-related toxicities. Conclusions There is a wide variability of results about the association of body composition and chemotherapy-related toxicity in PC patients. Furthermore, cut-off values to define sarcopenia in PC patients are not yet uniformly defined. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42022337753, identifier CRD42022337753.},
  pmcid = {PMC9556864},
  pmid = {36249069},
  keywords = {Pancreatic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MX7BK4GB\\Rizzo et al_2022_Body composition as a predictor of chemotherapy-related toxicity in pancreatic.pdf}
}

@article{rockwood17,
  type = {Journal {{Article}}},
  title = {Frailty Defined by Deficit Accumulation and Geriatric Medicine Defined by Frailty},
  author = {Rockwood, K. and Mitnitski, A.},
  year = {2011},
  journal = {Clin Geriatr Med},
  volume = {27},
  number = {1},
  pages = {17--26},
  issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
  doi = {10.1016/j.cger.2010.08.008}
}

@article{rockwood489,
  title = {A Global Clinical Measure of Fitness and Frailty in Elderly People},
  author = {Rockwood, Kenneth and Song, Xiaowei and MacKnight, Chris and Bergman, Howard and Hogan, David B. and McDowell, Ian and Mitnitski, Arnold},
  year = {2005},
  month = aug,
  journal = {CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne},
  volume = {173},
  number = {5},
  pages = {489--495},
  issn = {1488-2329},
  doi = {10.1503/cmaj.050051},
  abstract = {BACKGROUND: There is no single generally accepted clinical definition of frailty. Previously developed tools to assess frailty that have been shown to be predictive of death or need for entry into an institutional facility have not gained acceptance among practising clinicians. We aimed to develop a tool that would be both predictive and easy to use. METHODS: We developed the 7-point Clinical Frailty Scale and applied it and other established tools that measure frailty to 2305 elderly patients who participated in the second stage of the Canadian Study of Health and Aging (CSHA). We followed this cohort prospectively; after 5 years, we determined the ability of the Clinical Frailty Scale to predict death or need for institutional care, and correlated the results with those obtained from other established tools. RESULTS: The CSHA Clinical Frailty Scale was highly correlated (r = 0.80) with the Frailty Index. Each 1-category increment of our scale significantly increased the medium-term risks of death (21.2\% within about 70 mo, 95\% confidence interval [CI] 12.5\%-30.6\%) and entry into an institution (23.9\%, 95\% CI 8.8\%-41.2\%) in multivariable models that adjusted for age, sex and education. Analyses of receiver operating characteristic curves showed that our Clinical Frailty Scale performed better than measures of cognition, function or comorbidity in assessing risk for death (area under the curve 0.77 for 18-month and 0.70 for 70-month mortality). INTERPRETATION: Frailty is a valid and clinically important construct that is recognizable by physicians. Clinical judgments about frailty can yield useful predictive information.},
  langid = {english},
  pmcid = {PMC1188185},
  pmid = {16129869},
  keywords = {Aged,Aged; 80 and over,Female,Frail Elderly,Frailty,Geriatric Assessment,Health Status,Humans,Institutionalization,Male,Mortality,Physical Fitness,Predictive Value of Tests,Prognosis,Prospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FJ2CPNUB\\Rockwood et al_2005_A global clinical measure of fitness and frailty in elderly people.pdf}
}

@article{rockwood722,
  title = {Frailty in Relation to the Accumulation of Deficits},
  author = {Rockwood, Kenneth and Mitnitski, Arnold},
  year = {2007},
  month = jul,
  journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
  volume = {62},
  number = {7},
  pages = {722--727},
  issn = {1079-5006},
  doi = {10.1093/gerona/62.7.722},
  abstract = {This review article summarizes how frailty can be considered in relation to deficit accumulation. Recalling that frailty is an age-associated, nonspecific vulnerability, we consider symptoms, signs, diseases, and disabilities as deficits, which are combined in a frailty index. An individual's frailty index score reflects the proportion of potential deficits present in that person, and indicates the likelihood that frailty is present. Although based on a simple count, the frailty index shows several interesting properties, including a characteristic rate of accumulation, a submaximal limit, and characteristic changes with age in its distribution. The frailty index, as a state variable, is able to quantitatively summarize vulnerability. Future studies include the application of network analyses and stochastic analytical techniques to the evaluation of the frailty index and the description of other state variables in relation to frailty.},
  langid = {english},
  pmid = {17634318},
  keywords = {Aged,Aged; 80 and over,Aging,eFI,Frail Elderly,Humans,Mathematics,Models; Theoretical},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RPH87P89\\Rockwood_Mitnitski_2007_Frailty in relation to the accumulation of deficits.pdf}
}

@article{rocquee935,
  title = {Choosing {{Wisely}} in {{Oncology}}: {{Are We Ready For Value-Based Care}}?},
  shorttitle = {Choosing {{Wisely}} in {{Oncology}}},
  author = {Rocque, Gabrielle and Blayney, Douglas W. and Jahanzeb, Mohammad and Knape, August and Markham, Merry Jennifer and Pham, Trang and Shelton, Jeremy and Sudheendra, Preeti and Evans, Tracey},
  year = {2017},
  month = nov,
  journal = {Journal of Oncology Practice},
  volume = {13},
  number = {11},
  pages = {e935-e943},
  issn = {1935-469X},
  doi = {10.1200/JOP.2016.019281},
  abstract = {INTRODUCTION: In 2012, ASCO created the Top Five Choosing Wisely (CW) list of low-value tests and procedures for which there is little evidence of benefit. ASCO's Quality Oncology Practice Initiative, an oncologist-led practice-based quality assessment program, includes measures on the basis of these recommendations. METHODS: CW test measures from spring and fall 2013, spring 2014, and spring 2015 were evaluated for concordance rates, change in the concordance over time, and variability by practice characteristics. Practice characteristics recorded included geographic location, academic affiliation, number of new cases, number of medical oncologists, and rounds of participation in Quality Oncology Practice Initiative. Medians, interquartile ranges, and percentages were calculated for concordance with recommendations and practice characteristics. Change in recommendation concordance over time was assessed using linear regression models. RESULTS: From 2013 to 2015, 341 unique oncology practices abstracted the CW measures. Performance varied for specific recommendations. The median concordance was best for measure 1 (patients with low or undocumented performance status who received chemotherapy), where concordance ranged from 78.4\% to 83.3\%. The lowest concordance was for measure 3 (use of biomarkers or advanced imaging tests for surveillance in early breast cancer), where concordance ranged from 67.7\% to 74.2\%. Performance on CW measures varied markedly by individual practice. Variability over time and by practice characteristics was observed. CONCLUSION: Performance on ASCO's CW demonstrates room for improvement. Concordance rates varied substantially by practice. Further education on CW measures is needed to improve patient care and enhance value.},
  langid = {english},
  pmid = {28783425},
  keywords = {Cost-Benefit Analysis,ECOG,Humans,Medical Oncology,Neoplasms,Practice Guidelines as Topic,Quality Assurance; Health Care,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\I5HPC93F\\Rocque et al_2017_Choosing Wisely in Oncology.pdf}
}

@article{roh5124,
  title = {Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients with Carcinoma of the Rectum: {{NSABP R-03}}},
  shorttitle = {Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients with Carcinoma of the Rectum},
  author = {Roh, Mark S. and Colangelo, Linda H. and O'Connell, Michael J. and Yothers, Greg and Deutsch, Melvin and Allegra, Carmen J. and Kahlenberg, Morton S. and {Baez-Diaz}, Luis and Ursiny, Carol S. and Petrelli, Nicholas J. and Wolmark, Norman},
  year = {2009},
  month = nov,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {27},
  number = {31},
  pages = {5124--5130},
  issn = {1527-7755},
  doi = {10.1200/JCO.2009.22.0467},
  abstract = {PURPOSE: Although chemoradiotherapy plus resection is considered standard treatment for operable rectal carcinoma, the optimal time to administer this therapy is not clear. The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma. PATIENTS AND METHODS: Patients with clinical T3 or T4 or node-positive rectal cancer were randomly assigned to preoperative or postoperative chemoradiotherapy. Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boost within the original margins of treatment. In the preoperative group, surgery was performed within 8 weeks after completion of radiotherapy. In the postoperative group, chemotherapy began after recovery from surgery but no later than 4 weeks after surgery. The primary end points were disease-free survival (DFS) and overall survival (OS). RESULTS: From August 1993 to June 1999, 267 patients were randomly assigned to NSABP R-03. The intended sample size was 900 patients. Excluding 11 ineligible and two eligible patients without follow-up data, the analysis used data on 123 patients randomly assigned to preoperative and 131 to postoperative chemoradiotherapy. Surviving patients were observed for a median of 8.4 years. The 5-year DFS for preoperative patients was 64.7\% v 53.4\% for postoperative patients (P = .011). The 5-year OS for preoperative patients was 74.5\% v 65.6\% for postoperative patients (P = .065). A complete pathologic response was achieved in 15\% of preoperative patients. No preoperative patient with a complete pathologic response has had a recurrence. CONCLUSION: Preoperative chemoradiotherapy, compared with postoperative chemoradiotherapy, significantly improved DFS and showed a trend toward improved OS.},
  langid = {english},
  pmcid = {PMC2773471},
  pmid = {19770376},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Combined Modality Therapy,Digestive System Surgical Procedures,Disease-Free Survival,Female,Fluorouracil,Humans,Kaplan-Meier Estimate,Leucovorin,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Preoperative Care,Radiotherapy; Adjuvant,Rectal Neoplasms,Rectal;RT},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5JTW4E96\\Roh et al. - 2009 - Preoperative multimodality therapy improves diseas.pdf}
}

@article{rollins1103,
  title = {The Impact of Sarcopenia and Myosteatosis on Outcomes of Unresectable Pancreatic Cancer or Distal Cholangiocarcinoma},
  author = {Rollins, Katie E. and Tewari, Nilanjana and Ackner, Abigail and Awwad, Amir and Madhusudan, Srinivasan and Macdonald, Ian A. and Fearon, Kenneth C. H. and Lobo, Dileep N.},
  year = {2016},
  month = oct,
  journal = {Clinical Nutrition},
  volume = {35},
  number = {5},
  pages = {1103--1109},
  issn = {0261-5614},
  doi = {10.1016/j.clnu.2015.08.005},
  abstract = {Background \& aims Patients with pancreatic cancer have a poor prognosis, are often cachectic, and frequently demonstrate features of systemic inflammation, which may contribute to the phenomenon of myosteatosis. Analysis of body composition from CT scans has been used to study sarcopenia and its association with prognosis in a number of types of cancer, particular in combination with obesity. It has also been suggested that myosteatosis, defined as attenuated mean skeletal muscle Hounsfield units (HU), is associated with reduced survival in cancer. This study aimed to assess the association between body composition (sarcopenia and myosteatosis) and outcome in patients with unresectable pancreatic cancer. Methods All patients diagnosed with unresectable pancreatic cancer at Nottingham University Hospitals NHS Trust between 2006 and 2013 were considered for the study. A total of 228 patients were included retrospectively. Body composition was assessed using cross-sectional CT analysis to calculate a skeletal muscle index (SMI) for sarcopenia and use mean skeletal muscle HU for myosteatosis. Results The prevalence of sarcopenia in the whole patient group at baseline was 60.5\% (138/228). Overall, patients who were sarcopenic had no significant difference in overall survival versus those who were not (p~=~0.779). However, patients who were overweight/obese and sarcopenic had a significantly lower survival (p~=~0.013). Of the 58 patients who were overweight or obese and sarcopenic, 32 were also myosteatotic. The prevalence of myosteatosis overall at baseline was 55.3\% (126/228) and this was associated with significant reduction in overall survival (p~=~0.049). Univariate Cox regression revealed myosteatosis but not sarcopenia to be predictive of reduced survival, however this relationship was lost on multivariate testing. Myosteatosis was associated with significantly greater levels of systemic inflammation (white cell count, neutrophil-lymphocyte ratio and C-reactive protein), anaemia and worsening of baseline blood urea. This relationship was not seen with sarcopenia. Conclusions This is the largest study on the association between body composition and survival in patients with unresectable pancreatic cancer and has shown that although sarcopenia alone did not have a bearing on survival, the presence of myosteatosis was associated significantly with the presence of systemic inflammation and reduced survival.},
  langid = {english},
  keywords = {Cholangiocarcinoma,Inflammation,Myosteatosis,Pancreatic,Pancreatic cancer,Sarcopenia,Survival},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GWEACYPB\\Rollins - 2016 - The impact of sarcopenia and myosteatosis on outco.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\L3NDDD3A\\S0261561415002265.html}
}

@article{romanowski3,
  title = {Computed {{Tomography Measurements}} of {{Sarcopenia Predict Length}} of {{Stay}} in {{Older Burn Patients}}},
  author = {Romanowski, Kathleen S. and Fuanga, Praman and Siddiqui, Sheryar and Lenchik, Leon and Palmieri, Tina L. and Boutin, Robert D.},
  year = {2021},
  month = feb,
  journal = {Journal of Burn Care \& Research: Official Publication of the American Burn Association},
  volume = {42},
  number = {1},
  pages = {3--8},
  issn = {1559-0488},
  doi = {10.1093/jbcr/iraa149},
  abstract = {Sarcopenia and frailty are associated with aging. In older burn patients, frailty has been associated with mortality and discharge disposition, but sarcopenia has not been examined. This study aims to investigate the relationship between frailty and computed tomography (CT)-derived sarcopenia with length of stay and mortality in older burn patients. Burn patients {$\geq$}60 years old admitted between 2008 and 2017 who had chest or abdomen CT scans within 1 week of admission were evaluated. Frailty was assessed using the Canadian Study of Health and Aging Clinical Frailty Scale (CFS). Sarcopenia was assessed on CT exams by measuring skeletal muscle index (SMI) of paraspinal muscles at T12 and all skeletal muscles at L3. The relationship between frailty scores and SMI with length of stay (LOS) and mortality was determined using logistic regression. Eighty-three patients (59 men; mean age 70.2 {$\pm$} 8.5 years) had chest (n = 50) or abdomen (n = 60) CT scans. Mean TBSA = 14.3 {$\pm$} 14.0\%, LOS = 25.8 {$\pm$} 21.3 days, CFS = 4.36 {$\pm$} 0.99. Sixteen patients (19.3\%) died while in the hospital. CT-derived measurement of SMI at T12 was significantly associated with LOS (P {$<$} .05), but not with mortality (P = .561). CT-derived metrics at L3 were not significantly associated with outcomes. CFS was not associated with LOS (P = .836) or mortality (P = .554). In older burn patients, low SMI of the paraspinal muscles at T12 was associated with longer LOS.},
  langid = {english},
  pmcid = {PMC7856456},
  pmid = {32841333},
  keywords = {Aged,Burns,Female,Frailty,Hospital Mortality,Humans,Length of Stay,Male,Middle Aged,Predictive Value of Tests,Sarcopenia,Tomography; X-Ray Computed,WFU},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\57I43L4N\\Romanowski et al_2021_Computed Tomography Measurements of Sarcopenia Predict Length of Stay in Older.pdf}
}

@article{rosa-caldwell17,
  title = {Muscle Alterations in the Development and Progression of Cancer-Induced Muscle Atrophy: A Review},
  author = {{Rosa-Caldwell}, Megan E and Fix, Dennis K and Washington, Tyrone A and Greene, Nicholas P},
  journal = {J Appl Physiol},
  pages = {17},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H9M6GYRI\\Rosa-Caldwell et al. - Muscle alterations in the development and progress.pdf}
}

@article{rosati578,
  title = {Oxaliplatin-{{Based Chemotherapy}} in {{Patients}} with {{Metastatic Colorectal Cancer Aged}} at {{Least}} 75 {{Years}}: {{A Post-Hoc Subgroup Analysis}} of {{Three Phase II Trials}}},
  shorttitle = {Oxaliplatin-{{Based Chemotherapy}} in {{Patients}} with {{Metastatic Colorectal Cancer Aged}} at {{Least}} 75 {{Years}}},
  author = {Rosati, Gerardo and Cordio, Stefano and Reggiardo, Giorgio and Aprile, Giuseppe and Butera, Alfredo and Avallone, Antonio and Tucci, Aniello and Novello, Giuseppe and Blanco, Giuseppina and Caputo, Giuseppe and Bilancia, Domenico and Bordonaro, Roberto},
  year = {2019},
  month = apr,
  journal = {Cancers},
  volume = {11},
  number = {4},
  pages = {578},
  issn = {2072-6694},
  doi = {10.3390/cancers11040578},
  abstract = {Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45\%, comparable to younger patients (51\%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3-4 adverse events included diarrhea (13\%), fatigue (13\%), peripheral neuropathy (10\%), and neutropenia (7\%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients {$\geq$}75 years.},
  langid = {english},
  pmcid = {PMC6521155},
  pmid = {31022922},
  keywords = {colorectal cancer,CRC,doublet chemotherapy,elderly patients,oxaliplatin},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\56YYA8GF\\Rosati et al_2019_Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.pdf}
}

@article{rosenbek93,
  type = {Journal {{Article}}},
  title = {A Penetration-Aspiration Scale},
  author = {Rosenbek, J. C. and Robbins, J. A. and Roecker, E. B. and Coyle, J. L. and Wood, J. L.},
  year = {1996},
  journal = {Dysphagia},
  volume = {11},
  number = {2},
  pages = {93--8},
  issn = {0179-051X (Print) 0179-051X (Linking)}
}

@article{rosenberg337,
  type = {Journal {{Article}}},
  title = {Sarcopenia: Origins and Clinical Relevance},
  author = {Rosenberg, I. H.},
  year = {2011},
  journal = {Clin Geriatr Med},
  volume = {27},
  number = {3},
  pages = {337--9},
  issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
  doi = {10.1016/j.cger.2011.03.003}
}

@article{ruden2918,
  title = {Exercise Behavior, Functional Capacity, and Survival in Adults with Malignant Recurrent Glioma},
  author = {Ruden, Emily and Reardon, David A. and Coan, April D. and Herndon, James E. and Hornsby, Whitney E. and West, Miranda and Fels, Diane R. and Desjardins, Annick and Vredenburgh, James J. and Waner, Emily and Friedman, Allan H. and Friedman, Henry S. and Peters, Katherine B. and Jones, Lee W.},
  year = {2011},
  month = jul,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {29},
  number = {21},
  pages = {2918--2923},
  issn = {1527-7755},
  doi = {10.1200/JCO.2011.34.9852},
  abstract = {PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this population. PATIENTS AND METHODS: Using a prospective design, 243 patients with WHO grades 3 to 4 recurrent malignant glioma and Karnofsky performance status (KPS) {$\geq$} 70 completed a self-administered questionnaire that assessed exercise behavior and performed a 6-minute walk test (6MWT) to assess functional capacity. Cox proportional models were used to estimate the risk of all-cause mortality according to 6MWT distance (6MWD; {$<$} 390 meters, 390-489 meters, {$>$} 489 meters) and exercise behavior (metabolic equivalent [MET] -h/wk) adjusted for KPS and other important clinical factors. RESULTS: Median follow-up was 27.43 months. During this period, 149 deaths were recorded (61\% of the total sample). Exercise behavior was an independent predictor of survival (P = .0081). Median survival was 13.03 months for patients reporting {$<$} 9 MET-h/wk relative to 21.84 months for those reporting {$\geq$} 9 MET-h/wk. Exercise behavior added incremental prognostic value beyond that provided by KPS, age, sex, grade, and number of prior progressions (P {$<$} .001). Compared with patients reporting {$<$} 9 MET-h/wk, the adjusted hazard ratio for mortality was 0.64 (95\% CI, 0.46 to 0.91) for patients reporting {$\geq$} 9 MET-h/wk. Functional capacity was not an independent predictor of prognosis. CONCLUSION: Exercise behavior is a strong independent predictor of survival that provides incremental prognostic value to KPS as well as traditional markers of prognosis in malignant recurrent glioma.},
  langid = {english},
  pmcid = {PMC3138718},
  pmid = {21690470},
  keywords = {Adult,Aged,Brain Neoplasms,Exercise,Exercise Test,Female,Glioma,Health Behavior,Humans,Karnofsky Performance Status,Male,METs,Middle Aged,Neoplasm Recurrence; Local,North Carolina,Predictive Value of Tests,Proportional Hazards Models,Prospective Studies,Risk Assessment,Risk Factors,Surveys and Questionnaires,Survival Analysis,Survival Rate,Time Factors,Treatment Outcome,Walking},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ADW89BUB\\Ruden et al_2011_Exercise behavior, functional capacity, and survival in adults with malignant.pdf}
}

@article{rusch444,
  title = {Are Cancers of the Esophagus, Gastroesophageal Junction, and Cardia One Disease, Two, or Several?},
  author = {Rusch, Valerie W.},
  year = {2004},
  month = aug,
  journal = {Seminars in Oncology},
  volume = {31},
  number = {4},
  pages = {444--449},
  issn = {0093-7754},
  doi = {10.1053/j.seminoncol.2004.04.023},
  abstract = {Recent epidemiological shifts have led to controversy about the etiology and treatment of gastroesophageal (GE) junction adenocarcinomas. The Siewert classification conveniently describes the anatomical location of these tumors relative to the GE junction. However, available data suggest that there may be epidemiological, clinical, and molecular differences among GE junction adenocarcinomas, depending on whether they are predominantly esophageal or gastric in location. Much more investigation is required to confirm or refute these apparent differences, which can affect clinical treatment.},
  langid = {english},
  pmid = {15297937},
  keywords = {Adenocarcinoma,Cardia,Esophageal Neoplasms,Esophagogastric Junction,Humans,Neoplasm Staging,Stomach Neoplasms,Terminology as Topic}
}

@article{rutten630,
  type = {Journal {{Article}}},
  title = {Psoas Muscle Area Is Not Representative of Total Skeletal Muscle Area in the Assessment of Sarcopenia in Ovarian Cancer},
  author = {Rutten, I. J. G. and Ubachs, J. and Kruitwagen, Rfpm and {Beets-Tan}, R. G. H. and Olde Damink, S. W. M. and Van Gorp, T.},
  year = {2017},
  journal = {J Cachexia Sarcopenia Muscle},
  volume = {8},
  number = {4},
  pages = {630--638},
  issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
  doi = {10.1002/jcsm.12180}
}

@article{ryan14,
  title = {Cancer-Associated Malnutrition, Cachexia and Sarcopenia: The Skeleton in the Hospital Closet 40 Years Later},
  author = {Ryan, Aoife M and Power, Derek G and Daly, Louise and Cushen, Samantha J and Prado, Carla M},
  journal = {Proceedings of the Nutrition Society},
  pages = {14},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZPAA8KGX\\Ryan et al. - Cancer-associated malnutrition, cachexia and sarco.pdf}
}

@article{sabel210,
  title = {Esophageal Resection for Carcinoma in Patients Older than 70 Years},
  author = {Sabel, Michael S. and Smith, Judy L. and Nava, Hector R. and Mollen, Kevin and Douglass, Harold O. and Gibbs, John F.},
  year = {2002},
  month = mar,
  journal = {Annals of Surgical Oncology},
  volume = {9},
  number = {2},
  pages = {210--214},
  issn = {1068-9265},
  doi = {10.1007/BF02557376},
  abstract = {BACKGROUND: A larger number of older patients are presenting as candidates for esophageal resection. An aggressive surgical approach in this population is controversial. METHODS: Four hundred thirteen patients with esophageal cancer who presented to Roswell Park Cancer Institute from 1991 to 1998 were retrospectively reviewed. Clinical data, perioperative details, and postoperative courses were compared for patients older and younger than 70 years. RESULTS: One hundred forty-seven patients (36\%) were older than 70 years. Risk factors, clinical symptoms, histology, and stage at presentation were equivalent for both age groups. A higher percentage of patients {$<$}70 years were candidates for curative resection. There were no significant differences between groups for estimated blood loss, intraoperative transfusions, length of stay, overall morbidity, or mortality. Only postoperative myocardial infarction and atrial fibrillation were increased in the older group. Excluding stage IV disease, there was a significant and similar improvement in median survival after resection for patients both {$<$}70 years and {$>$}70 years. CONCLUSIONS: In conclusion, esophageal cancer in older patients warrants surgical resection because the benefit to the patient is the same as it is for younger patients, without a significant increase in operative morbidity or mortality.},
  langid = {english},
  pmid = {11888881},
  keywords = {Adenocarcinoma,Age Factors,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,New York,Patient Selection,Postoperative Complications,Prognosis,Retrospective Studies,Survival Rate}
}

@article{sadana116,
  title = {Promoting {{High-Value Practice}} by {{Reducing Unnecessary Transfusions With}} a {{Patient Blood Management Program}}},
  author = {Sadana, Divyajot and Pratzer, Ariella and Scher, Lauren J. and Saag, Harry S. and Adler, Nicole and Volpicelli, Frank M. and Auron, Moises and Frank, Steven M.},
  year = {2018},
  month = jan,
  journal = {JAMA internal medicine},
  volume = {178},
  number = {1},
  pages = {116--122},
  issn = {2168-6114},
  doi = {10.1001/jamainternmed.2017.6369},
  abstract = {Although blood transfusion is a lifesaving therapy for some patients, transfusion has been named 1 of the top 5 overused procedures in US hospitals. As unnecessary transfusions only increase risk and cost without providing benefit, improving transfusion practice is an effective way of promoting high-value care. Most high-quality clinical trials supporting a restrictive transfusion strategy have been published in the past 5 to 10 years, so the value of a successful patient blood management program has only recently been recognized. We review the most recent transfusion practice guidelines and the evidence supporting these guidelines. We also discuss several medical societies' Choosing Wisely campaigns to reduce or eliminate overuse of transfusions. A blueprint is presented for developing a patient blood management program, which includes discussion of specific methods for optimizing transfusion practice.},
  langid = {english},
  pmid = {29159367},
  keywords = {Blood Transfusion,Humans,Medical Audit,Medical Overuse,Program Development,United States,Unnecessary Procedures}
}

@article{salo188,
  type = {Journal {{Article}}},
  title = {{{ASO Author Reflections}}: {{Quality Improvement}} in {{Minimally Invasive Esophagectomy}}},
  author = {Salo, J. C.},
  year = {2019},
  journal = {Ann Surg Oncol},
  volume = {26},
  number = {1},
  pages = {188--189},
  issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
  doi = {10.1245/s10434-018-7079-0}
}

@article{sanoff2624,
  title = {Effect of Adjuvant Chemotherapy on Survival of Patients with Stage {{III}} Colon Cancer Diagnosed after Age 75 Years},
  author = {Sanoff, Hanna K. and Carpenter, William R. and St{\"u}rmer, Til and Goldberg, Richard M. and Martin, Christopher F. and Fine, Jason P. and McCleary, Nadine Jackson and Meyerhardt, Jeffrey A. and Niland, Joyce and Kahn, Katherine L. and Schymura, Maria J. and Schrag, Deborah},
  year = {2012},
  month = jul,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {30},
  number = {21},
  pages = {2624--2634},
  issn = {1527-7755},
  doi = {10.1200/JCO.2011.41.1140},
  abstract = {PURPOSE: Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown. METHODS: A total of 5,489 patients {$\geq$} 75 years of age with resected stage III CC, diagnosed between 2004 and 2007, were selected from four data sets containing demographic, stage, treatment, and survival information. These data sets included SEER-Medicare, a linkage between the New York State Cancer Registry (NYSCR) and its Medicare programs, and prospective cohort studies Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) and the National Comprehensive Cancer Network. Data sets were analyzed in parallel using covariate adjusted and propensity score (PS) matched proportional hazards models to evaluate the effect of treatment on survival. PS trimming was used to mitigate the effects of selection bias. RESULTS: Use of adjuvant therapy declined with age and comorbidity. Chemotherapy receipt was associated with a survival benefit of comparable magnitude to clinical trials results (SEER-Medicare PS-matched mortality, hazard ratio [HR], 0.60; 95\% CI, 0.53 to 0.68). The incremental benefit of oxaliplatin over non-oxaliplatin-containing regimens was also of similar magnitude to clinical trial results (SEER-Medicare, HR, 0.84; 95\% CI, 0.69 to 1.04; NYSCR-Medicare, HR, 0.82, 95\% CI, 0.51 to 1.33) in two of three examined data sources. However, statistical significance was inconsistent. The beneficial effect of chemotherapy and oxaliplatin did not seem solely attributable to confounding. CONCLUSION: The noninvestigational experience suggests patients with stage III CC {$\geq$} 75 years of age may anticipate a survival benefit from adjuvant chemotherapy. Oxaliplatin offers no more than a small incremental benefit. Use of adjuvant chemotherapy after the age of 75 years merits consideration in discussions that weigh individual risks and preferences.},
  langid = {english},
  pmcid = {PMC3412313},
  pmid = {22665536},
  keywords = {Age Factors,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Colonic Neoplasms,Female,Humans,Kaplan-Meier Estimate,Male,Medical Record Linkage,Medicare,Neoplasm Staging,Odds Ratio,Organoplatinum Compounds,Oxaliplatin,Practice Patterns; Physicians',Proportional Hazards Models,SEER Program,Treatment Outcome,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QYZUF4GL\\Sanoff et al_2012_Effect of adjuvant chemotherapy on survival of patients with stage III colon.pdf}
}

@article{sargent1948,
  title = {Pooled {{Safety}} and {{Efficacy Analysis Examining}} the {{Effect}} of {{Performance Status}} on {{Outcomes}} in {{Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer}}},
  author = {Sargent, Daniel J. and K{\"o}hne, Claus Henning and Sanoff, Hanna Kelly and Bot, Brian M. and Seymour, Matthew T. and {de Gramont}, Aimery and Porschen, Ranier and Saltz, Leonard B. and Rougier, Philippe and Tournigand, Christopher and Douillard, Jean-Yves and Stephens, Richard J. and Grothey, Axel and Goldberg, Richard M.},
  year = {2009},
  month = apr,
  journal = {Journal of Clinical Oncology},
  volume = {27},
  number = {12},
  pages = {1948--1955},
  issn = {0732-183X},
  doi = {10.1200/JCO.2008.20.2879},
  abstract = {Purpose Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10\% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain. Patients and Methods Individual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade {$\geq$} 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy. Results Compared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade {$\geq$} 3 nausea (8.5\% v 16.4\%, respectively; P {$<$} .0001) and vomiting (7.6\% v 11.9\%, respectively; P = .006) and 60-day all-cause mortality (2.8\% v 12.0\%, respectively; P {$<$} .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P {$<$} .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P {$<$} .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P {$<$} .0001; 43.8\% for PS 0 or 1 v 32.0\% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients. Conclusion In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12\% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.},
  pmcid = {PMC2669760},
  pmid = {19255311},
  keywords = {CRC},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\ZRBP7NZ8\\Sargent et al_2009_Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status.pdf}
}

@article{sato1008,
  type = {Journal {{Article}}},
  title = {Impact of Preoperative Hand Grip Strength on Morbidity Following Gastric Cancer Surgery},
  author = {Sato, T. and Aoyama, T. and Hayashi, T. and Segami, K. and Kawabe, T. and Fujikawa, H. and Yamada, T. and Yamamoto, N. and Oshima, T. and Rino, Y. and Masuda, M. and Ogata, T. and Cho, H. and Yoshikawa, T.},
  year = {2016},
  journal = {Gastric Cancer},
  volume = {19},
  number = {3},
  pages = {1008--15},
  issn = {1436-3305 (Electronic) 1436-3291 (Linking)},
  doi = {10.1007/s10120-015-0554-4}
}

@article{sato1413,
  title = {Resting Energy Expenditure in Patients Undergoing Transhiatal or Transthoracic Oesophagectomy for Carcinoma of the Thoracic Oesophagus},
  author = {Sato, N. and Kusama, A. and Ohkawa, A. and Koyama, Y. and Oyamatsu, M. and Kayama, S. and Yoshikawa, K. and Tanaka, O. and Muto, T.},
  year = {1993},
  month = nov,
  journal = {The British Journal of Surgery},
  volume = {80},
  number = {11},
  pages = {1413--1415},
  issn = {0007-1323},
  doi = {10.1002/bjs.1800801119},
  abstract = {Resting energy expenditure (REE) was studied in five patients undergoing transhiatal and in 14 undergoing transthoracic oesophagectomy for carcinoma. All resections were performed with an intention to cure. REE was measured by indirect calorimetry before operation and on days 1, 3, 5 and 7 after surgery. Following transthoracic oesophagectomy, REE increased significantly on days 1, 3, 5 and 7 after operation, and on day 7 the value was significantly higher (P {$<$} 0.05) than that obtained after transhiatal surgery. Energy expenditure following transhiatal oesophagectomy is lower than that after transthoracic oesophagectomy; this may be a result of reduced surgical stress.},
  langid = {english},
  pmid = {8252352},
  keywords = {Adult,Aged,Basal Metabolism,Calorimetry; Indirect,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Humans,Male,Middle Aged,REE,Stress; Physiological,Time Factors}
}

@article{sauer173,
  title = {Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer. {{A}} Progress Report of a Phase-{{III}} Randomized Trial (Protocol {{CAO}}/{{ARO}}/{{AIO-94}})},
  author = {Sauer, R. and Fietkau, R. and Wittekind, C. and Martus, P. and R{\"o}del, C. and Hohenberger, W. and Jatzko, G. and Sabitzer, H. and Karstens, J. H. and Becker, H. and Hess, C. and Raab, R.},
  year = {2001},
  month = apr,
  journal = {Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al]},
  volume = {177},
  number = {4},
  pages = {173--181},
  issn = {0179-7158},
  doi = {10.1007/pl00002396},
  abstract = {AIM: The standard treatment for patients with clinically resectable rectal cancer is surgery. Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+). In recent years, encouraging results of preoperative radiotherapy have been reported. This prospective randomized phase-III trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant radiochemotherapy to standard postoperative radiochemotherapy. We report on the design of the study and first results with regard to toxicity of radiochemotherapy and postoperative morbidity. PATIENTS AND METHODS: Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumor and the pelvic lymph nodes. 5-FU (1,000 mg/m2/d) was administered concomitantly in the first and fifth week of radiation as 120-h continuous infusion. Four additional cycles of 5-FU chemotherapy (500 mg/m2/d, i.v. bolus) were applied. Radiochemotherapy was identical in both arms except for a small-volume boost of 5.4 Gy in the postoperative setting. Time interval between radiochemotherapy and surgery was 4-6 weeks in both arms. Techniques of surgery were standardized and included total mesorectal excision. In addition, stratification according to surgeons involved has been provided for. Primary endpoints of the study are 5-year overall-survival, local and distant control, secondary endpoints include rate of curative (R0) resections and sphincter saving procedures, toxicity of radiochemotherapy, surgical complications and quality of life. RESULTS: As of 15th November 2000, 628 patients were randomized from 26 participating institutions: 310 patients were randomized to postoperative radiochemotherapy, 318 patients to preoperative radiochemotherapy. Acute toxicity (WHO) of radiochemotherapy was low, with less than 15\% of patients experiencing Grade 3 or higher toxicity: The principal toxicity was diarrhea, with 12\% in the postoperative radiochemotherapy arm and 10\% in the preoperative radiochemotherapy arm having Grade-3, and 1\% in either arm having Grade-4 diarrhea. Erythema, nausea and leukopenia were the next common toxicities, with less than 3\% of patients in either arm suffering Grade 3 or greater leukopenia or nausea. Postoperative complication rates were similar in both arms, with 12\% (postoperative radiochemotherapy) and 13\% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4\% (postoperative radiochemotherapy) and 3\% (preoperative radiochemotherapy) from postoperative bleeding, and 6\% (postoperative radiochemotherapy) and 5\% (preoperative radiochemotherapy) from delayed wound healing. CONCLUSION: The patient accrual of our trial is satisfactory, neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.},
  langid = {english},
  pmid = {11370551},
  keywords = {Adjuvant;Rectal,Adult,Aged,Antimetabolites; Antineoplastic,Chemotherapy; Adjuvant,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Patient Selection,Postoperative Complications,Quality of Life,Radiotherapy Dosage,Radiotherapy; Adjuvant,Rectal Neoplasms,Survival Analysis,Treatment Outcome}
}

@article{savitch581,
  title = {Racial {{Disparities}} in {{Rates}} of {{Surgery}} for {{Esophageal Cancer}}: A {{Study}} from the {{National Cancer Database}}},
  shorttitle = {Racial {{Disparities}} in {{Rates}} of {{Surgery}} for {{Esophageal Cancer}}},
  author = {Savitch, Samantha L. and Grenda, Tyler R. and Scott, Walter and Cowan, Scott W. and Posey, James and Mitchell, Edith P. and Cohen, Steven J. and Yeo, Charles J. and Evans, Nathaniel R.},
  year = {2021},
  month = mar,
  journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
  volume = {25},
  number = {3},
  pages = {581--592},
  issn = {1873-4626},
  doi = {10.1007/s11605-020-04653-z},
  abstract = {BACKGROUND: Treatment guidelines for stage I-III esophageal cancer indicate that management should include surgery in appropriate patients. Variations in utilization of surgery may contribute to racial differences observed in survival. We sought to identify factors associated with racial disparities in surgical resection of esophageal cancer and evaluate associated survival differences. METHODS: Patients diagnosed with stage I-III esophageal cancer from 2004 to 2015 were identified using the National Cancer Database. Matched patient cohorts were created to reduce confounding. Multivariate logistic regression was used to identify factors associated with receipt of surgery. Multi-level modeling was performed to control for random effects of individual hospitals on surgical utilization. RESULTS: A total of 60,041 patients were included (4402 black; 55,639 white). After 1:1 matching, there were 5858 patients evenly distributed across race. For all stages, significantly fewer black than white patients received surgery. Black race independently conferred lower likelihood of receiving surgery in single-level multivariable analysis (OR (95\% CI); stage I, 0.67 (0.48-0.94); stage II, 0.76 (0.60-0.96); stage III, 0.62 (0.50-0.76)) and after controlling for hospital random effects. Hospital-level random effects accounted for one third of the unexplained variance in receipt of surgery. Risk-adjusted 1-, 3-, and 5-year mortality was higher for patients who did not undergo surgery. CONCLUSION: Black patients with esophageal cancer are at higher risk of mortality compared to white patients. This increased risk may be influenced by decreased likelihood of receiving surgical intervention for resectable disease, in part because of between-hospital differences. Improving access to surgical care may improve disparities in esophageal cancer survival.},
  langid = {english},
  pmid = {32500418},
  keywords = {African Americans,Databases; Factual,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Healthcare Disparities,Humans,NCDB,Race,Racial disparities,United States,Whites}
}

@article{saxton1223,
  type = {Journal {{Article}}},
  title = {Preoperative Frailty and Quality of Life as Predictors of Postoperative Complications},
  author = {Saxton, A. and Velanovich, V.},
  year = {2011},
  journal = {Ann Surg},
  volume = {253},
  number = {6},
  pages = {1223--9},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0b013e318214bce7}
}

@article{scarpa156,
  type = {Journal {{Article}}},
  title = {Sleep Disturbances and Quality of Life in Postoperative Management after Esophagectomy for Esophageal Cancer},
  author = {Scarpa, M. and Pinto, E. and Saadeh, L. M. and Parotto, M. and Da Roit, A. and Pizzolato, E. and Alfieri, R. and Cagol, M. and Saraceni, E. and Baratto, F. and Castoro, C.},
  year = {2014},
  journal = {World J Surg Oncol},
  volume = {12},
  pages = {156},
  issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
  doi = {10.1186/1477-7819-12-156}
}

@article{schandl2385,
  title = {Predicting the {{Risk}} of {{Weight Loss After Esophageal Cancer Surgery}}},
  author = {Schandl, Anna and Kauppila, Joonas H. and Anandavadivelan, Poorna and Johar, Asif and Lagergren, Pernilla},
  year = {2019},
  month = aug,
  journal = {Annals of Surgical Oncology},
  volume = {26},
  number = {8},
  pages = {2385--2391},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07352-5},
  abstract = {BACKGROUND: Malnutrition after esophageal cancer surgery is associated with reduced health-related qualify of life. Therefore, a prediction model identifying patients at risk for severe weight loss after surgery was developed. METHODS: Data from a Swedish population-based cohort study, including 616 patients undergoing esophageal cancer surgery in 2001-2005, was used. Candidate predictors included risk factors available before and immediately after surgery. Severe weight loss was defined as {$\geq$}\,15\% loss of body weight between the time of surgery and 6~months postoperatively. The prediction model was developed using multivariable models. The accuracy of the model was measured by the area under the receiver operating characteristics curve (AUC) with bootstrap validation. The model was externally validated in a hospital-based cohort of 91 surgically treated esophageal cancer patients in the United Kingdom in 2011-2016. Each predictor in the final model was assigned a corresponding risk score. The sum of risk scores was equivalent to an estimated probability for severe weight loss. RESULTS: Among the 351 patients with 6~months follow-up data, 125 (36\%) suffered from severe postoperative weight loss. The final prediction model included body mass index at diagnosis, preoperative weight loss, and neoadjuvant therapy. The AUC for the model was 0.78 (95\% CI 0.74-0.83). In the validation cohort, the AUC was 0.76. A clinical risk assessment guide was derived from the prediction model. CONCLUSIONS: This prediction model can preoperatively identify individuals with high risk of severe weight loss after esophageal cancer surgery. Intensive nutritional interventions for these patients are recommended.},
  langid = {english},
  pmcid = {PMC6611892},
  pmid = {31004297},
  keywords = {Aged,Body Mass Index,Carcinoma; Squamous Cell,Cohort Studies,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Malnutrition,Models; Statistical,Predictive Value of Tests,Quality of Life,Risk Assessment,Risk Factors,ROC Curve,Weight Loss}
}

@article{schlottmanndoz045,
  title = {Disparities in Esophageal Cancer: Less Treatment, Less Surgical Resection, and Poorer Survival in Disadvantaged Patients},
  shorttitle = {Disparities in Esophageal Cancer},
  author = {Schlottmann, Francisco and Gaber, Charles and Strassle, Paula D. and Herbella, Fernando A. M. and Molena, Daniela and Patti, Marco G.},
  year = {2020},
  month = mar,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {33},
  number = {2},
  pages = {doz045},
  issn = {1442-2050},
  doi = {10.1093/dote/doz045},
  abstract = {The incidence of esophageal cancer has increased steadily in the last decades in the United States. The aim of this paper was to characterize disparities in esophageal cancer treatment in different racial and socioeconomic population groups and compare long-term survival among different treatment modalities. A retrospective analysis of the National Cancer Database was performed including adult patients ({$\geq$}18 years old) with a diagnosis of resectable (stages I-III) esophageal cancer between 2004 and 2015. Multivariable logistic regression models were used to determine the odds of being offered no treatment at all and surgical treatment across race, primary insurance, travel distance, income, and education levels. Multivariable Cox proportional hazards models were used to compare 5-year survival rates across different treatment modalities. A total of 60,621 esophageal cancer patients were included. Black patients, uninsured patients, and patients living in areas with lower levels of education were more likely to be offered no treatment. Similarly, black race, female patients, nonprivately insured patients, and those living in areas with lower median residential income and lower education levels were associated with lower rates of surgery. Patients receiving surgical treatment, compared to both no treatment and definitive chemoradiation, had significant better long-term survival in stage I, II, and III esophageal cancer. In conclusion, underserved patients with esophageal cancer appear to have limited access to surgical care, and are, in fact, more likely to not be offered any treatment at all. Considering the survival benefits associated with surgical resection, greater public health efforts to reduce disparities in esophageal cancer are needed.},
  langid = {english},
  pmcid = {PMC8205620},
  pmid = {31076759},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Chemoradiotherapy,Databases; Factual,disparity,esophageal cancer,Esophageal Neoplasms,Esophagectomy,Ethnicity,Female,Health Services Accessibility,Health Status Disparities,Healthcare Disparities,Humans,Logistic Models,Male,Middle Aged,Proportional Hazards Models,Race,Retrospective Studies,Social Determinants of Health,Socioeconomic Factors,surgery,survival,Survival Rate,United States,Vulnerable Populations,Young Adult}
}

@article{schmidt814,
  type = {Journal {{Article}}},
  title = {Defining {{Benchmarks}} for {{Transthoracic Esophagectomy}}: {{A Multicenter Analysis}} of {{Total Minimally Invasive Esophagectomy}} in {{Low Risk Patients}}},
  author = {Schmidt, H. M. and Gisbertz, S. S. and Moons, J. and Rouvelas, I. and Kauppi, J. and Brown, A. and Asti, E. and Luyer, M. and Lagarde, S. M. and Berlth, F. and Philippron, A. and Bruns, C. and Holscher, A. and Schneider, P. M. and Raptis, D. A. and {van Berge Henegouwen}, M. I. and Nafteux, P. and Nilsson, M. and Rasanen, J. and Palazzo, F. and Rosato, E. and Mercer, S. and Bonavina, L. and Nieuwenhuijzen, G. and Wijnhoven, B. P. L. and Schroder, W. and Pattyn, P. and Grimminger, P. P. and Gutschow, C. A.},
  year = {2017},
  journal = {Ann Surg},
  volume = {266},
  number = {5},
  pages = {814--821},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0000000000002445}
}

@article{schmidt931,
  title = {Accelerated {{Recovery Within Standardized Recovery Pathways After Esophagectomy}}: {{A~Prospective Cohort Study Assessing}} the {{Effects}} of~{{Early Discharge}} on {{Outcomes}}, {{Readmissions}}, {{Patient Satisfaction}}, and {{Costs}}},
  shorttitle = {Accelerated {{Recovery Within Standardized Recovery Pathways After Esophagectomy}}},
  author = {Schmidt, Henner M. and El Lakis, Mustapha A. and Markar, Sheraz R. and Hubka, Michal and Low, Donald E.},
  year = {2016},
  month = sep,
  journal = {The Annals of Thoracic Surgery},
  volume = {102},
  number = {3},
  pages = {931--939},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2016.04.005},
  abstract = {BACKGROUND: After esophagectomy, some patients exceed targeted discharge goal within enhanced recovery after surgery programs. This study reviews the demographics, outcomes, cost, readmission rates, and patient satisfaction for the accelerated recovery (AR) group. METHODS: Between 2010 and 2013, 137 consecutive esophagectomy patients were compared according to the length of hospital stay: AR 5 to 6 days, targeted recovery (TR) 7 to 8 days, and delayed recovery (DR) 9 days or more. RESULTS: The AR patients increased from 3\% to 46\% during the study period. The AR patients were younger, but all groups were comparable regarding comorbidities (Charlson, American Society of Anesthesiologists, and Eastern Cooperative Oncology Group score), cancer stage, and treatment approach. The AR patients were more likely to have neoadjuvant therapy, shorter operations, and less blood loss. The DR patients were more likely to have complications (40\% AR versus 45\% TR versus 90\% DR, p {$<$} 0.001). Inhospital and 90-day mortality was 1.5\%. All AR patients were discharged home (100\% AR versus 87\% TR versus 63\% DR, p {$<$} 0.001), and 30-day readmission rates were comparable between groups (14\% AR versus 19\% TR versus 5\% DR, p~= 0.122). Overall mean costs (\$38,385 AR versus \$41,607 TR versus \$61,199 DR, p~{$<$} 0.001) as well as readmission costs (\$7,470 AR versus \$27,695 TR versus \$33,398 DR, p~= 0.202) were lower in the AR group. Patient satisfaction scores were comparable between groups. CONCLUSIONS: Accelerated recovery is achievable in a significant proportion of patients undergoing esophagectomy. Accelerated recovery is associated with decreased treatment costs but does not lead to increased readmissions or decreased patient satisfaction. Enhanced recovery after surgery programs should be designed to accommodate patients appropriate for AR.},
  langid = {english},
  pmid = {27283109},
  keywords = {Adult,Aged,Aged; 80 and over,Cohort Studies,Esophagectomy,Female,Health Care Costs,Humans,Length of Stay,Male,Middle Aged,Patient Discharge,Patient Readmission,Patient Satisfaction,Prospective Studies,Time Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CD2UC9NI\\Schmidt et al_2016_Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy.pdf}
}

@article{schnipper10,
  title = {American {{Society}} of {{Clinical Oncology Identifies Five Key Opportunities}} to {{Improve Care}} and {{Reduce Costs}}: {{The Top Five List}} for {{Oncology}}},
  author = {Schnipper, Lowell E and Smith, Thomas J and Raghavan, Derek and Blayney, Douglas W and Ganz, Patricia A and Mulvey, Therese Marie and Wollins, Dana S},
  journal = {JOURNAL OF CLINICAL ONCOLOGY},
  pages = {10},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\WX3I9Q2W\\Schnipper et al. - American Society of Clinical Oncology Identifies F.pdf}
}

@article{sebag-montefiore811,
  title = {Preoperative Radiotherapy versus Selective Postoperative Chemoradiotherapy in Patients with Rectal Cancer ({{MRC CR07}} and {{NCIC-CTG C016}}): A Multicentre, Randomised Trial},
  shorttitle = {Preoperative Radiotherapy versus Selective Postoperative Chemoradiotherapy in Patients with Rectal Cancer ({{MRC CR07}} and {{NCIC-CTG C016}})},
  author = {{Sebag-Montefiore}, David and Stephens, Richard J. and Steele, Robert and Monson, John and Grieve, Robert and Khanna, Subhash and Quirke, Phil and Couture, Jean and de Metz, Catherine and Myint, Arthur Sun and Bessell, Eric and Griffiths, Gareth and Thompson, Lindsay C. and Parmar, Mahesh},
  year = {2009},
  month = mar,
  journal = {The Lancet},
  volume = {373},
  number = {9666},
  pages = {811--820},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(09)60484-0},
  langid = {english},
  pmid = {19269519},
  keywords = {Rectal;Adjuvant},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BUKM6DM2\\fulltext.html}
}

@article{seder1646,
  type = {Journal {{Article}}},
  title = {The {{Society}} of {{Thoracic Surgeons General Thoracic Surgery Database Update}} on {{Outcomes}} and {{Quality}}},
  author = {Seder, C. W. and Wright, C. D. and Chang, A. C. and Han, J. M. and McDonald, D. and Kozower, B. D.},
  year = {2016},
  journal = {Ann Thorac Surg},
  volume = {101},
  number = {5},
  pages = {1646--54},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2016.02.099}
}

@article{sedrak78,
  title = {Older Adult Participation in Cancer Clinical Trials: {{A}} Systematic Review of Barriers and Interventions},
  shorttitle = {Older Adult Participation in Cancer Clinical Trials},
  author = {Sedrak, Mina S. and Freedman, Rachel A. and Cohen, Harvey J. and Muss, Hyman B. and Jatoi, Aminah and Klepin, Heidi D. and Wildes, Tanya M. and {Le-Rademacher}, Jennifer G. and Kimmick, Gretchen G. and Tew, William P. and George, Kevin and Padam, Simran and Liu, Jennifer and Wong, Andrew R. and Lynch, Andrea and Djulbegovic, Benjamin and Mohile, Supriya G. and Dale, William},
  year = {2021},
  month = jan,
  journal = {CA: a cancer journal for clinicians},
  volume = {71},
  number = {1},
  pages = {78--92},
  issn = {0007-9235},
  doi = {10.3322/caac.21638},
  abstract = {Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly underrepresented in research that sets the standards for cancer treatments. Consequently, most of what we know about cancer therapeutics is based on clinical trials conducted in younger, healthier patients, and effective strategies to improve clinical trial participation of older adults with cancer remain sparse. This systematic review evaluated published studies regarding barriers to participation and interventions to improve participation of older adults in cancer trials. The quality of the available evidence was low and, despite a literature describing multifaceted barriers, only one intervention study aimed to increase enrollment of older adults in trials. Our findings starkly amplify the paucity of evidence-based effective strategies to improve participation of this underrepresented population in cancer trials. Within these limitations, we provide our opinion on how the current cancer research infrastructure must be modified to accommodate the needs of older patients. We offer several underutilized solutions to expand clinical trials to include older adults with cancer. However, as currently constructed, these recommendations alone will not solve the evidence gap in geriatric oncology, and efforts are needed to meet older and frail adults where they are by expanding clinical trials designed specifically for this population and leveraging real-world data.},
  pmcid = {PMC7854940},
  pmid = {33002206},
  keywords = {Cancer},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MT7W8EDW\\Sedrak et al_2021_Older adult participation in cancer clinical trials.pdf}
}

@article{seo9,
  title = {Association of Nutritional Status-Related Indices and Chemotherapy-Induced Adverse Events in Gastric Cancer Patients},
  author = {Seo, Seung Hee},
  year = {2016},
  pages = {9},
  abstract = {Background: Malnutrition in gastrectomized patients receiving chemotherapy is associated with the susceptibility to chemotherapy-related adverse events. This study evaluated pre-operative nutritional status-related indices associated with adverse events in post-operation gastric cancer patients receiving chemotherapy. Methods: Medical records of 234 gastrectomized patients under adjuvant tegafur/gimeracil/oteracil chemotherapy with extended lymph node dissection were analyzed. Nutritional status assessment included Patient-Generated Subjective Global Assessment (PG-SGA), body weight, body mass index, serum albumin concentration, and Nutrition Risk Index (NRI). Chemotherapy-originated adverse events were determined using Common Terminology Criteria for Adverse Events. Results: PG-SGA indicated 59\% of the patients were malnourished, and 27.8\% of the patients revealed serious malnutrition with PG-SGA score of {$\geq$}9. Fifteen \% of patients lost {$\geq$}10\% of the initial body weight, 14.5\% of the patients had hypoalbuminemia ({$<$}3.5 g/dL), and 66.2\% had NRI score less than 97.5 indicating moderate to severe malnutrition. Hematological adverse events were present in 94\% ({$\geq$}grade 1) and 16.2\% ({$\geq$}grade 3). Non-hematological adverse events occurred in 95.7\% ({$\geq$}grade1) and 16.7\% ({$\geq$}grade 3) of the patients. PG-SGA and NRI score was not associated with treatment-induced adverse events. Multivariate analyses indicated that female, low body mass index, and hypoalbuminemia were independent risk factors for grade 3/4 hematological adverse events. Age was an independent risk factor for grade 3/4 non-hematological adverse events. Neutropenia was the most frequently occurring adverse event, and associated risk factors were female, total gastrectomy, and hypoalbuminemia. Conclusions: Hypoalbuminemia, not PG-SGA or NRI may predict chemotherapy-induced adverse events in gastrectomized cancer patients.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XGRI5CE7\\Seo - 2016 - Association of nutritional status-related indices .pdf}
}

@article{sgourakis3031,
  title = {Minimally Invasive versus Open Esophagectomy: Meta-Analysis of Outcomes},
  shorttitle = {Minimally Invasive versus Open Esophagectomy},
  author = {Sgourakis, George and Gockel, Ines and Radtke, Arnold and Musholt, Thomas J. and Timm, Stephan and Rink, Andreas and Tsiamis, Achilleas and Karaliotas, Constantine and Lang, Hauke},
  year = {2010},
  month = nov,
  journal = {Digestive Diseases and Sciences},
  volume = {55},
  number = {11},
  pages = {3031--3040},
  issn = {1573-2568},
  doi = {10.1007/s10620-010-1153-1},
  abstract = {BACKGROUND: A meta-analysis of the current literature was performed to compare the perioperative outcome measures and oncological impact between minimally invasive and open esophagectomy. METHODS: Using the electronic databases Medline, Embase, Pubmed and the Cochrane Library, we performed a meta-analysis pooling the effects of outcomes of 1,008 patients enrolled into eight comparative studies, using classic and modern meta-analytic methods. RESULTS: Two comparisons were considered for this systematic review: (I) open thoracotomy vs. VATS/laparoscopy esophagectomy and (II) open thoracotomy vs. VATS esophagectomy. In comparison I: both procedures report equally comparable outcomes (removed lymph nodes, 30-day mortality, 3-year survival) with the exception of overall morbidity (P~=~0.038; in favor of the MIE arm) and anastomotic stricture (P~{$<~$}0.001; in favor of the open thoracotomy arm). In comparison II: No differences were noted between treatment arms concerning postoperative outcomes and survival. CONCLUSIONS: In summary, both arms were comparable with regard to perioperative results and prognosis. Further prospective comparative or randomized-controlled trials focusing on the oncological impact of MIE are needed.},
  langid = {english},
  pmid = {20186484},
  keywords = {Esophageal Neoplasms,Esophagectomy,Humans,Laparoscopy,Laparotomy,Prognosis,ROC Curve,Thoracic Surgery; Video-Assisted,Thoracotomy,Treatment Outcome}
}

@article{shachar1203,
  title = {The Association between Geriatric Assessment, Muscle Measures, and Treatment-Related Toxicity in Older Adults with Cancer: {{An Israeli}} Prospective Study},
  shorttitle = {The Association between Geriatric Assessment, Muscle Measures, and Treatment-Related Toxicity in Older Adults with Cancer},
  author = {Shachar, Shlomit S. and {Bar-Sela}, Gil and Peer, Avivit and Moskovitz, Mor Tal and {Bareket-Samish}, Avital and Epstein, Jessica and Wollner, Mira and Shafran, Itamar and Boukal, Amit and Williams, Grant R.},
  year = {2022},
  month = nov,
  journal = {Journal of Geriatric Oncology},
  volume = {13},
  number = {8},
  pages = {1203--1207},
  issn = {1879-4068},
  doi = {10.1016/j.jgo.2022.08.007},
  abstract = {Introduction We investigated the associations among frailty, as determined via the comprehensive geriatric assessment (CGA), muscle measures (i.e., sarcopenia), and treatment-related toxicity in older adults with cancer in Israel. Materials and methods This prospective cohort study enrolled patients {$\geq$}65~years with newly-diagnosed stage IV lung, breast, or genitourinary cancer. Patients were enrolled and completed CGA before their first line of systemic therapy (chemotherapy, biologic therapy, immunologic therapy, or a combination thereof). CGA was used to classify patients as robust, pre-frail, or frail, and routine pre-treatment computed tomography (CT) images were used to quantify skeletal muscle index (SMI) and skeletal muscle density (SMD) at L3 cross-section. Two sarcopenia definitions were used: i. for women SMI {$<$}41~cm2/m2 regardless of body mass index (BMI), and for men SMI {$<$}43~cm2/m2 for those with BMI of {$<$}25 and~{$<~$}53~cm2/m2 for those with BMI {$\geq$}25; and ii. SMI {$<$}38~cm2/m2 for women and~{$<~$}41~cm2/m2 for men, regardless of BMI. The associations between frailty and muscle measures with the occurrence of at least one adverse event (AE) grade~{$\geq~$}2 were examined using the chi-square test, and logistic regression to determine odds ratio (OR) and 95\% confidence interval (CI). Results In total, 51 patients were included in the analysis. The median (interquartile range) age was 72 (68\textendash 76) years, 30 (59\%) were male, and 26 (51\%) had lung cancer. CGA data were available for 48 patients: fifteen (31\%), thirteen (27\%), and twenty (42\%) were defined as robust, pre-frail, and frail, respectively. Overall, 33 (65\%) were sarcopenic by the first aforementioned definition, and sixteen (31\%) by the second. No statistically significant associations were identified between frailty and having at least one AE grade~{$\geq~$}2, or between frailty and sarcopenia. Statistically significant associations were found between having sarcopenia (the second definition) and having at least one AE grade~{$\geq~$}2 (P~=~0.0217). The corresponding odds ratio (95\% CI) was 4.2 (1.2\textendash 15.0), P~=~0.026. Discussion Our findings suggests that sarcopenia is significantly associated with treatment-related toxicity. Further studies with larger sample sizes are warranted.},
  langid = {english},
  pmid = {35989184},
  keywords = {Aging,Cancer,CGA,Geriatric assessment,Geriatric oncology,Israel,Sarcopenia,Skeletal muscle index,SMI,Toxicity},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CREJVMTY\\S1879406822001989.html}
}

@article{shachar18,
  title = {Skeletal {{Muscle Measures}} as {{Predictors}} of {{Toxicity}}, {{Hospitalization}}, and {{Survival}} in {{Patients}} with {{Metastatic Breast Cancer Receiving Taxane Based Chemotherapy}}},
  author = {Shachar, Shlomit Strulov and Deal, Allison M and Weinberg, Marc and Nyrop, Kirsten A and Williams, Grant R and Nishijima, Tomohiro F and Benbow, Julia M and Muss, Hyman B},
  year = {2017},
  pages = {18},
  abstract = {Purpose\textemdash Severe skeletal muscle (SM) loss (sarcopenia), is associated with poor cancer outcomes including reduced survival and increased toxicity. This study investigates SM measures in metastatic breast cancer (MBC) patients receiving first line taxane-based chemotherapy and evaluates associations with treatment toxicity and other outcomes. Experimental Design\textemdash Using computerized tomography (CT) images taken for the evaluation of disease burden, skeletal muscle area (SMA) and density (SMD) were measured at the 3rd lumbar vertebrae. Sarcopenia was defined as Skeletal Muscle Index (SMI=SMA/height2) {$\leq$}41. Skeletal Muscle Gauge (SMG) was created by multiplying SMI x SMD. Fisher's exact tests, ttests, the Kaplan-Meier method, and Cox regression modeling were used. Results\textemdash MBC patients (N=40), median age 55 (rang 34\textendash 80), 58\% sarcopenic, median SMG 1296 AU (SD 522). Grade 3\textendash 4 toxicity was found in 57\% of sarcopenic vs 18\% of non-sarcopenic patients (p=0.02). Toxicity-related hospitalizations were also higher in sarcopenic patients (39\% vs 0\%, p=0.005) as were any adverse events -- defined as any grade 3\textendash 4 toxicities, hospitalizations, dose reductions, or dose delay -- (74\% vs 35\%, p=0.02). Low SMG was associated with grade 3\textendash 4 toxicity (p=0.04), hospitalization (p=0.01) and time to treatment failure (for progression or toxicity) (p=0.03). Low SMG had a borderline significant association with any adverse event (p=0.06) and overall survival (p=0.07). Conclusions\textemdash SM measures are associated with toxicity outcomes and survival in MBC patients receiving first line taxane-based chemotherapy. Further studies are needed to explore how routinely obtained CT scans can be used to individualize dosing and improve treatment planning.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\C7UYKN8V\\Shachar et al. - 2017 - Skeletal Muscle Measures as Predictors of Toxicity.pdf}
}

@article{shachar8,
  title = {Body {{Composition}} as a {{Predictor}} of {{Toxicity}} in {{Patients Receiving Anthracycline}} and {{Taxane}}\textendash{{Based Chemotherapy}} for {{Early-Stage Breast Cancer}}},
  author = {Shachar, Shlomit Strulov and Deal, Allison M and Weinberg, Marc and Williams, Grant R and Nyrop, Kirsten A and Popuri, Karteek and Choi, Seul Ki and Muss, Hyman B},
  journal = {Clinical Cancer Research},
  pages = {8},
  abstract = {Purpose: Poor body composition metrics (BCM) are associated with inferior cancer outcomes; however, in early breast cancer (EBC), there is a paucity of evidence regarding the impact of BCM on toxicities. This study investigates associations between BCM and treatment-related toxicity in patients with EBC receiving anthracyclines and taxane\textendash based chemotherapy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7F5Q3B9Q\\Shachar et al. - Body Composition as a Predictor of Toxicity in Pat.pdf}
}

@article{shaheen2277,
  ids = {shaheen2277a},
  title = {Radiofrequency Ablation in {{Barrett}}'s Esophagus with Dysplasia},
  author = {Shaheen, Nicholas J. and Sharma, Prateek and Overholt, Bergein F. and Wolfsen, Herbert C. and Sampliner, Richard E. and Wang, Kenneth K. and Galanko, Joseph A. and Bronner, Mary P. and Goldblum, John R. and Bennett, Ana E. and Jobe, Blair A. and Eisen, Glenn M. and Fennerty, M. Brian and Hunter, John G. and Fleischer, David E. and Sharma, Virender K. and Hawes, Robert H. and Hoffman, Brenda J. and Rothstein, Richard I. and Gordon, Stuart R. and Mashimo, Hiroshi and Chang, Kenneth J. and Muthusamy, V. Raman and Edmundowicz, Steven A. and Spechler, Stuart J. and Siddiqui, Ali A. and Souza, Rhonda F. and Infantolino, Anthony and Falk, Gary W. and Kimmey, Michael B. and Madanick, Ryan D. and Chak, Amitabh and Lightdale, Charles J.},
  year = {2009},
  month = may,
  journal = {The New England Journal of Medicine},
  volume = {360},
  number = {22},
  pages = {2277--2288},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa0808145},
  abstract = {BACKGROUND: Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression. METHODS: In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group) or a sham procedure (control group). Randomization was stratified according to the grade of dysplasia and the length of Barrett's esophagus. Primary outcomes at 12 months included the complete eradication of dysplasia and intestinal metaplasia. RESULTS: In the intention-to-treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia occurred in 90.5\% of those in the ablation group, as compared with 22.7\% of those in the control group (P{$<$}0.001). Among patients with high-grade dysplasia, complete eradication occurred in 81.0\% of those in the ablation group, as compared with 19.0\% of those in the control group (P{$<$}0.001). Overall, 77.4\% of patients in the ablation group had complete eradication of intestinal metaplasia, as compared with 2.3\% of those in the control group (P{$<$}0.001). Patients in the ablation group had less disease progression (3.6\% vs. 16.3\%, P=0.03) and fewer cancers (1.2\% vs. 9.3\%, P=0.045). Patients reported having more chest pain after the ablation procedure than after the sham procedure. In the ablation group, one patient had upper gastrointestinal hemorrhage, and five patients (6.0\%) had esophageal stricture. CONCLUSIONS: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression. (ClinicalTrials.gov number, NCT00282672.)},
  langid = {english},
  pmid = {19474425},
  keywords = {Aged,Aged; 80 and over,Barrett Esophagus,Catheter Ablation,Disease Progression,Esophagus,Female,Humans,Logistic Models,Male,Metaplasia,Middle Aged,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K5YB5ZII\\Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\XSBVNK7Y\\Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf}
}

@article{shaheen30,
  title = {{{ACG Clinical Guideline}}: {{Diagnosis}} and {{Management}} of {{Barrett}}'s {{Esophagus}}},
  shorttitle = {{{ACG Clinical Guideline}}},
  author = {Shaheen, Nicholas J. and Falk, Gary W. and Iyer, Prasad G. and Gerson, Lauren B. and {American College of Gastroenterology}},
  year = {2016},
  month = jan,
  journal = {The American Journal of Gastroenterology},
  volume = {111},
  number = {1},
  pages = {30-50; quiz 51},
  issn = {1572-0241},
  doi = {10.1038/ajg.2015.322},
  abstract = {Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist. In this document, the American College of Gastroenterology updates its guidance for the best practices in caring for these patients. These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors. Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years. Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time. Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma. Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative. Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals. Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.},
  langid = {english},
  pmid = {26526079},
  keywords = {Barrett Esophagus,Decision Trees,Humans,Risk Factors}
}

@article{shaker1314,
  type = {Journal {{Article}}},
  title = {Rehabilitation of Swallowing by Exercise in Tube-Fed Patients with Pharyngeal Dysphagia Secondary to Abnormal {{UES}} Opening},
  author = {Shaker, R. and Easterling, C. and Kern, M. and Nitschke, T. and Massey, B. and Daniels, S. and Grande, B. and Kazandjian, M. and Dikeman, K.},
  year = {2002},
  journal = {Gastroenterology},
  volume = {122},
  number = {5},
  pages = {1314--21},
  issn = {0016-5085 (Print) 0016-5085 (Linking)}
}

@article{shaoe31113,
  title = {Pretreatment "Prognostic Nutritional Index" as an Indicator of Outcome in Lung Cancer Patients Receiving {{ICI-based}} Treatment: {{Systematic}} Review and Meta-Analysis},
  shorttitle = {Pretreatment "Prognostic Nutritional Index" as an Indicator of Outcome in Lung Cancer Patients Receiving {{ICI-based}} Treatment},
  author = {Shao, Yifeng and Cao, Wei and Gao, Xinliang and Tang, Mingbo and Zhu, Dongshan and Liu, Wei},
  year = {2022},
  month = oct,
  journal = {Medicine},
  volume = {101},
  number = {43},
  pages = {e31113},
  issn = {1536-5964},
  doi = {10.1097/MD.0000000000031113},
  abstract = {BACKGROUND: The pretreatment prognostic nutritional index (PNI) is an indicator of nutritional and immune status, and has potential use as a predictor of survival in cancer patients. Several retrospective studies have used the PNI to predict the outcome of lung cancer patients receiving different immune checkpoint inhibitors (ICIs), but the results have been inconsistent. The objective of our study is to assess the relationship of pretreatment PNI with survival outcomes in lung cancer patients who received ICI-based treatments by meta-analysis. METHODS: We searched the EMBASE, PubMed, Cochrane Library, American Society of Clinical Oncology, and European Society of Medical Oncology databases to identify studies that reported overall survival (OS) or progression-free survival (PFS) in eligible patients. Eight studies were eligible based on predefined inclusion and exclusion criteria. Data and pooled indicators were extracted from these studies. Meta-analysis was used to analyze hazard ratios (HRs) and 95\% confidence intervals (CIs) for OS and/or PFS and the prognostic value of pretreatment PNI. We completed the registration of the research protocol (Registration number: INPLASY202240087, DOI number: 10.37766/inplasy2022.4.0087). RESULTS: We analyzed data from 8 eligible studies (831 patients). Meta-analysis showed that relative to patients with low pretreatment PNI, those with a high pretreatment PNI had better OS (HR = 2.50, 95\% CI = 1.44-4.33, P = .001) and better PFS (HR = 1.94, 95\% CI = 1.56-2.42, P {$<$} .001). Sensitivity analysis indicated these results were robust. There was also no evidence of publication bias. CONCLUSION: Lung cancer patients receiving ICI-based treatments who had higher pretreatment PNI had better OS and PFS.},
  langid = {english},
  pmcid = {PMC9622676},
  pmid = {36316884},
  keywords = {Humans,Lung,Lung Neoplasms,Nutrition Assessment,PNI,Prognosis,Proportional Hazards Models,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\3JRLERQJ\\Shao et al_2022_Pretreatment prognostic nutritional index as an indicator of outcome in lung.pdf}
}

@article{shapiro1090,
  type = {Journal {{Article}}},
  ids = {shapiroNeoadjuvantChemoradiotherapySurgery2015},
  title = {Neoadjuvant Chemoradiotherapy plus Surgery versus Surgery Alone for Oesophageal or Junctional Cancer ({{CROSS}}): Long-Term Results of a Randomised Controlled Trial},
  author = {Shapiro, J. and {van Lanschot}, J. J. B. and Hulshof, Mccm and {van Hagen}, P. and {van Berge Henegouwen}, M. I. and Wijnhoven, B. P. L. and {van Laarhoven}, H. W. M. and Nieuwenhuijzen, G. A. P. and Hospers, G. A. P. and Bonenkamp, J. J. and Cuesta, M. A. and Blaisse, R. J. B. and Busch, O. R. C. and Ten Kate, F. J. W. and Creemers, G. M. and Punt, C. J. A. and Plukker, J. T. M. and Verheul, H. M. W. and Bilgen, E. J. S. and {van Dekken}, H. and {van der Sangen}, M. J. C. and Rozema, T. and Biermann, K. and Beukema, J. C. and Piet, A. H. M. and {van Rij}, C. M. and Reinders, J. G. and Tilanus, H. W. and Steyerberg, E. W. and {van der Gaast}, A. and study {group}, Cross},
  year = {2015},
  journal = {Lancet Oncol},
  volume = {16},
  number = {9},
  pages = {1090--1098},
  issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
  doi = {10.1016/S1470-2045(15)00040-6},
  pmid = {26254683},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Carboplatin,Chemoradiotherapy,Disease-Free Survival,Esophageal Neoplasms,Esophagogastric Junction,Female,Fluorouracil,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Neoplasm Staging,Paclitaxel}
}

@article{shapiro807,
  type = {Journal {{Article}}},
  title = {Prolonged Time to Surgery after Neoadjuvant Chemoradiotherapy Increases Histopathological Response without Affecting Survival in Patients with Esophageal or Junctional Cancer},
  author = {Shapiro, J. and {van Hagen}, P. and Lingsma, H. F. and Wijnhoven, B. P. and Biermann, K. and {ten Kate}, F. J. and Steyerberg, E. W. and {van der Gaast}, A. and {van Lanschot}, J. J. and Group, Cross Study},
  year = {2014},
  journal = {Ann Surg},
  volume = {260},
  number = {5},
  pages = {807-13; discussion 813-4},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0000000000000966}
}

@article{sharma258,
  title = {Role of Esophageal Stents in Benign and Malignant Diseases},
  author = {Sharma, Prateek and Kozarek, Richard and {Practice Parameters Committee of American College of Gastroenterology}},
  year = {2010},
  month = feb,
  journal = {The American Journal of Gastroenterology},
  volume = {105},
  number = {2},
  pages = {258-273; quiz 274},
  issn = {1572-0241},
  doi = {10.1038/ajg.2009.684},
  abstract = {These recommendations provide an evidence-based approach to the role of esophageal stents in the management of benign and malignant diseases. These guidelines have been developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. The following guidelines are based on a critical review of the available scientific literature on the topic identified in Medline and PubMed (January 1992-December 2008) using search terms that included stents, self-expandable metal stents, self-expandable plastic stents, esophageal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, esophageal stricture, perforations, anastomotic leaks, tracheoesophageal fistula, and achalasia. These guidelines are intended for use by health-care providers and apply to adult, but not pediatric, patients. As with other practice guidelines, these guidelines are not intended to replace clinical judgment but rather to provide general guidelines applicable to the majority of patients. Clinicians need to integrate recommendations with their own clinical judgment, and with individual patient circumstances, values, and preferences. They are intended to be flexible, in contrast to standards of care, which are inflexible policies designed to be followed in every case. Specific recommendations are based on relevant published information. The quality of evidence and strength of recommendations have been assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, which is a system that has been adopted by multiple national and international societies. The GRADE system is based on a sequential assessment of quality of evidence, followed by assessment of the balance between benefits vs. downsides (harms, burden, and costs) and subsequent judgment regarding the strength of recommendation.},
  langid = {english},
  pmid = {20029413},
  keywords = {Adult,Endoscopy,Equipment Design,Equipment Failure,Esophageal Diseases,Humans,Severity of Illness Index,Stents,Treatment Outcome,United States}
}

@article{shaw47,
  title = {Comparison of a Novel, Simple Nutrition Screening Tool for Adult Oncology Inpatients and the {{Malnutrition Screening Tool}} ({{MST}}) against the {{Patient-Generated Subjective Global Assessment}} ({{PG-SGA}})},
  author = {Shaw, Clare and Fleuret, Catherine and Pickard, Jennifer M. and Mohammed, Kabir and Black, Gayle and Wedlake, Linda},
  year = {2015},
  month = jan,
  journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
  volume = {23},
  number = {1},
  pages = {47--54},
  issn = {1433-7339},
  doi = {10.1007/s00520-014-2319-8},
  abstract = {BACKGROUND: Oncology inpatients are at high risk of malnutrition. Identification of at risk patients by nutrition screening requires a practical and easy to use tool. In this study, we have compared a simple, novel nutrition screening tool designed for an oncology inpatient setting and the Malnutrition Screening Tool (MST) against the Patient-Generated Subjective Global Assessment (PG-SGA). METHODS: This was an observational study to compare assessment of nutritional status by PG-SGA with nutrition screening using the Royal Marsden Nutrition Screening Tool (RMNST) and the MST. Patients were recruited from a single tertiary cancer centre. RESULTS: One hundred and twenty-six oncology inpatients underwent a full nutritional assessment and nutrition screening. The PG-SGA tool identified 90 (71\%) patients as malnourished or at risk and 36 (29\%) patients as well-nourished. The RMNST had a sensitivity of 93\% and a specificity of 53\%, and the MST had a sensitivity of 66\% and a specificity of 83 \%. Predictive value (ROC AUC) of both screening tools was excellent at 0.84 and 0.83 for RMNST and MST, respectively. CONCLUSIONS: This study identified a high prevalence of malnutrition in the population with 71\% of patients being identified as malnourished or at risk of malnutrition. The RMNST had an excellent sensitivity for identifying patients who were malnourished or at risk of malnutrition in the inpatient setting although it had a poor specificity. The MST had a poorer sensitivity of 66 \%. We would recommend that the RMNST is trialled in other oncology inpatient settings and also in the outpatient setting.},
  langid = {english},
  pmid = {24947056},
  keywords = {Adult,Aged,Female,Humans,Inpatients,Male,Malnutrition,Mass Screening,Middle Aged,Neoplasms,Nutrition Assessment,Nutritional Status,Outpatients,Prevalence,Reproducibility of Results,Risk,Surveys and Questionnaires}
}

@article{sheetz716,
  title = {Decreased Core Muscle Size Is Associated with Worse Patient Survival Following Esophagectomy for Cancer},
  author = {Sheetz, K. H. and Zhao, L. and Holcombe, S. A. and Wang, S. C. and Reddy, R. M. and Lin, J. and Orringer, M. B. and Chang, A. C.},
  year = {2013},
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {26},
  number = {7},
  pages = {716--722},
  issn = {1442-2050},
  doi = {10.1111/dote.12020},
  abstract = {Preoperative risk assessment, particularly for patient frailty, remains largely subjective. This study evaluated the relationship between core muscle size and patient outcomes following esophagectomy for malignancy. Using preoperative computed tomography scans in 230 subjects who had undergone transhiatal esophagectomy for cancer between 2001 and 2010, lean psoas area (LPA), measured at the fourth lumbar vertebra, was determined. Cox proportional hazards regression was employed to analyze overall survival (OS) and disease-free survival (DFS) adjusted for age, gender, and stage, and the Akaike information criterion was used to determine each covariate contribution to OS and DFS. Univariate analysis demonstrated that increasing LPA correlated with both OS (P = 0.017) and DFS (P = 0.038). In multivariate analysis controlling for patient and tumor characteristics, LPA correlated with OS and DFS in patients who had not received neoadjuvant treatment (n = 64), with higher LPA associated with improved OS and DFS. Moreover, LPA was of equivalent, or slightly higher importance than pathologic stage. These measures were not predictive among patients (n = 166) receiving neoadjuvant chemoradiation. Core muscle size appears to be an independent predictor of both OS and DFS, as significant as tumor stage, in patients following transhiatal esophagectomy. Changes in muscle mass related to preoperative treatment may confound this effect. Assessment of core muscle size may provide an additional objective measure for risk stratification prior to undergoing esophagectomy.},
  langid = {english},
  pmcid = {PMC4171877},
  pmid = {23350746},
  keywords = {Adenocarcinoma,Aged,Carcinoma; Squamous Cell,Chemoradiotherapy,Combined Modality Therapy,Disease-Free Survival,esophageal cancer,Esophageal Neoplasms,esophageal surgery,Esophagectomy,Female,Humans,Male,Middle Aged,Multivariate Analysis,Neoplasm Staging,Organ Size,Prognosis,Proportional Hazards Models,Psoas Muscles,Retrospective Studies,Risk Factors,risk stratification,Tomography; X-Ray Computed,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\P4DQBXSP\\Sheetz et al_2013_Decreased core muscle size is associated with worse patient survival following.pdf}
}

@article{shen1267,
  title = {The Impact of Tidal Volume on Pulmonary Complications Following Minimally Invasive Esophagectomy: A Randomized and Controlled Study},
  shorttitle = {The Impact of Tidal Volume on Pulmonary Complications Following Minimally Invasive Esophagectomy},
  author = {Shen, Yaxing and Zhong, Ming and Wu, Wei and Wang, Hao and Feng, Mingxiang and Tan, Lijie and Wang, Qun},
  year = {2013},
  month = nov,
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  volume = {146},
  number = {5},
  pages = {1267-1273; discussion 1273-1274},
  issn = {1097-685X},
  doi = {10.1016/j.jtcvs.2013.06.043},
  abstract = {BACKGROUND: Minimally invasive esophagectomy (MIE) has been advantageous for lowering pulmonary complications compared with open approaches.(1) However, pulmonary complications remain the most common morbidity after surgical resection of esophageal cancer.(2,3) The aim of this prospective, randomized, controlled, clinical trial was designed to see whether low tidal volume (VT) could further minimize pulmonary complications after MIE. METHODS: Between June 2011 and July 2012, a total of 101 patients who underwent MIE received left-lung ventilation during thoracoscopic esophagectomy. All patients received left-lung ventilation during thoracoscopic esophagectomy. Patients were randomly assigned to a low VT (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV) group (n~=~53) and a conventional VT (8 mL/kg) controlled ventilation (CV) group (n~=~48) in the thoracic stage. Alveolar lavage fluid was harvested from the ventilated lung at intubation and at 18 hours after surgery for analysis of interleukin (IL)-1\ss, IL-6, and IL-8 levels. Clinical characteristics, including patient demographics, operation features, and changes in oxygenation index, were recorded and analyzed. Pulmonary complications were identified and statistically compared between the 2 groups. RESULTS: The clinical characteristics and operation features were comparable between the 2 groups. IL-1\ss, IL-6, and IL-8 expressions in preoperative alveolar lavage fluid were similar between the 2 groups. Significantly lower~IL expressions were observed in the PV group than those in the CV group at 18 hours after MIE (IL-1\ss, 25.42 {$\pm$} 31.01 vs 94.96 {$\pm$} 118.24 pg/mL; IL-6, 30.86 {$\pm$} 75.78 vs 92.99 {$\pm$} 72.90 pg/mL; IL-8, 258.75~{$\pm$} 188.24 vs 403.95 {$\pm$} 151.44 pg/mL; all P~{$<~$}.05). The 18-hour postoperative oxygenation index was lower in the CV group than that in the PV group (292.85 {$\pm$} 28.74 vs 326.35 {$\pm$} 34.43; P~=~.046). Pulmonary complications were observed in 18 cases of our series, occurring more frequently on the ventilation side (right, 6 cases; and left, 12 cases). All patients were cured by conservative therapy without severe sequelae. The~occurrence of pulmonary complications in the PV group was lower than that in the CV group (9.43\%~vs~27.08\%; P~=~.021). CONCLUSIONS: Lung injury due to intraoperative single-lung ventilation may contribute to pulmonary complications after MIE. Low VT ventilation could decrease ventilation-associated lung inflammation, thus minimizing pulmonary complications after MIE. Further studies, based on a larger volume of populations, are required to confirm these findings.},
  langid = {english},
  pmid = {23993028},
  keywords = {28,41.2,7,Bronchoalveolar Lavage Fluid,Chi-Square Distribution,China,controlled ventilation,CV,end-tidal carbon dioxide concentration,Esophageal Neoplasms,Esophagectomy,EtCO(2),Humans,ICS,IL,Inflammation Mediators,intercostal space,interleukin,Interleukin-1beta,Interleukin-6,Interleukin-8,Lung,MIE,minimally invasive esophagectomy,OI,oxygenation index,PC,PEEP,positive end-expiratory pressure,Positive-Pressure Respiration,preserved ventilation,Prospective Studies,pulmonary complication,PV,single-lung ventilation,SLV,Thoracoscopy,tidal volume,Tidal Volume,Time Factors,Treatment Outcome,Ventilator-Induced Lung Injury,VT},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\A688KF3D\\Shen et al_2013_The impact of tidal volume on pulmonary complications following minimally.pdf}
}

@article{shen2333,
  title = {Total Body Skeletal Muscle and Adipose Tissue Volumes: Estimation from a Single Abdominal Cross-Sectional Image},
  shorttitle = {Total Body Skeletal Muscle and Adipose Tissue Volumes},
  author = {Shen, Wei and Punyanitya, Mark and Wang, ZiMian and Gallagher, Dympna and {St-Onge}, Marie-Pierre and Albu, Jeanine and Heymsfield, Steven B. and Heshka, Stanley},
  year = {2004},
  month = dec,
  journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
  volume = {97},
  number = {6},
  pages = {2333--2338},
  issn = {8750-7587},
  doi = {10.1152/japplphysiol.00744.2004},
  abstract = {A single abdominal cross-sectional computerized axial tomography and magnetic resonance image is often obtained in studies examining adipose tissue (AT) distribution. An abdominal image might also provide additional useful information on total body skeletal muscle (SM) and AT volumes with related physiological insights. We therefore investigated the relationships between abdominal SM and AT areas from single images and total body component volumes in a large and diverse sample of healthy adult subjects. Total body SM and AT volumes were derived by whole body multislice magnetic resonance imaging in 123 men [age (mean +/- SD) of 41.6 +/- 15.8 yr; body mass index of 25.9 +/- 3.4 kg/m(2)] and 205 women (age of 47.8 +/- 18.7 yr; body mass index of 26.7 +/- 5.6 kg/m(2)). Single abdominal SM and AT slice areas were highly correlated with total body SM (r = 0.71-0.92; r = 0.90 at L(4)-L(5) intervertebral space) and AT (r = 0.84-0.96; r = 0.94 at L(4)-L(5) intervertebral space) volumes, respectively. R(2) increased by only 5.7-6.1\% for SM and 2.7-4.4\% for AT with the inclusion of subject sex, age, ethnicity, scanning position, body mass index, and waist circumference in the model. The developed SM and AT models were validated in an additional 49 subjects. To achieve equivalent power to a study measuring total body SM or AT volumes, a study using a single abdominal image would require 17-24\% more subjects for SM and 6-12\% more subjects for AT. Measurement of a single abdominal image can thus provide estimates of total body SM and AT for group studies of healthy adults.},
  langid = {english},
  pmid = {15310748},
  keywords = {Abdomen,Adipose Tissue,Adult,Aged,Body Composition,Female,Humans,Magnetic Resonance Imaging,Male,Middle Aged,Muscle; Skeletal,Predictive Value of Tests,Reproducibility of Results}
}

@article{shen9113,
  title = {The Effect of Enhanced Recovery after Minimally Invasive Esophagectomy: A Randomized Controlled Trial},
  shorttitle = {The Effect of Enhanced Recovery after Minimally Invasive Esophagectomy},
  author = {Shen, Yaxing and Chen, Xiaosang and Hou, Junyi and Chen, Youwen and Fang, Yong and Xue, Zhanggang and D'Journo, Xavier Benoit and Cerfolio, Robert J. and Fernando, Hiran C. and Fiorelli, Alfonso and Brunelli, Alessandro and Cang, Jing and Tan, Lijie and Wang, Hao and {Written on behalf of the AME Thoracic Surgery Collaborative Group}},
  year = {2022},
  month = dec,
  journal = {Surgical Endoscopy},
  volume = {36},
  number = {12},
  pages = {9113--9122},
  issn = {1432-2218},
  doi = {10.1007/s00464-022-09385-6},
  abstract = {BACKGROUND: The purpose of this randomized controlled trial was to determine if enhanced recovery after surgery (ERAS) would improve outcomes for three-stage minimally invasive esophagectomy (MIE). METHODS: Patients with esophageal cancer undergoing MIE between March 2016 and August 2018 were consecutively enrolled, and were randomly divided into 2 groups: ERAS+group that received a guideline-based ERAS protocol, and ERAS- group that received standard care. The primary endpoint was morbidity after MIE. The secondary endpoints were the length of stay (LOS) and time to ambulation after the surgery. The perioperative results including the Surgical Apgar Score (SAS) and Visualized Analgesia Score (VAS) were also collected and compared. RESULTS: A total of 60 patients in the ERAS+ group and 58 patients in the ERAS- group were included. Postoperatively, lower morbidity and pulmonary complication rate were recorded in the ERAS+ group (33.3\% vs. 51.7\%; p\,=\,0.04, 16.7\% vs. 32.8\%; p\,=\,0.04), while the incidence of anastomotic leakage remained comparable (11.7\% vs. 15.5\%; p\,=\,0.54). There was an earlier ambulation (3 [2-3] days vs. 3 [3-4] days, p\,=\,0.001), but comparable LOS (10 [9-11.25] days vs. 10 [9-13] days; p\,=\,0.165) recorded in ERAS+ group. The ERAS protocol led to close scores in both SAS (7.80\,{$\pm$}\,1.03 vs. 8.07\,{$\pm$}\,0.89, p\,=\,0.21) and VAS (1.74\,{$\pm$}\,0.85 vs. 1.78\,{$\pm$}\,1.06, p\,=\,0.84). CONCLUSIONS: Implementation of an ERAS protocol for patients undergoing MIE resulted in earlier ambulation and lower pulmonary complications, without a change in anastomotic leakage or length of hospital stay. Further studies on minimizing leakage should be addressed in ERAS for MIE.},
  langid = {english},
  pmcid = {PMC9652161},
  pmid = {35773604},
  keywords = {Anastomotic Leak,Enhanced recovery after surgery; ERAS,Esophageal Neoplasms,Esophagectomy,Humans,Length of Stay,Length of stay; LOS,Minimally invasive esophagectomy; MIE,Minimally Invasive Surgical Procedures,Morbidity,Postoperative Complications,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IT9BHIQN\\Shen et al_2022_The effect of enhanced recovery after minimally invasive esophagectomy.pdf}
}

@article{shewale1114,
  type = {Journal {{Article}}},
  title = {Impact of a {{Fast-track Esophagectomy Protocol}} on {{Esophageal Cancer Patient Outcomes}} and {{Hospital Charges}}},
  author = {Shewale, J. B. and Correa, A. M. and Baker, C. M. and {Villafane-Ferriol}, N. and Hofstetter, W. L. and Jordan, V. S. and Kehlet, H. and Lewis, K. M. and Mehran, R. J. and Summers, B. L. and Schaub, D. and Wilks, S. A. and Swisher, S. G. and {University of Texas}, M. D. Anderson Esophageal Cancer Collaborative Group},
  year = {2015},
  journal = {Ann Surg},
  volume = {261},
  number = {6},
  pages = {1114--23},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0000000000000971}
}

@article{shih2841,
  title = {Systematic Reviews of Guidelines and Studies for Single versus Multiple Unit Transfusion Strategies},
  author = {Shih, Andrew W. and Liu, Aixin and Elsharawi, Radwa and Crowther, Mark A. and Cook, Richard J. and Heddle, Nancy M.},
  year = {2018},
  month = dec,
  journal = {Transfusion},
  volume = {58},
  number = {12},
  pages = {2841--2860},
  issn = {1537-2995},
  doi = {10.1111/trf.14952},
  abstract = {BACKGROUND: Recent recommendations indicate that one red blood cell (RBC) unit should be transfused at a time, with reassessment after each transfusion, which may be extrapolated from literature supporting restrictive transfusion triggers rather than specific evidence. Therefore, two systematic reviews were performed to identify the following: 1) RBC transfusion guidelines and review articles to determine if single- or multiple-unit transfusion strategies are recommended and 2) studies comparing strategies for evidence of benefit. STUDY DESIGN AND METHODS: MEDLINE, EMBASE, CINAHL, Web of Science, National Guideline Clearinghouse, and Trip Database were searched (inception to June 2017). For the first review, the proportion of articles with single/multiple-unit recommendations was assessed and stratified by article type. For the second review, the primary outcome was RBC use. Secondary outcomes included proportion of transfusion episodes using a single-unit strategy, length of stay, and mortality. RESULTS: The first review identified 145 articles for analysis, with 51 transfusion guidelines. Only 14 guidelines (27\%) made a recommendation, with most (93\%) recommending single-unit transfusions. The second review identified seven cohort studies comparing preimplementation and postimplementation of a policy encouraging single-unit transfusion strategies. Meta-analysis could not be performed for outcomes given inconsistencies in reporting. RBC use decreased by approximately 10 to 41\% across studies. CONCLUSION: Transfusion guidelines lack recommendations to transfuse to a single-unit strategy. Mostly retrospective cohort studies (six of seven) are inconsistent in outcome reporting but suggest improved RBC use. Further high-quality studies could identify the benefits of a single-unit transfusion strategy, determine the applicability to different clinical settings, and inform future practice guidelines.},
  langid = {english},
  pmid = {30345619},
  keywords = {Erythrocyte Transfusion,Female,Humans,Male,Practice Guidelines as Topic,SingleUnit}
}

@article{shuster1,
  title = {The Clinical Importance of Visceral Adiposity: A Critical Review of Methods for Visceral Adipose Tissue Analysis},
  shorttitle = {The Clinical Importance of Visceral Adiposity},
  author = {Shuster, A. and Patlas, M. and Pinthus, J. H. and Mourtzakis, M.},
  year = {2012},
  month = jan,
  journal = {The British Journal of Radiology},
  volume = {85},
  number = {1009},
  pages = {1--10},
  issn = {1748-880X},
  doi = {10.1259/bjr/38447238},
  abstract = {As a result of the rising epidemic of obesity, understanding body fat distribution and its clinical implications is critical to timely treatment. Visceral adipose tissue is a hormonally active component of total body fat, which possesses unique biochemical characteristics that influence several normal and pathological processes in the human body. Abnormally high deposition of visceral adipose tissue is known as visceral obesity. This body composition phenotype is associated with medical disorders such as metabolic syndrome, cardiovascular disease and several malignancies including prostate, breast and colorectal cancers. Quantitative assessment of visceral obesity is important for evaluating the potential risk of development of these pathologies, as well as providing an accurate prognosis. This review aims to compare different methods of measuring visceral adiposity with emphasis on their advantages and drawbacks in clinical practice.},
  langid = {english},
  pmcid = {PMC3473928},
  pmid = {21937614},
  keywords = {Absorptiometry; Photon,Humans,ICC,Intra-Abdominal Fat,Magnetic Resonance Imaging,Methods,Obesity; Abdominal,Plethysmography,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VIG5AWNG\\Shuster et al_2012_The clinical importance of visceral adiposity.pdf}
}

@article{siegel7,
  type = {Journal {{Article}}},
  title = {Cancer Statistics, 2020},
  author = {Siegel, R. L. and Miller, K. D. and Jemal, A.},
  year = {2020},
  journal = {CA Cancer J Clin},
  volume = {70},
  number = {1},
  pages = {7--30},
  issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
  doi = {10.3322/caac.21590}
}

@article{siewert260,
  title = {Adenocarcinoma of the Esophago-Gastric Junction},
  author = {Siewert, J. R. and Stein, H. J. and Feith, M.},
  year = {2006},
  journal = {Scandinavian journal of surgery: SJS: official organ for the Finnish Surgical Society and the Scandinavian Surgical Society},
  volume = {95},
  number = {4},
  pages = {260--269},
  issn = {1457-4969},
  doi = {10.1177/145749690609500409},
  abstract = {BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction. We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification. METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors. Demographic data, morphologic and histopathologic tumor characteristics, and long-term survival rates were compared among the three tumor subclassifiations. RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities. The degree of resection and lymph node status were the dominating independent prognostic factors by multivariate analysis. The data show no significant differences of long-term survival after abdomino-thoracic esophagectomy and extended total gastrectomy in these patients. CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach. Complete tumor resection and adequate lymphadenectomy are associated with good long-term prognosis. Better surgical management and standardized procedures will improve the outcome also of patients who need to undergo more radical surgery, i.e. abdomino-thoracic esophagectomy.},
  langid = {english},
  pmid = {17249275},
  keywords = {Adenocarcinoma,Esophageal Neoplasms,Esophagogastric Junction,Female,Humans,Kaplan-Meier Estimate,Lymphatic Metastasis,Male,Middle Aged,Prognosis,Sex Distribution,Stomach Neoplasms,Treatment Outcome}
}

@article{simmonds531,
  title = {Palliative Chemotherapy for Advanced Colorectal Cancer: Systematic Review and Meta-Analysis. {{Colorectal Cancer Collaborative Group}}},
  shorttitle = {Palliative Chemotherapy for Advanced Colorectal Cancer},
  author = {Simmonds, P. C.},
  year = {2000},
  month = sep,
  journal = {BMJ (Clinical research ed.)},
  volume = {321},
  number = {7260},
  pages = {531--535},
  issn = {0959-8138},
  doi = {10.1136/bmj.321.7260.531},
  abstract = {OBJECTIVES: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer and to compare the outcomes for elderly and younger patients. DESIGN: Meta-analysis of individual patient data and published summary statistics from trials for which individual patient data could not be obtained from the investigators. STUDIES: All randomised controlled trials comparing palliative chemotherapy with supportive care in patients with advanced colorectal cancer that were identified by computerised and hand searches of the literature, scanning references, and contacting investigators. MAIN OUTCOME MEASURES: Survival, disease progression, quality of life, and toxicity. RESULTS: 13 randomised controlled trials including a total of 1365 patients met the inclusion criteria. Meta-analysis of seven trials that provided individual patient data (866 patients) showed that palliative chemotherapy was associated with a 35\% reduction in the risk of death (95\% confidence interval 24\% to 44\%). This translates into an absolute improvement in survival of 16\% at both six and 12 months and an improvement in median survival of 3.7 months. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. The overall quality of evidence relating to treatment toxicity, symptom control, and quality of life was poor. CONCLUSIONS: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated in this analysis as some patients in the control arms received chemotherapy.},
  langid = {english},
  pmcid = {PMC27466},
  pmid = {10968812},
  keywords = {Aged,Antimetabolites; Antineoplastic,Colorectal Neoplasms,CRC,Databases; Bibliographic,Disease Progression,ECOG,Fluorouracil,Humans,Middle Aged,Odds Ratio,Palliative Care,Proportional Hazards Models,Randomized Controlled Trials as Topic,Survival Analysis,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\EP5HUFWD\\Simmonds_2000_Palliative chemotherapy for advanced colorectal cancer.pdf}
}

@article{simonsen58,
  title = {Sarcopenia and {{Postoperative Complication Risk}} in {{Gastrointestinal Surgical Oncology}}: {{A Meta-analysis}}},
  shorttitle = {Sarcopenia and {{Postoperative Complication Risk}} in {{Gastrointestinal Surgical Oncology}}},
  author = {Simonsen, Casper and {de Heer}, Pieter and Bjerre, Eik D. and Suetta, Charlotte and Hojman, Pernille and Pedersen, Bente K. and Svendsen, Lars B. and Christensen, Jesper F.},
  year = {2018},
  month = jul,
  journal = {Annals of Surgery},
  volume = {268},
  number = {1},
  pages = {58--69},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002679},
  abstract = {OBJECTIVE: The aim of the study was to evaluate sarcopenia as a predictor of postoperative risk of major and total complications after surgery for gastrointestinal cancer. BACKGROUND: Sarcopenia is associated with poor survival in gastrointestinal cancer patients, but the role of sarcopenia as prognostic tool in surgical oncology has not been established, and no consensus exists regarding assessment and management of sarcopenic patients. METHODS: We performed a systematic search for citations in EMBASE, Web of Science, and PubMed from 2004 to January 31, 2017. Random effects meta-analyses were used to estimate the pooled risk ratio for postoperative complications by Clavien-Dindo grade (total complications: grade {$\geq$}2; major complications: grade {$\geq$}3) in patients with sarcopenia versus patients without sarcopenia. Stratified analyses were performed by sarcopenia criteria, cutoff level, assessment methods, study quality, cancer diagnosis, and "Enhanced Recovery After Surgery" care. RESULTS: Twenty-nine studies (n = 7176) were included with sarcopenia prevalence ranging between 12\% and 78\%. Preoperative incidence of sarcopenia was associated with increased risk of major complications (risk ratio 1.40; 95\% confidence interval, 1.20-1.64; P {$<$} 0.001; I = 52\%) and total complications (risk ratio 1.35; 95\% confidence interval, 1.12-1.61; P = 0.001; I = 60\%). Moderate heterogeneity was found for both meta-analyses. Subgroup analyses showed that sarcopenia remained a consistent risk factor across stratification by sarcopenia criteria, assessment methods, study quality, and diagnoses. CONCLUSIONS: Sarcopenia was associated with an increased risk of complications after gastrointestinal tumor resection, but lack of methodological consensus hampers the interpretation and clinical utilization of these findings. Combining assessment of muscle mass with measures of physical function may increase the prognostic value and accuracy in preoperative risk stratification.},
  langid = {english},
  pmid = {29373365},
  keywords = {Gastrointestinal Neoplasms,GI,Humans,Incidence,Models; Statistical,Postoperative Complications,Preoperative Period,Prevalence,Prognosis,Review,Risk Factors,Sarcopenia},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\2NG8VSKH\\Simonsen et al_2018_Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical.pdf}
}

@article{sjoblom7,
  title = {Low Muscle Mass Is Associated with Chemotherapy-Induced Haematological Toxicity in Advanced Non-Small Cell Lung Cancer},
  author = {Sj{\o}blom, Bj{\o}rg and Gr{\o}nberg, Bj{\o}rn H and Fl{\o}tten, {\O}ystein and Hjermstad, Marianne J and Aass, Nina and Jordh{\o}y, Marit},
  year = {2015},
  journal = {Lung Cancer},
  pages = {7},
  abstract = {Background: Recent research suggests a significant relationship between lean body mass (LBM) and toxicity from chemotherapeutic agents. We investigated if higher drug doses per kg LBM were associated with increased toxicity in stage IIIB/IV non-small cell lung cancer (NSCLC) patients receiving a first-line chemotherapy regimen dosed according to body surface area (BSA). Methods: Data from patients randomised to receive intravenous gemcitabine 1000 mg/m2 plus orally vinorelbine 60 mg/m2 days 1 and 8 in a phase III trial comparing two chemotherapy regimens were analysed. LBM was estimated from assessment of the cross-sectional muscle area at the third lumbar level (L3) on computed tomography images obtained before chemotherapy commenced. Common terminology criteria for adverse events (CTCAE) grade 3\textendash 4 haematological toxicity and dose reduction and/or stop of treatment after the first course of chemotherapy were defined as primary and secondary toxicity outcomes. Results: The study sample included 153 patients, mean age was 66 years, 55\% were men, 87\% had disease stage IV and 75\% had performance status (PS) 0\textendash 1. Gemcitabine doses per kg LBM varied from 23.2 to 53.1 mg/kg LBM, and vinorelbine doses from 1.5 to 3.3 mg/kg LBM. Higher doses of gemcitabine per kg LBM were significantly associated with grade 3\textendash 4 haematological toxicity in bivariate (OR = 1.12, 95\% CI 1.03\textendash 1.23, p = 0.008) and multivariate analyses (OR = 1.15, 95\% CI 1.01\textendash 1.29, p = 0.018), as were also higher doses of vinorelbine per kg LBM. No significant association was found between drug doses per kg LBM and dose reduction and/or stop of treatment. Conclusion: The study showed that dose estimates according to BSA lead to a substantial variation in drug dose per kg LBM, and higher doses per kg LBM are a significant predictor for chemotherapy-induced haematological toxicity. The results indicate that taking LBM into account may lead to a better dose individualisation of chemotherapy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SW8Q2DL2\\SjÃ¸blom et al. - 2015 - Low muscle mass is associated with chemotherapy-in.pdf}
}

@article{sjoblom8,
  title = {Skeletal Muscle Radiodensity Is Prognostic for Survival in Patients with Advanced Non-Small Cell Lung Cancer},
  author = {Sj{\o}blom, Bj{\o}rg},
  year = {2016},
  journal = {Clinical Nutrition},
  pages = {8},
  abstract = {Background \& aims: Recent research indicates that severe muscular depletion (sarcopenia) is frequent in cancer patients and linked to cachexia and poor survival. Our aim was to investigate if measures of skeletal muscle hold prognostic information in advanced non-small cell lung cancer (NSCLC). Methods: We included NSCLC patients with disease stage IIIB/IV, performance status 0e2, enrolled in three randomised trials of first-line chemotherapy (n {$\frac{1}{4}$} 1305). Computed tomography (CT) images obtained before start of treatment were used for body composition analyses at the level of the third lumbar vertebra (L3). Skeletal muscle mass was assessed by measures of the cross sectional muscle area, from which the skeletal muscle index (SMI) was obtained. Skeletal muscle radiodensity (SMD) was measured as the mean Hounsfield unit (HU) of the measured muscle area. A high level of mean HU indicates a high SMD. Results: Complete data were available for 734 patients, mean age 65 years. Both skeletal muscle index (SMI) and muscle radiodensity (SMD) varied largely. Mean SMI and SMD were 47.7 cm2/m2 and 37.4 HU in men (n {$\frac{1}{4}$} 420), 39.6 cm2/m2 and 37.0 HU in women (n {$\frac{1}{4}$} 314). Multivariable Cox regression analyses, adjusted for established prognostic factors, showed that SMD was independently prognostic for survival (Hazard ratio (HR) 0.98, 95\% CI 0.97e0.99, p {$\frac{1}{4}$} 0.001), whereas SMI was not (HR 0.99, 95\% CI 0.98e1.01, p {$\frac{1}{4}$} 0.329). Conclusion: Low SMD is associated with poorer survival in advanced NSCLC. Further research is warranted to establish whether muscle measures should be integrated into routine practice to improve prognostic accuracy.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\EJ6TAQK7\\SjÃ¸blom - 2016 - Skeletal muscle radiodensity is prognostic for sur.pdf}
}

@article{sjoquist681,
  title = {Survival after Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma: An Updated Meta-Analysis},
  shorttitle = {Survival after Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma},
  author = {Sjoquist, Katrin M. and Burmeister, Bryan H. and Smithers, B. Mark and Zalcberg, John R. and Simes, R. John and Barbour, Andrew and Gebski, Val and {Australasian Gastro-Intestinal Trials Group}},
  year = {2011},
  month = jul,
  journal = {The Lancet. Oncology},
  volume = {12},
  number = {7},
  pages = {681--692},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(11)70142-5},
  abstract = {BACKGROUND: In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy. METHODS: To identify additional studies and published abstracts from major scientific meetings, we searched Medline, Embase, and Central (Cochrane clinical trials database) for studies published since January, 2006, and also manually searched for abstracts from major conferences from the same period. Only randomised studies analysed by intention to treat were included, and searches were restricted to those databases citing articles in English. We used published hazard ratios (HRs) if available or estimates from other survival data. We also investigated treatment effects by tumour histology and relations between risk (survival after surgery alone) and effect size. FINDINGS: We included all 17 trials from the previous meta-analysis and seven further studies. 12 were randomised comparisons of neoadjuvant chemoradiotherapy versus surgery alone (n=1854), nine were randomised comparisons of neoadjuvant chemotherapy versus surgery alone (n=1981), and two compared neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy (n=194) in patients with resectable oesophageal carcinoma; one factorial trial included two comparisons and was included in analyses of both neoadjuvant chemoradiotherapy (n=78) and neoadjuvant chemotherapy (n=81). The updated analysis contained 4188 patients whereas the previous publication included 2933 patients. This updated meta-analysis contains about 3500 events compared with about 2230 in the previous meta-analysis (estimated 57\% increase). The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95\% CI 0.70-0.88; p{$<$}0.0001); the HR for squamous-cell carcinoma only was 0.80 (0.68-0.93; p=0.004) and for adenocarcinoma only was 0.75 (0.59-0.95; p=0.02). The HR for all-cause mortality for neoadjuvant chemotherapy was 0.87 (0.79-0.96; p=0.005); the HR for squamous-cell carcinoma only was 0.92 (0.81-1.04; p=0.18) and for adenocarcinoma only was 0.83 (0.71-0.95; p=0.01). The HR for the overall indirect comparison of all-cause mortality for neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy was 0.88 (0.76-1.01; p=0.07). INTERPRETATION: This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemoradiotherapy or chemotherapy over surgery alone in patients with oesophageal carcinoma. A clear advantage of neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy has not been established. These results should help inform decisions about patient management and design of future trials. FUNDING: Cancer Australia and the NSW Cancer Institute.},
  langid = {english},
  pmid = {21684205},
  keywords = {Antineoplastic Agents,Australia,Carcinoma; Squamous Cell,Databases as Topic,Disease-Free Survival,Esophageal Neoplasms,Female,Follow-Up Studies,Humans,Male,Neoadjuvant Therapy,Radiotherapy; Adjuvant}
}

@article{skipper709,
  title = {Position of the {{Academy}} of {{Nutrition}} and {{Dietetics}}: {{Malnutrition}} ({{Undernutrition}}) {{Screening Tools}} for {{All Adults}}},
  shorttitle = {Position of the {{Academy}} of {{Nutrition}} and {{Dietetics}}},
  author = {Skipper, Annalynn and Coltman, Anne and Tomesko, Jennifer and Charney, Pamela and Porcari, Judith and Piemonte, Tami A. and Handu, Deepa and Cheng, Feon W.},
  year = {2020},
  month = apr,
  journal = {Journal of the Academy of Nutrition and Dietetics},
  volume = {120},
  number = {4},
  pages = {709--713},
  issn = {2212-2672},
  doi = {10.1016/j.jand.2019.09.011},
  abstract = {It is the position of the Academy of Nutrition and Dietetics that, based upon current evidence, the Malnutrition Screening Tool should be used to screen adults for malnutrition (undernutrition) regardless of their age, medical history, or setting. Malnutrition (undernutrition) screening is a simple process intended to quickly recognize individuals who may have a malnutrition diagnosis. While numerous malnutrition screening tools are in use, their levels of validity, agreement, reliability, and generalizability vary. The Academy of Nutrition and Dietetics reviewed the body of evidence supporting malnutrition screening tools and determined a single tool for identifying adults in all settings who may have malnutrition, regardless of their age or medical history. The Nutrition Screening for Adults Workgroup conducted a systematic review of the most robust evidence to promote using the highest-quality malnutrition screening tool available.},
  langid = {english},
  pmid = {31866359},
  keywords = {Academies and Institutes,Adult,Dietetics,Female,Humans,Male,Malnutrition,Mass Screening,Nutrition Assessment,Reproducibility of Results}
}

@article{smalley2327,
  title = {Updated Analysis of {{SWOG-directed}} Intergroup Study 0116: A Phase {{III}} Trial of Adjuvant Radiochemotherapy versus Observation after Curative Gastric Cancer Resection},
  shorttitle = {Updated Analysis of {{SWOG-directed}} Intergroup Study 0116},
  author = {Smalley, Stephen R. and Benedetti, Jacqueline K. and Haller, Daniel G. and Hundahl, Scott A. and Estes, Norman C. and Ajani, Jaffer A. and Gunderson, Leonard L. and Goldman, Bryan and Martenson, James A. and Jessup, J. Milburn and Stemmermann, Grant N. and Blanke, Charles D. and Macdonald, John S.},
  year = {2012},
  month = jul,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {30},
  number = {19},
  pages = {2327--2333},
  issn = {1527-7755},
  doi = {10.1200/JCO.2011.36.7136},
  abstract = {PURPOSE: Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures. We performed a randomized phase III trial of postoperative radiochemotherapy in those at moderate risk of locoregional failure (LRF) following surgery. We originally reported results with 4-year median follow-up. This update, with a more than 10-year median follow-up, presents data on failure patterns and second malignancies and explores selected subset analyses. PATIENTS AND METHODS: In all, 559 patients with primaries {$\geq$} T3 and/or node-positive gastric cancer were randomly assigned to observation versus radiochemotherapy after R0 resection. Fluorouracil and leucovorin were administered before, during, and after radiotherapy. Radiotherapy was given to all LRF sites to a dose of 45 Gy. RESULTS: Overall survival (OS) and relapse-free survival (RFS) data demonstrate continued strong benefit from postoperative radiochemotherapy. The hazard ratio (HR) for OS is 1.32 (95\% CI, 1.10 to 1.60; P = .0046). The HR for RFS is 1.51 (95\% CI, 1.25 to 1.83; P {$<$} .001). Adjuvant radiochemotherapy produced substantial reduction in both overall relapse and locoregional relapse. Second malignancies were observed in 21 patients with radiotherapy versus eight with observation (P = .21). Subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology who exhibited minimal nonsignificant treatment effect. CONCLUSION: Intergroup 0116 (INT-0116) demonstrates strong persistent benefit from adjuvant radiochemotherapy. Toxicities, including second malignancies, appear acceptable, given the magnitude of RFS and OS improvement. LRF reduction may account for the majority of overall relapse reduction. Adjuvant radiochemotherapy remains a rational standard therapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes.},
  langid = {english},
  pmcid = {PMC4517071},
  pmid = {22585691},
  keywords = {Adenocarcinoma,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy; Adjuvant,Female,Fluorouracil,Gastrectomy,Humans,Leucovorin,Male,Stomach Neoplasms,Survival Analysis,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\G4JPLSTN\\Smalley et al. - 2012 - Updated analysis of SWOG-directed intergroup study.pdf}
}

@article{smith657,
  title = {Watch and {{Wait}} in {{Rectal Cancer}} or {{More Wait}} and {{See}}?},
  author = {Smith, J. Joshua and Paty, Philip B. and {Garcia-Aguilar}, Julio},
  year = {2020},
  month = jul,
  journal = {JAMA surgery},
  volume = {155},
  number = {7},
  pages = {657--658},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2020.0226},
  langid = {english},
  pmcid = {PMC7483390},
  pmid = {32347912},
  keywords = {Humans,Rectal Neoplasms,Rectal;NonOp,Watchful Waiting}
}

@article{smith767,
  title = {Organ {{Preservation}} in {{Rectal Adenocarcinoma}}: A Phase {{II}} Randomized Controlled Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Nonoperative Management},
  shorttitle = {Organ {{Preservation}} in {{Rectal Adenocarcinoma}}},
  author = {Smith, J. Joshua and Chow, Oliver S. and Gollub, Marc J. and Nash, Garrett M. and Temple, Larissa K. and Weiser, Martin R. and Guillem, Jos{\'e} G. and Paty, Philip B. and Avila, Karin and {Garcia-Aguilar}, Julio and {Rectal Cancer Consortium}},
  year = {2015},
  month = oct,
  journal = {BMC cancer},
  volume = {15},
  pages = {767},
  issn = {1471-2407},
  doi = {10.1186/s12885-015-1632-z},
  abstract = {BACKGROUND: Treatment of patients with non-metastatic, locally advanced rectal cancer (LARC) includes pre-operative chemoradiation, total mesorectal excision (TME) and post-operative adjuvant chemotherapy. This trimodality treatment provides local tumor control in most patients; but almost one-third ultimately die from distant metastasis. Most survivors experience significant impairment in quality of life (QoL), due primarily to removal of the rectum. A current challenge lies in identifying patients who could safely undergo rectal preservation without sacrificing survival benefit and QoL. METHODS/DESIGN: This multi-institutional, phase II study investigates the efficacy of total neoadjuvant therapy (TNT) and selective non-operative management (NOM) in LARC. Patients with MRI-staged Stage II or III rectal cancer amenable to TME will be randomized to receive FOLFOX/CAPEOX: a) before induction neoadjuvant chemotherapy (INCT); or b) after consolidation neoadjuvant chemotherapy (CNCT), with 5-FU or capecitabine-based chemoradiation. Patients in both arms will be re-staged after completing all neoadjuvant therapy. Those with residual tumor at the primary site will undergo TME. Patients with clinical complete response (cCR) will receive non-operative management (NOM). NOM patients will be followed every 3 months for 2 years, and every 6 months thereafter. TME patients will be followed according to NCCN guidelines. All will be followed for at least 5 years from the date of surgery or--in patients treated with NOM--the last day of treatment. DISCUSSION: The studies published thus far on the safety of NOM in LARC have compared survival between select groups of patients with a cCR after NOM, to patients with a pathologic complete response (pCR) after TME. The current study compares 3-year disease-free survival (DFS) in an entire population of patients with LARC, including those with cCR and those with pCR. We will compare the two arms of the study with respect to organ preservation at 3 years, treatment compliance, adverse events and surgical complications. We will measure QoL in both groups. We will analyze molecular indications that may lead to more individually tailored treatments in the future. This will be the first NOM trial utilizing a regression schema for response assessment in a prospective fashion. TRIAL REGISTRATION: NCT02008656.},
  langid = {english},
  pmcid = {PMC4619249},
  pmid = {26497495},
  keywords = {Adenocarcinoma,Adult,Antineoplastic Combined Chemotherapy Protocols,Capecitabine,Chemoradiotherapy,Consolidation Chemotherapy,Disease-Free Survival,Female,Fluorouracil,Humans,Induction Chemotherapy,Leucovorin,Male,Neoadjuvant Therapy,Organ Sparing Treatments,Organoplatinum Compounds,Oxaliplatin,Prospective Studies,Quality of Life,Rectal Neoplasms,Rectal;TNT},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5XQIDGNA\\Smith et al. - 2015 - Organ Preservation in Rectal Adenocarcinoma a pha.pdf}
}

@article{smithe185896,
  title = {Assessment of a {{Watch-and-Wait Strategy}} for {{Rectal Cancer}} in {{Patients With}} a {{Complete Response After Neoadjuvant Therapy}}},
  author = {Smith, J. Joshua and Strombom, Paul and Chow, Oliver S. and Roxburgh, Campbell S. and Lynn, Patricio and Eaton, Anne and Widmar, Maria and Ganesh, Karuna and Yaeger, Rona and Cercek, Andrea and Weiser, Martin R. and Nash, Garrett M. and Guillem, Jose G. and Temple, Larissa K. F. and Chalasani, Sree B. and Fuqua, James L. and Petkovska, Iva and Wu, Abraham J. and Reyngold, Marsha and Vakiani, Efsevia and Shia, Jinru and Segal, Neil H. and Smith, James D. and Crane, Christopher and Gollub, Marc J. and Gonen, Mithat and Saltz, Leonard B. and {Garcia-Aguilar}, Julio and Paty, Philip B.},
  year = {2019},
  month = apr,
  journal = {JAMA oncology},
  volume = {5},
  number = {4},
  pages = {e185896},
  issn = {2374-2445},
  doi = {10.1001/jamaoncol.2018.5896},
  abstract = {IMPORTANCE: The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection. OBJECTIVE: To analyze the outcomes of WW among patients with rectal cancer who had a clinical complete response to neoadjuvant therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series analysis conducted at a comprehensive cancer center in New York included patients who received a diagnosis of rectal adenocarcinoma between January 1, 2006, and January 31, 2015. The median follow-up was 43 months. Data analyses were conducted from June 1, 2016, to October 1, 2018. EXPOSURES: Patients had a clinical complete response after completing neoadjuvant therapy and agreed to a WW strategy of active surveillance and possible salvage surgery (n\,=\,113), or patients underwent total mesorectal excision and were found to have a pathologic complete response (pCR) at resection (n\,=\,136). MAIN OUTCOMES AND MEASURES: Kaplan-Meier estimates were used for analyses of local regrowth and 5-year rates of overall survival, disease-free survival, and disease-specific survival. RESULTS: Compared with the 136 patients in the pCR group, the 113 patients in the WW group were older (median [range], 67.2 [32.1-90.9] vs 57.3 [25.0-87.9] years, P\,{$<$}\,.001) with cancers closer to the anal verge (median [range] height from anal verge, 5.5 [0.0-15.0] vs 7.0 [0.0-13.0] cm). All 22 local regrowths in the WW group were detected on routine surveillance and treated by salvage surgery (20 total mesorectal excisions plus 2 transanal excisions). Pelvic control after salvage surgery was maintained in 20 of 22 patients (91\%). No pelvic recurrences occurred in the pCR group. Rectal preservation was achieved in 93 of 113 patients (82\%) in the WW group (91 patients with no local regrowths plus 2 patients with local regrowths salvaged with transanal excision). At 5 years, overall survival was 73\% (95\% CI, 60\%-89\%) in the WW group and 94\% (95\% CI, 90\%-99\%) in the pCR group; disease-free survival was 75\% (95\% CI, 62\%-90\%) in the WW group and 92\% (95\% CI, 87\%-98\%) in the pCR group; and disease-specific survival was 90\% (95\% CI, 81\%-99\%) in the WW group and 98\% (95\% CI, 95\%-100\%) in the pCR group. A higher rate of distant metastasis was observed among patients in the WW group who had local regrowth vs those who did not have local regrowth (36\% vs 1\%, P\,{$<$}\,.001). CONCLUSIONS AND RELEVANCE: A WW strategy for select rectal cancer patients who had a clinical complete response after neoadjuvant therapy resulted in excellent rectal preservation and pelvic tumor control; however, in the WW group, worse survival was noted along with a higher incidence of distant progression in patients with local regrowth vs those without local regrowth.},
  langid = {english},
  pmcid = {PMC6459120},
  pmid = {30629084},
  keywords = {Adult,Aged,Aged; 80 and over,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Rectal Neoplasms,Rectal;WatchWait,Remission Induction,Retrospective Studies,Treatment Outcome,Watchful Waiting},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QXWKQR3E\\Smith et al. - 2019 - Assessment of a Watch-and-Wait Strategy for Rectal.pdf}
}

@article{smithe74373,
  type = {Journal {{Article}}},
  title = {Skill Set or Mind Set? {{Associations}} between Health Literacy, Patient Activation and Health},
  author = {Smith, S. G. and Curtis, L. M. and Wardle, J. and {von Wagner}, C. and Wolf, M. S.},
  year = {2013},
  journal = {PLoS One},
  volume = {8},
  number = {9},
  pages = {e74373},
  issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
  doi = {10.1371/journal.pone.0074373}
}

@article{soetikno4490,
  title = {Endoscopic Mucosal Resection for Early Cancers of the Upper Gastrointestinal Tract},
  author = {Soetikno, Roy and Kaltenbach, Tonya and Yeh, Ronald and Gotoda, Takuji},
  year = {2005},
  month = jul,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {23},
  number = {20},
  pages = {4490--4498},
  issn = {0732-183X},
  doi = {10.1200/JCO.2005.19.935},
  abstract = {The purpose of this literature review is to examine recent advances in technique and technology of endoscopic mucosal resection of superficial early cancers of the upper gastrointestinal tract. Endoscopic mucosal resection (EMR) of superficial early cancers of the upper gastrointestinal tract is standard technique in Japan and is increasingly used in Western countries. Newer techniques of EMR allow removal of larger lesions en-bloc. These minimally invasive techniques, when applied correctly, allow safe and efficacious treatment in situations that would otherwise require major surgery. Through the establishment of long-term outcomes data, standardization of endoscopic and pathologic reporting, and newer EMR technology and techniques, the future treatment of early cancers in the upper gastrointestinal tract may be achieved primarily through the endoscope.},
  langid = {english},
  pmid = {16002839},
  keywords = {Endoscopy; Gastrointestinal,Esophageal Neoplasms,Humans,Intestinal Mucosa,Lymphatic Metastasis,Stomach Neoplasms}
}

@article{sohalpkx009,
  title = {Clinical {{Predictors}} of {{Early Mortality}} in {{Colorectal Cancer Patients Undergoing Chemotherapy}}: {{Results From}} a {{Global Prospective Cohort Study}}},
  shorttitle = {Clinical {{Predictors}} of {{Early Mortality}} in {{Colorectal Cancer Patients Undergoing Chemotherapy}}},
  author = {Sohal, Davendra P. S. and Kuderer, Nicole M. and Shepherd, Frances A. and Pabinger, Ingrid and Agnelli, Giancarlo and Liebman, Howard A. and Meyer, Guy and Kalady, Matthew F. and McCrae, Keith and Lyman, Gary H. and Khorana, Alok A.},
  year = {2017},
  month = sep,
  journal = {JNCI cancer spectrum},
  volume = {1},
  number = {1},
  pages = {pkx009},
  issn = {2515-5091},
  doi = {10.1093/jncics/pkx009},
  abstract = {BACKGROUND: Early mortality is a major problem in colorectal cancer (CRC). We have shown that Khorana Score is predictive of early mortality in other cancers. Here, we evaluated the value of this score and other prognostic variables in predicting early mortality in CRC. METHODS: CANTARISK was a prospective, noninterventional, global cohort study in patients with CRC initiating a new chemotherapy regimen. Data were collected at zero, two, four, and six months. Early mortality was defined as death within six months of enrollment. All data were compiled centrally and analyzed after the study closed. Statistically significant univariate associations were tested in multivariable models; adjusted odds ratios (ORs) are presented. Statistical tests were two-sided. RESULTS: From 2011 to 2012, 1789 CRC patients were enrolled. The median age was 62 years; 71\% were Caucasian. One-third (35\%) had a rectal primary, and 65\% had metastatic disease. There were 184 (10.3\%) patients who died during their first six months in the study. For low, intermediate, and high Khorana Score, there were 8.1\%, 11.2\% and 32.5\% deaths, respectively. In multivariable analyses, Khorana Score was an independent predictor of early death (OR for high/intermediate vs low score = 1.70, P = .0027), in addition to age (OR for each incremental year = 1.03, P = .0014), presence of metastatic disease (OR\,=\,3.28, P {$<$} .0001), and Easter Cooperative Oncology Group Performance Status Score of 2 or higher (OR\,=\,3.85, P {$<$} .0001). CONCLUSIONS: This study demonstrates that Khorana Score is predictive of early mortality in CRC patients. Intermediate- or high-risk patients, as defined by this score, may benefit from additional interventions aimed at reducing early mortality.},
  langid = {english},
  pmcid = {PMC6649852},
  pmid = {31360835},
  keywords = {CRC},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\68964A7Z\\Sohal et al_2017_Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing.pdf}
}

@article{sonoda8,
  title = {Total {{Lesion Glycolysis Ratio}} in {{Positron Emission Tomography}}/{{Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade}} and {{Prognosis}} in {{Patients}} with {{Locally Advanced Squamous Cell Carcinoma}} of the {{Esophagus}}},
  author = {Sonoda, Akari},
  pages = {8},
  abstract = {Background. The usefulness of quantitating tumor lesion glycolysis (TLG) from 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/ CT) findings as a tool for determining the effect of neoadjuvant chemotherapy (NAC) in esophageal squamous cell carcinoma (ESCC) has not yet been established.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7NHRUFY3\\Sonoda - Total Lesion Glycolysis Ratio in Positron Emission.pdf}
}

@article{soriano192,
  title = {Long-{{Term Nutritional Outcome}} and {{Health Related Quality}} of {{Life}} of {{Patients Following Esophageal Cancer Surgery}}: {{A Meta-Analysis}}},
  shorttitle = {Long-{{Term Nutritional Outcome}} and {{Health Related Quality}} of {{Life}} of {{Patients Following Esophageal Cancer Surgery}}},
  author = {Soriano, Trang Thuy and Eslick, Guy D. and Vanniasinkam, Thiru},
  year = {2018 Feb-Mar},
  journal = {Nutrition and Cancer},
  volume = {70},
  number = {2},
  pages = {192--203},
  issn = {1532-7914},
  doi = {10.1080/01635581.2018.1412471},
  abstract = {Long term health related quality of life (HRQL) and nutritional outcome of patients following esophagectomy for cancer has become increasingly significant as the 5-year survival rate in this patient group is increasing. This meta-analysis aims to investigate the HRQOL, nutritional impact symptoms and nutritional outcomes of patients following an esophagectomy at greater than 12~months after surgery. In studies reporting on HRQL as an outcome, global QOL score at 6-month compare to greater than 12-month showed no statistically significant difference (65.92~vs. 75.78, p = 0.07). Forty-one percent of patients reported a greater than 10\% weight loss at six-month follow-up (95\% CI: 20-65\%; I2 = 94.27, p {$<$} 0.001), and at the greater than 12-month follow-up, 33\% of patients had the greater than 10\% weight loss (95\% CI: 15-57\%; I2 = 96.18, p {$<$} 0.001). At the 12-month or longer post esophagectomy, just over half the patients reported dysphagia (51\%, 95\% CI: 25-76\%; I2 = 95.70, p {$<$} 0.001), nausea was reported by 11\% (95\% CI: 7-19\%; I2 = 59.31, p = 0.09), dumping syndrome reported by 60\% (95\% CI: 43-76\%; I2 = 96.92, p {$<$} 0.001). Symptoms such as dysphagia, diarrhea, reflux, dumping syndrome, and nausea were found to persist following esophagectomy. There were insufficient robust research investigating how these symptoms impact on the adequacy of dietary intake and micronutrient status.},
  langid = {english},
  pmid = {29281327},
  keywords = {Body Mass Index,Deglutition Disorders,Diet,Dumping Syndrome,Esophageal Neoplasms,Esophagectomy,GE,Humans,Mortality,Nausea,Nutritional Status,Quality of Life}
}

@article{soto-perez-de-celise305,
  title = {Functional versus Chronological Age: Geriatric Assessments to Guide Decision Making in Older Patients with Cancer},
  shorttitle = {Functional versus Chronological Age},
  author = {{Soto-Perez-de-Celis}, Enrique and Li, Daneng and Yuan, Yuan and Lau, Yat Ming and Hurria, Arti},
  year = {2018},
  month = jun,
  journal = {The Lancet. Oncology},
  volume = {19},
  number = {6},
  pages = {e305-e316},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(18)30348-6},
  abstract = {As the worldwide population ages, oncologists are often required to make difficult and complex decisions regarding the treatment of older people (aged 65 years and older) with cancer. Chronological age alone is often a poor indicator of the physiological and functional status of older adults, and thus should not be the main factor guiding treatment decisions in oncology. By contrast, a geriatric assessment can provide a much more comprehensive understanding of the functional and physiological age of an older person with cancer. The geriatric assessment is a multidimensional tool that evaluates several domains, including physical function, cognition, nutrition, comorbidities, psychological status, and social support. In this Series paper, we discuss the use of a geriatric assessment-based approach to cancer care, and provide clinicians with tools to better assess the risks and benefits of treatment to engage in shared decision making and provide better personalised care for older people with cancer.},
  langid = {english},
  pmid = {29893262},
  keywords = {Age Factors,Aged,Aged; 80 and over,Aging,Biomarkers,CGA,Clinical Decision-Making,Comorbidity,Female,Geriatric Assessment,Humans,Male,Neoplasms,Nutrition Assessment,Nutritional Status,Patient Selection,Polypharmacy,Predictive Value of Tests,Prognosis,Quality of Life,Risk Factors}
}

@article{spahn2201,
  title = {Effect of Ultra-Short-Term Treatment of Patients with Iron Deficiency or Anaemia Undergoing Cardiac Surgery: A Prospective Randomised Trial},
  shorttitle = {Effect of Ultra-Short-Term Treatment of Patients with Iron Deficiency or Anaemia Undergoing Cardiac Surgery},
  author = {Spahn, Donat R. and Schoenrath, Felix and Spahn, Gabriela H. and Seifert, Burkhardt and Stein, Philipp and Theusinger, Oliver M. and Kaserer, Alexander and Hegemann, Inga and Hofmann, Axel and Maisano, Francesco and Falk, Volkmar},
  year = {2019},
  month = jun,
  journal = {Lancet (London, England)},
  volume = {393},
  number = {10187},
  pages = {2201--2212},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(18)32555-8},
  abstract = {BACKGROUND: Anaemia and iron deficiency are frequent in patients scheduled for cardiac surgery. This study assessed whether immediate preoperative treatment could result in reduced perioperative red blood cell (RBC) transfusions and improved outcome. METHODS: In this single-centre, randomised, double-blind, parallel-group controlled study, patients undergoing elective cardiac surgery with anaemia (n=253; haemoglobin concentration (Hb) {$<$}120 g/L in women and Hb {$<$}130 g/L in men) or isolated iron deficiency (n=252; ferritin {$<$}100 mcg/L, no anaemia) were enrolled. Participants were randomly assigned (1:1) with the use of a computer-generated range minimisation (allocation probability 0{$\cdot$}8) to receive either placebo or combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40\hphantom{,}000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12, and 5 mg oral folic acid or placebo on the day before surgery. Primary outcome was the number of RBC transfusions during the first 7 days. This trial is registered with ClinicalTrials.gov, number NCT02031289. FINDINGS: Between Jan 9, 2014, and July 19, 2017, 1006 patients were enrolled; 505 with anaemia or isolated iron deficiency and 501 in the registry. The combination treatment significantly reduced RBC transfusions from a median of one unit in the placebo group (IQR 0-3) to zero units in the treatment group (0-2, during the first 7 days (odds ratio 0{$\cdot$}70 [95\% CI 0{$\cdot$}50-0{$\cdot$}98] for each threshold of number of RBC transfusions, p=0{$\cdot$}036) and until postoperative day 90 (p=0{$\cdot$}018). Despite fewer RBC units transfused, patients in the treatment group had a higher haemoglobin concentration, higher reticulocyte count, and a higher reticulocyte haemoglobin content during the first 7 days (p{$\leq$}0{$\cdot$}001). Combined allogeneic transfusions were less in the treatment group (0 [IQR 0-2]) versus the placebo group (1 [0-3]) during the first 7 days (p=0{$\cdot$}038) and until postoperative day 90 (p=0{$\cdot$}019). 73 (30\%) serious adverse events were reported in the treatment group group versus 79 (33\%) in the placebo group. INTERPRETATION: An ultra-short-term combination treatment with intravenous iron, subcutaneous erythropoietin alpha, vitamin B12, and oral folic acid reduced RBC and total allogeneic blood product transfusions in patients with preoperative anaemia or isolated iron deficiency undergoing elective cardiac surgery. FUNDING: Vifor Pharma and Swiss Foundation for Anaesthesia Research.},
  langid = {english},
  pmid = {31036337},
  keywords = {Administration; Intravenous,Administration; Oral,Aged,Aged; 80 and over,Anemia; Iron-Deficiency,Cardiac Surgical Procedures,Double-Blind Method,Drug Therapy; Combination,Erythrocyte Transfusion,Erythropoietin,Female,Ferric Compounds,Folic Acid,Heart Diseases,Humans,Iron,Male,Maltose,Middle Aged,Preoperative Care,Prospective Studies,Surgery,Time Factors,Vitamin B 12}
}

@article{speicher1195,
  ids = {speicher1195a},
  title = {Induction Therapy Does Not Improve Survival for Clinical Stage {{T2N0}} Esophageal Cancer},
  author = {Speicher, Paul J. and Ganapathi, Asvin M. and Englum, Brian R. and Hartwig, Matthew G. and Onaitis, Mark W. and D'Amico, Thomas A. and Berry, Mark F.},
  year = {2014},
  month = aug,
  journal = {Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer},
  volume = {9},
  number = {8},
  pages = {1195--1201},
  issn = {1556-1380},
  doi = {10.1097/JTO.0000000000000228},
  abstract = {INTRODUCTION: This study compared survival after initial treatment with esophagectomy as primary therapy to induction therapy followed by esophagectomy for patients with clinical T2N0 (cT2N0) esophageal cancer in the National Cancer Database (NCDB). METHODS: Predictors of therapy selection for patients with cT2N0 esophageal cancer in the NCDB from 1998 to 2011 were identified with multivariable logistic regression. Survival was evaluated using Kaplan-Meier and Cox proportional hazards methods. RESULTS: Surgery was used in 42.9\% (2057 of 4799) of cT2N0 patients. Of 1599 esophagectomy patients for whom treatment timing was recorded, induction therapy was used in 44.1\% (688). Pretreatment staging was proven accurate in only 26.7\% of patients (210 of 786) who underwent initial surgery without induction treatment and had complete pathologic data available: 41.6\% (n = 327) were upstaged and 31.7\% (n = 249) were downstaged. Adjuvant therapy (chemotherapy or radiation therapy) was given to 50.2\% of patients treated initially with surgery who were found after resection to have nodal disease. There was no significant difference in long-term survival between strategies of primary surgery and induction therapy followed by surgery (median 41.1 versus 41.9 months, p = 0.51). In multivariable analysis, induction therapy was not independently associated with risk of death (hazard ratio [HR], 1.16, p = 0.32). CONCLUSIONS: Current clinical staging for early-stage esophageal cancer is highly inaccurate, with only a quarter of surgically resected cT2N0 patients found to have had accurate pretreatment staging. Induction therapy for patients with cT2N0 esophageal cancer in the NCDB is not associated with improved survival.},
  langid = {english},
  pmcid = {PMC4145610},
  pmid = {25157773},
  keywords = {Adenocarcinoma,Aged,Carcinoma; Squamous Cell,Chemoradiotherapy; Adjuvant,Chemotherapy; Adjuvant,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Radiotherapy; Adjuvant,Retrospective Studies,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QJQEDGSE\\Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\S53GQMPN\\Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf}
}

@article{splaingard637,
  type = {Journal {{Article}}},
  title = {Aspiration in Rehabilitation Patients: Videofluoroscopy vs Bedside Clinical Assessment},
  author = {Splaingard, M. L. and Hutchins, B. and Sulton, L. D. and Chaudhuri, G.},
  year = {1988},
  journal = {Arch Phys Med Rehabil},
  volume = {69},
  number = {8},
  pages = {637--40},
  issn = {0003-9993 (Print) 0003-9993 (Linking)}
}

@article{sridhar1472,
  title = {Esophageal {{Cancer Presentation}}, {{Treatment}}, and {{Outcomes Vary With Hospital Safety-Net Burden}}},
  author = {Sridhar, Praveen and Bhatt, Maunil and Qureshi, Muhammad M. and Asokan, Sainath and Truong, Minh Tam and Suzuki, Kei and Mak, Kimberley S. and Litle, Virginia R.},
  year = {2019},
  month = may,
  journal = {The Annals of Thoracic Surgery},
  volume = {107},
  number = {5},
  pages = {1472--1479},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2018.11.065},
  abstract = {BACKGROUND: Social determinants of health affect diagnosis and delivery of care to patients with esophageal cancer. This study hypothesized that hospital safety-net burden affects presentation, treatment, and outcomes in patients with esophageal cancer. METHODS: The National Cancer Database was queried for patients with esophageal cancer (2004 to 2013). Treating facilities were categorized according to their relative burden of uninsured or Medicaid-insured patients. Hospitals with low (LBH), medium (MBH), and high (HBH) safety-net burden were compared with respect to patient demographics, disease and treatment characteristics, and survival using {$\chi$}2 analysis, Kaplan-Meier survival analysis, and multivariable modeling. RESULTS: There were 56,115 patients from 1,215 facilities. HBH treated a greater proportion of racial and ethnic minorities and patients with lower socioeconomic status. Patients at HBH presented at later stages and received primary surgical therapy less often than at MBH and LBH. Survival for patients with esophageal adenocarcinoma did not differ significantly between HBH and LBH after adjusting for age, sex, race, ethnicity, income, comorbidity, stage, histologic type, tumor location, facility type, insurance status, and treatment modality (hazard ratio, 1.06; 95\% confidence interval, 0.99 to 1.14; p~= 0.093). HBH were associated with a higher mortality risk than LBH for patients with squamous cell carcinoma (hazard ratio, 1.11; 95\% confidence interval, 1.02 to 1.20; p~= 0.014). CONCLUSIONS: There is a mortality risk for patients with squamous cell carcinoma, but not for adenocarcinoma at HBH compared with LBH. Further analysis of unadjusted variables such as performance status, completion of therapy, and continuity of care, and others should be undertaken among safety-net hospitals with the goal of creating appropriate clinical pathways for care of esophageal cancer in vulnerable populations.},
  langid = {english},
  pmid = {30605641},
  keywords = {Adenocarcinoma,Aged,Carcinoma; Squamous Cell,Combined Modality Therapy,Databases; Factual,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Race,Retrospective Studies,Safety-net Providers,Socioeconomic Factors,Survival Rate,Treatment Outcome}
}

@article{srpcic237,
  title = {Sarcopenia and {{Myosteatosis}} at {{Presentation Adversely Affect Survival After Esophagectomy}} for {{Esophageal Cancer}}},
  author = {Srpcic, Matevz and Jordan, Taja and Popuri, Karteek and Sok, Mihael},
  year = {2020},
  month = mar,
  journal = {Radiology and Oncology},
  volume = {54},
  number = {2},
  pages = {237--246},
  issn = {1318-2099},
  doi = {10.2478/raon-2020-0016},
  abstract = {Background Esophageal cancer remains a disease with poor survival and many complications. Measuring muscle mass and quality can identify patients with diminished muscle mass (sarcopenia) and muscle fat infiltration (myosteatosis). We studied the impact of sarcopenia and myosteatosis in resectable esophageal cancer on overall survival and complications. Patients and methods 139 patients received a radical esophagectomy. Skeletal muscle area (SMA) and muscle attenuation (MA) in CT images at L3 level were recorded and groups with and without sarcopenia and myosteatosis were compared for overall survival (OS), perioperative mortality, conduit complications, pleuropulmonary complications, respiratory failure requiring mechanical ventilation and other significant complications. Results Prevalence of sarcopenia and myosteatosis at presentation was 16.5\% and 51.8\%, respectively. Both were associated with decreased OS. Median survival was 18.3 months (CI 5.4\textendash 31.1) vs 31.0 months (CI 7.4\textendash 54.6) for sarcopenia/no sarcopenia (log rank p = 0.042) and 19.0 months (CI 13.3\textendash 24.7) vs 57.1 months (CI 15.2\textendash 99.0) for myosteatosis (log rank p = 0.044), respectively. A relationship between sarcopenia and myosteatosis and other negative outcomes after esophagectomy could not be established. Conclusions Sarcopenia and myosteatosis before esophagectomy are associated with decreased overall survival but not with more frequent perioperative complications. Identification of patients at risk can guide therapeutic decisions and interventions aimed at replenishing muscle reserves.},
  pmcid = {PMC7276641},
  pmid = {32229679},
  keywords = {Adult,Aged,Aged; 80 and over,Body Composition,esophageal cancer,Esophageal Neoplasms,esophagectomy,Esophagectomy,Female,GE,Humans,Kaplan-Meier Estimate,Male,Middle Aged,muscle depletion,Muscular Diseases,myosteatosis,Postoperative Complications,Prospective Studies,sarcopenia,Sarcopenia,survival},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Q34EEI95\\Srpcic et al. - Sarcopenia and myosteatosis at presentation advers.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\VMPDVSIS\\Srpcic et al. - 2020 - Sarcopenia and Myosteatosis at Presentation Advers.pdf}
}

@article{stahl183,
  title = {Preoperative Chemotherapy versus Chemoradiotherapy in~Locally Advanced Adenocarcinomas of the Oesophagogastric Junction ({{POET}}): {{Long-term}} Results of~a Controlled Randomised Trial},
  shorttitle = {Preoperative Chemotherapy versus Chemoradiotherapy in~Locally Advanced Adenocarcinomas of the Oesophagogastric Junction ({{POET}})},
  author = {Stahl, Michael and Walz, Martin K. and {Riera-Knorrenschild}, Jorge and Stuschke, Martin and Sandermann, Andreas and Bitzer, Michael and Wilke, Hansjochen and Budach, Wilfried},
  year = {2017},
  month = aug,
  journal = {European Journal of Cancer (Oxford, England: 1990)},
  volume = {81},
  pages = {183--190},
  issn = {1879-0852},
  doi = {10.1016/j.ejca.2017.04.027},
  abstract = {BACKGROUND: Results of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study. PATIENTS AND METHODS: Patients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery. RESULTS: The primary end-point of the study was overall survival at 3 years. The study was closed early after 119 patients having been randomised and were eligible. Local progression-free survival after tumour resection was significantly improved by CRT (hazard ratio [HR] 0.37; 0.16-0.85, p~=~value 0.01) and 20 versus 12 patients were free of local tumour progression at 5 years (p~=~0.03). Although the rate of postoperative in-hospital mortality was somewhat higher with CRT (10.2\% versus 3.8\%, p~=~0.26), more patients were alive at 3 and 5 years after CRT (46.7\% and 39.5\%) compared with chemotherapy (26.1\% and 24.4\%). Thus, overall survival showed a trend in favour of preoperative CRT (HR 0.65, 95\% confidence interval [CI] 0.42-1.01, p~=~0.055). CONCLUSION: Although the primary end-point overall survival of the study was not met, our long-term follow-up data suggest a benefit in local progression-free survival when radiotherapy was added to preoperative chemotherapy in patients with locally advanced adenocarcinoma of the oesophagogastric junction.},
  langid = {english},
  pmid = {28628843},
  keywords = {Adenocarcinoma,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy,Esophageal Neoplasms,Esophagogastric Junction,Female,Germany,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Oesophagogastric adenocarcinoma,Phase III trial,Preoperative chemoradiotherapy,Preoperative chemotherapy,Prospective Studies,Stomach Neoplasms,Survival Analysis}
}

@article{stahl2310,
  title = {Chemoradiation with and without Surgery in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus},
  author = {Stahl, Michael and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and Walz, Martin K. and Seeber, Siegfried and Klump, Bodo and Budach, Wilfried and Teichmann, Reinhard and Schmitt, Marcus and Schmitt, Gerd and Franke, Claus and Wilke, Hansjochen},
  year = {2005},
  month = apr,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {23},
  number = {10},
  pages = {2310--2317},
  issn = {0732-183X},
  doi = {10.1200/JCO.2005.00.034},
  abstract = {PURPOSE: Combined chemoradiotherapy with and without surgery are widely accepted alternatives for the curative treatment of patients with locally advanced esophageal cancer. The value of adding surgery to chemotherapy and radiotherapy is unknown. PATIENTS AND METHODS: Patients with locally advanced squamous cell carcinoma (SCC) of the esophagus were randomly allocated to either induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B). Primary outcome was overall survival time. RESULTS: The median observation time was 6 years. The analysis of 172 eligible, randomized patients (86 patients per arm) showed overall survival to be equivalent between the two treatment groups (log-rank test for equivalence, P {$<$} .05). Local progression-free survival was better in the surgery group (2-year progression-free survival, 64.3\%; 95\% CI, 52.1\% to 76.5\%) than in the chemoradiotherapy group (2-year progression-free survival, 40.7\%; 95\% CI, 28.9\% to 52.5\%; hazard ratio [HR] for arm B v arm A, 2.1; 95\% CI, 1.3 to 3.5; P = .003). Treatment-related mortality was significantly increased in the surgery group than in the chemoradiotherapy group (12.8\% v 3.5\%, respectively; P = .03). Cox regression analysis revealed clinical tumor response to induction chemotherapy to be the single independent prognostic factor for overall survival (HR, 0.30; 95\% CI, 0.19 to 0.47; P {$<$} .0001). CONCLUSION: Adding surgery to chemoradiotherapy improves local tumor control but does not increase survival of patients with locally advanced esophageal SCC. Tumor response to induction chemotherapy identifies a favorable prognostic group within these high-risk patients, regardless of the treatment group.},
  langid = {english},
  pmid = {15800321},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Carcinoma; Squamous Cell,ChemoRT_Surgery,Cisplatin,Combined Modality Therapy,Esophageal Neoplasms,Etoposide,Female,Fluorouracil,Humans,Leucovorin,Male,Middle Aged,Neoadjuvant Therapy,Survival Analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\A89BCRRC\\Stahl et al. - 2005 - Chemoradiation with and without surgery in patient.pdf}
}

@article{stahl851,
  title = {Phase {{III}} Comparison of Preoperative Chemotherapy Compared with Chemoradiotherapy in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction},
  author = {Stahl, Michael and Walz, Martin K. and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and {Riera-Knorrenschild}, Jorge and Langer, Peter and {Engenhart-Cabillic}, Rita and Bitzer, Michael and K{\"o}nigsrainer, Alfred and Budach, Wilfried and Wilke, Hansjochen},
  year = {2009},
  month = feb,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {27},
  number = {6},
  pages = {851--856},
  issn = {1527-7755},
  doi = {10.1200/JCO.2008.17.0506},
  abstract = {PURPOSE: Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown. PATIENTS AND METHODS: Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B). Primary outcome was overall survival time. A total of 354 patients were needed to detect a 10\% increase in 3-year survival from 25\% to 35\% by addition of radiation therapy. The study was prematurely closed due to low accrual. RESULTS: The median observation time was 46 months. A total of 126 patients were randomly assigned and 119 eligible patients were evaluated. The number of patients undergoing complete tumor resection was not different between treatment groups (69.5\% v 71.5\%). Patients in arm B had a significant higher probability of showing pathologic complete response (15.6\% v 2.0\%) or tumor-free lymph nodes (64.4\% v 37.7\%) at resection. Preoperative radiation therapy improved 3-year survival rate from 27.7\% to 47.4\% (log-rank P = .07, hazard ratio adjusted for randomization strata variables 0.67, 95\% CI, 0.41 to 1.07). Postoperative mortality was nonsignificantly increased in the chemoradiotherapy group (10.2\% v 3.8\%; P = .26). CONCLUSION: Although the study was closed early and statistical significance was not achieved, results point to a survival advantage for preoperative chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas of the esophagogastric junction.},
  langid = {english},
  pmid = {19139439},
  keywords = {Adenocarcinoma,Antineoplastic Agents,Combined Modality Therapy,Esophageal Neoplasms,Esophagogastric Junction,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Prospective Studies,Radiotherapy,Stomach Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\LY6ZPTBQ\\Stahl et al. - 2009 - Phase III comparison of preoperative chemotherapy .pdf}
}

@article{steffens510,
  type = {Journal {{Article}}},
  title = {Is Preoperative Physical Activity Level of Patients Undergoing Cancer Surgery Associated with Postoperative Outcomes? {{A}} Systematic Review and Meta-Analysis},
  author = {Steffens, D. and Beckenkamp, P. R. and Young, J. and Solomon, M. and {da Silva}, T. M. and Hancock, M. J.},
  year = {2019},
  journal = {Eur J Surg Oncol},
  volume = {45},
  number = {4},
  pages = {510--518},
  issn = {1532-2157 (Electronic) 0748-7983 (Linking)},
  doi = {10.1016/j.ejso.2018.10.063}
}

@article{stein383,
  type = {Journal {{Article}}},
  title = {Was {{This Readmission Preventable}}? {{Qualitative Study}} of {{Patient}} and {{Provider Perceptions}} of {{Readmissions}}},
  author = {Stein, J. and Ossman, P. and Viera, A. and Moore, C. and Brubaker, B. A. and French, J. and Liles, E. A.},
  year = {2016},
  journal = {South Med J},
  volume = {109},
  number = {6},
  pages = {383--9},
  issn = {1541-8243 (Electronic) 0038-4348 (Linking)},
  doi = {10.14423/SMJ.0000000000000465}
}

@article{stewart199,
  type = {Journal {{Article}}},
  title = {A Systematic Review of Resilience in the Physically Ill},
  author = {Stewart, D. E. and Yuen, T.},
  year = {2011},
  journal = {Psychosomatics},
  volume = {52},
  number = {3},
  pages = {199--209},
  issn = {1545-7206 (Electronic) 0033-3182 (Linking)},
  doi = {10.1016/j.psym.2011.01.036}
}

@article{straatman232,
  title = {Minimally {{Invasive Versus Open Esophageal Resection}}: {{Three-year Follow-up}} of the {{Previously Reported Randomized Controlled Trial}}: The {{TIME Trial}}},
  shorttitle = {Minimally {{Invasive Versus Open Esophageal Resection}}},
  author = {Straatman, Jennifer and {van der Wielen}, Nicole and Cuesta, Miguel A. and Daams, Freek and Roig Garcia, Josep and Bonavina, Luigi and Rosman, Camiel and {van Berge Henegouwen}, Mark I. and Gisbertz, Suzanne S. and {van der Peet}, Donald L.},
  year = {2017},
  month = aug,
  journal = {Annals of Surgery},
  volume = {266},
  number = {2},
  pages = {232--236},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002171},
  abstract = {OBJECTIVE: The aim of this study was to investigate 3-year survival following a randomized controlled trial comparing minimally invasive with open esophagectomy in patients with esophageal cancer. BACKGROUND: Research on minimally invasive esophagectomy (MIE) has shown faster postoperative recovery and a marked decrease in pulmonary complications. Debate is ongoing as to whether the procedure is equivalent to open resection regarding oncologic outcomes. The study is a follow-up study of the TIME-trial (traditional invasive vs minimally invasive esophagectomy, a multicenter, randomized trial). METHODS: Between June 2009 and March 2011, patients with a resectable intrathoracic esophageal carcinoma, including the gastroesophageal junction tumors (Siewert I), were randomized between open and MI esophagectomy with curative intent. Primary outcome was 3-year disease-free survival. Secondary outcomes include overall survival, lymph node yield, short-term morbidity, mortality, complications, radicality, local recurrence, and metastasis. Analysis was by intention-to-treat. This trial is registered with the Netherlands Trial Register, NTR TC 2452. Both trial protocol and short-term results have been published previously. RESULTS: One hundred fifteen patients were included from 5 European hospitals and randomly assigned to open (n = 56) or MI esophagectomy (n = 59). Combined overall 3-year survival was 40.4\% (SD 7.7\%) in the open group versus 50.5\% (SD 8\%) in the minimally invasive group (P = 0.207). The hazard ratio (HR) is 0.883 (0.540 to 1.441) for MIE compared with open surgery. Disease-free 3-year survival was 35.9\% (SD 6.8\%) in the open versus 40.2\% (SD 6.9\%) in the MI group [HR 0.691 (0.389 to 1.239). CONCLUSIONS: The study presented here depicted no differences in disease-free and overall 3-year survival for open and MI esophagectomy. These results, together with short-term results, further support the use of minimally invasive surgical techniques in the treatment of esophageal cancer.},
  langid = {english},
  pmid = {28187044},
  keywords = {Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Laparoscopy,Length of Stay,Male,Middle Aged,Neoadjuvant Therapy,Patient Reported Outcome Measures,Postoperative Complications,Quality of Life,RCT}
}

@article{sts1661,
  type = {Journal {{Article}}},
  title = {The {{Society}} of {{Thoracic Surgeons Composite Score}} for {{Evaluating Esophagectomy}} for {{Esophageal Cancer}}},
  author = {STS, Force},
  year = {2017},
  journal = {Ann Thorac Surg},
  volume = {103},
  number = {5},
  pages = {1661--1667},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2016.10.027}
}

@article{studenski50,
  title = {Gait Speed and Survival in Older Adults},
  author = {Studenski, Stephanie and Perera, Subashan and Patel, Kushang and Rosano, Caterina and Faulkner, Kimberly and Inzitari, Marco and Brach, Jennifer and Chandler, Julie and Cawthon, Peggy and Connor, Elizabeth Barrett and Nevitt, Michael and Visser, Marjolein and Kritchevsky, Stephen and Badinelli, Stefania and Harris, Tamara and Newman, Anne B. and Cauley, Jane and Ferrucci, Luigi and Guralnik, Jack},
  year = {2011},
  month = jan,
  journal = {JAMA},
  volume = {305},
  number = {1},
  pages = {50--58},
  issn = {1538-3598},
  doi = {10.1001/jama.2010.1923},
  abstract = {CONTEXT: Survival estimates help individualize goals of care for geriatric patients, but life tables fail to account for the great variability in survival. Physical performance measures, such as gait speed, might help account for variability, allowing clinicians to make more individualized estimates. OBJECTIVE: To evaluate the relationship between gait speed and survival. DESIGN, SETTING, AND PARTICIPANTS: Pooled analysis of 9 cohort studies (collected between 1986 and 2000), using individual data from 34,485 community-dwelling older adults aged 65 years or older with baseline gait speed data, followed up for 6 to 21 years. Participants were a mean (SD) age of 73.5 (5.9) years; 59.6\%, women; and 79.8\%, white; and had a mean (SD) gait speed of 0.92 (0.27) m/s. MAIN OUTCOME MEASURES: Survival rates and life expectancy. RESULTS: There were 17,528 deaths; the overall 5-year survival rate was 84.8\% (confidence interval [CI], 79.6\%-88.8\%) and 10-year survival rate was 59.7\% (95\% CI, 46.5\%-70.6\%). Gait speed was associated with survival in all studies (pooled hazard ratio per 0.1 m/s, 0.88; 95\% CI, 0.87-0.90; P {$<$} .001). Survival increased across the full range of gait speeds, with significant increments per 0.1 m/s. At age 75, predicted 10-year survival across the range of gait speeds ranged from 19\% to 87\% in men and from 35\% to 91\% in women. Predicted survival based on age, sex, and gait speed was as accurate as predicted based on age, sex, use of mobility aids, and self-reported function or as age, sex, chronic conditions, smoking history, blood pressure, body mass index, and hospitalization. CONCLUSION: In this pooled analysis of individual data from 9 selected cohorts, gait speed was associated with survival in older adults.},
  langid = {english},
  pmcid = {PMC3080184},
  pmid = {21205966},
  keywords = {Aged,Cohort Studies,Female,Gait,Geriatric Assessment,Humans,Life Expectancy,Male,Survival Analysis,United States},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\KH2EQ52J\\Studenski et al_2011_Gait speed and survival in older adults.pdf}
}

@article{su82,
  title = {{{CT-assessed}} Sarcopenia Is a Predictive Factor for Both Long-Term and Short-Term Outcomes in Gastrointestinal Oncology Patients: A Systematic Review and Meta-Analysis},
  shorttitle = {{{CT-assessed}} Sarcopenia Is a Predictive Factor for Both Long-Term and Short-Term Outcomes in Gastrointestinal Oncology Patients},
  author = {Su, Huaiying and Ruan, Junxian and Chen, Tianfeng and Lin, Enyi and Shi, Lijing},
  year = {2019},
  month = dec,
  journal = {Cancer Imaging: The Official Publication of the International Cancer Imaging Society},
  volume = {19},
  number = {1},
  pages = {82},
  issn = {1470-7330},
  doi = {10.1186/s40644-019-0270-0},
  abstract = {BACKGROUND: The impact of sarcopenia on the outcome of gastrointestinal (GI) oncological patients is still controversial. We aim to discuss the prevalence of sarcopenia and its relation to the oncological outcome. METHODS: Embase, Medline, PubMed, and the Cochrane library were systematically searched for related keywords. Studies using CT to assess sarcopenia and evaluate its relationship with the outcome of GI oncological patients were included. Long-term outcomes, including overall survival and disease-free survival, were compared by hazard ratios (HRs) with 95\% confidence intervals (CIs). Short-term outcomes, including total complications and major complications (Clavien-Dindo {$\geq$}IIIa) after curable surgery, were compared by the risk ratio (RR) and 95\% CI. RESULTS: A total of 70 studies including 21,875 patients were included in our study. The median incidence of sarcopenia was 34.7\% (range from 2.1 to 83.3\%). A total of 88.4\% of studies used skeletal muscle index (SMI) in the third lumbar level on CT to define sarcopenia, and a total of 19 cut-offs were used to define sarcopenia. An increasing trend was found in the prevalence of sarcopenia when the cut-off of SMI increased ({$\beta$}\,=\,0.22, 95\% CI\,=\,0.12-0.33, p\,{$<$}\,0.001). The preoperative incidence of sarcopenia was associated both with an increased risk of overall mortality (HR\,=\,1.602, 95\% CI\,=\,1.369-1.873, P\,{$<$}\,0.001) and with disease-free mortality (HR\,=\,1.461, 95\% CI\,=\,1.297-1.646, P\,{$<$}\,0.001). Moreover, preoperative sarcopenia was a risk factor for both total complications (RR\,=\,1.188, 95\% CI\,=\,1.083-1.303, P\,{$<$}\,0.001) and major complications (RR\,=\,1.228, 95\% CI\,=\,1.042-1.448, P\,=\,0.014). CONCLUSION: The prevalence of sarcopenia depends mostly on the diagnostic cut-off points of different criteria. Preoperative sarcopenia is a risk factor for both long-term and short-term outcomes.},
  langid = {english},
  pmcid = {PMC6892174},
  pmid = {31796090},
  keywords = {Gastrointestinal Neoplasms,Gastrointestinal oncology,Humans,Nutrient,Operation,Sarcopenia,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AAZLIMEF\\Su et al_2019_CT-assessed sarcopenia is a predictive factor for both long-term and short-term.pdf}
}

@article{subramaniam17,
  title = {New 5-{{Factor Modified Frailty Index Using American College}} of {{Surgeons NSQIP Data}}},
  author = {Subramaniam, Sneha},
  year = {2012},
  pages = {17},
  abstract = {BACKGROUND: The modified frailty index (mFI-11) is a NSQIP-based 11-factor index that has been proven to adequately reflect frailty and predict mortality and morbidity. These 11 factors, made of 16 variables, map to the original 70-item Canada Study of Health and Aging Frailty Index. In past years, certain NSQIP variables have been removed from the database; as of 2015, only 5 of the original 11 factors remained. The predictive power and usefulness of these 5 factors in an index (mFI-5) have not been proven in past literature. The goal of our study was to compare the mFI-5 to the mFI-11 in terms of value and predictive ability for mortality, postoperative infection, and unplanned 30-day readmission. STUDY DESIGN: The mFI was calculated by dividing the number of factors present for a patient by the number of available factors for which there were no missing data. Spearman's rho was used to assess correlation between the mFI-5 and mFI-11. Predictive models, using both unadjusted and adjusted logistic regressions, were created for each outcome for 9 surgical subspecialties using 2012 NSQIP data, the last year all mFI-11 variables existed. RESULTS: Correlation between the mFI-5 and mFI-11 was above 0.9 across all surgical specialties except for cardiac and vascular surgery. Adjusted and unadjusted models showed similar c-statistics for mFI-5 and mFI-11, and strong predictive ability for mortality and postoperative complications. CONCLUSIONS: The mFI-5 and the mFI-11 are equally effective predictors in all sub-specialties and the mFI5 is a strong predictor of mortality and postoperative complications. It has credibility for future use to study frailty within the NSQIP database. It also has potential in other databases and for clinical use. (J Am Coll Surg 2018;226:173e182. \'O 2017 Published by Elsevier Inc. on behalf of the American College of Surgeons.)},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IIFRQCVT\\Subramaniam - 2012 - New 5-Factor Modified Frailty Index Using American.pdf}
}

@article{sudo3400,
  title = {Importance of Surveillance and Success of Salvage Strategies after Definitive Chemoradiation in Patients with Esophageal Cancer},
  author = {Sudo, Kazuki and Xiao, Lianchun and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Taketa, Takashi and Blum, Mariela A. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Ross, William A. and Komaki, Ritsuko and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Maru, Dipen M. and Skinner, Heath D. and Ajani, Jaffer A.},
  year = {2014},
  month = oct,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {32},
  number = {30},
  pages = {3400--3405},
  issn = {1527-7755},
  doi = {10.1200/JCO.2014.56.7156},
  abstract = {PURPOSE: Patients with esophageal carcinoma (EC) who are treated with definitive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses. In a large cohort, we assessed the timing, frequency, and types of relapses during an aggressive surveillance program and the value of the salvage strategies. PATIENTS AND METHODS: Patients with EC (N = 276) who received BMT were analyzed. Patients who had surgery within 6 months of chemoradiotherapy were excluded to reduce bias. We focused on local relapse (LR) and distant metastases (DM) and the salvage treatment of patients with LR only. Standard statistical methods were applied. RESULTS: The median follow-up time was 54.3 months (95\% CI, 48.4 to 62.4). First relapses included LR only in 23.2\% (n = 64), DM with or without LR in 43.5\% (n = 120), and no relapses in 33.3\% (n = 92) of patients. Final relapses included no relapses in 33.3\%, LR only in 14.5\%, DM only in 15.9\%, and DM plus LR in 36.2\% of patients. Ninety-one percent of LRs occurred within 2 years and 98\% occurred within 3 years of BMT. Twenty-three (36\%) of 64 patients with LR only underwent salvage surgery, and their median overall survival was 58.6 months (95\% CI, 28.8 to not reached) compared with those patients with LR only who were unable to undergo surgery (9.5 months; 95\% CI, 7.8 to 13.3). CONCLUSION: Unlike in patients undergoing trimodality therapy, for whom surveillance/salvage treatment plays a lesser role,(1) in the BMT population, approximately 8\% of all patients (or 36\% of patients with LR only) with LRs occurring more than 6 months after chemoradiotherapy can undergo salvage treatment, and their survival is excellent. Our data support vigilant surveillance, at least in the first 24 months after chemotherapy, in these patients.},
  langid = {english},
  pmcid = {PMC4195852},
  pmid = {25225435},
  keywords = {Adult,Aged,Aged; 80 and over,Chemoradiotherapy,Esophageal Neoplasms,Female,Follow-Up Studies,Humans,Male,Middle Aged,Salvage Therapy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\IFSMZGKM\\Sudo et al. - 2014 - Importance of surveillance and success of salvage .pdf}
}

@article{sudo4306,
  title = {Locoregional Failure Rate after Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies},
  author = {Sudo, Kazuki and Taketa, Takashi and Correa, Arlene M. and Campagna, Maria-Claudia and Wadhwa, Roopma and Blum, Mariela A. and Komaki, Ritsuko and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Skinner, Heath D. and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
  year = {2013},
  month = dec,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {31},
  number = {34},
  pages = {4306--4310},
  issn = {1527-7755},
  doi = {10.1200/JCO.2013.51.7250},
  abstract = {PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort. PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used. RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36\%), and LRF only occurred in 27 patients (5\%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89\%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37\%) survived more than 2 years. Thus, only 2\% of all 518 patients benefited from surveillance/salvage strategies. CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.},
  langid = {english},
  pmcid = {PMC3837091},
  pmid = {24145339},
  keywords = {Adenocarcinoma,Adult,Aged,Chemoradiotherapy; Adjuvant,Disease-Free Survival,Esophageal Neoplasms,Esophagectomy,Female,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Multivariate Analysis,Neoadjuvant Therapy,Neoplasm Recurrence; Local,Proportional Hazards Models,Reoperation,Retrospective Studies,Risk Factors,Salvage Therapy,Time Factors,Treatment Failure,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7CNQWK75\\Sudo et al. - 2013 - Locoregional failure rate after preoperative chemo.pdf}
}

@article{sugawara2305,
  title = {Preoperative {{Low Vital Capacity Influences Survival After Esophagectomy}} for {{Patients}} with {{Esophageal Carcinoma}}},
  author = {Sugawara, Kotaro and Mori, Kazuhiko and Okumura, Yasuhiro and Yagi, Koichi and Aikou, Susumu and Uemura, Yukari and Yamashita, Hiroharu and Seto, Yasuyuki},
  year = {2020},
  month = jul,
  journal = {World Journal of Surgery},
  volume = {44},
  number = {7},
  pages = {2305--2313},
  issn = {1432-2323},
  doi = {10.1007/s00268-020-05450-0},
  abstract = {BACKGROUND: Assessment of preoperative physiological status is crucial for optimizing clinical outcomes in patients undergoing surgery for esophageal carcinoma (EC). We aimed to evaluate the prognostic impact of pulmonary dysfunctions and their relationships with other physiological factors, especially sarcopenia, in EC patients receiving esophagectomy. METHODS: In total, 411 EC patients who underwent esophagectomy between 2006 and 2016 were retrospectively reviewed. Preoperative pulmonary functions were evaluated based on \%vital capacity (\%VC) and forced expiratory volume (FEV) 1.0\%. The thresholds were set as the lowest quartile (99\% for \%VC and 68.6\% for FEV1.0\%) in this cohort. RESULTS: One hundred and two patients (24.8\%) had low \%VC (\%VC\,{$<$}\,99\%), which was significantly associated with age, comorbidity, sarcopenia and postoperative complications, while not correlating with pathological variables. The overall survival (OS) of patients in the low \%VC group was significantly poorer than that of those in the high \%VC group (P\,{$<$}\,0.001), especially in those with pStage 0-II diseases (P\,{$<$}\,0.001). In contrast, survival was not stratified by FEV1.0\% (P\,=\,0.80). Notably, patients with both low \%VC and sarcopenia showed very poor 5-year OS (30.3\%). Multivariate analysis revealed low \%VC to be independently associated with poor OS (P\,=\,0.03). In the cause-specific survival analyses, low \%VC was an independent predictor of deaths from non-EC-related causes (P\,=\,0.03). CONCLUSIONS: Preoperative low \%VC was independently associated with poor survival outcomes, especially when present in combination with sarcopenia, due to an increased risk of death from non-EC-related causes. Preoperative spirometry testing is useful for predicting long-term outcomes in EC patients undergoing esophagectomy.},
  langid = {english},
  pmid = {32123980},
  keywords = {Adult,Aged,Aged; 80 and over,Carcinoma,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Forced Expiratory Volume,Health Status Indicators,Humans,Male,Middle Aged,PFT,Postoperative Complications,Preoperative Period,Prognosis,Retrospective Studies,Risk Factors,Sarcopenia,Survival Analysis,Vital Capacity},
  file = {C\:\\Users\\jcsal\\Downloads\\s00268-020-05450-0.pdf}
}

@article{sugiyama5859,
  title = {Baseline {{Sarcopenia}} and {{Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes}} in {{Metastatic Gastric Cancer}}},
  author = {Sugiyama, Keiji and Narita, Yukiya and Mitani, Seiichiro and Honda, Kazunori and Masuishi, Toshiki and Taniguchi, Hiroya and Kadowaki, Shigenori and Ura, Takashi and Ando, Masashi and Tajika, Masahiro and Muro, Kei},
  year = {2018},
  month = oct,
  journal = {Anticancer Research},
  volume = {38},
  number = {10},
  pages = {5859--5866},
  publisher = {{International Institute of Anticancer Research}},
  issn = {0250-7005, 1791-7530},
  doi = {10.21873/anticanres.12928},
  abstract = {{$<$}p{$>$}Aim: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. Patients and Methods: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a {$\geq$}10\% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). Results: Of 118 patients, 89\% had baseline sarcopenia and 31\% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. Conclusion: Muscle loss during chemotherapy negatively affected survival among patients with mGC.{$<$}/p{$>$}},
  chapter = {Clinical Studies},
  copyright = {Copyright\textcopyright{} 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved},
  langid = {english},
  pmid = {30275211},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Body Mass Index,Case-Control Studies,chemo,Chemotherapy,Female,Follow-Up Studies,gastric,gastric cancer,Humans,Liver Neoplasms,Male,Middle Aged,Muscle; Skeletal,Peritoneal Neoplasms,Prognosis,prognostic factor,Retrospective Studies,sarcopenia,Sarcopenia,skeletal muscle loss,Stage4,Stomach Neoplasms,Survival Rate},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DFP429QJ\\Sugiyama et al. - 2018 - Baseline Sarcopenia and Skeletal Muscle Loss Durin.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\3KU4EEAZ\\5859.html}
}

@article{sullivan1702,
  title = {Association of {{Early Palliative Care Use With Survival}} and {{Place}} of {{Death Among Patients With Advanced Lung Cancer Receiving Care}} in the {{Veterans Health Administration}}},
  author = {Sullivan, Donald R. and Chan, Benjamin and Lapidus, Jodi A. and Ganzini, Linda and Hansen, Lissi and Carney, Patricia A. and Fromme, Erik K. and Marino, Miguel and Golden, Sara E. and Vranas, Kelly C. and Slatore, Christopher G.},
  year = {2019},
  month = dec,
  journal = {JAMA oncology},
  volume = {5},
  number = {12},
  pages = {1702--1709},
  issn = {2374-2445},
  doi = {10.1001/jamaoncol.2019.3105},
  abstract = {IMPORTANCE: Palliative care is a patient-centered approach associated with improvements in quality of life; however, results regarding its association with a survival benefit have been mixed, which may be a factor in its underuse. OBJECTIVE: To assess whether early palliative care is associated with a survival benefit among patients with advanced lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective population-based cohort study was conducted among patients with lung cancer who were diagnosed with cancer between January 1, 2007, and December 31, 2013, with follow-up until January 23, 2017. Participants comprised 23\,154 patients with advanced lung cancer (stage IIIB and stage IV) who received care in the Veterans Affairs health care system. Data were analyzed from February 15, 2019, to April 28, 2019. EXPOSURE: Palliative care defined as a specialist-delivered palliative care encounter received after lung cancer diagnosis. MAIN OUTCOMES AND MEASURES: The primary outcome was survival. The association between palliative care and place of death was also examined. Propensity score and time-varying covariate methods were used to calculate Cox proportional hazards and to perform regression modeling. RESULTS: Of the 23\,154 patients enrolled in the study, 57\% received palliative care. The mean (SD) age of participants was 68 (9.5) years, and 98\% of participants were men. An examination of the timing of palliative care receipt relative to cancer diagnosis found that palliative care received 0 to 30 days after diagnosis was associated with decreases in survival (adjusted hazard ratio [aHR],\,2.13; 95\% CI, 1.97-2.30), palliative care received 31 to 365 days after diagnosis was associated with increases in survival (aHR, 0.47; 95\% CI, 0.45-0.49), and palliative care received more than 365 days after diagnosis was associated with no difference in survival (aHR, 1.00; 95\% CI, 0.94-1.07) compared with nonreceipt of palliative care. Receipt of palliative care was also associated with a reduced risk of death in an acute care setting (adjusted odds ratio, 0.57; 95\% CI, 0.52-0.64) compared with nonreceipt of palliative care. CONCLUSIONS AND RELEVANCE: The results suggest that palliative care was associated with a survival benefit among patients with advanced lung cancer. Palliative care should be considered a complementary approach to disease-modifying therapy in patients with advanced lung cancer.},
  langid = {english},
  pmcid = {PMC6753505},
  pmid = {31536133},
  keywords = {Aged,Complementary Therapies,Female,Humans,Lung Neoplasms,Male,Middle Aged,Neoplasm Staging,Palliative Care,Propensity Score,Retrospective Studies,Survival Analysis,Time-to-Treatment,Veterans Health,Veterans Health Services},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7Q4ZWX6X\\Sullivan et al_2019_Association of Early Palliative Care Use With Survival and Place of Death Among.pdf}
}

@article{sultana2607,
  title = {Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer},
  author = {Sultana, Asma and Smith, Catrin Tudur and Cunningham, David and Starling, Naureen and Neoptolemos, John P. and Ghaneh, Paula},
  year = {2007},
  month = jun,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {25},
  number = {18},
  pages = {2607--2615},
  issn = {1527-7755},
  doi = {10.1200/JCO.2006.09.2551},
  abstract = {PURPOSE: There are a large number of randomized controlled trials involving chemotherapy in the management of advanced pancreatic cancer. Several chemotherapeutic agents, either alone or in combination with other chemotherapy or novel agents, have been used. The aim of these meta-analyses was to examine the different therapeutic approaches, and the comparisons examined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy. METHODS: Relevant trials were identified by searching databases, trial registers, and conference proceedings. The primary end point was overall survival. RESULTS: One hundred thirteen randomized controlled trials were identified, of which 51 trials involving 9,970 patients met the inclusion criteria. Chemotherapy improved survival compared with best supportive care (hazard ratio [HR] = 0.64; 95\% CI, 0.42 to 0.98). FU-based combination chemotherapy did not result in better overall survival compared with FU alone (HR = 0.94; 95\% CI, 0.82 to 1.08). There was insufficient evidence of a survival difference between gemcitabine and FU, but the wide CI includes clinically important differences in both directions, making a clear conclusion difficult (HR = 0.75; 95\% CI, 0.42 to 1.31). Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone (HR = 0.91; 95\% CI, 0.85 to 0.97). CONCLUSION: There was a significant survival benefit for chemotherapy over best supportive care and gemcitabine combinations over gemcitabine alone. This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pancreatic cancer.},
  langid = {english},
  pmid = {17577041},
  keywords = {Antineoplastic Agents,Antineoplastic Combined Chemotherapy Protocols,Deoxycytidine,Fluorouracil,Gemcitabine,Humans,Neoplasm Metastasis,Outcome Assessment; Health Care,Pancreatic Neoplasms,Randomized Controlled Trials as Topic}
}

@article{sun852,
  type = {Journal {{Article}}},
  title = {Wireless {{Monitoring Program}} of {{Patient-Centered Outcomes}} and {{Recovery Before}} and {{After Major Abdominal Cancer Surgery}}},
  author = {Sun, V. and Dumitra, S. and Ruel, N. and Lee, B. and Melstrom, L. and Melstrom, K. and Woo, Y. and Sentovich, S. and Singh, G. and Fong, Y.},
  year = {2017},
  journal = {JAMA Surg},
  volume = {152},
  number = {9},
  pages = {852--859},
  issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
  doi = {10.1001/jamasurg.2017.1519}
}

@article{sun924,
  title = {Sarcopenia among Older Patients with Cancer: {{A}} Scoping Review of the Literature},
  shorttitle = {Sarcopenia among Older Patients with Cancer},
  author = {Sun, Qian and Jiang, Xiaohan and Qin, Rui and Yang, Yuanyuan and Gong, Yabo and Wang, Kunyuan and Peng, Junsheng},
  year = {2022},
  month = sep,
  journal = {Journal of Geriatric Oncology},
  volume = {13},
  number = {7},
  pages = {924--934},
  issn = {1879-4076},
  doi = {10.1016/j.jgo.2022.03.008},
  abstract = {INTRODUCTION: In the older patients with cancer, the combination of aging and cancer makes sarcopenia more likely to occur. However, previous studies paid less attention to the sarcopenia of older patients with cancer. To address these gaps, we conducted a scoped review of the prevalence, measurement, prognostic value, and clinical interventions of sarcopenia in this population. MATERIALS AND METHODS: A comprehensive search of PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and Wangfang electronic databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews. Two independent reviewers screened all abstracts and full-text studies for inclusion. RESULTS: We identified 10,850 studies, and 39 met the inclusion criteria. Two reviewers extracted data on study characteristics, study design, measuring tools and main outcomes. This review included works from 11 countries. All studies were quantitative and most used a cross-sectional (n~=~17) or retrospective (n~=~16) design. The prevalence of sarcopenia in elderly cancer survivors ranged from 18.5\% to 83\%, and skeletal muscle mass index (SMI) by computed tomography (CT) scan at lumbar 3 (L3) was the most commonly used way to define sarcopenia. Meanwhile, pre-therapeutic sarcopenia was significantly related to postoperative complications, lower overall survival and impaired physical function. DISCUSSION: This review emphasizes sarcopenia is highly prevalent in older patients with cancer, which leads to poor outcomes and urgently needs attention from nutritionists, surgeons, oncologists, psychologists and nurses.},
  langid = {english},
  pmid = {35644850},
  keywords = {Aged,Aging,Cancer,Cross-Sectional Studies,Humans,Muscle; Skeletal,Neoplasms,Older adults,Retrospective Studies,Sarcopenia}
}

@article{suzuki2854,
  title = {Results of the Baseline Positron Emission Tomography Can Customize Therapy of Localized Esophageal Adenocarcinoma Patients Who Achieve a Clinical Complete Response after Chemoradiation},
  author = {Suzuki, A. and Xiao, L. and Taketa, T. and Sudo, K. and Wadhwa, R. and Blum, M. A. and Skinner, H. and Komaki, R. and Weston, B. and Lee, J. H. and Bhutani, M. S. and Rice, D. C. and Maru, D. M. and Erasmus, J. and Swisher, S. G. and Hofstetter, W. L. and Ajani, J. A.},
  year = {2013},
  month = nov,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {24},
  number = {11},
  pages = {2854--2859},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdt340},
  abstract = {BACKGROUND: Patients with localized esophageal adenocarcinoma (EAC) who achieve a clinical complete response (clinCR) after preoperative chemoradiation (trimodality therapy; TMT) or definitive chemoradiation (bimodality therapy; BMT) live longer than those who achieve a},
  langid = {english},
  pmid = {23994746},
  keywords = {Adenocarcinoma,Aged,chemoradiation,Chemoradiotherapy,ChemoRT,clinical biology,Combined Modality Therapy,Disease-Free Survival,esophageal cancer,Esophageal Neoplasms,Female,Humans,imaging,Male,Middle Aged,organ preservation,PET,Positron-Emission Tomography,Prognosis,Prospective Studies,Radiography,Remission Induction,subpopulations,Treatment Outcome}
}

@article{suzuki347,
  title = {Localized Gastric Cancer Treated with Chemoradation without Surgery: {{UTMD Anderson Cancer Center}} Experience},
  shorttitle = {Localized Gastric Cancer Treated with Chemoradation without Surgery},
  author = {Suzuki, Akihiro and Xiao, Lianchun and Taketa, Takashi and Blum, Mariela A. and Matamoros, Aurelio and Chien, Pamela L. and Mansfield, Paul F. and Fournier, Keith F. and Weston, Brian and Lee, Jeffrey H. and Bhutani, Manoop S. and Estrella, Jeannelyn S. and Delclos, Marc E. and Krishnan, Sunil and Das, Prajnan and Ajani, Jaffer A.},
  year = {2012},
  journal = {Oncology},
  volume = {82},
  number = {6},
  pages = {347--351},
  issn = {1423-0232},
  doi = {10.1159/000338318},
  abstract = {BACKGROUND: In patients with localized gastric cancer (LGC) who are unfit for surgery, decline surgery, or have unresectable cancer, chemoradiotherapy may provide palliation; however, data in the literature are sparse. METHODS: We identified 66 LGC patients who had definitive chemoradiation but no surgery. All patients had baseline and postchemoradiation staging including an endoscopic biopsy. Multiple statistical methods were used to analyze outcomes. RESULTS: Most patients were men and most had stage III or IV cancer. Five patients were surgery eligible but declined to have surgery. The median follow-up time was 33.9 months (95\% CI 18.3-49.6). The median survival time (MST) for 66 patients was only 14.5 months (95\% CI 10.8-19.7) and the median relapse-free survival (RFS) was 5.03 months (95\% CI 4.67-6.40). The estimated overall survival (OS) and RFS rates at 3 years were 22.6\% (95\% CI 13.7-37.3) and 7.7\% (95\% CI 3.2-18.6), respectively. Twenty-three (35\%) patients who achieved a clinical complete response (cCR; negative postchemoradiation biopsy and no progression by imaging) fared better than those who achieved less than cCR (},
  langid = {english},
  pmid = {22677933},
  keywords = {Chemoradiotherapy,dCRT,Disease Progression,Disease-Free Survival,Female,Follow-Up Studies,Humans,Male,Middle Aged,Neoplasm Staging,Prognosis,Retrospective Studies,Stomach Neoplasms,Survival Rate,Treatment Outcome}
}

@article{swedishrectalcancertrial980,
  title = {Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer},
  author = {{Swedish Rectal Cancer Trial} and Cedermark, B. and Dahlberg, M. and Glimelius, B. and P{\aa}hlman, L. and Rutqvist, L. E. and Wilking, N.},
  year = {1997},
  month = apr,
  journal = {The New England Journal of Medicine},
  volume = {336},
  number = {14},
  pages = {980--987},
  issn = {0028-4793},
  doi = {10.1056/NEJM199704033361402},
  abstract = {BACKGROUND: Adjuvant radiotherapy for rectal cancer has been extensively studied, but no trial has unequivocally demonstrated improved overall survival with radiotherapy, despite a reduction in the rate of local recurrence. METHODS: Between March 1987 and February 1990, we randomly assigned 1168 patients younger than 80 years of age who had resectable rectal cancer to undergo preoperative irradiation (25 Gy delivered in five fractions in one week) followed by surgery within one week or to have surgery alone. RESULTS: The irradiation did not increase postoperative mortality. After five years of follow-up, the rate of local recurrence was 11 percent (63 of 553 patients) in the group that received radiotherapy before surgery and 27 percent (150 of 557) in the group treated with surgery alone (P{$<$}0.001). This difference was found in all subgroups defined according to Dukes' stage. The overall five-year survival rate was 58 percent in the radiotherapy-plus-surgery group and 48 percent in the surgery-alone group (P=0.004). The cancer-specific survival rates at nine years among patients treated with curative resection were 74 percent and 65 percent, respectively (P=0.002). CONCLUSIONS: A short-term regimen of high-dose preoperative radiotherapy reduces rates of local recurrence and improves survival among patients with resectable rectal cancer.},
  langid = {english},
  pmid = {9091798},
  keywords = {Follow-Up Studies,Humans,Neoplasm Recurrence; Local,Neoplasm Staging,Preoperative Care,Radiation Dosage,Radiotherapy; Adjuvant,Rectal Neoplasms,Rectal;RT,Survival Rate}
}

@article{swisher1152,
  title = {Utility of {{PET}}, {{CT}}, and {{EUS}} to Identify Pathologic Responders in Esophageal Cancer},
  author = {Swisher, Stephen G. and Maish, Mary and Erasmus, Jeremy J. and Correa, Arlene M. and Ajani, Jaffer A. and Bresalier, Robert and Komaki, Ritsuko and Macapinlac, Homer and Munden, Reginald F. and Putnam, Joe B. and Rice, David and Smythe, W. Roy and Vaporciyan, Ara A. and Walsh, Garrett L. and Wu, Tsung T. and Roth, Jack A.},
  year = {2004},
  month = oct,
  journal = {The Annals of Thoracic Surgery},
  volume = {78},
  number = {4},
  pages = {1152-1160; discussion 1152-1160},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2004.04.046},
  abstract = {BACKGROUND: This study evaluates the utility of positron emission tomography (PET), endoscopic ultrasonography (EUS), and computed tomographic (CT) scans to predict pathologic response and survival following preoperative chemoradiation (CRT) in esophageal cancer. METHODS: One hundred three sequential patients with locoregionally advanced esophageal cancer, who were treated with CRT and esophageal resection between May 2001 and November 2003 at the University of Texas M.D. Anderson Cancer Center, were retrospectively reviewed. PET, EUS, and CT were performed before (pre) or after (post) CRT and before surgical resection. PET standardized uptake value (SUV) was defined as maximal uptake in primary tumor. RESULTS: Most patients were male (91 [88\%]) with adenocarcinoma (90 [87\%]). Pretreatment clinical stages were: IIA (42 [41\%]), IIB (5 [5\%]), III (50 [49\%]), and IVA (6 [6\%]). At the time of surgery, 58 patients (56\%) had a pathologic response to CRT ({$<$} or =10\% viable cells). Post-CRT measurements that correlated with pathologic response were: CT esophageal wall thickness (13.3 vs 15.3 mm, p = 0.04), EUS mass size (0.7 vs 1.7 cm, p = 0.01) and PET SUV (3.1 vs 5.8, p = 0.01). Post-CRT PET SUV equal to or greater than 4 had the highest accuracy for pathologic response (76\%). Univariate and multivariate Cox regression analysis demonstrated that a post-CRT PET SUV equal to or greater than 4 was an independent predictor of survival (HR, 3.5, p = 0.04). CONCLUSIONS: The FDG-PET SUV is the most accurate noninvasive test to predict long-term survival after preoperative CRT and before surgical resection. Post-CRT FDG-PET cannot, however, rule out residual microscopic disease so esophagectomy should remain a therapeutic option even if the post-CRT imaging modalities are normal.},
  langid = {english},
  pmid = {15464463},
  keywords = {Adenocarcinoma,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Camptothecin,Carboplatin,Carcinoma; Squamous Cell,Chemotherapy; Adjuvant,Cisplatin,Combined Modality Therapy,Docetaxel,Endosonography,Esophageal Neoplasms,Esophagectomy,Female,Fluorodeoxyglucose F18,Fluorouracil,Humans,Irinotecan,Life Tables,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Paclitaxel,Positron-Emission Tomography,Preoperative Care,Prognosis,Proportional Hazards Models,Radiopharmaceuticals,Radiotherapy; Adjuvant,Retrospective Studies,Sensitivity and Specificity,Survival Analysis,Taxoids,Tomography; X-Ray Computed,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\UKFRNVPG\\Swisher et al. - 2004 - Utility of PET, CT, and EUS to identify pathologic.pdf}
}

@article{swisher175,
  title = {Salvage Esophagectomy for Recurrent Tumors after Definitive Chemotherapy and Radiotherapy},
  author = {Swisher, Stephen G. and Wynn, Paula and Putnam, Joe B. and Mosheim, Melinda B. and Correa, Arlene M. and Komaki, Ritsuko R. and Ajani, Jaffer A. and Smythe, W. Roy and Vaporciyan, Ara A. and Roth, Jack A. and Walsh, Garrett L.},
  year = {2002},
  month = jan,
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  volume = {123},
  number = {1},
  pages = {175--183},
  issn = {0022-5223},
  doi = {10.1067/mtc.2002.119070},
  abstract = {OBJECTIVES: Some patients and oncologists choose to treat localized esophageal cancer with definitive chemotherapy and radiation therapy rather than surgery. A subset of these patients have local relapse without distant metastases and therefore have no other curative intent treatment option but salvage esophagectomy. METHODS: We reviewed our experience with salvage esophagectomy from 1987 to 2000 at M.D. Anderson Cancer Center (n = 13, salvage after chemotherapy and radiotherapy group) and compared the data with those of patients receiving esophagectomy in a planned fashion 4 to 6 weeks after preoperative chemotherapy and radiation therapy (n = 99, preoperative chemotherapy and radiotherapy group). RESULTS: Increases in morbidity were seen after resection in the salvage after chemotherapy and radiotherapy group relative to the preoperative chemotherapy and radiotherapy group: mechanical ventilation (9.0 days vs 3.3 days, P =.08), intensive care unit stay (11.2 days vs 5.1 days, P =.07), hospital stay (29.4 days vs 18.4 days, P =.03), and anastomotic leak rates (5/13 [39\%] vs 7/99 [7\%], P =.005). Operative mortality (within 30 days) also tended to be increased statistically nonsignificantly (2/13 [15\%] vs 6/99 [6\%], P =.2). Salvage esophagectomy resulted in long-term survival (25\% 5-year survival) in a subset of patients. Improved survival after salvage esophagectomy was associated with early pathologic stage (T1 N0, T2 N0), prolonged time to relapse, and R0 surgical resection. CONCLUSION: Patients who undergo salvage esophagectomy for relapse of tumor after definitive chemoradiation therapy have increased morbidity, mortality, and hospital use relative to patients undergoing planned esophagectomy after preoperative chemoradiation. Nevertheless, long-term survival can be achieved in this group, and such treatment should be considered for carefully selected patients at an experienced center.},
  langid = {english},
  pmid = {11782772},
  keywords = {Adult,Aged,Aged; 80 and over,Combined Modality Therapy,Esophageal Neoplasms,Esophagectomy,Female,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Salvage Therapy,Survival Rate}
}

@article{swords333,
  title = {Size and {{Importance}} of {{Socioeconomic Status-Based Disparities}} in {{Use}} of {{Surgery}} in {{Nonadvanced Stage Gastrointestinal Cancers}}},
  author = {Swords, Douglas S. and Mulvihill, Sean J. and Brooke, Benjamin S. and Firpo, Matthew A. and Scaife, Courtney L.},
  year = {2020},
  month = feb,
  journal = {Annals of Surgical Oncology},
  volume = {27},
  number = {2},
  pages = {333--341},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07922-7},
  abstract = {BACKGROUND: The size and importance of socioeconomic status (SES)-based disparities in use of surgery for non-advanced stage gastrointestinal (GI) cancers have not been quantified. METHODS: The exposure in this study of patients age 18-80 with one of nine non-advanced stage GI cancers in the 2007-2015 SEER database was a census tract-level SES composite. Multivariable models assessed associations of SES with use of surgery. Causal mediation analysis was used to estimate the proportion of survival disparities in SES quintiles 1 versus 5 that were mediated by disparities in use of surgery. RESULTS: Lowest SES quintile patients underwent surgery at significantly lower rates than highest quintile patients in each cancer. SES-based disparities in use of surgery were large and graded in esophagus adenocarcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma. Smaller but clinically relevant disparities were present in stomach, ampulla, and small bowel adenocarcinoma, whereas disparities were small in colorectal adenocarcinoma. Five-year all-stage overall survival (OS) was correlated with the size of disparities in use of surgery in SES quintiles 1 versus 5 (r\,=\,-\,0.87; p\,=\,0.003). Mean OS was significantly longer (range 3.5-8.9~months) in SES quintile 5 versus 1. Approximately one third of SES-based survival disparities in poor prognosis GI cancers were mediated by disparities in use of surgery. The size of disparities in use of surgery in SES quintiles 1 versus 5 was correlated with the proportion mediated (r\,=\,0.98; p\,{$<$}\,0.001). CONCLUSIONS: Low SES patients with poor prognosis GI cancers are at substantial risk of undertreatment. Disparities in use of surgery contribute to diminished survival.},
  langid = {english},
  pmid = {31605347},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Female,Follow-Up Studies,Gastrointestinal Neoplasms,Healthcare Disparities,Humans,Male,Middle Aged,Prognosis,Race,Retrospective Studies,SEER Program,Social Class,Socioeconomic Factors,Survival Rate,Young Adult}
}

@article{taioli377,
  type = {Journal {{Article}}},
  title = {Quality of {{Life}} after {{Open}} or {{Minimally Invasive Esophagectomy}} in {{Patients With Esophageal Cancer-A Systematic Review}}},
  author = {Taioli, E. and Schwartz, R. M. and {Lieberman-Cribbin}, W. and Moskowitz, G. and {van Gerwen}, M. and Flores, R.},
  year = {2017},
  journal = {Semin Thorac Cardiovasc Surg},
  volume = {29},
  number = {3},
  pages = {377--390},
  issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
  doi = {10.1053/j.semtcvs.2017.08.013}
}

@article{takahari358,
  title = {Determination of {{Prognostic Factors}} in {{Japanese Patients With Advanced Gastric Cancer Using}} the {{Data From}} a {{Randomized Controlled Trial}}, {{Japan Clinical Oncology Group}} 9912},
  author = {Takahari, Daisuke and Boku, Narikazu and Mizusawa, Junki and Takashima, Atsuo and Yamada, Yasuhide and Yoshino, Takayuki and Yamazaki, Kentaro and Koizumi, Wasaburo and Fukase, Kazutoshi and Yamaguchi, Kensei and Goto, Masahiro and Nishina, Tomohiro and Tamura, Takao and Tsuji, Akihito and Ohtsu, Atsushi},
  year = {2014},
  month = apr,
  journal = {The Oncologist},
  volume = {19},
  number = {4},
  pages = {358--366},
  issn = {1083-7159},
  doi = {10.1634/theoncologist.2013-0306},
  abstract = {In this study, the authors explored baseline prognostic factors in Japanese advanced gastric cancer (AGC) patients. They propose a new prognostic index for patients with AGC. This can be used for more appropriate patient stratification in future clinical trials.},
  pmcid = {PMC3983816},
  pmid = {24668328},
  keywords = {Stage4},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GF4USAIG\\Takahari et al. - 2014 - Determination of Prognostic Factors in Japanese Pa.pdf}
}

@article{takahashi3727,
  title = {Prognostic {{Significance}} of {{Skeletal Muscle Loss During Early Postoperative Period}} in {{Elderly Patients}} with {{Esophageal Cancer}}},
  author = {Takahashi, Keita and Watanabe, Masayuki and Kozuki, Ryotaro and Toihata, Tasuku and Okamura, Akihiko and Imamura, Yu and Mine, Shinji and Ishizuka, Naoki},
  year = {2019},
  month = oct,
  journal = {Annals of Surgical Oncology},
  volume = {26},
  number = {11},
  pages = {3727--3735},
  issn = {1534-4681},
  doi = {10.1245/s10434-019-07616-0},
  abstract = {Skeletal muscle loss during the early postoperative period frequently occurs during post-esophagectomy. Preoperative sarcopenia is a known prognostic factor. However, the prognostic significance of postoperative skeletal muscle loss remains unclear. This study was designed to clarify the impact of skeletal muscle loss during the early postoperative period on the prognosis of elderly patients undergoing esophagectomy.},
  langid = {english},
  keywords = {Esophagectomy}
}

@article{takesueS802,
  title = {A {{Prospective Randomized Trial}} of {{Enteral Nutrition After Thoracoscopic Esophagectomy}} for {{Esophageal Cancer}}},
  author = {Takesue, Tomoko and Takeuchi, Hiroya and Ogura, Masaharu and Fukuda, Kazumasa and Nakamura, Rieko and Takahashi, Tsunehiro and Wada, Norihito and Kawakubo, Hirofumi and Kitagawa, Yuko},
  year = {2015},
  month = dec,
  journal = {Annals of Surgical Oncology},
  volume = {22 Suppl 3},
  pages = {S802-809},
  issn = {1534-4681},
  doi = {10.1245/s10434-015-4767-x},
  abstract = {BACKGROUND: Several studies have reported that postoperative enteral nutrition (EN) reduced complications and decreased weight loss and hospital stay periods; however, the majority of patients analyzed in these studies underwent open thoracic surgery. No studies have been conducted regarding EN in patients after thoracoscopic esophagectomy as a less invasive surgery. The aim of this study was to investigate the efficacy of EN after thoracoscopic esophagectomy. METHODS: Fifty patients who underwent thoracoscopic esophagectomy for esophageal cancer were divided into two groups: parenteral nutrition (PN; n = 25) and EN (n = 25). The rate of weight loss at postoperative day (POD) 14, levels of prealbumin at POD 10, postoperative complications until POD 14, and other perioperative data were collected for each group. RESULTS: This study analyzed data for 47 patients. The rate of weight loss at POD 14 was significantly lower in the EN group (3.0 {$\pm$} 3.2 \%) than in the PN group (5.1 {$\pm$} 3.7 \%; p = 0.020). Prealbumin levels were 21.0 {$\pm$} 7.5 mg/dL in the PN group and 18.4 {$\pm$} 5.8 mg/dL in the EN group at POD 10, with no significant differences between the groups. However, the incidence of postoperative pneumonia was higher in the PN group (30.4 \%) than in the EN group (12.5 \%). CONCLUSIONS: EN could suppress weight loss and reduce the incidence of pneumonia after thoracoscopic esophagectomy.},
  langid = {english},
  pmid = {26219242},
  keywords = {Aged,Enteral Nutrition,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Length of Stay,Male,Middle Aged,Neoplasm Invasiveness,Neoplasm Metastasis,Neoplasm Staging,Neutropenia,Postoperative Complications,Prognosis,Prospective Studies,Thoracic Surgical Procedures}
}

@article{taketa1139,
  title = {Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients with Esophageal Adenocarcinoma},
  author = {Taketa, Takashi and Sudo, Kazuki and Correa, Arlene M. and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Campagna, Maria-Claudia and Blum, Mariela A. and Skinner, Heath D. and Komaki, Ritsuko U. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian R. and Rice, David C. and Swisher, Stephen G. and Maru, Dipen M. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
  year = {2014},
  month = aug,
  journal = {Journal of the National Comprehensive Cancer Network: JNCCN},
  volume = {12},
  number = {8},
  pages = {1139--1144},
  issn = {1540-1413},
  doi = {10.6004/jnccn.2014.0111},
  abstract = {Current algorithms for surveillance of patients with esophageal adenocarcinoma (EAC) after chemoradiation and surgery (trimodality therapy [TMT]) remain empiric. The authors hypothesized that the frequency, type, and timing of relapses after TMT would be highly associated with surgical pathology stage (SPS), and therefore SPS could be used to individualize the surveillance strategy. Between 2000 and 2010, 518 patients with EAC were identified who underwent TMT at The University of Texas MD Anderson Cancer Center and were frequently surveyed. Frequency, type, and timing of the first relapse (locoregional and/or distant) were tabulated according to SPS. Standard statistical approaches were used. The median follow-up time after esophageal surgery was 55.4 months (range, 1.0-149.2 months). Disease relapse occurred in 215 patients (41.5\%). Higher SPS was associated with a higher rate of relapse (0/I vs II/III, P{$\leq$}.001; 0/I vs II, P=.002; SPS 0/I vs III, P{$\leq$}.001; and SPS II vs III, P=.005) and with shorter time to relapse (P{$<$}.001). Irrespective of the SPS, approximately 95\% of all relapses occurred within 36 months of surgery. The 3- and 5-year overall survival rates were shorter for patients with a higher SPS than those with a lower SPS (0/I vs II/III, P{$\leq$}.001; 0/I vs II, P{$\leq$}.001; 0/I vs III, P{$\leq$}.001; and II vs III, P=.014). The compelling data show an excellent association between SPS and frequency/type/timing of relapses after TMT in patients with EAC. Thus, the surveillance strategy can potentially be customized based on SPS. These data can inform a future evidence-based surveillance strategy that can be efficient and cost-effective.},
  langid = {english},
  pmid = {25099446},
  keywords = {Adenocarcinoma,Adult,Aged,Combined Modality Therapy,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,Retrospective Studies},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GQA733Q2\\Taketa et al. - 2014 - Post-chemoradiation surgical pathology stage can c.pdf}
}

@article{taketa300,
  type = {Journal {{Article}}},
  ids = {taketa6},
  title = {Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation},
  author = {Taketa, Takashi and Correa, Arlene M. and Suzuki, Akihiro and Blum, Mariela A. and Chien, Pamela and Lee, Jeffrey H. and Welsh, James and Lin, Steven H. and Maru, Dipen M. and Erasmus, Jeremy J. and Bhutani, Manoop S. and Weston, Brian and Rice, David C. and Vaporciyan, Ara A. and Hofstetter, Wayne L. and Swisher, Stephen G. and Ajani, Jaffer A.},
  year = {2012},
  journal = {Oncology},
  volume = {83},
  number = {5},
  pages = {300--304},
  issn = {1423-0232},
  doi = {10.1159/000341353},
  abstract = {BACKGROUND: For patients with localized esophageal cancer (EC) who can withstand surgery, the preferred therapy is chemoradiation followed by surgery (trimodality). However, after achieving a clinical complete response [clinCR; defined as both post-chemoradiation endoscopic biopsy showing no cancer and physiologic uptake by positron emission tomography (PET)], some patients decline surgery. The literature on the outcome of such patients is sparse. METHOD: Between 2002 and 2011, we identified 622 trimodality-eligible EC patients in our prospectively maintained databases. All patients had to be trimodality eligible and must have completed preoperative staging after chemoradiation that included repeat endoscopic biopsy and PET among other routine tests. RESULTS: Out of 622 trimodality-eligible patients identified, 61 patients (9.8\%) declined surgery. All 61 patients had a clinCR. The median age was 69 years (range 47-85). Males (85.2\%) and Caucasians (88.5\%) were dominant. Baseline stage was II (44.2\%) or III (52.5\%), and histology was adenocarcinoma (65.6\%) or squamous cell carcinoma (29.5\%). Forty-two patients are alive at a median follow-up of 50.9 months (95\% CI 39.5-62.3). The 5-year overall and relapse-free survival rates were 58.1 {$\pm$} 8.4 and 35.3 {$\pm$} 7.6\%, respectively. Of 13 patients with local recurrence during surveillance, 12 had successful salvage resection. CONCLUSION: Although the outcome of 61 EC patients with clinCR who declined surgery appears reasonable, in the absence of a validated prediction/prognosis model, surgery must be encouraged for all trimodality-eligible patients.},
  langid = {english},
  pmcid = {PMC3832345},
  pmid = {22964903},
  keywords = {Adenocarcinoma,Aged,Aged; 80 and over,Biopsy,Carcinoma; Squamous Cell,Chemoradiotherapy,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Esophagoscopy,Female,Gastrectomy,Gastroscopy,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Staging,Positron-Emission Tomography,Prospective Studies,Remission Induction,Retrospective Studies,Salvage Therapy,Stomach Neoplasms,Treatment Refusal},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\469VTSGV\\taketa300.pdf}
}

@article{taketa95,
  title = {Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation},
  author = {Taketa, Takashi and Xiao, Lianchun and Sudo, Kazuki and Suzuki, Akihiro and Wadhwa, Roopma and Blum, Mariela A. and Lee, Jeffrey H. and Weston, Brian and Bhutani, Manoop S. and Skinner, Heath and Komaki, Ritsuko and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
  year = {2013},
  journal = {Oncology},
  volume = {85},
  number = {2},
  pages = {95--99},
  issn = {1423-0232},
  doi = {10.1159/000351999},
  abstract = {BACKGROUND: Trimodality therapy (TMT; chemoradiation plus surgery) has level-1 evidence for survival advantage for TMT-eligible esophagogastric cancer patients. Some patients, however, decline surgery after preoperative chemoradiation. The question of which patient should have esophagectomy and which one should not is unlikely to be answered by a prospective comparison; therefore, we matched the clinical covariates of several patients who had surgery with those who declined surgery (DS). METHODS: Between 2002 and 2011, we identified 623 patients in our databases. Of 623 patients, 244 patients had TMT and 61 TMT-eligible patients were in the DS group. Using the propensity-score method, we matched 16 covariates between 36 DS patients and 36 TMT patients. RESULTS: Baseline characteristics between the two groups were balanced (p = NS). The median overall survival times were: 57.9 months (95\% CI: 27.7 to not applicable, NA) for the DS group and 50.8 months (95\% CI: 30.7 to NA) for the TMT group (p = 0.28). The median relapse-free survival times were: 18.5 (95\% CI: 11.5-30.4) for the DS group and 26.5 months (95\% CI: 15.5-NA) for the TMT group (p = 0.45). Eleven (31\%) of 36 patients in the DS group had salvage surgery. CONCLUSIONS: Our results are intriguing but skewed by the patients who had salvage surgery in the DS group. Until highly reliable predictive models are developed for esophageal preservation, TMT must be encouraged for all TMT-eligible gastroesophageal cancer patients.},
  langid = {english},
  pmid = {23860252},
  keywords = {Adenocarcinoma,Aged,Carcinoma; Squamous Cell,Chemoradiotherapy; Adjuvant,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Female,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Preoperative Period,Retrospective Studies,Treatment Outcome,Treatment Refusal}
}

@article{tamandl1359a,
  title = {Markers of Sarcopenia Quantified by Computed Tomography Predict Adverse Long-Term Outcome in Patients with Resected Oesophageal or Gastro-Oesophageal Junction Cancer},
  author = {Tamandl, Dietmar and Paireder, Matthias and Asari, Reza and Baltzer, Pascal A. and Schoppmann, Sebastian F. and {Ba-Ssalamah}, Ahmed},
  year = {2016},
  month = may,
  journal = {European Radiology},
  volume = {26},
  number = {5},
  pages = {1359--1367},
  issn = {1432-1084},
  doi = {10.1007/s00330-015-3963-1},
  abstract = {OBJECTIVES: To assess the impact of sarcopenia and alterations in body composition parameters (BCPs) on survival after surgery for oesophageal and gastro-oesophageal junction cancer (OC). METHODS: 200 consecutive patients who underwent resection for OC between 2006 and 2013 were selected. Preoperative CTs were used to assess markers of sarcopenia and body composition (total muscle area [TMA], fat-free mass index [FFMi], fat mass index [FMi], subcutaneous, visceral and retrorenal fat [RRF], muscle attenuation). Cox regression was used to assess the primary outcome parameter of overall survival (OS) after surgery. RESULTS: 130 patients (65\%) had sarcopenia based on preoperative CT examinations. Sarcopenic patients showed impaired survival compared to non-sarcopenic individuals (hazard ratio [HR] 1.87, 95\% confidence interval [CI] 1.15-3.03, p\,=\,0.011). Furthermore, low skeletal muscle attenuation (HR 1.91, 95\% CI 1.12-3.28, p\,=\,0.019) and increased FMi (HR 3.47, 95\% CI 1.27-9.50, p\,=\,0.016) were associated with impaired outcome. In the multivariate analysis, including a composite score (CSS) of those three parameters and clinical variables, only CSS, T-stage and surgical resection margin remained significant predictors of OS. CONCLUSION: Patients who show signs of sarcopenia and alterations in BCPs on preoperative CT images have impaired long-term outcome after surgery for OC. KEY POINTS: \textbullet{} Sarcopenia is associated with impaired OS after surgery for oesophageal cancer. \textbullet{} Other body composition parameters are also associated with impaired survival. \textbullet{} This influence on survival is independent of established clinical parameters. \textbullet{} Sarcopenia provides a better estimation of cachexia than BMI. \textbullet{} Sarcopenia assessment could be considered in risk/benefit stratification before oesophagectomy.},
  langid = {english},
  pmid = {26334504},
  keywords = {Aged,Body composition measurements,Computed tomography,Esophageal Neoplasms,Esophagectomy,Esophagogastric Junction,Esophagus,Female,Humans,Male,Middle Aged,Oesophageal cancer,Outcome analysis,Postoperative Complications,Prognosis,Proportional Hazards Models,Retrospective Studies,Sarcopenia,Stomach Neoplasms,Survival Analysis,Tomography; X-Ray Computed,Treatment Outcome}
}

@article{tan333,
  title = {Sarcopenia Is Associated with Toxicity in Patients Undergoing Neo-Adjuvant Chemotherapy for Oesophago-Gastric Cancer},
  author = {Tan, B. H. L. and Brammer, K. and Randhawa, N. and Welch, N. T. and Parsons, S. L. and James, E. J. and Catton, J. A.},
  year = {2015},
  month = mar,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {41},
  number = {3},
  pages = {333--338},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2014.11.040},
  abstract = {BACKGROUND: Patients with potentially curative oesophago-gastric cancer typically undergo neo-adjuvant chemotherapy prior to surgery. The majority of anti-cancer drugs have a narrow therapeutic index. The aim of this study was to determine if features of body composition, assessed using computed tomography (CT) scans, may be predictive of dose-limiting toxicity (DLT) in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. The influence of sarcopenia and DLT on overall survival was also evaluated. METHODS: 89 Patients having potentially curative oesophago-gastric cancer surgery were studied. Patients studied had histologically confirmed oesophago-gastric cancer with no evidence of distant metastasis on pre-operative staging. CT scan was performed in all cases at diagnosis. DLT was defined as toxicity leading to postponement of treatment, a drug dose reduction or definitive interruption of drug administration. RESULTS: DLT occurred in 37 out of 89 patients (41.6\%) undergoing chemotherapy. Sarcopenia (odds ratio, 2.95; 95\% confidence interval, 1.23-7.09; p = 0.015) was associated with DLT on multivariate analysis. Median overall survival for patients who were sarcopenic was 569 days (IQ range: 357-1230 days) vs. 1013 days (IQ range: 496-1318 days) for patients who were not sarcopenic (p = 0.04). There was no significant difference in overall survival in patients who experienced DLT compared with those that did not (p = 0.665). CONCLUSIONS: Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy. These results raise the potential for use of assessment of skeletal muscle mass using CT scans to predict toxicity and individualize chemotherapy dosing.},
  langid = {english},
  pmid = {25498359},
  keywords = {Adenocarcinoma,Aged,Antineoplastic Combined Chemotherapy Protocols,Body composition,Body Composition,Capecitabine,Carcinoma; Squamous Cell,Chemotherapy toxicity,Cisplatin,Deoxycytidine,Epirubicin,Esophageal Neoplasms,Esophagogastric Junction,Female,Fluorouracil,Humans,Male,Middle Aged,Neoadjuvant Therapy,Oesophago-gastric cancer,Prognosis,Sarcopenia,Stomach Neoplasms,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BTD4W4ZT\\Tan - 2015 - Sarcopenia is associated with toxicity in patients.pdf}
}

@article{tan6973,
  title = {Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer},
  author = {Tan, Benjamin H. L. and Birdsell, Laura A. and Martin, Lisa and Baracos, Vickie E. and Fearon, Kenneth C. H.},
  year = {2009},
  month = nov,
  journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
  volume = {15},
  number = {22},
  pages = {6973--6979},
  issn = {1557-3265},
  doi = {10.1158/1078-0432.CCR-09-1525},
  abstract = {PURPOSE: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also evaluated. EXPERIMENTAL DESIGN: A total of 111 patients entering a palliative therapy program, who had CT images and had undergone nutritional screening, were studied. In patients for whom follow-up scans were available (n = 44), longitudinal changes in body composition were studied at a mean of 230 +/- 62 and 95 +/- 60 days prior to demise. RESULTS: Sixty-two patients (55.9\%) were sarcopenic, 44 (39.6\%) were overweight/obese, and 18 (16.2\%) were both. Age {$>$} or =59 years (hazard ratio, 1.71; 95\% confidence interval, 1.10-2.66; P = 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95\% confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass index decreased from 15.5 +/- 2.5 kg/m(2) to 14.5 +/- 2.0 kg/m2 (P = 0.002), and total fat mass index decreased from 7.5 +/- 2.0kg/m2 to 6.0 +/- 1.5kg/m2 (P {$<$} 0.0001) over 135 days. CONCLUSIONS: Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult condition but can be identified using CT scans. This condition is an independent adverse prognostic indicator that should be considered for stratification of patients' entering clinical trials, systemic therapy, or support care programs.},
  langid = {english},
  pmid = {19887488},
  keywords = {Aged,Body Composition,Body Weight,Female,Humans,Male,Middle Aged,Obesity,Overweight,Pancreatic,Pancreatic Neoplasms,Prognosis,Risk,Sarcopenia,Tomography; X-Ray Computed,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\S7WDW42K\\Tan et al. - 2009 - Sarcopenia in an Overweight or Obese Patient Is an.pdf}
}

@article{tanaka146,
  title = {The Significance of Abdominal Para-Aortic Lymph Node Metastasis in Patients with Lower Thoracic Esophageal Cancer},
  author = {Tanaka, K. and Yano, M. and Motoori, M. and Doki, Y. and Kishi, K. and Miyashiro, I. and Shingai, T. and Gotoh, K. and Noura, S. and Takahashi, H. and Ohue, M. and Yamada, T. and Ohigashi, H. and Ishikawa, O.},
  year = {2012},
  month = feb,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {25},
  number = {2},
  pages = {146--152},
  issn = {1442-2050},
  doi = {10.1111/j.1442-2050.2011.01222.x},
  abstract = {Para-aortic lymph node (PALN) recurrence is often seen in patients with lower thoracic esophageal cancer treated by esophagectomy with extended lymph node dissection. However, the clinicopathological characteristics of patients with PALN metastasis and the significance of PALN dissection are unknown. A total of 283 patients with lower thoracic esophageal cancer underwent esophagectomy with lymphadenectomy at our hospital between April 1984 and March 2007. Among these 283 patients, 60 patients were enrolled in this retrospective study according to following criteria: (i) clinical T2 to T4 tumor, (ii) no clinical PALN metastasis, and (iii) received PALN dissection. PALN dissection was indicated by a tumor depth of at least T2 and no severe complications. The clinicopathological data, recurrence pattern, and overall survival were compared between patients with PALN and without PALN metastasis. The mean length of surgery was 587 min and the mean blood loss was 1383 mL. The morbidity was 33.3\% and mortality was 5\% in this series. Sixteen patients (26.7\%) had PALN metastasis; these showed significantly more lymph node metastases (15.8 {$\pm$} 13.2 vs. 3.0 {$\pm$} 3.2, P {$<$} 0.0001) and significantly worse survival rates (53.3\% vs. 79.9\% at 1 year, 6.7\% vs. 62.0\% at 3 years, P {$<$} 0.0001) than patients without PALN metastasis. The incidence of lymph node recurrence (P {$<$} 0.0001) and hematogenous recurrence (P= 0.0487) was also higher in patients with PALN metastasis than in patients without PALN metastasis. Among the 16 patients with PALN metastasis, a univariate analysis revealed total number of metastatic nodes {$<$} 8 (P= 0.0325) to be a significant prognostic factor. A multivariate logistic regression analysis of the regional lymph nodes identified the invasion of the lower mediastinal nodes (hazard ratio = 6.120) and retroperitoneal nodes (hazard ratio = 15.167) to be significantly correlated with PALN metastasis. PALN metastasis is suggested to be related to the systemic spread of lymphatic metastasis even in lower thoracic esophageal cancer. PALN dissection for pathological PALN(+) patients should not be performed. It remains to be determined in future prospective studies whether patients without pathological PALN metastasis, but showing PALN micrometastasis, could achieve improved survival with PALN dissection.},
  langid = {english},
  pmid = {21762280},
  keywords = {Abdominal Neoplasms,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Lymph Node Excision,Lymph Nodes,Lymphatic Metastasis,Male,Neoplasm Recurrence; Local,Nodes,PET,Postoperative Complications,Prognosis,Retrospective Studies,Survival Analysis}
}

@article{taniguchi184,
  ids = {taniguchi184a},
  title = {Effects of Goal-Directed Fluid Therapy on Enhanced Postoperative Recovery: {{An}} Interventional Comparative Observational Study with a Historical Control Group on Oesophagectomy Combined with {{ERAS}} Program},
  shorttitle = {Effects of Goal-Directed Fluid Therapy on Enhanced Postoperative Recovery},
  author = {Taniguchi, Hideki and Sasaki, Toshio and Fujita, Hisae and Kobayashi, Hiroko and Kawasaki, Rieko and Ogata, Takashi and Cho, Haruhiko and Yoshikawa, Takaki and Ushigome, Keiko and Tanaka, Akemi and Takano, Osami},
  year = {2018},
  month = feb,
  journal = {Clinical nutrition ESPEN},
  volume = {23},
  pages = {184--193},
  issn = {2405-4577},
  doi = {10.1016/j.clnesp.2017.10.002},
  abstract = {BACKGROUND AND AIMS: The Enhanced Recovery after Surgery (ERAS) program has been proposed as a postoperative recovery-enhancing strategy. We frequently apply the Modified-ERAS program following oesophagectomy. This study aims to elucidate the impact of goal-directed fluid therapy (GDT) for the perioperative management of oesophageal cancer on the postoperative recovery of patients undergoing oesophagectomy. METHODS: This is an interventional before-after comparative observational study conducted at Kanagawa Cancer Centre, Japan. Patients who underwent elective oesophagectomy for oesophageal cancer were recruited. Group H (retrospectively collected) received intraoperative and postoperative management consisting of fluid administration without haemodynamic monitoring and the M-ERAS program, while Group S prospectively received management consisting of GDT and the M-ERAS program. The primary endpoint was the speed of gastrointestinal functional recovery, while secondary endpoints were the level of postoperative mobilisation, incidence of complications, postoperative length of hospital stay (LOS), and nutritional status after discharge. RESULTS: The proportion of patients who completely egested Gastrografin by postoperative day 4, the level of postoperative mobilisation, and achievement ratio for a 100-m walk on the first postoperative attempt were significantly higher in Group S than in Group H (P~=~0.034, P~=~0.0197, and P~{$<~$}0.0001, respectively). No significant differences were observed in the postoperative LOS and incidence of complications within 30 days between the groups. The serum albumin levels at 6 months after discharge was higher in Group S than in Group H (P~=~0.0002). CONCLUSIONS: The GDT-ERAS program enhanced postoperative gastrointestinal recovery and mobilisation, as well as postoperative nutritional status and protein synthesis. The program did not affect either postoperative LOS or the incidence of complications. TRIAL REGISTRATION: UMIN registration number: UMIN000013705, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr\_view.cgi?recptno=R000015999.},
  langid = {english},
  pmid = {29460796},
  keywords = {Aged,Body Mass Index,Elective Surgical Procedures,Enhanced recovery after surgery (ERAS),Enteral Nutrition,Esophagectomy,Female,Goal-directed fluid therapy (GDT),Humans,Intensive Care Units,Japan,Length of Stay,Male,Middle Aged,Nutritional Status,Oesophagectomy,Patient Discharge,Postoperative gastrointestinal recovery,Postoperative mobilisation,Postoperative Period,Retrospective Studies,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\HRHUVYZJ\\Taniguchi et al_2018_Effects of goal-directed fluid therapy on enhanced postoperative recovery.pdf}
}

@article{tatematsu47,
  type = {Journal {{Article}}},
  title = {Association between Physical Activity and Postoperative Complications after Esophagectomy for Cancer: A Prospective Observational Study},
  author = {Tatematsu, N. and Park, M. and Tanaka, E. and Sakai, Y. and Tsuboyama, T.},
  year = {2013},
  journal = {Asian Pac J Cancer Prev},
  volume = {14},
  number = {1},
  pages = {47--51},
  issn = {2476-762X (Electronic) 1513-7368 (Linking)},
  doi = {10.7314/apjcp.2013.14.1.47}
}

@article{taylor34,
  title = {Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-up Results of the {{MERCURY}} Study},
  shorttitle = {Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence},
  author = {Taylor, Fiona G. M. and Quirke, Philip and Heald, Richard J. and Moran, Brendan J. and Blomqvist, Lennart and Swift, Ian R. and {Sebag-Montefiore}, David and Tekkis, Paris and Brown, Gina and {Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group}},
  year = {2014},
  month = jan,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {32},
  number = {1},
  pages = {34--43},
  issn = {1527-7755},
  doi = {10.1200/JCO.2012.45.3258},
  abstract = {PURPOSE: The prognostic relevance of preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin (CRM) involvement is unknown. This follow-up study of 374 patients with rectal cancer reports the relationship between preoperative MRI assessment of CRM staging, American Joint Committee on Cancer (AJCC) TNM stage, and clinical variables with overall survival (OS), disease-free survival (DFS), and time to local recurrence (LR). PATIENTS AND METHODS: Patients underwent protocol high-resolution pelvic MRI. Tumor distance to the mesorectal fascia of {$\leq$} 1 mm was recorded as an MRI-involved CRM. A Cox proportional hazards model was used in multivariate analysis to determine the relationship of MRI assessment of CRM to survivorship after adjusting for preoperative covariates. RESULTS: Surviving patients were followed for a median of 62 months. The 5-year OS was 62.2\% in patients with MRI-clear CRM compared with 42.2\% in patients with MRI-involved CRM with a hazard ratio (HR) of 1.97 (95\% CI, 1.27 to 3.04; P {$<$} .01). The 5-year DFS was 67.2\% (95\% CI, 61.4\% to 73\%) for MRI-clear CRM compared with 47.3\% (95\% CI, 33.7\% to 60.9\%) for MRI-involved CRM with an HR of 1.65 (95\% CI, 1.01 to 2.69; P {$<$} .05). Local recurrence HR for MRI-involved CRM was 3.50 (95\% CI, 1.53 to 8.00; P {$<$} .05). MRI-involved CRM was the only preoperative staging parameter that remained significant for OS, DFS, and LR on multivariate analysis. CONCLUSION: High-resolution MRI preoperative assessment of CRM status is superior to AJCC TNM-based criteria for assessing risk of LR, DFS, and OS. Furthermore, MRI CRM involvement is significantly associated with distant metastatic disease; therefore, colorectal cancer teams could intensify treatment and follow-up accordingly to improve survival outcomes.},
  langid = {english},
  pmid = {24276776},
  keywords = {Adult,Aged,Aged; 80 and over,Analysis of Variance,Confounding Factors; Epidemiologic,Disease Progression,Disease-Free Survival,Europe,Female,Follow-Up Studies,Humans,Kaplan-Meier Estimate,Magnetic Resonance Imaging,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,Odds Ratio,Predictive Value of Tests,Preoperative Period,Prognosis,Proportional Hazards Models,Rectal Neoplasms,Rectal; MRI,Research Design}
}

@article{teigen933,
  title = {Impact of {{Software Selection}} and {{ImageJ Tutorial Corrigendum}} on {{Skeletal Muscle Measures}} at the {{Third Lumbar Vertebra}} on {{Computed Tomography Scans}} in {{Clinical Populations}}},
  author = {Teigen, Levi M. and Kuchnia, Adam J. and Nagel, Emily and Deuth, Christopher and Vock, David M. and Mulasi, Urvashi and Earthman, Carrie P.},
  year = {2018},
  month = jul,
  journal = {JPEN. Journal of parenteral and enteral nutrition},
  volume = {42},
  number = {5},
  pages = {933--941},
  issn = {1941-2444},
  doi = {10.1002/jpen.1036},
  abstract = {BACKGROUND: There is growing interest in computed tomography (CT) measures of skeletal muscle cross-sectional area (CSA) for nutrition assessment. Multiple software programs are available, but little work has been done comparing programs. We aimed to determine if CT-derived measures of skeletal muscle CSA at the level of the L3 are influenced by the software program used. We also demonstrate the importance of the ImageJ corrigendum published in this journal. METHODS: Two software programs, National Institutes of Health ImageJ and Tomovision sliceOmatic, were compared. ImageJ measures were obtained using both the original tutorial and corrigendum instructions. Skeletal muscle CSA at the level of the L3 was measured in advanced heart failure and head and neck cancer populations by 3 different investigators. Intraclass correlation coefficients were used to calculate intrarater and interrater reliability. Bland-Altman analysis was used to assess agreement. RESULTS: Both software programs yielded excellent intrarater and interrater reliability scores (intraclass correlation coefficients, 0.985-1.000). The overall mean difference (ImageJ tutorial with corrigendum - sliceOmatic) for the entire sample (N = 51) was found to be 1.53 cm2 (95\% CI, 0.59-2.47 cm2 ). The overall mean difference (ImageJ corrected - original) for the entire sample (N = 51) was found to be -11.35 cm2 (95\% CI, -12.75 to -9.95 cm2 ). CONCLUSION: Measures of skeletal muscle CSA at the L3 were found to be {$\sim$}1.53 cm2 higher with ImageJ than sliceOmatic. This difference was not found to affect interpretation against a published cut point. The importance of accounting for the ImageJ tutorial corrigendum was shown to be clinically significant when applied to published cut points.},
  langid = {english},
  pmid = {30001463},
  keywords = {body composition,Body Composition,computed tomography,Head and Neck Neoplasms,Heart Failure,Humans,Lumbar Vertebrae,malnutrition,Methods,Muscle; Skeletal,Reproducibility of Results,Sarcopenia,skeletal muscle,software,Software,Tomography; X-Ray Computed}
}

@article{teoh1,
  type = {Journal {{Article}}},
  title = {Functional Performance and Quality of Life in Patients with Squamous Esophageal Carcinoma Receiving Surgery or Chemoradiation: Results from a Randomized Trial},
  author = {Teoh, A. Y. and Yan Chiu, P. W. and Wong, T. C. and Liu, S. Y. and Hung Wong, S. K. and Ng, E. K.},
  year = {2011},
  journal = {Ann Surg},
  volume = {253},
  number = {1},
  pages = {1--5},
  issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
  doi = {10.1097/SLA.0b013e3181fcd991}
}

@article{terheggen783,
  title = {A Randomised Trial of Endoscopic Submucosal Dissection versus Endoscopic Mucosal Resection for Early {{Barrett}}'s Neoplasia},
  author = {Terheggen, Grischa and Horn, Eva Maria and Vieth, Michael and Gabbert, Helmut and Enderle, Markus and Neugebauer, Alexander and Schumacher, Brigitte and Neuhaus, Horst},
  year = {2017},
  month = may,
  journal = {Gut},
  volume = {66},
  number = {5},
  pages = {783--793},
  issn = {1468-3288},
  doi = {10.1136/gutjnl-2015-310126},
  abstract = {BACKGROUND: For endoscopic resection of early GI neoplasia, endoscopic submucosal dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal resection (EMR). However, ESD is technically more difficult and evidence from randomised trial is missing. OBJECTIVE: We compared the efficacy and safety of ESD and EMR in patients with neoplastic Barrett's oesophagus (BO). DESIGN: BO patients with a focal lesion of high-grade intraepithelial neoplasia (HGIN) or early adenocarcinoma (EAC) {$\leq$}3\hspace{0.25em}cm were randomised to either ESD or EMR. Primary outcome was R0 resection; secondary outcomes were complete remission from neoplasia, recurrences and adverse events (AEs). RESULTS: There were no significant differences in patient and lesion characteristics between the groups randomised to ESD (n=20) or EMR (n=20). Histology of the resected specimen showed HGIN or EAC in all but six cases. Although R0 resection defined as margins free of HGIN/EAC was achieved more frequently with ESD (10/17 vs 2/17, p=0.01), there was no difference in complete remission from neoplasia at 3\hspace{0.25em}months (ESD 15/16 vs EMR 16/17, p=1.0). During a mean follow-up period of 23.1{$\pm$}6.4\hspace{0.25em}months, recurrent EAC was observed in one case in the ESD group. Elective surgery was performed in four and three cases after ESD and EMR, respectively (p=1.0). Two severe AEs were recorded for ESD and none for EMR (p=0.49). CONCLUSIONS: In terms of need for surgery, neoplasia remission and recurrence, ESD and EMR are both highly effective for endoscopic resection of early BO neoplasia. ESD achieves a higher R0 resection rate, but for most BO patients this bears little clinical relevance. ESD is, however, more time consuming and may cause severe AE. TRIAL REGISTRATION NUMBER: NCT1871636.},
  langid = {english},
  pmcid = {PMC5531224},
  pmid = {26801885},
  keywords = {Adenocarcinoma,Aged,Barrett Esophagus,BARRETTâS OESOPHAGUS,Carcinoma in Situ,Endoscopic Mucosal Resection,ENDOSCOPIC PROCEDURES,ENDOSCOPY,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Humans,Male,Margins of Excision,Middle Aged,Neoplasm Recurrence; Local,Neoplasm; Residual,Prospective Studies,Reoperation},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\M5KNJB2X\\Terheggen et al. - 2017 - A randomised trial of endoscopic submucosal dissec.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\XZZ6HHIX\\baldwin.pdf}
}

@article{tevis505,
  type = {Journal {{Article}}},
  title = {Postdischarge Complications Are an Important Predictor of Postoperative Readmissions},
  author = {Tevis, S. E. and Kohlnhofer, B. M. and Weber, S. M. and Kennedy, G. D.},
  year = {2014},
  journal = {Am J Surg},
  volume = {208},
  number = {4},
  pages = {505--10},
  issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
  doi = {10.1016/j.amjsurg.2014.05.013}
}

@article{thanh415,
  ids = {thanh415a},
  title = {An Economic Evaluation of the {{Enhanced Recovery After Surgery}} ({{ERAS}}) Multisite Implementation Program for Colorectal Surgery in {{Alberta}}},
  author = {Thanh, Nguyen X. and Chuck, Anderson W. and Wasylak, Tracy and Lawrence, Jeannette and Faris, Peter and Ljungqvist, Olle and Nelson, Gregg and Gramlich, Leah M.},
  year = {2016},
  month = dec,
  journal = {Canadian Journal of Surgery. Journal Canadien De Chirurgie},
  volume = {59},
  number = {6},
  pages = {415--421},
  issn = {1488-2310},
  doi = {10.1503/cjs.006716},
  abstract = {BACKGROUND: In February 2013, Alberta Health Services established an Enhanced Recovery After Surgery (ERAS) implementation program for adopting the ERAS Society colorectal guidelines into 6 sites (initial phase) that perform more than 75\% of all colorectal surgeries in the province. We conducted an economic evaluation of this initiative to not only determine its cost-effectiveness, but also to inform strategy for the spread and scale of ERAS to other surgical protocols and sites. METHODS: We assessed the impact of ERAS on patients\&\#8217; health services utilization (HSU; length of stay [LOS], readmissions, emergency department visits, general practitioner and specialist visits) within 30 days of discharge by comparing pre- and post-ERAS groups using multilevel negative binomial regressions. We estimated the net health care costs/savings and the return on investment (ROI) associated with those impacts for post-ERAS patients using a decision analytic modelling technique. RESULTS: We included 331 pre- and 1295 post-ERAS patients in our analyses. ERAS was associated with a reduction in all HSU outcomes except visits to specialists. However, only the reduction in primary LOS was significant. The net health system savings were estimated at \$2 290 000 (range \$1 191 000\&\#8211;\$3 391 000), or \$1768 (range \$920\&\#8211;\$2619) per patient. The probability for the program to be cost-saving was 73\%\&\#8211;83\%. In terms of ROI, every \$1 invested in ERAS would bring \$3.8 (range \$2.4\&\#8211;\$5.1) in return. CONCLUSION: The initial phase of ERAS implementation for colorectal surgery in Alberta is cost-saving. The total savings has the potential to be more substantial when ERAS is spread for other surgical protocols and across additional sites.},
  langid = {english},
  pmcid = {PMC5125924},
  pmid = {28445024},
  keywords = {CRC,ERAS},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RSPEYJKT\\Thanh et al_2016_An economic evaluation of the Enhanced Recovery After Surgery (ERAS) multisite.pdf}
}

@article{then55,
  type = {Journal {{Article}}},
  title = {Esophageal {{Cancer}}: {{An Updated Surveillance Epidemiology}} and {{End Results Database Analysis}}},
  author = {Then, E. O. and Lopez, M. and Saleem, S. and Gayam, V. and Sunkara, T. and Culliford, A. and Gaduputi, V.},
  year = {2020},
  journal = {World J Oncol},
  volume = {11},
  number = {2},
  pages = {55--64},
  issn = {1920-454X (Electronic) 1920-4531 (Linking)},
  doi = {10.14740/wjon1254}
}

@article{thomas1609,
  title = {Trimodal Imaging-Assisted Endoscopic Mucosal Resection of Early {{Barrett}}'s Neoplasia},
  author = {Thomas, T. and Singh, R. and Ragunath, K.},
  year = {2009},
  month = jul,
  journal = {Surgical Endoscopy},
  volume = {23},
  number = {7},
  pages = {1609--1613},
  issn = {1432-2218},
  doi = {10.1007/s00464-009-0429-z},
  abstract = {BACKGROUND: Chromoendoscopy is traditionally used to identify inconspicuous Barrett's neoplasia and mark the boundaries before endoscopic mucosal resection (EMR). Trimodal imaging endoscopy is useful in identifying early neoplasia in Barrett's esophagus. The purpose of this study was to determine the efficacy (lateral and deep margin clearance) of trimodal imaging endoscopy-assisted EMR in early Barrett's neoplasia in a tertiary referral setting. METHODS: The entire Barrett's segment was visualized by high-resolution endoscopy followed by autofluorescence imaging, and suspicious areas were identified. Narrow band imaging and magnification was used to confirm the suspicious areas. The outer boundary of the lesion was then marked using the tip of a snare diathermy and EMR was performed using multiband mucosectomy technique by a single operator (KR). RESULTS: Sixteen patients were included: 13 patients had high-grade intraepithelial neoplasia (HGIN); 3 patients had intramucosal carcinoma (IMC); (8 males, median age, 69.5 (range, 50-77) years with Barrett's esophagus (interquartile range (IQR), 2-5 cm; median length, 3 cm). All lesions were successfully identified, using trimodal imaging endoscopy. Overall EMR was complete in 14 of 16 (81.2\%) patients with early Barrett's neoplasia. Four of 16 patients (18\%; all with pre-EMR HGIN) were considered to have incomplete EMR (deep margins involved), but operative histology showed only Barrett's metaplasia in 2 (histological false positive) and IMC in 1. Thus, overall 14 of 16 (87.5\%) patients had complete EMR of the original lesions. In patients who did not undergo esophagectomy, there was no disease recurrence on endoscopic biopsies at a mean follow-up of 8 (IQR, 6-12) months. Three of the 16 patients (18.75\%) with post-EMR bleeding were successfully treated with APC/hemoclips. CONCLUSIONS: Trimodal imaging endoscopy is a feasible alternative to chromoendoscopy to identify inconspicuous neoplasia and assist EMR of early neoplasia in Barrett's esophagus.},
  langid = {english},
  pmid = {19296171},
  keywords = {Adenocarcinoma,Aged,Aged; 80 and over,Barrett Esophagus,Carcinoma in Situ,Diathermy,Disease Progression,Esophageal Neoplasms,Esophagoscopy,Female,Fluorometry,Follow-Up Studies,Gastroscopes,Hemostasis; Surgical,Humans,Male,Middle Aged,Mucous Membrane,Postoperative Hemorrhage,Retrospective Studies,Video-Assisted Surgery}
}

@article{tisdale243S,
  title = {Wasting in Cancer},
  author = {Tisdale, M. J.},
  year = {1999},
  month = jan,
  journal = {The Journal of Nutrition},
  volume = {129},
  number = {1S Suppl},
  pages = {243S-246S},
  issn = {0022-3166},
  doi = {10.1093/jn/129.1.243S},
  abstract = {Progressive weight loss is a common feature of many types of cancer and is responsible not only for a poor quality of life and poor response to chemotherapy, but also a shorter survival time than is found in patients with comparable tumors without weight loss. Although anorexia is common, a decreased food intake alone is unable to account for the changes in body composition seen in cancer patients, and increasing nutrient intake is unable to reverse the wasting syndrome. Although energy expenditure is increased in some patients, cachexia can occur even with a normal energy expenditure. Various factors have been investigated as mediators of tissue wasting in cachexia. These include cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and leukemia inhibitory factor (LIF), as well as tumor-derived factors such as lipid mobilizing factor (LMF) and protein mobilizing factor (PMF), which can directly mobilize fatty acids and amino acids from adipose tissue and skeletal muscle respectively. Induction of lipolysis by the cytokines is thought to result from an inhibition of lipoprotein lipase (LPL), although clinical studies provide no evidence for an inhibition of LPL in the adipose tissue of cancer patients. Instead there is an increased expression of hormone sensitive lipase, the enzyme activated by LMF. Protein degradation in cachexia is associated with an increased activity of the ATP-ubiquitin-proteasome pathway. The biological activity of both the LMF and PMF was shown to be attenuated by eicosapentaenoic acid (EPA). Clinical studies show that this polyunsaturated fatty acid is able to stabilize the rate of weight loss and adipose tissue and muscle mass in cachectic patients with unresectable pancreatic cancer. Knowledge of the mechanism of cancer cachexia should lead to the development of new therapeutic agents.},
  langid = {english},
  pmid = {9915907},
  keywords = {Anorexia,Energy Metabolism,HIV Wasting Syndrome,Humans,Lipid Metabolism,Muscles,Weight Loss},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9Z43I6S7\\Tisdale - 1999 - Wasting in cancer.pdf}
}

@article{tisdale301,
  type = {Journal {{Article}}},
  title = {Amiodarone for Prevention of Atrial Fibrillation Following Esophagectomy},
  author = {Tisdale, J. E. and Jaynes, H. A. and Watson, M. R. and Corya, A. L. and Shen, C. and Kesler, K. A.},
  year = {2019},
  journal = {J Thorac Cardiovasc Surg},
  volume = {158},
  number = {1},
  pages = {301-310 e1},
  issn = {1097-685X (Electronic) 0022-5223 (Linking)},
  doi = {10.1016/j.jtcvs.2019.01.095}
}

@article{tisminetzky1549,
  title = {Research {{Priorities}} to {{Advance}} the {{Health}} and {{Health Care}} of {{Older Adults}} with {{Multiple Chronic Conditions}}},
  author = {Tisminetzky, Mayra and Bayliss, Elizabeth A. and Magaziner, Jay S. and Allore, Heather G. and Anzuoni, Kathryn and Boyd, Cynthia M. and Gill, Thomas M. and Go, Alan S. and Greenspan, Susan L. and Hanson, Leah R. and Hornbrook, Mark C. and Kitzman, Dalane W. and Larson, Eric B. and Naylor, Mary D. and Shirley, Benjamin E. and {Tai-Seale}, Ming and Teri, Linda and Tinetti, Mary E. and Whitson, Heather E. and Gurwitz, Jerry H.},
  year = {2017},
  month = jul,
  journal = {Journal of the American Geriatrics Society},
  volume = {65},
  number = {7},
  pages = {1549--1553},
  issn = {1532-5415},
  doi = {10.1111/jgs.14943},
  abstract = {OBJECTIVES: To prioritize research topics relevant to the care of the growing population of older adults with multiple chronic conditions (MCCs). DESIGN: Survey of experts in MCC practice, research, and policy. Topics were derived from white papers, funding announcements, or funded research projects relating to older adults with MCCs. SETTING: Survey conducted through the Health Care Systems Research Network (HCSRN) and Claude D. Pepper Older Americans Independence Centers (OAICs) Advancing Geriatrics Infrastructure and Network Growth Initiative, a joint endeavor of the HCSRN and OAICs. PARTICIPANTS: Individuals affiliated with the HCSRN or OAICs and national MCC experts, including individuals affiliated with funding agencies having MCC-related grant portfolios. MEASUREMENTS: A "top box" methodology was used, counting the number of respondents selecting the top response on a 5-point Likert scale and dividing by the total number of responses to calculate a top box percentage for each of 37 topics. RESULTS: The highest-ranked research topics relevant to the health and healthcare of older adults with MCCs were health-related quality of life in older adults with MCCs; development of assessment tools (to assess, e.g., symptom burden, quality of life, function); interactions between medications, disease processes, and health outcomes; disability; implementation of novel (and scalable) models of care; association between clusters of chronic conditions and clinical, financial, and social outcomes; role of caregivers; symptom burden; shared decision-making to enhance care planning; and tools to improve clinical decision-making. CONCLUSION: Study findings serve to inform the development of a comprehensive research agenda to address the challenges relating to the care of this "high-need, high-cost" population and the healthcare delivery systems responsible for serving it.},
  langid = {english},
  pmcid = {PMC5507733},
  pmid = {28555750},
  keywords = {aging,Caregivers,Chronic Disease,Delivery of Health Care,Drug Interactions,Elderly,geriatrics,Health Services Research,Humans,multimorbidity,multiple chronic conditions,Multiple Chronic Conditions,Outcome and Process Assessment; Health Care,Quality of Life,Research,Surveys and Questionnaires},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\DU7FJAEE\\Tisminetzky et al_2017_Research Priorities to Advance the Health and Health Care of Older Adults with.pdf}
}

@article{tobllie0125528,
  title = {Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status},
  shorttitle = {Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose},
  author = {Toblli, Jorge Eduardo and Di Gennaro, Federico},
  year = {2015},
  journal = {PloS One},
  volume = {10},
  number = {4},
  pages = {e0125528},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0125528},
  abstract = {BACKGROUND: Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce ESA requirements and improve iron status and hemoglobin in patients with ND-CKD. METHODS: This prospective, single arm and single-center study included adult patients with ND-CKD (creatinine clearance {$\leq$}40 mL/min), hemoglobin 11-12 g/dL and iron deficiency (ferritin {$<$}100 {$\mu$}g/L or transferrin saturation {$<$}20\%), who were regularly treated with oral iron and ESA during 6 months prior to inclusion. Study patients received an intravenous ferric carboxymaltose dose of 1,000 mg iron, followed by a 6-months ESA/ ferric carboxymaltose maintenance regimen (target: hemoglobin 12 g/dL, transferrin saturation {$>$}20\%). Outcome measures were ESA dose requirements during the observation period after initial ferric carboxymaltose treatment (primary endpoint); number of hospitalizations and transfusions, renal function before and after ferric carboxymaltose administration, number of adverse reactions (secondary endpoints). Hemoglobin, mean corpuscular volume, ferritin and transferrin saturation were measured monthly from baseline until end of study. Creatinine clearance, proteinuria, C-reactive protein, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase bimonthly from baseline until end of study. RESULTS: Thirty patients were enrolled (age 70.1{$\pm$}11.4 years; mean{$\pm$}SD). Mean ESA consumption was significantly reduced by 83.2{$\pm$}10.9\% (from 41,839{$\pm$}3,668 IU/patient to 6,879{$\pm$}4,271 IU/patient; p{$<$}0.01). Hemoglobin increased by 0.7{$\pm$}0.3 g/dL, ferritin by 196.0{$\pm$}38.7 {$\mu$}g/L and transferrin saturation by 5.3{$\pm$}2.9\% (month 6 vs. baseline; all p{$<$}0.01). No ferric carboxymaltose-related adverse events were reported and no patient withdrew or required transfusions during the study. CONCLUSION: Among patients with ND-CKD and stable normal or borderline hemoglobin, switching from oral iron to intravenous ferric carboxymaltose was associated with significant improvements in hematological and iron parameters and a significant reduction in ESA dose requirements in this single-center pilot study. TRIAL REGISTRATION: ClinicalTrials.gov NCT02232906.},
  langid = {english},
  pmcid = {PMC4415953},
  pmid = {25928811},
  keywords = {Administration; Intravenous,Administration; Oral,Aged,Aged; 80 and over,CRF,Erythropoiesis,Female,Ferric Compounds,Hemoglobins,Humans,Iron,Male,Maltose,Middle Aged,Prospective Studies,Renal Insufficiency; Chronic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\GM3XY87H\\Toblli_Di Gennaro_2015_Switching patients with non-dialysis chronic kidney disease from oral iron to.pdf}
}

@article{tramontano2880,
  title = {Survival {{Disparities}} by {{Race}} and {{Ethnicity}} in {{Early Esophageal Cancer}}},
  author = {Tramontano, Angela C. and Nipp, Ryan and Mercaldo, Nathaniel D. and Kong, Chung Yin and Schrag, Deborah and Hur, Chin},
  year = {2018},
  month = nov,
  journal = {Digestive Diseases and Sciences},
  volume = {63},
  number = {11},
  pages = {2880--2888},
  issn = {1573-2568},
  doi = {10.1007/s10620-018-5238-6},
  abstract = {BACKGROUND: Survival outcome disparities among esophageal cancer patients exist, but are not fully understood. AIMS: We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to determine whether survival differences among racial/ethnic patient populations persist after adjusting for demographic and clinical characteristics. METHODS: Our study included T1-3N0M0 adenocarcinoma and squamous cell cancer patients diagnosed between 2003 and 2011. We compared survival among two racial/ethnic patient subgroups using Cox proportional hazards methods, adjusting for age, sex, histology, marital status, socioeconomics, SEER region, comorbidities, T stage, tumor location, diagnosis year, and treatment received. RESULTS: Among 2025 patients, 87.9\% were White and 12.1\% were Nonwhite. Median survival was 18.7~months for Whites vs 13.8~months for Nonwhites (p\,=\,0.01). In the unadjusted model, Nonwhite patients had higher risk of mortality (HR\,=\,1.29, 95\% CI 1.11-1.49, p\,{$<$}\,0.0001) when compared to White patients; however, in the Cox regression adjusted model there was no significant difference (HR\,=\,0.94, 95\% CI 0.80-1.10, p\,=\,0.44). Surgery, chemotherapy, younger age, lower T stage, and lower Charlson comorbidity score were significant predictors in the full adjusted model. CONCLUSIONS: Differences in mortality risk by race/ethnicity appear to be largely explained by additional factors. In particular, associations were seen in surgery and T stage. Further research is needed to understand potential mechanisms underlying the differences and to better target patients who can benefit from treatment options.},
  langid = {english},
  pmcid = {PMC6738563},
  pmid = {30109578},
  keywords = {Adenocarcinoma,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Disparities,Esophageal cancer,Esophageal Neoplasms,Female,Humans,Male,Outcomes,Race,SEER Program,SEER-Medicare,Survival},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NLTSEKJD\\Tramontano et al. - 2018 - Survival Disparities by Race and Ethnicity in Earl.pdf}
}

@article{tran3,
  title = {The Impact of Gender, Race, Socioeconomic Status, and Treatment on Outcomes in Esophageal Cancer: {{A}} Population-Based Analysis},
  shorttitle = {The Impact of Gender, Race, Socioeconomic Status, and Treatment on Outcomes in Esophageal Cancer},
  author = {Tran, Phu N. and Taylor, Thomas H. and Klempner, Samuel J. and Zell, Jason A.},
  year = {2017},
  journal = {Journal of Carcinogenesis},
  volume = {16},
  pages = {3},
  issn = {1477-3163},
  doi = {10.4103/jcar.JCar_4_17},
  abstract = {BACKGROUND: African Americans and Hispanics are reported to have higher mortality from esophageal cancer (EC) than Caucasians. In this study, we analyzed the independent effects of race, gender, treatment, and socioeconomic status (SES) on overall survival (OS). METHODS: Data for all EC cases between 2004 and 2010 with follow-up through 2012 were obtained from the California Cancer Registry. We conducted descriptive analyses of clinical variables and survival analyses by Kaplan-Meier and Cox proportional hazards methods. RESULTS: African Americans and Hispanics were more likely to be in the lower SES strata and less likely to receive surgery than Caucasians in this cohort. The proportion of patients receiving chemotherapy and radiotherapy was similar across different racial/ethnic groups. After adjustment for stage, grade, histology, treatments, and SES in multivariate analyses, the mortality risk in African Americans (hazard ratio [HR] 0.96, 95\% confidence interval [CI] 0.85-1.07) and Hispanics (HR 0.96, 95\% CI 0.89-1.07) did not differ from Caucasians (HR = 1.00, referent), with histology, SES, and surgery largely accounting for unadjusted OS differences. We also observed that African American men had higher adjusted risk of death relative to Caucasian men (HR 1.24, 95\% CI 1.07-1.42), but this effect was not observed for African American women compared to Caucasian women (HR 1.12, 95\% CI 0.94-1.35). CONCLUSIONS: Race is not an independent risk factor for OS in our population-based analysis of EC cases. Rather, observed differences in OS by race/ethnicity result from differences in cancer histology, SES, surgery, and gender. Our findings support further health disparities research for this disease.},
  langid = {english},
  pmcid = {PMC5615860},
  pmid = {28974922},
  keywords = {Esophageal cancer,ethnicity,outcomes,race,Race,survival disparity}
}

@article{urschel160,
  title = {Pyloric Drainage (Pyloroplasty) or No Drainage in Gastric Reconstruction after Esophagectomy: A Meta-Analysis of Randomized Controlled Trials},
  shorttitle = {Pyloric Drainage (Pyloroplasty) or No Drainage in Gastric Reconstruction after Esophagectomy},
  author = {Urschel, John D. and Blewett, Chris J. and Young, J. Edward M. and Miller, John D. and Bennett, W. Frederick},
  year = {2002},
  journal = {Digestive Surgery},
  volume = {19},
  number = {3},
  pages = {160--164},
  issn = {0253-4886},
  doi = {10.1159/000064206},
  abstract = {BACKGROUND/AIM: A gastric conduit is usually used to reconstruct the foregut after esophagectomy for cancer. The gastric emptying may be impaired after this operation, so some esophageal surgeons routinely add a pyloric drainage procedure (pyloroplasty or pyloromyotomy). We performed a meta-analysis of randomized controlled trials (RCTs) to determine the effect of pyloric drainage on patient outcomes. METHODS: Medline and manual searches were done (completed independently and in duplicate) to identify all published RCTs that addressed the issue of pyloric drainage procedures during gastric conduit reconstruction of the esophagus. The selection process was inclusive; no trials were excluded. Trial validity assessment was done, and a trial quality score was assigned. Early outcomes assessed by meta-analysis included operative mortality, esophagogastric anastomotic leaks, pulmonary morbidity, pyloric drainage complications, fatal pulmonary aspiration, and gastric outlet obstruction. A random-effects model was used, and the relative risk was the principal measure of effect. Systematic semiquantitative review was used for late outcomes such as gastric emptying, bile reflux, nutritional status, and obstructive foregut symptoms. RESULTS: Nine RCTs, that included a total of 553 patients, were selected, with quality scores ranging from 1 to 4 (5-point Jadad scale). Selection and validity agreement was strong. The relative risk (95\% CI; p value), expressed as pyloric drainage versus no drainage (treatment vs. control), was 0.92 (0.34, 2.44; p = 0.86) for operative mortality, 0.90 (0.47, 1.76; p = 0.77) for esophagogastric anastomotic leaks, 0.69 (0.42, 1.14; p = 0.15) for pulmonary morbidity, 2.55 (0.34, 18.98; p = 0.36) for pyloric drainage complications, 0.25 (0.04, 1.60; p = 0.14) for fatal pulmonary aspiration, and 0.18 (0.03, 0.97; p = 0.046) for gastric outlet obstruction. Systematic semiquantitative review showed a nonsignificant trend favoring pyloric drainage for the late outcomes of gastric emptying, nutritional status, and obstructive foregut symptoms. For the late outcome of bile reflux, there was a nonsignificant trend favoring the no-drainage group. The scintographic gastric emptying time, expressed as a ratio (pyloric drainage/no drainage), was 0.53. CONCLUSIONS: Data synthesized from existing RCTs show that pyloric drainage procedures reduce the occurrence of early postoperative gastric outlet obstruction after esophagectomy with gastric reconstruction, but they have little effect on other early and late patient outcomes.},
  langid = {english},
  pmid = {12119515},
  keywords = {Drainage,Esophageal Neoplasms,Esophagectomy,Gastroplasty,Humans,Pyloris,Pylorus,Randomized Controlled Trials as Topic,Treatment Outcome}
}

@article{uspreventiveservicestaskforce1965,
  title = {Screening for {{Colorectal Cancer}}: {{US Preventive Services Task Force Recommendation Statement}}},
  shorttitle = {Screening for {{Colorectal Cancer}}},
  author = {{US Preventive Services Task Force} and Davidson, Karina W. and Barry, Michael J. and Mangione, Carol M. and Cabana, Michael and Caughey, Aaron B. and Davis, Esa M. and Donahue, Katrina E. and Doubeni, Chyke A. and Krist, Alex H. and Kubik, Martha and Li, Li and Ogedegbe, Gbenga and Owens, Douglas K. and Pbert, Lori and Silverstein, Michael and Stevermer, James and Tseng, Chien-Wen and Wong, John B.},
  year = {2021},
  month = may,
  journal = {JAMA},
  volume = {325},
  number = {19},
  pages = {1965--1977},
  issn = {1538-3598},
  doi = {10.1001/jama.2021.6238},
  abstract = {IMPORTANCE: Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52\,980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5\% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15\% from 2000-2002 to 2014-2016. In 2016, 26\% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31\% were not up to date with screening. OBJECTIVE: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies. POPULATION: Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]). EVIDENCE ASSESSMENT: The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit. RECOMMENDATION: The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).},
  langid = {english},
  pmid = {34003218},
  keywords = {Age Factors,Aged,Aged; 80 and over,Colonoscopy,Colorectal Neoplasms,Early Detection of Cancer,Female,Humans,Male,Middle Aged,Occult Blood,Risk,Screening,Sigmoidoscopy,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\RRUFEPFX\\US Preventive Services Task Force et al_2021_Screening for Colorectal Cancer.pdf}
}

@article{vakil1791,
  title = {A Prospective, Randomized, Controlled Trial of Covered Expandable Metal Stents in the Palliation of Malignant Esophageal Obstruction at the Gastroesophageal Junction},
  author = {Vakil, N. and Morris, A. I. and Marcon, N. and Segalin, A. and Peracchia, A. and Bethge, N. and Zuccaro, G. and Bosco, J. J. and Jones, W. F.},
  year = {2001},
  month = jun,
  journal = {The American Journal of Gastroenterology},
  volume = {96},
  number = {6},
  pages = {1791--1796},
  issn = {0002-9270},
  doi = {10.1111/j.1572-0241.2001.03923.x},
  abstract = {OBJECTIVE: Palliation of malignant esophageal obstruction is an important clinical problem. Expandable metal stents are a major advance in therapy, but many stents become obstructed because of tumor ingrowth. The aim of this study was to compare a new, membrane-covered expandable metal stent to conventional prostheses in a randomized controlled trial. METHODS: Sixty-two patients with malignant inoperable esophageal obstruction at the gastroesophageal junction participated in the study. Patients were randomly assigned to covered or uncovered stents. The principal outcome measure was the need for reintervention because of recurrent dysphagia or migration. Secondary endpoints were relief of dysphagia measured by a dysphagia score (grade 0 = no dysphagia, grade 1 = able to eat solid food, grade 2 = semisolids only, grade 3 = liquids only, grade 4 = complete dysphagia) and the rate of complications and functional status. All patients were observed at monthly intervals until death or for 6 months. RESULTS: One week after stenting the dysphagia score improved significantly in both the uncovered (n = 32, 3 +/- 0.1 to 1 +/- 0.1 [means +/- SEMs], p {$<$} 0.001) and covered (n = 30, 3 +/- 0.1 to 1 +/- 0.2 [means +/- SEMs], p {$<$} 0.001) stents. Obstructing tumor ingrowth was significantly more likely in the uncovered stent group (9/30) than in the covered group (1/32) (p = 0.005). Significant stent migration occurred in 2/30 patients with uncovered stents, as compared with 4/32 patients in the covered group (p = 0.44). Reinterventions for tumor ingrowth were significantly greater in the uncovered stent group (27\%), as compared with 0\% in the covered group (p = 0.002). Life table analysis showed similar survival in both groups. CONCLUSION: Membrane-covered stents have significantly better palliation than conventional bare metal stents because of decreased rates of tumor ingrowth that necessitate endoscopic reintervention for dysphagia.},
  langid = {english},
  pmid = {11419831},
  keywords = {Adenocarcinoma,Aged,Deglutition Disorders,Esophageal Neoplasms,Esophagogastric Junction,Humans,Intestinal Obstruction,Karnofsky Performance Status,Palliative Care,Stents,Survival Rate,Treatment Outcome}
}

@article{valkema1553,
  title = {Accuracy of {{18F-FDG PET}}/{{CT}} in {{Predicting Residual Disease After Neoadjuvant Chemoradiotherapy}} for {{Esophageal Cancer}}},
  author = {Valkema, Maria J. and Noordman, Bo Jan and Wijnhoven, Bas P. L. and Spaander, Manon C. W. and Biermann, Katharina and Lagarde, Sjoerd M. and Bennink, Roel J. and Schreurs, Wendy M. J. and Roef, Mark J. and Hobbelink, Monique G. G. and Janssen, Marcel J. R. and Graven, Laura H. and {van Lanschot}, J. Jan B. and Valkema, Roelf},
  year = {2019},
  month = nov,
  journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
  volume = {60},
  number = {11},
  pages = {1553--1559},
  issn = {1535-5667},
  doi = {10.2967/jnumed.118.224196},
  abstract = {Our purpose was to prospectively investigate optimal evaluation of qualitative and quantitative 18F-FDG PET/CT in response evaluations 12-14 wk after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients. Methods: This was a side study of the prospective diagnostic pre-SANO trial. 18F-FDG PET/CT scans at baseline and at 12-14 wk after nCRT were qualitatively assessed for the presence of tumor. Maximum SUVs normalized for lean body mass (SULmax) were measured in all scans. The primary endpoint was the proportion of false-negative patients with tumor regression grade (TRG) 3-4 ({$>$}10\% vital residual tumor) in qualitative and quantitative analyses. Receiver-operating-characteristic curve analysis for TRG1 versus TRG3-4 using SULmax, SULmax tumor-to-esophagus ratio, and {$\Delta\%$}SULmax was performed to define optimal cutoffs. Secondary endpoints were sensitivity, specificity, negative predictive value, and positive predictive value for TRG1 versus TRG2-4. Results: In total, 129 of 219 patients were analyzed. Qualitative 18F-FDG PET/CT was unable to detect TRG3-4 in 15\% of patients. Sensitivity, specificity, negative predictive value, and positive predictive value in qualitative analysis for detecting TRG1 versus TRG2-4 was 80\%, 37\%, 42\%, and 77\%, respectively. In 18 of 190 patients (10\%) with follow-up scans after nCRT, 18F-FDG PET/CT identified new interval metastases. Quantitative parameters did not detect TRG3-4 tumor in 27\%-61\% of patients. The optimal cutoff for detecting TRG1 versus TRG2-4 was a post-nCRT SULmax of 2.93 (area under receiver-operating-characteristic curve, 0.70). Conclusion: Qualitative and quantitative analyses of 18F-FDG PET/CT are unable to accurately detect TRG3-4 and to discriminate substantial residual disease from benign inflammation-induced 18F-FDG uptake after nCRT. However, 18F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial 18F-FDG PET/CT scanning.},
  langid = {english},
  pmid = {30877177},
  keywords = {18F-FDG PET/CT,Aged,Chemoradiotherapy,esophageal cancer,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Male,Middle Aged,neoadjuvant chemoradiotherapy,Neoadjuvant Therapy,Neoplasm; Residual,Positron Emission Tomography Computed Tomography,response evaluation,Sensitivity and Specificity,tumor regression grade},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\HLXQM4IE\\Valkema et al. - 2019 - Accuracy of 18F-FDG PETCT in Predicting Residual .pdf}
}

@article{vanamsterdam1191,
  title = {The {{Association}} between {{Muscle Quantity}} and {{Overall Survival Depends}} on {{Muscle Radiodensity}}: {{A Cohort Study}} in {{Non-Small-Cell Lung Cancer Patients}}},
  shorttitle = {The {{Association}} between {{Muscle Quantity}} and {{Overall Survival Depends}} on {{Muscle Radiodensity}}},
  author = {{van Amsterdam}, Wouter A. C. and Harlianto, Netanja I. and Verhoeff, Joost J. C. and Moeskops, Pim and {de Jong}, Pim A. and Leiner, Tim},
  year = {2022},
  month = jul,
  journal = {Journal of Personalized Medicine},
  volume = {12},
  number = {7},
  pages = {1191},
  issn = {2075-4426},
  doi = {10.3390/jpm12071191},
  abstract = {The prognostic value of CT-derived muscle quantity for overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) is uncertain due to conflicting evidence. We hypothesize that increased muscle quantity is associated with better OS in patients with normal muscle radiodensity but not in patients with fatty degeneration of muscle tissue and low muscle radiodensity. We performed an observational cohort study in NSCLC patients treated with radiotherapy. A deep learning algorithm was used to measure muscle quantity as psoas muscle index (PMI) and psoas muscle radiodensity (PMD) on computed tomography. The potential interaction between PMI and PMD for OS was investigated using Cox proportional-hazards regression. Baseline adjustment variables were age, sex, histology, performance score and body mass index. We investigated non-linear effects of continuous variables and imputed missing values using multiple imputation. We included 2840 patients and observed 1975 deaths in 5903 patient years. The average age was 68.9 years (standard deviation 10.4, range 32 to 96) and 1692 patients (59.6\%) were male. PMI was more positively associated with OS for higher values of PMD (hazard ratio for interaction 0.915; 95\% confidence interval 0.861-0.972; p-value 0.004). We found evidence that high muscle quantity is associated with better OS when muscle radiodensity is higher, in a large cohort of NSCLC patients treated with radiotherapy. Future studies on the association between muscle status and OS should accommodate this interaction in their analysis for more accurate and more generalizable results.},
  langid = {english},
  pmcid = {PMC9322608},
  pmid = {35887688},
  keywords = {cachexia,carcinoma,Lung,Myosteatosis,non-small-cell lung,prognosis,survival analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\R7U6CY6G\\van Amsterdam et al_2022_The Association between Muscle Quantity and Overall Survival Depends on Muscle.pdf}
}

@article{vanblarigan218,
  type = {Journal {{Article}}},
  title = {Self-Monitoring and Reminder Text Messages to Increase Physical Activity in Colorectal Cancer Survivors ({{Smart Pace}}): A Pilot Randomized Controlled Trial},
  author = {Van Blarigan, E. L. and Chan, H. and Van Loon, K. and Kenfield, S. A. and Chan, J. M. and Mitchell, E. and Zhang, L. and Paciorek, A. and Joseph, G. and Laffan, A. and Atreya, C. E. and Fukuoka, Y. and Miaskowski, C. and Meyerhardt, J. A. and Venook, A. P.},
  year = {2019},
  journal = {BMC Cancer},
  volume = {19},
  number = {1},
  pages = {218},
  issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
  doi = {10.1186/s12885-019-5427-5}
}

@article{vanderschaaf490,
  title = {The Influence of Preoperative Weight Loss on the Postoperative Course after Esophageal Cancer Resection},
  author = {{van der Schaaf}, Maartje K. and Tilanus, Hugo W. and {van Lanschot}, Jan J. B. and Johar, Asif M. and Lagergren, Pernilla and Lagergren, Jesper and Wijnhoven, Bas P. L.},
  year = {2014},
  month = jan,
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  volume = {147},
  number = {1},
  pages = {490--495},
  issn = {1097-685X},
  doi = {10.1016/j.jtcvs.2013.07.072},
  abstract = {OBJECTIVE: Preoperative weight loss might increase the risk of postoperative morbidity and mortality after esophagectomy for cancer. We hypothesized that patients with esophageal cancer with {$>$}10\% weight loss during the 3 months before their diagnosis would be at an increased risk of postoperative complications, have a longer length of stay, and have worse overall survival. METHODS: In the present hospital-based cohort study, all patients who had undergone surgery for esophageal cancer in 1990 to 2010 at the Erasmus University Medical Center Rotterdam were included. Weight loss was defined as "no, or limited" ({$\leq$}10\%) or "severe" ({$>$}10\%). Logistic regression analysis was used to estimate the relative risk of complications, expressed as odds ratios (ORs) with 95\% confidence intervals (CIs). Hazard ratios were calculated to assess the length of hospital stay and survival. The risk estimates were adjusted for potential confounding factors. RESULTS: Of 922 included patients, 155 (17\%) had experienced severe weight loss. These patients had no increased risk of early surgical, early nonsurgical, or late surgical complications (OR, 0.83 and 95\% CI, 0.54-1.24; OR, 0.90 and 95\% CI, 0.63-1.30; OR, 1.14 and 95\% CI, 0.79-1.66, respectively) and had no increased length of stay (hazard ratio, 1.09; 95\% CI, 0.89-1.35). Preoperative weight loss was followed by increased 5-year mortality (hazard ratio, 1.34; 95\% CI, 1.02-1.74). CONCLUSIONS: A {$>$}10\% preoperative weight loss was followed by decreased 5-year survival after esophageal cancer surgery but no increased risk of postoperative complications.},
  langid = {english},
  pmid = {24060365},
  keywords = {7,Academic Medical Centers,Aged,BMI,body mass index,Chi-Square Distribution,CI,confidence interval,Esophageal Neoplasms,Esophagectomy,Female,hazard ratio,Hospital Mortality,HR,Humans,Kaplan-Meier Estimate,Length of Stay,Logistic Models,Male,Middle Aged,Multivariate Analysis,Netherlands,odds ratio,Odds Ratio,OR,Postoperative Complications,Risk Factors,Time Factors,Treatment Outcome,Weight Loss,Weight Loss;GE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\4UBCDHQZ\\van der Schaaf et al. - 2014 - The influence of preoperative weight loss on the p.pdf;C\:\\Users\\jsalo01\\Zotero\\storage\\MAS99SQ2\\van der Schaaf et al. - 2014 - The influence of preoperative weight loss on the p.pdf}
}

@article{vandervalk75,
  title = {Compliance and Tolerability of Short-Course Radiotherapy Followed by Preoperative Chemotherapy and Surgery for High-Risk Rectal Cancer - {{Results}} of the International Randomized {{RAPIDO-trial}}},
  author = {{van der Valk}, Maxime J. M. and Marijnen, Corrie A. M. and {van Etten}, Boudewijn and Dijkstra, Esm{\'e}e A. and Hilling, Denise E. and Kranenbarg, Elma Meershoek-Klein and Putter, Hein and Roodvoets, Annet G. H. and Bahadoer, Renu R. and Fokstuen, Tone and Ten Tije, Albert Jan and Capdevila, Jaume and Hendriks, Mathijs P. and Edhemovic, Ibrahim and Cervantes, Andr{\`e}s M. R. and {de Groot}, Derk Jan A. and Nilsson, Per J. and Glimelius, Bengt and {van de Velde}, Cornelis J. H. and Hospers, Geke A. P. and {Collaborative investigators}},
  year = {2020},
  month = jun,
  journal = {Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology},
  volume = {147},
  pages = {75--83},
  issn = {1879-0887},
  doi = {10.1016/j.radonc.2020.03.011},
  abstract = {BACKGROUND: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy is advised in several international guidelines, although the survival benefit remains unclear and compliance is poor. The current multidisciplinary approach has led to major improvements in local control, yet the occurrence of distant metastases has not decreased accordingly. The combination of short-course radiotherapy (SCRT) and chemotherapy in the waiting period before surgery might have several benefits, including higher compliance, downstaging and better effect of systemic therapy. METHODS: This is an investigator-initiated, international multicentre randomized phase III trial. High-risk rectal cancer patients were randomized to SCRT followed by chemotherapy (6 cycles CAPOX or alternatively 9 cycles FOLFOX4) and subsequent surgery, or long-course radiotherapy (25-28~\texttimes ~2-1.8~Gy) with concomitant capecitabine followed by surgery and optional postoperative chemotherapy (8 cycles CAPOX or 12 cycles FOLFOX4) according to local institutions' policy. The primary endpoint is time to disease-related treatment failure. Here, we report the compliance, toxicity and postoperative complications in both study groups. FINDINGS: Between June 2011 and June 2016, 920 patients were enrolled. Of these, 901 were evaluable (460 in the experimental arm and 441 in the standard arm). All patients in the experimental arm received 5~\texttimes ~5 Gy radiotherapy, and 84\% of all patients received at least 75\% of the prescribed chemotherapy. In the standard arm, the compliance for CRT was 93\% and 58\% for postoperative chemotherapy. Toxicity {$\geq$}grade 3 occurred in 48\% of patients in the experimental arm, compared to 25\% of patients in the standard arm during preoperative treatment and 35\% of patients during postoperative chemotherapy. No statistically significant differences in surgical procedures or postoperative complications were observed. INTERPRETATION: High compliance (84\%) of preoperative systemic treatment could be achieved with the experimental approach. Although considerable toxicity was observed during preoperative therapy, this did not lead to differences in surgical procedures or postoperative complications. Longer follow-up time is needed to assess the primary endpoint and related outcomes.},
  langid = {english},
  pmid = {32240909},
  keywords = {Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy,Chemotherapy,Chemotherapy; Adjuvant,Fluorouracil,Humans,Multimodal treatment,Neoadjuvant Therapy,Neoplasm Staging,Preoperative radiotherapy,Rectal cancer,Rectal Neoplasms,Rectal;TNT,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\3RD49MU7\\van der Valk et al. - 2020 - Compliance and tolerability of short-course radiot.pdf}
}

@article{vanderwerf366,
  title = {Skeletal Muscle Analyses: Agreement between Non-Contrast and Contrast {{CT}} Scan Measurements of Skeletal Muscle Area and Mean Muscle Attenuation},
  shorttitle = {Skeletal Muscle Analyses},
  author = {{van der Werf}, Anne and Dekker, Ingeborg M. and Meijerink, Martijn R. and Wierdsma, Nicolette J. and {de van der Schueren}, Marian A. E. and Langius, Jacqueline A. E.},
  year = {2018},
  month = may,
  journal = {Clinical Physiology and Functional Imaging},
  volume = {38},
  number = {3},
  pages = {366--372},
  issn = {1475-097X},
  doi = {10.1111/cpf.12422},
  abstract = {Low skeletal muscle area (SMA) and muscle radiation attenuation (MRA) have been associated with poor prognosis in various patient populations. Both non-contrast and contrast CT scans are used to determine SMA and MRA. The effect of the use of a contrast agent on SMA and MRA is unknown. Therefore, we investigated agreement between these two scan options. SMA and MRA of 41 healthy individuals were analysed on a paired non-contrast and contrast single CT scan, and agreement between paired scan results was assessed with use of Bland-Altman plots, intraclass correlation coefficients (ICCs), standard error of measurements (SEM) and smallest detectable differences at a 95\% confidence level (SDD95 ). Analyses were stratified by tube voltage. Difference in SMA between non-contrast and contrast scans made with a different tube voltage was 7{$\cdot$}0~{$\pm~$}7{$\cdot$}5~cm2 ; for scans made with the same tube voltage this was 2{$\cdot$}3~{$\pm~$}1{$\cdot$}7~cm2 . Agreement was excellent for both methods: ICC: 0{$\cdot$}952, SEM: 7{$\cdot$}2~cm2 , SDD95 : 19{$\cdot$}9~cm2 and ICC: 0{$\cdot$}997, SEM: 2{$\cdot$}0~cm2 , SDD95 : 5{$\cdot$}6~cm2 , respectively. MRA of scans made with a different tube voltage differed 1{$\cdot$}3~{$\pm~$}11{$\cdot$}3 HU, and agreement was poor (ICC: 0{$\cdot$}207, SEM: 7{$\cdot$}9 HU, SDD95 : 21{$\cdot$}8 HU). For scans made with the same tube voltage the difference was 6{$\cdot$}7~{$\pm~$}3{$\cdot$}2 HU, and agreement was good (ICC: 0{$\cdot$}682, SEM: 5{$\cdot$}3 HU, SDD95 : 14{$\cdot$}6 HU). In conclusion, SMA and MRA can be slightly influenced by the use of contrast agent. To minimise measurement error, image acquisition parameters of the scans should be similar.},
  langid = {english},
  pmid = {28419687},
  keywords = {Administration; Intravenous,computed tomography,Contrast,contrast agent,Contrast Media,Healthy Volunteers,Humans,Method,Multidetector Computed Tomography,muscle density,muscle mass,Muscle; Skeletal,Observer Variation,Predictive Value of Tests,Reproducibility of Results,single slice},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BBT4S2W2\\van der Werf et al_2018_Skeletal muscle analyses.pdf}
}

@article{vanderwilk462,
  title = {Towards an {{Organ-Sparing Approach}} for {{Locally Advanced Esophageal Cancer}}},
  author = {{van der Wilk}, Berend Jan and Eyck, Ben M. and Spaander, Manon C. W. and Valkema, Roelf and Lagarde, Sjoerd M. and Wijnhoven, Bas P. L. and {van Lanschot}, J. Jan B.},
  year = {2019},
  journal = {Digestive Surgery},
  volume = {36},
  number = {6},
  pages = {462--469},
  issn = {1421-9883},
  doi = {10.1159/000493435},
  abstract = {BACKGROUND: Active surveillance after neoadjuvant therapies has emerged among several malignancies. During active surveillance, frequent assessments are performed to detect residual disease and surgery is only reserved for those patients in whom residual disease is proven or highly suspected without distant metastases. After neoadjuvant chemoradiotherapy (nCRT), nearly one-third of esophageal cancer patients achieve a pathologically complete response (pCR). Both patients that achieve a pCR and patients that harbor subclinical disseminated disease after nCRT could benefit from an active surveillance strategy. SUMMARY: Esophagectomy is still the cornerstone of treatment in patients with esophageal cancer. Non-surgical treatment via definitive chemoradiotherapy (dCRT) is currently reserved only for patients not eligible for esophagectomy. Since salvage esophagectomy after dCRT (50-60 Gy) results in increased complications, morbidity and mortality compared to surgery after nCRT (41.4 Gy), the latter seems preferable in the setting of active surveillance. Clinical response evaluations can detect substantial (i.e., tumor regression grade [TRG] 3-4) tumors after nCRT with a sensitivity of 90\%, minimizing the risk of development of non-resectable recurrences. Current scarce and retrospective literature suggests that active surveillance following nCRT might not jeopardize overall survival and postponed surgery could be performed safely. Key Message: Before an active surveillance approach could be considered standard treatment, results of phase III randomized trials should be awaited.},
  langid = {english},
  pmcid = {PMC6878756},
  pmid = {30227434},
  keywords = {Active surveillance,Chemoradiotherapy,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Humans,Neoadjuvant chemoradiotherapy,Neoadjuvant Therapy,Organ Sparing Treatments,Organ-sparing treatment,Watchful Waiting},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\VNUPTADR\\van der Wilk et al. - 2019 - Towards an Organ-Sparing Approach for Locally Adva.pdf}
}

@article{vangestel371,
  title = {Influence of Comorbidity and Age on 1-, 2-, and 3-Month Postoperative Mortality Rates in Gastrointestinal Cancer Patients},
  author = {{van Gestel}, Yvette R. B. M. and Lemmens, Valery E. P. P. and {de Hingh}, Ignace H. J. T. and Steevens, Jessie and Rutten, Harm J. T. and Nieuwenhuijzen, Grard A. P. and {van Dam}, Ronald M. and Siersema, Peter D.},
  year = {2013},
  month = feb,
  journal = {Annals of Surgical Oncology},
  volume = {20},
  number = {2},
  pages = {371--380},
  issn = {1534-4681},
  doi = {10.1245/s10434-012-2663-1},
  abstract = {BACKGROUND: Studies on the impact of comorbidity and age on postoperative outcome after gastrointestinal tumor resection are scarce. In this study we investigated the impact of comorbidity and age on 30-, 60-, and 90-day mortality after resection of esophageal, gastric, periampullary, colon, and rectal cancer. METHODS: The study included 8,583 patients recorded in the population-based Netherlands Cancer Registry, regions Eindhoven (Eindhoven Cancer Registry) and Mid and South Limburg, who underwent resection for cancer stage I-III. Patients were diagnosed between 2005 and 2010. Age was categorized as {$<$}65, 65-74, and {$\geq$}75 years. RESULTS: Comorbidity was present in more than two-thirds (n = 5,910) of patients. The 30-day mortality rates ranged from 0.5 \% for rectal cancer patients {$<$}65 years to 12.8 \% for gastric cancer patients {$\geq$}75 years. Patients with comorbidity who underwent esophageal tumor resection had the highest mortality rates, ranging from 8.4 \% for 30-day to 12.0 \% for 90-day mortality, while rectal cancer patients had the lowest rates, that is, 4.3-6.4 \%, respectively. In multivariable analyses, cardiac disease (odds ratio [OR] = 1.74, 95 \% confidence interval [95 \% CI] = 1.32-2.30), vascular disease (OR = 1.41, 95 \% CI = 1.02-1.95) and previous malignancies (OR = 1.38, 95 \% CI = 1.02-1.86) in colon cancer, and cardiac disease (OR = 1.81, 95 \% CI = 1.10-2.98) and vascular disease (OR = 1.95, 95 \% CI = 1.11-3.42) in rectal cancer were associated with the highest 30-day mortality. CONCLUSIONS: Postoperative mortality extends beyond 30 days. Comorbidity and older age are associated with early postoperative mortality after gastrointestinal cancer resection. Underlying comorbidity should be identified preoperatively with attention to patients' specific needs to optimally attenuate risk prior to surgery. A less aggressive treatment approach may well be considered in these groups.},
  langid = {english},
  pmid = {22987098},
  keywords = {Age Factors,Aged,Chemotherapy; Adjuvant,Combined Modality Therapy,Comorbidity,Diabetes Mellitus,Female,Follow-Up Studies,Gastrointestinal Neoplasms,Heart Diseases,Humans,Lung Diseases,Male,Neoadjuvant Therapy,Neoplasm Staging,Netherlands,Postoperative Period,Prognosis,Radiotherapy; Adjuvant,Risk Factors,Survival Rate,United States,Vascular Diseases}
}

@article{vangijn575,
  title = {Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-up of the Multicentre, Randomised Controlled {{TME}} Trial},
  shorttitle = {Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer},
  author = {{van Gijn}, Willem and Marijnen, Corrie A. M. and Nagtegaal, Iris D. and Kranenbarg, Elma Meershoek-Klein and Putter, Hein and Wiggers, Theo and Rutten, Harm J. T. and P{\aa}hlman, Lars and Glimelius, Bengt and {van de Velde}, Cornelis J. H. and {Dutch Colorectal Cancer Group}},
  year = {2011},
  month = jun,
  journal = {The Lancet. Oncology},
  volume = {12},
  number = {6},
  pages = {575--582},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(11)70097-3},
  abstract = {BACKGROUND: The TME trial investigated the value of preoperative short-term radiotherapy in combination with total mesorectal excision (TME). Long-term results are reported after a median follow-up of 12 years. METHODS: Between Jan 12, 1996, and Dec 31, 1999, 1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 \texttimes{} 5 Gy radiotherapy or TME alone (ratio 1:1). Randomisation was based on permuted blocks of six with stratification according to centre and expected type of surgery. The primary endpoint was local recurrence, analysed for all eligible patients who underwent a macroscopically complete local resection. FINDINGS: 10-year cumulative incidence of local recurrence was 5\% in the group assigned to radiotherapy and surgery and 11\% in the surgery-alone group (p{$<$}0{$\cdot$}0001). The effect of radiotherapy became stronger as the distance from the anal verge increased. However, when patients with a positive circumferential resection margin were excluded, the relation between distance from the anal verge and the effect of radiotherapy disappeared. Patients assigned to radiotherapy had a lower overall recurrence and when operated with a negative circumferential resection margin, cancer-specific survival was higher. Overall survival did not differ between groups. For patients with TNM stage III cancer with a negative circumferential resection margin, 10-year survival was 50\% in the preoperative radiotherapy group versus 40\% in the surgery-alone group (p=0{$\cdot$}032). INTERPRETATION: For all eligible patients, preoperative short-term radiotherapy reduced 10-year local recurrence by more than 50\% relative to surgery alone without an overall survival benefit. For patients with a negative resection margin, the effect of radiotherapy was irrespective of the distance from the anal verge and led to an improved cancer-specific survival, which was nullified by an increase in other causes of death, resulting in an equal overall survival. Nevertheless, preoperative short-term radiotherapy significantly improved 10-year survival in patients with a negative circumferential margin and TNM stage III. Future staging techniques should offer possibilities to select patient groups for which the balance between benefits and side-effects will result in sufficiently large gains. FUNDING: The Dutch Cancer Society, the Dutch National Health Council, and the Swedish Cancer Society.},
  langid = {english},
  pmid = {21596621},
  keywords = {Adult,Aged,Aged; 80 and over,Combined Modality Therapy,Female,Follow-Up Studies,Humans,Male,Middle Aged,Neoplasm Recurrence; Local,Neoplasm Staging,Rectal,Rectal Neoplasms,Rectum,TME}
}

@article{vanhagen2074,
  title = {Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer},
  author = {{van Hagen}, P. and Hulshof, M. C. C. M. and {van Lanschot}, J. J. B. and Steyerberg, E. W. and {van Berge Henegouwen}, M. I. and Wijnhoven, B. P. L. and Richel, D. J. and Nieuwenhuijzen, G. a. P. and Hospers, G. a. P. and Bonenkamp, J. J. and Cuesta, M. A. and Blaisse, R. J. B. and Busch, O. R. C. and {ten Kate}, F. J. W. and Creemers, G.-J. and Punt, C. J. A. and Plukker, J. T. M. and Verheul, H. M. W. and Spillenaar Bilgen, E. J. and {van Dekken}, H. and {van der Sangen}, M. J. C. and Rozema, T. and Biermann, K. and Beukema, J. C. and Piet, A. H. M. and {van Rij}, C. M. and Reinders, J. G. and Tilanus, H. W. and {van der Gaast}, A. and {CROSS Group}},
  year = {2012},
  month = may,
  journal = {The New England Journal of Medicine},
  volume = {366},
  number = {22},
  pages = {2074--2084},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1112088},
  abstract = {BACKGROUND: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. METHODS: We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery. RESULTS: From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75\%) had adenocarcinoma, 84 (23\%) had squamous-cell carcinoma, and 7 (2\%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6\%) and neutropenia (2\%); the most common major nonhematologic toxic effects were anorexia (5\%) and fatigue (3\%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92\% of patients in the chemoradiotherapy-surgery group versus 69\% in the surgery group (P{$<$}0.001). A pathological complete response was achieved in 47 of 161 patients (29\%) who underwent resection after chemoradiotherapy. Postoperative complications were similar in the two treatment groups, and in-hospital mortality was 4\% in both. Median overall survival was 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group. Overall survival was significantly better in the chemoradiotherapy-surgery group (hazard ratio, 0.657; 95\% confidence interval, 0.495 to 0.871; P=0.003). CONCLUSIONS: Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF Kankerbestrijding]; Netherlands Trial Register number, NTR487.).},
  langid = {english},
  pmid = {22646630},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Carboplatin,Chemoradiotherapy; Adjuvant,Esophageal Neoplasms,Esophagogastric Junction,Female,Follow-Up Studies,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Neoadjuvant Therapy,Paclitaxel,Preoperative Care},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\PE99HMXM\\van Hagen et al_2012_Preoperative chemoradiotherapy for esophageal or junctional cancer.pdf}
}

@article{vanheijl23,
  type = {Journal {{Article}}},
  title = {Preoperative and Early Postoperative Quality of Life Predict Survival in Potentially Curable Patients with Esophageal Cancer},
  author = {{van Heijl}, M. and Sprangers, M. A. and {de Boer}, A. G. and Lagarde, S. M. and Reitsma, H. B. and Busch, O. R. and Tilanus, H. W. and {van Lanschot}, J. J. and {van Berge Henegouwen}, M. I.},
  year = {2010},
  journal = {Ann Surg Oncol},
  volume = {17},
  number = {1},
  pages = {23--30},
  issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
  doi = {10.1245/s10434-009-0731-y}
}

@article{vanremoortel103,
  title = {Effectiveness of {{Iron Supplementation With}} or {{Without Erythropoiesis-Stimulating Agents}} on {{Red Blood Cell Utilization}} in {{Patients With Preoperative Anaemia Undergoing Elective Surgery}}: {{A Systematic Review}} and {{Meta-Analysis}}},
  shorttitle = {Effectiveness of {{Iron Supplementation With}} or {{Without Erythropoiesis-Stimulating Agents}} on {{Red Blood Cell Utilization}} in {{Patients With Preoperative Anaemia Undergoing Elective Surgery}}},
  author = {Van Remoortel, Hans and Laermans, Jorien and Avau, Bert and Bekkering, Geertruida and Georgsen, J{\o}rgen and Manzini, Paola Maria and Meybohm, Patrick and Ozier, Yves and De Buck, Emmy and Compernolle, Veerle and Vandekerckhove, Philippe},
  year = {2021},
  month = apr,
  journal = {Transfusion Medicine Reviews},
  volume = {35},
  number = {2},
  pages = {103--124},
  issn = {1532-9496},
  doi = {10.1016/j.tmrv.2021.03.004},
  abstract = {Patient Blood Management (PBM) is an evidence-based, multidisciplinary, patient-centred approach to optimizing the care of patients who might need a blood transfusion. This systematic review aimed to collect the best available evidence on the effectiveness of preoperative iron supplementation with or without erythropoiesis-stimulating agents (ESAs) on red blood cell (RBC) utilization in all-cause anaemic patients scheduled for elective surgery. Five databases and two trial registries were screened. Primary outcomes were the number of patients and the number of RBC units transfused. Effect estimates were synthesized by conducting meta-analyses. GRADE (Grades of Recommendation, Assessment, Development and Evaluation) was used to assess the certainty of evidence. We identified 29 randomized controlled trials (RCTs) and 2 non-RCTs comparing the effectiveness of preoperative iron monotherapy, or iron~+~ESAs, to control (no treatment, usual care, placebo). We found that: (1) IV and/or oral iron monotherapy may not result in a reduced number of units transfused and IV iron may not reduce the number of patients transfused (low-certainty evidence); (2) uncertainty exists whether the administration route of iron therapy (IV vs oral) differentially affects RBC utilization (very low-certainty evidence); (3) IV ferric carboxymaltose monotherapy may not result in a different number of patients transfused compared to IV iron sucrose monotherapy (low-certainty evidence); (4) oral iron~+~ESAs probably results in a reduced number of patients transfused and number of units transfused (moderate-certainty evidence); (5) IV iron~+~ESAs may result in a reduced number of patients transfused (low-certainty evidence); (6) oral and/or IV iron~+~ESAs probably results in a reduced number of RBC units transfused in transfused patients (moderate-certainty evidence); (7) uncertainty exists about the effect of oral and/or IV iron~+~ESAs on the number of patients requiring transfusion of multiple units (very low-certainty evidence). Effect estimates of different haematological parameters and length of stay were synthesized as secondary outcomes. In conclusion, in patients with anaemia of any cause scheduled for elective surgery, the preoperative administration of iron monotherapy may not result in a reduced number of patients or units transfused (low-certainty evidence). Iron supplementation in addition to ESAs probably results in a reduced RBC utilization (moderate-certainty evidence).},
  langid = {english},
  pmid = {33965294},
  keywords = {Anemia,Blood Transfusion,Dietary Supplements,Elective Surgical Procedures,Epo,Erythrocytes,Erythropoiesis,Hematinics,Hemoglobins,Humans,Iron,Preoperative Care,Surgery,Systematic Review [Publication Type]},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\H8NYYVWW\\Van Remoortel et al_2021_Effectiveness of Iron Supplementation With or Without.pdf}
}

@article{vanrossum691,
  title = {The {{Incremental Value}} of {{Subjective}} and {{Quantitative Assessment}} of {{18F-FDG PET}} for the {{Prediction}} of {{Pathologic Complete Response}} to {{Preoperative Chemoradiotherapy}} in {{Esophageal Cancer}}},
  author = {{van Rossum}, Peter S. N. and Fried, David V. and Zhang, Lifei and Hofstetter, Wayne L. and {van Vulpen}, Marco and Meijer, Gert J. and Court, Laurence E. and Lin, Steven H.},
  year = {2016},
  month = may,
  journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
  volume = {57},
  number = {5},
  pages = {691--700},
  issn = {1535-5667},
  doi = {10.2967/jnumed.115.163766},
  abstract = {A reliable prediction of a pathologic complete response (pathCR) to chemoradiotherapy before surgery for esophageal cancer would enable investigators to study the feasibility and outcome of an organ-preserving strategy after chemoradiotherapy. So far no clinical parameters or diagnostic studies are able to accurately predict which patients will achieve a pathCR. The aim of this study was to determine whether subjective and quantitative assessment of baseline and postchemoradiation (18)F-FDG PET can improve the accuracy of predicting pathCR to preoperative chemoradiotherapy in esophageal cancer beyond clinical predictors. METHODS: This retrospective study was approved by the institutional review board, and the need for written informed consent was waived. Clinical parameters along with subjective and quantitative parameters from baseline and postchemoradiation (18)F-FDG PET were derived from 217 esophageal adenocarcinoma patients who underwent chemoradiotherapy followed by surgery. The associations between these parameters and pathCR were studied in univariable and multivariable logistic regression analysis. Four prediction models were constructed and internally validated using bootstrapping to study the incremental predictive values of subjective assessment of (18)F-FDG PET, conventional quantitative metabolic features, and comprehensive (18)F-FDG PET texture/geometry features, respectively. The clinical benefit of (18)F-FDG PET was determined using decision-curve analysis. RESULTS: A pathCR was found in 59 (27\%) patients. A clinical prediction model (corrected c-index, 0.67) was improved by adding (18)F-FDG PET-based subjective assessment of response (corrected c-index, 0.72). This latter model was slightly improved by the addition of 1 conventional quantitative metabolic feature only (i.e., postchemoradiation total lesion glycolysis; corrected c-index, 0.73), and even more by subsequently adding 4 comprehensive (18)F-FDG PET texture/geometry features (corrected c-index, 0.77). However, at a decision threshold of 0.9 or higher, representing a clinically relevant predictive value for pathCR at which one may be willing to omit surgery, there was no clear incremental value. CONCLUSION: Subjective and quantitative assessment of (18)F-FDG PET provides statistical incremental value for predicting pathCR after preoperative chemoradiotherapy in esophageal cancer. However, the discriminatory improvement beyond clinical predictors does not translate into a clinically relevant benefit that could change decision making.},
  langid = {english},
  pmid = {26795288},
  keywords = {18F-FDG PET,Adenocarcinoma,Chemoradiotherapy,esophageal cancer,Esophageal Neoplasms,Female,Fluorodeoxyglucose F18,Humans,Male,Middle Aged,Multivariate Analysis,positron emission tomography,Positron-Emission Tomography,Preoperative Period,Retrospective Studies,texture features,treatment response},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\YYDZ6ELB\\van Rossum et al. - 2016 - The Incremental Value of Subjective and Quantitati.pdf}
}

@article{vanveer600,
  type = {Journal {{Article}}},
  title = {Validation of a New Approach for Mortality Risk Assessment in Oesophagectomy for Cancer Based on Age- and Gender-Corrected Body Mass Index},
  author = {Van Veer, H. and Moons, J. and Darling, G. and Lerut, T. and Coosemans, W. and Waddell, T. and De Leyn, P. and Nafteux, P.},
  year = {2015},
  journal = {Eur J Cardiothorac Surg},
  volume = {48},
  number = {4},
  pages = {600--7},
  issn = {1873-734X (Electronic) 1010-7940 (Linking)},
  doi = {10.1093/ejcts/ezu503}
}

@article{vanvliet547,
  title = {Staging Investigations for Oesophageal Cancer: A Meta-Analysis},
  shorttitle = {Staging Investigations for Oesophageal Cancer},
  author = {{van Vliet}, E. P. M. and {Heijenbrok-Kal}, M. H. and Hunink, M. G. M. and Kuipers, E. J. and Siersema, P. D.},
  year = {2008},
  month = feb,
  journal = {British Journal of Cancer},
  volume = {98},
  number = {3},
  pages = {547--557},
  issn = {0007-0920},
  doi = {10.1038/sj.bjc.6604200},
  abstract = {The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT, and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT, and FDG-PET for regional lymph node metastases were 0.80 (95\% confidence interval 0.75-0.84), 0.50 (0.41-0.60), and 0.57 (0.43-0.70), respectively, and specificities were 0.70 (0.65-0.75), 0.83 (0.77-0.89), and 0.85 (0.76-0.95), respectively. Diagnostic performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and specificity were 0.85 (0.72-0.99) and 0.96 (0.92-1.00), respectively. For abdominal lymph node metastases by CT, these values were 0.42 (0.29-0.54) and 0.93 (0.86-1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62-0.79) and 0.93 (0.89-0.97) for FDG-PET and 0.52 (0.33-0.71) and 0.91 (0.86-0.96) for CT, respectively. Diagnostic performance of FDG-PET for distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients. For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining the location(s).},
  langid = {english},
  pmcid = {PMC2243147},
  pmid = {18212745},
  keywords = {Endosonography,Esophageal Neoplasms,Fluorodeoxyglucose F18,Humans,Lymphatic Metastasis,Neoplasm Metastasis,Neoplasm Staging,Positron-Emission Tomography,Sensitivity and Specificity,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\S2GH3SWG\\van Vliet et al. - 2008 - Staging investigations for oesophageal cancer a m.pdf}
}

@article{vanvugt1707,
  title = {Contrast-Enhancement Influences Skeletal Muscle Density, but Not Skeletal Muscle Mass, Measurements on Computed Tomography},
  author = {{van Vugt}, Jeroen L. A. and {Coebergh van den Braak}, Robert R. J. and Schippers, Henk J. W. and Veen, Kevin M. and Levolger, Stef and {de Bruin}, Ron W. F. and Koek, Marcel and Niessen, Wiro J. and IJzermans, Jan N. M. and Willemsen, Fran{\c c}ois E. J. A.},
  year = {2018},
  month = oct,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {37},
  number = {5},
  pages = {1707--1714},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2017.07.007},
  abstract = {BACKGROUND \& AIMS: Low skeletal muscle mass and density have recently been discovered as prognostic and predictive parameters to guide interventions in various populations, including cancer patients. The gold standard for body composition analysis in cancer patients is computed tomography (CT). To date, the effect of contrast-enhancement on muscle composition measurements has not been established. The aim of this study was to determine the effect of contrast-enhancement on skeletal muscle mass and density measurements on four-phase CT studies. DESIGN: In this observational study, two observers measured cross-sectional skeletal muscle area corrected for patients' height (skeletal muscle index [SMI]) and density (SMD) at the level of the third lumbar vertebra on 50 randomly selected CT examinations with unenhanced, arterial, and portal-venous phases. The levels of agreement between enhancement phases for SMI and SMD were calculated using intra-class correlation coefficients (ICCs). RESULTS: Mean SMI was 42.5 ({$\pm$}9.9)~cm2/m2 on the unenhanced phase, compared with 42.8 ({$\pm$}9.9) and 43.6 ({$\pm$}9.9)~cm2/m2 for the arterial and portal-venous phase, respectively (both p~{$<~$}0.01). Mean SMD was lower for the unenhanced phase (30.9~{$\pm~$}8.0~Hounsfield units [HU]) compared with the arterial (38.0~{$\pm~$}9.9~HU) and portal-venous (38.7~{$\pm~$}9.2~HU) phase (both p~{$<~$}0.001). No significant difference was found between SMD in the portal-venous and arterial phase (p~=~0.161). The ICCs were excellent ({$\geq$}0.992) for all SMIs and for SMD between the contrast-enhanced phases (0.949). The ICCs for the unenhanced phase compared with the arterial (0.676) and portal-venous (0.665) phase were considered fair to good. CONCLUSIONS: Statistically significant differences in SMI were observed between different enhancement phases. However, further work is needed to assess the clinical relevance of these small differences. Contrast-enhancement strongly influenced SMD values. Studies using this measure should therefore use the portal-venous phase of contrast-enhanced CT examinations.},
  langid = {english},
  pmid = {28743427},
  keywords = {Arteries,Body Height,Body Mass Index,Body Weight,Computed tomography,Contrast,Contrast Media,Contrast-enhancement,Female,Humans,Male,Methods,Muscle; Skeletal,Portal Vein,Sarcopenia,Skeletal muscle density,Skeletal muscle mass,Tomography; X-Ray Computed}
}

@article{varadhan488,
  title = {A Meta-Analysis of Randomised Controlled Trials of Intravenous Fluid Therapy in Major Elective Open Abdominal Surgery: Getting the Balance Right},
  shorttitle = {A Meta-Analysis of Randomised Controlled Trials of Intravenous Fluid Therapy in Major Elective Open Abdominal Surgery},
  author = {Varadhan, Krishna K. and Lobo, Dileep N.},
  year = {2010},
  month = nov,
  journal = {The Proceedings of the Nutrition Society},
  volume = {69},
  number = {4},
  pages = {488--498},
  issn = {1475-2719},
  doi = {10.1017/S0029665110001734},
  abstract = {The terminology used for describing intervention groups in randomised controlled trials (RCT) on the effect of intravenous fluid on outcome in abdominal surgery has been imprecise, and the lack of standardised definitions of the terms 'standard', 'restricted' and 'liberal' has led to some confusion and difficulty in interpreting the literature. The aims of this paper were to clarify these definitions and to use them to perform a meta-analysis of nine RCT on primarily crystalloid-based peri-operative intravenous fluid therapy in 801 patients undergoing elective open abdominal surgery. Patients who received more or less fluids than those who received a 'balanced' amount were considered to be in a state of 'fluid imbalance'. When 'restricted' fluid regimens were compared with 'standard or liberal' fluid regimens, there was no difference in post-operative complication rates (risk ratio 0.83 (95\% CI 0.49, 1.39, P = 0.47) [corrected] or length of hospital stay (weighted mean difference (WMD) - 1.77 (95\% CI - 4.36, 0.81) d, P = 0.18). However, when the fluid regimens were reclassified and patients were grouped into those who were managed in a state of fluid 'balance' or 'imbalance', the former group had significantly fewer complications (risk ratio 0{$\cdot$}59 (95\% CI 0{$\cdot$}44, 0{$\cdot$}81), P=0{$\cdot$}0008) and a shorter length of stay (WMD -3{$\cdot$}44 (95\% CI -6{$\cdot$}33, -0{$\cdot$}54) d, P=0{$\cdot$}02) than the latter. Using imprecise terminology, there was no apparent difference between the effects of fluid-restricted and standard or liberal fluid regimens on outcome in patients undergoing elective open abdominal surgery. However, patients managed in a state of fluid balance fared better than those managed in a state of fluid imbalance.},
  langid = {english},
  pmid = {20515521},
  keywords = {Abdomen,Digestive System Surgical Procedures,Elective Surgical Procedures,Fluid Therapy,Humans,Infusions; Intravenous,Length of Stay,Postoperative Complications,Randomized Controlled Trials as Topic,Terminology as Topic,Water-Electrolyte Balance},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SDJDUBA5\\Varadhan_Lobo_2010_A meta-analysis of randomised controlled trials of intravenous fluid therapy in.pdf}
}

@article{vaughan95,
  title = {Cancer Cachexia: Impact, Mechanisms and Emerging Treatments},
  shorttitle = {Cancer Cachexia},
  author = {Vaughan, Vanessa C. and Martin, Peter and Lewandowski, Paul A.},
  year = {2013},
  month = jun,
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  volume = {4},
  number = {2},
  pages = {95--109},
  issn = {2190-5991},
  doi = {10.1007/s13539-012-0087-1},
  abstract = {Many forms of cancer present with a complex metabolic profile characterised by loss of lean body mass known as cancer cachexia. The physical impact of cachexia contributes to decreased patient quality of life, treatment success and survival due to gross alterations in protein metabolism, increased oxidative stress and systemic inflammation. The psychological impact also contributes to decreased quality of life for both patients and their families. Combination therapies that target multiple pathways, such as eicosapentaenoic acid administered in combination with exercise, appetite stimulants, antioxidants or anti-inflammatories, have potential in the treatment of this complex syndrome and require further development.},
  langid = {english},
  pmcid = {PMC3684701},
  pmid = {23097000},
  keywords = {GE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\JIB7JJG2\\Vaughan et al. - 2013 - Cancer cachexia impact, mechanisms and emerging t.pdf}
}

@article{vellayappanCD010511,
  title = {Chemoradiotherapy versus Chemoradiotherapy plus Surgery for Esophageal Cancer},
  author = {Vellayappan, Balamurugan A. and Soon, Yu Yang and Ku, Geoffrey Y. and Leong, Cheng Nang and Lu, Jiade J. and Tey, Jeremy Cs},
  year = {2017},
  month = aug,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {8},
  pages = {CD010511},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD010511.pub2},
  abstract = {BACKGROUND: Please see Appendix 4 for a glossary of terms.The outcome of patients with esophageal cancer is generally poor. Although multimodal therapy is standard, there is conflicting evidence regarding the addition of esophagectomy to chemoradiotherapy. OBJECTIVES: To compare the effectiveness and safety of chemoradiotherapy plus surgery with that of chemoradiotherapy alone in people with nonmetastatic esophageal carcinoma. SEARCH METHODS: We performed a computerized search for relevant studies, up to Feburary 2017, on the CENTRAL, MEDLINE, and Embase databases using MeSH headings and keywords. We searched five online databases of clinical trials, handsearched conference proceedings, and screened reference lists of retrieved papers. SELECTION CRITERIA: We included randomized controlled trials (RCTs) comparing chemoradiotherapy plus esophagectomy with chemoradiotherapy alone for localized esophageal carcinoma. We excluded RCTs comparing chemotherapy or radiotherapy alone with esophagectomy. DATA COLLECTION AND ANALYSIS: Two authors independently selected studies, extracted data, and assessed risk of bias and the quality of the evidence, using standardized Cochrane methodological procedures. The primary outcome was overall survival (OS), estimated with Hazard Ratio (HR). Secondary outcomes, estimated with risk ratio (RR), were local and distant progression-free survival (PFS), quality of life (QoL), treatment-related mortality and morbidity, and use of salvage procedures for dysphagia. Data were analyzed using a random effects model in Review Manager 5.3 software. MAIN RESULTS: From 2667 references, we identified two randomized studies, in six reports, that included 431 participants. All participants were clinically staged to have at least T3 and/or node positive thoracic esophageal carcinoma, 93\% of which was squamous cell histology. The risk of methodological bias of the included studies was low to moderate.High-quality evidence found the addition of esophagectomy had little or no difference on overall survival (HR 0.99, 95\% CI 0.79 to 1.24; P = 0.92; I{$^2$} = 0\%; two trials). Neither study reported PFS, therefore, freedom from loco-regional relapse was used as a proxy. Moderate-quality evidence suggested that the addition of esophagectomy probably improved freedom from locoregional relapse (HR 0.55, 95\% CI 0.39 to 0.76; P = 0.0004; I{$^2$} = 0\%; two trials), but low-quality evidence suggested it may increase the risk of treatment-related mortality (RR 5.11, 95\% CI 1.74 to 15.02; P = 0.003; I{$^2$} = 2\%; two trials).The other pre-specified outcomes (quality of life, treatment-related toxicity, and use of salvage procedures for dysphagia) were reported by only one study, which found very low-quality evidence that use of esophagectomy was associated with reduced short-term QoL (MD 0.93, 95\% CI 0.24 to 1.62), and low-quality evidence that it reduced use of salvage procedures for dysphagia (HR 0.52, 95\% CI 0.36 to 0.75). Neither study compared treatment-related morbidity between treatment groups. AUTHORS' CONCLUSIONS: Based on the available evidence, the addition of esophagectomy to chemoradiotherapy in locally advanced esophageal squamous cell carcinoma, provides little or no difference on overall survival, and may be associated with higher treatment-related mortality. The addition of esophagectomy probably delays locoregional relapse, however, this end point was not well defined in the included studies. It is undetermined whether these results can be applied to the treatment of adenocarcinomas, tumors involving the distal esophagus and gastro-esophageal junction, and to people with poor response to chemoradiation.},
  langid = {english},
  pmcid = {PMC6483706},
  pmid = {28829911},
  keywords = {Carcinoma,Carcinoma; Squamous Cell,Chemoradiotherapy,Cisplatin,Combined Modality Therapy,Deglutition Disorders,Esophageal Neoplasms,Esophagectomy,Fluorouracil,Humans,Neoplasm Recurrence; Local,Quality of Life,Randomized Controlled Trials as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\K98URFEM\\Vellayappan et al_2017_Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.pdf}
}

@article{verduzco-aguirre68,
  title = {Predicting {{Life Expectancy}} for {{Older Adults}} with {{Cancer}} in {{Clinical Practice}}: {{Implications}} for {{Shared Decision-making}}},
  shorttitle = {Predicting {{Life Expectancy}} for {{Older Adults}} with {{Cancer}} in {{Clinical Practice}}},
  author = {{Verduzco-Aguirre}, Haydee Cristina and {Gomez-Moreno}, Carolina and {Chavarri-Guerra}, Yanin and {Soto-Perez-de-Celis}, Enrique},
  year = {2019},
  month = jun,
  journal = {Current Oncology Reports},
  volume = {21},
  number = {8},
  pages = {68},
  issn = {1534-6269},
  doi = {10.1007/s11912-019-0821-3},
  abstract = {PURPOSE OF REVIEW: The calculation of noncancer-specific life expectancy can guide shared decision-making and avoid over- and undertreatment in older adults with cancer. Several factors determine life expectancy, including socio-demographic background, comorbidities, physical performance, and geriatric assessment variables. We present an overview of existing tools to estimate life expectancy, as well as practical examples of how to take into account the patient's noncancer-specific life expectancy when discussing screening decisions, initiation of treatment, and end-of-life care. RECENT FINDINGS: Life expectancy prognostication has been recently recommended by international societies as part of the initial assessment of all older adults with cancer. Additionally, online resources have been created in order to make life expectancy calculation tools accessible for clinicians. Understanding available methods to estimate life expectancy, as well as how to utilize them, is a fundamental part of geriatric oncology that should be integrated into everyday clinical practice.},
  langid = {english},
  pmid = {31240500},
  keywords = {Adjuvant chemotherapy,Aged,Benefit risk assessment,Cancer screening,Decision Making; Shared,Decision-making,Early Detection of Cancer,End of life care,Geriatric assessment,Geriatric Assessment,Geriatrics,Humans,Life expectancy,Life Expectancy,Medical Oncology,Mortality,Neoplasms,Older adults,Prognosis,Survival analysis}
}

@article{vincent714,
  title = {Transfusion Thresholds: The Dangers of Guidelines Based on Randomized Controlled Trials},
  shorttitle = {Transfusion Thresholds},
  author = {Vincent, Jean-Louis},
  year = {2020},
  month = apr,
  journal = {Intensive Care Medicine},
  volume = {46},
  number = {4},
  pages = {714--716},
  issn = {1432-1238},
  doi = {10.1007/s00134-019-05889-3},
  langid = {english},
  pmid = {31912204},
  keywords = {Blood Transfusion,Erythrocyte Transfusion,Humans,Randomized Controlled Trials as Topic},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TKK2S9RS\\Vincent_2020_Transfusion thresholds.pdf}
}

@article{visbal1803,
  title = {Ivor {{Lewis}} Esophagogastrectomy for Esophageal Cancer},
  author = {Visbal, A. L. and Allen, M. S. and Miller, D. L. and Deschamps, C. and Trastek, V. F. and Pairolero, P. C.},
  year = {2001},
  month = jun,
  journal = {The Annals of Thoracic Surgery},
  volume = {71},
  number = {6},
  pages = {1803--1808},
  issn = {0003-4975},
  doi = {10.1016/s0003-4975(01)02601-7},
  abstract = {BACKGROUND: To examine the efficacy of the Ivor Lewis esophagogastrectomy for esophageal carcinoma prior to the widespread use of preoperative chemotherapy and irradiation, we reviewed our experience. METHODS: We reexamined the cases of 220 consecutive patients who underwent an Ivor Lewis esophagogastrectomy for esophageal cancer from January 1992 through December 1995. RESULTS: There were 196 men (89.1\%) and 24 women. Median age was 65 years (range, 29 to 85 years). The results of pathological study showed adenocarcinoma in 188 patients (85.5\%), squamous cell carcinoma in 31 (14.1\%), and leiomyosarcoma in 1 patient (0.5\%). Postsurgical staging was as follows: stage 0 in 10 patients, stage I in 19, stage IIa in 38, stage IIb in 28, stage III in 111, and stage IV in 14. The operative mortality rate was 1.4\% (3 patients), and complications occurred in 83 patients (37.7\%). Follow-up was 98.6\% complete. Median survival for operative survivors was 1.9 years (range, 32 days to 8.7 years). The overall 5-year survival rate was 25.2\%; it was 80\% for patients in stage 0, 94.4\% for those in stage I, 36.0\% for those in stage IIa, 14.3\% for patients in stage IIb, 10\% for those in stage III and 0\% for patients in stage IV. CONCLUSIONS: Ivor Lewis esophagogastrectomy for esophageal cancer is a safe operation. Long-term survival is stage dependent. The low survival associated with advanced cancers should stimulate the search for effective neoadjuvant therapy.},
  langid = {english},
  pmid = {11426751},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Carcinoma; Squamous Cell,Esophageal Neoplasms,Esophagectomy,Female,Follow-Up Studies,Gastrectomy,Humans,Male,Middle Aged,Neoplasm Staging,Survival Rate}
}

@article{visser1,
  title = {Postoperative Pain Management after Esophagectomy: A Systematic Review and Meta-Analysis},
  shorttitle = {Postoperative Pain Management after Esophagectomy},
  author = {Visser, E. and Marsman, M. and {van Rossum}, P. S. N. and Cheong, E. and {Al-Naimi}, K. and {van Klei}, W. A. and Ruurda, J. P. and {van Hillegersberg}, R.},
  year = {2017},
  month = oct,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {30},
  number = {10},
  pages = {1--11},
  issn = {1442-2050},
  doi = {10.1093/dote/dox052},
  abstract = {Effective pain management after esophagectomy is essential for patient comfort, early recovery, low surgical morbidity, and short hospitalization. This systematic review and meta-analysis aims to determine the best pain management modality focusing on the balance between benefits and risks. Medline, Embase, and the Cochrane library were systematically searched to identify all studies investigating different pain management modalities after esophagectomy in relation to primary outcomes (postoperative pain scores at 24 and 48 hours, technical failure, and opioid consumption), and secondary outcomes (pulmonary complications, nausea and vomiting, hypotension, urinary retention, and length of hospital stay). Ten studies investigating systemic, epidural, intrathecal, intrapleural and paravertebral analgesia involving 891 patients following esophagectomy were included. No significant differences were found in postoperative pain scores between systemic and epidural analgesia at 24 (mean difference (MD) 0.89; 95\% confidence interval (CI) -0.47-2.24) and 48 hours (MD 0.15; 95\%CI -0.60-0.91), nor described for systemic and other regional analgesia. Also, no significant differences in pulmonary complication rates were identified between systemic and epidural analgesia (relative risk (RR) 1.69; 95\%CI 0.86-3.29), or between systemic and paravertebral analgesia (RR 1.49; 95\%CI 0.31-7.12). Technical failure ranged from 17\% to 22\% for epidural analgesia. Sample sizes were too small to draw inferences on opioid consumption, the risk of nausea and vomiting, hypotension, urinary retention, and length of hospital stay when comparing the different pain management modalities including systemic, epidural, intrathecal, intrapleural, and paravertebral analgesia. This systematic review and meta-analysis shows no differences in postoperative pain scores or pulmonary complications after esophagectomy between systemic and epidural analgesia, and between systemic and paravertebral analgesia. Further randomized controlled trails are warranted to determine the optimal pain management modality after esophagectomy.},
  langid = {english},
  pmid = {28859388},
  keywords = {Analgesia; Epidural,Analgesics,Analgesics; Opioid,complications,esophagectomy,Esophagectomy,Humans,Lung Diseases,Nerve Block,pain management,Pain Management,pain scores,Pain; Postoperative}
}

@article{voeten1271,
  title = {Definitive {{Chemoradiotherapy Versus Trimodality Therapy}} for {{Resectable Oesophageal Carcinoma}}: {{Meta-analyses}} and {{Systematic Review}} of {{Literature}}},
  shorttitle = {Definitive {{Chemoradiotherapy Versus Trimodality Therapy}} for {{Resectable Oesophageal Carcinoma}}},
  author = {Voeten, Daan M. and {den Bakker}, Chantal M. and Heineman, David J. and Ket, Johannes C. F. and Daams, Freek and {van der Peet}, Donald L.},
  year = {2019},
  month = may,
  journal = {World Journal of Surgery},
  volume = {43},
  number = {5},
  pages = {1271--1285},
  issn = {1432-2323},
  doi = {10.1007/s00268-018-04901-z},
  abstract = {BACKGROUND: Standard therapy for loco-regionally advanced, resectable oesophageal carcinoma is trimodality therapy (TMT) consisting of neoadjuvant chemoradiotherapy and oesophagectomy. Evidence of survival advantage of TMT over organ-preserving definitive chemoradiotherapy (dCRT) is inconclusive. The aim of this study is to compare survival between TMT and dCRT. METHODS: A systematic review and meta-analyses were conducted. Randomised controlled trials and observational studies on resectable, curatively treated, oesophageal carcinoma patients above 18~years were included. Three online databases were searched for studies comparing TMT with dCRT. Primary outcomes were 1-, 2-, 3- and 5-year overall survival rates. Risk of bias was assessed using the Cochrane risk of bias tools for RCTs and cohort studies. Quality of evidence was evaluated according to Grading of Recommendation Assessment, Development and Evaluation. RESULTS: Thirty-two studies described in 35 articles were included in this systematic review, and 33 were included in the meta-analyses. Two-, three- and five-year overall survival was significantly lower in dCRT compared to TMT, with relative risks (RRs) of 0.69 (95\% CI 0.57-0.83), 0.76 (95\% CI 0.63-0.92) and 0.57 (95\% CI 0.47-0.71), respectively. When only analysing studies with equal patient groups at baseline, no significant differences for 2-, 3- and 5-year overall survival were found with RRs of 0.83 (95\% CI 0.62-1.10), 0.81 (95\% CI 0.57-1.14) and 0.63 (95\% CI 0.36-1.12). CONCLUSION: These meta-analyses do not show clear survival advantage for TMT over dCRT. Only a non-significant trend towards better survival was seen, assuming comparable patient groups at baseline. Non-operative management of oesophageal carcinoma patients might be part of a personalised and tailored treatment approach in future. However, to date hard evidence proving its non-inferiority compared to operative management is lacking.},
  langid = {english},
  pmid = {30607604},
  keywords = {Chemoradiotherapy,Esophageal Neoplasms,Esophagectomy,Humans,Neoadjuvant Therapy,Survival Rate}
}

@article{voeten6344,
  title = {Length of Hospital Stay after Uncomplicated Esophagectomy. {{Hospital}} Variation Shows Room for Nationwide Improvement},
  author = {Voeten, Daan M. and {van der Werf}, Leonie R. and {van Sandick}, Johanna W. and {van Hillegersberg}, Richard and {van Berge Henegouwen}, Mark I. and {on behalf of the Dutch Upper Gastrointestinal Cancer Audit Group}},
  year = {2021},
  month = nov,
  journal = {Surgical Endoscopy},
  volume = {35},
  number = {11},
  pages = {6344--6357},
  issn = {1432-2218},
  doi = {10.1007/s00464-020-08103-4},
  abstract = {Within the scope of value-based health care, this study aimed to analyze Dutch hospital performance in terms of length of hospital stay after esophageal cancer surgery and its association with 30-day readmission rates. Since both parameters are influenced by the occurrence of complications, this study only included patients with an uneventful recovery after esophagectomy.},
  langid = {english},
  keywords = {MIE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\9TY57EFJ\\Voeten et al. - 2021 - Length of hospital stay after uncomplicated esopha.pdf}
}

@article{vogel148,
  title = {The {{American Society}} of {{Colon}} and {{Rectal Surgeons Clinical Practice Guidelines}} for the {{Management}} of {{Colon Cancer}}},
  author = {Vogel, Jon D. and Felder, Seth I. and Bhama, Anuradha R. and Hawkins, Alexander T. and Langenfeld, Sean J. and Shaffer, Virginia O. and Thorsen, Amy J. and Weiser, Martin R. and Chang, George J. and Lightner, Amy L. and Feingold, Daniel L. and Paquette, Ian M.},
  year = {2022},
  month = feb,
  journal = {Diseases of the Colon and Rectum},
  volume = {65},
  number = {2},
  pages = {148--177},
  issn = {1530-0358},
  doi = {10.1097/DCR.0000000000002323},
  langid = {english},
  pmid = {34775402},
  keywords = {Colectomy,Colonic Neoplasms,Combined Modality Therapy,Guidelines,Humans,Magnetic Resonance Imaging,Neoplasm Staging,Patient Selection,Tomography; X-Ray Computed}
}

@article{vondobelne53,
  type = {Journal {{Article}}},
  title = {Pulmonary Function and Cardiac Stress Test after Multimodality Treatment of Esophageal Cancer},
  author = {{von Dobeln}, G. A. and Nilsson, M. and Adell, G. and Johnsen, G. and Hatlevoll, I. and Tsai, J. and Lundell, L. and Lund, M. and Lind, P.},
  year = {2016},
  journal = {Pract Radiat Oncol},
  volume = {6},
  number = {3},
  pages = {e53-e59},
  issn = {1879-8519 (Electronic) 1879-8500 (Linking)},
  doi = {10.1016/j.prro.2015.10.015}
}

@article{vonheymann971,
  title = {Liberal {{Transfusion Practice}} or {{Perioperative Treatment}} of {{Anemia}} to {{Avoid Transfusion}}?},
  author = {{von Heymann}, Christian and Rosenthal, Christoph and Sander, Michael and Balzer, Felix and Kraemer, Michael and Kaufner, Lutz},
  year = {2015},
  month = oct,
  journal = {Anesthesiology},
  volume = {123},
  number = {4},
  pages = {971--973},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000803},
  langid = {english},
  pmid = {26372131},
  keywords = {Abdominal Neoplasms,Erythrocyte Transfusion,Female,Humans,Male,SurgOnc}
}

@article{wagnild165,
  type = {Journal {{Article}}},
  title = {Development and Psychometric Evaluation of the {{Resilience Scale}}},
  author = {Wagnild, G. M. and Young, H. M.},
  year = {1993},
  journal = {J Nurs Meas},
  volume = {1},
  number = {2},
  pages = {165--78},
  issn = {1061-3749 (Print) 1061-3749 (Linking)}
}

@article{walker166,
  title = {Integrated {{PET}}/{{CT}} Fusion Imaging and Endoscopic Ultrasound in the Pre-Operative Staging and Evaluation of Esophageal Cancer},
  author = {Walker, Andrew J. and Spier, Bret J. and Perlman, Scott B. and Stangl, Jason R. and Frick, Terrence J. and Gopal, Deepak V. and Lindstrom, Mary J. and Weigel, Tracey L. and Pfau, Patrick R.},
  year = {2011},
  month = feb,
  journal = {Molecular Imaging and Biology},
  volume = {13},
  number = {1},
  pages = {166--171},
  issn = {1860-2002},
  doi = {10.1007/s11307-010-0306-0},
  abstract = {PURPOSE: Accurate staging of esophageal cancer (ECA) is critical in determining appropriate therapy. Endoscopic ultrasound (EUS), computed tomography (CT) and positron emission tomography (PET) scanning can be used, but limited data exists regarding the use of combined PET/CT fusion imaging and EUS in ECA staging. The objective of this study is to evaluate the role of integrated PET/CT imaging and EUS in the staging of ECA. PROCEDURES: Identification of patients diagnosed with ECA from 2004 to 2007 that underwent staging PET/CT and EUS. Data regarding tumor detection, lymph node identification, presence of metastatic disease, and affect on patient management were collected and compared between PET/CT and EUS. RESULTS: Eighty-one patients (65 male, 16 female) were identified with mean age of 63.5 years who underwent EUS and PET/CT to stage known ECA. PET/CT identified the primary tumor in 74/81 (91.4\%) of cases, compared to 81/81 (100\%) with EUS. Locoregional adenopathy was seen by PET/CT in 29/81 (35.8\%) of cases, compared to 49/81 (60.5\%) by EUS (p = 0.0001). PET/CT identified celiac axis adenopathy in 8/81 (9.9\%) of cases, compared to 11/81 (13.6\%) with EUS (p = 0.5050). PET/CT identified 17/81 (21.0\%) of patients with distant metastases who subsequently did not undergo attempt at curative surgical resection. CONCLUSIONS: In ECA, EUS is superior to PET/CT for T staging and in identifying locoregional nodes, while PET/CT provides M staging. EUS and integrated PET/CT appear to independently affect treatment decisions, indicating complimentary and necessary roles in the staging of ECA.},
  langid = {english},
  pmid = {20379789},
  keywords = {Esophageal Neoplasms,Female,Humans,Male,Positron-Emission Tomography,Tomography; X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\YVUZXYSY\\Walker et al. - 2011 - Integrated PETCT fusion imaging and endoscopic ul.pdf}
}

@article{wallington14,
  title = {30-Day Mortality after Systemic Anticancer Treatment for Breast and Lung Cancer in {{England}}: A Population-Based, Observational Study},
  author = {Wallington, Michael},
  year = {2016},
  volume = {17},
  pages = {14},
  abstract = {Background 30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this indicator are limited. The Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England allows the assessment of factors affecting 30-day mortality in a national patient population. The aim of this first study based on the SACT dataset was to establish national 30-day mortality benchmarks for breast and lung cancer patients receiving SACT in England, and to start to identify where patient care could be improved.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6AB7IL9T\\Wallington - 2016 - 30-day mortality after systemic anticancer treatme.pdf}
}

@article{walston1173,
  type = {Journal {{Article}}},
  title = {Frailty and the Older Man},
  author = {Walston, J. and Fried, L. P.},
  year = {1999},
  journal = {Med Clin North Am},
  volume = {83},
  number = {5},
  pages = {1173--94},
  issn = {0025-7125 (Print) 0025-7125 (Linking)}
}

@incollection{walvekar,
  type = {Book {{Section}}},
  title = {Complications of {{Percutaneous Gastrostomy}}},
  booktitle = {Complications in {{Head}} and {{Neck Surgery}} ({{Second Edition}})},
  author = {Walvekar, Rohan R. and Ferris, Robert L.},
  editor = {Eisele, David W. and Smith, Richard V.},
  year = {2009},
  edition = {2nd edition},
  publisher = {{Elsevier B.V.}},
  doi = {10.1016/B978-1-4160-4220-4.X5001-9}
}

@article{wang2053,
  type = {Journal {{Article}}},
  title = {Validation and Application of a Module of the {{M}}. {{D}}. {{Anderson Symptom Inventory}} for Measuring Multiple Symptoms in Patients with Gastrointestinal Cancer (the {{MDASI-GI}})},
  author = {Wang, X. S. and Williams, L. A. and Eng, C. and Mendoza, T. R. and Shah, N. A. and Kirkendoll, K. J. and Shah, P. K. and Trask, P. C. and Palos, G. R. and Cleeland, C. S.},
  year = {2010},
  journal = {Cancer},
  volume = {116},
  number = {8},
  pages = {2053--63},
  issn = {0008-543X (Print) 0008-543X (Linking)},
  doi = {10.1002/cncr.24920}
}

@article{wang209,
  title = {Analysis of the Associated Factors for Severe Weight Loss after Minimally Invasive {{McKeown}} Esophagectomy},
  author = {Wang, Peiyu and Li, Yin and Sun, Haibo and Zhang, Ruixiang and Liu, Xianben and Liu, Shilei and Wang, Zongfei and Zheng, Yan and Yu, Yongkui and Chen, Xiankai and Li, Haomiao and Zhang, Jun and Liu, Qi},
  year = {2019},
  month = feb,
  journal = {Thoracic Cancer},
  volume = {10},
  number = {2},
  pages = {209--218},
  issn = {1759-7714},
  doi = {10.1111/1759-7714.12934},
  abstract = {BACKGROUND: This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy. METHODS: Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as the initial body weight. RESULTS: Forty-four patients were enrolled and successfully followed up for one year. Median weight loss was 7.4\% (quartile: 5.3-8.1\%) and 12.6\% (quartile: 8.8-17.7\%) four weeks and one year after surgery, respectively. Accelerated weight loss occurred during the first two weeks after discharge, with median weight loss of 5.6\% (quartile: 4.2-7.1\%). Multivariable analysis showed that age {$\geq$} 70 years (odds ratio [OR] 7.65; P = 0.030), preoperative sarcopenia (OR 7.18; P = 0.030), the first surgery in the daily schedule (OR 6.87; P = 0.032) and vocal cord paralysis (OR 12.30; P = 0.046) were independent risk factors for short-term (4 weeks) SWL ({$>$} 7.5\% PBW), while an American Society of Anesthesiologists score of 3-4 (OR 6.58; P = 0.047), a high fat-free mass (OR 21.91; P = 0.003), and vocal cord paralysis (OR 25.83; P = 0.017) were independent risk factors for long-term (1 year) SWL ({$>$} 13.0\% PBW) after esophagectomy. Postoperative symptoms of insomnia, appetite loss, dysphagia, eating difficulties, and taste issues were also related to SWL. CONCLUSIONS: In esophageal cancer patients who have undergone esophagectomy, the first two weeks after hospital discharge is a key period for nutrition intervention. Patients with associated factors for SWL require postoperative nutrition support.},
  langid = {english},
  pmcid = {PMC6360231},
  pmid = {30578600},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Esophageal neoplasm,Esophageal Neoplasms,esophagectomy,Esophagectomy,Female,Follow-Up Studies,GE,Humans,Male,Middle Aged,Postoperative Complications,Prognosis,Prospective Studies,Quality of Life,risk factor,Risk Factors,Severity of Illness Index,weight loss,Weight Loss,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\MMYUUH5F\\Wang et al. - 2019 - Analysis of the associated factors for severe weig.pdf}
}

@article{wang25,
  title = {Myosteatosis Reduces Overall Survival in Patients with Digestive System Malignancies: A Meta-Analysis with Trial Sequential Analysis},
  shorttitle = {Myosteatosis Reduces Overall Survival in Patients with Digestive System Malignancies},
  author = {Wang, Yue and Tian, Guangwei and Chen, Song and Li, Nan},
  year = {2021},
  month = oct,
  journal = {Nutrition Research (New York, N.Y.)},
  volume = {94},
  pages = {25--33},
  issn = {1879-0739},
  doi = {10.1016/j.nutres.2021.08.003},
  abstract = {The impact of myosteatosis on the outcomes of digestive malignancies has gained great attention recently. However, studies on the impact of myosteatosis~show inconsistent results. We conducted a meta-analysis to clarify the relationship between myosteatosis and the overall survival of digestive cancer patients. The systematic literature search was conducted on PubMed/MEDLINE, Web of Science, and Embase from inception through March 27, 2021. Meta-analysis was performed using the random-effects model. Out of 3451 studies screened, 47 studies including 21,194 patients passed the screening criteria. The average prevalence of myosteatosis was 46.4\%. Patients with myosteatosis had 44\% increased mortality risk compared with non-myosteatosis patients (HR: 1.44, 95\% CI: 1.33-1.55, P {$<$} .05). The predictive value of myosteatosis held regardless of country zone, study design, statistical model, Newcastle-Ottawa Scale (NOS) scores, treatment, sample size, and tumor stage. Nevertheless, the predictive value of myosteatosis was only evident for patients with esophagogastric cancers, cholangiocarcinoma/pancreatic cancers, or colorectal cancers. Overall, the results of this meta-analysis were robust based on sensitivity, subgroup, meta-regression, and trial sequential analyses and suggested that myosteatosis predicted worse overall survival (OS) in digestive malignancies patients.},
  langid = {english},
  pmid = {34583210},
  keywords = {Adipose Tissue,Adiposity,Body composition,Body Composition,Digestive malignancy,Digestive System Neoplasms,Female,Humans,Male,Meta-analysis,Muscle; Skeletal,Myosteatosis,Overall survival,Prognosis}
}

@article{wang255,
  title = {Survival after Neoadjuvant Chemoradiotherapy and Oesophagectomy versus Definitive Chemoradiotherapy for Patients with Oesophageal Squamous Cell Carcinoma},
  author = {Wang, B.-Y. and Wu, S.-C. and Chen, H.-C. and Hung, W.-H. and Lin, C.-H. and Huang, C.-L. and Chen, H.-S.},
  year = {2019},
  month = feb,
  journal = {The British Journal of Surgery},
  volume = {106},
  number = {3},
  pages = {255--262},
  issn = {1365-2168},
  doi = {10.1002/bjs.11004},
  abstract = {BACKGROUND: Whether there is a difference in survival after neoadjuvant chemoradiotherapy plus surgery (CRT-S) compared with definitive chemoradiotherapy (dCRT) in patients with locally advanced oesophageal squamous cell carcinoma (SCC) remains controversial. METHODS: Patients with SCC who underwent curative treatment from 2008 to 2014 were identified from the Taiwan Cancer Registry. Propensity score matching was undertaken to balance pretreatment clinical variables. Overall survival was compared between patients undergoing CRT-S or dCRT. Univariable and multivariable analyses were performed to identify prognostic factors for overall survival. RESULTS: A total of 5832 patients with clinical stage II and III oesophageal SCC receiving CRT-S (1754) or dCRT (4078) were included. After propensity score matching, each group included 1661 patients. The 3-year overall survival rate for patients treated with CRT-S was 41{$\cdot$}1 per cent compared with 17{$\cdot$}9 per cent for those who had dCRT (P {$<$} 0{$\cdot$}001). In multivariable analysis, treatment modality was an independent prognostic factor in the overall cohort before propensity score matching: hazard ratio 0{$\cdot$}45 (95 per cent c.i. 0{$\cdot$}40 to 0{$\cdot$}51) for CRT-S versus dCRT (P {$<$} 0{$\cdot$}001). In separate analyses of patients with clinical stage II and those with stage III disease, CRT-S was associated with significantly better overall survival than dCRT. CONCLUSION: Neoadjuvant chemoradiotherapy and oesophagectomy is associated with better overall survival than dCRT in patients with stage II and III oesophageal SCC.},
  langid = {english},
  pmid = {30395362},
  keywords = {Adult,Aged,Chemoradiotherapy,Cohort Studies,dCRT,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Female,Humans,Male,Middle Aged,Propensity Score,Survival Rate,Taiwan,Treatment Outcome,Tri}
}

@article{wang751,
  title = {Muscle {{Density}}, but {{Not Size}}, {{Correlates Well With Muscle Strength}} and {{Physical Performance}}},
  author = {Wang, Ling and Yin, Lu and Zhao, Yue and Su, Yongbin and Sun, Wei and Chen, Shuo and Liu, Yandong and Yang, Minghui and Yu, Aihong and Guglielmi, Giuseppe and Blake, Glen M. and Cheng, Xiaoguang and Wu, Xinbao and {Veldhuis-Vlug}, Annegreet G. and Engelke, Klaus},
  year = {2021},
  month = apr,
  journal = {Journal of the American Medical Directors Association},
  volume = {22},
  number = {4},
  pages = {751-759.e2},
  issn = {1525-8610},
  doi = {10.1016/j.jamda.2020.06.052},
  abstract = {Objectives There is increasing evidence that muscle volume and mass are poor predictors of muscle strength and physical performance. Other assessments of muscle quality such as skeletal muscle density measured by computed tomography (CT) may be more important. The aim of this study was to explore associations of muscle size and density with handgrip strength (HGS) and the Timed Up and Go test (TUG). We also hypothesized that the strength of these associations would depend on the specific muscle of muscle group, namely trunk, hip, and mid-thigh muscles. Design Cross-sectional study. Setting and Participants University hospital; 316 volunteers aged 59 to 85~years. Methods HGS, TUG, and quantitative CT imaging of the lumber, hip, and mid-thigh were performed in volunteers. From the CT images, cross-sectional area and attenuation were determined for the gluteus muscle, trunk muscle at vertebrae L2 level, and mid-thigh muscle. Results In men and women, associations of muscle area with TUG were insignificant after adjustment for age, height, and weight. Associations with HGS were only significant in men for the gluteus maximus and the mid-thigh but slopes were rather low ({$\beta~<~$}0.20). Associations between muscle density and TUG/HGS were more pronounced, in particular for HGS. After adjustment, associations with TUG were significant in women for the gluteus maximus and trunk muscle even ({$\beta~-$}0.06, P .001 and {$\beta~-$}0.07, P .031, respectively). Conclusions and Implications Muscle density is more strongly associated with muscle strength than muscle size andin women muscle density was also more strongly associated than muscle size with physical performance. Therefore, muscle density may represent a more clinically meaningful surrogate of muscle performance than muscle size. Muscle density measurements of trunk and gluteus muscles can be easily obtained from routine CT scan and, therefore, may become an important measurement to diagnose and screen for sarcopenia.},
  langid = {english},
  keywords = {computed tomography,grip strength,Muscle density,muscle size,Myosteatosis,sarcopenia,Timed Up and Go test},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\7PKCKLE7\\S1525861020305740.html}
}

@article{watanabe160,
  type = {Journal {{Article}}},
  title = {Recent Progress in Perioperative Management of Patients Undergoing Esophagectomy for Esophageal Cancer},
  author = {Watanabe, M. and Okamura, A. and Toihata, T. and Yamashita, K. and Yuda, M. and Hayami, M. and Fukudome, I. and Imamura, Y. and Mine, S.},
  year = {2018},
  journal = {Esophagus},
  volume = {15},
  number = {3},
  pages = {160--164},
  issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
  doi = {10.1007/s10388-018-0617-9}
}

@article{waters966,
  title = {A {{Different Perspective}} on {{Transfusion Requirements}} in {{Surgical Oncology Patients}}},
  author = {Waters, Jonathan H. and Triulzi, Darrell J. and Yazer, Mark H.},
  year = {2015},
  month = oct,
  journal = {Anesthesiology},
  volume = {123},
  number = {4},
  pages = {966--967},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000799},
  langid = {english},
  pmid = {26372127},
  keywords = {Abdominal Neoplasms,Erythrocyte Transfusion,Female,Humans,Male,SurgOnc}
}

@article{watson421,
  type = {Journal {{Article}}},
  ids = {watson421a},
  title = {Jejunostomy at the Time of Esophagectomy Is Associated with Improved Short-Term Perioperative Outcomes: Analysis of the {{NSQIP}} Database},
  author = {Watson, M. and Trufan, S. and Benbow, J. H. and Gower, N. L. and Hill, J. and Salo, J. C.},
  year = {2020},
  journal = {J Gastrointest Oncol},
  volume = {11},
  number = {2},
  pages = {421--430},
  issn = {2078-6891 (Print) 2078-6891 (Linking)},
  doi = {10.21037/jgo.2020.02.06},
  pmcid = {PMC7212114},
  pmid = {32399282},
  keywords = {Jejunostomy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NDYWXZCF\\Watson et al_2020_Jejunostomy at the time of esophagectomy is associated with improved short-term.pdf}
}

@article{webster79,
  type = {Journal {{Article}}},
  title = {The {{Functional Assessment}} of {{Chronic Illness Therapy}} ({{FACIT}}) {{Measurement System}}: Properties, Applications, and Interpretation},
  author = {Webster, K. and Cella, D. and Yost, K.},
  year = {2003},
  journal = {Health Qual Life Outcomes},
  volume = {1},
  pages = {79},
  issn = {1477-7525 (Electronic) 1477-7525 (Linking)},
  doi = {10.1186/1477-7525-1-79}
}

@article{weeks321,
  type = {Journal {{Article}}},
  title = {Short-Term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer: A Randomized Trial},
  author = {Weeks, J. C. and Nelson, H. and Gelber, S. and Sargent, D. and Schroeder, G. and {Clinical Outcomes of Surgical Therapy Study}, Group},
  year = {2002},
  journal = {JAMA},
  volume = {287},
  number = {3},
  pages = {321--8},
  issn = {0098-7484 (Print) 0098-7484 (Linking)}
}

@article{weijs1,
  title = {Nasogastric Decompression Following Esophagectomy: A Systematic Literature Review and Meta-Analysis},
  shorttitle = {Nasogastric Decompression Following Esophagectomy},
  author = {Weijs, Teus J. and Kumagai, Koshi and Berkelmans, Gijs H. K. and Nieuwenhuijzen, Grard A. P. and Nilsson, Magnus and Luyer, Misha D. P.},
  year = {2017},
  month = feb,
  journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
  volume = {30},
  number = {3},
  pages = {1--8},
  issn = {1442-2050},
  doi = {10.1111/dote.12530},
  abstract = {Routine use of nasogastric tubes for gastric decompression has been abolished in nearly all types of gastro-intestinal surgery after introduction of enhanced recovery after surgery programs. However, in esophagectomy the routine use of nasogastric decompression is still a matter of debate. To determine the effects of routine nasogastric decompression following esophagectomy compared with early or peroperative removal of the nasogastric tube on pulmonary complications, anastomotic leakage, mortality, and postoperative recovery. A systematic literature review and meta-analysis of studies comparing early or peroperative versus late removal of nasogastric tubes. A total of seven comparative studies were included (n\,=\,608). In two randomized trials, and one retrospective cohort study, peroperative removal of the nasogastric tube was compared with routine nasogastric decompression. In one randomized trial early removal of the nasogastric tube (on postoperative day 2) was compared with removal of the nasogastric tube on the 6th-10th postoperative day. In the remaining three trials a fast-track protocol without a nasogastric tube was compared with conventional care with a nasogastric tube during the first postoperative days. Peroperative or early removal of the nasogastric tube did not result in a significantly different rate of anastomotic leakage, pulmonary complications or mortality in individual studies, nor in the meta-analysis. In the meta-analysis, hospital stay was significantly shorter with peroperative or early removal of the nasogastric tube when all studies were included, but not when the meta-analysis was limited to randomized trials. This systematic review did not find a difference in adverse outcomes between nasogastric decompression or no nasogastric decompression following esophagectomy.},
  langid = {english},
  pmid = {27627872},
  keywords = {Adult,anastomotic leak,Anastomotic Leak,Decompression; Surgical,esophagectomy,Esophagectomy,Female,Humans,Intubation; Gastrointestinal,Length of Stay,Male,Middle Aged,nasogatric tube,pneumonia,Postoperative Care,Postoperative Complications,Time Factors},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\TDSPX9XC\\Weijs et al_2017_Nasogastric decompression following esophagectomy.pdf}
}

@article{weiss304,
  type = {Journal {{Article}}},
  title = {Validation of Patient and Nurse Short Forms of the {{Readiness}} for {{Hospital Discharge Scale}} and Their Relationship to Return to the Hospital},
  author = {Weiss, M. E. and Costa, L. L. and Yakusheva, O. and Bobay, K. L.},
  year = {2014},
  journal = {Health Serv Res},
  volume = {49},
  number = {1},
  pages = {304--17},
  issn = {1475-6773 (Electronic) 0017-9124 (Linking)},
  doi = {10.1111/1475-6773.12092}
}

@article{whibley594,
  title = {Poor Performance in Incremental Shuttle Walk and Cardiopulmonary Exercise Testing Predicts Poor Overall Survival for Patients Undergoing Esophago-Gastric Resection},
  author = {Whibley, Jessica and Peters, Christopher J. and Halliday, Laura J. and Chaudry, Asif M. and Allum, William H.},
  year = {2018},
  month = may,
  journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  volume = {44},
  number = {5},
  pages = {594--599},
  issn = {1532-2157},
  doi = {10.1016/j.ejso.2018.01.242},
  abstract = {INTRODUCTION: Esophageal and gastric cancer have a poor prognosis and surgical intervention is associated with considerable morbidity, highlighting the need for careful preoperative assessment. The Incremental Shuttle Walk Test (ISWT) and Cardiopulmonary exercise testing (CPET) can assess preoperative fitness. This study aims to investigate their correlation with both postoperative respiratory complications and overall survival. PATIENTS AND METHODS: Patients were identified who underwent esophageal or gastric resections for cancer between 2010 and 2014 and had ISWT and/or CPET assessments. Tumor differentiation, stage, postoperative respiratory complications, and outcome were documented and then correlated with the results of the preoperative fitness assessments. RESULTS: Neither the ISWT result, anaerobic threshold (AT) nor VO2 Max correlated well with perioperative complications. However, ISWT (p~{$<~$}0.001), AT (p~{$<~$}0.001) and VO2 Max (p~{$<~$}0.001) all correlated strongly with overall survival. No patient with a score of less than 350~m on ISWT survived beyond 3 years. In a subset of patients with ISWT results both pre and post chemotherapy (n~=~49), those that had an improvement in result had a 19\% incidence of post-operative respiratory complications compared to 45\% where the result did not change or declined, though due to small numbers this only approached significance (p~=~0.08). CONCLUSION: ISWT and CPET can be useful preoperative tools to predict overall survival for patients undergoing esophago-gastric resection. Furthermore, patients that improve their functional status during chemotherapy seem to do better than those where it remains static or declines.},
  langid = {english},
  pmid = {29459017},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Esophageal neoplasms,Esophageal Neoplasms,Esophagectomy,Exercise test,Exercise Test,Exercise tolerance,Exercise Tolerance,Female,Gastrectomy,Humans,Incidence,Male,Middle Aged,Neoplasm Staging,Postoperative complications,Postoperative Complications,Preoperative care,Prognosis,Respiratory Tract Diseases,Stomach neoplasms,Stomach Neoplasms,Survival,Survival rate,Survival Rate,Walk Test}
}

@article{white730,
  title = {Consensus Statement of the {{Academy}} of {{Nutrition}} and {{Dietetics}}/{{American Society}} for {{Parenteral}} and {{Enteral Nutrition}}: Characteristics Recommended for the Identification and Documentation of Adult Malnutrition (Undernutrition)},
  shorttitle = {Consensus Statement of the {{Academy}} of {{Nutrition}} and {{Dietetics}}/{{American Society}} for {{Parenteral}} and {{Enteral Nutrition}}},
  author = {White, Jane V. and Guenter, Peggi and Jensen, Gordon and Malone, Ainsley and Schofield, Marsha and {Academy of Nutrition and Dietetics Malnutrition Work Group} and {A.S.P.E.N. Malnutrition Task Force} and {A.S.P.E.N. Board of Directors}},
  year = {2012},
  month = may,
  journal = {Journal of the Academy of Nutrition and Dietetics},
  volume = {112},
  number = {5},
  pages = {730--738},
  issn = {2212-2672},
  doi = {10.1016/j.jand.2012.03.012},
  abstract = {The Academy of Nutrition and Dietetics (Academy) and the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) recommend that a standardized set of diagnostic characteristics be used to identify and document adult malnutrition in routine clinical practice. An etiologically based diagnostic nomenclature that incorporates a current understanding of the role of the inflammatory response on malnutrition's incidence, progression, and resolution is proposed. Universal use of a single set of diagnostic characteristics will facilitate malnutrition's recognition, contribute to more valid estimates of its prevalence and incidence, guide interventions, and influence expected outcomes. This standardized approach will also help to more accurately predict the human and financial burdens and costs associated with malnutrition's prevention and treatment, and further ensure the provision of high quality, cost effective nutritional care.},
  langid = {english},
  pmid = {22709779},
  keywords = {Adult,Humans,Incidence,Malnutrition,Severity of Illness Index,Terminology as Topic}
}

@article{wong239,
  title = {Development and {{Assessment}} of a {{Systematic Approach}} for {{Detecting Disparities}} in {{Surgical Access}}},
  author = {Wong, Jan H. and Irish, William D. and DeMaria, Eric J. and Vohra, Nasreen A. and Pories, Walter J. and Brownstein, Michelle R. and Altieri, Maria S. and Akram, Warqaa and Haisch, Carl E. and Leeser, David B. and Tuttle, Janet E.},
  year = {2021},
  month = mar,
  journal = {JAMA surgery},
  volume = {156},
  number = {3},
  pages = {239--245},
  issn = {2168-6262},
  doi = {10.1001/jamasurg.2020.5668},
  abstract = {Importance: Although optimal access is accepted as the key to quality care, an accepted methodology to ascertain potential disparities in surgical access has not been defined. Objective: To develop a systematic approach to detect surgical access disparities. Design, Setting, and Participants: This cross-sectional study used publicly available data from the Health Cost and Utilization Project State Inpatient Database from 2016. Using the surgical rate observed in the 5 highest-ranked counties (HRCs), the expected surgical rate in the 5 lowest-ranked counties (LRCs) in North Carolina were calculated. Patients 18 years and older who underwent an inpatient general surgery procedure and patients who underwent emergency inpatient cholecystectomy, herniorrhaphy, or bariatric surgery in 2016 were included. Data were collected from January to December 2016, and data were analyzed from March to July 2020. Exposures: Health outcome county rank as defined by the Robert Wood Johnson Foundation. Main Outcomes and Measures: The primary outcome was the proportional surgical ratio (PSR), which was the disparity in surgical access defined as the observed number of surgical procedures in the 5 LRCs relative to the expected number of procedures using the 5 HRCs as the standardized reference population. Results: In 2016, approximately 1.9 million adults lived in the 5 HRCs, while approximately 246\,854 lived in the 5 LRCs. A total of 28\,924 inpatient general surgical procedures were performed, with 4521 being performed in those living in the 5 LRCs and 24\,403 in those living in the 5 HRCs. The rate of general surgery in the 5 HRCs was 13.09 procedures per 1000 population. Using the 5 HRCs as the reference, the PSR for the 5 LRCs was 1.40 (95\% CI, 1.35-1.44). For emergent/urgent cholecystectomy, the PSR for the 5 LRCs was 2.26 (95\% CI, 2.02-2.51), and the PSR for emergent/urgent herniorrhaphy was 1.83 (95\% CI, 1.33-2.45). Age-adjusted rate of obesity (body mass index [calculated as weight in kilograms divided by height in meters squared] greater than 30), on average, was 36.6\% (SD, 3.4) in the 5 LRCs vs 25.4\% (SD, 4.6) in the 5 HRCs (P\,=\,.002). The rate of bariatric surgery in the 5 HRCs was 33.07 per 10\,000 population with obesity. For the 5 LRCs, the PSR was 0.60 (95\% CI, 0.51-0.69). Conclusions and Relevance: The PSR is a systematic approach to define potential disparities in surgical access and should be useful for identifying, investigating, and monitoring interventions intended to mitigate disparities in surgical access that effects the health of vulnerable populations.},
  langid = {english},
  pmcid = {PMC7745135},
  pmid = {33326009},
  keywords = {Adult,Aged,Cross-Sectional Studies,Databases; Factual,Female,Health Services Accessibility,Healthcare Disparities,Hospitalization,Humans,Male,Middle Aged,North Carolina,Procedures and Techniques Utilization,Race,Socioeconomic Factors,Surgical Procedures; Operative}
}

@article{wong385,
  title = {Clinical and Palliative Care Outcomes for Patients of Poor Performance Status Treated with Antiprogrammed Death-1 Monoclonal Antibodies for Advanced Melanoma},
  author = {Wong, Annie and Williams, Molly and Milne, Donna and Morris, Kortnye and Lau, Peter and Spruyt, Odette and Fullerton, Sonia and McArthur, Grant},
  year = {2017},
  month = dec,
  journal = {Asia-Pacific Journal of Clinical Oncology},
  volume = {13},
  number = {6},
  pages = {385--390},
  issn = {1743-7563},
  doi = {10.1111/ajco.12702},
  abstract = {BACKGROUND: Antiprogrammed death-1 antibodies (anti-PD1) have response rates of 40\% in metastatic melanoma. Patients with poor performance status (PS) were excluded from clinical trials, yet use of anti-PD1 is widespread in clinical practice. Literature regarding clinical and palliative care outcomes in patients with poor PS treated with anti-PD1 is lacking. METHODS: Retrospective review of outcomes for all patients with advanced melanoma treated with anti-PD1 between 2012 and June 2015 at Peter MacCallum Cancer Centre, a tertiary specialist cancer center in Australia. RESULTS: Between 2012 and 2015, 91 patients received anti-PD1: median age 63, 65\% males, 77\% elevated LDH{$>$}1xULN (37/48 patients). Fifty-eight patients had baseline ECOG PS of 0-1 (64\%), 24 patients ECOG PS 2-3 (26\%) and ECOG PS was not recorded in nine patients (10\%). Median overall survival (OS) for the ECOG PS 0-1 group was 19.5 months and 1.8 months for ECOG PS 2-3 (HR 5.5; 95\% CI, 9.1-50.3; P = 0.0001). Tumor response was 23/58 (39\%) in ECOG PS 0-1, 2/16 (12\%) in ECOG PS 2 and 0/8 in ECOG PS 3. Toxicity did not differ between different groups. ECOG PS 2-3 patients were more likely to be treated and hospitalized within the last month of life compared to ECOG PS 0-1 patients, RR 1.75 (95\% CI, 1.04-2.56, P = 0.019) and RR 1.73 (95\% CI, 1.10-2.16, P = 0.009), respectively. ECOG PS 2-3 patients were more likely to die in an acute hospital RR 2.68 (95\% CI, 1.17-6.51, P = 0.016). CONCLUSIONS: Patients with poor baseline PS have a significantly lower OS and reduced response to anti-PD1. Further quality of life and palliative care research is needed.},
  langid = {english},
  pmid = {28661584},
  keywords = {Adult,Aged,Aged; 80 and over,Antibodies; Monoclonal,antiprogrammed death-1,Female,Humans,ICI,immunotherapy,Male,melanoma,Melanoma,Middle Aged,palliative care,Palliative Care,Retrospective Studies,Survival Analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\X5YTBJHB\\Wong et al_2017_Clinical and palliative care outcomes for patients of poor performance status.pdf}
}

@article{worrell484,
  title = {Accuracy of {{Clinical Staging}} and {{Outcome With Primary Resection}} for {{Local-Regionally Limited Esophageal Adenocarcinoma}}},
  author = {Worrell, Stephanie G. and Alicuben, Evan T. and Oh, Daniel S. and Hagen, Jeffrey A. and DeMeester, Steven R.},
  year = {2018},
  month = mar,
  journal = {Annals of Surgery},
  volume = {267},
  number = {3},
  pages = {484--488},
  issn = {1528-1140},
  doi = {10.1097/SLA.0000000000002139},
  abstract = {OBJECTIVE: The aim of this study was to determine the accuracy of clinical staging, to assess survival with surgical resection alone, and to determine factors associated with understaging in patients with esophageal adenocarcinoma thought to have limited local-regional disease. BACKGROUND: Primary surgical resection is the preferred treatment in patients with esophageal adenocarcinoma clinically staged to have limited nodal disease. This approach requires reliable clinical staging. METHODS: A retrospective chart review was performed of all patients who had primary esophagectomy for clinical stage T1-3 N0-1 adenocarcinoma (seventh edition AJCC) from January 2002 to May 2013. Clinical and pathologic stages were compared and overall survival was analyzed. RESULTS: There were 88 patients who met inclusion criteria. Final pathology confirmed appropriate clinical staging ({$\leq$}T3N1) in 76\% of patients (67/88). There were 21 patients who were understaged ({$>$}T3N1), and in all cases, understaging was based on the presence of advanced nodal (N2 or N3) disease. Factors independently associated with understaging were the presence of dysphagia, tumor length {$>$}3{$\mkern1mu$}cm, and poor differentiation. At a median follow-up of 35 months, 63\% of all patients (55/88) remain alive. The 5-year survival in correctly staged patients was 67\%, compared with 33\% for those who were understaged (P {$<$} 0.0001). CONCLUSIONS: Modern clinical staging will accurately identify the majority of patients with esophageal adenocarcinoma and limited local-regional disease ({$\leq$}pT3N1). Survival with surgery alone in correctly staged patients was excellent and unlikely to be improved with neoadjuvant therapy. A combination of dysphagia, poor differentiation, and tumor length {$>$}3{$\mkern1mu$}cm was associated with understaging in 92\% of patients. Patients with these factors are likely to have more advanced disease than clinically suspected and may benefit from neoadjuvant therapy before resection.},
  langid = {english},
  pmid = {28151801},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Esophageal Neoplasms,Esophagectomy,Female,Humans,Lymphatic Metastasis,Male,Middle Aged,Neoplasm Staging,Retrospective Studies,Risk Factors,Survival Rate,Treatment Outcome}
}

@article{wu862,
  title = {Comparing {{Western}} and {{Eastern}} Criteria for Sarcopenia and Their Association with Survival in Patients with Pancreatic Cancer},
  author = {Wu, Chih-Horng and Chang, Ming-Chu and Lyadov, Vladimir K. and Liang, Po-Chin and Chen, Chyi-Mong and Shih, Tiffany Ting-Fang and Chang, Yu-Ting},
  year = {2019},
  month = apr,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {38},
  number = {2},
  pages = {862--869},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2018.02.016},
  abstract = {BACKGROUND \& AIMS: Sarcopenia and cachexia are associated with pancreatic cancer and serve as important adverse prognostic factors. Body composition can be analyzed by routine computed tomography (CT) for cancer staging and has been used to study many types of cancer. The CT measurements are robust, but the diagnostic criteria for sarcopenia vary among different studies. Age, sex and race are important factors that affect muscle and fat masses. This study aimed to analyze the effect of different sarcopenia diagnostic criteria on the prognosis of patients with pancreatic cancer. METHODS: Patients with newly diagnosed pancreatic cancer at National Taiwan University Hospital between October 2013 and October 2016 were retrospectively reviewed in this study. Body composition was assessed using cross-sectional CT images to calculate the total skeletal muscle (TSM) index. The concordance and interobserver variability of the TSM measurements were evaluated using both the Western criteria and the Eastern criteria. Kaplan-Meier analyses and the Cox proportional hazard ratio with two different diagnostic criteria for sarcopenia were used to compare the effect on overall survival (OS). RESULTS: A total of 146 patients with pancreatic cancer were enrolled. The TSM index measured by the Western institute was highly correlated with that measured by the Eastern institute (r~=~0.953, p~{$<~$}0.001). The prevalence of sarcopenia in the patient group at baseline was 66.4\% (97/146) by the Western criteria and 11.0\% (16/146) by the Eastern criteria, and only low agreement was found between the Western and Eastern criteria (Kappa value~=~0.028, p~=~0.149). Patients who were sarcopenic by the Western criteria showed no significant difference in OS versus those who were not sarcopenic (p~=~0.807). However, patients who were sarcopenic by the Eastern criteria showed a significant difference in OS versus those who were not sarcopenic in a univariate analysis (p~=~0.008) and multivariate analysis after adjustment for AJCC stage (p~=~0.014). CONCLUSIONS: Our study demonstrates that different diagnostic criteria may result in different diagnoses and that sarcopenia is an important poor prognostic factor for pancreatic cancer when appropriate diagnostic criteria are selected.},
  langid = {english},
  pmid = {29503056},
  keywords = {Adult,Aged,Aged; 80 and over,Body compositions,Female,Humans,Intra-abdominal fat,Kaplan-Meier Estimate,Male,Middle Aged,Muscle; Skeletal,Pancreatic,Pancreatic neoplasms,Pancreatic Neoplasms,Prognosis,Retrospective Studies,Sarcopenia,Taiwan,Tomography scanners,Tomography; X-Ray Computed,X-ray computed}
}

@article{xiao615,
  title = {The Association of Medical and Demographic Characteristics with Sarcopenia and Low Muscle Radiodensity in Patients with Nonmetastatic Colorectal Cancer},
  author = {Xiao, Jingjie and Caan, Bette J. and Cespedes Feliciano, Elizabeth M. and Meyerhardt, Jeffrey A. and Kroenke, Candyce H. and Baracos, Vickie E. and Weltzien, Erin and Kwan, Marilyn L. and Alexeeff, Stacey E. and Castillo, Adrienne L. and Prado, Carla M.},
  year = {2019},
  month = mar,
  journal = {The American Journal of Clinical Nutrition},
  volume = {109},
  number = {3},
  pages = {615--625},
  issn = {1938-3207},
  doi = {10.1093/ajcn/nqy328},
  abstract = {BACKGROUND: Sarcopenia and low skeletal muscle radiodensity (SMD) have been associated with adverse outcomes in patients with colorectal cancer (CRC); however, factors contributing to these 2 muscle abnormalities are unclear. OBJECTIVES: The aim of this study was to investigate the association of medical and demographic characteristics with muscle abnormalities among patients with nonmetastatic CRC. METHODS: Patients with stage I-III invasive CRC (2006-11) who had diagnostic computed tomography (CT) available from Kaiser Permanente Northern California electronic medical records were included. CT-assessed sarcopenia and low SMD were defined according to optimal stratification. Logistic regressions including age, stage, site, total adipose tissue (TAT), race/ethnicity, neutrophil-lymphocyte ratio, smoking history, alcohol use, and Charlson Comorbidity Score were performed to identify characteristics associated with muscle abnormalities. RESULTS: The study included 3262 patients (49.9\% females) with a mean {$\pm$} SD age of 62.6 {$\pm$} 11.4 y. Sarcopenia and low SMD were highly prevalent (42.4\% and 29.6\%, respectively). Age and sex interactions were noted for muscle mass, but not SMD. Age was associated with higher odds of muscle abnormalities in a dose-response manner. Compared with those aged {$\leq$}50 y, patients aged 70-80 y had considerably higher odds (OR: 6.19; 95\% CI: 4.72, 8.11) of sarcopenia, and low SMD (OR: 17.81; 95\% CI: 11.73, 27.03). High TAT was related to a higher odds of low SMD (OR: 9.62; 95\% CI: 7.37, 12.56), but lower odds of sarcopenia (OR: 0.59; 95\% CI: 0.48, 0.71). Compared with Caucasians, African Americans had lower odds of sarcopenia and low SMD. Patients with a higher neutrophil-lymphocyte ratio had higher odds of having both muscle abnormalities. Patients who were smokers or had any comorbidity had higher odds of low SMD, but not sarcopenia. CONCLUSIONS: Muscle abnormalities were common in patients with nonmetastatic CRC, with great variability in muscle mass and SMD across age, TAT, and race/ethnicity. Factors associated with muscle abnormalities may be used to facilitate risk stratification and the guidance of targeted strategies to counteract these abnormalities.},
  langid = {english},
  pmcid = {PMC6408202},
  pmid = {30850836},
  keywords = {Adipose Tissue,adiposity,Adolescent,Adult,Aged,Aged; 80 and over,Body Composition,Colorectal Neoplasms,computed tomography (CT),Demography,Disparities;Colorectal,Female,Humans,inflammation,Male,Middle Aged,muscle radiodensity,Muscle; Skeletal,nonmetastatic colorectal cancer,race/ethnicity,sarcopenia,Sarcopenia,Tomography; X-Ray Computed,Young Adult},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\Q9ZRSELU\\Xiao et al. - 2019 - The association of medical and demographic charact.pdf}
}

@article{xiao8,
  title = {Association of {{Low Muscle Mass}} and {{Low Muscle Radiodensity With Morbidity}} and {{Mortality}} for {{Colon Cancer Surgery}}},
  author = {Xiao, Jingjie and Caan, Bette J and Feliciano, Elizabeth M Cespedes and Meyerhardt, Jeffrey A and Peng, Peter D and Baracos, Vickie E and Lee, Valerie S and Ely, Sora and Gologorsky, Rebecca C and Weltzien, Erin and Kroenke, Candyce H and Kwan, Marilyn L and Alexeeff, Stacey E and Castillo, Adrienne L and Prado, Carla M},
  year = {2020},
  pages = {8},
  abstract = {OBJECTIVE To examine the associations of muscle characteristics with postoperative complications, length of hospital stay (LOS), readmission, and mortality in patients with colon cancer. DESIGN, SETTING, AND PARTICIPANTS This population-based retrospective cohort study was conducted among 1630 patients who received a diagnosis of stage I to III colon cancer from January 2006 to December 2011 at Kaiser Permanente Northern California, an integrated health care system. Preliminary data analysis started in 2017. Because major complication data were collected between 2018 and 2019, the final analysis using the current cohort was conducted between 2019 and 2020. EXPOSURES Low skeletal muscle index (SMI) and/or low skeletal muscle radiodensity (SMD) levels were assessed using preoperative computerized tomography images. MAIN OUTCOMES AND MEASURES Length of stay, any complication (Õ1 predefined complications) or major complications (Clavien-Dindo classification score Õ3), 30-day mortality and readmission up to 30 days postdischarge, and overall mortality. RESULTS The mean (SD) age at diagnosis was 64.0 (11.3) years and 906 (55.6\%) were women. Patients with low SMI or low SMD were more likely to remain hospitalized 7 days or longer after surgery (odds ratio [OR], 1.33; 95\% CI, 1.05-1.68; OR, 1.39; 95\% CI, 1.05-1.84, respectively) and had higher risks of overall mortality (hazard ratio, 1.40; 95\% CI, 1.13-1.74; hazard ratio, 1.44; 95\% CI, 1.12-1.85, respectively). Additionally, patients with low SMI were more likely to have 1 or more postsurgical complications (OR, 1.31; 95\% CI, 1.04-1.65) and had higher risk of 30-day mortality (OR, 4.85; 95\% CI, 1.23-19.15). Low SMD was associated with higher odds of having major complications (OR, 2.41; 95\% CI, 1.44-4.04). CONCLUSIONS AND RELEVANCE Low SMI and low SMD were associated with longer LOS, higher risk of postsurgical complications, and short-term and long-term mortality. Research should evaluate whether targeting potentially modifiable factors preoperatively, such as preserving muscle mass, could reverse the observed negative associations with postoperative outcomes.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\B4HL8ARX\\Xiao et al. - 2020 - Association of Low Muscle Mass and Low Muscle Radi.pdf}
}

@article{xuAnalysisDefinitiveChemoradiotherapy2018,
  title = {Analysis of Definitive Chemo-Radiotherapy for Esophageal Cancer with Supra-Clavicular Node Metastasis Based on {{CT}} in a Single Institutional Retrospective Study: {{A}} Propensity Score Matching Analysis},
  shorttitle = {Analysis of Definitive Chemo-Radiotherapy for Esophageal Cancer with Supra-Clavicular Node Metastasis Based on {{CT}} in a Single Institutional Retrospective Study},
  author = {Xu, Hong-Yao and Wu, Sheng-Xi and Luo, He-San and Chen, Chu-Yun and Lin, Lian-Xing and Huang, He-Cheng},
  year = {2018},
  month = oct,
  journal = {Radiation Oncology},
  volume = {13},
  number = {1},
  pages = {200},
  issn = {1748-717X},
  doi = {10.1186/s13014-018-1145-4},
  abstract = {BACKGROUND: The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear. METHOD: From January 2009 to December 2015, a survival analysis was performed to retrospectively identify the prognostic value of SCLN metastasis on survival on 751 patients with EC treated with definitive chemo-radiotherapy (dCRT). RESULTS: The median follow-up duration for living patients was 56.6 months. The median overall survival (OS) for all patients was 16.6 months. Patients with SCLN metastasis had a much poorer prognosis for OS ({$\chi$}2 = 17.342, P\,{$<$}\,0.001), distant metastasis-free survival (DMFS) ({$\chi$}2 = 24.793, P\,{$<$} 0.001) and progression-free survival (PFS) ({$\chi$}2 = 25.802, P\,{$<$} 0.001) than those without SCLN metastasis. The same results were found after propensity score matching. Nonetheless, the prognosis of patients with cervical or upper thoracic EC metastasis in SCLN was better than those of patients with middle or lower thoracic EC metastasis in SCLN for OS ({$\chi$}2 = 4.516, P\,= 0.038), DMFS ({$\chi$}2 = 8.326, P\,=\,0.004) and PFS ({$\chi$}2 = 6.255, P\,= 0.012). Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for PFS. Gender, age, middle or lower thoracic EC with SCLN metastasis, tumor diameter, tumor length, and number of lymph nodes were prognostic factors for DMFS. According to the multivariate analysis, only middle or lower thoracic EC with SCLN metastasis and number of lymph nodes were independent prognostic factors for DMFS and PFS. CONCLUSION: For patients with cervical or upper thoracic EC, metastasis in SCLN should be considered to be regional lymph nodes and treated with curative intent if the total number of lymph nodes is limited. However, for patients with middle or lower thoracic EC, metastasis should be considered to be a higher level N stage or M1 stage, and it is thus necessary to provide consolidation chemotherapy after dCRT.},
  langid = {english},
  pmcid = {PMC6192107},
  pmid = {30326912},
  keywords = {Aged,Carcinoma,Chemoradiotherapy,Clavicle,Definitive chemo-radiotherapy,Esophageal cancer,Esophageal Neoplasms,Female,Follow-Up Studies,Humans,Lymph Nodes,Lymphatic Metastasis,Male,Prognosis,Retrospective Studies,Squamous Cell,Supra-clavicular lymph node,Survival Rate,Tomography,X-Ray Computed},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\XMX7K26T\\Xu et al. - 2018 - Analysis of definitive chemo-radiotherapy for esop.pdf}
}

@article{xue967,
  title = {Association of {{Postoperative Transfusion Strategy}} with {{Short-term Outcomes}} in {{Surgical Oncology Patients}}},
  author = {Xue, Fu-Shan and Liu, Gao-Pu and Li, Rui-Ping},
  year = {2015},
  month = oct,
  journal = {Anesthesiology},
  volume = {123},
  number = {4},
  pages = {967--968},
  issn = {1528-1175},
  doi = {10.1097/ALN.0000000000000800},
  langid = {english},
  pmid = {26372128},
  keywords = {Abdominal Neoplasms,Erythrocyte Transfusion,Female,Humans,Male,SurgOnc}
}

@article{yagi71,
  title = {Prognostic Factors in Stage {{IV}} Gastric Cancer: Univariate and Multivariate Analyses},
  shorttitle = {Prognostic Factors in Stage {{IV}} Gastric Cancer},
  author = {Yagi, Yoshinori and Seshimo, Akiyoshi and Kameoka, Shingo},
  year = {2000},
  month = sep,
  journal = {Gastric Cancer},
  volume = {3},
  number = {2},
  pages = {71--80},
  issn = {1436-3291},
  doi = {10.1007/PL00011699},
  langid = {english},
  keywords = {Stage4},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8LNHURYR\\Yagi et al. - 2000 - Prognostic factors in stage IV gastric cancer uni.pdf}
}

@article{yanagawa872,
  title = {Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: {{PET}} Response Criteria in Solid Tumors versus Response Evaluation Criteria in Solid Tumors},
  shorttitle = {Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer},
  author = {Yanagawa, Masahiro and Tatsumi, Mitsuaki and Miyata, Hiroshi and Morii, Eiichi and Tomiyama, Noriyuki and Watabe, Tadashi and Isohashi, Kayako and Kato, Hiroki and Shimosegawa, Eku and Yamasaki, Makoto and Mori, Masaki and Doki, Yuichiro and Hatazawa, Jun},
  year = {2012},
  month = jun,
  journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
  volume = {53},
  number = {6},
  pages = {872--880},
  issn = {1535-5667},
  doi = {10.2967/jnumed.111.098699},
  abstract = {Recently, PET response criteria in solid tumors (PERCIST) have been proposed as a new standardized method to assess chemotherapeutic response metabolically and quantitatively. The aim of this study was to evaluate therapeutic response to neoadjuvant chemotherapy for locally advanced esophageal cancer, comparing PERCIST with the currently widely used response evaluation criteria in solid tumors (RECIST). METHODS: Fifty-one patients with locally advanced esophageal cancer who received neoadjuvant chemotherapy (5-fluorouracil, adriamycin, and cisplatin), followed by surgery were studied. Chemotherapeutic lesion responses were evaluated using (18)F-FDG PET and CT according to the RECIST and PERCIST methods. The PET/CT scans were obtained before chemotherapy and about 2 wk after completion of chemotherapy. Associations were statistically analyzed between survival (overall and disease-free survival) and clinicopathologic results (histology [well-, moderately, and poorly differentiated squamous cell carcinoma], lymphatic invasion, venous invasion, clinical stage, pathologic stage, resection level, reduction rate of tumor diameter, reduction rate of tumor uptake, chemotherapeutic responses in RECIST and PERCIST, and pathologic response). RESULTS: There was a significant difference in response classification between RECIST and PERCIST (Wilcoxon signed-rank test, P {$<$} 0.0001). Univariate analysis showed that lymphatic invasion, venous invasion, resection level, pathologic stage, and PERCIST were significant factors associated with disease-free or overall survival in this study. Although multivariate analysis demonstrated that venous invasion (disease-free survival: hazard ratio [HR] = 4.519, P = 0.002; overall survival: HR = 5.591, P = 0.003) and resection level (disease-free survival: HR = 11.078, P = 0.001) were the significant predictors, PERCIST was also significant in noninvasive therapy response assessment before surgery (disease-free survival: HR = 4.060, P = 0.025; overall survival: HR = 8.953, P = 0.034). CONCLUSION: RECIST based on the anatomic size reduction rate did not demonstrate the correlation between therapeutic responses and prognosis in patients with esophageal cancer receiving neoadjuvant chemotherapy. However, PERCIST was found to be the strongest independent predictor of outcomes. Given the significance of noninvasive radiologic imaging in formulating clinical treatment strategies, PERCIST might be considered more suitable for evaluation of chemotherapeutic response to esophageal cancer than RECIST.},
  langid = {english},
  pmid = {22582049},
  keywords = {Aged,Chemotherapy; Adjuvant,Esophageal Neoplasms,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Positron-Emission Tomography,Proportional Hazards Models},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\QC5NW4XD\\Yanagawa et al. - 2012 - Evaluation of response to neoadjuvant chemotherapy.pdf}
}

@article{yang101,
  title = {Prognostic {{Value}} of {{Sarcopenia}} in {{Lung Cancer}}: {{A Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Prognostic {{Value}} of {{Sarcopenia}} in {{Lung Cancer}}},
  author = {Yang, Ming and Shen, Yanjiao and Tan, Lingling and Li, Weimin},
  year = {2019},
  month = jul,
  journal = {Chest},
  volume = {156},
  number = {1},
  pages = {101--111},
  issn = {1931-3543},
  doi = {10.1016/j.chest.2019.04.115},
  abstract = {BACKGROUND: Evidence regarding the association between sarcopenia (skeletal muscle depletion) and outcomes in patients with lung cancer varies across studies. We aimed to systematically review the prognostic value of sarcopenia in lung cancer. METHODS: We searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through July 23, 2018 to identify retrospective or prospective cohort studies. We applied the Quality in Prognostic Studies instrument to assess the risk of bias in individual studies. We examined the heterogeneity and publication bias and performed subgroup analyses and sensitivity analyses. RESULTS: We included 13 studies (1,810 participants). The pooled prevalence of sarcopenia was 43\%~in patients with non-small cell lung cancer (NSCLC) and 52\%~in patients with small cell lung cancer (SCLC). Sarcopenia was associated with a shorter overall survival (OS) in patients with lung cancer (hazard ratio [HR], 2.23; 95\%~CI, 1.68-2.94). This association existed for both NSCLC (HR, 2.57; 95\%~CI, 1.79-3.68) and SCLC (HR, 1.59; 95\%~CI, 1.17-2.14). Sarcopenia was an independent predictor of shorter OS in both stage I-II NSCLC (HR, 3.23; 95\%~CI, 1.68-6.23) and stage III-IV NSCLC (HR, 2.19; 95\%~CI, 1.14-4.24). However, sarcopenia was not an independent predictor of disease-free survival in patients with NSCLC (HR, 1.28; 95\%~CI, 0.44-3.69). CONCLUSIONS: Sarcopenia is highly prevalent in patients with lung cancer (approximately one in two) and an important predictor of impaired OS in patients with SCLC or with different stages of NSCLC.},
  langid = {english},
  pmid = {31128115},
  keywords = {Carcinoma; Non-Small-Cell Lung,Carcinoma; Small Cell,Humans,Lung,lung cancer,Lung Neoplasms,prognosis,Prognosis,sarcopenia,Sarcopenia,Survival Analysis,systematic review}
}

@article{yang2796,
  title = {Neoadjuvant {{Chemoradiotherapy Followed}} by {{Surgery Versus Surgery Alone}} for {{Locally Advanced Squamous Cell Carcinoma}} of the {{Esophagus}} ({{NEOCRTEC5010}}): {{A Phase III Multicenter}}, {{Randomized}}, {{Open-Label Clinical Trial}}},
  shorttitle = {Neoadjuvant {{Chemoradiotherapy Followed}} by {{Surgery Versus Surgery Alone}} for {{Locally Advanced Squamous Cell Carcinoma}} of the {{Esophagus}} ({{NEOCRTEC5010}})},
  author = {Yang, Hong and Liu, Hui and Chen, Yuping and Zhu, Chengchu and Fang, Wentao and Yu, Zhentao and Mao, Weimin and Xiang, Jiaqing and Han, Yongtao and Chen, Zhijian and Yang, Haihua and Wang, Jiaming and Pang, Qingsong and Zheng, Xiao and Yang, Huanjun and Li, Tao and Lordick, Florian and D'Journo, Xavier Benoit and Cerfolio, Robert J. and Korst, Robert J. and Novoa, Nuria M. and Swanson, Scott J. and Brunelli, Alessandro and Ismail, Mahmoud and Fernando, Hiran C. and Zhang, Xu and Li, Qun and Wang, Geng and Chen, Baofu and Mao, Teng and Kong, Min and Guo, Xufeng and Lin, Ting and Liu, Mengzhong and Fu, Jianhua and {AME Thoracic Surgery Collaborative Group}},
  year = {2018},
  month = sep,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {36},
  number = {27},
  pages = {2796--2803},
  issn = {1527-7755},
  doi = {10.1200/JCO.2018.79.1483},
  abstract = {Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients and Methods From June 2007 to December 2014, 451 patients with potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated to NCRT plus surgery (group CRT; n = 224) and surgery alone (group S; n = 227). In group CRT, patients received vinorelbine 25 mg/m2 intravenously (IV) on days 1 and 8 and cisplatin 75 mg/m2 IV day 1, or 25 mg/m2 IV on days 1 to 4 every 3 weeks for two cycles, with a total concurrent radiation dose of 40.0 Gy administered in 20 fractions of 2.0 Gy on 5 days per week. In both groups, patients underwent McKeown or Ivor Lewis esophagectomy. The primary end point was overall survival. Results The pathologic complete response rate was 43.2\% in group CRT. Compared with group S, group CRT had a higher R0 resection rate (98.4\% v 91.2\%; P = .002), a better median overall survival (100.1 months v 66.5 months; hazard ratio, 0.71; 95\% CI, 0.53 to 0.96; P = .025), and a prolonged disease-free survival (100.1 months v 41.7 months; hazard ratio, 0.58; 95\% CI, 0.43 to 0.78; P {$<$} .001). Leukopenia (48.9\%) and neutropenia (45.7\%) were the most common grade 3 or 4 adverse events during chemoradiotherapy. Incidences of postoperative complications were similar between groups, with the exception of arrhythmia (group CRT: 13\% v group S: 4.0\%; P = .001). Peritreatment mortality was 2.2\% in group CRT versus 0.4\% in group S ( P = .212). Conclusion This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.},
  langid = {english},
  pmcid = {PMC6145832},
  pmid = {30089078},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemoradiotherapy; Adjuvant,Cisplatin,Disease-Free Survival,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Female,Humans,Incidence,Male,Middle Aged,Neoadjuvant Therapy,Postoperative Complications,Treatment Outcome,Vinorelbine},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\6NCLMHG8\\Yang et al. - 2018 - Neoadjuvant Chemoradiotherapy Followed by Surgery .pdf}
}

@article{yange2012534,
  title = {Association of {{Sex}}, {{Age}}, and {{Eastern Cooperative Oncology Group Performance Status With Survival Benefit}} of {{Cancer Immunotherapy}} in {{Randomized Clinical Trials}}: {{A Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Association of {{Sex}}, {{Age}}, and {{Eastern Cooperative Oncology Group Performance Status With Survival Benefit}} of {{Cancer Immunotherapy}} in {{Randomized Clinical Trials}}},
  author = {Yang, Fang and Markovic, Svetomir N. and Molina, Julian R. and Halfdanarson, Thorvardur R. and Pagliaro, Lance C. and Chintakuntlawar, Ashish V. and Li, Rutian and Wei, Jia and Wang, Lifeng and Liu, Baorui and Nowakowski, Grzegorz S. and Wang, Michael L. and Wang, Yucai},
  year = {2020},
  month = aug,
  journal = {JAMA network open},
  volume = {3},
  number = {8},
  pages = {e2012534},
  issn = {2574-3805},
  doi = {10.1001/jamanetworkopen.2020.12534},
  abstract = {IMPORTANCE: Sex, age, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) may affect immune response. However, the association of these factors with the survival benefit of cancer immunotherapy with immune checkpoint inhibitors (ICIs) remains unclear. OBJECTIVE: To assess the potential sex, age, and ECOG PS differences of immunotherapy survival benefit in patients with advanced cancer. DATA SOURCES: PubMed, Web of Science, Embase, and Scopus were searched from inception to August 31, 2019. STUDY SELECTION: Published randomized clinical trials comparing overall survival (OS) in patients with advanced cancer treated with ICI immunotherapy vs non-ICI control therapy were included. DATA EXTRACTION AND SYNTHESIS: Pooled OS hazard ratio (HR) and 95\% CI for patients of different sex, age ({$<$}65 and {$\geq$}65 years) or ECOG PS (0 and {$\geq$}1) were calculated separately using a random-effects model, and the heterogeneity between paired estimates was assessed using an interaction test by pooling study-specific interaction HRs. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. MAIN OUTCOMES AND MEASURES: The difference in survival benefit of ICIs between sex, age ({$<$}65 vs {$\geq$}65 years), and ECOG PS (0 vs {$\geq$}1), as well as the difference stratified by cancer type, line of therapy, agent of immunotherapy, and immunotherapy strategy in the intervention arm. RESULTS: Thirty-seven phase 2 or 3 randomized clinical trials involving 23\,760 patients were included. An OS benefit of immunotherapy was found for both men (HR, 0.75; 95\% CI, 0.71-0.81) and women (HR, 0.79; 95\% CI, 0.72-0.88); for both younger ({$<$}65 years: HR, 0.77; 95\% CI, 0.71-0.83) and older ({$\geq$}65 years: HR, 0.78; 95\% CI, 0.72-0.84) patients; and for both patients with ECOG PS 0 (HR, 0.81; 95\% CI, 0.73-0.90) and PS greater than or equal to 1 (HR, 0.79; 95\% CI, 0.74-0.84). No significant difference of relative benefit from immunotherapy over control therapy was found in patients of different sex (P\,=\,.25, I2\,=\,19.02\%), age (P\,=\,.94, I2\,=\,15.57\%), or ECOG PS (P\,=\,.74, I2\,=\,0\%). No significant difference was found in subgroup analyses by cancer type, line of therapy, agent of immunotherapy, and immunotherapy strategy in the intervention arm. CONCLUSIONS AND RELEVANCE: This meta-analysis found no evidence of an association of sex, age ({$<$}65 vs {$\geq$}65 years), or ECOG PS (0 vs {$\geq$}1) with cancer immunotherapy survival benefit. This finding suggests that the use of ICIs in advanced cancer should not be restricted to certain patients in sex, age, or ECOG PS categories.},
  langid = {english},
  pmcid = {PMC7414387},
  pmid = {32766800},
  keywords = {Age Factors,Aged,Female,Humans,ICI,Immunotherapy,Male,Middle Aged,Neoplasms,Randomized Controlled Trials as Topic,Sex Factors,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\8NZYN5C5\\Yang et al_2020_Association of Sex, Age, and Eastern Cooperative Oncology Group Performance.pdf}
}

@article{yao543,
  title = {Diagnosing Sarcopenia at the Point of Imaging Care: Analysis of Clinical, Functional, and Opportunistic {{CT}} Metrics},
  shorttitle = {Diagnosing Sarcopenia at the Point of Imaging Care},
  author = {Yao, Lawrence and Petrosyan, Anahit and Fuangfa, Praman and Lenchik, Leon and Boutin, Robert D.},
  year = {2021},
  month = mar,
  journal = {Skeletal Radiology},
  volume = {50},
  number = {3},
  pages = {543--550},
  issn = {1432-2161},
  doi = {10.1007/s00256-020-03576-9},
  abstract = {OBJECTIVE: To determine the relationship between CT-derived muscle metrics and standardized metrics of sarcopenia in patients undergoing routine CT imaging. MATERIALS AND METHODS: Data collected in 443 consecutive patients included body CT, grip strength, usual gait speed, and responses to SARC-F and FRAIL scale questionnaires. Functional and clinical metrics of sarcopenia were acquired at the time of CT. Metrics were analyzed using the diagnostic framework of the European Working Group on Sarcopenia in Older People (EWGSOP2). The skeletal muscle index (SMI) and skeletal muscle density (SMD) were measured at the T12 and L3 levels. Statistical methods include linear prediction models and ROC analysis. RESULTS: T12-SMD and L3-SMD in women and T12-SMD and L3-SMI in men show weak but significant (p\,{$<$}\,0.05) predictive value for gait speed, after adjusting for subject age and body mass index. The prevalence of abnormal CT SMI at T12 and L3 was 29\% and 71\%, respectively, corresponding to prevalences of confirmed sarcopenia by EWGSOP2 of 10\% and 15\%, respectively. The agreement of abnormal SARC-F and FRAIL scale screening and EWGSOP2 confirmed sarcopenia was slight to fair (kappa: 0.20-0.28). CT cutpoints, based on EWGSOP2 criteria for abnormal grip strength or gait speed, are generally lower than cutpoints based on normative population data. CONCLUSION: Collection of clinical and functional sarcopenia information at the point of imaging care can be accomplished quickly and safely. CT-derived muscle metrics show convergent validity with gait speed. Only a minority of subjects with low CT metrics have confirmed sarcopenia by EWGSOP2 definition.},
  langid = {english},
  pmid = {32892227},
  keywords = {Aged,Benchmarking,Cross-Sectional Studies,CT,Female,Frailty,Geriatric Assessment,Humans,Male,Muscle,Opportunistic CT,Physiometry,Sarcopenia,Screening,Tomography; X-Ray Computed}
}

@article{ychou1715,
  title = {Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An {{FNCLCC}} and {{FFCD}} Multicenter Phase {{III}} Trial},
  shorttitle = {Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma},
  author = {Ychou, Marc and Boige, Val{\'e}rie and Pignon, Jean-Pierre and Conroy, Thierry and Bouch{\'e}, Olivier and Lebreton, Gilles and Ducourtieux, Muriel and Bedenne, Laurent and Fabre, Jean-Michel and {Saint-Aubert}, Bernard and Gen{\`e}ve, Jean and Lasser, Philippe and Rougier, Philippe},
  year = {2011},
  month = may,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {29},
  number = {13},
  pages = {1715--1721},
  issn = {1527-7755},
  doi = {10.1200/JCO.2010.33.0597},
  abstract = {PURPOSE: After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma. PATIENTS AND METHODS: Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS. RESULTS: Compared with the S group, the CS group had a better OS (5-year rate 38\% v 24\%; hazard ratio [HR] for death: 0.69; 95\% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34\% v 19\%; HR, 0.65; 95\% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P {$<$} .01). Perioperative chemotherapy significantly improved the curative resection rate (84\% v 73\%; P = .04). Grade 3 to 4 toxicity occurred in 38\% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups. CONCLUSION: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.},
  langid = {english},
  pmid = {21444866},
  keywords = {Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Cisplatin,Combined Modality Therapy,Disease-Free Survival,Drug Administration Schedule,Esophageal Neoplasms,Esophagogastric Junction,Female,Fluorouracil,Humans,Male,Middle Aged,Perioperative Period,Stomach Neoplasms}
}

@article{ye1734,
  title = {Para-Aortic Lymph Node Metastasis in Lower {{Thoracic Esophageal Squamous Cell Carcinoma}} after {{Radical Esophagectomy}}: A {{CT-based}} Atlas and Its Clinical Implications for {{Adjuvant Radiotherapy}}},
  shorttitle = {Para-Aortic Lymph Node Metastasis in Lower {{Thoracic Esophageal Squamous Cell Carcinoma}} after {{Radical Esophagectomy}}},
  author = {Ye, Luxi and Zhou, Lijun and Wang, Shengping and Sun, Lining and Wang, Jiazhou and Liu, Quan and Yang, Xi and Chu, Li and Zhang, Xiaofei and Hu, Weigang and Lin, Jie and Zhu, Zhengfei},
  year = {2021},
  journal = {Journal of Cancer},
  volume = {12},
  number = {6},
  pages = {1734--1741},
  issn = {1837-9664},
  doi = {10.7150/jca.51212},
  abstract = {Background: Our previous work showed that para-aortic lymph node (PALN) metastasis was the major failure pattern in lower thoracic esophageal squamous cell carcinoma (LTESCC) patients who presented abdominal LN failure after curative surgery. We thereby aim to generate a computerized tomography (CT)-based documentation of PALNs and to propose a clinical target volume (CTV) for this region. Methods: Sixty-five patients were enrolled. The epicentre of each PALN was drawn onto an axial CT image of a standard patient with reference to the surrounding anatomical landmarks. A CTV for PALN was generated based on the final result of node distribution, and was evaluated for dosimetric performance in three simulated patients. Results: All the studied 248 LNs were below the level of 1.0 cm above the celiac artery (CA), and 94.76\% were above the bottom of vertebra L3. Horizontally, 93.33\% of the LNs in the celiac level were located within an expansion of 1.5 cm on the CA, and 94.12\% of the LNs in the superior mesenteric artery (SMA) level were within 1.5 cm on the left side of the SMA. Below the SMA, all the LNs were behind the left renal vein, left to the right border of the inferior vena cava, and 98.51\% of the LNs were medial to the lateral surface of the left psoas major. The proposed CTV could cover 92.74\% of the LNs and was dosimetrically feasible. Conclusions: The proposed CTV is the first one to focus on the high-risk area of abdominal failure in LTESCC patients after surgery and can serve as a reference in the adjuvant radiotherapy for LTESCC patients.},
  langid = {english},
  pmcid = {PMC7890317},
  pmid = {33613762},
  keywords = {adjuvant radiotherapy,computed tomography,esophageal squamous cell carcinoma,lymph node,Nodes,PET,radiation therapy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\T8UHB5C9\\Ye et al_2021_Para-aortic lymph node metastasis in lower Thoracic Esophageal Squamous Cell.pdf}
}

@article{yeungCD009121,
  title = {Paravertebral Block versus Thoracic Epidural for Patients Undergoing Thoracotomy},
  author = {Yeung, Joyce H. Y. and Gates, Simon and Naidu, Babu V. and Wilson, Matthew J. A. and Gao Smith, Fang},
  year = {2016},
  month = feb,
  journal = {The Cochrane Database of Systematic Reviews},
  volume = {2},
  pages = {CD009121},
  issn = {1469-493X},
  doi = {10.1002/14651858.CD009121.pub2},
  abstract = {BACKGROUND: Operations on structures in the chest (usually the lungs) involve cutting between the ribs (thoracotomy). Severe post-thoracotomy pain can result from pleural (lung lining) and muscular damage, costovertebral joint (ribcage) disruption and intercostal nerve (nerves that run along the ribs) damage during surgery. Poor pain relief after surgery can impede recovery and increase the risks of developing complications such as lung collapse, chest infections and blood clots due to ineffective breathing and clearing of secretions. Effective management of acute pain following thoracotomy may prevent these complications and reduce the likelihood of developing chronic pain. A multi-modal approach to analgesia is widely employed by thoracic anaesthetists using a combination of regional anaesthetic blockade and systemic analgesia, with both non-opioid and opioid medications and local anaesthesia blockade.There is some evidence that blocking the nerves as they emerge from the spinal column (paravertebral block, PVB) may be associated with a lower risk of major complications in thoracic surgery but the majority of thoracic anaesthetists still prefer to use a thoracic epidural blockade (TEB) as analgesia for their patients undergoing thoracotomy. In order to bring about a change in practice, anaesthetists need a review that evaluates the risk of all major complications associated with thoracic epidural and paravertebral block in thoracotomy. OBJECTIVES: To compare the two regional techniques of TEB and PVB in adults undergoing elective thoracotomy with respect to:1. analgesic efficacy;2. the incidence of major complications (including mortality);3. the incidence of minor complications;4. length of hospital stay;5. cost effectiveness. SEARCH METHODS: We searched for studies in the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 9); MEDLINE via Ovid (1966 to 16 October 2013); EMBASE via Ovid (1980 to 16 October 2013); CINAHL via EBSCO host (1982 to 16 October 2013); and reference lists of retrieved studies. We handsearched the Journal of Cardiothoracic Surgery and Journal of Cardiothoracic and Vascular Anesthesia (16 October 2013). We reran the search on 31st January 2015. We found one additional study which is awaiting classification and will be addressed when we update the review. SELECTION CRITERIA: We included all randomized controlled trials (RCTs) comparing PVB with TEB in thoracotomy, including upper gastrointestinal surgery. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. Two review authors (JY and SG) independently assessed the studies for inclusion and then extracted data as eligible for inclusion in qualitative and quantitative synthesis (meta-analysis). MAIN RESULTS: We included 14 studies with a total of 698 participants undergoing thoracotomy. There are two studies awaiting classification. The studies demonstrated high heterogeneity in insertion and use of both regional techniques, reflecting real-world differences in the anaesthesia techniques. Overall, the included studies have a moderate to high potential for bias, lacking details of randomization, group allocation concealment or arrangements to blind participants or outcome assessors. There was low to very low-quality evidence that showed no significant difference in 30-day mortality (2 studies, 125 participants. risk ratio (RR) 1.28, 95\% confidence interval (CI) 0.39 to 4.23, P value = 0.68) and major complications (cardiovascular: 2 studies, 114 participants. Hypotension RR 0.30, 95\% CI 0.01 to 6.62, P value = 0.45; arrhythmias RR 0.36, 95\% CI 0.04 to 3.29, P value = 0.36, myocardial infarction RR 3.19, 95\% CI 0.13, 76.42, P value = 0.47); respiratory: 5 studies, 280 participants. RR 0.62, 95\% CI 0.26 to 1.52, P value = 0.30). There was moderate-quality evidence that showed comparable analgesic efficacy across all time points both at rest and after coughing or physiotherapy (14 studies, 698 participants). There was moderate-quality evidence that showed PVB had a better minor complication profile than TEB including hypotension (8 studies, 445 participants. RR 0.16, 95\% CI 0.07 to 0.38, P value {$<$} 0.0001), nausea and vomiting (6 studies, 345 participants. RR 0.48, 95\% CI 0.30 to 0.75, P value = 0.001), pruritis (5 studies, 249 participants. RR 0.29, 95\% CI 0.14 to 0.59, P value = 0.0005) and urinary retention (5 studies, 258 participants. RR 0.22, 95\% CI 0.11 to 0.46, P value {$<$} 0.0001). There was insufficient data in chronic pain (six or 12 months). There was no difference found in and length of hospital stay (3 studies, 124 participants). We found no studies that reported costs. AUTHORS' CONCLUSIONS: Paravertebral blockade reduced the risks of developing minor complications compared to thoracic epidural blockade. Paravertebral blockade was as effective as thoracic epidural blockade in controlling acute pain. There was a lack of evidence in other outcomes. There was no difference in 30-day mortality, major complications, or length of hospital stay. There was insufficient data on chronic pain and costs. Results from this review should be interpreted with caution due to the heterogeneity of the included studies and the lack of reliable evidence. Future studies in this area need well-conducted, adequately-powered RCTs that focus not only on acute pain but also on major complications, chronic pain, length of stay and costs.},
  langid = {english},
  pmcid = {PMC7151756},
  pmid = {26897642},
  keywords = {Acute Pain,Anesthesia; Epidural,Delirium,Humans,Hypotension,Length of Stay,Lung Diseases,Nerve Block,Pain; Postoperative,Randomized Controlled Trials as Topic,Thoracotomy},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\FNJBYISX\\Yeung et al_2016_Paravertebral block versus thoracic epidural for patients undergoing thoracotomy.pdf}
}

@article{yi-frazier51,
  type = {Journal {{Article}}},
  title = {A {{Person-Focused Analysis}} of {{Resilience Resources}} and {{Coping}} in {{Diabetes Patients}}},
  author = {{Yi-Frazier}, J. P. and Smith, R. E. and Vitaliano, P. P. and Yi, J. C. and Mai, S. and Hillman, M. and Weinger, K.},
  year = {2010},
  journal = {Stress Health},
  volume = {26},
  number = {1},
  pages = {51--60},
  issn = {1532-2998 (Electronic) 1532-3005 (Linking)}
}

@article{yibulayin304,
  type = {Journal {{Article}}},
  ids = {yibulayin304a},
  title = {Minimally Invasive Oesophagectomy versus Open Esophagectomy for Resectable Esophageal Cancer: A Meta-Analysis},
  author = {Yibulayin, W. and Abulizi, S. and Lv, H. and Sun, W.},
  year = {2016},
  journal = {World J Surg Oncol},
  volume = {14},
  number = {1},
  pages = {304},
  issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
  doi = {10.1186/s12957-016-1062-7},
  pmcid = {PMC5143462},
  pmid = {27927246},
  keywords = {Blood Loss; Surgical,Complications,Esophageal Neoplasms,Esophagectomy,Hospital Mortality,Humans,Length of Stay,Minimally invasive esophagectomy,Minimally Invasive Surgical Procedures,Mortality,Odds Ratio,Open esophagectomy,Operative Time,Postoperative Complications,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BKTXVEV5\\Yibulayin et al_2016_Minimally invasive oesophagectomy versus open esophagectomy for resectable.pdf}
}

@article{yoon10,
  title = {Predicting Unintentional Weight Loss in Patients with Gastrointestinal Cancer},
  author = {Yoon, Saunjoo L and Kim, Jung A and Kelly, Debra Lynch and Lyon, Debra and George, Thomas J},
  pages = {10},
  abstract = {Background Unintentional weight loss is a major problem for patients with gastrointestinal (GI) cancers because it affects treatment, survival outcomes, and quality of life. To date, little is known about the trajectory of weight loss and the relationship between baseline body mass index (BMI), location of the cancer, and outcomes. The aims of this study were to investigate patterns of weight loss over time in patients with GI cancer according to BMI groups (low, normal, and high) and location of cancer. Methods We examined de-identified electronic medical record data of 801 adults ({$>$}21 years) with GI cancer using ICD-9 codes (150\textendash 159). Descriptive statistics and linear mixed models were used to examine unintentional weight loss over time by BMI group (low, normal, and high) and to determine the effect of primary cancer site and patient characteristics on weight loss. Results The mean age of patients was 66.5 {$\pm$} 11.9 years (21\textendash 95 years), with 58\% male and 86\% White. Mean weight loss over 3 years was 21.39 kg. At the first observation point, 7.8\% were in the low BMI group, 30.1\% were in the normal, and 62\% were in the high group. At the end of observation, a majority of deaths (35.5\%) occurred in the low BMI group (BMI {$<$} 20 kg/m2). Significant weight loss was observed in patients with gastric (t = \`A5.11, P {$<$} 0.001), oesophageal (t = \`A4.18, P {$<$} 0.001), and pancreatic (35.8\%, t = \`A3.58, P {$<$} 0.001) cancers. Predictors of weight change were gender (F = 64.93, P {$<$} 0.001), cancer stage (F = 7.28, P {$<$} 0.001), and site by days (F = 8.24, P {$<$} 0.001). Weight loss rates were similar among the three BMI groups, but patterns were different based on primary cancer type as a function of days within each group. Conclusions Weight loss in patients with GI cancers has implications for survival. Patients with upper GI cancers experienced more weight loss and decreased survival rates compared with patients with lower GI cancers. Patients with a combination of upper GI cancer (oesophagogastric or pancreatic) and low baseline BMI had the fewest survival days and worst patient outcomes. Early intervention for weight management plays a critical role for improving the health outcomes and fatality rates of these patients.},
  langid = {english},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\BH873RZ8\\Yoon et al. - Predicting unintentional weight loss in patients w.pdf}
}

@article{yoshida346,
  type = {Journal {{Article}}},
  title = {Original Scoring System for Predicting Postoperative Morbidity after Esophagectomy for Esophageal Cancer},
  author = {Yoshida, N. and Baba, Y. and Watanabe, M. and Ida, S. and Ishimoto, T. and Karashima, R. and Iwagami, S. and Imamura, Y. and Sakamoto, Y. and Miyamoto, Y. and Baba, H.},
  year = {2015},
  journal = {Surg Today},
  volume = {45},
  number = {3},
  pages = {346--54},
  issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
  doi = {10.1007/s00595-014-0958-5}
}

@article{yuen,
  type = {Journal {{Article}}},
  title = {Long-Term Pharyngeal Dysphagia after Esophagectomy for Esophageal Cancer-an Investigation Using Videofluoroscopic Swallow Studies},
  author = {Yuen, M. T. Y. and Tsang, R. K. and Wong, I. Y. H. and Chan, D. K. K. and Chan, F. S. Y. and Law, S. Y. K.},
  year = {2018},
  journal = {Dis Esophagus},
  issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
  doi = {10.1093/dote/doy068}
}

@article{zhang2881,
  title = {Sarcopenia as a Predictor of Poor Surgical and Oncologic Outcomes after Abdominal Surgery for Digestive Tract Cancer: {{A}} Prospective Cohort Study},
  shorttitle = {Sarcopenia as a Predictor of Poor Surgical and Oncologic Outcomes after Abdominal Surgery for Digestive Tract Cancer},
  author = {Zhang, Shuze and Tan, Shanjun and Jiang, Yi and Xi, Qiulei and Meng, Qingyang and Zhuang, Qiulin and Han, Yusong and Sui, Xiangyu and Wu, Guohao},
  year = {2019},
  month = dec,
  journal = {Clinical Nutrition (Edinburgh, Scotland)},
  volume = {38},
  number = {6},
  pages = {2881--2888},
  issn = {1532-1983},
  doi = {10.1016/j.clnu.2018.12.025},
  abstract = {BACKGROUND \& AIMS: Sarcopenia has been widely recognized as an important predictor of poor outcomes in patients with cancer after surgery, but the controversy remains, and its impact on surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer is poorly described. The aim of this study was to evaluate the prognostic impact of sarcopenia on surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer. METHODS: Six thousand four hundred and forty-seven consecutive patients who underwent abdominal surgery for digestive tract cancer in our institution were prospectively included. Sarcopenia was defined as skeletal muscle index below the lowest sex-specific quartile using computed tomography scan at L3 before surgery. The surgical and oncologic outcomes were recorded, and univariate and multivariate analyses were performed. RESULTS: Sarcopenia was present in 1638 of 6447 patients (25.4\%) with digestive tract cancer before surgery based on the diagnostic cut-off values (43.13~cm2/m2 for men and 37.81~cm2/m2 for women). The incidence of postoperative total and pulmonary complications, and 30-day readmission were significantly higher in sarcopenic group than in nonsarcopenic group (37.4\% vs 12.9\%, P~{$<~$}0.001; 3.1\% vs 2.1\%, P~=~0.026; 1.1\% vs 0.4\%, P~=~0.003, respectively). The postoperative hospital stay was significantly longer in sarcopenic patients (9.42~{$\pm~$}3.40 vs 8.51~{$\pm~$}3.17 days, P~{$<~$}0.001). There were significantly more patients receiving postoperative chemotherapy or radiotherapy in sarcopenic group than in nonsarcopenic group (73.1\% vs 69.2\%, P~=~0.003; 10.6\% vs 8.8\%, P~=~0.038, respectively), and patients with sarcopenia had significantly more chemotherapy modifications including delay, dose reduction, or termination (48.5\% vs 44.2\%, P~=~0.018). In addition, during the follow-up period, sarcopenic patients had significantly lower rate of overall survival and disease-free survival than nonsarcopenic patients (53.9\% vs 69.3\%, P~=~0.002; 36.8\% vs 59.7\%, P~=~0.000, respectively). In multivariate analysis, sarcopenia was found to be a risk factor for postoperative complications [odds ratio (OR)~=~5.418, 95\% confidence interval (CI)~=~2.986-9.828, P~{$<~$}0.001], and was an unfavorable prognostic factor for poor overall survival [hazard ratio (HR)~=~0.649, 95\% CI~=~0.426-0.991, P~=~0.045] and disease-free survival (HR~=~0.514, 95\% CI~=~0.348-0.757, P~=~0.001). CONCLUSIONS: Sarcopenia could be used as a strong and independent prognostic factor for poor surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer. Identification of preoperative sarcopenia in digestive surgery for cancer and targeted approaches may improve its negative outcomes.},
  langid = {english},
  pmid = {30630709},
  keywords = {Abdominal surgery,China,Cohort Studies,Comorbidity,Digestive tract cancer,Female,Gastrointestinal Neoplasms,Gastrointestinal Tract,Humans,Length of Stay,Male,Middle Aged,Patient Readmission,Postoperative Complications,Prognosis,Prospective Studies,Risk Factors,Sarcopenia,Skeletal muscle index,Survival Analysis,Tomography; X-Ray Computed}
}

@article{zhang2894,
  title = {The Impact of Body Mass Index on Complication and Survival in Resected Oesophageal Cancer: A Clinical-Based Cohort and Meta-Analysis},
  shorttitle = {The Impact of Body Mass Index on Complication and Survival in Resected Oesophageal Cancer},
  author = {Zhang, S. S. and Yang, H. and Luo, K. J. and Huang, Q. Y. and Chen, J. Y. and Yang, F. and Cai, X. L. and Xie, X. and Liu, Q. W. and Bella, A. E. and Hu, R. G. and Wen, J. and Hu, Y. and Fu, J. H.},
  year = {2013},
  month = nov,
  journal = {British Journal of Cancer},
  volume = {109},
  number = {11},
  pages = {2894--2903},
  issn = {1532-1827},
  doi = {10.1038/bjc.2013.666},
  abstract = {BACKGROUND: Body mass index (BMI) has been associated with the risk of oesophageal cancer. But the influence of BMI on postoperative complication and prognosis has always been controversial. METHODS: In total, 2031 consecutive patients who underwent oesophagectomy between 1998 and 2008 were classified according to Asian-specific BMI (kg\,m(-2)) cutoff values. The impact of BMI on overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. We performed a meta-analysis to examine the association of BMI with OS and postoperative complication. RESULTS: Patients with higher BMI had more postoperative complication (P=0.002), such as anastomotic leakage (P=0.016) and cardiovascular diseases (P{$<$}0.001), but less incidence of chylous leakage (P=0.010). Logistic regression analysis showed that BMI (P=0.005) was a confounding factor associated with postoperative complication. Multivariate analysis showed that overweight and obese patients had a more favourable survival than normal weight patients (HR (hazard ratio) = 0.80, 95\% CI (confidence interval): 0.70-0.92, P=0.001). Subgroup analysis showed that the association with higher BMI and increased OS was observed in patients with oesophageal squamous cell carcinoma (ESCC) (P{$<$}0.001), oesophageal adenocarcinoma (EA) (P=0.034), never-smoking (P=0.035), ever-smoking (P=0.035), never alcohol consumption (P=0.005), weight loss (P=0.003) and advanced pathological stage (P{$<$}0.001). The meta-analysis further corroborated that higher BMI was associated with increased complication of anastomotic leakage (RR (risk ratio)=1.04, 95\% CI: 1.02-1.06, P=0.001), wound infection (RR=1.03, 95\% CI: 1.00-1.05, P=0.031) and cardiovascular diseases (RR=1.02, 95\% CI: 1.00-1.05, P=0.039), but decreased incidence of chylous leakage (RR=0.98, 95\% CI: 0.96-0.99, P{$<$}0.001). In addition, high BMI could significantly improved OS (HR=0.78, 95\% CI: 0.71-0.85, P{$<$}0.001). CONCLUSION: Preoperative BMI was an independent prognostic factor for survival, and strongly associated with postoperative complications in oesophageal cancer.},
  langid = {english},
  pmcid = {PMC3844915},
  pmid = {24201750},
  keywords = {Adenocarcinoma,Adult,Aged,Aged; 80 and over,Body Mass Index,Carcinoma; Squamous Cell,China,Cohort Studies,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Female,GE,Humans,Male,Middle Aged,Postoperative Complications,Prognosis,Survival Analysis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\D48XZT6K\\Zhang et al. - 2013 - The impact of body mass index on complication and .pdf}
}

@article{zhang429,
  type = {Journal {{Article}}},
  ids = {zhang429a},
  title = {Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage {{T2 N0}} Esophageal Cancer Patients Due to Inaccurate Preoperative Staging},
  author = {Zhang, J. Q. and Hooker, C. M. and Brock, M. V. and Shin, J. and Lee, S. and How, R. and Franco, N. and Prevas, H. and Hulbert, A. and Yang, S. C.},
  year = {2012},
  journal = {Ann Thorac Surg},
  volume = {93},
  number = {2},
  pages = {429-35; discussion 436-7},
  issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
  doi = {10.1016/j.athoracsur.2011.10.061},
  pmcid = {PMC4365971},
  pmid = {22269708},
  keywords = {Adenocarcinoma,Aged,Antineoplastic Combined Chemotherapy Protocols,Combined Modality Therapy,Diagnostic Errors,Disease Progression,Esophageal Neoplasms,Esophagectomy,Female,Fluorouracil,Follow-Up Studies,Humans,Induction Chemotherapy,Kaplan-Meier Estimate,Lymphatic Metastasis,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Invasiveness,Neoplasm Staging,Organoplatinum Compounds,Postoperative Complications,Preoperative Care,Proportional Hazards Models,Radiotherapy Dosage,Retrospective Studies,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SJIWBSXX\\Zhang et al. - 2012 - Neoadjuvant chemoradiation therapy is beneficial f.pdf}
}

@article{zhaoe0202185,
  title = {Neoadjuvant Chemotherapy versus Neoadjuvant Chemoradiotherapy for Cancer of the Esophagus or the Gastroesophageal Junction: {{A}} Meta-Analysis Based on Clinical Trials},
  shorttitle = {Neoadjuvant Chemotherapy versus Neoadjuvant Chemoradiotherapy for Cancer of the Esophagus or the Gastroesophageal Junction},
  author = {Zhao, Xin and Ren, Yiming and Hu, Yong and Cui, Naiqiang and Wang, Ximo and Cui, Yunfeng},
  year = {2018},
  journal = {PloS One},
  volume = {13},
  number = {8},
  pages = {e0202185},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0202185},
  abstract = {BACKGROUND: The benefit of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for treating cancer of the esophagus or the gastroesophageal junction remains controversial. In the present study, we conducted a comprehensive meta-analysis to examine the efficacy of these two management strategies. METHODS: The MEDLINE (PubMed), SinoMed, Embase, and Cochrane Library databases were searched for eligible studies. We searched for the most relevant studies published until the end of September 2017. Data were extracted independently and were analyzed using RevMan statistical software version 5.3 (Cochrane Collaboration, http://tech.cochrane.org/revman/download). Weighted mean differences, risk ratios (RRs), and 95\% confidence intervals (CIs) were calculated. Cochrane Collaboration's risk of bias tool was used to assess the risk of bias. In this comprehensive meta-analysis, we examined the efficiency of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for the treatment of cancer of the esophagus or the gastroesophageal junction as reported in qualified clinical trials. RESULTS: Six qualified articles that included a total of 866 patients were identified. The meta-analysis showed that for 3-year and 5-year survival rates in primary outcomes, the results favored neoadjuvant chemoradiotherapy strategies compared with neoadjuvant chemotherapy (RR = 0.78, 95\% CI = 0.62-0.98, P = 0.03; RR = 0.69, 95\% CI = 0.50-0.96, P = 0.03, respectively). In terms of secondary outcomes, neoadjuvant chemoradiotherapy significantly increased the rate of R0 resection and pathological complete response as well (RR = 0.87, 95\% CI = 0.81-0.92, P {$<$} 0.0001; RR = 0.16, 95\% CI = 0.09-0.28, P {$<$} 0.00001, respectively). However, there were no significant differences in postoperative mortality between the two groups (RR = 1.85, 95\% CI = 0.93-3.65, P = 0.08). For the results of postoperative complications, revealed that there was a statistically significant difference between the two groups in the incidence of postoperative complications such as pulmonary, anastomotic leak and cardiovascular complications. The subgroup analysis of patients with esophageal adenocarcinoma or squamous cell carcinoma showed that both esophageal adenocarcinoma and squamous cell carcinoma patients achieved a high rate of R0 resection (RR = 0.85, 95\% CI = 0.77-0.93, P = 0.0006; RR = 0.88, 95\% CI = 0.81-0.96, P = 0.005, respectively) and pathological complete response benefit of neoadjuvant chemoradiotherapy (RR = 0.23, 95\% CI = 0.09-0.57, P = 0.001; RR = 0.18, 95\% CI = 0.03-0.96, P = 0.05, respectively). CONCLUSION: Our findings suggested that compared with neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy should be recommended with a significant long-term survival benefit in patients with cancer of the esophagus or the gastroesophageal junction. In view of the clinical heterogeneity, whether these conclusions are broadly applicable should be further determined.},
  langid = {english},
  pmcid = {PMC6107145},
  pmid = {30138325},
  keywords = {Chemoradiotherapy,Esophageal Neoplasms,Esophagogastric Junction,Humans,Neoadjuvant Therapy,Randomized Controlled Trials as Topic,Stomach Neoplasms},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\AITR5E6P\\Zhao et al. - 2018 - Neoadjuvant chemotherapy versus neoadjuvant chemor.pdf}
}

@article{zheng4427,
  title = {Optimal Timing and Route of Nutritional Support after Esophagectomy: {{A}} Review of the Literature},
  shorttitle = {Optimal Timing and Route of Nutritional Support after Esophagectomy},
  author = {Zheng, Richard and Devin, Courtney L. and Pucci, Michael J. and Berger, Adam C. and Rosato, Ernest L. and Palazzo, Francesco},
  year = {2019},
  month = aug,
  journal = {World Journal of Gastroenterology},
  volume = {25},
  number = {31},
  pages = {4427--4436},
  issn = {2219-2840},
  doi = {10.3748/wjg.v25.i31.4427},
  abstract = {Some controversy surrounds the postoperative feeding regimen utilized in patients who undergo esophagectomy. Variation in practices during the perioperative period exists including the type of nutrition started, the delivery route, and its timing. Adequate nutrition is essential for this patient population as these patients often present with weight loss and have altered eating patterns after surgery, which can affect their ability to regain or maintain weight. Methods of feeding after an esophagectomy include total parenteral nutrition, nasoduodenal/nasojejunal tube feeding, jejunostomy tube feeding, and oral feeding. Recent evidence suggests that early oral feeding is associated with shorter LOS, faster return of bowel function, and improved quality of life. Enhanced recovery pathways after surgery pathways after esophagectomy with a component of early oral feeding also seem to be safe, feasible, and cost-effective, albeit with limited data. However, data on anastomotic leaks is mixed, and some studies suggest that the incidence of leaks may be higher with early oral feeding. This risk of anastomotic leak with early feeding may be heavily modulated by surgical approach. No definitive data is currently available to definitively answer this question, and further studies should look at how these early feeding regimens vary by surgical technique. This review aims to discuss the existing literature on the optimal route and timing of feeding after esophagectomy.},
  langid = {english},
  pmcid = {PMC6710171},
  pmid = {31496622},
  keywords = {Anastomosis; Surgical,Anastomotic Leak,Cachexia,Delayed feeding,Early feeding,Enhanced Recovery After Surgery,Enteral nutrition,Enteral Nutrition,Esophageal cancer,Esophageal Neoplasms,Esophagectomy,Humans,Incidence,Intubation; Gastrointestinal,Jejunostomy,Jejunostomy tube,Nutrition,Oral feeding,Parenteral Nutrition,Postoperative complications,Quality of Life,Standard of Care,Time Factors,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5A5B6JKJ\\Zheng et al. - 2019 - Optimal timing and route of nutritional support af.pdf}
}

@article{zhou1207,
  title = {Analysis of Trimodal and Bimodal Therapy in a Selective-Surgery Paradigm for Locally Advanced Oesophageal Squamous Cell Carcinoma},
  author = {Zhou, N. and Mitchell, K. G. and Corsini, E. M. and Truong, V. T. T. and Antonoff, M. B. and Mehran, R. J. and Rajaram, R. and Rice, D. C. and Roth, J. A. and Sepesi, B. and Swisher, S. G. and Vaporciyan, A. A. and Walsh, G. L. and Ajani, J. A. and Hofstetter, W. L.},
  year = {2021},
  month = oct,
  journal = {The British Journal of Surgery},
  volume = {108},
  number = {10},
  pages = {1207--1215},
  issn = {1365-2168},
  doi = {10.1093/bjs/znab162},
  abstract = {BACKGROUND: Long-term survival outcomes of trimodal therapy (TMT; chemoradiation plus surgery) and bimodal therapy (BMT; chemoradiation) have seldom been analysed. In a selective-surgery paradigm, the benefit of TMT in patients with a complete clinical response is controversial. Factors associated with survival in patients with a clinical complete response to chemoradiation were evaluated. METHODS: Patients with stage II-III oesophageal squamous cell carcinoma treated with TMT or BMT from 2002 to 2017 were evaluated. The BMT group consisted of patients who were otherwise eligible for surgery but underwent chemoradiation alone followed by observation. This group included patients who later had salvage oesophagectomy. Survival was evaluated and compared between TMT and BMT groups. Elastic net regularization was performed to select co-variables for Cox multivariable survival analysis in patients with a clinical complete response. RESULTS: Of 143 patients, 60 (41.9 per cent) underwent TMT and 83 (58.0 per cent) BMT. Patients who underwent TMT had longer median overall survival than those who had BMT (77 versus 33\,months; P\,=\,0.019). For patients with a clinical complete response, TMT achieved longer median overall survival than BMT (123 versus 55\,months; P\,=\,0.04). BMT had a high locoregional recurrence rate (48 versus 6 per cent; P\,{$<$}\,0.001); 26 of 29 patients with locoregional recurrence in the BMT groupunderwent salvage resection. Cox multivariable analysis demonstrated that upper-mid oesophageal tumour location (hazard ratio (HR) 2.04; P\,=\,0.024) and tumour length (HR 1.18; P\,=\,0.046) were associated with worse survival. Although TMT was not associated with survival, it was a predictor of reduced recurrence (HR 0.28; P\,=\,0.028). The maximum standardized uptake value after chemoradiation also predicted recurrence (HR 1.33; P\,{$<$}\,0.001). CONCLUSION: In patients who achieve a clinical complete response, TMT reduces locoregional recurrence but may not prolong survival. The differences in survival outcomes may be due to patient selection; therefore, a selective-surgery strategy in oesophageal squamous cell carcinoma is a reasonable approach.},
  langid = {english},
  pmid = {34095952},
  keywords = {Aged,Chemoradiotherapy; Adjuvant,Disease-Free Survival,Esophageal Neoplasms,Esophageal Squamous Cell Carcinoma,Esophagectomy,Female,Humans,Male,Middle Aged,Neoadjuvant Therapy,Neoplasm Metastasis,Neoplasm Recurrence; Local,Neoplasm Staging,Proportional Hazards Models,Salvage Therapy}
}

@article{zhoue0132889,
  ids = {zhoue0132889a},
  title = {Superiority of {{Minimally Invasive Oesophagectomy}} in {{Reducing In-Hospital Mortality}} of {{Patients}} with {{Resectable Oesophageal Cancer}}: {{A Meta-Analysis}}},
  shorttitle = {Superiority of {{Minimally Invasive Oesophagectomy}} in {{Reducing In-Hospital Mortality}} of {{Patients}} with {{Resectable Oesophageal Cancer}}},
  author = {Zhou, Can and Zhang, Li and Wang, Hua and Ma, Xiaoxia and Shi, Bohui and Chen, Wuke and He, Jianjun and Wang, Ke and Liu, Peijun and Ren, Yu},
  year = {2015},
  journal = {PloS One},
  volume = {10},
  number = {7},
  pages = {e0132889},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0132889},
  abstract = {BACKGROUND: Compared with open oesophagectomy (OE), minimally invasive oesophagectomy (MIO) proves to have benefits in reducing the risk of pulmonary complications for patients with resectable oesophageal cancer. However, it is unknown whether MIO has superiority in reducing the occurrence of in-hospital mortality (IHM). OBJECTIVE: The objective of this meta-analysis was to explore the effect of MIO vs. OE on the occurrence of in-hospital mortality (IHM). DATA SOURCES: Sources such as Medline (through December 31, 2014), Embase (through December 31, 2014), Wiley Online Library (through December 31, 2014), and the Cochrane Library (through December 31, 2014) were searched. STUDY SELECTION: Data of randomized and non-randomized clinical trials related to MIO versus OE were included. INTERVENTIONS: Eligible studies were those that reported patients who underwent MIO procedure. The control group included patients undergoing conventional OE. STUDY APPRAISAL AND SYNTHESIS METHODS: Fixed or random -effects models were used to calculate summary odds ratios (ORs) or relative risks (RRs) for quantification of associations. Heterogeneity among studies was evaluated by using Cochran's Q and I2 statistics. RESULTS: A total of 48 studies involving 14,311 cases of resectable oesophageal cancer were included in the meta-analysis. Compared to patients undergoing OE, patients undergoing MIO had statistically reduced occurrence of IHM (OR=0.69, 95\%CI =0.55 -0.86). Patients undergoing MIO also had significantly reduced incidence of pulmonary complications (PCs) (RR=0.73, 95\%CI = 0.63-0.86), pulmonary embolism (PE) (OR=0.71, 95\%CI= 0.51-0.99) and arrhythmia (OR=0.79, 95\%CI = 0.68-0.92). Non-significant reductions were observed among the included studies in the occurrence of anastomotic leak (AL) (OR=0.93, 95\%CI =0.78-1.11), or Gastric Tip Necrosis (GTN) (OR=0.89, 95\%CI =0.54-1.49). LIMITATION: Most of the included studies were non-randomized case-control studies, with a diversity of study designs, demographics of participants and surgical intervention. CONCLUSIONS: Minimally invasive oesophagectomy (MIO) has superiority over open oesophagectomy (OE) in terms of the occurrence of in-hospital mortality (IHM) and should be the first-choice surgical procedure in esophageal surgery.},
  langid = {english},
  pmcid = {PMC4509855},
  pmid = {26196135},
  keywords = {Anastomotic Leak,Arrhythmias; Cardiac,Clinical Trials as Topic,Esophageal Neoplasms,Esophagectomy,Esophagus,Hospital Mortality,Humans,Minimally Invasive Surgical Procedures,Necrosis,Odds Ratio,Risk,Treatment Outcome},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\NN3TAP3B\\Zhou et al. - 2015 - Superiority of Minimally Invasive Oesophagectomy i.pdf}
}

@misc{zotero-1760,
  title = {Timed {{Stair Climbing Is}} the {{Single Strongest Predictor}} of {{Perioperative Complications}} in {{Patients Undergoing Abdominal Surgery}} - {{PubMed}}},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/26920993/},
  keywords = {Stairs},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\YK7ELDWI\\26920993.html}
}

@misc{zotero-1775,
  title = {Percutaneous Endoscopic Gastrostomy Risks Rendering the Gastric Conduit Unusable for Esophagectomy - {{Ohnmacht}} - 2006 - {{Diseases}} of the {{Esophagus}} - {{Wiley Online Library}}},
  howpublished = {https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1442-2050.2006.00588.x},
  keywords = {PEG},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\SPX47VU4\\j.1442-2050.2006.00588.html}
}

@misc{zotero-1791,
  title = {Prognostic Value of Sarcopenia in Adults with Solid Tumours: {{A}} Meta-Analysis and Systematic Review - {{PubMed}}},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/26882087/},
  keywords = {Prognosis},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\CIK8YWKN\\26882087.html}
}

@incollection{zotero-2,
  type = {Book {{Section}}},
  title = {{{BEST}} ({{Biomarkers}}, {{EndpointS}}, and Other {{Tools}}) {{Resource Glossary}}},
  booktitle = {{{BEST}} ({{Biomarkers}}, {{EndpointS}}, and Other {{Tools}}) {{Resource}}},
  year = {2016},
  address = {{Silver Spring (MD)}}
}

@misc{zotero-860,
  title = {Race/Ethnicity and Socio-Economic Differences in Colorectal Cancer Surgery Outcomes: Analysis of the Nationwide Inpatient Sample - {{PubMed}}},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/27595733/},
  keywords = {Race},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\5GZYITMC\\27595733.html}
}

@article{zuckerman1403,
  title = {Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with {{Stage III}} Colon Cancer},
  author = {Zuckerman, Ilene H. and Rapp, Thomas and Onukwugha, Ebere and Davidoff, Amy and Choti, Michael A. and Gardner, James and Seal, Brian and Mullins, C. Daniel},
  year = {2009},
  month = aug,
  journal = {Journal of the American Geriatrics Society},
  volume = {57},
  number = {8},
  pages = {1403--1410},
  issn = {1532-5415},
  doi = {10.1111/j.1532-5415.2009.02355.x},
  abstract = {OBJECTIVES: To estimate the modifying effect of age on the survival benefit associated with adjuvant chemotherapy receipt in elderly patients with a diagnosis of Stage III colon cancer. DESIGN: Observational, retrospective cohort study using two samples: an overall sample of 7,182 patients to provide externally valid analyses and a propensity score-matched sample of 3,016 patients to provide more internally valid analyses by reducing the presence of treatment endogeneity. An interval-censored survival model with a complementary log-log link was used. Hazard ratios and 95\% confidence intervals were obtained for all regressions. SETTINGS: Data from the National Cancer Institute's Surveillance, Epidemiology and End Results database and the linked Medicare enrollment and claims database were used. PARTICIPANTS: Selected patients were aged 66 and older and had a diagnosis of Stage III colon cancer. Patients were followed from surgery to time of death or censorship. MEASUREMENTS: The outcome was colon cancer-specific death during the follow-up period. Receipt of adjuvant chemotherapy was measured according to the presence of a claim for 5-fluorouracil or leucovorin within 6 months after surgery. RESULTS: All elderly patients had a significant survival benefit associated with adjuvant chemotherapy receipt, although the survival benefit of adjuvant chemotherapy was not uniform across all age groups. CONCLUSION: These findings have important clinical and policy implications for the risk-benefit calculation induced by treatment in older patients with Stage III colon cancer. The results suggest that there is a benefit from chemotherapy, but the benefit is lower with older age.},
  langid = {english},
  pmid = {19563521},
  keywords = {Age Factors,Aged,Aged; 80 and over,Antineoplastic Combined Chemotherapy Protocols,Chemotherapy; Adjuvant,Colonic Neoplasms,CRC,Female,Fluorouracil,Humans,Leucovorin,Logistic Models,Male,Medicare,Neoplasm Staging,Proportional Hazards Models,Retrospective Studies,SEER Program,Survival Analysis,Treatment Outcome,United States}
}

@article{zwischenberger489,
  title = {Venous {{Thromboembolism Prophylaxis For Esophagectomy}}: {{A Survey}} of {{Practice Patterns Among Thoracic Surgeons}}},
  shorttitle = {Venous {{Thromboembolism Prophylaxis For Esophagectomy}}},
  author = {Zwischenberger, Brittany A. and Tzeng, Ching-Wei D. and Ward, Nicholas D. and Zwischenberger, Joseph B. and Martin, Jeremiah T.},
  year = {2016},
  month = feb,
  journal = {The Annals of Thoracic Surgery},
  volume = {101},
  number = {2},
  pages = {489--494},
  issn = {1552-6259},
  doi = {10.1016/j.athoracsur.2015.07.023},
  abstract = {BACKGROUND: Current guidelines for gastrointestinal cancer surgical intervention in high-risk patients recommend postoperative venous thromboembolism (VTE) chemical prophylaxis for 4 weeks with low-dose unfractionated heparin or low-molecular-weight heparin, but specific guidelines for esophagectomy are lacking. This survey identified the clinical patterns affecting postesophagectomy VTE chemoprophylaxis use among general thoracic surgeons. METHODS: General Thoracic Surgery Club members were invited to complete an online survey on VTE prophylaxis to analyze clinical factors affecting their choices. RESULTS: Seventy-seven surgeons (37\% membership) responded; of these, 94\% (72 of 77) completed fellowships, and 76\% (58 of 77) worked at universities. VTE chemoprophylaxis administration varied widely in drug, dosing, and duration, with 30\% using suboptimal dosing of unfractionated heparin (every 12 hours). Participants agreed that esophagectomy patients are at high VTE risk, yet 29\% (22 of 76) of surgeons delay VTE chemoprophylaxis until postoperative day 1. Only 13\% (10 of 77) prescribe postdischarge chemoprophylaxis. Minimally invasive surgeons ({$>$}90\% of cases) were more likely to prescribe postdischarge prophylaxis (p~= 0.007). Epidurals, routinely used by 65\% (51 of 78), led to less compliance with recommended dosing. Only 53\% (27 of 51) of pain teams allow unfractionated heparin every 8~hours, yet 73\% (37 of 51) allow suboptimal dosing (every 12 h). Postoperative major complications were identified as a VTE risk factor by only 21\% (15 of 72) of surgeons. Most (92\% [68 of 74]) would follow esophagectomy-specific guidelines, if developed. CONCLUSIONS: Thoracic surgeons agree that VTE chemoprophylaxis is necessary for esophagectomy, yet substantial variability exists in current practice. A noteworthy proportion use suboptimal dosing, and very few choose postdischarge prophylaxis. To improve postesophagectomy morbidity and mortality outcomes, thoracic surgeons are willing to follow evidence-based guidelines for VTE chemoprophylaxis.},
  langid = {english},
  pmid = {26409709},
  keywords = {Anticoagulants,Esophagectomy,Heparin,Humans,Postoperative Complications,Practice Patterns; Physicians',Surveys and Questionnaires,Thoracic Surgery,Venous Thromboembolism,VTE},
  file = {C\:\\Users\\jsalo01\\Zotero\\storage\\EWFGX2F2\\Zwischenberger et al_2016_Venous Thromboembolism Prophylaxis For Esophagectomy.pdf}
}


